
<html lang="en"     class="pb-page"  data-request-id="d570d853-2e7a-4ec0-b18d-3fe3b92dd12f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c00925;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective" /></meta><meta name="dc.Creator" content="Xi  Feng" /></meta><meta name="dc.Creator" content="Dongdong  Liao" /></meta><meta name="dc.Creator" content="Dongyu  Liu" /></meta><meta name="dc.Creator" content="An  Ping" /></meta><meta name="dc.Creator" content="Zhiyu  Li" /></meta><meta name="dc.Creator" content="Jinlei  Bian" /></meta><meta name="dc.Description" content="Indoleamine 2,3-dioxygenase 1 (IDO1) has received increasing attention due to its immunosuppressive function in connection with various diseases, including cancer. A recent increase in the understa..." /></meta><meta name="Description" content="Indoleamine 2,3-dioxygenase 1 (IDO1) has received increasing attention due to its immunosuppressive function in connection with various diseases, including cancer. A recent increase in the understa..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 20, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00925" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00925" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00925" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00925" /></link>
        
    
    

<title>Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00925" /></meta><meta property="og:title" content="Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0011.jpeg" /></meta><meta property="og:description" content="Indoleamine 2,3-dioxygenase 1 (IDO1) has received increasing attention due to its immunosuppressive function in connection with various diseases, including cancer. A recent increase in the understanding of IDO1 has significantly contributed to the discovery of numerous novel inhibitors, but the latest clinical outcomes raised questions and have indicated a future direction of IDO1 inhibition for therapeutic approaches. Herein, we present a comprehensive review of IDO1, discussing the latest advances in understanding the IDO1 structure and mechanism, an overview of recent IDO1 inhibitor discoveries and potential therapeutic applications to provide helpful information for medicinal chemists investigating IDO1 inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00925"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00925">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00925&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00925&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00925&amp;href=/doi/10.1021/acs.jmedchem.0c00925" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15115-15139</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00913" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01082" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xi Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xi Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xi++Feng">Xi Feng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0117-1234" title="Orcid link">http://orcid.org/0000-0003-0117-1234</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dongdong Liao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dongdong Liao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dongdong++Liao">Dongdong Liao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dongyu Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dongyu Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dongyu++Liu">Dongyu Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">An Ping</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">An Ping</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=An++Ping">An Ping</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhiyu Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiyu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: +86-139-5167-8592. Email <a href="/cdn-cgi/l/email-protection#e3998b8a9a968f8aa3809396cd868796cd808d"><span class="__cf_email__" data-cfemail="146e7c7d6d61787d547764613a7170613a777a">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiyu++Li">Zhiyu Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6492-9511" title="Orcid link">http://orcid.org/0000-0001-6492-9511</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jinlei Bian</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinlei Bian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>Tel: +86-151-5186-5295. Email: <a href="/cdn-cgi/l/email-protection#0a68636b6460664a697a7f246f6e7f246964"><span class="__cf_email__" data-cfemail="5f3d363e3135331f3c2f2a713a3b2a713c31">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinlei++Bian">Jinlei Bian</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4552-1195" title="Orcid link">http://orcid.org/0000-0003-4552-1195</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00925&amp;href=/doi/10.1021%2Facs.jmedchem.0c00925" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15115–15139</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 20, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 May 2020</li><li><span class="item_label"><b>Published</b> online</span>20 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00925" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00925</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15115%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXi%2BFeng%252C%2BDongdong%2BLiao%252C%2BDongyu%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c00925%26title%3DDevelopment%2Bof%2BIndoleamine%2B2%252C3-Dioxygenase%2B1%2BInhibitors%2Bfor%2BCancer%2BTherapy%2Band%2BBeyond%253A%2BA%2BRecent%2BPerspective%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15139%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00925"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2134</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00925" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xi&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Dongdong&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Dongyu&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;An&quot;,&quot;last_name&quot;:&quot;Ping&quot;},{&quot;first_name&quot;:&quot;Zhiyu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jinlei&quot;,&quot;last_name&quot;:&quot;Bian&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15115-15139&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00925&quot;},&quot;abstract&quot;:&quot;Indoleamine 2,3-dioxygenase 1 (IDO1) has received increasing attention due to its immunosuppressive function in connection with various diseases, including cancer. A recent increase in the understanding of IDO1 has significantly contributed to the discovery of numerous novel inhibitors, but the latest clinical outcomes raised questions and have indicated a future direction of IDO1 inhibition for therapeutic approaches. Herein, we present a comprehensive review of IDO1, discussing the latest advances in understanding the IDO1 structure and mechanism, an overview of recent IDO1 inhibitor discoveries and potential therapeutic applications to provide helpful information for medicinal chemists investigating IDO1 inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00925&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00925" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00925&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00925" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00925&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00925" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00925&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00925&amp;href=/doi/10.1021/acs.jmedchem.0c00925" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00925" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00925" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00925%26sid%3Dliteratum%253Aachs%26pmid%3D33215494%26genre%3Darticle%26aulast%3DFeng%26date%3D2020%26atitle%3DDevelopment%2Bof%2BIndoleamine%2B2%252C3-Dioxygenase%2B1%2BInhibitors%2Bfor%2BCancer%2BTherapy%2Band%2BBeyond%253A%2BA%2BRecent%2BPerspective%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15115%26epage%3D15139%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292460" title="Bioinorganic chemistry">Bioinorganic chemistry</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Indoleamine 2,3-dioxygenase 1 (IDO1) has received increasing attention due to its immunosuppressive function in connection with various diseases, including cancer. A recent increase in the understanding of IDO1 has significantly contributed to the discovery of numerous novel inhibitors, but the latest clinical outcomes raised questions and have indicated a future direction of IDO1 inhibition for therapeutic approaches. Herein, we present a comprehensive review of IDO1, discussing the latest advances in understanding the IDO1 structure and mechanism, an overview of recent IDO1 inhibitor discoveries and potential therapeutic applications to provide helpful information for medicinal chemists investigating IDO1 inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer immunotherapy offers a powerful weapon against solid malignancies with the development of mAbs that target the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) axis and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and has received significant attention over the past decade. However, a subset of cancer patients does not respond to checkpoint blockade therapy, suggesting the existence of additional tumor immunosuppressive and resistance pathways.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Preclinical studies have revealed multiple mechanisms contributing to local immunosuppression in the tumor microenvironment (TME), including <span class="smallcaps smallerCapital">l</span>-tryptophan (Trp) metabolism.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Trp is an essential amino acid in mammals, the metabolic fate of which is systematically regulated by various routes.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The tryptophan-kynurenine (Trp-Kyn) pathway is the primary route of Trp metabolism, and over 95% of free Trp is consumed and converted to kynurenine (Kyn) and other secondary metabolites through this pathway.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Preclinical studies have revealed that heightened Trp-Kyn pathway activity in the TME may contribute to tumor-associated immunosuppression and tumor progression through two proposed molecular mechanisms: depleting local Trp storage and producing pathway metabolites.<a onclick="showRef(event, 'ref3 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref3 ref7 ref8 ref9">(3,7−9)</a> Degradation of local Trp is associated with cell cycle arrest and anergy of infiltrating T cells as a consequence of mTOR inhibition and GCN2 activation. However, recent studies have questioned the impact of local Trp degradation on immunomodulation, which may indicate that the immunosuppressive properties of the Trp-Kyn pathway are primarily a consequence of Trp metabolites.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> Accumulated Kyn and its metabolites act as potent agonists of the aryl hydrocarbon receptor (AhR) and further induce immune modulation by activating regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Indeed, the Trp-Kyn pathway has been recognized as a promising target of cancer immunotherapy, but effective strategies for inhibiting this pathway are still under development.</div><div class="NLM_p">Along the Trp-Kyn axis, three heme-containing enzymes catalyze the first and rate-limiting step of Trp metabolism to Kyn: indoleamine 2,3-dioxygenase 1 (IDO1, EC 1.13.11.52), indoleamine 2,3-dioxygenase 2 (IDO2, EC 1.13.11), and Trp 2,3-dioxygenase (TDO, EC 1.13.11.11). Under catalytic conditions, the Trp substrate is intracellularly oxidized in one reaction with the participation of molecular oxygen (O<sub>2</sub>) to afford the primary metabolite <i>N</i>-formylkynurenine (NFK).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Among the three metabolic enzymes mentioned above, the immunosuppressive impact of IDO1 has been addressed in several preclinical models, and importantly, IDO1 has received the most significant attention from both industry and academia in recent decades.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> To date, thousands of small-molecule compounds have been reported as IDO1 inhibitors, including several clinical candidates, although they are still in proof-of-concept trials. Preclinical studies and clinical data have supported that the majority of cancer cells and intratumoral cells express IDO1, and elevated IDO1 activity and Kyn levels are associated with advanced tumor grade and poor prognosis in a variety of cancer types.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> In addition, IDO1 is also involved in the development of resistance against immune checkpoint blockade therapies.<a onclick="showRef(event, 'ref1 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref1 ref20 ref21">(1,20,21)</a> Based on the promising potential of IDO1, dozens of clinical trials on IDO1 inhibitors have been launched as monotherapies or in combination with immune checkpoint inhibitors (ICIs) for the treatment of cancers. It had been widely anticipated that the leading IDO1 candidates would pass clinical tests and reach approval; however, the recent failure of a phase 3 trial testing an IDO1 inhibitor has highlighted the need for deeper insight into the Trp-Kyn pathway in diseases, raising new questions on the design of better and more rationalized compounds targeting the pathway coupled with improved rationalized trial design.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a></div><div class="NLM_p last">The more recently identified IDO1-related enzyme IDO2 has a distinct expression pattern and exhibits lower Trp degradation activity.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Although the physiological functions of IDO2 and its roles in disease conditions involving the Trp-Kyn pathway remain unclear, this IDO1-related enzyme has been found to be expressed in some cancer cells and is considered to support IDO1-mediated immune tolerance.<a onclick="showRef(event, 'ref8 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref8 ref24 ref25">(8,24,25)</a> In addition to IDO2, TDO, which was initially thought to be a hepatic enzyme responsible for metabolizing dietary Trp, is ectopically expressed by malignant cells in some cancers and has been implicated in both immune tolerance and metastatic progression.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> A recent understanding of the molecular pathway in Trp metabolism-linked local immunosuppression indicates that intratumoral TDO similarly restrains the antitumor response and suppresses tumor immune infiltration.<a onclick="showRef(event, 'ref12 ref26'); return false;" href="javascript:void(0);" class="ref ref12 ref26">(12,26)</a> Preclinical studies have revealed that TDO could serve as an additional target for sufficient Trp-Kyn pathway inhibition and durable immunosuppression relief.<a onclick="showRef(event, 'ref12 ref26'); return false;" href="javascript:void(0);" class="ref ref12 ref26">(12,26)</a> Currently, two IDO1/TDO dual inhibitors are in clinical evaluations for the treatment of cancer.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> In this review, we summarize the latest understanding of IDO1 and highlight the discovery and structural features of recently disclosed IDO1 inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Structure and Mechanisms of IDO</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05357" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05357" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure and Active Sites of IDO1</h3><div class="NLM_p">Human IDO1 (hIDO1) is a monomeric oxidase expressed in most tissues at low levels that contains a large C-terminal domain (CTD) and a small N-terminal domain (NTD). The CTD comprises a large domain that anchors the heme cofactor and accounts for the catalytic activity of IDO1, while the NTD contains two small domains that are implicated in signaling functions and defined as immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).<a onclick="showRef(event, 'ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33">(30−33)</a> Since 2006, the crystal structures of hIDO1 in complex with Trp and a variety of inhibitors have been disclosed.<a onclick="showRef(event, 'ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37">(34−37)</a> Most of these inhibitors occupy the active site (S<sub>a</sub>) of the catalytically competent heme-bound IDO1 (holoIDO1), where coordination to heme could be generated via an N atom or an O atom of the inhibitors (iron coordination could theoretically also be generated by S atom). Structurally, the S<sub>a</sub> site of IDO1 is located at the CTD and comprises two distinct clefts: a deeper hydrophobic pocket A inside the protein that contains a heme group as the key moiety for the substrate conversion and an outward pocket B at the entrance of the binding site.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In addition, a distal pocket nearing the solvent region is named pocket C but is rarely exploited.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of hIDO1 and hTDO complexed with ligands. (A) Crystal structure of the hIDO1–Trp-IDE complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WMV">5WMV</a>). IDO1 contains a larger CTD that compromises the S<sub>a</sub> site and the S<sub>i</sub> site and a smaller NTD that contains the ITIM site. Substrate Trp (light salmon) occupies the S<sub>a</sub> site in both pockets A and B, and effector 3-indole ethanol (IDE, lime) binds to pocket D. (B) Crystal structure of the hIDO1–epacadostat (green) complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WN8">5WN8</a>). Epacadostat coordinates heme iron with the O atom and occupies both pockets A and B. (C) Superimposed structure of apo-IDO1 complexed with BMS986205 and BMS116 (cyan) and their chemical structures (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MQ6">6MQ6</a>/<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZW">6AZW</a>). These inhibitors extend to pocket D and occupy pocket A. (D) Crystal structure of the hTDO-PF-06840002 (pink) adduct (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYY">6PYY</a>). Pocket A in the S<sub>a</sub> site of TDO is completed by a neighboring TDO N-terminal chain (residues in violet), and the S<sub>i</sub> site is blocked by Phe158 and Trp324.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2017, the crystal structure of the hIDO1–Trp complex reported by Lewis-Ballester et al. revealed that the Trp substrate is located in the distal heme pocket, and the indole group is located perpendicular upon the heme ring and is surrounded by a group of hydrophobic residues from pocket A (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WMV">5WMV</a>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The indole group is further secured by key residue Ser167 and interacts with the heme group via an intervening iron-bound CN molecule; meanwhile, the backbone of Trp extends into pocket B, and the carboxylate group is stabilized by a polar interaction with Arg231, which is considered critical for recognizing and binding substrates.<a onclick="showRef(event, 'ref14 ref34'); return false;" href="javascript:void(0);" class="ref ref14 ref34">(14,34)</a> Simultaneously, the crystal structure of IDO1 in complex with epacadostat (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WN8">5WN8</a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B), which has been the most advanced IDO1 inhibitor in clinical trials, has been reported to exhibit a similar binding mode to the hIDO1–Trp complex.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Pocket A is occupied by the bulky benzene group, which is surrounded by a group of hydrophobic residues, including Phe126, Val130, Phe164, Leu234, Phe163, and Ser167.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The terminal halogen atoms are adjacent to Cys129 in the N-terminal domain, leading to an additional fluorine–sulfur contact that is considered beneficial for protein inhibitor stabilization.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The linear alkyl chain extends into pocket B, and the sulfamide group is further anchored by Arg231.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Uniquely, epacadostat coordinates to the heme iron via an O atom of the hydroxyamidine group, which is distinguished from other IDO1–heme-inhibitor complexes in which heme has been considered blocked by N-iron-mediated coordination. Another exception is PF-06840003 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), a clinical candidate IDO1 inhibitor that has been observed to sit perpendicular to the heme group with no direct interaction with the central iron.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In recent years, with the support of crystal structure and <i>in silico</i> simulation of the IDO1–inhibitor complex, it has been recognized that most high-affinity inhibitors usually branch two fragments into both pockets A and B, while inhibitors with smaller scaffolds typically occupy only pocket A and may exhibit deficient potency. Structure–activity relationship (SAR) studies performed by medicinal chemists have indicated that seeking additional interactions with key residues in pocket B, such as Arg231, is beneficial for improving the inhibitory efficacy.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Selected Small-Molecule Inhibitors Targeting IDO1 in Clinical Trials</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0010.gif" alt="" id="fx1" /></img><div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of Trp/indole analogues in recent literature. (A) Inhibitors with indole scaffolds. The PDB code for the hIDO1–<b>11</b> complex is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WHR">5WHR</a>. (B) Inhibitors with indolin-2-one and indole-2-carboxylic acid scaffolds. (C) Inhibitors with indazole scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recent studies of the heme-competitive inhibitor BMS986205 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C) have revealed a unique inhibitory mechanism, as well as a distinct binding mode of IDO1 inhibitor. Nelp et al. reported that BMS986205 irreversibly inhibits IDO1 activity by targeting its intrinsic apo-form, which is the enzyme without the prosthetic group, blocking the rebinding of heme.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Another report by Ortiz-Meoz et al. also supported that their IDO1 inhibitor, GSK5628 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), inhibits IDO1 by binding to the heme-free form and preventing enzymatic reactivation.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> However, studies from Pham et al. delineated a process of heme release triggered by BMS986205, which ultimately leads to a distinct conformation of inhibitor in the IDO1 binding site.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Despite disagreements and questions regarding the mechanism of heme-competitive inhibitors, these reported compounds usually exhibit more potent activities in cellular assays, which may further indicate that apo-IDO1 may represent an efficient target for IDO1 inhibition.<a onclick="showRef(event, 'ref35 ref40 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref35 ref40 ref41 ref42 ref43">(35,40−43)</a> Supported by coordination via the His346-iron bond, the heme group covers its proximal site, which was previously identified as the inhibitory substrate binding site (S<sub>i</sub> site, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A), and the release of heme makes this spacious hydrophobic cavity (also called pocket D) accessible for small molecular inhibitors.<a onclick="showRef(event, 'ref34 ref44'); return false;" href="javascript:void(0);" class="ref ref34 ref44">(34,44)</a> According to the crystal structures of the hIDO1–BMS986205/BMS116 complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MQ6">6MQ6</a>/6AZW, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C), the inhibitors occupy both pockets A and D in stretched conformations: (i) the phenyl group occupies hydrophobic pocket A, and the propanamide moiety is further secured by hydrogen bonds (H-bonds) from Ser167 and His346; (ii) the quinoline group extends to the additional pocket and is surrounded by a group of hydrophobic residues, including Phe270, Leu342, and Ala174, which is further stabilized by π-stacking with Phe270 and an H-bond with Arg343.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a></div><div class="NLM_p">Through deep analysis of the crystal structure, it has been realized that the binding pocket of IDO1 is shaped according to the bound inhibitor.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Diverse inhibitors may induce conformational rearrangements that further change the volume of the catalytic site. Recent studies have suggested that binding of inhibitors in the S<sub>a</sub> site may also induce conformational changes in the remote small domain in NTD, indicating that inhibitors may further affect signaling and contribute to additional efficacy.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In addition to catalytic activity, IDO1 also acts as a signal-transducing molecule that plays a basic role in immunological and inflammatory modulation.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> The IDO1 signaling function relies on two ITIMs (ITIM1 and 2) that are both located quite distant from the catalytic site (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). Phosphorylated ITIMs act as docking sites that allow IDO1 to associate with different molecular partners responsible for different physiological effects: phosphorylation of ITIM1 triggers immunosuppressive effects by binding to the protein tyrosine phosphatases (SHP1 and SHP2) and inducing sustained IDO1 expression; in contrast, phosphorylated ITIM2 binds to the suppressor of cytokine signaling 3 (SOCS3) and accelerates proteasomal degradation of IDO1, which promotes inflammatory responses.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33">(30−33)</a></div><div class="NLM_p last">Structure-based drug design (SBDD) is an efficient approach in modern drug development for specific targets, but a deeper insight into hIDO1–ligand interactions within the binding site of the target is necessary. <i>In silico</i> virtual screening (VS) has attracted attention as a complementary approach to high-throughput screening (HTS) and has contributed to the identification of novel IDO1 inhibitors in many cases. Despite 45 entries of IDO1 structures that have been disclosed in the protein data bank (PDB) database (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00925/suppl_file/jm0c00925_si_001.pdf" class="ext-link">Table S1</a>), few of these entries have been employed in the VS campaign.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> The flexibility of IDO1 may cause problems for IDO1 docking studies, as the binding region in the receptor is usually held rigid compared to ligands.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Another issue is that the presence of heme iron interacts with the ligands in the docking experiment, and importantly, it has been difficult to reliably describe the electronic environment of the heme in computational simulation. Hence, pretests, such as native-docking and cross-docking processes based on the reported IDO1 crystallographic coordinates, might be beneficial prior to a VS campaign.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Structures and Biofunctions of TDO and IDO2</h3><div class="NLM_p">Although the focus in targeting the Trp-Kyn pathway has been largely on IDO1, two other related Trp metabolism enzymes have also been considered potential therapeutic targets. Importantly, recent observations, as well as clinical outcomes, have supported that the development of combined IDO/TDO inhibitors may represent an advanced and future strategy in this field.<a onclick="showRef(event, 'ref22 ref48'); return false;" href="javascript:void(0);" class="ref ref22 ref48">(22,48)</a> The TDO enzyme is a homotetramer with a distinct structural basis compared to IDO1, while the distal heme pocket in the S<sub>a</sub> site of TDO is similar to that of IDO1.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The recently disclosed crystal structures of TDO–substrate and inhibitor complexes (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYY">6PYY</a>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>D) have revealed structural insights into TDO, including (i) the S<sub>a</sub> site in TDO has been observed to be rigid in contrast to IDO1, which may be responsible for restricting substrate selectivity and further imply the challenge of characterizing specific scaffolds of potent TDO inhibitors, (ii) the indole-based compounds occupy pocket “A” with their indole groups, where the indole rings are surrounded by a set of hydrophobic residues, including Phe72, Leu46, and Phe45, and the N atoms of indole scaffolds interact with His76 (equivalent to Ser167 of IDO1) through an H-bond, while the succinimide moieties extend to pocket “B” and are further anchored by Arg144, which could be considered Arg231 in IDO1, and (iii) pocket “D” on the proximal side of the enzyme is blocked by bulky residues; correspondingly, a distant exo site exists and binds to Trp for cellular stability rather than catalytic activity.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a></div><div class="NLM_p last">In addition, the IDO2 protein shares 43% sequence homology with IDO1 but exhibits distinct physiological activities.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Observations have suggested that IDO2 may be part of the feedforward loop of IDO1-induced Trp metabolism, as the IDO2 gene is regulated in response to the downstream AhR of the IDO1 pathway.<a onclick="showRef(event, 'ref8 ref51'); return false;" href="javascript:void(0);" class="ref ref8 ref51">(8,51)</a> IDO2 has also emerged as a potential target, and recent studies have reported several compounds with micromolar IC<sub>50</sub> values against IDO2, whereas challenges remain in the establishment of IDO2 enzymatic assays and avoidance of cross-reactivity to IDO1.<a onclick="showRef(event, 'ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54">(52−54)</a> As a homologue of IDO1, IDO2 comprises an active site similar to IDO1, which may support the correlation of dual inhibitory activity of IDO1/IDO2.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, IDO2 exhibits extremely low activity of Trp degradation only <i>in vitro</i>, and the biological significance of IDO2 has also been questioned in the literature.<a onclick="showRef(event, 'ref24 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref24 ref55 ref56">(24,55,56)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Mechanism of IDO1 and Its Inhibition</h3><div class="NLM_p">Studies have shown the low substrate specificity of IDO1 and that other indole-bearing compounds (e.g., melatonin, serotonin, and tryptamine) could serve as substrates.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> With the help of a heme cofactor, IDO1 oxidatively cleaves the 2,3-position of the indole ring in Trp to produce NFK using dioxygen. To initiate the reaction, the reduced ferrous (Fe<sup>2+</sup>) state of heme iron is required, and a reductant is necessary to reactivate the enzyme as IDO1 is prone to autoxidation. Therefore, ascorbate and methylene blue (MB) are usually employed for enzymatic assays <i>in vitro</i>. It has been shown that two substrates of IDO1 are involved in the catalytic cycle, including Trp and O<sub>2</sub>. Binding of O<sub>2</sub> to the heme cofactor is recognized as the first step prior to the binding of Trp.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> Accordingly, a heme superoxide intermediate is formed and consequently attacks Trp via two possible pathways: an electrophilic addition or a radical addition.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> These two additional reactions both contribute to the formation of another key intermediate, Trp epoxide, as the precursor of the ring-opening product.</div><div class="NLM_p">The substrate inhibition behavior of IDO1 at a high-level concentration of Trp was previously noted, but the mechanism is still under debate.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> It has been suggested that this substrate-controlled regulation is responsible for balancing levels of Trp-Kyn pathway metabolites when dietary Trp levels increase.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Previous studies indicated that substrate inhibition of IDO1 might be a result of the reversed binding order of O<sub>2</sub> and Trp when Trp is present at high levels.<a onclick="showRef(event, 'ref60 ref64'); return false;" href="javascript:void(0);" class="ref ref60 ref64">(60,64)</a> Interestingly, recent studies by Yeh et al. reported that a second Trp could bind to the inhibitory S<sub>i</sub> site, suggesting an explanation for the substrate inhibition behavior (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).<a onclick="showRef(event, 'ref34 ref65'); return false;" href="javascript:void(0);" class="ref ref34 ref65">(34,65)</a> Questions about this mechanism remain as Trp binding to pocket D was only detected in the F270G mutant of hIDO1. That is, bulky residues in wild-type IDO1, including Phe214 and Phe270, may restrict the accessibility of pocket D. A recent study by this group revealed that substrate-induced inhibition is a result of Trp epoxide detaining, which was rescued by an effector 3-indole ethanol (IDE) bound in pocket D.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Furthermore, the S167H mutant in IDO1, which abolishes enzymatic activity, is implicated in slowing O<sub>2</sub> binding with ferrous heme.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> A more recent study by Mondanelli et al. indicated that the Trp metabolite <i>N</i>-acetylserotonin potentiates IDO1 catalytic activity as a positive allosteric modulator by binding to pocket D of IDO1.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> In general, these independent studies revealed the possible biological function of the S<sub>i</sub> site in modulating enzymatic activity and further supported pocket D as a potential binding site for IDO1 inhibition.</div><div class="NLM_p">Based on current understanding, present IDO1 inhibitors are classified according to their inhibition kinetics. Recently, Röhrig et al. proposed a classification comprising 5 defined types of IDO1 inhibitors.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Type I, II, and III inhibitors bind to heme-bound IDO1 in the S<sub>a</sub> site and prevent the initial steps of substrate binding, whereas type IV inhibitors (e.g., BMS986205) occupy the heme-free apo-IDO1 for inhibition activities. Specifically, type I inhibitors (e.g., L-1 MT, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) bind to O<sub>2</sub>-bound heme IDO1 in competition with Trp, while type II inhibitors (e.g., epacadostat) interact with active ferrous-heme (Fe<sup>2+</sup>) and compete with O<sub>2</sub> for the six-iron binding site. Compounds such as 4-phenylimidazole (4PI, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), which has been suggested to bind to ferric-heme IDO1 and hinder the reductive reactivation of enzymes, are described as type III inhibitors. In addition, compounds with an inhibitory activity that act by perturbing the redox cycle, particularly quinone-based compounds, do not specifically target the IDO1 enzyme and are thus defined as type X inhibitors.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative structures of imidazole/triazole derivatives in recent literature. (A) Phenyl-imidazole derivatives and tricyclic fused phenyl-imidazole derivatives. PDB codes for hIDO1–4PI and hIDO1–<b>4</b> are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2D0T">2D0T</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O3I">6O3I</a>. (B) Imidazothiazole derivatives. PDB codes for hIDO1–<b>25</b> and hIDO1–<b>28</b> are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5">4PK5</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KOF">6KOF</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Assays for Screening IDO1 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The common preliminary evaluation employed in compound screening is indicated by target inhibitory assays based on either recombinant human IDO1 (rhIDO1) protein or cell lines, through monitoring and detecting concentration changes in Trp or enzymatic reaction products. Literature by Röhrig et al. and related references have exhaustively described and explained the enzymatic assays and cellular assays of small molecular compounds that induce IDO1 inhibition.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> It should be noted that, in many cases, inhibitory values in the cellular assay may be better than results from the enzyme-based assay, which is unusual, as various issues, including permeability, may lower the potency in cellular conditions. The incompetent rhIDO1 protein environment and complex catalytic cycle <i>in vivo</i> have been considered responsible for divergent results, such as different pH values, different reducing cofactors, and oxidation states.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Intriguingly, studies of newly characterized heme-competitive inhibitors have indicated that these compounds display the most significant inhibitory activities with single-digit nanomolar IC<sub>50</sub> values in cellular assays, whereas insufficient potency was observed in enzymatic assays, except under prolonged incubation times and elevated temperatures.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> On the other hand, testing quinone-based inhibitors in enzymatic assays usually leads to nanomolar potency. In the cell-based assay, quinones could undergo redox cycling in the cellular environment; therefore, cytochrome P450 reductase/NADPH and cytochrome b5 could be used as reductants to clarify the inhibitory results.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p last">In cellular assays, IDO1 protein is initially expressed by tool cells under certain stimulation conditions prior to treatment with test compounds. Expression of IDO1 protein is usually achieved in two ways: (i) stimulating cells with interferon γ (IFNγ) and (ii) transfecting cells with <i>ido1</i> recombinant plasmid. The IFNγ-stimulated cell line employed in IDO1 cellular evaluation could be a cancer cell line, including HeLa, MDA-MB-231, THP1, SKOV3, A375, LXF289, MCF7, HepG2, and DAN-G cells, or human whole blood and peripheral blood mononuclear cells. On the other hand, the HEK293 cell line is commonly used to express IDO1 protein before performing cellular assays, as well as murine P1. HTR cells.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">IDO1 Inhibitors in Clinical Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Recent years have witnessed many attempts to identify and develop potential IDO1 inhibitors since the participation of IDO1 in oncogenesis was first uncovered in 2003.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Despite a large number of IDO1 inhibitors reported in the literature and patent applications, only a few compounds have entered clinical trials. To the best of our knowledge, eight remaining new chemical entity (NCE) candidates for use as IDO1 inhibitors are currently undergoing clinical evaluation for the treatment of cancers as monotherapies or in combination with ICIs. Notably, only six candidates have been structurally disclosed, including three advanced compounds that have entered phase 3 clinical evaluation (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Despite promising results that have emerged in preclinical and initial studies, negative outcomes of potential candidates in the past 2 years have brought the viability of IDO1 inhibition into question and urged essential speculation and further evaluation of this approach. Recent studies have highlighted the clinical progression of IDO1 inhibitors;<a onclick="showRef(event, 'ref7 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref7 ref70 ref71">(7,70,71)</a> here, we briefly present the structural basis of small-molecule clinical candidates with recent advances and opinions on IDO1 inhibitors in clinical trials.</div><div class="NLM_p">Trp analogue <b>1</b> (indoximod, NLG8189, D-1 MT, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) is the first clinical candidate developed by NewLink Co., Ltd. and has been evaluated in a phase 3 clinical trial administered with ICIs beginning in 2017 for the treatment of melanoma. In addition, the prodrug form of <b>1</b> coded NLG802 (<b>6</b>) entered phase 1 clinical trials in 2017.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> However, <b>1</b> and its prodrug are not specific IDO1 inhibitors (hIDO1 IC<sub>50</sub> > 100 mM, HeLa IDO1 IC<sub>50</sub> > 2.5 mM for <b>1</b>), and their mechanism of action remains controversial.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Indeed, studies have suggested that <b>1</b> has pleiotropic effects on downstream signaling of the Trp-Kyn pathway.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> Another IDO1 inhibitor <b>2</b> (epacadostat, INCB24360, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) is an <i>N</i>-hydroxyamidine derivative developed by Incyte Co., Ltd., through the HTS strategy and the first candidate compound entered phase 3 as a selective IDO1 inhibitor (hIDO1 IC<sub>50</sub> = 73 nM, HeLa IDO1 IC<sub>50</sub> = 7.4 nM).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Unexpectedly, the first large phase 3 trial (ECHO-301/KEYNOTE-252) did not meet its two end points and was terminated in April 2018; namely, <b>2</b> did not provide evidential benefit for survival.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Questions and discussions have emerged regarding this failure. One of the key phenomena is that inhibition of Kyn was insufficient <i>in vivo</i>, which may be a result of multiple factors, including selective IDO1 inhibition.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Despite the negative outcomes of clinical studies, <b>2</b> has served as a model lead for numerous mimics, as the <i>N</i>-hydroxyamidine scaffold exhibits good potential for inhibitory activities.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The quinoline-containing compound <b>3</b> (BMS-986205, linrodostat, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) from Bristol-Myers Squibb Co. (originator Flexus) is a heme-competitive inhibitor (also defined as “suicide inhibitor” in the literature) that exhibits the best cell-based potencies (HeLa IDO1 IC<sub>50</sub> = 0.5 nM).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In 2018, Bristol-Myers Squibb launched a large phase 3 clinical trial of <b>3</b> to recruit 1200 patients with bladder cancer.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Recently, however, two of the phase 3 trials with head and neck squamous cell carcinoma (HNSCC) and nonsmall cell lung cancer (NSCLC) to evaluate <b>3</b> have been withdrawn due to changed business objectives. The 4-phenylimidazole derivative <b>4</b> (navoximod, GDC0919, NLG919, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) is another approach of NewLink Co., Ltd. and has finished its phase 1 trial as a selective IDO1 inhibitor (hIDO1 IC<sub>50</sub> = 28 nM, 293 IDO1 EC<sub>50</sub> = 75 nM).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Despite the moderate IDO1 inhibitory activity and preclinical antitumor efficacy, a further clinical program using <b>4</b> ceased in 2017. Recent literature by Kumar et al. systematically described the discovery of this tricyclic compound and revealed the structural basis of its activity.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Indole-based compound <b>5</b> (PF-06840003, EOS-200271, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) from Pfizer Inc. (originator iTeos) is a selective IDO1 inhibitor (hIDO1 IC<sub>50</sub> = 0.41 μM, HeLa IDO1 IC<sub>50</sub> = 1.8 μM), which has been evaluated in phase 1 clinical trials for the treatment of malignant gliomas.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Similarly, further clinical development of <b>5</b> was suspended in 2018. The <b>5</b>-bearing indole group has been a reliable scaffold for medicinal researchers as a mimic of Trp, especially in the preliminary stage. However, the reported indole derivatives usually show moderate potencies with micromolar activities. Indoline derivative <b>7</b> (LY3381916, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was developed by Lilly as a selective IDO1 inhibitor and has been in phase 1 clinical evaluation for the treatment of cancer since 2017. Compound <b>7</b> was reported to act as a heme-competitive inhibitor with a single-digit nanomolar IC<sub>50</sub> value (cell IDO1 IC<sub>50</sub> = 7 nM) in a cell-based assay.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> However, in 2020, this phase 1 trial was terminated.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> In addition, another two undisclosed IDO1 inhibitors, KHK-2455 from Hakko Kirin and MK-7162 from Merck, are currently under active phase 1 trials for the treatment of unspecific solid tumors.<a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82,83)</a></div><div class="NLM_p last">Notably, in 2019, a phase 1 program launched by Hengrui Co., Ltd., to evaluate HTI-1090 (SHR-9146, structure undisclosed) as an IDO1/TDO dual inhibitor was completed, and further evaluation was planned.<a onclick="showRef(event, 'ref28 ref84'); return false;" href="javascript:void(0);" class="ref ref28 ref84">(28,84)</a> Subsequently, another IDO1/TDO dual inhibitor DN1406131 (structure undisclosed) developed by De Novo Pharmatech has entered a phase 1 trial for the treatment of cancer.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Recently Disclosed IDO1 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33871" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33871" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A large variety of compound series has emerged as IDO1 inhibitors in recent years. In previous studies, some IDO1 inhibitors have been classified according to their structural scaffolds, providing a significant foundation for researchers in this field.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Hence, in the following section, we primarily focus on renewing the classification and updating the recently published IDO1 inhibitors based on their structural basis and interaction details during the period of 2016–2020.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Inhibitors Targeting the S<sub>a</sub> Site of holoIDO1</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Trp/Indole Analogues</h4><div class="NLM_p">Many Trp analogues or indole-based scaffolds were first identified as IDO1 inhibitors and provided important proof-of-principle demonstrations in early stages.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> 1-Methyl-Trp (1 MT) has been the most frequently used IDO1 inhibitor, showing moderate inhibitory activities. However, two stereoisomers of 1-MT exhibit distinct potencies: (i) D-1 MT (<b>1</b>), described above, is a clinical candidate in a phase 3 trial as a Trp-Kyn pathway inhibitor and does not inhibit IDO1 <i>in vitro</i>; (ii) on the other hand, L-1 MT (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) serves as the substrate competitor and inhibits IDO1 with moderate activity (hIDO1 IC<sub>50</sub> = 42 μM, HeLa IDO1 IC<sub>50</sub> = 18.4 μM).<a onclick="showRef(event, 'ref47 ref85'); return false;" href="javascript:void(0);" class="ref ref47 ref85">(47,85)</a> Previously, Trp-derived inhibitors were typically reported with moderate inhibitory activities that bear an indole group and various side chains. Recently, disclosed structures of IDO1–indole complexes have revealed that the indole group stands perpendicular on the heme group, and importantly, the N atom is adjacent to Ser167 and does not directly coordinate to the iron in heme.<a onclick="showRef(event, 'ref34 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref37">(34,37)</a> This unique binding mode could be a specific feature of Trp/indole analogues, and the lack of coordination with heme iron may be responsible for their moderate potencies.</div><div class="NLM_p">In 2016, Coluccia et al. reported a series of indole derivatives as IDO1 inhibitors based on a VS campaign, and 3-arylthioindole derivative <b>9</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) was identified with moderate activity (hIDO1 IC<sub>50</sub> = 7 μM).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Subsequently, another 3-substituted indole derivative <b>10</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) was identified through a VS campaign and was further demonstrated to be a potential lead with moderate binding affinity and inhibitory activity (hIDO1 <i>K</i><sub>d</sub> = 17.8 μM, cell-based IDO1 IC<sub>50</sub> = 14.4 μM).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Similar to 1 MT, recent studies have reported that two enantiomers of clinical candidate <b>5</b> showed distinct priority in inhibitory activities, whereas candidate <b>5</b> has been clinically employed as a racemic complex.<a onclick="showRef(event, 'ref37 ref88'); return false;" href="javascript:void(0);" class="ref ref37 ref88">(37,88)</a> Interestingly, it was shown that compound <b>11</b> (PF-06840002, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), which is the <i>R</i>-enantiomer of <b>5</b>, functions as an enantiomer and is approximately 190-fold more potent than the inactive <i>S</i>-enantiomer (hIDO1 IC<sub>50</sub> = 0.20 μM and HeLa IDO1 IC<sub>50</sub> = 1.0 μM for <b>11</b> versus hIDO1 IC<sub>50</sub> > 10 μM and HeLa IDO1 IC<sub>50</sub> = 13 μM for <i>S</i>-<b>5</b>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Although racemate <b>5</b> (hIDO1 IC<sub>50</sub> = 0.41 μM, HeLa IDO1 IC<sub>50</sub> = 1.8 μM) is less potent than the active enantiomer, rapid autoracemization of <b>11</b> in plasma negated the benefits of using a single enantiomer for further tests.<a onclick="showRef(event, 'ref37 ref88'); return false;" href="javascript:void(0);" class="ref ref37 ref88">(37,88)</a> The crystal structure of the hIDO1–<b>11</b> complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WHR">5WHR</a>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) indicated that the succinimide ring lies parallel to the heme without direct interaction with iron, while the indole group stands perpendicular to the heme, interacts with Ser167, and occupies pocket A.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">Some indole analogues have also been developed as IDO1 inhibitors in recent years. In 2016, Pantouris et al. reported an oxindole derivative <b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B) based on the isatin scaffold as an IDO1/TDO dual inhibitor (hIDO1 <i>K</i><sub>i</sub> = 1 μM, hTDO <i>K</i><sub>i</sub> = 4 μM).<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The next year, Paul et al. reported a series of 3-substituted oxindoles as selective IDO1 inhibitors with submicromolar activities, including 1-(5-chloro-2-oxoindolin-3-ylidene)pentane-2,4-dione <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B, hIDO1 IC<sub>50</sub> = 0.19 μM, MDA-MB-231 IDO1 IC<sub>50</sub> = 0.33 μM).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Importantly, the <i>in silico</i> docking experiments indicated that the oxindole derivatives bind to IDO1 with a typical “indole-like” binding mode, except 2-carbonyl orienting to heme.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> A more recently published study by Cui et al. reported their efforts in investigating indole-2-carboxylic acid derivatives for IDO1 inhibition.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The most potent compound <b>14</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B) exhibited dual inhibitory activities against IDO1/TDO with IC<sub>50</sub> values of 1.17 μM and 1.55 μM, respectively. SAR studies revealed that the 2-carboxyl group is essential for inhibitory activity, which was further demonstrated to be an electron donor for binding with a key residue rather than heme iron. Interestingly, one oxidation product (9p-O from ref <a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a>) was accidentally found and exhibited significant improvement of inhibitory activity (hIDO1 IC<sub>50</sub> = 18 nM, hTDO IC<sub>50</sub> = 25 nM) compared to the original compound in the enzymatic assay.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> However, most of the compounds exhibited poor activities in cellular assays, and attention should be paid to the fact that the autoxidation reaction and the oxidative product 9p-O (a benzoquinone derivative) could both affect the oxidation state of IDO1 for enzymatic inhibitory activity.</div><div class="NLM_p last">In addition, a group of indazole derivatives has shown promising potential in IDO1 inhibition. Qian and co-workers reported the discovery of 4,6-substituted-1<i>H</i>-indazoles as IDO1 inhibitors with micromolar IC<sub>50</sub> values (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C).<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> It was demonstrated that a halogen atom at the 6-position is important for the inhibitory activity, and <b>15</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) emerged as an initial lead (hIDO1 IC<sub>50</sub> = 5.3 μM).<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Later, in a separate study, the authors optimized the side chains at the 4-position and reported <b>16</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) bearing the benzo-oxadiazole group with improved potency (hIDO1 IC<sub>50</sub> = 0.74 μM, HeLa IDO1 IC<sub>50</sub> = 1.37 μM), which further exhibited antitumor efficacy <i>in vivo</i>.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Simultaneously, Tsujino et al. reported another 4,6-disubstituted indazole <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) with moderate binding affinity to ferrous hIDO1 (<i>K</i><sub>d</sub> = 0.14 μM).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Importantly, the direct coordination between a model compound of 4-trimethylsilyl-6-methyl-1<i>H</i>-indazole (compound <b>1</b> in ref <a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a>) and IDO1 was observed through a spectroscopy test. A further docking study of <b>17</b> suggested that the indazole ring stands perpendicular to the heme group, while the phenylethanol moiety on the C4 position extends to pocket B. These results may indicate that the indazole derivatives are more like inhibitors of the following group according to their similar binding mode.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Imidazole/Triazole Derivatives</h4><div class="NLM_p">The first lead scaffold was 4PI (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). 4PI is a known heme binder that was previously identified as a weak IDO1 inhibitor (hIDO1 IC<sub>50</sub> = 48 μM) in 1989, and its cocrystallization with IDO1 (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2D0T">2D0T</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) first revealed its interaction as an inhibitor in the binding site in 2006.<a onclick="showRef(event, 'ref14 ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref14 ref95 ref96">(14,95,96)</a> It has been recognized that 4PI is located at the S<sub>a</sub> site and coordinates to the heme iron through its N1 atom of the imidazole group and occupies pocket A with a phenyl group. In addition, pocket B is further occupied by two molecules of 2-(<i>N</i>-cyclohexylamino)ethane sulfonic acid in this crystal form, which is the additive component of the crystallization buffer. These initial crystal structures have paved the way for structure-based <i>in silico</i> design of IDO1 inhibitors and provided a structural basis for developing phenylimidazole derivatives based on the binding mode. The previous modification of the lead 4PI has been focused on screening substituents on the phenyl group and has led to various derivatives with minor optimization and moderate IC<sub>50</sub> values. Recently, further screening of phenylimidazole derivatives has been reported with significantly improved potencies by searching for additional interactions in unoccupied pocket B. In 2016, Fallarini et al. screened a series of disubstituted imidazole derivatives based on an <i>in silico</i> strategy for better IDO1 inhibition.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> According to subsequent evaluation, 4,5-diaryl-substituted derivatives emerged with improved activities, including <b>18</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, hIDO1 IC<sub>50</sub> = 2.8 μM, A375 IDO1 IC<sub>50</sub> = 2.9 μM), whereas 1,5-disubstituted compounds almost showed inefficiency in this screening. The docking pose of <b>18</b> indicated that the designed <i>p</i>-acetamidophenyl group may extend into pocket B, while the 4-phenyl imidazole motif is similar to lead 4PI. In subsequent work, 1,5-disubstituted imidazole derivatives were reported with nanomolar activities in enzymatic assays and lower micromolar activities in cellular assays. Specifically, <b>19</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) with a 5-fluoroindole group at the N1-position, which was speculated to bind in pocket B, showed the most potent activity for IDO1 inhibition (hIDO1 IC<sub>50</sub> = 33.8 nM, HEK293 IDO1 IC<sub>50</sub> = 0.26 μM).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The chlorophenol ring may occupy pocket A and be stabilized by an interaction between the hydroxyl group and Ser167, which shares a common scaffold with a previously reported 4-phenyl-1,2,3-triazole IDO1 inhibitor <b>20</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, hIDO1 IC<sub>50</sub> = 0.33 μM).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> However, bioisosteric replacements of the imidazole ring in 4PI with various five-membered nitrogen-containing rings have shown high selectivity in enzymatic inhibition due to their complicated electronic nature.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Röhrig et al. further evaluated and reported the potential of 4-phenyl-1,2,3-triazole derivatives as IDO2 inhibitors that showed selectivity toward IDO1.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> In 2018, 4-amino-1,2,3-triazole <b>21</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) was discovered through HTS with potent cellular activities (HeLa IDO1 IC<sub>50</sub> = 23 nM, HEK293 IDO1 IC<sub>50</sub> = 67 nM); however, much weaker enzymatic inhibitory activity was observed (hIDO1 IC<sub>50</sub> = 11.3 μM).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> According to the cocomplex crystal of <b>21</b>-bound IDO1 (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F0A">6F0A</a>), <b>21</b> is located at pocket A of IDO1 in a binding mode similar to that of 4PI, including one additional buffer-sourced <span class="smallcaps smallerCapital">l</span>-alanine molecule in pocket B interacting with Arg231, propionate group of heme, and N3 atom of <b>21</b>. Importantly, extended kinetic and spectroscopic studies demonstrated that <b>21</b> is prone to forming a tighter complex with ferrous IDO1 (<i>K</i><sub>d</sub> = 2.3 μM) compared to ferric IDO1 with the slow association and dissociation kinetics, which shows, namely, a distinct inhibitory mechanism with 4PI. Later, in 2019, Panda et al. reported 4,5-disubstituted 1,2,3-triazole derivatives with nanomolar activities both in enzymatic and cellular IDO1 inhibition assays and potent activities in an <i>in vivo</i> antitumor assay.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The initial compound <b>22</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) with a carboxamide group at the C4-position showed good potencies (hIDO1 IC<sub>50</sub> = 110 nM, MDA-MB-231 IDO1 EC<sub>50</sub> = 74 nM), while further optimization, including installing a sulfamide group in the 4-carboxamide moiety (compound <b>4k</b> from ref <a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a>) for occupying pocket B, barely improved the inhibitory activities (hIDO1 IC<sub>50</sub> = 92 nM, MDA-MB-231 IDO1 EC<sub>50</sub> = 74 nM).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Compounds <b>20</b>–<b>22</b> are examples of potent inhibitors that only occupy pocket A.</div><div class="NLM_p">Tricyclic compounds bearing the fused phenyl-imidazole scaffold were initially described in an application of NewLink Co., Ltd., as potent IDO1 inhibitors in 2012.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Indeed, the search for phenylimidazole derivatives as IDO1 inhibitors has been intensely pursued by NewLink, and tricyclic imidazoisoindoles were then developed as a result of rational drug design based on lead 4PI. Reducing the rotatable bonds for molecular rigidification has been a potential strategy for improving the binding affinity and potency of small-molecule inhibitors, which was successful and led to the discovery of clinical candidate <b>4</b> according to a recently disclosed literature by NewLink.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Fused rigid imidazo[5,1-<i>a</i>]isoindole initially emerged as a promising lead with improved IDO1 inhibitory activity (hIDO1 IC<sub>50</sub> = 5.7 μM) through incorporating a methylene linker at the N1 and 2′-positions of 4PI, and the related derivative with ethylcyclohexyl at the C5-position was subsequently found with an enzymatic IC<sub>50</sub> value of 0.135 μM. Further optimization for the purpose of interacting with the propionate group of heme and Ser235 or Arg231 of pocket B was achieved by introducing additional hydroxyl groups at the C11 and C15 positions, which finally led to <b>4</b> as selective IDO1 inhibitors with nanomolar activities (hIDO1 IC<sub>50</sub> = 28 nM, 293 IDO1 EC<sub>50</sub> = 75 nM). Importantly, the cocrystal structure of <b>4</b> bound to IDO1 (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O3I">6O3I</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) revealed that the imidazoisoindole core coordinates to heme iron with the N2 atom, and the phenyl group fits in hydrophobic pocket A, which may account for the dramatic and negative impact of halogen substituents at the C7 or C8 position.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In addition, imidazoisoindole <b>23</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), bearing a longer side chain, was reported by Lai’s group in 2017 with moderate activities in a cellular assay (HeLa IDO1 IC<sub>50</sub> = 0.84 μM).<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> In subsequent work, another imidazoisoindole derivative, <b>24</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), was developed by Hengrui as a potent IDO1/TDO dual inhibitor with nanomolar activities in both enzymatic and cellular assays (hIDO1 IC<sub>50</sub> = 9.7 nM, HeLa IDO1 IC<sub>50</sub> = 76 nM, hTDO IC<sub>50</sub> = 47 nM) and exhibited favorable pharmacokinetic (PK) properties, including improved cytochrome p450 enzyme inhibition profiles.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Docking studies indicated that the extended side chain stuck deeper into pocket B, while the methylpyrazol group engaged in a cation−π interaction with Arg231, which was speculated to be a reason for potent IDO1 inhibitory activity.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><div class="NLM_p last">Thiazolotriazole <b>25</b> (AMG-1, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) was initially developed by Amgen in 2011 through the HTS strategy and was reported as a selective IDO1 inhibitor with an IC<sub>50</sub> value of 3 μM.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Later, the crystal structure of the hIDO1–<b>25</b> complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5">4PK5</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) confirmed the coordination between the N atom of triazole and heme iron, which led to the identification of imidazothiazole derivatives with nanomolar activities.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Recently, imidazothiazole <b>26</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) was reported by Pirali et al. with moderate activity (hIDO1 IC<sub>50</sub> = 0.2 μM), and in their subsequent work, compound <b>27</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) was synthesized, exploiting click chemistry, and showed equivalent inhibitory activity (hIDO1 IC<sub>50</sub> = 0.2 μM).<a onclick="showRef(event, 'ref39 ref106'); return false;" href="javascript:void(0);" class="ref ref39 ref106">(39,106)</a> Among the reported compounds, <i>p</i>-bromophenyl at the C3-position was demonstrated to be crucial for activity, whereas a linearly rigid linker bearing hydroxyl or cyano groups at its terminus was beneficial for interacting with Phe226 and Arg231 in pocket B.<a onclick="showRef(event, 'ref39 ref105'); return false;" href="javascript:void(0);" class="ref ref39 ref105">(39,105)</a> A more recent study reported the discovery of thiourea-based <b>28</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), a highly potent IDO1 inhibitor (hIDO1 IC<sub>50</sub> = 16.4 nM), through rational structural optimization.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> The S1 atom of the imidazothiazole core forms an S–O interaction with gate residue Ser167, and specifically, the unique (prop-1-ynyl)-cyclopropane moiety at the C3-position occupies pocket A and forms an additional interaction with Cys129 via the cyclopropane ring, which exhibits a π-like property.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Furthermore, the cocrystal structure of hIDO1–<b>28</b> (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KOF">6KOF</a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) also revealed that an additional sulfur–aromatic interaction network was established between the thiourea moiety and the neighboring Phe163/Phe226, which may account for a 6-fold improvement in IDO1 inhibition compared to urea-based <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B, hIDO1 IC<sub>50</sub> = 102 nM).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> However, imidazothiazole inhibitors usually showed moderate to weak potency for inhibiting IDO1 in cellular assays, despite effective activities in enzymatic assays, which might be explained by poor membrane permeability.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> <i>N</i>-Hydroxyamidine Derivatives</h4><div class="NLM_p">The <i>N</i>-hydroxyamidine scaffold was initially identified through HTS of Incyte’s corporate collection and led to the discovery of <b>30</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, INCB14943) as a potential lead with nanomolar activities (hIDO1 IC<sub>50</sub> = 75 nM, HeLa IDO1 IC<sub>50</sub> = 19 nM).<a onclick="showRef(event, 'ref76 ref108'); return false;" href="javascript:void(0);" class="ref ref76 ref108">(76,108)</a> Further optimization of incorporating polar side chains at the C4-position of the amino-furazan core provided highly potent derivatives with improved PK profiles, including clinical candidate <b>2</b> (hIDO1 IC<sub>50</sub> = 73 nM, HeLa IDO1 IC<sub>50</sub> = 7.4 nM).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> As described above, the <i>N</i>-hydroxyamidine derivatives were mostly observed to coordinate heme iron with the O atom and occupy both pockets A and B with the halogenated phenyl and their side chain, respectively.<a onclick="showRef(event, 'ref34 ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref34 ref109 ref110">(34,109,110)</a> One exception is that <b>30</b> was reported to bind to the heme iron through the N atom of the oxime moiety (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XE1">5XE1</a>).<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Subsequently, Röhrig et al. published their work in resolving the optimized binding mode of <b>30</b> in IDO1 using combined <i>in silico</i> calculations and proposed that compounds of the <i>N</i>-hydroxyamidine family are prone to bind through their deprotonated oxygen atom to heme.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> It has been recognized that the <i>N</i>′-halogenphenyl-1,2,5-oxadiazole-3-carboximidamide core plays a fundamental role in IDO1 inhibition, while the side chain at the C4-position shows a minor impact on potency. Recently reported <i>N</i>-hydroxyamidine-based inhibitors usually exhibit nanomolar activities with well-designed side chains for various purposes, including pursuing better PK profiles or multitargeting effects (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In 2019, Zhang et al. reported a series of <i>N</i>-hydroxyamidine derivatives through the rigidification strategy based on the original HTS hit of <b>30</b>.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Among them, <b>31</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) emerged and selectively inhibited IDO1 with IC<sub>50</sub> values of 81 nM and 49 nM in the enzymatic and HeLa cellular assays, respectively.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> After screening side chains, <b>31</b> exhibited the best potential as a combination of good IDO1 inhibition and improved metabolic stability.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Recently, a group of phosphonamidite-based derivatives was screened and discovered as potential IDO1 inhibitors and initially found that lead <b>32</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) showed the most potent <i>in vitro</i> and <i>in vivo</i> activities (hIDO1 IC<sub>50</sub> = 104 nM, HeLa IDO1 IC<sub>50</sub> = 10.1 nM).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Furthermore, derivative <b>33</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) with an extended side chain was identified with improved antitumor efficacies in multiple <i>in vivo</i> models, which could be ascribed to enhanced Trp-Kyn pathway inhibition according to subsequent evaluation.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> It was found that <b>33</b> exhibits pan activities across the three Trp metabolism enzymes IDO1/IDO2/TDO (hIDO1 IC<sub>50</sub> = 94 nM, HeLa IDO1 IC<sub>50</sub> = 12.6 nM, hIDO2 IC<sub>50</sub> = 310 nM, hTDO IC<sub>50</sub> = 2.6 μM), which may account for the enhanced potencies.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Recently, Meng’s group reported <i>N</i>-hydroxyamidine IDO1 inhibitors based on a cyclizing strategy that showed improved PK profiles and optimal safety.<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115,116)</a> Cycling the sulfamoylamino component of <b>2</b> led to <b>34</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) with IC<sub>50</sub> values of 56.2 nM and 33 nM in enzymatic and cellular assays, respectively.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> In addition, by incorporating a piperidine group into the side chain, <b>35</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) was obtained with improved PK properties, despite diminished IDO1 inhibitory activities (hIDO1 IC<sub>50</sub> = 178 nM, HEK293T IDO1 IC<sub>50</sub> = 68 nM).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> In more recent studies, <i>N</i>-hydroxyamidine inhibitors with sulfonamide groups were reported. Steeneck et al. developed a sulfonamide-based derivative, <b>36</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), bearing a thioether-containing side chain that exhibited potent activities for IDO1 inhibition (hIDO1 IC<sub>50</sub> = 21 nM, SKOV3 IDO1 IC<sub>50</sub> = 10 nM) and improved metabolic stability against the glucuronidation pathway.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> In subsequent work, another sulfonamide-based derivative, <b>37</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), with a shorter side chain was reported by Zhao’s group with nanomolar activities (hIDO1 IC<sub>50</sub> = 71 nM, HeLa IDO1 IC<sub>50</sub> = 11 nM).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> In our previous work, isoindoline-based <b>38</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) was identified as a selective moderate IDO1 inhibitor (HeLa IDO1 IC<sub>50</sub> = 1.57 μM) with efficient <i>in vivo</i> antitumor effects.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> It was speculated that the potential metabolites of <b>38</b> might be much more effective in triggering tumor regression.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representative structures of <i>N</i>-hydroxyamidine derivatives. The PDB code for hIDO1–<b>30</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XE1">5XE1</a>. Colored structures represent different optimization strategies based on the scaffold of <b>30</b>. Blue represents extensions in pocket B, red represents aryl moieties in pocket A, and green represents the central oxadiazole moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition, maintaining the <i>N</i>-hydroxyamidine moiety, introducing a nitrobenzofurazan group at the <i>N</i>′-position, led to <b>39</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) with a distinct scaffold as a competitive IDO1 inhibitor.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Compound <b>39</b> was observed to selectively inhibit IDO1 in enzymatic (hIDO1 IC<sub>50</sub> = 59 nM) and cellular tests (MDA-MB-231 IDO1 IC<sub>50</sub> = 50 nM) with negligible cytotoxicity. In 2017, Lee et al. reported indazole-carboximidamide <b>40</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) with moderate activity of IDO1 inhibition (HEK293 IDO1 IC<sub>50</sub> = 2.13 μM).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Inhibitors Targeting apo-IDO1</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Heme-Competitive Inhibitors</h4><div class="NLM_p">As described above, apo-IDO1 has emerged as a potential target, which is further supported by recent literature. To our knowledge, most currently identified inhibitors in this class were discovered through HTS, and the mechanism of inhibition remains controversial (see the <a class="ref internalNav" href="#sec2_1" aria-label="Structure and Active Sites of IDO1">Structure and Active Sites of IDO1</a> section). It was demonstrated that these inhibitors showed the most potent activities in cellular assays with low nanomolar to picomolar cellular IC<sub>50</sub> values. In addition to clinical candidate <b>3</b>, <i>N</i>-aryl urea derivative <b>41</b> (BMS978587, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) was initially described in the published patent application of Bristol-Myers Squibb and subsequently reported to target apo-IDO1 with potent activity (HeLa IDO1 IC<sub>50</sub> = 4.2 nM).<a onclick="showRef(event, 'ref35 ref122'); return false;" href="javascript:void(0);" class="ref ref35 ref122">(35,122)</a> The crystal structure of the hIDO1–<b>41</b> complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZV">6AZV</a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A) revealed that the methylphenyl group extends to pocket A in a similar orientation as <b>3</b>/BMS116, while the 2-aminophenylurea core occupies the vacated heme pocket. H-bonds were observed between the carboxyl group and residues, including Ala264 and His346, the latter being a key residue for stabilizing the heme group. Unlike <b>3</b>, the diisobutylamino group of <b>41</b> did not extend deeply to pocket D, which may indicate that a bulky group is required. Simultaneously, in a preprint study by GlaxoSmithKline, another <i>N</i>-aryl urea derivative, <b>42</b> (GSK5628, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A), was reported to exhibit robust IDO1 inhibition in a cellular assay (HeLa IDO1 IC<sub>50</sub> = 5.9 nM) and in an enzymatic assay (hIDO1 IC<sub>50</sub> = 39 nM) when the preincubation time and temperature were increased.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> A similar mechanism of inhibition was demonstrated: <b>42</b> targeted IDO1 in its apo-form prevented the reloading of heme due to a higher binding affinity for apo-IDO1.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Further details of <i>N</i>-aryl urea derivatives reported in recent years are classified and summarized in the following group (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of heme-competitive inhibitors. PDB codes for hIDO1–<b>41</b> and hIDO1–<b>44</b> complexes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZV">6AZV</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V52">6V52</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative structures of (A) <i>N</i>-aryl urea derivatives and (B) preliminary SAR conclusions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More recently, a novel class of IDO1 inhibitors bearing a spiro piperidine-chromane motif was discovered by GlaxoSmithKline by screening a unique indole-based DNA-encoded library. Compound <b>43</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B) emerged as the most potent molecule with low nanomolar activities in PBMC (IDO1 IC<sub>50</sub> = 5.4 nM) and HeLa (IDO1 IC<sub>50</sub> = 7.9 nM) assays.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> SAR studies revealed that the <i>S</i>-conformation was essential for activity, as a 300-fold loss of potency was observed when testing the <i>R</i>-enantiomer. A much improved IC<sub>50</sub> value (hIDO1 IC<sub>50</sub> = 66.1 nM) of <b>43</b> in the enzymatic assay was obtained at a higher incubation temperature of 37 °C, while <b>43</b> was inactive at the common temperature of 25 °C. The spectroscopic study revealed that <b>43</b> is consistent with the known heme-competitive IDO1 inhibitor <b>42</b>, further indicating that <b>43</b> targets apo-IDO1 for inhibition. Importantly, a prodrug approach was deployed, as <b>43</b> exhibited poor solubility and bioavailability, and a phosphonooxymethyl prodrug was thus developed with significantly improved PK profiles.</div><div class="NLM_p last">Subsequently, Merck reported their work in discovering heme-competitive inhibitors <b>45</b> and <b>46</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Initial hit <b>44</b> was identified through a mass spectrometry-based HTS with potent activities (HeLa IDO1 IC<sub>50</sub> = 9.2 nM, human unbound whole blood (hWBu) IDO1 IC<sub>50</sub> = 22 nM) and served as a promising lead for optimization.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Further incorporation of polarity into the molecular scaffold for improving metabolic stability and solubility led to 2-pyridyl oxetane analogue <b>45</b> with improved PK profiles and enhanced cellular potencies (HeLa IDO1 IC<sub>50</sub> = 3.2 nM, hWBu IDO1 IC<sub>50</sub> = 0.6 nM). Crystalline results of the initial hit <b>44</b> and IDO1 complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V52">6V52</a>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C) revealed that the inhibitor actually binds to apo-IDO1 by occupying both pockets A and D in a binding mode similar to that of BMS116. In their subsequent work, efforts to improve the metabolic stability of these compounds were made and reported. It was reported that hydrolysis of the amide bond of the benzamide moiety could be a major issue for <i>in vitro</i> and <i>in vivo</i> metabolic instability. Displacing the central 1,4-substituted aromatic moiety with a saturated bicyclo[1.1.1]pentane moiety led to <b>46</b> with improved metabolic stability, potent HeLa IDO1 inhibitory activity (IC<sub>50</sub> = 1.9 nM), and equipotent uncorrected WB activity (hWB IDO1 IC<sub>50</sub> = 36 nM).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> It should be noted that the compounds with bicycloalkyl moieties usually show inferior WB potency relative to the aryl ring-bearing compounds, which may be explained by plasma protein binding issues.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> N-Aryl Urea Derivatives</h4><div class="NLM_p">Apart from the aforementioned verified heme-competitive inhibitors <b>41</b>–<b>42</b>, derivatives bearing this scaffold were reported with SAR in recent years (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B). Compounds in this class usually show single-digit nanomolar activities in the cell-based assay, which may be due to the specific inhibitory mechanism, although most of the inhibitors were not experimentally verified. <b>47</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) was developed by Bristol-Meyers Squib as a derivative of <b>41</b>. By introducing isoxazole and cyclohexyl groups, a 4-fold increase in cellular activity (HEK293 IDO1 IC<sub>50</sub> = 0.5 nM) was obtained from <b>47</b>.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Subsequently, Williams and Markwalder et al. from Bristol-Myers Squibb reported the discovery of <b>48</b>–<b>49</b> as IDO1 inhibitors. Compound <b>48</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) was identified from the initial optimization effort of an HTS hit from the Bristol-Myers Squibb compound library to inhibit IDO1 with an IC<sub>50</sub> value of 22 nM in the HeLa assay but also showed high lipophilicity (clogP = 7.8) and poor aqueous solubility.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Replacing the aryl ether moiety with a dialkylamino group and incorporating the carboxylic acid mimicking the 1<i>H</i>-tetrazole group reduced lipophilicity and led to the most potent compound <b>49</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) of the series (HeLa IDO1 IC<sub>50</sub> = 4 nM).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div><div class="NLM_p last">Recently, Zhang et al. reported their work in developing <i>N</i>-aryl urea derivatives <b>50</b> and <b>51</b> as IDO1 inhibitors. Heterocyclic groups, including furan and thiadiazole, were incorporated into the <i>N</i>-aryl urea core, which slightly shifted the cellular potency of <b>50</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A, HeLa IDO1 IC<sub>50</sub> = 4.0 nM).<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> In their subsequent work, <b>51</b> was reported as an IDO1 inhibitor that exhibited enhanced cellular activities (HeLa IDO1 IC<sub>50</sub> = 2.6 nM) and was demonstrated to impede tumor growth <i>in vivo</i>.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> However, the authors claimed that <b>50</b> and <b>51</b> bind to heme, which should be reconsidered and experimentally validated due to the compound’s high structural similarities to the heme-competitive inhibitors <b>41</b> and <b>42</b>.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Multifunctional Conjugates</h3><div class="NLM_p">The efficacy of IDO1 inhibitors as single agents in treating tumors has proven limited, which has prompted investigations on combination therapy with various agents. Based on this, chimeric compounds bearing IDO1 inhibitor scaffolds in conjugation with selected biofunctional moieties have been designed in recent years. In 2015, Pt(IV)-<b>1</b> conjugate <b>52</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) was reported by Lippard et al. as a combination of IDO inhibition and DNA cross-link-triggered apoptosis, which could either block Kyn production or induce cell death across ovarian cancer cell lines <i>in vitro</i>.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Subsequently, Gou et al. reported Pt(IV) complex <b>53</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A) derived from cisplatin and an IDO1/TDO inhibitor<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> and demonstrated its efficacy in tumor-bearing mice.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of multifunctional conjugates targeting IDO. (A) IDO inhibitors in conjunction with the DNA cross-linking agent Pt complex. (B) <i>N</i>-Hydroxyamidine-based dual-target molecules. (C) Click chemistry-based dual inhibitors of IDO1 and tubulin. (D) IDO1–PROTAC molecule. (E) Inhibitor functions by modulating the ITIM site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on the well-studied <i>N</i>-hydroxyamidine scaffold, Sheng et al. merged two known anticancer agents into an IDO1 inhibitor, which afforded dual-target molecules <b>54</b> and <b>55</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). As shown, incorporating the DNA targeting nitrogen mustard into the side chain of <b>2</b> led to <b>54</b> but decreased the IDO1 inhibitory activity (hIDO1 IC<sub>50</sub> = 130 nM, HeLa IDO1 EC<sub>50</sub> = 270 nM).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Hybrid molecule <b>54</b> exhibited improved antiproliferative activities by triggering apoptosis and inducing tumor regression <i>in vivo</i>. Compound <b>55</b> was reported as an IDO1/histone deacetylase (HDAC, an anticancer target) dual inhibitor, comprising a combination of <b>2</b> and a benzamide group, which is a specific Zn iron-binding moiety targeting HDAC protein. Conjugate <b>55</b> inherited nanomolar inhibitory activities toward both target enzymes (hIDO1 IC<sub>50</sub> = 69.0 nM, HeLa EC<sub>50</sub> = 23 nM, HDAC IC<sub>50</sub> = 66.5 nM) and exhibited enhanced antitumor efficacy in Lewis lung cancer tumor-bearing mice.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_p">In more recent studies, dual-function conjugates comprising IDO1/TDO and tubulin (an anticancer target) inhibitors were reported by Gou et al. <b>1</b>, and a quinone inhibitor<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> was connected with the natural tubulin inhibitor CA-4 via click chemistry, which led to <b>56</b> and <b>57</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C), respectively.<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a> Comprehensive studies revealed that these compounds inhibit tumor growth with higher potencies and induce T cell activation and proliferation.</div><div class="NLM_p last">Proteolysis-targeting chimeras (PROTACs) serve as heterobifunctional chimeric molecules that function to induce target protein degradation via the ubiquitin–proteasome pathway and have been a research focus for years.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Hu et al. recently reported an IDO1–PROTAC molecule <b>58</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D) that comprises a substructure of <b>2</b> as the ligand for IDO1 and a cereblon (CRBN) ligand pomalidomide for E3 ligase. PROTAC <b>58</b> was reported to induce IDO1 degradation in stimulated HeLa cells with half of the degradation concentration value (DC<sub>50</sub>) of 2.84 μM and to exhibit micromolar IDO1 inhibitory activity and cytotoxicity in HeLa cells (HeLa IDO1 IC<sub>50</sub> = 1.07 μM, HeLa CC<sub>50</sub> = 37.43 μM).<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Despite the rationality of the IDO1 degradation strategy, the degradation potency of <b>58</b> was actually insufficient compared to other reported PROTACs (subnanomolar to picomolar DC<sub>50</sub>s), and importantly, <b>58</b> was not demonstrated to reduce Kyn levels.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Inhibitor Modulating ITIM Site</h3><div class="NLM_p last">The 2-propanol analogue <b>59</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E) was discovered by Orabona et al. to be a specific IDO1 modulator of the NTD functional domain ITIMs, which was reported to induce IDO1 activity inhibition in a murine cellular assay (IC<sub>50</sub> = 11.4 μM) but was incompetent in an enzymatic assay.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> It was demonstrated that <b>59</b> positively activated the ITIM-mediated signaling of IDO1 and conferred an immunosuppressive phenotype in plasmacytoid dendritic cells (DCs) <i>in vivo</i>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Other IDO1 Inhibitors</h3><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Naturally Derived Inhibitors</h4><div class="NLM_p">Natural products have been a fundamental source for discovering novel scaffolds as a potential lead for IDO1 inhibitors.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Norharman was the first known natural product inhibitor of IDO1 with weak activity (<i>K</i><sub>i</sub> = 180 μM) for decades.<a onclick="showRef(event, 'ref95 ref138'); return false;" href="javascript:void(0);" class="ref ref95 ref138">(95,138)</a> In 2006, various naphthoquinones were identified and reported as IDO1 inhibitors for the first time, including menadione and annulin derivatives with submicromolar activities.<a onclick="showRef(event, 'ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref139 ref140">(139,140)</a> Since then, quinone-based inhibitors have received significant attention, especially for previously identified β-lapachone (<i>K</i><sub>i</sub> = 0.1 μM to IDO1), which entered phase 2 evaluations as an anticancer agent and is involved in multiple mechanisms,<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141,142)</a> as well as other recently reported quinone derivatives.<a onclick="showRef(event, 'ref143 ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref143 ref144 ref145">(143−145)</a> Studies have revealed that quinones inhibit IDO1 enzymatic activity with distinct mechanisms: (i) binding to the S<sub>a</sub> site, such as type I–III inhibitors, or (ii) interfering with the redox cycle as a type X inhibitor. These inhibitors usually exhibit low micromolar to nanomolar activities in the enzymatic assay but less potency in cellular assays, as quinones undergo NQO1-dependent redox cycling in the cellular environment.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> In 2018, Meng et al. reported a series of naphthoquinone derivatives as potent IDO1 inhibitors. Among them, indolizinoquinoline-5,12-dione <b>60</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A) showed the most potent activity in the enzymatic assay (hIDO1 IC<sub>50</sub> = 23 nM); however, similar inhibition was not observed in the HeLa IDO1 assay.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Interestingly, it was demonstrated that the hydrophilic thiourea group provided the greatest improvement in enzymatic inhibition but impeded cellular activities, as one analogue exhibited an IC<sub>50</sub> value of 372 nM in the HeLa IDO1 assay. In their parallel work, naphthothiazole, <b>61</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A), was synthesized and showed nanomolar activities against both IDO1 and TDO in an enzymatic assay (hIDO1 IC<sub>50</sub> = 18 nM, hTDO IC<sub>50</sub> = 214 nM).<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> SAR studies revealed that replacing the 4-thiazole group with a 4-pyridine group significantly weakened activity toward TDO but showed less impact on the IDO1 inhibitory activity. Through screening an in-house compound library of natural products, compound <b>62</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A) with a furanonaphthoquinone scaffold was identified as a potential lead IDO1 inhibitor with a micromolar IC<sub>50</sub> value in the cellular assay (HeLa IDO1 IC<sub>50</sub> = 1.01 μM).<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> A naphthoquinone derivative, <b>63</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A), emerged as a VS hit, which was demonstrated to have moderate IDO1 cellular activities (SKOV3 IDO1 IC<sub>50</sub> > 40 μM) and higher potency in the dual IDO1/TDO-expressing cell line BT549 (IC<sub>50</sub> = 3.42 μM).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Recently, a set of well-designed naphthoquinone derivatives in conjunction with amide-oxime groups were reported to be potent IDO1 inhibitors and effective anticancer agents. A nanomolar enzymatic IC<sub>50</sub> value was reported for <b>64</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, hIDO1 IC<sub>50</sub> = 46 nM), which was subsequently demonstrated to bind to IDO1 and directly interact with ferric heme.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Cellular IDO1 inhibitory activities of these compounds were not reported, presumably due to the nanomolar cytotoxicity toward various cancer cell lines. SAR studies revealed that the oxime group was essential for IDO1 inhibition, and substituents of the phenylamino group showed a significant influence on enzymatic activities, which was proposed to occupy pocket B. Similar to previous reports, the antiproliferative activities of naphthoquinone derivative <b>64</b> were simultaneously confirmed with nanomolar IC<sub>50</sub> values against multiple cancer cell lines by suppressing the signal transducer and activator of transcription 3 (STAT3) signaling.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Benzoquinone <b>65</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A) was derived from coenzyme-Q1 and reported to inhibit IDO1 with micromolar activities in enzymatic and cellular assays (hIDO1 IC<sub>50</sub> = 0.13 μM, HeLa IDO1 IC<sub>50</sub> = 11.2 μM), which could also induce equivalent cytotoxicity toward the HEK293T cell line (IC<sub>50</sub> = 28 μM).<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> In a recent study, indoledione <b>66</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A) was reported as a derivative of bioactive natural products and exhibited IC<sub>50</sub> values of 160 nM and 3.58 μM in enzymatic and cellular assays, respectively.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> However, cellular toxicities of this compound should be measured to clarify the cellular IDO1 inhibitory activities. Despite better <i>in vitro</i> IDO enzymatic activities, quinones usually show less cellular inhibitory potency but higher cellular toxicity and other activities. In general, quinones may be pan assay interference compounds (PAINS)<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> that are involved in multiple mechanisms. Therefore, the target selectivity and safety of quinones should be validated prior to further evaluation. However, the multitarget effect of quinone IDO1 inhibitors may be an advantage, as selective IDO1 inhibitors have shown limited benefit in clinical trials, namely, combining the effect of immune elimination by modulating Trp metabolism and cellular toxicity (e.g., NQO1/IDO1 dual-target compounds). Hence, in our view, quinone IDO1 inhibitors also show potential for drug discovery and clinical evaluation, but potential toxicity should be noted.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of IDO1 inhibitors based on natural products in recent studies. (A) Inhibitors with a quinone scaffold. (B) Tryptanthrin derivatives. (C) Other natural product inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2013, the natural product tryptanthrin was discovered to inhibit IDO1 in both enzymatic and cellular assays and showed anticancer efficacy <i>in vivo</i>.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Distinguished from quinones, tryptanthrin derivatives usually displayed higher inhibitory efficiencies in cell-based assays, and recent studies have indicated that these natural analogues could show equal potency for TDO inhibition.<a onclick="showRef(event, 'ref154 ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref154 ref155 ref156">(154−156)</a> 8-Fluoro-substituted tryptanthrin <b>67</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B) exhibited dual inhibitory activities toward IDO1/TDO with nanomolar IC<sub>50</sub> values in cellular assays (HEK293 IDO1 IC<sub>50</sub> = 23 nM, HEK293 TDO IC<sub>50</sub> = 68 nM).<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(153,154)</a> Incorporating a dimethylamino methyl group into the C2-position of <b>67</b> further enhanced the cellular inhibitory activities across IDO1/IDO2/TDO (<b>68</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B, HeLa IDO1 IC<sub>50</sub> = 20 nM, U87 MG IDO2 IC<sub>50</sub> = 3.81 μM, HEK293 TDO IC<sub>50</sub> = 60 nM).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Replacement of the <i>N</i>-alkyl moiety with the β-acrylic acid group led to an approximately 30-fold increase in TDO enzymatic activity (<b>69</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B, hIDO1 IC<sub>50</sub> = 120 nM, HeLa IDO1 IC<sub>50</sub> = 60 nM, hTDO IC<sub>50</sub> = 30 nM) but did not improve IDO1 activity.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Interestingly, it was demonstrated that the tryptanthrin derivative directly interacts with the three target proteins, while coordination to heme iron was not observed.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></div><div class="NLM_p last">In addition, <i>ortho</i>-naphthoquinone derivatives, including synthetic <b>70</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C) and natural product <b>71</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C), were identified as IDO1 inhibitors with submicromolar activities.<a onclick="showRef(event, 'ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref157 ref158">(157,158)</a> In addition to quinones and tryptanthrins, some flavonoid derivatives isolated from <i>Sophora flavescens</i> have been recently reported as IDO1 inhibitors. Flavonoid <b>72</b> (Kushenol E, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C) exhibited micromolar activities in both enzymatic and cellular assays (hIDO1 IC<sub>50</sub> = 7.7 μM, HeLa IDO1 IC<sub>50</sub> = 4.3 μM) and was demonstrated to directly bind to IDO1 with a <i>K</i><sub>d</sub> value of 6.5 μM.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Compound <b>73</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C) was synthesized based on the scaffold of marine-derived pyrrolopiperazinone alkaloid and identified to be a weak IDO1 inhibitor (hIDO1 IC<sub>50</sub> = 92 μM).<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Other Scaffolds</h4><div class="NLM_p">The VS strategy has significantly contributed to identifying novel inhibitors with structural features that are distinct from the aforementioned compounds. <i>In silico</i> screening of a commercial compound library led to β-naphthol <b>74</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) with micromolar activities in both enzymatic and cellular assays (hIDO1 IC<sub>50</sub> = 18.7 μM, HeLa IDO1 IC<sub>50</sub> = 18.2 μM).<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Docking results suggested that the β-hydroxyl group may participate in the coordination with heme iron. Symmetric compound <b>75</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) was discovered from VS, which reportedly inhibited IDO1 with an IC<sub>50</sub> value of 1 nM in an enzymatic assay and displayed good selectivity in a kinome inhibition assay.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Lai et al. reported the discovery of potent IDO1 inhibitor <b>76</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) based on a combined VS strategy, which showed nanomolar inhibitory activity in the HeLa assay (HeLa IDO1 IC<sub>50</sub> = 59.8 nM) and suppressed tumor growth in a murine CT26 syngeneic model.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Notably, despite the structural resemblance of <b>76</b> and heme-competitive inhibitor <b>3</b>, the authors demonstrated that <b>76</b> may inhibit IDO1 by a discrepant mechanism, which was further supported by spectroscopic results of the initial hit compounds. In our separate work, cyanopyridine derivatives were identified as IDO1 inhibitors through a ligand-based VS campaign. Further lead optimization led to <b>77</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) with submicromolar IC<sub>50</sub> values in the enzymatic assay (hIDO1 IC<sub>50</sub> = 0.84 μM).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Similar to <b>76</b>, <b>77</b> was also proven to interact with heme iron; thus, the 3-cyano group was speculated to induce coordination. A recent study by Massarotti et al. described the identification of benzimidazole derivative <b>78</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) as a selective IDO1 inhibitor (A375 IDO1 IC<sub>50</sub> = 16 nM, hIDO1 <i>K</i><sub>d</sub> = 0.55 μM).<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> The linear molecule <b>78</b> emerged as a potent hit from a VS project and was able to inhibit IDO1 enzyme activity with nanomolar to submicromolar IC<sub>50</sub> values across various cell lines. Further molecular dynamics (MD) simulations indicated that the benzimidazole moiety was stabilized in pocket A while interacting with heme iron via the N1 atom, and the bromopyrrole group could either protrude toward a distal pocket (also named pocket C<a onclick="showRef(event, 'ref39 ref106'); return false;" href="javascript:void(0);" class="ref ref39 ref106">(39,106)</a>) nearing the solvent region or form cation−π interactions with Arg231 in pocket B. Despite the fact that <b>78</b> was proposed to coordinate to heme iron, the binding mode should be further assessed due to the high structural similarity of <b>78</b> with reported heme-competitive inhibitors. In <a href="/doi/suppl/10.1021/acs.jmedchem.0c00925/suppl_file/jm0c00925_si_001.pdf" class="ext-link">Figure S1</a>, the shape-based models of compounds <b>78</b>, <b>3</b>, and <b>7</b> are shown, and the calculated overlay similarity of the three compounds is listed to illustrate the similarity. In addition, it will be interesting and meaningful to uncover potential heme-competitive inhibitors from numerous current inhibitors in future searches. Hydrazonoindanone derivative <b>79</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) was another VS hit that was identified to inhibit IDO1 with moderate activities (hIDO1 IC<sub>50</sub> = 2.7 μM, HeLa IDO1 IC<sub>50</sub> = 9.1 μM).<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Recently disclosed IDO1 inhibitors with other scaffolds. (A) Inhibitors discovered from the VS strategy. Highlighted atoms (blue for the N atom and red for the O atom) are proposed to interact with heme iron. Colored areas represent different pockets of the IDO1 S<sub>a</sub> site (cyan for pocket A, salmon for pocket B, and pale yellow for the distal pocket C). (B) Other IDO1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Benzenesulfonylhydrazide <b>80</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) was discovered with nanomolar inhibitory activities (hIDO1 IC<sub>50</sub> = 36 nM, HeLa IDO1 EC<sub>50</sub> = 68 nM) via lead optimization based on a previous HTS work.<a onclick="showRef(event, 'ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref166 ref167">(166,167)</a> Importantly, the lead compound bearing an acetamido group at the para-position of the phenylsulfonyl moiety was demonstrated to be potent <i>in vitro</i> (hIDO1 IC<sub>50</sub> = 130 nM, HeLa IDO1 EC<sub>50</sub> = 85 nM) but ineffective <i>in vivo</i>. Rigidifying the <i>N</i>-acetamide substituent led to oxoindole <b>80</b> with improved <i>in vitro</i> potency and <i>in vivo</i> antitumor efficacy in a murine CT26 model. Panda et al. screened a series of fused heterocyclic compounds for IDO1 inhibition and reported that dipyrazolopyran <b>81</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) showed the most potent activities (hIDO1 IC<sub>50</sub> = 151 nM, MDA-MB-231 IDO1 EC<sub>50</sub> = 48 nM).<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> The nearly symmetric molecule showed selectivity toward TDO and was proven to interact with the ferrous IDO1 enzyme.</div><div class="NLM_p"><i>O</i>-Arylhydroxylamines were previously identified as IDO1 inhibitors with submicromolar IC<sub>50</sub> values in enzymatic and cellular assays.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Further modifying the monoaryl molecule afforded diaryl derivatives, which were initially conceived in an effort to exploit an additional pocket for enhanced potency and selectivity, as Winters et al. reported, however, provided pan or dual inhibitory activities across three dioxygenases IDO1/IDO2/TDO.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> As shown, <b>82</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) inhibited IDO1/IDO2/TDO with IC<sub>50</sub> values within 10 μM in both enzymatic and cellular assays (hIDO1 IC<sub>50</sub> = 3 μM, HeLa IDO1 IC<sub>50</sub> = 0.35 μM).</div><div class="NLM_p last">In 2014, certain antifungal agents, including miconazole, were identified by Röhrig et al. as potential IDO1 inhibitors by screening a library of approved drugs.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> In a follow-up study, Lu et al. reported miconazole derivative <b>83</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) as a dual inhibitor of IDO1 and butyrylcholinesterase (BuChE) (hIDO1 IC<sub>50</sub> = 1.0 μM, BuChE IC<sub>50</sub> = 16.5 μM) for the treatment of Alzheimer’s disease (AD), which may represent an example of an “old drug for new use” strategy in discovering IDO1 inhibitors.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusions and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">IDO1 catalyzes the first step of the Trp-Kyn pathway and induces immunosuppression via two proposed mechanisms: local Trp depletion and downstream metabolite accumulation. Due to its pivotal role in immune modulation, pharmacological inhibitors of IDO1 have been regarded as potential drugs for various diseases involving cancers (e.g., melanoma, lung carcinoma, bladder carcinoma), neurodegeneration (e.g., Huntington’s disease, Alzheimer’s disease),<a onclick="showRef(event, 'ref3 ref172 ref173'); return false;" href="javascript:void(0);" class="ref ref3 ref172 ref173">(3,172,173)</a> and infection (e.g., HIV).<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><div class="NLM_p">In recent years, numerous compounds with various chemical scaffolds (e.g., Trp analogues, <i>N</i>-hydroxyamidines, natural derivatives) or inhibitory mechanisms (e.g., substrate Trp/O<sub>2</sub>-competitive, heme-competitive) have been developed. The recent understanding of IDO1’s structure, function, and mechanism has significantly contributed to identifying novel IDO1 inhibitors. In this review, most of the collected inhibitors were discovered via SBDD, while the initial lead may derive from HTS, VS, and natural products. Several heme-competitive inhibitors of IDO1 have been recently discovered, and related studies have led to the identification of the additional binding pocket D and a distinct inhibitory mechanism. However, few efforts have been reported for developing heme-competitive inhibitors. Future SBDD or VS campaigns may be viable in identifying these inhibitors since several cocomplexes of heme-competitive inhibitors with IDO1 have been disclosed, and biological assays are also available.</div><div class="NLM_p">Eleven small-molecule drugs targeting IDO1 or the IDO pathway have entered clinical trials for the treatment of cancer, and eight of them are still under active evaluation. However, an advanced phase 3 trial (ECHO-301) on the selective IDO1 inhibitor epacadostat (<b>2</b>) with pembrolizumab for the treatment of melanoma did not show improved responses compared to pembrolizumab alone, raising questions on the viability of this approach and the need for greater understanding of the Trp-Kyn pathway.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> This failure frustrated the research community and prompted the suspension of several ongoing pivotal trials. Incytes terminated all of phase 3 trials of epacadostat (<b>2</b>) after negative results of the ECHO-301 trial. Bristol-Myers Squibb suspended two phase 3 trials of linrodostat (<b>3</b>) in HNSCC and NSCLC, while NewLink Genetics halted a phase 2/3 study of indoximod (<b>1</b>) in melanoma. Queries and comments have also been addressed regarding this trial design, including the following: (i) the dose of 100 mg BID in ECHO-301 may not have been sufficient to reduce Kyn levels and block immunosuppressive effects, which requires further deliberation; (ii) patient populations were not stratified according to IDO1 expression; and (iii) a potential compensatory metabolic pathway of Trp involving TDO and/or IDO2 exists and (iv) other combined therapy choices.<a onclick="showRef(event, 'ref1 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref1 ref22 ref23">(1,22,23)</a> Hence, comprehensive consideration of the indications, therapeutic combinations, and trial designs may be required prior to resuming phase 3 trials.<a onclick="showRef(event, 'ref22 ref23 ref48'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref48">(22,23,48)</a></div><div class="NLM_p">In small-molecule drug discovery, exploring Trp-Kyn pathway inhibitors or new IDO1 inhibition mechanisms and strategies might be the next approach. The combination of IDO/TDO dual inhibition and downstream signaling (e.g., AhR) blockade may represent an improved solution for fully inhibiting the Trp-Kyn pathway. Notably, two IDO1/TDO inhibitors and the first AhR antagonist entered clinical trials as cancer immunotherapies in 2019.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> On the other hand, increasing apo-IDO1 targeted inhibitors have been recently reported, and at least 2 of them are still under active clinical evaluation (linrodostat (<b>3</b>) and KHK-2455). Except for better enzymatic inhibitory activities, apo-targeting inhibitors do not induce inadvertent AhR agonism, which, however, could be activated by several heme-binding inhibitors, including epacadostat (<b>2</b>).<a onclick="showRef(event, 'ref80 ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref80 ref176 ref177">(80,176,177)</a></div><div class="NLM_p last">Recently reported analogues of clinical heme-binding inhibitors have shown improvement in various fields, including inhibitory potency and PK profiles, which may still be a possible approach in IDO1 inhibitor discovery. For example, tricyclic derivative <b>24</b> showed improvement in enzymatic inhibitory activity and metabolic stability compared to navoximod (<b>4</b>). <i>N</i>-Hydroxyamidine derivative <b>31</b> showed improved oral bioavailability and drug clearance, whereas epacadostat (<b>2</b>) suffered a short half-life; thus, BID was required. Meanwhile, developing epacadostat (<b>2</b>) or <i>N</i>-hydroxyamidine derivatives is still an appealing approach, which may be further supported by the fact that select phase 1/2 studies of epacadostat are currently recruiting. The use of novel IDO1 inhibitors and those listed in this review should help to increase our understanding of the pharmacological roles of the Trp-Kyn pathway, allowing IDO1 inhibitors to potentially successfully contribute to the treatment of cancer and other diseases in the future.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00925" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00925?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00925</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Reported IDO1 structures in the past 5 years; compound <b>78</b> showing high structural similarity with reported heme-competitive inhibitors <b>3</b> and <b>7</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00925/suppl_file/jm0c00925_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00925/suppl_file/jm0c00925_si_001.pdf">jm0c00925_si_001.pdf (264.37 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00925" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiyu Li</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6492-9511" title="Orcid link">http://orcid.org/0000-0001-6492-9511</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4b312322323e27220b283b3e652e2f3e652825"><span class="__cf_email__" data-cfemail="413b292838342d28012231346f2425346f222f">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinlei Bian</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4552-1195" title="Orcid link">http://orcid.org/0000-0003-4552-1195</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#600209010e0a0c200310154e0504154e030e"><span class="__cf_email__" data-cfemail="4c2e252d2226200c2f3c3962292839622f22">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xi Feng</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0117-1234" title="Orcid link">http://orcid.org/0000-0003-0117-1234</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dongdong Liao</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dongyu Liu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">An Ping</span> - <span class="hlFld-Affiliation affiliation">Jiangsu Key Laboratory of
Drug Design and Optimization, Department of Medicinal Chemistry, School
of Pharmacy, China Pharmaceutical University, Nanjing 211100, People’s Republic of China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Xi Feng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=BIO-d7e3104-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xi Feng</b> received his Bachelor’s and Master’s degree from China Pharmaceutical University (CPU) in 2019. Currently, he is a Ph.D. candidate of the Department of Medicinal Chemistry, CPU, under the supervision of Dr. Zhiyu Li. His research focuses on the discovery of novel immune modulators as anticancer agents including the (i) indoleamine 2,3-dioxygenase 1 inhibitor and (ii) STING modulator.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Dongdong Liao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=BIO-d7e3109-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dongdong Liao</b> got his Bachelor’s degree from Shenyang Pharmaceutical University in 2018. He is currently a postgraduate student at the Department of Medicinal Chemistry, China Pharmaceutical University, under the supervision of Dr. Zhiyu Li. During his postgraduate stage, his research work mainly focused on the optimization of synthetic processes.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Dongyu Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=BIO-d7e3114-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dongyu Liu</b> received his Bachelor’s degree from China Pharmaceutical University in 2020 and obtained recommendation for further study as a postgraduate candidate exempt from the admission exam. Currently, he is a postgraduate student at the Department of Medicinal Chemistry, China Pharmaceutical University, under the supervision of Dr. Zhiyu Li.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">An Ping</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=BIO-d7e3119-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>An Ping</b> is currently an undergraduate student of China Pharmaceutical University and majors in medicinal chemistry. She will soon receive her Bachelor’s degree and will continue pursuing her Ph.D. degree at China Pharmaceutical University.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Zhiyu Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=BIO-d7e3124-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhiyu Li</b> graduated from China Pharmaceutical University with his Bachelor’s and Master’s degrees in 1988. He received his Ph.D. in medicinal chemistry at the same institute in 2000. Currently, he is the director and a full professor of the Department of Medical Chemistry, School of Pharmacy, at CPU. He has published more than 50 papers in peer-reviewed journals and owns approximately 30 granted patents. His major research interests focus on the discovery and development of targeted anticancer drugs.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Jinlei Bian</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=BIO-d7e3129-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jinlei Bian</b> received his Bachelor’s degree from China Pharmaceutical University, where he also obtained his Ph.D. in Medicinal Chemistry under the supervision of Professor Qi-Dong You. He is currently a member of the Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University. He works as a medicinal chemist, and his main research topics focus on the rational design of modulators targeting tumor metabolism.</p></figure></div><div class="ack" id="ACK-d7e3134-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25267" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25267" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge financial support from the National Natural Science Foundation of China (073702, 21672260, and 21372260), the “Double First-class” University Project (CPU2018GY07), and the State Key Laboratory of Drug Research (SIMM1903KF-03). We thank Miss Zhen Qin for the continued support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">IDO1</td><td class="NLM_def"><p class="first last">indoleamine 2,3-dixoygenase 1</p></td></tr><tr><td class="NLM_term">IDO2</td><td class="NLM_def"><p class="first last">indoleamine 2,3-dixoygenase 2</p></td></tr><tr><td class="NLM_term">TDO</td><td class="NLM_def"><p class="first last">tryptophan 2,3-dixoygenase</p></td></tr><tr><td class="NLM_term">CTLA-4</td><td class="NLM_def"><p class="first last">cytotoxic T-lymphocyte-associated protein 4</p></td></tr><tr><td class="NLM_term">PD-1/PD-L1</td><td class="NLM_def"><p class="first last">programmed cell death protein 1/ligand 1</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure activity relationship</p></td></tr><tr><td class="NLM_term">AhR</td><td class="NLM_def"><p class="first last">hydrocarbon receptor</p></td></tr><tr><td class="NLM_term">Treg</td><td class="NLM_def"><p class="first last">regulatory T cell</p></td></tr><tr><td class="NLM_term">MDSC</td><td class="NLM_def"><p class="first last">myeloid-derived suppressor cell</p></td></tr><tr><td class="NLM_term">TME</td><td class="NLM_def"><p class="first last">tumor microenvironment</p></td></tr><tr><td class="NLM_term">Trp</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-tryptophan</p></td></tr><tr><td class="NLM_term">Trp-Kyn</td><td class="NLM_def"><p class="first last">tryptophan-kynurenine</p></td></tr><tr><td class="NLM_term">Kyn</td><td class="NLM_def"><p class="first last">kynurenine</p></td></tr><tr><td class="NLM_term">NFK</td><td class="NLM_def"><p class="first last"><i>N</i>-formylkynurenine</p></td></tr><tr><td class="NLM_term">ICI</td><td class="NLM_def"><p class="first last">immune checkpoint inhibitor</p></td></tr><tr><td class="NLM_term">CTD</td><td class="NLM_def"><p class="first last">C-terminal domain</p></td></tr><tr><td class="NLM_term">NTD</td><td class="NLM_def"><p class="first last">N-terminal domain</p></td></tr><tr><td class="NLM_term">ITIM</td><td class="NLM_def"><p class="first last">immunoreceptor tyrosine-based inhibitory motif</p></td></tr><tr><td class="NLM_term">S<sub>a</sub> site</td><td class="NLM_def"><p class="first last">active site</p></td></tr><tr><td class="NLM_term">S<sub>i</sub> site</td><td class="NLM_def"><p class="first last">inhibitory substrate binding site</p></td></tr><tr><td class="NLM_term">H-bond</td><td class="NLM_def"><p class="first last">hydrogen bond</p></td></tr><tr><td class="NLM_term">IDE</td><td class="NLM_def"><p class="first last">effector 3-indole ethanol</p></td></tr><tr><td class="NLM_term">VS</td><td class="NLM_def"><p class="first last">virtual screening</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">protein data bank</p></td></tr><tr><td class="NLM_term">MB</td><td class="NLM_def"><p class="first last">methylene blue</p></td></tr><tr><td class="NLM_term">4PI</td><td class="NLM_def"><p class="first last">4-phenylimidazole</p></td></tr><tr><td class="NLM_term">IFNγ</td><td class="NLM_def"><p class="first last">interferon γ</p></td></tr><tr><td class="NLM_term">NCE</td><td class="NLM_def"><p class="first last">new chemical entity</p></td></tr><tr><td class="NLM_term">HNSCC</td><td class="NLM_def"><p class="first last">head and neck squamous cell carcinoma</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">1MT</td><td class="NLM_def"><p class="first last">1-methyl-Trp</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">hWBu</td><td class="NLM_def"><p class="first last">human unbound whole blood</p></td></tr><tr><td class="NLM_term">DC</td><td class="NLM_def"><p class="first last">dendritic cell</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan assay interference compounds</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">MD</td><td class="NLM_def"><p class="first last">molecular dynamic</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">BuChE</td><td class="NLM_def"><p class="first last">butyrylcholinesterase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 177 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurjao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signoretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen Hodi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choueiri, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannakis, M.</span></span> <span> </span><span class="NLM_article-title">Metabolomic Adaptations and Correlates of Survival to Immune Checkpoint Blockade</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4346</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-12361-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41467-019-12361-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31554815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BB3MnitFagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=4346&author=H.+Liauthor=K.+Bullockauthor=C.+Gurjaoauthor=D.+Braunauthor=S.+A.+Shuklaauthor=D.+Bosseauthor=A.+A.+Lalaniauthor=S.+Gopalauthor=C.+Jinauthor=C.+Horakauthor=M.+Wind-Rotoloauthor=S.+Signorettiauthor=D.+F.+McDermottauthor=G.+J.+Freemanauthor=E.+M.+Van+Allenauthor=S.+L.+Schreiberauthor=F.+Stephen+Hodiauthor=W.+R.+Sellersauthor=L.+A.+Garrawayauthor=C.+B.+Clishauthor=T.+K.+Choueiriauthor=M.+Giannakis&title=Metabolomic+Adaptations+and+Correlates+of+Survival+to+Immune+Checkpoint+Blockade&doi=10.1038%2Fs41467-019-12361-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomic adaptations and correlates of survival to immune checkpoint blockade</span></div><div class="casAuthors">Li Haoxin; Gurjao Carino; Braun David; Shukla Sachet A; Bosse Dominick; Lalani Aly-Khan A; Signoretti Sabina; Freeman Gordon J; Van Allen Eliezer M; Stephen Hodi F; Sellers William R; Garraway Levi A; Choueiri Toni K; Giannakis Marios; Li Haoxin; Bullock Kevin; Gurjao Carino; Gopal Shuba; Van Allen Eliezer M; Schreiber Stuart L; Sellers William R; Garraway Levi A; Clish Clary B; Giannakis Marios; Li Haoxin; Schreiber Stuart L; Jin Chelsea; Horak Christine; Wind-Rotolo Megan; McDermott David F; Van Allen Eliezer M; Stephen Hodi F; Garraway Levi A; Choueiri Toni K; Giannakis Marios</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4346</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits.  Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an antibody against programmed cell death protein 1 (PD1).  We identify serum kynurenine/tryptophan ratio increases as an adaptive resistance mechanism associated with worse overall survival.  This advocates for patient stratification and metabolic monitoring in immunotherapy clinical trials including those combining PD1 blockade with indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase   (IDO/TDO) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzEc3gtF2lse-MdeMhXAHkfW6udTcc2eZiUoNhClFbk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnitFagtg%253D%253D&md5=162c0b46ddf93b675b9d501bf4fc694a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-12361-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-12361-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DBullock%26aufirst%3DK.%26aulast%3DGurjao%26aufirst%3DC.%26aulast%3DBraun%26aufirst%3DD.%26aulast%3DShukla%26aufirst%3DS.%2BA.%26aulast%3DBosse%26aufirst%3DD.%26aulast%3DLalani%26aufirst%3DA.%2BA.%26aulast%3DGopal%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DC.%26aulast%3DHorak%26aufirst%3DC.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DSignoretti%26aufirst%3DS.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DVan%2BAllen%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DStephen%2BHodi%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DGiannakis%26aufirst%3DM.%26atitle%3DMetabolomic%2520Adaptations%2520and%2520Correlates%2520of%2520Survival%2520to%2520Immune%2520Checkpoint%2520Blockade%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D4346%26doi%3D10.1038%2Fs41467-019-12361-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Macedo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin-Breneman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenwald, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawbi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glitza, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaria, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Integrated Molecular Analysis of Tumor Biopsies on Sequential Ctla-4 and Pd-1 Blockade Reveals Markers of Response and Resistance</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">eaah3560</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aah3560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1126%2Fscitranslmed.aah3560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28251903" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaah3560&author=W.+Rohauthor=P.+L.+Chenauthor=A.+Reubenauthor=C.+N.+Spencerauthor=P.+A.+Prietoauthor=J.+P.+Millerauthor=V.+Gopalakrishnanauthor=F.+Wangauthor=Z.+A.+Cooperauthor=S.+M.+Reddyauthor=C.+Gumbsauthor=L.+Littleauthor=Q.+Changauthor=W.+S.+Chenauthor=K.+Waniauthor=M.+P.+De+Macedoauthor=E.+Chenauthor=J.+L.+Austin-Brenemanauthor=H.+Jiangauthor=J.+Roszikauthor=M.+T.+Tetzlaffauthor=M.+A.+Daviesauthor=J.+E.+Gershenwaldauthor=H.+Tawbiauthor=A.+J.+Lazarauthor=P.+Hwuauthor=W.+J.+Hwuauthor=A.+Diabauthor=I.+C.+Glitzaauthor=S.+P.+Patelauthor=S.+E.+Woodmanauthor=R.+N.+Amariaauthor=V.+G.+Prietoauthor=J.+Huauthor=P.+Sharmaauthor=J.+P.+Allisonauthor=L.+Chinauthor=J.+Zhangauthor=J.+A.+Wargoauthor=P.+A.+Futreal&title=Integrated+Molecular+Analysis+of+Tumor+Biopsies+on+Sequential+Ctla-4+and+Pd-1+Blockade+Reveals+Markers+of+Response+and+Resistance&doi=10.1126%2Fscitranslmed.aah3560"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aah3560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aah3560%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DP.%2BL.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DC.%2BN.%26aulast%3DPrieto%26aufirst%3DP.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BP.%26aulast%3DGopalakrishnan%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DReddy%26aufirst%3DS.%2BM.%26aulast%3DGumbs%26aufirst%3DC.%26aulast%3DLittle%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DW.%2BS.%26aulast%3DWani%26aufirst%3DK.%26aulast%3DDe%2BMacedo%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DAustin-Breneman%26aufirst%3DJ.%2BL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRoszik%26aufirst%3DJ.%26aulast%3DTetzlaff%26aufirst%3DM.%2BT.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DTawbi%26aufirst%3DH.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DHwu%26aufirst%3DP.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DDiab%26aufirst%3DA.%26aulast%3DGlitza%26aufirst%3DI.%2BC.%26aulast%3DPatel%26aufirst%3DS.%2BP.%26aulast%3DWoodman%26aufirst%3DS.%2BE.%26aulast%3DAmaria%26aufirst%3DR.%2BN.%26aulast%3DPrieto%26aufirst%3DV.%2BG.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DIntegrated%2520Molecular%2520Analysis%2520of%2520Tumor%2520Biopsies%2520on%2520Sequential%2520Ctla-4%2520and%2520Pd-1%2520Blockade%2520Reveals%2520Markers%2520of%2520Response%2520and%2520Resistance%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26spage%3Deaah3560%26doi%3D10.1126%2Fscitranslmed.aah3560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Platten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nollen, E. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C. A.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Metabolism as a Common Therapeutic Target in Cancer, Neurodegeneration and Beyond</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0016-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41573-019-0016-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30760888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ymurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=379-401&author=M.+Plattenauthor=E.+A.+A.+Nollenauthor=U.+F.+Rohrigauthor=F.+Fallarinoauthor=C.+A.+Opitz&title=Tryptophan+Metabolism+as+a+Common+Therapeutic+Target+in+Cancer%2C+Neurodegeneration+and+Beyond&doi=10.1038%2Fs41573-019-0016-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond</span></div><div class="casAuthors">Platten, Michael; Nollen, Ellen A. A.; Roehrig, Ute F.; Fallarino, Francesca; Opitz, Christiane A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">379-401</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  L-Tryptophan (Trp) metab. through the kynurenine pathway (KP) is involved in the regulation of immunity, neuronal function and intestinal homeostasis.  Imbalances in Trp metab. in disorders ranging from cancer to neurodegenerative disease have stimulated interest in therapeutically targeting the KP, particularly the main rate-limiting enzymes indoleamine-2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan-2,3-dioxygenase (TDO) as well as kynurenine monooxygenase (KMO).  However, although small-mol. IDO1 inhibitors showed promise in early-stage cancer immunotherapy clin. trials, a phase III trial was neg.  This Review summarizes the physiol. and pathophysiol. roles of Trp metab., highlighting the vast opportunities and challenges for drug development in multiple diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro8x_NYzQ8rLVg90H21EOLACvtfcHk0ljcOzE812gQow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ymurw%253D&md5=4d6d9b9c7791e83403cb8fdc34a7a4ae</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0016-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0016-5%26sid%3Dliteratum%253Aachs%26aulast%3DPlatten%26aufirst%3DM.%26aulast%3DNollen%26aufirst%3DE.%2BA.%2BA.%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DOpitz%26aufirst%3DC.%2BA.%26atitle%3DTryptophan%2520Metabolism%2520as%2520a%2520Common%2520Therapeutic%2520Target%2520in%2520Cancer%252C%2520Neurodegeneration%2520and%2520Beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D379%26epage%3D401%26doi%3D10.1038%2Fs41573-019-0016-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskesund, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao-Feng Qin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span> <span> </span><span class="NLM_article-title">Tumor-Repopulating Cells Induce Pd-1 Expression in Cd8(+) T Cells by Transferring Kynurenine and Ahr Activation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ccell.2018.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29533786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVent7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=480-494&author=Y.+Liuauthor=X.+Liangauthor=W.+Dongauthor=Y.+Fangauthor=J.+Lvauthor=T.+Zhangauthor=R.+Fiskesundauthor=J.+Xieauthor=J.+Liuauthor=X.+Yinauthor=X.+Jinauthor=D.+Chenauthor=K.+Tangauthor=J.+Maauthor=H.+Zhangauthor=J.+Yuauthor=J.+Yanauthor=H.+Liangauthor=S.+Moauthor=F.+Chengauthor=Y.+Zhouauthor=H.+Zhangauthor=J.+Wangauthor=J.+Liauthor=Y.+Chenauthor=B.+Cuiauthor=Z.+W.+Huauthor=X.+Caoauthor=F.+Xiao-Feng+Qinauthor=B.+Huang&title=Tumor-Repopulating+Cells+Induce+Pd-1+Expression+in+Cd8%28%2B%29+T+Cells+by+Transferring+Kynurenine+and+Ahr+Activation&doi=10.1016%2Fj.ccell.2018.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation</span></div><div class="casAuthors">Liu, Yuying; Liang, Xiaoyu; Dong, Wenqian; Fang, Yi; Lv, Jiadi; Zhang, Tianzhen; Fiskesund, Roland; Xie, Jing; Liu, Jinyan; Yin, Xiaonan; Jin, Xun; Chen, Degao; Tang, Ke; Ma, Jingwei; Zhang, Huafeng; Yu, Jing; Yan, Jun; Liang, Huaping; Mo, Siqi; Cheng, Feiran; Zhou, Yabo; Zhang, Haizeng; Wang, Jing; Li, Jingnan; Chen, Yang; Cui, Bing; Hu, Zhuo-Wei; Cao, Xuetao; Qin, F. Xiao-Feng; Huang, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">480-494.e7</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite the clin. successes fostered by immune checkpoint inhibitors, mechanisms underlying PD-1 upregulation in tumor-infiltrating T cells remain an enigma.  Here, we show that tumor-repopulating cells (TRCs) drive PD-1 upregulation in CD8+ T cells through a transcellular kynurenine (Kyn)-aryl hydrocarbon receptor (AhR) pathway.  Interferon-γ produced by CD8+ T cells stimulates release of high levels of Kyn produced by TRCs, which is transferred into adjacent CD8+ T cells via the transporters SLC7A8 and PAT4.  Kyn induces and activates AhR and thereby upregulates PD-1 expression.  This Kyn-AhR pathway is confirmed in both tumor-bearing mice and cancer patients and its blockade enhances antitumor adoptive T cell therapy efficacy.  Thus, we uncovered a mechanism of PD-1 upregulation with potential tumor immunotherapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgGqEf4d4Vh7Vg90H21EOLACvtfcHk0ljcOzE812gQow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVent7g%253D&md5=8cfdf5a8665f56866af781a515c74d4e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DW.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DFiskesund%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DMo%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DZ.%2BW.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DXiao-Feng%2BQin%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DB.%26atitle%3DTumor-Repopulating%2520Cells%2520Induce%2520Pd-1%2520Expression%2520in%2520Cd8%2528%252B%2529%2520T%2520Cells%2520by%2520Transferring%2520Kynurenine%2520and%2520Ahr%2520Activation%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26spage%3D480%26epage%3D494%26doi%3D10.1016%2Fj.ccell.2018.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Floc’h, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlot, E.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Metabolism, from Nutrition to Potential Therapeutic Applications</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1205</span>, <span class="refDoi"> DOI: 10.1007/s00726-010-0752-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1007%2Fs00726-010-0752-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=20872026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC3MbltFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=1195-1205&author=N.+Le%0AFloc%E2%80%99hauthor=W.+Ottenauthor=E.+Merlot&title=Tryptophan+Metabolism%2C+from+Nutrition+to+Potential+Therapeutic+Applications&doi=10.1007%2Fs00726-010-0752-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan metabolism, from nutrition to potential therapeutic applications</span></div><div class="casAuthors">Le Floc'h Nathalie; Otten Winfried; Merlot Elodie</div><div class="citationInfo"><span class="NLM_cas:title">Amino acids</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1195-205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tryptophan is an indispensable amino acid that should to be supplied by dietary protein.  Apart from its incorporation into body proteins, tryptophan is the precursor for serotonin, an important neuromediator, and for kynurenine, an intermediary metabolite of a complex metabolic pathway ending with niacin, CO(2), and kynurenic and xanthurenic acids.  Tryptophan metabolism within different tissues is associated with numerous physiological functions.  The liver regulates tryptophan homeostasis through degrading tryptophan in excess.  Tryptophan degradation into kynurenine by immune cells plays a crucial role in the regulation of immune response during infections, inflammations and pregnancy.  Serotonin is synthesized from tryptophan in the gut and also in the brain, where tryptophan availability is known to influence the sensitivity to mood disorders.  In the present review, we discuss the major functions of tryptophan and its role in the regulation of growth, mood, behavior and immune responses with regard to the low availability of this amino acid and the competition between tissues and metabolic pathways for tryptophan utilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiNDKY6a1l9hBrI9DTGjC0fW6udTcc2eZwrWswcMReibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbltFGmsA%253D%253D&md5=9920bbbe24950dcf3e744d15aeff96cc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00726-010-0752-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-010-0752-7%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BFloc%25E2%2580%2599h%26aufirst%3DN.%26aulast%3DOtten%26aufirst%3DW.%26aulast%3DMerlot%26aufirst%3DE.%26atitle%3DTryptophan%2520Metabolism%252C%2520from%2520Nutrition%2520to%2520Potential%2520Therapeutic%2520Applications%26jtitle%3DAmino%2520Acids%26date%3D2011%26volume%3D41%26spage%3D1195%26epage%3D1205%26doi%3D10.1007%2Fs00726-010-0752-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Goot, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nollen, E. A.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Metabolism: Entering the Field of Aging and Age-Related Pathologies</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2013.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.molmed.2013.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=23562344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1CnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=336-344&author=A.+T.+van%0Ader+Gootauthor=E.+A.+Nollen&title=Tryptophan+Metabolism%3A+Entering+the+Field+of+Aging+and+Age-Related+Pathologies&doi=10.1016%2Fj.molmed.2013.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan metabolism: entering the field of aging and age-related pathologies</span></div><div class="casAuthors">van der Goot, Annemieke T.; Nollen, Ellen A. A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">336-344</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Aging is an important risk factor for many debilitating diseases, including cancer and neurodegeneration.  In model organisms, interfering with metabolic signaling pathways, including the insulin/insulin-like growth factor (IGF) 1 (IIS) and TOR pathways, can protect against age-related pathologies and increase lifespan.  Recent studies in multiple organisms have implicated tryptophan metab. as a powerful regulator of age-related diseases and lifespan.  Its high conservation throughout evolution has enabled studies that begin to dissect the contribution of individual enzymes and metabolites.  Here, we focus on the emerging view of tryptophan metab. as a pathway that integrates environmental and metabolic signals to regulate animal biol. and health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJwqXRFdIxGrVg90H21EOLACvtfcHk0lg-ZF8mGPrqFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1CnsLw%253D&md5=2da4be2be0a30e22eb6dbbad7a71b2af</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2013.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2013.02.007%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BGoot%26aufirst%3DA.%2BT.%26aulast%3DNollen%26aufirst%3DE.%2BA.%26atitle%3DTryptophan%2520Metabolism%253A%2520Entering%2520the%2520Field%2520of%2520Aging%2520and%2520Age-Related%2520Pathologies%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D336%26epage%3D344%26doi%3D10.1016%2Fj.molmed.2013.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">Targeting Metabolism to Regulate Immune Responses in Autoimmunity and Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0032-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41573-019-0032-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31363227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=669-688&author=C.+H.+Patelauthor=R.+D.+Leoneauthor=M.+R.+Hortonauthor=J.+D.+Powell&title=Targeting+Metabolism+to+Regulate+Immune+Responses+in+Autoimmunity+and+Cancer&doi=10.1038%2Fs41573-019-0032-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting metabolism to regulate immune responses in autoimmunity and cancer</span></div><div class="casAuthors">Patel, Chirag H.; Leone, Robert D.; Horton, Maureen R.; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">669-688</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Metabolic programming is emerging as a crit. mechanism to alter immune cell activation, differentiation and function.  Targeting metab. does not completely suppress or activate the immune system but selectively regulates immune responses.  The different metabolic requirements of the diverse cells that constitute an immune response provide a unique opportunity to sep. effector functions from regulatory functions.  Likewise, cells can be metabolically reprogram to promote either their short-term effector functions or long-term memory capacity.  Studies in the growing field of immunometabolism support a paradigm of 'cellular selectivity based on demand', in which generic inhibitors of ubiquitous metabolic processes selectively affect cells with the greatest metabolic demand and have few effects on other cells of the body.  Targeting metab., rather than particular cell types or cytokines, in metabolically demanding processes such as autoimmunity, graft rejection, cancer and uncontrolled inflammation could lead to successful strategies in controlling the pathogenesis of these complex disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHF7lCdfVkZbVg90H21EOLACvtfcHk0lgWw2IwaGLafQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgtr3F&md5=cce3d41f0d3f68bf19dfd5f2154e7e32</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0032-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0032-5%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DC.%2BH.%26aulast%3DLeone%26aufirst%3DR.%2BD.%26aulast%3DHorton%26aufirst%3DM.%2BR.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DTargeting%2520Metabolism%2520to%2520Regulate%2520Immune%2520Responses%2520in%2520Autoimmunity%2520and%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D669%26epage%3D688%26doi%3D10.1038%2Fs41573-019-0032-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer</span>. <i>Int. Rev. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>336</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/bs.ircmb.2017.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fbs.ircmb.2017.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29413890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFequrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2018&pages=175-203&author=G.+C.+Prendergastauthor=W.+J.+Malachowskiauthor=A.+Mondalauthor=P.+Scherleauthor=A.+J.+Muller&title=Indoleamine+2%2C3-Dioxygenase+and+Its+Therapeutic+Inhibition+in+Cancer&doi=10.1016%2Fbs.ircmb.2017.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer</span></div><div class="casAuthors">Prendergast, George C.; Malachowski, William J.; Mondal, Arpita; Scherle, Peggy; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-203</span>CODEN:
                <span class="NLM_cas:coden">IRCMAH</span>;
        ISSN:<span class="NLM_cas:issn">1937-6448</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The tryptophan catabolic enzyme indoleamine 2,3-dioxygenase-1 (IDO1) has attracted enormous attention in driving cancer immunosuppression, neovascularization, and metastasis.  IDO1 suppresses local CD8 + T effector cells and natural killer cells and induces CD4 + T regulatory cells (iTreg) and myeloid-derived suppressor cells (MDSC).  The structurally distinct enzyme tryptophan dioxygenase (TDO) also has been implicated recently in immune escape and metastatic progression.  Lastly, emerging evidence suggests that the IDO1-related enzyme IDO2 may support IDO1-mediated iTreg and contribute to B-cell inflammed states in certain cancers.  IDO1 and TDO are upregulated widely in neoplastic cells but also variably in stromal, endothelial, and innate immune cells of the tumor microenvironment and in tumor-draining lymph nodes.  Pharmacol. and genetic proofs in preclin. models of cancer have validated IDO1 as a cancer therapeutic target.  IDO1 inhibitors have limited activity on their own but greatly enhance "immunogenic" chemotherapy or immune checkpoint drugs.  IDO/TDO function is rooted in inflammatory programming, thereby influencing tumor neovascularization, MDSC generation, and metastasis beyond effects on adaptive immune tolerance.  Discovery and development of two small mol. enzyme inhibitors of IDO1 have advanced furthest to date in Phase II/III human trials (epacadostat and navoximod, resp.).  Indoximod, a tryptophan mimetic compd. with a different mechanism of action in the IDO pathway has also advanced in multiple Phase II trials.  Second generation combined IDO/TDO inhibitors may broaden impact in cancer treatment, for example, in addressing IDO1 bypass (inherent resistance) or acquired resistance to IDO1 inhibitors.  This review surveys knowledge about IDO1 function and how IDO1 inhibitors reprogram inflammation to heighten therapeutic responses in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSKEq3iNdyrVg90H21EOLACvtfcHk0lgWw2IwaGLafQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFequrrI&md5=75faf654a3c62b133fca5fb01c9ed6b1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fbs.ircmb.2017.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.ircmb.2017.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMalachowski%26aufirst%3DW.%2BJ.%26aulast%3DMondal%26aufirst%3DA.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520and%2520Its%2520Therapeutic%2520Inhibition%2520in%2520Cancer%26jtitle%3DInt.%2520Rev.%2520Cell%2520Mol.%2520Biol.%26date%3D2018%26volume%3D336%26spage%3D175%26epage%3D203%26doi%3D10.1016%2Fbs.ircmb.2017.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoumian, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenhals, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caetano, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdecanas, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niknam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, J. W.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase 1 Inhibition Targets Anti-Pd1-Resistant Lung Tumors by Blocking Myeloid-Derived Suppressor Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>431</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.canlet.2018.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29746927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2018&pages=54-63&author=A.+Liauthor=H.+B.+Barsoumianauthor=J.+E.+Schoenhalsauthor=T.+R.+Cushmanauthor=M.+S.+Caetanoauthor=X.+Wangauthor=D.+R.+Valdecanasauthor=S.+Niknamauthor=A.+I.+Younesauthor=G.+Liauthor=W.+A.+Woodwardauthor=M.+A.+Cortezauthor=J.+W.+Welsh&title=Indoleamine+2%2C3-Dioxygenase+1+Inhibition+Targets+Anti-Pd1-Resistant+Lung+Tumors+by+Blocking+Myeloid-Derived+Suppressor+Cells&doi=10.1016%2Fj.canlet.2018.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells</span></div><div class="casAuthors">Li, Ailin; Barsoumian, Hampartsoum B.; Schoenhals, Jonathan E.; Cushman, Taylor R.; Caetano, Mauricio S.; Wang, Xiaohong; Valdecanas, David R.; Niknam, Sharareh; Younes, Ahmed I.; Li, Guang; Woodward, Wendy A.; Cortez, Maria Angelica; Welsh, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54-63</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), involved in the catabolism of tryptophan (Trp) to kynurenine (Kyn) is an important regulator of tumor-mediated immunosuppression implicated in resistance to anti-PD1 immunotherapy.  We investigated the role of IDO1 in an anti-PD1-resistant lung cancer model (344SQ_R) compared to the parental 344SQ tumors (344SQ_P).  IDO1 was overexpressed in tumor-infiltrating leukocytes, and plasma Kyn levels were increased, in 344SQ_R vs. 344SQ_P.  The IDO1 inhibitor INCB023843 retarded tumor growth and reduced lung metastases in 344SQ_R.  IDO1 was expressed at higher levels in F4/80+Gr1intCD11b+ myeloid-derived suppressor cells (MDSCs) that were prominent in 344SQ_R.  The INCB023843 reduced IDO1 expression and percentages of these MDSCs while increasing CD8+ T cells infiltration, hence reactivating antitumor T-cell responses in 344SQ_R.  Therefore, IDO1 inhibition holds promise for treating lung cancer that does not respond to anti-PD1 therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouljZFOOi7nbVg90H21EOLACvtfcHk0ljtpC-850aPcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjur7M&md5=a9fbceec8ccbb0b426433ae785ac96ae</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DBarsoumian%26aufirst%3DH.%2BB.%26aulast%3DSchoenhals%26aufirst%3DJ.%2BE.%26aulast%3DCushman%26aufirst%3DT.%2BR.%26aulast%3DCaetano%26aufirst%3DM.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DValdecanas%26aufirst%3DD.%2BR.%26aulast%3DNiknam%26aufirst%3DS.%26aulast%3DYounes%26aufirst%3DA.%2BI.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWoodward%26aufirst%3DW.%2BA.%26aulast%3DCortez%26aufirst%3DM.%2BA.%26aulast%3DWelsh%26aufirst%3DJ.%2BW.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%25201%2520Inhibition%2520Targets%2520Anti-Pd1-Resistant%2520Lung%2520Tumors%2520by%2520Blocking%2520Myeloid-Derived%2520Suppressor%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D431%26spage%3D54%26epage%3D63%26doi%3D10.1016%2Fj.canlet.2018.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badawy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namboodiri, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffett, J. R.</span></span> <span> </span><span class="NLM_article-title">The End of the Road for the Tryptophan Depletion Concept in Pregnancy and Infection</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1333</span>, <span class="refDoi"> DOI: 10.1042/CS20160153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1042%2FCS20160153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWhs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2016&pages=1327-1333&author=A.+A.+Badawyauthor=A.+M.+Namboodiriauthor=J.+R.+Moffett&title=The+End+of+the+Road+for+the+Tryptophan+Depletion+Concept+in+Pregnancy+and+Infection&doi=10.1042%2FCS20160153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The end of the road for the tryptophan depletion concept in pregnancy and infection</span></div><div class="casAuthors">Badawy, Abdulla A.-B.; Namboodiri, Aryan M. A.; Moffett, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1327-1333</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">We hypothesize that: (1) L-tryptophan (Trp) is greatly utilized and not depleted in pregnancy; (2) fetal tolerance is achieved in part through immunosuppressive kynurenine (Kyn) metabolites produced by the flux of plasma free (non-albumin-bound) Trp down the Kyn pathway; (3) the role of indoleamine 2,3-dioxygenase (IDO) in infection is not related to limitation of an essential amino acid, but is rather assocd. with stress responses and the prodn. of Kyn metabolites that regulate the activities of antigen presenting cells and T-cells, as well as increased NAD+ synthesis in IDO-expressing cells; (4) Trp depletion is not a host defense mechanism, but is a consequence of Trp utilization.  We recommend that future studies in normal and abnormal pregnancies and in patients with infections or cancer should include measurements of plasma free Trp, determinants of Trp binding (albumin and non-esterified fatty acids), total Trp, determinants of activities of the Trp-degrading enzymes Trp 2,3-dioxygenase (TDO) (cortisol) and IDO (cytokines) and levels of Kyn metabolites.  We also hypothesize that abnormal pregnancies and failure to combat infections or cancer may be assocd. with excessive Trp metab. that can lead to pathol. immunosuppression by excessive prodn. of Kyn metabolites.  Mounting evidence from many labs. indicates that Trp metabolites are key regulators of immune cell behavior, whereas Trp depletion is an indicator of extensive utilization of this key amino acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWp0RbJKPR1rVg90H21EOLACvtfcHk0ljtpC-850aPcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWhs77F&md5=8448bba73349f49c3dfa92df670a3ece</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1042%2FCS20160153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20160153%26sid%3Dliteratum%253Aachs%26aulast%3DBadawy%26aufirst%3DA.%2BA.%26aulast%3DNamboodiri%26aufirst%3DA.%2BM.%26aulast%3DMoffett%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520End%2520of%2520the%2520Road%2520for%2520the%2520Tryptophan%2520Depletion%2520Concept%2520in%2520Pregnancy%2520and%2520Infection%26jtitle%3DClin.%2520Sci.%26date%3D2016%26volume%3D130%26spage%3D1327%26epage%3D1333%26doi%3D10.1042%2FCS20160153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonner, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deumelandt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thome, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauschenbach, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munteanu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohapatra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofer, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuerer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platten, M.</span></span> <span> </span><span class="NLM_article-title">The Stress Kinase Gcn2 Does Not Mediate Suppression of Antitumor T Cell Responses by Tryptophan Catabolism in Experimental Melanomas</span>. <i>Oncoimmunology.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1240858</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2016.1240858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1080%2F2162402X.2016.1240858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28123877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2msbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e1240858&author=J.+K.+Sonnerauthor=K.+Deumelandtauthor=M.+Ottauthor=C.+M.+Thomeauthor=K.+J.+Rauschenbachauthor=S.+Schulzauthor=B.+Munteanuauthor=S.+Mohapatraauthor=I.+Adamauthor=A.+C.+Hoferauthor=M.+Feuererauthor=C.+A.+Opitzauthor=C.+Hopfauthor=W.+Wickauthor=M.+Platten&title=The+Stress+Kinase+Gcn2+Does+Not+Mediate+Suppression+of+Antitumor+T+Cell+Responses+by+Tryptophan+Catabolism+in+Experimental+Melanomas&doi=10.1080%2F2162402X.2016.1240858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas</span></div><div class="casAuthors">Sonner, Jana K.; Deumelandt, Katrin; Ott, Martina; Thome, Carina M.; Rauschenbach, Katharina J.; Schulz, Sandra; Munteanu, Bogdan; Mohapatra, Soumya; Adam, Isabell; Hofer, Ann-Cathrin; Feuerer, Markus; Opitz, Christiane A.; Hopf, Carsten; Wick, Wolfgang; Platten, Michael</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e1240858/1-e1240858/11</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Tryptophan metab. is a key process that shapes the immunosuppressive tumor microenvironment.  The two rate-limiting enzymes that mediate tryptophan depletion, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO), have moved into the focus of research and inhibitors targeting IDO and TDO have entered clin. trials.  Local tryptophan depletion is generally viewed as the crucial immunosuppressive mechanism.  In T cells, the kinase general control non-derepressible 2 (GCN2) has been identified as a mol. sensor of tryptophan deprivation.  GCN2 activation by tryptophan depletion induces apoptosis and mitigates T cell proliferation.  Here, we investigated whether GCN2 attenuates tumor rejection in exptl. B16 melanoma using T cell-specific Gcn2 knockout mice.  Our data demonstrate that GCN2 in T cells did not affect immunity to B16 tumors even when animals were treated with antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA4).  GCN2-deficient gp100 TCR-transgenic T cells were equally effective as wild-type pmel T cells against gp100-expressing B16 melanomas after adoptive transfer and gp100 peptide vaccination.  Even augmentation of tumoral tryptophan metab. in B16 tumors by lentiviral overexpression of Tdo did not differentially affect GCN2-proficient vs.  GCN2-deficient T cells in vivo.  Importantly, GCN2 target genes were not upregulated in tumor-infiltrating T cells.  MALDI-TOF MS imaging of B16 melanomas demonstrated maintenance of intratumoral tryptophan levels despite high tryptophan turnover, which prohibits a drop in tryptophan sufficient to activate GCN2 in tumor-infiltrating T cells.  In conclusion, our results do not suggest that suppression of antitumor immune responses by tryptophan metab. is driven by local tryptophan depletion and subsequent GCN2-mediated T cell anergy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKukQoYLS6bVg90H21EOLACvtfcHk0ljtpC-850aPcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2msbvM&md5=b603a916e7314a7a907fe49293493493</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1240858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1240858%26sid%3Dliteratum%253Aachs%26aulast%3DSonner%26aufirst%3DJ.%2BK.%26aulast%3DDeumelandt%26aufirst%3DK.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DThome%26aufirst%3DC.%2BM.%26aulast%3DRauschenbach%26aufirst%3DK.%2BJ.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DMunteanu%26aufirst%3DB.%26aulast%3DMohapatra%26aufirst%3DS.%26aulast%3DAdam%26aufirst%3DI.%26aulast%3DHofer%26aufirst%3DA.%2BC.%26aulast%3DFeuerer%26aufirst%3DM.%26aulast%3DOpitz%26aufirst%3DC.%2BA.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DPlatten%26aufirst%3DM.%26atitle%3DThe%2520Stress%2520Kinase%2520Gcn2%2520Does%2520Not%2520Mediate%2520Suppression%2520of%2520Antitumor%2520T%2520Cell%2520Responses%2520by%2520Tryptophan%2520Catabolism%2520in%2520Experimental%2520Melanomas%26jtitle%3DOncoimmunology.%26date%3D2016%26volume%3D5%26spage%3De1240858%26doi%3D10.1080%2F2162402X.2016.1240858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzenburger, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tritschler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jestaedt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jugold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemin, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radlwimmer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platten, M.</span></span> <span> </span><span class="NLM_article-title">An Endogenous Tumour-Promoting Ligand of the Human Aryl Hydrocarbon Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>478</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1038/nature10491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fnature10491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=21976023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ylt7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=478&publication_year=2011&pages=197-203&author=C.+A.+Opitzauthor=U.+M.+Litzenburgerauthor=F.+Sahmauthor=M.+Ottauthor=I.+Tritschlerauthor=S.+Trumpauthor=T.+Schumacherauthor=L.+Jestaedtauthor=D.+Schrenkauthor=M.+Wellerauthor=M.+Jugoldauthor=G.+J.+Guilleminauthor=C.+L.+Millerauthor=C.+Lutzauthor=B.+Radlwimmerauthor=I.+Lehmannauthor=A.+von+Deimlingauthor=W.+Wickauthor=M.+Platten&title=An+Endogenous+Tumour-Promoting+Ligand+of+the+Human+Aryl+Hydrocarbon+Receptor&doi=10.1038%2Fnature10491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">An endogenous tumor-promoting ligand of the human aryl hydrocarbon receptor</span></div><div class="casAuthors">Opitz, Christiane A.; Litzenburger, Ulrike M.; Sahm, Felix; Ott, Martina; Tritschler, Isabel; Trump, Saskia; Schumacher, Theresa; Jestaedt, Leonie; Schrenk, Dieter; Weller, Michael; Jugold, Manfred; Guillemin, Gilles J.; Miller, Christine L.; Lutz, Christian; Radlwimmer, Bernhard; Lehmann, Irina; von Deimling, Andreas; Wick, Wolfgang; Platten, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">478</span>
        (<span class="NLM_cas:issue">7368</span>),
    <span class="NLM_cas:pages">197-203</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the aryl hydrocarbon receptor (AHR) by environmental xenobiotic toxic chems., for instance 2,3,7,8-tetrachlorodibenzo-p-dioxin, has been implicated in a variety of cellular processes such as embryogenesis, transformation, tumorigenesis and inflammation.  But the identity of an endogenous ligand activating the AHR under physiol. conditions in the absence of environmental toxic chems. is still unknown.  Here we identify the tryptophan (Trp) catabolite kynurenine (Kyn) as an endogenous ligand of the human AHR that is constitutively generated by human tumor cells via tryptophan-2,3-dioxygenase (TDO), a liver- and neuron-derived Trp-degrading enzyme not yet implicated in cancer biol.  TDO-derived Kyn suppresses antitumor immune responses and promotes tumor-cell survival and motility through the AHR in an autocrine/paracrine fashion.  The TDO-AHR pathway is active in human brain tumors and is assocd. with malignant progression and poor survival.  Because Kyn is produced during cancer progression and inflammation in the local microenvironment in amts. sufficient for activating the human AHR, these results provide evidence for a previously unidentified pathophysiol. function of the AHR with profound implications for cancer and immune biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-ctjy8u-ULLVg90H21EOLACvtfcHk0lhp2aiuLwSZxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ylt7nI&md5=5f0e0f411501a26b2f79684e0e59830e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature10491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10491%26sid%3Dliteratum%253Aachs%26aulast%3DOpitz%26aufirst%3DC.%2BA.%26aulast%3DLitzenburger%26aufirst%3DU.%2BM.%26aulast%3DSahm%26aufirst%3DF.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DTritschler%26aufirst%3DI.%26aulast%3DTrump%26aufirst%3DS.%26aulast%3DSchumacher%26aufirst%3DT.%26aulast%3DJestaedt%26aufirst%3DL.%26aulast%3DSchrenk%26aufirst%3DD.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3DJugold%26aufirst%3DM.%26aulast%3DGuillemin%26aufirst%3DG.%2BJ.%26aulast%3DMiller%26aufirst%3DC.%2BL.%26aulast%3DLutz%26aufirst%3DC.%26aulast%3DRadlwimmer%26aufirst%3DB.%26aulast%3DLehmann%26aufirst%3DI.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DPlatten%26aufirst%3DM.%26atitle%3DAn%2520Endogenous%2520Tumour-Promoting%2520Ligand%2520of%2520the%2520Human%2520Aryl%2520Hydrocarbon%2520Receptor%26jtitle%3DNature%26date%3D2011%26volume%3D478%26spage%3D197%26epage%3D203%26doi%3D10.1038%2Fnature10491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seok, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltenberger, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satyshur, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortopassi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefcoate, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradfield, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span> <span> </span><span class="NLM_article-title">Trace Derivatives of Kynurenine Potently Activate the Aryl Hydrocarbon Receptor (Ahr)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">1994</span>– <span class="NLM_lpage">2005</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA117.000631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1074%2Fjbc.RA117.000631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29279331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVymsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=1994-2005&author=S.+H.+Seokauthor=Z.+X.+Maauthor=J.+B.+Feltenbergerauthor=H.+Chenauthor=H.+Chenauthor=C.+Scarlettauthor=Z.+Linauthor=K.+A.+Satyshurauthor=M.+Cortopassiauthor=C.+R.+Jefcoateauthor=Y.+Geauthor=W.+Tangauthor=C.+A.+Bradfieldauthor=Y.+Xing&title=Trace+Derivatives+of+Kynurenine+Potently+Activate+the+Aryl+Hydrocarbon+Receptor+%28Ahr%29&doi=10.1074%2Fjbc.RA117.000631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR)</span></div><div class="casAuthors">Seok, Seung-Hyeon; Ma, Zhi-Xiong; Feltenberger, John B.; Chen, Hongbo; Chen, Hui; Scarlett, Cameron; Lin, Ziqing; Satyshur, Kenneth A.; Cortopassi, Marissa; Jefcoate, Colin R.; Ge, Ying; Tang, Weiping; Bradfield, Christopher A.; Xing, Yongna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1994-2005</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cellular metabolites act as important signaling cues, but are subject to complex unknown chem.  Kynurenine is a tryptophan metabolite that plays a crucial role in cancer and the immune system.  Despite its atypical, non-ligand-like, highly polar structure, kynurenine activates the aryl hydrocarbon receptor (AHR), a PER, ARNT, SIM (PAS) family transcription factor that responds to diverse environmental and cellular ligands.  The activity of kynurenine is increased 100-1000-fold by incubation or long-term storage and relies on the hydrophobic ligand-binding pocket of AHR, with identical structural signatures for AHR induction before and after activation.  We purified trace-active derivs. of kynurenine and identified two novel, closely related condensation products, named trace-extended arom. condensation products (TEACOPs), which are active at low picomolar levels.  The synthesized compd. for one of the predicted structures matched the purified compd. in both chem. structure and AHR pharmacol.  Our study provides evidence that kynurenine acts as an AHR pro-ligand, which requires novel chem. conversions to act as a receptor agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiJoODc3vS_7Vg90H21EOLACvtfcHk0lhp2aiuLwSZxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVymsL0%253D&md5=022f04b780654f2ad45c91c98e50c466</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA117.000631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA117.000631%26sid%3Dliteratum%253Aachs%26aulast%3DSeok%26aufirst%3DS.%2BH.%26aulast%3DMa%26aufirst%3DZ.%2BX.%26aulast%3DFeltenberger%26aufirst%3DJ.%2BB.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DScarlett%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DSatyshur%26aufirst%3DK.%2BA.%26aulast%3DCortopassi%26aufirst%3DM.%26aulast%3DJefcoate%26aufirst%3DC.%2BR.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DBradfield%26aufirst%3DC.%2BA.%26aulast%3DXing%26aufirst%3DY.%26atitle%3DTrace%2520Derivatives%2520of%2520Kynurenine%2520Potently%2520Activate%2520the%2520Aryl%2520Hydrocarbon%2520Receptor%2520%2528Ahr%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26spage%3D1994%26epage%3D2005%26doi%3D10.1074%2Fjbc.RA117.000631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiro, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of Human Indoleamine 2,3-Dioxygenase: Catalytic Mechanism of O2 Incorporation by a Heme-Containing Dioxygenase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">2611</span>– <span class="NLM_lpage">2616</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508996103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.0508996103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=16477023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD28XksF2rsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=2611-2616&author=H.+Sugimotoauthor=S.+Odaauthor=T.+Otsukiauthor=T.+Hinoauthor=T.+Yoshidaauthor=Y.+Shiro&title=Crystal+Structure+of+Human+Indoleamine+2%2C3-Dioxygenase%3A+Catalytic+Mechanism+of+O2+Incorporation+by+a+Heme-Containing+Dioxygenase&doi=10.1073%2Fpnas.0508996103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase</span></div><div class="casAuthors">Sugimoto, Hiroshi; Oda, Shun-ichiro; Otsuki, Takashi; Hino, Tomoya; Yoshida, Tadashi; Shiro, Yoshitsugu</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2611-2616</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase (IDO) catalyzes the cleavage of the pyrrole ring of L-tryptophan and incorporates both atoms of an O2 mol.  Here, the authors report on the x-ray crystal structure of human IDO, complexed with the inhibitors, 4-phenylimidazole and cyanide.  The overall structure of IDO showed 2 α-helical domains with the heme between them.  Residue Ala-264 of the flexible loop on the heme distal side was in close proximity to the Fe.  A mutant anal. showed that none of the polar amino acid residues in the distal heme pocket were essential for activity, suggesting that, unlike the heme-contg. monooxygenases (e.g., peroxidase and cytochrome P 450), no protein group of IDO is essential in O2 activation or proton abstraction.  These characteristics of the IDO structure provided support for a reaction mechanism involving the abstraction of a proton from the substrate by Fe-bound O2.  The inactive mutants (F226A, F227A, and R231A) retained substrate-binding affinity, and an electron d. map revealed that 2-(N-cyclohexylamino)ethanesulfonic acid (CHES), a component of the crystn. buffer, was bound to these residues, mimicking the substrate.  These findings suggest that strict shape complementarities between the indole ring of the substrate and the protein side-chains are required, not for binding, but, rather, to permit the interaction between the substrate and Fe-bound O2 in the 1st step of the reaction.  This study provides the structural basis for a heme-contg. dioxygenase mechanism, a missing piece in the understanding of heme chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdrCQcNUKrrVg90H21EOLACvtfcHk0lhLkdjxIxLhXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksF2rsb4%253D&md5=aaf94d532920b2b855bf6fe1a58dfa92</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508996103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508996103%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DOda%26aufirst%3DS.%26aulast%3DOtsuki%26aufirst%3DT.%26aulast%3DHino%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DShiro%26aufirst%3DY.%26atitle%3DCrystal%2520Structure%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%253A%2520Catalytic%2520Mechanism%2520of%2520O2%2520Incorporation%2520by%2520a%2520Heme-Containing%2520Dioxygenase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D2611%26epage%3D2616%26doi%3D10.1073%2Fpnas.0508996103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9421</span>– <span class="NLM_lpage">9437</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9421-9437&author=U.+F.+Rohrigauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=Challenges+in+the+Discovery+of+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9421-9437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies.  Many novel IDO1 inhibitor scaffolds have been described, and a few potent compds. have entered clin. trials.  However, a significant no. of the reported compds. contain problematic functional groups, suggesting that enzyme inhibition could be the result of undesirable side reactions instead of selective binding to IDO1.  Here, we describe issues in the employed exptl. protocols, review and classify reported IDO1 inhibitors, and suggest different approaches for confirming viable inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR3nr-l4vgNLVg90H21EOLACvtfcHk0lhLkdjxIxLhXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D&md5=1b44178d33badc00215915c28d027b5d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00326%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DChallenges%2520in%2520the%2520Discovery%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9421%26epage%3D9437%26doi%3D10.1021%2Facs.jmedchem.5b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Recent Discovery of Indoleamine-2,3-Dioxygenase 1 Inhibitors Targeting Cancer Immunotherapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2017.11.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29220788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejt7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=656-669&author=T.+Wengauthor=X.+Qiuauthor=J.+Wangauthor=Z.+Liauthor=J.+Bian&title=Recent+Discovery+of+Indoleamine-2%2C3-Dioxygenase+1+Inhibitors+Targeting+Cancer+Immunotherapy&doi=10.1016%2Fj.ejmech.2017.11.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy</span></div><div class="casAuthors">Weng, Tianwei; Qiu, Xiaqiu; Wang, Jubo; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">656-669</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  There has been great attention on indoleamine-2,3-dioxygenase 1 (IDO1) around cancer immunotherapy because of its role in enabling cancers to evade the immune system.  The most recent spurt of high potent IDO1 inhibitors has been driven by the soln. of the increased crystal structures of inhibitors with IDO1.  Though the structural information of the active site of IDO1 obtained from the crystals are quite similar, the structures of reported potent inhibitors are quite different.  Besides, while thousands of bioactive small mol. inhibitors of IDO1 exist, to date, only five compds. have entered clin. trials.  In an effort to obtain more clin. drugs targeting IDO1, more comprehensive understanding of the active site of IDO1 and the structures of existing potent IDO1 inhibitors are necessary.  Thus, this review mainly focus on the key features reported from specific crystal structures of IDO1 and an overview of the most recently developed IDO1 inhibitors under investigation and their other derived applications which may contribute to a better usage in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYo7DIaMiLULVg90H21EOLACvtfcHk0ljk4Sba0kkEag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejt7jL&md5=c31f1baddbed4d5270d4a76e9f02f321</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.088%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DT.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DRecent%2520Discovery%2520of%2520Indoleamine-2%252C3-Dioxygenase%25201%2520Inhibitors%2520Targeting%2520Cancer%2520Immunotherapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D656%26epage%3D669%26doi%3D10.1016%2Fj.ejmech.2017.11.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Research Progress of Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.4155%2Ffmc.14.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25686005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=185-201&author=T.+Jiangauthor=Y.+Sunauthor=Z.+Yinauthor=S.+Fengauthor=L.+Sunauthor=Z.+Li&title=Research+Progress+of+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.4155%2Ffmc.14.151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Research progress of indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Jiang, Tianze; Sun, Yingying; Yin, Zhichao; Feng, Sen; Sun, Liping; Li, Zhiyu</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-201</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase (IDO, subsequently named IDO1) can degrade the level of essential amino acid tryptophan in mammals, and catalyze the initial and rate-limiting step through the kynurenine pathway.  Broad evidence implies that IDO is overexpressed in both tumor cells and antigen-presenting cells, facilitating the escape of malignant tumors from immune surveillance.  In the past decades, the inhibition of IDO has been one of the most promising areas in cancer immunotherapy and many potential inhibitors of IDO have been designed, synthesized and evaluated, among which d-1-methyl-tryptophan and INCB24360 have advanced to clin. trial stage.  This review aims to give an overview of the rationale for IDO as a therapeutic target as well as the research progress of IDO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXd5sCUii9PLVg90H21EOLACvtfcHk0lg9meMUHUUi-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrk%253D&md5=5006b4f16ba69b770210bf7416b4257b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.151%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DResearch%2520Progress%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D185%26epage%3D201%26doi%3D10.4155%2Ffmc.14.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornyak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koncz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanyi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szekvolgyi, L.</span></span> <span> </span><span class="NLM_article-title">The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">151</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.00151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffimmu.2018.00151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29445380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WrsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=151&author=L.+Hornyakauthor=N.+Dobosauthor=G.+Konczauthor=Z.+Karanyiauthor=D.+Pallauthor=Z.+Szaboauthor=G.+Halmosauthor=L.+Szekvolgyi&title=The+Role+of+Indoleamine-2%2C3-Dioxygenase+in+Cancer+Development%2C+Diagnostics%2C+and+Therapy&doi=10.3389%2Ffimmu.2018.00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy</span></div><div class="casAuthors">Hornyak, Lilla; Dobos, Nikoletta; Koncz, Gabor; Karanyi, Zsolt; Pall, Denes; Szabo, Zoltan; Halmos, Gabor; Szekvolgyi, Lorant</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151/1-151/8</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Tumors are composed of abnormally transformed cell types and tissues that differ from normal tissues in their genetic and epigenetic makeup, metab., and immunol.  Mol. compds. that modulate the immune response against neoplasms offer promising new strategies to combat cancer.  Inhibitors targeting the indoleamine-2,3- dioxygenase 1 enzyme (IDO1) represent one of the most potent therapeutic opportunities to inhibit tumor growth.  Herein, we assess the biochem. role of IDO1 in tumor metab. and immune surveillance, and review current diagnostic and therapeutic approaches that are intended to increase the effectiveness of immunotherapies against highly aggressive and difficult-to-treat IDO-expressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWxC9Vek4FX7Vg90H21EOLACvtfcHk0lg9meMUHUUi-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WrsrnN&md5=f4395174d6614557b6e2538a31eaa465</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.00151%26sid%3Dliteratum%253Aachs%26aulast%3DHornyak%26aufirst%3DL.%26aulast%3DDobos%26aufirst%3DN.%26aulast%3DKoncz%26aufirst%3DG.%26aulast%3DKaranyi%26aufirst%3DZ.%26aulast%3DPall%26aufirst%3DD.%26aulast%3DSzabo%26aufirst%3DZ.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DSzekvolgyi%26aufirst%3DL.%26atitle%3DThe%2520Role%2520of%2520Indoleamine-2%252C3-Dioxygenase%2520in%2520Cancer%2520Development%252C%2520Diagnostics%252C%2520and%2520Therapy%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D151%26doi%3D10.3389%2Ffimmu.2018.00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting the Ido1 Pathway in Cancer: From Bench to Bedside</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">100</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0644-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1186%2Fs13045-018-0644-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30068361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=100&author=M.+Liuauthor=X.+Wangauthor=L.+Wangauthor=X.+Maauthor=Z.+Gongauthor=S.+Zhangauthor=Y.+Li&title=Targeting+the+Ido1+Pathway+in+Cancer%3A+From+Bench+to+Bedside&doi=10.1186%2Fs13045-018-0644-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the IDO1 pathway in cancer: from bench to bedside</span></div><div class="casAuthors">Liu, Ming; Wang, Xu; Wang, Lei; Ma, Xiaodong; Gong, Zhaojian; Zhang, Shanshan; Li, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100/1-100/12</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase (TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into kynurenine.  The depletion of tryptophan and the increase in kynurenine exert important immunosuppressive functions by activating T regulatory cells and myeloid-derived suppressor cells, suppressing the functions of effector T and natural killer cells, and promoting neovascularization of solid tumors.  Targeting IDO1 represents a therapeutic opportunity in cancer immunotherapy beyond checkpoint blockade or adoptive transfer of chimeric antigen receptor T cells.  In this review, we discuss the function of the IDO1 pathway in tumor progression and immune surveillance.  We highlight recent preclin. and clin. progress in targeting the IDO1 pathway in cancer therapeutics, including peptide vaccines, expression inhibitors, enzymic inhibitors, and effector inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR8DO7cQ8EH7Vg90H21EOLACvtfcHk0lg9meMUHUUi-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqurk%253D&md5=22d837bc560deee6c172e246bca37266</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0644-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0644-y%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DTargeting%2520the%2520Ido1%2520Pathway%2520in%2520Cancer%253A%2520From%2520Bench%2520to%2520Bedside%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D100%26doi%3D10.1186%2Fs13045-018-0644-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toulmonde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevreau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cesne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bompas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piperno-Neumann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grellety, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckewaert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessede, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiringhelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span> <span> </span><span class="NLM_article-title">Use of Pd-1 Targeting, Macrophage Infiltration, and Ido Pathway Activation in Sarcomas: A Phase 2 Clinical Trial</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2017.1617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1001%2Fjamaoncol.2017.1617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28662235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC1cjjtVejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=93-97&author=M.+Toulmondeauthor=N.+Penelauthor=J.+Adamauthor=C.+Chevreauauthor=J.+Y.+Blayauthor=A.+Le+Cesneauthor=E.+Bompasauthor=S.+Piperno-Neumannauthor=S.+Cousinauthor=T.+Grelletyauthor=T.+Ryckewaertauthor=A.+Bessedeauthor=F.+Ghiringhelliauthor=M.+Pulidoauthor=A.+Italiano&title=Use+of+Pd-1+Targeting%2C+Macrophage+Infiltration%2C+and+Ido+Pathway+Activation+in+Sarcomas%3A+A+Phase+2+Clinical+Trial&doi=10.1001%2Fjamaoncol.2017.1617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial</span></div><div class="casAuthors">Toulmonde Maud; Cousin Sophie; Grellety Thomas; Italiano Antoine; Penel Nicolas; Adam Julien; Adam Julien; Chevreau Christine; Blay Jean-Yves; Le Cesne Axel; Bompas Emmanuelle; Piperno-Neumann Sophie; Ryckewaert Thomas; Bessede Alban; Ghiringhelli Francois; Pulido Marina; Pulido Marina</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  There is a strong rationale for treating sarcomas with immunotherapy.  Objective:  To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas.  Design, Setting, and Participants:  This was an open-label, multicenter, phase 2 study of 4 cohorts of patients with advanced soft-tissue sarcoma (STS), including leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), other sarcomas (others), and gastrointestinal stromal tumor (GIST).  All patients received 50 mg twice daily cyclophosphamide 1 week on and 1 week off and 200 mg of intravenous pembrolizumab every 3 weeks.  Intervention or Exposure:  Pembrolizumab in combination with metronomic cyclophosphamide.  Main Outcomes and Measures:  There was a dual primary end point, encompassing both the nonprogression and objective responses at 6 months per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 for LMS, UPS, and others and 6-month nonprogression for GIST.  An objective response rate of 20% and/or a 6-month nonprogression rate of 60% were determined as reasonable objectives for treatment with meaningful effect.  Correlative studies of immune biomarkers were planned from patient tumor and plasma samples.  Results:  Between June 2015 and July 2016, 57 patients were included (median [range] age, 59.5 [18.5-84.0] years; 24 women [42%]); 50 patients were assessable for the efficacy end point.  Three patients experienced tumor shrinkage, resulting in a partial response in a single solitary fibrous tumor.  The 6-month nonprogression rates were 0%, 0%, 14.3% (95% CI, 1.8%-42.8%) for LMS, UPS, and others, respectively, and 11.1% (95% CI, 2.8%-48.3%) for GIST.  The most frequent adverse events were grade 1 or 2 fatigue, diarrhea, and anemia.  The only patient who experienced partial response was the only one with strong programmed cell death 1 ligand 1-positive staining in immune cell.  Strong infiltration by macrophage expressing the inhibitory enzyme indoleamine 2,3-dioxygenase 1 (IDO1) was observed in the majority of cases.  Moreover, a significant increase in the kynurenine to tryptophan ratio was observed in patient plasma samples during the study treatment.  Conclusions and Relevance:  We found that PD-1 inhibition has limited activity in selected STS and GIST.  This may be explained by an immunosuppressive tumor microenvironment resulting from macrophage infiltration and IDO1 pathway activation.  Trial Registration:  clinicaltrials.gov Identifier: NCT02406781.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmP7k1aAt8B3T4ugvCDgnZfW6udTcc2eZcMSQkiau33rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjjtVejsQ%253D%253D&md5=0d4c2df318b06dc4d8bd4017202173eb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2017.1617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2017.1617%26sid%3Dliteratum%253Aachs%26aulast%3DToulmonde%26aufirst%3DM.%26aulast%3DPenel%26aufirst%3DN.%26aulast%3DAdam%26aufirst%3DJ.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DBompas%26aufirst%3DE.%26aulast%3DPiperno-Neumann%26aufirst%3DS.%26aulast%3DCousin%26aufirst%3DS.%26aulast%3DGrellety%26aufirst%3DT.%26aulast%3DRyckewaert%26aufirst%3DT.%26aulast%3DBessede%26aufirst%3DA.%26aulast%3DGhiringhelli%26aufirst%3DF.%26aulast%3DPulido%26aufirst%3DM.%26aulast%3DItaliano%26aufirst%3DA.%26atitle%3DUse%2520of%2520Pd-1%2520Targeting%252C%2520Macrophage%2520Infiltration%252C%2520and%2520Ido%2520Pathway%2520Activation%2520in%2520Sarcomas%253A%2520A%2520Phase%25202%2520Clinical%2520Trial%26jtitle%3DJAMA%2520Oncol.%26date%3D2018%26volume%3D4%26spage%3D93%26epage%3D97%26doi%3D10.1001%2Fjamaoncol.2017.1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmgaard, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamarin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase Is a Critical Resistance Mechanism in Antitumor T Cell Immunotherapy Targeting Ctla-4</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">1389</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.1084/jem.20130066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1084%2Fjem.20130066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=23752227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVGiurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=1389-1402&author=R.+B.+Holmgaardauthor=D.+Zamarinauthor=D.+H.+Munnauthor=J.+D.+Wolchokauthor=J.+P.+Allison&title=Indoleamine+2%2C3-Dioxygenase+Is+a+Critical+Resistance+Mechanism+in+Antitumor+T+Cell+Immunotherapy+Targeting+Ctla-4&doi=10.1084%2Fjem.20130066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4</span></div><div class="casAuthors">Holmgaard, Rikke B.; Zamarin, Dmitriy; Munn, David H.; Wolchok, Jedd D.; Allison, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1389-1402</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab results in durable responses in metastatic melanoma, though therapeutic benefit has been limited to a fraction of patients.  This calls for identification of resistance mechanisms and development of combinatorial strategies.  Here, we examine the inhibitory role of indoleamine 2,3-dioxygenase (IDO) on the antitumor efficacy of CTLA-4 blockade.  In IDO knockout mice treated with anti-CTLA-4 antibody, we demonstrate a striking delay in B16 melanoma tumor growth and increased overall survival when compared with wild-type mice.  This was also obsd. with antibodies targeting PD-1-PD-L1 and GITR.  To highlight the therapeutic relevance of these findings, we show that CTLA-4 blockade strongly synergizes with IDO inhibitors to mediate rejection of both IDO-expressing and nonexpressing poorly immunogenic tumors, emphasizing the importance of the inhibitory role of both tumor- and host-derived IDO.  This effect was T cell dependent, leading to enhanced infiltration of tumor-specific effector T cells and a marked increase in the effector-to-regulatory T cell ratios in the tumors.  Overall, these data demonstrate the immunosuppressive role of IDO in the context of immunotherapies targeting immune checkpoints and provide a strong incentive to clin. explore combination therapies using IDO inhibitors irresp. of IDO expression by the tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn2vZr-icci7Vg90H21EOLACvtfcHk0lgewKwhcTWPaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVGiurnP&md5=ed5a4e2074d7f0448eb503d7e11c2e91</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1084%2Fjem.20130066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20130066%26sid%3Dliteratum%253Aachs%26aulast%3DHolmgaard%26aufirst%3DR.%2BB.%26aulast%3DZamarin%26aufirst%3DD.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520Is%2520a%2520Critical%2520Resistance%2520Mechanism%2520in%2520Antitumor%2520T%2520Cell%2520Immunotherapy%2520Targeting%2520Ctla-4%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D1389%26epage%3D1402%26doi%3D10.1084%2Fjem.20130066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakharia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Ido Pathways to Treat Cancer: Lessons from the Echo-301 Trial and Beyond</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1007/s00281-018-0702-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1007%2Fs00281-018-0702-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30203227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=41-48&author=A.+J.+Mullerauthor=M.+G.+Manfrediauthor=Y.+Zakhariaauthor=G.+C.+Prendergast&title=Inhibiting+Ido+Pathways+to+Treat+Cancer%3A+Lessons+from+the+Echo-301+Trial+and+Beyond&doi=10.1007%2Fs00281-018-0702-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond</span></div><div class="casAuthors">Muller, Alexander J.; Manfredi, Mark G.; Zakharia, Yousef; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  With immunotherapy enjoying a rapid resurgence based on the achievement of durable remissions in some patients with agents that derepress immune function, commonly referred to as "checkpoint inhibitors," enormous attention developed around the IDO1 enzyme as a metabolic mediator of immune escape in cancer.  In particular, outcomes of multiple phase 1/2 trials encouraged the idea that small mol. inhibitors of IDO1 may improve patient responses to anti-PD1 immune checkpoint therapy.  However, recent results from ECHO-301, the first large phase 3 trial to evaluate an IDO1-selective enzyme inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in advanced melanoma, showed no indication that epacadostat provided an increased benefit.  Here it discuss several caveats assocd. with this failed trial.  First is the uncertainty as to whether the target was adequately inhibited.  In particular, there remains a lack of direct evidence regarding the degree of IDO1 inhibition within the tumor, and previous trial data suggest that sufficient drug exposure may not have been achieved at the dose tested in ECHO-301.  Second, while there is a mechanistic rationale for the combination tested, the preclin. data were not particularly compelling.  More efficacious combinations have been demonstrated with DNA damaging modalities which may therefore be a more attractive alternative.  Third, as a highly selective IDO1 inhibitor, epacadostat was advanced aggressively despite preclin. genetic evidence of tumors bypassing IDO1 blockade.  Indeed, a well-grounded literature starting in 2011 points to targeting strategies that account for both IDO and tryptophan 2,3-dioxygenase as more appealing directions to pursue, including dual inhibitors and inhibitors of nodal downstream effector pathways such as aryl hydrocarbon receptor blockade.  Overall, the clin. readout from a single trial with significant limitations is by no means a definitive test for the field.  While biomarker information yet to be gleaned from ECHO-301 may yet reveal useful information regarding IDO1 pathway drugs, better rationalized compds. and better rationalized trial designs will be important in the future to accurately gage medical impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-55ynvYhvLVg90H21EOLACvtfcHk0lgUAuKuvM-92Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI&md5=b672f039dcfd843d6c849167846e13a5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs00281-018-0702-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-018-0702-0%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DManfredi%26aufirst%3DM.%2BG.%26aulast%3DZakharia%26aufirst%3DY.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibiting%2520Ido%2520Pathways%2520to%2520Treat%2520Cancer%253A%2520Lessons%2520from%2520the%2520Echo-301%2520Trial%2520and%2520Beyond%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2019%26volume%3D41%26spage%3D41%26epage%3D48%26doi%3D10.1007%2Fs00281-018-0702-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baurain, J.-F.</span></span> <span> </span><span class="NLM_article-title">Is There a Clinical Future for Ido1 Inhibitors after the Failure of Epacadostat in Melanoma?</span>. <i>Annu. Rev. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1146/annurev-cancerbio-030419-033635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1146%2Fannurev-cancerbio-030419-033635" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=241-256&author=B.+J.+Van%0Aden+Eyndeauthor=N.+van+Barenauthor=J.-F.+Baurain&title=Is+There+a+Clinical+Future+for+Ido1+Inhibitors+after+the+Failure+of+Epacadostat+in+Melanoma%3F&doi=10.1146%2Fannurev-cancerbio-030419-033635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1146%2Fannurev-cancerbio-030419-033635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-cancerbio-030419-033635%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3Dvan%2BBaren%26aufirst%3DN.%26aulast%3DBaurain%26aufirst%3DJ.-F.%26atitle%3DIs%2520There%2520a%2520Clinical%2520Future%2520for%2520Ido1%2520Inhibitors%2520after%2520the%2520Failure%2520of%2520Epacadostat%2520in%2520Melanoma%253F%26jtitle%3DAnnu.%2520Rev.%2520Cancer%2520Biol.%26date%3D2020%26volume%3D4%26spage%3D241%26epage%3D256%26doi%3D10.1146%2Fannurev-cancerbio-030419-033635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jusof, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakmiwewa, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Too, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. J.</span></span> <span> </span><span class="NLM_article-title">Investigation of the Tissue Distribution and Physiological Roles of Indoleamine 2,3-Dioxygenase-2</span>. <i>Int. J. Tryptophan Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">117864691773509</span>, <span class="refDoi"> DOI: 10.1177/1178646917735098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1177%2F1178646917735098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=117864691773509&author=F.+F.+Jusofauthor=S.+M.+Bakmiwewaauthor=S.+Weiserauthor=L.+K.+Tooauthor=R.+Metzauthor=G.+C.+Prendergastauthor=S.+T.+Fraserauthor=N.+H.+Huntauthor=H.+J.+Ball&title=Investigation+of+the+Tissue+Distribution+and+Physiological+Roles+of+Indoleamine+2%2C3-Dioxygenase-2&doi=10.1177%2F1178646917735098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F1178646917735098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1178646917735098%26sid%3Dliteratum%253Aachs%26aulast%3DJusof%26aufirst%3DF.%2BF.%26aulast%3DBakmiwewa%26aufirst%3DS.%2BM.%26aulast%3DWeiser%26aufirst%3DS.%26aulast%3DToo%26aufirst%3DL.%2BK.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DFraser%26aufirst%3DS.%2BT.%26aulast%3DHunt%26aufirst%3DN.%2BH.%26aulast%3DBall%26aufirst%3DH.%2BJ.%26atitle%3DInvestigation%2520of%2520the%2520Tissue%2520Distribution%2520and%2520Physiological%2520Roles%2520of%2520Indoleamine%25202%252C3-Dioxygenase-2%26jtitle%3DInt.%2520J.%2520Tryptophan%2520Res.%26date%3D2017%26volume%3D10%26spage%3D117864691773509%26doi%3D10.1177%2F1178646917735098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baban, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigott, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keough, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rust, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandik-Nayak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Ido2 Is Critical for Ido1-Mediated T-Cell Regulation and Exerts a Non-Redundant Function in Inflammation</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxt073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1093%2Fintimm%2Fdxt073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24402311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyit7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=357-367&author=R.+Metzauthor=C.+Smithauthor=J.+B.+DuHadawayauthor=P.+Chandlerauthor=B.+Babanauthor=L.+M.+Merloauthor=E.+Pigottauthor=M.+P.+Keoughauthor=S.+Rustauthor=A.+L.+Mellorauthor=L.+Mandik-Nayakauthor=A.+J.+Mullerauthor=G.+C.+Prendergast&title=Ido2+Is+Critical+for+Ido1-Mediated+T-Cell+Regulation+and+Exerts+a+Non-Redundant+Function+in+Inflammation&doi=10.1093%2Fintimm%2Fdxt073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation</span></div><div class="casAuthors">Metz, Richard; Smith, Courtney; Du Hadaway, James B.; Chandler, Phillip; Baban, Babak; Merlo, Lauren M. F.; Pigott, Elizabeth; Keough, Martin P.; Rust, Sonja; Mellor, Andrew L.; Mandik-Nayak, Laura; Muller, Alexander J.; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">357-367</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">IDO2 and IDO1 cooperate in some inflammatory responses but IDO2 also has unique roles.  IDO2 is implicated in tryptophan catabolism and immunity but its physiol. functions are not well established.  Here we report the characterization of mice genetically deficient in IDO2, which develop normally but exhibit defects in IDO-mediated T-cell regulation and inflammatory responses.  Construction of this strain was prompted in part by our discovery that IDO2 function is attenuated in macrophages from Ido1 -/- mice due to altered message splicing, generating a functional mosaic with implications for interpreting findings in Ido1 -/- mice.  No apparent defects were obsd. in Ido2 -/- mice in embryonic development or hematopoietic differentiation, with wild-type profiles documented for kynurenine in blood serum and for immune cells in spleen, lymph nodes, peritoneum, thymus and bone marrow of naive mice.  In contrast, upon immune stimulation we detd. that IDO1-dependent T regulatory cell generation was defective in Ido2 -/- mice, supporting Ido1-Ido2 genetic interaction and establishing a functional role for Ido2 in immune modulation.  Pathophysiol., both Ido1 -/- and Ido2 -/- mice displayed reduced skin contact hypersensitivity responses, but mechanistic distinctions were apparent, with only Ido2 deficiency assocd. with a suppression of immune regulatory cytokines that included GM-CSF, G-CSF, IFN-γ, TNF-α, IL-6 and MCP-1/CCL2.  Different contributions to inflammation were likewise indicated by the finding that Ido2 -/- mice did not phenocopy Ido1 -/- mice in the reduced susceptibility of the latter to inflammatory skin cancer.  Taken together, our results offer an initial glimpse into immune modulation by IDO2, revealing its genetic interaction with IDO1 and distinguishing its non-redundant contributions to inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBg-WyevvaRrVg90H21EOLACvtfcHk0liJlMgWmgbcow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyit7vK&md5=2f9c4c96ead35f3885de16ea9ccb638c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxt073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxt073%26sid%3Dliteratum%253Aachs%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DChandler%26aufirst%3DP.%26aulast%3DBaban%26aufirst%3DB.%26aulast%3DMerlo%26aufirst%3DL.%2BM.%26aulast%3DPigott%26aufirst%3DE.%26aulast%3DKeough%26aufirst%3DM.%2BP.%26aulast%3DRust%26aufirst%3DS.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26aulast%3DMandik-Nayak%26aufirst%3DL.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DIdo2%2520Is%2520Critical%2520for%2520Ido1-Mediated%2520T-Cell%2520Regulation%2520and%2520Exerts%2520a%2520Non-Redundant%2520Function%2520in%2520Inflammation%26jtitle%3DInt.%2520Immunol.%26date%3D2014%26volume%3D26%26spage%3D357%26epage%3D367%26doi%3D10.1093%2Fintimm%2Fdxt073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolusic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Plaen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uyttenhove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masereel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Reversal of Tumoral Immune Resistance by Inhibition of Tryptophan 2,3-Dioxygenase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2502</span>, <span class="refDoi"> DOI: 10.1073/pnas.1113873109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.1113873109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=22308364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVKnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=2497-2502&author=L.+Pilotteauthor=P.+Larrieuauthor=V.+Stroobantauthor=D.+Colauauthor=E.+Dolusicauthor=R.+Frederickauthor=E.+De+Plaenauthor=C.+Uyttenhoveauthor=J.+Woutersauthor=B.+Masereelauthor=B.+J.+Van+den+Eynde&title=Reversal+of+Tumoral+Immune+Resistance+by+Inhibition+of+Tryptophan+2%2C3-Dioxygenase&doi=10.1073%2Fpnas.1113873109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Pilotte, Luc; Larrieu, Pierre; Stroobant, Vincent; Colau, Didier; Dolusic, Eduard; Frederick, Raphael; De Plaen, Etienne; Uyttenhove, Catherine; Wouters, Johan; Masereel, Bernard; Vand den Eynde, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2497-2502, S2497/1-S2497/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance, and IDO1 inhibition is an active area of drug development.  Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway.  Here, we show that enzymically active TDO is expressed in a significant proportion of human tumors.  In a preclin. model, TDO expression by tumors prevented their rejection by immunized mice.  We developed a TDO inhibitor, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors.  Our results describe a mechanism of tumoral immune resistance based on TDO expression and establish proof-of-concept for the use of TDO inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUOPsopvoi1LVg90H21EOLACvtfcHk0liJlMgWmgbcow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVKnt7o%253D&md5=e29b0d7a9180526a2b79173c75765e6c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1113873109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1113873109%26sid%3Dliteratum%253Aachs%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DLarrieu%26aufirst%3DP.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DDolusic%26aufirst%3DE.%26aulast%3DFrederick%26aufirst%3DR.%26aulast%3DDe%2BPlaen%26aufirst%3DE.%26aulast%3DUyttenhove%26aufirst%3DC.%26aulast%3DWouters%26aufirst%3DJ.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DReversal%2520of%2520Tumoral%2520Immune%2520Resistance%2520by%2520Inhibition%2520of%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D2497%26epage%3D2502%26doi%3D10.1073%2Fpnas.1113873109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouzin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daumerie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solvay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaessens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letellier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renauld, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelotte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbaix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-19-0040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F2326-6066.CIR-19-0040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31806639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Krur%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=19-31&author=D.+Hoffmannauthor=T.+Dvorakovaauthor=V.+Stroobantauthor=C.+Bouzinauthor=A.+Daumerieauthor=M.+Solvayauthor=S.+Klaessensauthor=M.+C.+Letellierauthor=J.+C.+Renauldauthor=N.+van+Barenauthor=J.+Lelotteauthor=E.+Marbaixauthor=B.+J.+Van+den+Eynde&title=Tryptophan+2%2C3-Dioxygenase+Expression+Identified+in+Human+Hepatocellular+Carcinoma+Cells+and+in+Intratumoral+Pericytes+of+Most+Cancers&doi=10.1158%2F2326-6066.CIR-19-0040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan 2,3-dioxygenase expression identified in human hepatocellular carcinoma cells and in intratumoral pericytes of most cancers</span></div><div class="casAuthors">Hoffmann, Delia; Dvorakova, Tereza; Stroobant, Vincent; Bouzin, Caroline; Daumerie, Aurelie; Solvay, Marie; Klaessens, Simon; Letellier, Marie-Claire; Renauld, Jean Christophe; van Baren, Nicolas; Lelotte, Julie; Marbaix, Etienne; Van den Eynde, Benoit J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-31</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tryptophan catabolism is used by tumors to resist immune attack.  It can be catalyzed by indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO).  IDO1 is frequently expressed in tumors and has been widely studied as a potential therapeutic target to reduce resistance to cancer immunotherapy.  In contrast, TDO expression in tumors is not well characterized.  Several human tumor cell lines constitutively express enzymically active TDO.  In human tumor samples, TDO expression has previously been detected by transcriptomics, but the lack of validated antibodies has precluded detection of the TDO protein and identification of TDO-expressing cells.  Here we developed novel TDO-specific monoclonal antibodies and confirmed by immunohistochem. the expression of TDO in the majority of human cancers.  In all hepatocarcinomas (10/10), TDO was expressed by most tumor cells.  Some glioblastomas (10/39) and kidney carcinomas (1/10) also expressed TDO in tumor cells themselves, but only in focal tumor areas.  In addn., all cancers tested contained foci of non-tumoral TDO-expressing cells, which were identified as pericytes by their expression of PDGFRβ and their location in vascular structures.  These TDO-expressing pericytes belonged to morphol. abnormal tumor vessels and were found in high-grade tumors in the vicinity of necrotic or hemorrhagic areas, which were characterized by neoangiogenesis.  We obsd. similar TDO-expressing pericytes in inflammatory pulmonary lesions contg. granulation tissue, and in chorionic villi, two tissue types that also feature neoangiogenesis.  Our results confirm TDO as a relevant immunotherapeutic target in hepatocellular carcinoma, and suggest a proangiogenic role of TDO in other cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCXx-A0Kw2LVg90H21EOLACvtfcHk0ljzD928Xj3rzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Krur%252FM&md5=047cf84e64d7472efd7c637ddd7ba520</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-19-0040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-19-0040%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DD.%26aulast%3DDvorakova%26aufirst%3DT.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DBouzin%26aufirst%3DC.%26aulast%3DDaumerie%26aufirst%3DA.%26aulast%3DSolvay%26aufirst%3DM.%26aulast%3DKlaessens%26aufirst%3DS.%26aulast%3DLetellier%26aufirst%3DM.%2BC.%26aulast%3DRenauld%26aufirst%3DJ.%2BC.%26aulast%3Dvan%2BBaren%26aufirst%3DN.%26aulast%3DLelotte%26aufirst%3DJ.%26aulast%3DMarbaix%26aufirst%3DE.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DTryptophan%25202%252C3-Dioxygenase%2520Expression%2520Identified%2520in%2520Human%2520Hepatocellular%2520Carcinoma%2520Cells%2520and%2520in%2520Intratumoral%2520Pericytes%2520of%2520Most%2520Cancers%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2020%26volume%3D8%26spage%3D19%26epage%3D31%26doi%3D10.1158%2F2326-6066.CIR-19-0040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03491631" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03491631</a> (accessed May 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03491631+%28accessed+May+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03641794" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03641794</a> (accessed May 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03641794+%28accessed+May+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioretti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span> <span> </span><span class="NLM_article-title">Socs3 Drives Proteasomal Degradation of Indoleamine 2,3-Dioxygenase (Ido) and Antagonizes Ido-Dependent Tolerogenesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">20828</span>– <span class="NLM_lpage">20833</span>, <span class="refDoi"> DOI: 10.1073/pnas.0810278105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.0810278105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=19088199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=20828-20833&author=C.+Orabonaauthor=M.+T.+Pallottaauthor=C.+Volpiauthor=F.+Fallarinoauthor=C.+Vaccaauthor=R.+Bianchiauthor=M.+L.+Belladonnaauthor=M.+C.+Fiorettiauthor=U.+Grohmannauthor=P.+Puccetti&title=Socs3+Drives+Proteasomal+Degradation+of+Indoleamine+2%2C3-Dioxygenase+%28Ido%29+and+Antagonizes+Ido-Dependent+Tolerogenesis&doi=10.1073%2Fpnas.0810278105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis</span></div><div class="casAuthors">Orabona, Ciriana; Pallotta, Maria T.; Volpi, Claudia; Fallarino, Francesca; Vacca, Carmine; Bianchi, Roberta; Belladonna, Maria L.; Fioretti, Maria C.; Grohmann, Ursula; Puccetti, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">20828-20833</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite their common ability to activate intracellular signaling through CD80/CD86 mols., cytotoxic T lymphocyte antigen 4 (CTLA-4)-Ig and CD28-Ig bias the downstream response in opposite directions, the latter promoting immunity, and CTLA-4-Ig tolerance, in dendritic cells (DCs) with opposite but flexible programs of antigen presentation.  Nevertheless, in the absence of suppressor of cytokine signaling 3 (SOCS3), CD28-Ig - and the assocd., dominant IL-6 response-become immunosuppressive and mimic the effect of CTLA-4-Ig, including a high functional expression of the tolerogenic enzyme indoleamine 2,3-dioxygenase (IDO).  Here we show that forced SOCS3 expression antagonized CTLA-4-Ig activity in a proteasome-dependent fashion.  Unrecognized by previous studies, IDO appeared to possess two tyrosine residues within two distinct putative immunoreceptor tyrosine-based inhibitory motifs, VPY115CEL and LLY253EGV.  We found that SOCS3 - known to interact with phosphotyrosine-contg. peptides and be selectively induced by CD28-Ig/IL-6 - would bind IDO and target the IDO/SOCS3 complex for ubiquitination and subsequent proteasomal degrdn.  This event accounted for the ability of CD28-Ig and IL-6 to convert otherwise tolerogenic, IDO-competent DCs into immunogenic cells.  Thus onset of immunity in response to antigen within an early inflammatory context requires that IDO be degraded in tolerogenic DCs.  In addn. to identifying SOCS3 as a candidate signature for mouse DC subsets programmed to direct immunity, this study demonstrates that IDO undergoes regulatory proteolysis in response to immunogenic stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX7Y39qFDWH7Vg90H21EOLACvtfcHk0ljzD928Xj3rzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFSnsw%253D%253D&md5=31aa780e675a4e11490f79a329ca2e01</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0810278105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0810278105%26sid%3Dliteratum%253Aachs%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DFioretti%26aufirst%3DM.%2BC.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DPuccetti%26aufirst%3DP.%26atitle%3DSocs3%2520Drives%2520Proteasomal%2520Degradation%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528Ido%2529%2520and%2520Antagonizes%2520Ido-Dependent%2520Tolerogenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D20828%26epage%3D20833%26doi%3D10.1073%2Fpnas.0810278105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunacci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvitti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicciato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazza, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioretti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase Is a Signaling Protein in Long-Term Tolerance by Dendritic Cells</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">870</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1038/ni.2077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fni.2077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=21804557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=870-878&author=M.+T.+Pallottaauthor=C.+Orabonaauthor=C.+Volpiauthor=C.+Vaccaauthor=M.+L.+Belladonnaauthor=R.+Bianchiauthor=G.+Servilloauthor=C.+Brunacciauthor=M.+Calvittiauthor=S.+Bicciatoauthor=E.+M.+Mazzaauthor=L.+Boonauthor=F.+Grassiauthor=M.+C.+Fiorettiauthor=F.+Fallarinoauthor=P.+Puccettiauthor=U.+Grohmann&title=Indoleamine+2%2C3-Dioxygenase+Is+a+Signaling+Protein+in+Long-Term+Tolerance+by+Dendritic+Cells&doi=10.1038%2Fni.2077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells</span></div><div class="casAuthors">Pallotta, Maria T.; Orabona, Ciriana; Volpi, Claudia; Vacca, Carmine; Belladonna, Maria L.; Bianchi, Roberta; Servillo, Giuseppe; Brunacci, Cinzia; Calvitti, Mario; Bicciato, Silvio; Mazza, Emilia M. C.; Boon, Louis; Grassi, Fabio; Fioretti, Maria C.; Fallarino, Francesca; Puccetti, Paolo; Grohmann, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">870-878</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Regulation of tryptophan metab. by indoleamine 2,3-dioxygenase (IDO) in dendritic cells (DCs) is a highly versatile modulator of immunity.  In inflammation, interferon-γ is the main inducer of IDO for the prevention of hyperinflammatory responses, yet IDO is also responsible for self-tolerance effects in the longer term.  Here we show that treatment of mouse plasmacytoid DCs (pDCs) with transforming growth factor-β (TGF-β) conferred regulatory effects on IDO that were mechanistically separable from its enzymic activity.  We found that IDO was involved in intracellular signaling events responsible for the self-amplification and maintenance of a stably regulatory phenotype in pDCs.  Thus, IDO has a tonic, nonenzymic function that contributes to TGF-β-driven tolerance in noninflammatory contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOrM5pvb6iRbVg90H21EOLACvtfcHk0lh2phYuObqrVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKrurg%253D&md5=a3dc34802dc62b40d2255ce20bff1e54</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fni.2077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2077%26sid%3Dliteratum%253Aachs%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DServillo%26aufirst%3DG.%26aulast%3DBrunacci%26aufirst%3DC.%26aulast%3DCalvitti%26aufirst%3DM.%26aulast%3DBicciato%26aufirst%3DS.%26aulast%3DMazza%26aufirst%3DE.%2BM.%26aulast%3DBoon%26aufirst%3DL.%26aulast%3DGrassi%26aufirst%3DF.%26aulast%3DFioretti%26aufirst%3DM.%2BC.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DPuccetti%26aufirst%3DP.%26aulast%3DGrohmann%26aufirst%3DU.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520Is%2520a%2520Signaling%2520Protein%2520in%2520Long-Term%2520Tolerance%2520by%2520Dendritic%2520Cells%26jtitle%3DNat.%2520Immunol.%26date%3D2011%26volume%3D12%26spage%3D870%26epage%3D878%26doi%3D10.1038%2Fni.2077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span> <span> </span><span class="NLM_article-title">Different Partners, Opposite Outcomes: A New Perspective of the Immunobiology of Indoleamine 2,3-Dioxygenase</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.2119/molmed.2012.00029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.2119%2Fmolmed.2012.00029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=22481272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOgu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=834-842&author=C.+Orabonaauthor=M.+T.+Pallottaauthor=U.+Grohmann&title=Different+Partners%2C+Opposite+Outcomes%3A+A+New+Perspective+of+the+Immunobiology+of+Indoleamine+2%2C3-Dioxygenase&doi=10.2119%2Fmolmed.2012.00029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase</span></div><div class="casAuthors">Orabona, Ciriana; Pallotta, Maria Teresa; Grohmann, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Manhasset, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">834-842</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    
            (<span class="NLM_cas:orgname">Feinstein Institute for Medical Research</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase (IDO), a metabolic enzyme that catalyzes tryptophan conversion into kynurenines, is a crucial regulator of immunity.  Altered IDO activity is often assocd. with pathol., including neoplasia and autoimmunity.  IDO is highly expressed in dendritic cells (DCs) that exploit the enzyme's activity and the prodn. of tryptophan catabolites to regulate immune responses by acting on several cell types, including T lymphocytes, of which they promote a regulatory phenotype.  IDO also contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that, once bound by distinct mol. partners, will either promote degrdn. or initiate signaling activity and self-maintenance of the enzyme.  We here discuss how ITIM-dependent mol. events can affect the functional plasticity of IDO by modifying the protein half-life and its enzymic and nonenzymic functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVWmgYosVfx7Vg90H21EOLACvtfcHk0lh2phYuObqrVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOgu7rL&md5=374d70b6c8d944b8d9821367f1e53210</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2119%2Fmolmed.2012.00029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2119%252Fmolmed.2012.00029%26sid%3Dliteratum%253Aachs%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DGrohmann%26aufirst%3DU.%26atitle%3DDifferent%2520Partners%252C%2520Opposite%2520Outcomes%253A%2520A%2520New%2520Perspective%2520of%2520the%2520Immunobiology%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DMol.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D834%26epage%3D842%26doi%3D10.2119%2Fmolmed.2012.00029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondanelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antognelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span> <span> </span><span class="NLM_article-title">Distinct Roles of Immunoreceptor Tyrosine-Based Motifs in Immunosuppressive Indoleamine 2,3-Dioxygenase 1</span>. <i>J. Cell Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1111%2Fjcmm.12954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27696702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis12m" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=165-176&author=E.+Albiniauthor=V.+Rosiniauthor=M.+Gargaroauthor=G.+Mondanelliauthor=M.+L.+Belladonnaauthor=M.+T.+Pallottaauthor=C.+Volpiauthor=F.+Fallarinoauthor=A.+Macchiaruloauthor=C.+Antognelliauthor=R.+Bianchiauthor=C.+Vaccaauthor=P.+Puccettiauthor=U.+Grohmannauthor=C.+Orabona&title=Distinct+Roles+of+Immunoreceptor+Tyrosine-Based+Motifs+in+Immunosuppressive+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1111%2Fjcmm.12954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Albini, Elisa; Rosini, Verdiana; Gargaro, Marco; Mondanelli, Giada; Belladonna, Maria L.; Pallotta, Maria Teresa; Volpi, Claudia; Fallarino, Francesca; Macchiarulo, Antonio; Antognelli, Cinzia; Bianchi, Roberta; Vacca, Carmine; Puccetti, Paolo; Grohmann, Ursula; Orabona, Ciriana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-176</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the initial, rate-limiting step in tryptophan (Trp) degrdn., resulting in tryptophan starvation and the prodn. of immunoregulatory kynurenines.  IDO1's catalytic function has long been considered as the one mechanism responsible for IDO1-dependent immune suppression by dendritic cells (DCs), which are master regulators of the balance between immunity and tolerance.  However, IDO1 also harbors immunoreceptor tyrosine-based inhibitory motifs, (ITIM1 and ITIM2), that, once phosphorylated, bind protein tyrosine phosphatases, (SHP-1 and SHP-2), and thus trigger an immunoregulatory signalling in DCs.  This mechanism leads to sustained IDO1 expression, in a feedforward loop, which is particularly important in restraining autoimmunity and chronic inflammation.  Yet, under specific conditions requiring that early and protective inflammation be unrelieved, tyrosine-phosphorylated ITIMs will instead bind the suppressor of cytokine signalling 3 (SOCS3), which drives IDO1 proteasomal degrdn. and shortens the enzyme half-life.  To dissect any differential roles of the two IDO1's ITIMs, we generated protein mutants by replacing one or both ITIM-assocd. tyrosines with phospho-mimicking glutamic acid residues.  Although all mutants lost their enzymic activity, the ITIM1 - but not ITIM2 mutant - did bind SHPs and conferred immunosuppressive effects on DCs, making cells capable of restraining an antigen-specific response in vivo.  Conversely, the ITIM2 mutant would preferentially bind SOCS3, and IDO1's degrdn. was accelerated.  Thus, it is the selective phosphorylation of either ITIM that controls the duration of IDO1 expression and function, in that it dictates whether enhanced tolerogenic signalling or shutdown of IDO1-dependent events will occur in a local microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolWXs-y6HUa7Vg90H21EOLACvtfcHk0ljZUX9pXeo2gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis12m&md5=641c240294f776eb3cfc79f042aab83b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12954%26sid%3Dliteratum%253Aachs%26aulast%3DAlbini%26aufirst%3DE.%26aulast%3DRosini%26aufirst%3DV.%26aulast%3DGargaro%26aufirst%3DM.%26aulast%3DMondanelli%26aufirst%3DG.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DAntognelli%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DPuccetti%26aufirst%3DP.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DOrabona%26aufirst%3DC.%26atitle%3DDistinct%2520Roles%2520of%2520Immunoreceptor%2520Tyrosine-Based%2520Motifs%2520in%2520Immunosuppressive%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2017%26volume%3D21%26spage%3D165%26epage%3D176%26doi%3D10.1111%2Fjcmm.12954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batabyal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkashon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1700</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-01725-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41467-017-01725-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29167421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ktFOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1693-1700&author=A.+Lewis-Ballesterauthor=K.+N.+Phamauthor=D.+Batabyalauthor=S.+Karkashonauthor=J.+B.+Bonannoauthor=T.+L.+Poulosauthor=S.+R.+Yeh&title=Structural+Insights+into+Substrate+and+Inhibitor+Binding+Sites+in+Human+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1038%2Fs41467-017-01725-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Lewis-Ballester Ariel; Pham Khoa N; Karkashon Shay; Yeh Syun-Ru; Batabyal Dipanwita; Poulos Thomas L; Batabyal Dipanwita; Poulos Thomas L; Batabyal Dipanwita; Poulos Thomas L; Bonanno Jeffrey B</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1693</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an attractive cancer immunotherapeutic target owing to its role in promoting tumoral immune escape.  However, drug development has been hindered by limited structural information.  Here, we report the crystal structures of hIDO1 in complex with its substrate, Trp, an inhibitor, epacadostat, and/or an effector, indole ethanol (IDE).  The data reveal structural features of the active site (Sa) critical for substrate activation; in addition, they disclose a new inhibitor-binding mode and a distinct small molecule binding site (Si).  Structure-guided mutation of a critical residue, F270, to glycine perturbs the Si site, allowing structural determination of an inhibitory complex, where both the Sa and Si sites are occupied by Trp.  The Si site offers a novel target site for allosteric inhibitors and a molecular explanation for the previously baffling substrate-inhibition behavior of the enzyme.  Taken together, the data open exciting new avenues for structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI81SqDTDg0dbHMBt0mMIXfW6udTcc2eYFv1TjZmgHn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ktFOhtQ%253D%253D&md5=36b0221b0726c73a6c4345e4cf2ec8be</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01725-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01725-8%26sid%3Dliteratum%253Aachs%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DBatabyal%26aufirst%3DD.%26aulast%3DKarkashon%26aufirst%3DS.%26aulast%3DBonanno%26aufirst%3DJ.%2BB.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DStructural%2520Insights%2520into%2520Substrate%2520and%2520Inhibitor%2520Binding%2520Sites%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D1693%26epage%3D1700%26doi%3D10.1038%2Fs41467-017-01725-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelp, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kates, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, J. T.</span></span> <span> </span><span class="NLM_article-title">Immune-Modulating Enzyme Indoleamine 2,3-Dioxygenase Is Effectively Inhibited by Targeting Its Apo-Form</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3249</span>– <span class="NLM_lpage">3254</span>, <span class="refDoi"> DOI: 10.1073/pnas.1719190115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.1719190115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29531094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Ckur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=3249-3254&author=M.+T.+Nelpauthor=P.+A.+Katesauthor=J.+T.+Huntauthor=J.+A.+Newittauthor=A.+Balogauthor=D.+Maleyauthor=X.+Zhuauthor=L.+Abellauthor=A.+Allentoffauthor=R.+Borzilleriauthor=H.+A.+Lewisauthor=Z.+Linauthor=S.+P.+Seitzauthor=C.+Yanauthor=J.+T.+Groves&title=Immune-Modulating+Enzyme+Indoleamine+2%2C3-Dioxygenase+Is+Effectively+Inhibited+by+Targeting+Its+Apo-Form&doi=10.1073%2Fpnas.1719190115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form</span></div><div class="casAuthors">Nelp, Micah T.; Kates, Patrick A.; Hunt, John T.; Newitt, John A.; Balog, Aaron; Maley, Derrick; Zhu, Xiao; Abelle, Lynn; Allentoff, Alban; Borzilleri, Robert; Lewis, Hal A.; Lin, Zeyu; Seitz, Steven P.; Yan, Chunhong; Groves, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3249-3254</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">For cancer cells to survive and proliferate, they must escape normal immune destruction.  One mechanism by which this is accomplished is through immune suppression effected by up-regulation of indole- amine 2,3-dioxygenase (IDO1), a heme enzyme that catalyzes the oxidn. of tryptophan to N-formylkynurenine.  On deformylation, kynurenine and downstream metabolites suppress T cell function.  The importance of this immunosuppressive mechanism has spurred intense interest in the development of clin. IDO1 inhibitors.  Herein, we describe the mechanism by which a class of compds. effectively and specifically inhibits IDO1 by targeting its apo- form.  We show that the in vitro kinetics of inhibition coincide with an unusually high rate of intrinsic enzyme-heme dissocn., esp. in the ferric form.  X-ray crystal structures of the inhibitor-enzyme complexes show that heme is displaced from the enzyme and blocked from rebinding by these compds.  The results reveal that apo-IDO1 serves as a unique target for inhibition and that heme lability plays an important role in posttranslational regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqG51BFbfm7Vg90H21EOLACvtfcHk0liRCtXuMmQoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Ckur7I&md5=b44352b022692d150053696bb984665f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1719190115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1719190115%26sid%3Dliteratum%253Aachs%26aulast%3DNelp%26aufirst%3DM.%2BT.%26aulast%3DKates%26aufirst%3DP.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DBalog%26aufirst%3DA.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DAbell%26aufirst%3DL.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DBorzilleri%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DGroves%26aufirst%3DJ.%2BT.%26atitle%3DImmune-Modulating%2520Enzyme%2520Indoleamine%25202%252C3-Dioxygenase%2520Is%2520Effectively%2520Inhibited%2520by%2520Targeting%2520Its%2520Apo-Form%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3D3249%26epage%3D3254%26doi%3D10.1073%2Fpnas.1719190115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">14538</span>– <span class="NLM_lpage">14541</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b07994</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b07994" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFygsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=14538-14541&author=K.+N.+Phamauthor=S.+R.+Yeh&title=Mapping+the+Binding+Trajectory+of+a+Suicide+Inhibitor+in+Human+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1021%2Fjacs.8b07994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1</span></div><div class="casAuthors">Pham, Khoa N.; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">14538-14541</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an important heme-contg. enzyme that is a key drug target for cancer immunotherapy.  Several hIDO1 inhibitors have entered clin. trials, among which BMS-986205 (BMS) stands out as the only suicide inhibitor.  Despite its "best-in-class" activity, the action mechanism of BMS remains elusive.  Here, we report three crystal structures of hIDO1-BMS complexes that define the complete binding trajectory of the inhibitor.  BMS first binds in a solvent exposed surface cleft near the active site in an extended conformation.  The initial binding partially unfolds the active site, which triggers heme release, thereby exposing a new binding pocket.  The inhibitor then undergoes a large scale movement to this new binding pocket, where it binds by adopting a high energy kinked conformation.  Finally, the inhibitor relaxes to a bent conformation, via an addnl. large scale rearrangement, culminating in the energy min. state.  The structural data offer a mol. explanation for the remarkable efficacy and suicide inhibition activity of the inhibitor.  They also suggest a novel strategy that can be applied for drug development targeting hIDO1 and related enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo49tBUq_145rVg90H21EOLACvtfcHk0liRCtXuMmQoFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFygsbfJ&md5=833164c8276bd3b8d9d93df197cf4780</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b07994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b07994%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DMapping%2520the%2520Binding%2520Trajectory%2520of%2520a%2520Suicide%2520Inhibitor%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D14538%26epage%3D14541%26doi%3D10.1021%2Fjacs.8b07994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottemanne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannelle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauwenberghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordonnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroose, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrerie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Eynde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (Ido-1) Inhibitor 3-(5-Fluoro-1h-Indol-3-Yl)Pyrrolidine-2,5-Dione (Eos200271/Pf-06840003) and Its Characterization as a Potential Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9617</span>– <span class="NLM_lpage">9629</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00974</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00974" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9617-9629&author=S.+Crosignaniauthor=P.+Binghamauthor=P.+Bottemanneauthor=H.+Cannelleauthor=S.+Cauwenberghsauthor=M.+Cordonnierauthor=D.+Dalvieauthor=F.+Derooseauthor=J.+L.+Fengauthor=B.+Gomesauthor=S.+Greasleyauthor=S.+E.+Kaiserauthor=M.+Krausauthor=M.+Negrerieauthor=K.+Maegleyauthor=N.+Millerauthor=B.+W.+Murrayauthor=M.+Schneiderauthor=J.+Soloweijauthor=A.+E.+Stewartauthor=J.+Tumangauthor=V.+R.+Tortiauthor=B.+Van+Den+Eyndeauthor=M.+Wythes&title=Discovery+of+a+Novel+and+Selective+Indoleamine+2%2C3-Dioxygenase+%28Ido-1%29+Inhibitor+3-%285-Fluoro-1h-Indol-3-Yl%29Pyrrolidine-2%2C5-Dione+%28Eos200271%2FPf-06840003%29+and+Its+Characterization+as+a+Potential+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b00974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate</span></div><div class="casAuthors">Crosignani, Stefano; Bingham, Patrick; Bottemanne, Pauline; Cannelle, Helene; Cauwenberghs, Sandra; Cordonnier, Marie; Dalvie, Deepak; Deroose, Frederik; Feng, Jun Li; Gomes, Bruno; Greasley, Samantha; Kaiser, Stephen E.; Kraus, Manfred; Negrerie, Michel; Maegley, Karen; Miller, Nichol; Murray, Brion W.; Schneider, Manfred; Soloweij, James; Stewart, Albert E.; Tumang, Joseph; Torti, Vince R.; Van Den Eynde, Benoit; Wythes, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9617-9629</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment.  IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function.  As such, IDO-1 is a nexus for the induction of a key immunosuppressive mechanism and represents an important immunotherapeutic target in oncol.  Starting from HTS hit I, IDO-1 inhibitor II has been developed.  The structure-activity relationship around II is described and rationalized using the x-ray crystal structure of II bound to human IDO-1, which shows that II, differently from most of the IDO-1 inhibitors described so far, does not bind to the heme iron atom and has a novel binding mode.  Clin. candidate II shows good potency in an IDO-1 human whole blood assay and also shows a very favorable ADME profile leading to favorable predicted human pharmacokinetic properties, including a predicted half-life of 16-19 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogfHmZRAC-dLVg90H21EOLACvtfcHk0ljRKFHOOTrdYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK&md5=dc2e45c243aa22c100ccc39db9b5918a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00974%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBottemanne%26aufirst%3DP.%26aulast%3DCannelle%26aufirst%3DH.%26aulast%3DCauwenberghs%26aufirst%3DS.%26aulast%3DCordonnier%26aufirst%3DM.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDeroose%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DGreasley%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DS.%2BE.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DNegrerie%26aufirst%3DM.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSoloweij%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTumang%26aufirst%3DJ.%26aulast%3DTorti%26aufirst%3DV.%2BR.%26aulast%3DVan%2BDen%2BEynde%26aufirst%3DB.%26aulast%3DWythes%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520and%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528Ido-1%2529%2520Inhibitor%25203-%25285-Fluoro-1h-Indol-3-Yl%2529Pyrrolidine-2%252C5-Dione%2520%2528Eos200271%252FPf-06840003%2529%2520and%2520Its%2520Characterization%2520as%2520a%2520Potential%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9617%26epage%3D9629%26doi%3D10.1021%2Facs.jmedchem.7b00974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosdidier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerundolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1172</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1021/jm9014718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9014718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1emsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1172-1189&author=U.+F.+Rohrigauthor=L.+Awadauthor=A.+Grosdidierauthor=P.+Larrieuauthor=V.+Stroobantauthor=D.+Colauauthor=V.+Cerundoloauthor=A.+J.+Simpsonauthor=P.+Vogelauthor=B.+J.+Van+den+Eyndeauthor=V.+Zoeteauthor=O.+Michielin&title=Rational+Design+of+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Fjm9014718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Awad, Loay; Grosdidier, Aurelien; Larrieu, Pierre; Stroobant, Vincent; Colau, Didier; Cerundolo, Vincenzo; Simpson, Andrew J. G.; Vogel, Pierre; Van den Eynde, Benoit J.; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1172-1189</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is an important therapeutic target for the treatment of diseases such as cancer that involve pathol. immune escape.  We have used the evolutionary docking algorithm EADock to design new inhibitors of this enzyme.  First, we investigated the modes of binding of all known IDO inhibitors.  On the basis of the obsd. docked conformations, we developed a pharmacophore model, which was then used to devise new compds. to be tested for IDO inhibition.  We also used a fragment-based approach to design and to optimize small org. mol. inhibitors.  Both approaches yielded several new low-mol. wt. inhibitor scaffolds, the most active being of nanomolar potency in an enzymic assay.  Cellular assays confirmed the potential biol. relevance of four different scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9k4hgz-V8J7Vg90H21EOLACvtfcHk0ljRKFHOOTrdYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1emsA%253D%253D&md5=be50f3dff0bcee6ae59f19d2fc4e5552</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm9014718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9014718%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DAwad%26aufirst%3DL.%26aulast%3DGrosdidier%26aufirst%3DA.%26aulast%3DLarrieu%26aufirst%3DP.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DCerundolo%26aufirst%3DV.%26aulast%3DSimpson%26aufirst%3DA.%2BJ.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DRational%2520Design%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1172%26epage%3D1189%26doi%3D10.1021%2Fjm9014718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griglio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coda Zabetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span> <span> </span><span class="NLM_article-title">A Multicomponent Approach in the Discovery of Indoleamine 2,3-Dioxygenase 1 Inhibitors: Synthesis, Biological Investigation and Docking Studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2018.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29398544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFejsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=651-657&author=A.+Griglioauthor=E.+Torreauthor=M.+Serafiniauthor=A.+Bianchiauthor=R.+Schmidauthor=G.+Coda+Zabettaauthor=A.+Massarottiauthor=G.+Sorbaauthor=T.+Piraliauthor=S.+Fallarini&title=A+Multicomponent+Approach+in+the+Discovery+of+Indoleamine+2%2C3-Dioxygenase+1+Inhibitors%3A+Synthesis%2C+Biological+Investigation+and+Docking+Studies&doi=10.1016%2Fj.bmcl.2018.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: Synthesis, biological investigation and docking studies</span></div><div class="casAuthors">Griglio, Alessia; Torre, Enza; Serafini, Marta; Bianchi, Alice; Schmid, Roberta; Coda Zabetta, Giulia; Massarotti, Alberto; Sorba, Giovanni; Pirali, Tracey; Fallarini, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">651-657</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase plays a crucial role in immune tolerance and has emerged as an attractive target for cancer immunotherapy.  The Passerini and Ugi multicomponent reactions were employed to assemble a small library of imidazothiazoles that target IDO1.  While the p-bromophenyl and the imidazothiazole moieties were kept fixed, a full SAR study was performed on the side-chain, leading to the discovery of nine compds. with sub-micromolar IC50 values in the enzyme-based assay.  Compd. 2(((3-(4-bromophenyl)imidazo[2,1-b]bromophenyl)thiazol-5-yl)methyl)amino-2-oxoethyl-2-(4-hydroxyphenyl)acetate displaying a α-acyloxyamide substructure, is the most potent compd., with an IC50 value of 0.20 μM, but a low activity in a cell-based assay.  Compd. N-(2-((((4-bromophenyl)imidazo[2,1-b]thiazol-yl)methyl)amino)-2-oxoethyl)-N-methyl-2-(4-nitrophenyl)acetamide, contg. a α-acylaminoamide moiety, shows an IC50 value of 0.81 μM in the IDO1-based assay, a full biocompatibility at 10 μM, together with a modest inhibitory activity in A375 cells.  Mol. docking studies show that both 2(((3-(4-bromophenyl)imidazo[2,1-b]bromophenyl)thiazol-5-yl)methyl)amino-2-oxoethyl-2-(4-hydroxyphenyl)acetate and N-(2-((((4-bromophenyl)imidazolo[2,1-b]thiazol-yl)methyl)amino)-2-oxoethyl)-N-methyl-2-(4-nitrophenyl)acetamide display a unique binding mode in the IDO1 active site, with the side-chain protruding in an addnl. pocket C, where a crucial hydrogen bond is formed with Lys238.  Overall, this work describes an isocyanide based-multicomponent approach as a straightforward and versatile tool to rapidly access IDO1 inhibitors, providing a new direction for their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64_p69vrWELVg90H21EOLACvtfcHk0lgBAOxR74e6iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFejsr4%253D&md5=4390159c52c08f3eb23e84f10ecb7138</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DGriglio%26aufirst%3DA.%26aulast%3DTorre%26aufirst%3DE.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DBianchi%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DR.%26aulast%3DCoda%2BZabetta%26aufirst%3DG.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DFallarini%26aufirst%3DS.%26atitle%3DA%2520Multicomponent%2520Approach%2520in%2520the%2520Discovery%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitors%253A%2520Synthesis%252C%2520Biological%2520Investigation%2520and%2520Docking%2520Studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D651%26epage%3D657%26doi%3D10.1016%2Fj.bmcl.2018.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Meoz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matico, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De la Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Midgett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mebrahtu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campobasso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mülbaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmierski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">324947</span>, <span class="refDoi"> DOI: 10.1002/cbic.202000298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcbic.202000298" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=324947&author=R.+Ortiz-Meozauthor=L.+Wangauthor=R.+Maticoauthor=A.+Rutkowskaauthor=M.+De+la+Rosaauthor=S.+Bedardauthor=R.+Midgettauthor=K.+Strohmerauthor=D.+Thomsonauthor=C.+Zhangauthor=M.+Mebrahtuauthor=J.+Gussauthor=R.+Totoritisauthor=T.+Conslerauthor=N.+Campobassoauthor=D.+Taylorauthor=T.+Lewisauthor=K.+Weaverauthor=M.+M%C3%BClbaierauthor=J.+Sealauthor=R.+Dunhamauthor=W.+Kazmierskiauthor=D.+Favreauthor=G.+Bergaminiauthor=L.+Shewchukauthor=A.+Rendinaauthor=G.+Zhang&title=Characterization+of+Apo-Form+Selective+Inhibition+of+Indoleamine+2%2C3-Dioxygenase&doi=10.1002%2Fcbic.202000298"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fcbic.202000298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.202000298%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz-Meoz%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMatico%26aufirst%3DR.%26aulast%3DRutkowska%26aufirst%3DA.%26aulast%3DDe%2Bla%2BRosa%26aufirst%3DM.%26aulast%3DBedard%26aufirst%3DS.%26aulast%3DMidgett%26aufirst%3DR.%26aulast%3DStrohmer%26aufirst%3DK.%26aulast%3DThomson%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMebrahtu%26aufirst%3DM.%26aulast%3DGuss%26aufirst%3DJ.%26aulast%3DTotoritis%26aufirst%3DR.%26aulast%3DConsler%26aufirst%3DT.%26aulast%3DCampobasso%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DLewis%26aufirst%3DT.%26aulast%3DWeaver%26aufirst%3DK.%26aulast%3DM%25C3%25BClbaier%26aufirst%3DM.%26aulast%3DSeal%26aufirst%3DJ.%26aulast%3DDunham%26aufirst%3DR.%26aulast%3DKazmierski%26aufirst%3DW.%26aulast%3DFavre%26aufirst%3DD.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DShewchuk%26aufirst%3DL.%26aulast%3DRendina%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520Apo-Form%2520Selective%2520Inhibition%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DChemBioChem%26date%3D2020%26spage%3D324947%26doi%3D10.1002%2Fcbic.202000298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Koenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacciapoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smotrov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-Dioxygenase-1 (Ido1)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">550</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=550-557&author=C.+Whiteauthor=M.+A.+McGowanauthor=H.+Zhouauthor=N.+Sciammettaauthor=X.+Fraderaauthor=J.+Limauthor=E.+M.+Joshiauthor=C.+Andrewsauthor=E.+B.+Nickbargauthor=P.+Cowleyauthor=S.+Trewickauthor=M.+Augustinauthor=K.+von+Koenigauthor=C.+A.+Lesburgauthor=K.+Otteauthor=I.+Knemeyerauthor=H.+Wooauthor=W.+Yuauthor=M.+Chengauthor=P.+Spacciapoliauthor=P.+Gedaauthor=X.+Songauthor=N.+Smotrovauthor=P.+Curranauthor=M.+R.+Heoauthor=P.+Abeywickremaauthor=J.+R.+Millerauthor=D.+J.+Bennettauthor=Y.+Han&title=Strategic+Incorporation+of+Polarity+in+Heme-Displacing+Inhibitors+of+Indoleamine-2%2C3-Dioxygenase-1+%28Ido1%29&doi=10.1021%2Facsmedchemlett.0c00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)</span></div><div class="casAuthors">White, Catherine; McGowan, Meredeth A.; Zhou, Hua; Sciammetta, Nunzio; Fradera, Xavier; Lim, Jongwon; Joshi, Elizabeth M.; Andrews, Christine; Nickbarg, Elliott B.; Cowley, Phillip; Trewick, Sarah; Augustin, Martin; von Koenig, Konstanze; Lesburg, Charles A.; Otte, Karin; Knemeyer, Ian; Woo, Hyun; Yu, Wensheng; Cheng, Mangeng; Spacciapoli, Peter; Geda, Prasanthi; Song, Xuelei; Smotrov, Nadya; Curran, Patrick; Heo, Mee Ra; Abeywickrema, Pravien; Miller, J. Richard; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">550-557</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as a target of significant interest to the field of cancer immunotherapy, as the upregulation of IDO1 in certain cancers has been linked to host immune evasion and poor prognosis for patients.  In particular, IDO1 inhibition is of interest as a combination therapy with immune checkpoint inhibition.  Through an Automated Ligand Identification System (ALIS) screen, a diamide class of compds. was identified as a promising lead for the inhibition of IDO1.  While hit 1() possessed attractive cell-based potency, it suffered from a significant right-shift in a whole blood assay, poor soly., and poor pharmacokinetic properties.  Through a physicochem. property-based approach, including a focus on lowering AlogP98 via the strategic introduction of polar substitution, compd. 13 was identified bearing a pyridyl oxetane core.  Compd. 13() demonstrated improved whole blood potency and soly., and an improved pharmacokinetic profile resulting in a low predicted human dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnzfQfxAahcbVg90H21EOLACvtfcHk0ljPbwrkG53N4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWksbc%253D&md5=cad9d7aa1db10d920c558cd4ba4af9cd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00010%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DC.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DAndrews%26aufirst%3DC.%26aulast%3DNickbarg%26aufirst%3DE.%2BB.%26aulast%3DCowley%26aufirst%3DP.%26aulast%3DTrewick%26aufirst%3DS.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3Dvon%2BKoenig%26aufirst%3DK.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DWoo%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DSpacciapoli%26aufirst%3DP.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSmotrov%26aufirst%3DN.%26aulast%3DCurran%26aufirst%3DP.%26aulast%3DHeo%26aufirst%3DM.%2BR.%26aulast%3DAbeywickrema%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DStrategic%2520Incorporation%2520of%2520Polarity%2520in%2520Heme-Displacing%2520Inhibitors%2520of%2520Indoleamine-2%252C3-Dioxygenase-1%2520%2528Ido1%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D550%26epage%3D557%26doi%3D10.1021%2Facsmedchemlett.0c00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazmierski, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De la Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mebrahtu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evindar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samano, V.</span></span> <span> </span><span class="NLM_article-title">DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (Ido1) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3552</span>– <span class="NLM_lpage">3562</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01799</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01799" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3552-3562&author=W.+M.+Kazmierskiauthor=B.+Xiaauthor=J.+Millerauthor=M.+De+la+Rosaauthor=D.+Favreauthor=R.+M.+Dunhamauthor=Y.+Washioauthor=Z.+Zhuauthor=F.+Wangauthor=M.+Mebrahtuauthor=H.+Dengauthor=J.+Basillaauthor=L.+Wangauthor=G.+Evindarauthor=L.+Fanauthor=A.+Olszewskiauthor=N.+Prabhuauthor=C.+Davieauthor=J.+A.+Messerauthor=V.+Samano&title=DNA-Encoded+Library+Technology-Based+Discovery%2C+Lead+Optimization%2C+and+Prodrug+Strategy+toward+Structurally+Unique+Indoleamine+2%2C3-Dioxygenase-1+%28Ido1%29+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors</span></div><div class="casAuthors">Kazmierski, Wieslaw M.; Xia, Bing; Miller, John; De la Rosa, Martha; Favre, David; Dunham, Richard M.; Washio, Yoshiaki; Zhu, Zhengrong; Wang, Feng; Mebrahtu, Makda; Deng, Hongfeng; Basilla, Jonathan; Wang, Liping; Evindar, Ghotas; Fan, Lijun; Olszewski, Alison; Prabhu, Ninad; Davie, Christopher; Messer, Jeffrey A.; Samano, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3552-3562</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the discovery of a novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor class through the affinity selection of a previously unreported indole-based DNA-encoded library (DEL).  The DEL exemplar, spiro-chromane 1, had moderate IDO1 potency but high in vivo clearance.  Series optimization quickly afforded a potent, low in vivo clearance lead 11.  Although amorphous 11 was highly bio-available, cryst. 11 was poorly sol. and suffered disappointingly low bio-availability because of soly.-limited absorption.  A prodrug approach was deployed and proved effective in discovering the highly bio-available phosphonooxymethyl 31, which rapidly converted to 11 in vivo.  Obtaining cryst. 31 proved problematic, however; thus salt screening was performed in an attempt to circumvent this obstacle and successfully delivered greatly sol. and bio-available cryst. tris-salt 32.  IDO1 inhibitor 32 is characterized by a low calcd. human dose, best-in-class potential, and an unusual inhibition mode by binding the IDO1 heme-free (apo) form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSTj0UyMSxbVg90H21EOLACvtfcHk0ljPbwrkG53N4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOms7k%253D&md5=8cddeffb12cefd9b3e1c2e0641ad7226</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01799%26sid%3Dliteratum%253Aachs%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26aulast%3DXia%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DJ.%26aulast%3DDe%2Bla%2BRosa%26aufirst%3DM.%26aulast%3DFavre%26aufirst%3DD.%26aulast%3DDunham%26aufirst%3DR.%2BM.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMebrahtu%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DBasilla%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEvindar%26aufirst%3DG.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DOlszewski%26aufirst%3DA.%26aulast%3DPrabhu%26aufirst%3DN.%26aulast%3DDavie%26aufirst%3DC.%26aulast%3DMesser%26aufirst%3DJ.%2BA.%26aulast%3DSamano%26aufirst%3DV.%26atitle%3DDNA-Encoded%2520Library%2520Technology-Based%2520Discovery%252C%2520Lead%2520Optimization%252C%2520and%2520Prodrug%2520Strategy%2520toward%2520Structurally%2520Unique%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3552%26epage%3D3562%26doi%3D10.1021%2Facs.jmedchem.9b01799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent and Orally Available Bicyclo[1.1.1]Pentane-Derived Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1548</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1548-1554&author=Q.+Puauthor=H.+Zhangauthor=L.+Guoauthor=M.+Chengauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=X.+Fraderaauthor=C.+A.+Lesburgauthor=M.+A.+McGowanauthor=J.+R.+Millerauthor=P.+Gedaauthor=X.+Songauthor=K.+Otteauthor=N.+Sciammettaauthor=N.+Solbanauthor=W.+Yuauthor=D.+L.+Slomanauthor=H.+Zhouauthor=A.+Lammensauthor=L.+Neumannauthor=D.+J.+Bennettauthor=A.+Pasternakauthor=Y.+Han&title=Discovery+of+Potent+and+Orally+Available+Bicyclo%5B1.1.1%5DPentane-Derived+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1021%2Facsmedchemlett.0c00195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Pu, Qinglin; Zhang, Hongjun; Guo, Liangqin; Cheng, Mangeng; Doty, Amy C.; Ferguson, Heidi; Fradera, Xavier; Lesburg, Charles A.; McGowan, Meredeth A.; Miller, J. Richard; Geda, Prasanthi; Song, Xuelei; Otte, Karin; Sciammetta, Nunzio; Solban, Nicolas; Yu, Wensheng; Sloman, David L.; Zhou, Hua; Lammens, Alfred; Neumann, Lars; Bennett, David Jonathan; Pasternak, Alexander; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1548-1554</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase 1 (IDO1) inhibition and its combination with immune checkpoint inhibitors like pembrolizumab have drawn considerable attention from both academia and the pharmaceutical industry.  Here, we describe the discovery of a novel class of highly potent IDO1 heme-displacing inhibitors featuring a unique bicyclo[1.1.1]pentane motif.  Compd. 1, evolving from an ALIS (automated ligand identification system) hit, exhibited excellent potency but lacked the desired pharmacokinetic profile due to extensive amide hydrolysis of the benzamide moiety.  Replacing the central Ph ring in 1 with a bicyclo[1.1.1]pentane bioisostere effectively circumvented the amide hydrolysis issue, resulting in the discovery of compd. 2(I) with a favorable overall profile such as excellent potency, selectivity, pharmacokinetics, and a low predicted human dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRMnzRWR18LVg90H21EOLACvtfcHk0ljkXxp94XYTLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtLbI&md5=d55b05877e5ee16eeaa7937ef0b83cef</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00195%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DSolban%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DSloman%26aufirst%3DD.%2BL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLammens%26aufirst%3DA.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Potent%2520and%2520Orally%2520Available%2520Bicyclo%255B1.1.1%255DPentane-Derived%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1548%26epage%3D1554%26doi%3D10.1021%2Facsmedchemlett.0c00195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (Ido1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8784</span>– <span class="NLM_lpage">8795</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00942</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00942" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOqu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8784-8795&author=U.+F.+Rohrigauthor=A.+Reynaudauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=F.+Pojerauthor=V.+Zoete&title=Inhibition+Mechanisms+of+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29&doi=10.1021%2Facs.jmedchem.9b00942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)</span></div><div class="casAuthors">Rohrig, Ute F.; Reynaud, Aline; Majjigapu, Somi Reddy; Vogel, Pierre; Pojer, Florence; Zoete, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8784-8795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in the kynurenine pathway of tryptophan metab., which is involved in immunity, neuronal function, and aging.  Its implication in pathologies such as cancer and neurodegenerative diseases has stimulated the development of IDO1 inhibitors.  However, neg. phase III clin. trial results of the IDO1 inhibitor epacadostat in cancer immunotherapy call for a better understanding of the role and the mechanisms of IDO1 inhibition.  In this work, we investigate the mol. inhibition mechanisms of four known IDO1 inhibitors and of two quinones in detail, using different exptl. and computational approaches.  We also det. for the first time the X-ray structure of the highly efficient 1,2,3-triazole inhibitor MMG-0358.  Based on our results and a comprehensive literature overview, we propose a classification scheme for IDO1 inhibitors according to their inhibition mechanism, which will be useful for further developments in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTZnLePiNWE7Vg90H21EOLACvtfcHk0ljkXxp94XYTLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOqu7%252FP&md5=01919796d4821743975fe01a5527008c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00942%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DReynaud%26aufirst%3DA.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DInhibition%2520Mechanisms%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8784%26epage%3D8795%26doi%3D10.1021%2Facs.jmedchem.9b00942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mammoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballarotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camaioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span> <span> </span><span class="NLM_article-title">New Insights from Crystallographic Data: Diversity of Structural Motifs and Molecular Recognition Properties between Groups of Ido1 Structures</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1002/cmdc.202000116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcmdc.202000116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32190988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFymsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=891-899&author=A.+Mammoliauthor=A.+Colettiauthor=M.+Ballarottoauthor=A.+Riccioauthor=A.+Carottiauthor=U.+Grohmannauthor=E.+Camaioniauthor=A.+Macchiarulo&title=New+Insights+from+Crystallographic+Data%3A+Diversity+of+Structural+Motifs+and+Molecular+Recognition+Properties+between+Groups+of+Ido1+Structures&doi=10.1002%2Fcmdc.202000116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New Insights from Crystallographic Data: Diversity of Structural Motifs and Molecular Recognition Properties between Groups of IDO1 Structures</span></div><div class="casAuthors">Mammoli, Andrea; Coletti, Alice; Ballarotto, Marco; Riccio, Alessandra; Carotti, Andrea; Grohmann, Ursula; Camaioni, Emidio; Macchiarulo, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A large no. of crystallog. structures of IDO1 in different ligand-bound and -unbound states have been disclosed over the last decade.  Yet, only a few of them have been exploited for structure-based drug design (SBDD) campaigns.  In this study, we analyzed the structural motifs and mol.-recognition properties of three groups of IDO1 structures: 1) structures contg. the heme group and inhibitors in the catalytic site; 2) heme-free structures of IDO1; 3) substrate-bound structures of IDO1.  The results suggest that unrelated conformations of the enzyme have been solved with different ligand-induced changes of secondary motifs that localize even in regions remote from the catalytic site.  Moreover, the study identified an uncharted region of mol.-recognition space covered by IDO1 binding sites that could guide the selection of diverse structures for addnl. SBDD studies aimed at the identification of novel lead compds. with differentiated chem. scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvEOO4u9CtwrVg90H21EOLACvtfcHk0ljq5m_s9Hpq1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFymsbo%253D&md5=c73af36eed2b144f3cc1c38f0d0772ac</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.202000116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.202000116%26sid%3Dliteratum%253Aachs%26aulast%3DMammoli%26aufirst%3DA.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DBallarotto%26aufirst%3DM.%26aulast%3DRiccio%26aufirst%3DA.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DNew%2520Insights%2520from%2520Crystallographic%2520Data%253A%2520Diversity%2520of%2520Structural%2520Motifs%2520and%2520Molecular%2520Recognition%2520Properties%2520between%2520Groups%2520of%2520Ido1%2520Structures%26jtitle%3DChemMedChem%26date%3D2020%26volume%3D15%26spage%3D891%26epage%3D899%26doi%3D10.1002%2Fcmdc.202000116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><a href="http://www.rcsb.org/" class="extLink">http://www.rcsb.org/</a> (accessed May
2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.rcsb.org%2F+%28accessed+May%0A2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Cyanopyridine Scaffold as Novel Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitors through Virtual Screening and Preliminary Hit Optimisation</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1080/14756366.2018.1480614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1080%2F14756366.2018.1480614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30734612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsVSqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=250-263&author=X.+Xuauthor=J.+Renauthor=Y.+Maauthor=H.+Liuauthor=Q.+Rongauthor=Y.+Fengauthor=Y.+Wangauthor=Y.+Chengauthor=R.+Geauthor=Z.+Liauthor=J.+Bian&title=Discovery+of+Cyanopyridine+Scaffold+as+Novel+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors+through+Virtual+Screening+and+Preliminary+Hit+Optimisation&doi=10.1080%2F14756366.2018.1480614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation</span></div><div class="casAuthors">Xu, Xi; Ren, Jie; Ma, Yinghe; Liu, Hongting; Rong, Quanjin; Feng, Yifan; Wang, Yameng; Cheng, Yu; Ge, Ruijia; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250-263</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">With the aim of discovering novel IDO1 inhibitors, a combined similarity search and mol. docking approach was employed to the discovery of 32 hit compds.  Testing the screened hit compds. has led to several novel submicromolar inhibitors.  Compds. with cyanopyridine scaffold showed good IDO1 inhibitory activity.  To discover more compds. with similar structures, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivs.  Mol. docking studies suggested a possible binding mode of cyanopyridine compd., which provides a good starting point for the development of cyanopyridine scaffold compds. as potent IDO1 inhibitor.  To improve potency of these hits, the authors further designed and synthesized another 14 derivs. of the cyanopyridine compd.  Among these compds., N-(3-chloro-4-fluorophenyl)-2-((3-cyano-6-(trifluoromethyl)pyridin-2-yl)thio)acetamide [2314464-14-5] (LBJ-10) showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analog.  LBJ-10 can serve as an ideal lead for further modifications as IDO1 inhibitors for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZpDOXHrMlwrVg90H21EOLACvtfcHk0ljq5m_s9Hpq1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsVSqtA%253D%253D&md5=ed7377b92b76dec05b9527c95ea6fcc0</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1080%2F14756366.2018.1480614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2018.1480614%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DRong%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Cyanopyridine%2520Scaffold%2520as%2520Novel%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%2520through%2520Virtual%2520Screening%2520and%2520Preliminary%2520Hit%2520Optimisation%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26spage%3D250%26epage%3D263%26doi%3D10.1080%2F14756366.2018.1480614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span> <span> </span><span class="NLM_article-title">Reimagining Ido Pathway Inhibition in Cancer Immunotherapy Via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1462</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-2882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F1078-0432.CCR-18-2882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30377198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=1462-1471&author=B.+W.+Labadieauthor=R.+Baoauthor=J.+J.+Luke&title=Reimagining+Ido+Pathway+Inhibition+in+Cancer+Immunotherapy+Via+Downstream+Focus+on+the+Tryptophan-Kynurenine-Aryl+Hydrocarbon+Axis&doi=10.1158%2F1078-0432.CCR-18-2882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis</span></div><div class="casAuthors">Labadie, Brian W.; Bao, Riyue; Luke, Jason J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1462-1471</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Significant progress has been made in cancer immunotherapy with checkpoint inhibitors targeting programmed cell death protein 1 (PD-l)-programmed death-ligand 1 signaling pathways.  Tumors from patients showing sustained treatment response predominately demonstrate a T cell-inflamed tumor microenvironment prior to, or early on, treatment.  Not all tumors with this phenotype respond, however, and one mediator of immuno suppression in 'I' cell-inflamed tumors is die tryptophan-kynurenine-aryl hydrocarbon receptor (Trp-Kyn-AhR) pathway.  Multiple mechanisms of immuno suppression may be mediated by this pathway including depletion of tryptophan, direct immuno suppression of Kyn, and activity of Kyn-bound AhR.  Indoleamine 2,3-dioxygenase 1 (IDO 1), a principle enzyme inTrp catabolism, is the target of small-mol. inhibitors in clin. development in combination with PD-I checkpoint inhibitors.  Despite promising results in early-phase clin. trials in a range of tumor types, a phase III study of the IDOl-selective inhibitor epacadostat in combination with pembrolizumab showed no difference between the epacadostat-treated group vs. placebo in patients with metastatic melanoma.  This has led to a diminution ofinterest in IDOl inhibitors; however, other approaches to inhibit this pathway continue to be considered.  Novel TrpKyn-AhR pathway inhibitors,such as Kyn-degrading enzymes, direct AhR antagonists, and tryptophan mimetics are advancing in early-stage or preclin. development.  Despite uncertainty surrounding IDOl inhibition, ample preclin. evidence supports continued development of Trp-Kyn-AhR pathway inhibitorsto augment immune-checkpoint and other cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBgR1gxNYFxrVg90H21EOLACvtfcHk0lgqxoqB744Dmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7rF&md5=29f1f1a3e300aa38c32167ecd03a552e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-2882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-2882%26sid%3Dliteratum%253Aachs%26aulast%3DLabadie%26aufirst%3DB.%2BW.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26atitle%3DReimagining%2520Ido%2520Pathway%2520Inhibition%2520in%2520Cancer%2520Immunotherapy%2520Via%2520Downstream%2520Focus%2520on%2520the%2520Tryptophan-Kynurenine-Aryl%2520Hydrocarbon%2520Axis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D1462%26epage%3D1471%26doi%3D10.1158%2F1078-0432.CCR-18-2882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">18771</span>– <span class="NLM_lpage">18779</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b08871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b08871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=18771-18779&author=K.+N.+Phamauthor=A.+Lewis-Ballesterauthor=S.+R.+Yeh&title=Structural+Basis+of+Inhibitor+Selectivity+in+Human+Indoleamine+2%2C3-Dioxygenase+1+and+Tryptophan+Dioxygenase&doi=10.1021%2Fjacs.9b08871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase</span></div><div class="casAuthors">Pham, Khoa N.; Lewis-Ballester, Ariel; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">18771-18779</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan dioxygenase (hTDO) are two of the only three heme-based dioxygenases in humans.  They have recently been identified as key cancer immunotherapeutic drug targets.  While structures of hIDO1 in complex with inhibitors have been documented, so far there are no structures of hTDO-inhibitor complexes available.  Here we use PF-06840003 (IPD), a hIDO1-selective inhibitor in clin. trials, as a structural probe to elucidate inhibitor-selectivity in hIDO1 vs. hTDO.  Spectroscopic studies show that IPD exhibits 400-fold higher inhibition activity towards hIDO1 with respect to hTDO.  Crystallog. structures reveal that the binding pocket of IPD in the active site in hIDO1 is much more flexible as compared to that in hTDO, which offer a mol. explanation for the superior inhibition activity of IPD in hIDO1 with respect to hTDO.  In addn. to the IPD bound in the active site, a second IPD mol. was identified in an inhibitory site on the proximal side of the heme in hIDO1 and in an exosite that is ∼40 Å away from the active site in hTDO.  Taken together the data provide new insights into structure-based design of mono and dual inhibitors targeting hIDO1 and/or hTDO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6hKwhl2zTBbVg90H21EOLACvtfcHk0lgqxoqB744Dmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hs7fF&md5=1f784cd43f5025672c10cf3c39a3913f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b08871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b08871%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DStructural%2520Basis%2520of%2520Inhibitor%2520Selectivity%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520and%2520Tryptophan%2520Dioxygenase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D18771%26epage%3D18779%26doi%3D10.1021%2Fjacs.9b08871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forouhar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkashon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seetharaman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batabyal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis for Catalysis and Substrate-Mediated Cellular Stabilization of Human Tryptophan 2,3-Dioxygenase</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">35169</span>, <span class="refDoi"> DOI: 10.1038/srep35169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fsrep35169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27762317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWis7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=35169&author=A.+Lewis-Ballesterauthor=F.+Forouharauthor=S.+M.+Kimauthor=S.+Lewauthor=Y.+Wangauthor=S.+Karkashonauthor=J.+Seetharamanauthor=D.+Batabyalauthor=B.+Y.+Chiangauthor=M.+Hussainauthor=M.+A.+Correiaauthor=S.+R.+Yehauthor=L.+Tong&title=Molecular+Basis+for+Catalysis+and+Substrate-Mediated+Cellular+Stabilization+of+Human+Tryptophan+2%2C3-Dioxygenase&doi=10.1038%2Fsrep35169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Lewis-Ballester, Ariel; Forouhar, Farhad; Kim, Sung-Mi; Lew, Scott; Wang, Yong Qiang; Karkashon, Shay; Seetharaman, Jayaraman; Batabyal, Dipanwita; Chiang, Bing-Yu; Hussain, Munif; Correia, Maria Almira; Yeh, Syun-Ru; Tong, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35169</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) play a central role in tryptophan metab. and are involved in many cellular and disease processes.  Here we report the crystal structure of human TDO (hTDO) in a ternary complex with the substrates L-Trp and O2 and in a binary complex with the product N-formylkynurenine (NFK), defining for the first time the binding modes of both substrates and the product of this enzyme.  The structure indicates that the dioxygenation reaction is initiated by a direct attack of O2 on the C2 atom of the L-Trp indole ring.  The structure also reveals an exo binding site for L-Trp, located ∼42 Å from the active site and formed by residues conserved among tryptophan-auxotrophic TDOs.  Biochem. and cellular studies indicate that Trp binding at this exo site does not affect enzyme catalysis but instead it retards the degrdn. of hTDO through the ubiquitin-dependent proteasomal pathway.  This exo site may therefore provide a novel L-Trp-mediated regulation mechanism for cellular degrdn. of hTDO, which may have important implications in human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrusyw4Y4d7-7Vg90H21EOLACvtfcHk0lhCTLSap-yI3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWis7fI&md5=d990ab3173c0c0b232016b92fab79741</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fsrep35169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep35169%26sid%3Dliteratum%253Aachs%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DForouhar%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DS.%2BM.%26aulast%3DLew%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKarkashon%26aufirst%3DS.%26aulast%3DSeetharaman%26aufirst%3DJ.%26aulast%3DBatabyal%26aufirst%3DD.%26aulast%3DChiang%26aufirst%3DB.%2BY.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DCorreia%26aufirst%3DM.%2BA.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26aulast%3DTong%26aufirst%3DL.%26atitle%3DMolecular%2520Basis%2520for%2520Catalysis%2520and%2520Substrate-Mediated%2520Cellular%2520Stabilization%2520of%2520Human%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D35169%26doi%3D10.1038%2Fsrep35169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandik-Nayak, L.</span></span> <span> </span><span class="NLM_article-title">Ido2 in Immunomodulation and Autoimmune Disease</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">585</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2014.00585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffimmu.2014.00585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25477879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC2Mzpt1yqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=585&author=G.+C.+Prendergastauthor=R.+Metzauthor=A.+J.+Mullerauthor=L.+M.+Merloauthor=L.+Mandik-Nayak&title=Ido2+in+Immunomodulation+and+Autoimmune+Disease&doi=10.3389%2Ffimmu.2014.00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">IDO2 in Immunomodulation and Autoimmune Disease</span></div><div class="casAuthors">Prendergast George C; Metz Richard; Muller Alexander J; Mandik-Nayak Laura; Merlo Lauren M F</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">585</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">IDO2 is a relative of IDO1 implicated in tryptophan catabolism and immune modulation but its specific contributions to normal physiology and pathophysiology are not known.  Evolutionary genetic studies suggest that IDO2 has a unique function ancestral to IDO1.  In mice, IDO2 gene deletion does not appreciably affect embryonic development or hematopoiesis, but it leads to defects in allergic or autoimmune responses and in the ability of IDO1 to influence the generation of T regulatory cells.  Gene expression studies indicate that IDO2 is a basally and more narrowly expressed gene than IDO1 and that IDO2 is uniquely regulated by AhR, which serves as a physiological receptor for the tryptophan catabolite kynurenine.  In the established KRN transgenic mouse model of rheumatoid arthritis, where IDO1 gene deletion has no effect, IDO2 deletion selectively blunts responses to autoantigen but has no effect on responses to neoantigen challenge.  In human populations, natural variations in IDO2 gene sequence that attenuate enzymatic activity have been reported to influence brain cancer control and adaptive immune responses to the IDO2 protein itself, consistent with the concept that IDO2 is involved in shaping immune tolerance in human beings.  Biochemical and pharmacological studies provide further evidence of differences in IDO2 enzymology and function relative to IDO1.  We suggest that IDO2 may act in a distinct manner from IDO1 as a set-point for tolerance to "altered-self" antigens along the self-non-self continuum where immune challenges from cancer and autoimmunity may arise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9Jutbth7-rBLDWw4HIq2sfW6udTcc2ea2pTdZemPfQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mzpt1yqtw%253D%253D&md5=985ae32af953b4281555f7236f81fe73</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2014.00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2014.00585%26sid%3Dliteratum%253Aachs%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DMerlo%26aufirst%3DL.%2BM.%26aulast%3DMandik-Nayak%26aufirst%3DL.%26atitle%3DIdo2%2520in%2520Immunomodulation%2520and%2520Autoimmune%2520Disease%26jtitle%3DFront.%2520Immunol.%26date%3D2014%26volume%3D5%26spage%3D585%26doi%3D10.3389%2Ffimmu.2014.00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldelari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilek, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichenbach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascencao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irving, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">1,2,3-Triazoles as Inhibitors of Indoleamine 2,3-Dioxygenase 2 (Ido2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4330</span>– <span class="NLM_lpage">4333</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2016.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27469130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Ghs7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4330-4333&author=U.+F.+Rohrigauthor=S.+R.+Majjigapuauthor=D.+Caldelariauthor=N.+Dilekauthor=P.+Reichenbachauthor=K.+Ascencaoauthor=M.+Irvingauthor=G.+Coukosauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=1%2C2%2C3-Triazoles+as+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+2+%28Ido2%29&doi=10.1016%2Fj.bmcl.2016.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Caldelari, Daniela; Dilek, Nahzli; Reichenbach, Patrick; Ascencao, Kelly; Irving, Melita; Coukos, George; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4330-4333</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 2 (IDO2) is a potential therapeutic target for the treatment of diseases that involve immune escape such as cancer.  In contrast to IDO1, only a very limited no. of inhibitors have been described for IDO2 due to inherent difficulties in expressing and purifying a functionally active, sol. form of the enzyme.  Starting from our previously discovered highly efficient 4-aryl-1,2,3-triazole IDO1 inhibitor scaffold, we used computational structure-based methods to design inhibitors of IDO2 which we then tested in cellular assays.  Our approach yielded low mol. wt. inhibitors of IDO2, the most active displaying an IC50 value of 51 μM for mIDO2, and twofold selectivity over hIDO1.  These compds. could be useful as mol. probes to investigate the biol. role of IDO2, and could inspire the design of new IDO2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIu_BQk1XmmrVg90H21EOLACvtfcHk0lhCTLSap-yI3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Ghs7zJ&md5=981c536378ef1bf11333c132b3de2c8b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DCaldelari%26aufirst%3DD.%26aulast%3DDilek%26aufirst%3DN.%26aulast%3DReichenbach%26aufirst%3DP.%26aulast%3DAscencao%26aufirst%3DK.%26aulast%3DIrving%26aufirst%3DM.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3D1%252C2%252C3-Triazoles%2520as%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25202%2520%2528Ido2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D4330%26epage%3D4333%26doi%3D10.1016%2Fj.bmcl.2016.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Establishment of a Human Indoleamine 2, 3-Dioxygenase 2 (Hido2) Bioassay System and Discovery of Tryptanthrin Derivatives as Potent Hido2 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2016.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27475108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1OntrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2016&pages=171-179&author=J.+Liauthor=Y.+Liauthor=D.+Yangauthor=N.+Huauthor=Z.+Guoauthor=C.+Kuangauthor=Q.+Yang&title=Establishment+of+a+Human+Indoleamine+2%2C+3-Dioxygenase+2+%28Hido2%29+Bioassay+System+and+Discovery+of+Tryptanthrin+Derivatives+as+Potent+Hido2+Inhibitors&doi=10.1016%2Fj.ejmech.2016.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors</span></div><div class="casAuthors">Li, Juanjuan; Li, Yang; Yang, Dan; Hu, Nan; Guo, Zhanling; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As an analog of IDO1 (indoleamine 2, 3-dioxygenase 1), the well-known new therapeutic target, IDO2 is receiving increased attention.  Herein, the expression and purifn. of recombinant human IDO2 (hIDO2) and the establishment of a hIDO2 bioassay system on both enzymic and cellular levels are described.  Nine tryptanthrin derivs. were screened for potential hIDO2 inhibitory activities, and their Ki values, enzymic and cellular IC50 values, as well as the types of inhibition were measured.  The tryptanthrin derivs. 5i, 5c and 5d (esp. 5i) were found to be potent hIDO2 inhibitors with superior efficiency far better than that of the most frequently-used inhibitor L-1-MT.  Two ultimate purposes of the present study have been achieved: establishing an IDO2 bioassay system and screening novel IDO2 inhibitors that can be used (directly or with some modifications) for potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJvpfpI4_MpbVg90H21EOLACvtfcHk0liVvEI-IG_z7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1OntrvN&md5=1e878364aad6db454a308b68ef472320</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DEstablishment%2520of%2520a%2520Human%2520Indoleamine%25202%252C%25203-Dioxygenase%25202%2520%2528Hido2%2529%2520Bioassay%2520System%2520and%2520Discovery%2520of%2520Tryptanthrin%2520Derivatives%2520as%2520Potent%2520Hido2%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D123%26spage%3D171%26epage%3D179%26doi%3D10.1016%2Fj.ejmech.2016.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakmiwewa, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fatokun, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. J.</span></span> <span> </span><span class="NLM_article-title">Identification of Selective Inhibitors of Indoleamine 2,3-Dioxygenase 2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7641</span>– <span class="NLM_lpage">7646</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2012.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=23122865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1WjsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7641-7646&author=S.+M.+Bakmiwewaauthor=A.+A.+Fatokunauthor=A.+Tranauthor=R.+J.+Payneauthor=N.+H.+Huntauthor=H.+J.+Ball&title=Identification+of+Selective+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+2&doi=10.1016%2Fj.bmcl.2012.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2</span></div><div class="casAuthors">Bakmiwewa, Supun M.; Fatokun, Amos A.; Tran, Anh; Payne, Richard J.; Hunt, Nicholas H.; Ball, Helen J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7641-7646</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The kynurenine pathway is responsible for the breakdown of the majority of the essential amino acid, tryptophan (Trp).  The first and rate-limiting step of the kynurenine pathway can be independently catalyzed by tryptophan 2,3-dioxygenase (Tdo2), indoleamine 2,3-dioxygenase 1 (Ido1) or indoleamine 2,3-dioxygenase 2 (Ido2).  Tdo2 or Ido1 enzymic activity has been implicated in a no. of actions of the kynurenine pathway, including immune evasion by tumors.  IDO2 is expressed in several human pancreatic cancer cell lines, suggesting it also may play a role in tumorigenesis.  Although Ido2 was originally suggested to be a target of the chemotherapeutic agent dextro-1-methyl-tryptophan, subsequent studies suggest this compd. does not inhibit Ido2 activity.  The development of selective Ido2 inhibitors could provide valuable tools for investigating its activity in tumor development and normal physiol.  In this study, a library of Food and Drug Administration-approved drugs was screened for inhibition of mouse Ido2 enzymic activity.  A no. of candidates were identified and IC50 values of each compd. for Ido1 and Ido2 were estd.  The Ido2 inhibitors were also tested for inhibition of Tdo2 activity.  Our results showed that compds. from a class of drugs used to inhibit proton pumps were the most potent and selective Ido2 inhibitors identified in the library screen.  These included tenatoprazole, which exhibited an IC50 value of 1.8 μM for Ido2 with no inhibition of Ido1 or Tdo2 activity detected at a concn. of 100 μM tenatoprazole.  These highly-selective Ido2 inhibitors will be useful for defining the distinct biol. roles of the three Trp-catabolizing enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0JQcC4uWoS7Vg90H21EOLACvtfcHk0liVvEI-IG_z7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1WjsrbE&md5=2b3da2f1699f032a0d9ebcf634a49dd7</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DBakmiwewa%26aufirst%3DS.%2BM.%26aulast%3DFatokun%26aufirst%3DA.%2BA.%26aulast%3DTran%26aufirst%3DA.%26aulast%3DPayne%26aufirst%3DR.%2BJ.%26aulast%3DHunt%26aufirst%3DN.%2BH.%26aulast%3DBall%26aufirst%3DH.%2BJ.%26atitle%3DIdentification%2520of%2520Selective%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7641%26epage%3D7646%26doi%3D10.1016%2Fj.bmcl.2012.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meininger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, C. L.</span></span> <span> </span><span class="NLM_article-title">Purification and Kinetic Characterization of Human Indoleamine 2,3-Dioxygenases 1 and 2 (Ido1 and Ido2) and Discovery of Selective Ido1 Inhibitors</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1814</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1954</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2011.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bbapap.2011.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=21835273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSjtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1814&publication_year=2011&pages=1947-1954&author=D.+Meiningerauthor=L.+Zalamedaauthor=Y.+Liuauthor=L.+P.+Stepanauthor=L.+Borgesauthor=J.+D.+McCarterauthor=C.+L.+Sutherland&title=Purification+and+Kinetic+Characterization+of+Human+Indoleamine+2%2C3-Dioxygenases+1+and+2+%28Ido1+and+Ido2%29+and+Discovery+of+Selective+Ido1+Inhibitors&doi=10.1016%2Fj.bbapap.2011.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors</span></div><div class="casAuthors">Meininger, David; Zalameda, Leeanne; Liu, Yichin; Stepan, Lara P.; Borges, Luis; McCarter, John D.; Sutherland, Claire L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1814</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1947-1954</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO1) catalyzes the 1st step in tryptophan breakdown along the kynurenine pathway.  Therapeutic inhibition of IDO1 is receiving much attention due to its proposed role in the pathogenesis of several diseases including cancer, hypotension, and neurodegenerative disorders.  A related enzyme, IDO2 has recently been described.  Here. the authors report the 1st purifn. and kinetic characterization of human IDO2 using a facile L-tryptophan consumption assay amenable to high throughput screening.  The authors found that the Km of human IDO2 for L-tryptophan was much higher than that of IDO1.  The authors also described the identification and characterization of a new IDO1 inhibitor compd., Amg-1, by high-throughput screening, and compared the inhibition profiles of IDO1 and IDO2 with Amg-1 and previously described compds.  The data indicated that human IDO1 and IDO2 have different kinetic parameters and different inhibition profiles.  Docking of Amg-1 and related analogs to the known structure of IDO1 and to homol.-modeled IDO2 suggested possible rationales for the different inhibition profiles of IDO1 and IDO2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkjKusST0FNrVg90H21EOLACvtfcHk0ljgDz64GvnZGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSjtbzN&md5=95b88d7de219c1dcc63da1003b73c8f5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2011.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2011.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DMeininger%26aufirst%3DD.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DStepan%26aufirst%3DL.%2BP.%26aulast%3DBorges%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DSutherland%26aufirst%3DC.%2BL.%26atitle%3DPurification%2520and%2520Kinetic%2520Characterization%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenases%25201%2520and%25202%2520%2528Ido1%2520and%2520Ido2%2529%2520and%2520Discovery%2520of%2520Selective%2520Ido1%2520Inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2011%26volume%3D1814%26spage%3D1947%26epage%3D1954%26doi%3D10.1016%2Fj.bbapap.2011.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pantouris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serys, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuasa, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C. G.</span></span> <span> </span><span class="NLM_article-title">Human Indoleamine 2,3-Dioxygenase-2 Has Substrate Specificity and Inhibition Characteristics Distinct from Those of Indoleamine 2,3-Dioxygenase-1</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2155</span>– <span class="NLM_lpage">2163</span>, <span class="refDoi"> DOI: 10.1007/s00726-014-1766-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1007%2Fs00726-014-1766-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24875753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVKmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=2155-2163&author=G.+Pantourisauthor=M.+Serysauthor=H.+J.+Yuasaauthor=H.+J.+Ballauthor=C.+G.+Mowat&title=Human+Indoleamine+2%2C3-Dioxygenase-2+Has+Substrate+Specificity+and+Inhibition+Characteristics+Distinct+from+Those+of+Indoleamine+2%2C3-Dioxygenase-1&doi=10.1007%2Fs00726-014-1766-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1</span></div><div class="casAuthors">Pantouris, Georgios; Serys, Martynas; Yuasa, Hajime J.; Ball, Helen J.; Mowat, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2155-2163</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-2 (IDO2) is one of three enzymes (alongside tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase (IDO1)) that catalyze dioxygenation of L-tryptophan as the first step in the kynurenine pathway.  Despite the reported expression of IDO2 in tumors, some fundamental characteristics of the enzyme, such as substrate specificity and inhibition selectivity, are still to be clearly defined.  In this study, the authors report the kinetic and inhibition characteristics of recombinant human IDO2.  Choosing from a series of likely IDO2 substrates, the authors screened 54 tryptophan derivs. and tryptophan-like mols., and characterized the 8 with which the enzyme was most active.  Specificity of IDO2 for the two isomers of 1-methyltryptophan was also evaluated and the findings compared with those obtained in other studies on IDO2 and IDO1.  Interestingly, IDO2 demonstrates behavior distinct from that of IDO1 in terms of substrate specificity and affinity, such that we have identified tryptophan derivs. that are mutually exclusive as substrates for IDO1 and IDO2.  Our results support the idea that the antitumor activity of 1-Me-D-Trp is unlikely to be related with competitive inhibition of IDO2, and also imply that there are subtle differences in active site structure in the two enzymes that may be exploited in the development of specific inhibitors of these enzymes, a route which may prove important in defining their role(s) in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVPhgndNQ9erVg90H21EOLACvtfcHk0ljgDz64GvnZGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVKmsr4%253D&md5=c76ded6a96502b50cdb118cbb5ce4de5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs00726-014-1766-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-014-1766-3%26sid%3Dliteratum%253Aachs%26aulast%3DPantouris%26aufirst%3DG.%26aulast%3DSerys%26aufirst%3DM.%26aulast%3DYuasa%26aufirst%3DH.%2BJ.%26aulast%3DBall%26aufirst%3DH.%2BJ.%26aulast%3DMowat%26aufirst%3DC.%2BG.%26atitle%3DHuman%2520Indoleamine%25202%252C3-Dioxygenase-2%2520Has%2520Substrate%2520Specificity%2520and%2520Inhibition%2520Characteristics%2520Distinct%2520from%2520Those%2520of%2520Indoleamine%25202%252C3-Dioxygenase-1%26jtitle%3DAmino%2520Acids%26date%3D2014%26volume%3D46%26spage%3D2155%26epage%3D2163%26doi%3D10.1007%2Fs00726-014-1766-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J. H.</span></span> <span> </span><span class="NLM_article-title">Heme-Containing Oxygenases</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">2841</span>– <span class="NLM_lpage">2888</span>, <span class="refDoi"> DOI: 10.1021/cr9500500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9500500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaK28Xmt1Gmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1996&pages=2841-2888&author=M.+Sonoauthor=M.+P.+Roachauthor=E.+D.+Coulterauthor=J.+H.+Dawson&title=Heme-Containing+Oxygenases&doi=10.1021%2Fcr9500500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Heme-Containing Oxygenases</span></div><div class="casAuthors">Sono, Masanori; Roach, Mark P.; Coulter, Eric D.; Dawson, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2841-2887</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, with 342 refs.  The authors review here structure and activity of cytochrome P 450, secondary amine monooxygenase, heme oxygenase, prostaglandin H synthase, indoleamine 2,3-dioxygenase, and tryptophan 2,3-dioxygenase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVfrK0pt1dkrVg90H21EOLACvtfcHk0lh04Y5aJnaycg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmt1Gmsr4%253D&md5=a7813ce8b87cd91b99ca9f9172222077</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fcr9500500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9500500%26sid%3Dliteratum%253Aachs%26aulast%3DSono%26aufirst%3DM.%26aulast%3DRoach%26aufirst%3DM.%2BP.%26aulast%3DCoulter%26aufirst%3DE.%2BD.%26aulast%3DDawson%26aufirst%3DJ.%2BH.%26atitle%3DHeme-Containing%2520Oxygenases%26jtitle%3DChem.%2520Rev.%26date%3D1996%26volume%3D96%26spage%3D2841%26epage%3D2888%26doi%3D10.1021%2Fcr9500500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Key Dioxygenases in Tryptophan-Kynurenine Metabolism for Immunomodulation and Cancer Chemotherapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.drudis.2014.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25478733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2gu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=609-617&author=C.+J.+Austinauthor=L.+M.+Rendina&title=Targeting+Key+Dioxygenases+in+Tryptophan-Kynurenine+Metabolism+for+Immunomodulation+and+Cancer+Chemotherapy&doi=10.1016%2Fj.drudis.2014.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy</span></div><div class="casAuthors">Austin, Christopher J. D.; Rendina, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">609-617</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tryptophan to kynurenine metab. is controlled by three distinct dioxygenase enzymes: tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 1 (IDO1), and indoleamine 2,3-dioxygenase 2 (IDO2).  Collectively, the activity of these enzymes contributes to tumor immune tolerance and immune dysregulation in a variety of disease pathologies, including cancer.  Whereas IDO1 inhibitor drug design has been the focus of study for more than two decades (with novel compds. currently in Phase II clin. trials), only recently have the roles of TDO and IDO2 been elucidated in immunosuppression.  Consequently, little comparative work on inhibitor cross-reactivity and selectivity has been performed.  Here, we provide an overview of the current and future drug discovery landscape for targeting TDO, IDO1, and IDO2 (individually and collectively) for pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOoUq5iFaItLVg90H21EOLACvtfcHk0lh04Y5aJnaycg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2gu7nJ&md5=3e49304fea87a6564ef051ac67332a06</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DC.%2BJ.%26aulast%3DRendina%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520Key%2520Dioxygenases%2520in%2520Tryptophan-Kynurenine%2520Metabolism%2520for%2520Immunomodulation%2520and%2520Cancer%2520Chemotherapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D609%26epage%3D617%26doi%3D10.1016%2Fj.drudis.2014.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolawole, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hixon, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dameron, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrisman, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnov, V. V.</span></span> <span> </span><span class="NLM_article-title">Catalytic Activity of Human Indoleamine 2,3-Dioxygenase (Hido1) at Low Oxygen</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>570</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2015.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.abb.2015.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25712221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1eis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=570&publication_year=2015&pages=47-57&author=A.+O.+Kolawoleauthor=B.+P.+Hixonauthor=L.+S.+Dameronauthor=I.+M.+Chrismanauthor=V.+V.+Smirnov&title=Catalytic+Activity+of+Human+Indoleamine+2%2C3-Dioxygenase+%28Hido1%29+at+Low+Oxygen&doi=10.1016%2Fj.abb.2015.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic activity of human indoleamine 2,3-dioxygenase (hIDO1) at low oxygen</span></div><div class="casAuthors">Kolawole, Ayodele O.; Hixon, Brian P.; Dameron, Laura S.; Chrisman, Ian M.; Smirnov, Valeriy V.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">570</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-57</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A cytokine-inducible extrahepatic human indoleamine 2,3-dioxygenase (hIDO1) catalyzes the 1st step of the kynurenine pathway.  Immunosuppressive activity of hIDO1 in tumor cells weakens host T-cell immunity, contributing to the progression of cancer.  Here, the authors report on the enzyme kinetics and catalytic mechanism of hIDO1, studied at varied levels of O2 and L-tryptophan.  Using a cytochrome b5-based activating system, the authors measured the initial rates of O2 decay with a Clark-type oxygen electrode at physiol.-relevant levels of both substrates.  Enzyme kinetics were also studied in the presence of 2 substrate analogs, 1-methyl-L-tryptophan and norharmane.  Quant. anal. supported a steady-state rather than a rapid equil. kinetic mechanism, where the rates of individual pathways, leading to a ternary complex, were significantly different, and the overall rate of catalysis depended on contributions of both routes.  One path, where O2 binds to ferrous hIDO1 1st, was faster than the 2nd route, which started with the binding of L-tryptophan.  However, L-tryptophan complexation with free ferrous hIDO1 was more rapid than that of O2.  As the level of L-tryptophan increased, the slower route became a significant contributor to the overall rate, resulting in obsd. substrate inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU55j_-1MfGLVg90H21EOLACvtfcHk0lh04Y5aJnaycg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1eis7Y%253D&md5=02a0adb017dc96032a573ff43fab35dc</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2015.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2015.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DKolawole%26aufirst%3DA.%2BO.%26aulast%3DHixon%26aufirst%3DB.%2BP.%26aulast%3DDameron%26aufirst%3DL.%2BS.%26aulast%3DChrisman%26aufirst%3DI.%2BM.%26aulast%3DSmirnov%26aufirst%3DV.%2BV.%26atitle%3DCatalytic%2520Activity%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528Hido1%2529%2520at%2520Low%2520Oxygen%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2015%26volume%3D570%26spage%3D47%26epage%3D57%26doi%3D10.1016%2Fj.abb.2015.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Efimov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raven, E. L.</span></span> <span> </span><span class="NLM_article-title">The Mechanism of Substrate Inhibition in Human Indoleamine 2,3-Dioxygenase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">3034</span>– <span class="NLM_lpage">3041</span>, <span class="refDoi"> DOI: 10.1021/ja208694g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja208694g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ehsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=3034-3041&author=I.+Efimovauthor=J.+Basranauthor=X.+Sunauthor=N.+Chauhanauthor=S.+K.+Chapmanauthor=C.+G.+Mowatauthor=E.+L.+Raven&title=The+Mechanism+of+Substrate+Inhibition+in+Human+Indoleamine+2%2C3-Dioxygenase&doi=10.1021%2Fja208694g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The Mechanism of Substrate Inhibition in Human Indoleamine 2,3-Dioxygenase</span></div><div class="casAuthors">Efimov, Igor; Basran, Jaswir; Sun, Xiao; Chauhan, Nishma; Chapman, Stephen K.; Mowat, Christopher G.; Raven, Emma Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3034-3041</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase catalyzes the O2-dependent oxidn. of L-tryptophan (L-Trp) to N-formylkynurenine (NFK) as part of the kynurenine pathway.  Inhibition of enzyme activity at high L-Trp concns. was first noted more than 30 years ago, but the mechanism of inhibition has not been established.  Using a combination of kinetic and redn. potential measurements, we present evidence showing that inhibition of enzyme activity in human indoleamine 2,3-dioxygenase (hIDO) and a no. of site-directed variants during turnover with L-tryptophan (L-Trp) can be accounted for by the sequential, ordered binding of O2 and L-Trp.  Anal. of the data shows that at low concns. of L-Trp, O2 binds first followed by the binding of L-Trp; at higher concns. of L-Trp, the order of binding is reversed.  In addn., we show that the heme redn. potential (Em0) has a regulatory role in controlling the overall rate of catalysis (and hence the extent of inhibition) because there is a quantifiable correlation between Em0 (that increases in the presence of L-Trp) and the rate const. for O2 binding.  This means that the initial formation of ferric superoxide (Fe3+-O2̇-) from Fe2+-O2 becomes thermodynamically less favorable as substrate binds, and we propose that it is the slowing down of this oxidn. step at higher concns. of substrate that is the origin of the inhibition.  In contrast, we show that regeneration of the ferrous enzyme (and formation of NFK) in the final step of the mechanism, which formally requires redn. of the heme, is facilitated by the higher redn. potential in the substrate-bound enzyme and the two consts. (kcat and Em0) are shown also to be correlated.  Thus, the overall catalytic activity is balanced between the equal and opposite dependencies of the initial and final steps of the mechanism on the heme redn. potential.  This tuning of the redn. potential provides a simple mechanism for regulation of the reactivity, which may be used more widely across this family of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQoUAJsxHgSrVg90H21EOLACvtfcHk0lhy02JAauUFOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ehsLk%253D&md5=ab8ebfbe728ed51d5a5ce1713f4db846</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fja208694g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja208694g%26sid%3Dliteratum%253Aachs%26aulast%3DEfimov%26aufirst%3DI.%26aulast%3DBasran%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DChauhan%26aufirst%3DN.%26aulast%3DChapman%26aufirst%3DS.%2BK.%26aulast%3DMowat%26aufirst%3DC.%2BG.%26aulast%3DRaven%26aufirst%3DE.%2BL.%26atitle%3DThe%2520Mechanism%2520of%2520Substrate%2520Inhibition%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D3034%26epage%3D3041%26doi%3D10.1021%2Fja208694g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijeratne, G. B.</span></span> <span> </span><span class="NLM_article-title">Modeling Tryptophan/Indoleamine 2,3-Dioxygenase with Heme Superoxide Mimics: Is Ferryl the Key Intermediate?</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">1846</span>– <span class="NLM_lpage">1856</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b10498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b10498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyitLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=1846-1856&author=P.+Mondalauthor=G.+B.+Wijeratne&title=Modeling+Tryptophan%2FIndoleamine+2%2C3-Dioxygenase+with+Heme+Superoxide+Mimics%3A+Is+Ferryl+the+Key+Intermediate%3F&doi=10.1021%2Fjacs.9b10498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling Tryptophan/Indoleamine 2,3-Dioxygenase with Heme Superoxide Mimics: Is Ferryl the Key Intermediate?</span></div><div class="casAuthors">Mondal, Pritam; Wijeratne, Gayan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1846-1856</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tryptophan oxidn. in biol. has been recently implicated in a vast array of paramount pathogenic conditions in humans, including multiple sclerosis, rheumatoid arthritis, type-I diabetes, and cancer.  This 2,3-dioxygenative cleavage of the indole ring of tryptophan with dioxygen is mediated by two heme enzymes, tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO), during its conversion to N-formylkynurenine in the first and rate-limiting step of kynurenine pathway.  Despite the pivotal significance of this enzymic transformation, a vivid viewpoint of the precise mechanistic events is far from complete.  A heme superoxide adduct is thought to be the active oxidant in both TDO and IDO, which, following O-O bond cleavage, presumably generates a key ferryl (FeIV=O) reaction intermediate.  This study, for the first time in model chem., demonstrates the potential of synthetic heme superoxide adducts to mimic the bioinorg. chem. of indole dioxygenation by TDO and IDO, challenging the widely accepted categorization of these metal adducts as weak oxidants.  Herein, an electronically divergent series of ferric heme superoxo oxidants mediates the facile conversion of an array of indole substrates into their corresponding 2,3-dioxygenated products, while shedding light on an unequivocally occurring, putative ferryl intermediate.  The oxygenated indole products have been isolated in ∼31% yield, and characterized by LC-MS, 1H and 13C NMR, and FT-IR methodologies, as well as by 18O2(g) labeling expts.  Distinctly, the most electron-deficient superoxo adduct is obsd. to react the fastest, specifically with the most electron-rich indole substrate, underscoring the cruciality of electrophilicity of the heme superoxide moiety in facilitating the initial indole activation step.  Comprehensive understanding of such mechanistic subtleties will benefit future attempts in the rational design of salient therapeutic agents, including next generation anticancer drug targets with amplified effectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF8LnnFDaoWbVg90H21EOLACvtfcHk0lhy02JAauUFOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyitLrE&md5=e4f32c8c24c0e46b5cd2b74b8da779f4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b10498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b10498%26sid%3Dliteratum%253Aachs%26aulast%3DMondal%26aufirst%3DP.%26aulast%3DWijeratne%26aufirst%3DG.%2BB.%26atitle%3DModeling%2520Tryptophan%252FIndoleamine%25202%252C3-Dioxygenase%2520with%2520Heme%2520Superoxide%2520Mimics%253A%2520Is%2520Ferryl%2520the%2520Key%2520Intermediate%253F%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D1846%26epage%3D1856%26doi%3D10.1021%2Fjacs.9b10498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Pyrrolase of Rabbit Intestine. D- and L-Tryptophan-Cleaving Enzyme or Enzymes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>242</i></span>,  <span class="NLM_fpage">5260</span>– <span class="NLM_lpage">5266</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=6065097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaF1cXkt1A%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=1967&pages=5260-5266&author=S.+Yamamotoauthor=O.+Hayaishi&title=Tryptophan+Pyrrolase+of+Rabbit+Intestine.+D-+and+L-Tryptophan-Cleaving+Enzyme+or+Enzymes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan pyrrolase of rabbit intestine.  D- and L-Tryptophan-cleaving enzyme or enzymes</span></div><div class="casAuthors">Yamamoto, Shozo; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">242</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5260-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">An enzyme that catalyzes the formation of formyl-D-kynurenine from D-tryptophan was purified ∼100-fold from a homogenate of rabbit small intestine.  Formyl-D-kynurenine thus produced was converted to D-kynurenine by formamidase present in rabbit intestine.  Methylene blue and ascorbic acid were required as cofactors.  Xanthine oxidase with hypoxanthine could replace ascorbic acid, but H2O2, added as such or enzymically generated by glucose oxidase or L-amino acid oxidase, was not effective.  Addn. of catalase failed to inhibit the enzyme.  Several lines of evidence indicated the involvement of heme in the catalysis by the enzyme.  An absorption spectrum characteristic of hemoprotein was observed in the purified active enzyme prepns.  Inhibition by KCN or CO was observed.  The inhibition by CO was reversed by illumination.  The purified enzyme could oxidize L-tryptophan as well as D-tryptophan.  Kynurenine derived from L-tryptophan via formylkynurenine was identified as the L-isomer.  Methylene blue and ascorbic acid were also required.  A marked substrate inhibition was observed with L-tryptophan, but not with D-tryptophan.  23 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5eCISBapnE7Vg90H21EOLACvtfcHk0lis1SsieS0tUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXkt1A%253D&md5=736f1863a116d5d17b05aabd6a9e031b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DTryptophan%2520Pyrrolase%2520of%2520Rabbit%2520Intestine.%2520D-%2520and%2520L-Tryptophan-Cleaving%2520Enzyme%2520or%2520Enzymes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1967%26volume%3D242%26spage%3D5260%26epage%3D5266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase. Equilibrium Studies of the Tryptophan Binding to the Ferric, Ferrous, and Co-Bound Enzymes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">1339</span>– <span class="NLM_lpage">1345</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=7354029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaL3cXhsF2lurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1980&pages=1339-1345&author=M.+Sonoauthor=T.+Taniguchiauthor=Y.+Watanabeauthor=O.+Hayaishi&title=Indoleamine+2%2C3-Dioxygenase.+Equilibrium+Studies+of+the+Tryptophan+Binding+to+the+Ferric%2C+Ferrous%2C+and+Co-Bound+Enzymes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase.  Equilibrium studies of the tryptophan binding to the ferric, ferrous, and carbon monoxide-bound enzymes</span></div><div class="casAuthors">Sono, Masanori; Taniguchi, Taketoshi; Watanabe, Yasuyoshi; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1339-45</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The equil. consts. for the tryptophan binding to rabbit intestinal indoleamine 2,3-dioxygenase (I), a protohemoprotein, in its Fe(III), Fe(II), and CO-bound (Fe(II)CO) forms were detd. by the spectrophotometric titrn. method.  All of these I derivs. showed marked spectral changes upon tryptophan binding.  Such a spectral change for Fe(III)-I was, however, specific for the L isomer and accompanied the spin state change of the Fe(III)-heme from high spin to low spin.  The dissocn. consts. (Kd) thus obtained for the complexes of L-tryptophan with Fe(III)-, Fe(III)CO-, and Fe(II)-I in 0.1M K phosphate buffer, pH 7.0 at 24°, were 5.8 mM, 350 μM, and 13 μM, resp., being a ratio of 450:27:1.  The Kd Fe(III)-I enzyme was ∼450-fold greater than the Km and agreed well with the Ki, indicating that L-tryptophan binding to the Fe(III)-I is not catalytically significant, but is directly correlated to the substrate inhibition which is stereospecific to the L isomer.  The Kd for Fe(II)-I showed a good agreement with the Km at various pH values examd.  Assuming that the Fe(II)CO-I has a tryptophan-binding property similar to the oxygenated enzyme (Fe(II)O2 of Fe(III)O2-), it is suggested that the binding of tryptophan to Fe(II)-I (Kd ≈ Km) rather than that of tryptophan to the oxygenated enzyme (Kd ≠ Km) is involved in a steady state of the catalytic reaction.  On the basis of the evidence described above, a reaction mechanism for I is proposed.  In the principal pathway of the sequence, Fe(II)-I binds predominantly with tryptophan, followed by O2.  Fe(III)-I, on the other hand, binds 1st with the superoxide anion and the resulting oxygenated enzyme reacts with tryptophan either directly or via Fe(II)-I to form the ternary complex.  The Fe(III)-I-tryptophan complex appears to be catalytically inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAoucco47SWLVg90H21EOLACvtfcHk0lhDM1eiR-6q3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhsF2lurk%253D&md5=b36c389e1058a9b51dd4c87f97804cac</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSono%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase.%2520Equilibrium%2520Studies%2520of%2520the%2520Tryptophan%2520Binding%2520to%2520the%2520Ferric%252C%2520Ferrous%252C%2520and%2520Co-Bound%2520Enzymes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1980%26volume%3D255%26spage%3D1339%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienhaus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienhaus, G. U.</span></span> <span> </span><span class="NLM_article-title">Substrate Inhibition in Human Indoleamine 2,3-Dioxygenase</span>. <i>J. Phys. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">761</span>, <span class="refDoi"> DOI: 10.1021/jz500220k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jz500220k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=756-761&author=B.+Weberauthor=E.+Nickelauthor=M.+Hornauthor=K.+Nienhausauthor=G.+U.+Nienhaus&title=Substrate+Inhibition+in+Human+Indoleamine+2%2C3-Dioxygenase&doi=10.1021%2Fjz500220k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate inhibition in human indoleamine 2,3-dioxygenase</span></div><div class="casAuthors">Weber, Benjamin; Nickel, Elena; Horn, Michael; Nienhaus, Karin; Nienhaus, G. Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">756-761</span>CODEN:
                <span class="NLM_cas:coden">JPCLCD</span>;
        ISSN:<span class="NLM_cas:issn">1948-7185</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase (I) catalyzes the oxidative cleavage of the L-tryptophan (II) pyrrole ring to produce N-formylkynurenine.  Catalysis is inhibited at high substrate concns.; mechanistic details of this observation are, however, still under debate.  Here, using time-resolved optical spectroscopy, the authors analyzed the dynamics of ternary complex formation between I, II, and a diat. ligand.  The physiol. ligand, O2 was replaced by CO to exclude enzymic turnover.  Quant. anal. of the kinetics revealed that the ternary complex forms whenever O2 binds 1st, whereas a II substrate mol. arriving prior to O2 in the active site causes self-inhibition.  Bound II prevents the ligand from approaching the heme Fe and, therefore, impedes the formation of the catalytically active ternary complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWqjrnO8kA4bVg90H21EOLACvtfcHk0lhDM1eiR-6q3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOqsbo%253D&md5=caa9a38bbe1a4097a34de8bd438ab949</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjz500220k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjz500220k%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DB.%26aulast%3DNickel%26aufirst%3DE.%26aulast%3DHorn%26aufirst%3DM.%26aulast%3DNienhaus%26aufirst%3DK.%26aulast%3DNienhaus%26aufirst%3DG.%2BU.%26atitle%3DSubstrate%2520Inhibition%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Phys.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D756%26epage%3D761%26doi%3D10.1021%2Fjz500220k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Inhibitory Substrate Binding Site of Human Indoleamine 2,3-Dioxygenase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">12866</span>– <span class="NLM_lpage">12867</span>, <span class="refDoi"> DOI: 10.1021/ja9029768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9029768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWku7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=12866-12867&author=C.+Luauthor=Y.+Linauthor=S.+R.+Yeh&title=Inhibitory+Substrate+Binding+Site+of+Human+Indoleamine+2%2C3-Dioxygenase&doi=10.1021%2Fja9029768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory Substrate Binding Site of Human Indoleamine 2,3-Dioxygenase</span></div><div class="casAuthors">Lu, Changyuan; Lin, Yu; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12866-12867</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase (hIDO) is an intracellular heme-contg. enzyme, which catalyzes the initial and rate-detg. step of L-tryptophan (L-Trp) metab. via the kynurenine pathway.  Due to its immunosuppressive function, hIDO has been recognized as an important drug target for cancer.  Here, evidence supporting the presence of an inhibitory substrate binding site (Si) in hIDO that is capable of binding mols. with a wide variety of structures, including substrates (L-Trp and 1-methyl-L-tryptophan), an effector (3-indole ethanol), and an uncompetitive inhibitor (Mitomycin C) is reported.  The data offer useful guidelines for future development of more potent hIDO inhibitors; they also call for the re-evaluation of the action mechanism of Mitomycin C (MtoC), a widely used antitumor chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiWLyIFomwX7Vg90H21EOLACvtfcHk0lhDM1eiR-6q3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWku7jK&md5=03246bbadb7c52484ad414500c8cf886</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fja9029768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9029768%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DInhibitory%2520Substrate%2520Binding%2520Site%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D12866%26epage%3D12867%26doi%3D10.1021%2Fja9029768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkashon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batabyal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Inhibition Mechanisms of Human Indoleamine 2,3 Dioxygenase 1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">8518</span>– <span class="NLM_lpage">8525</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b03691</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b03691" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFamtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=8518-8525&author=A.+Lewis-Ballesterauthor=S.+Karkashonauthor=D.+Batabyalauthor=T.+L.+Poulosauthor=S.+R.+Yeh&title=Inhibition+Mechanisms+of+Human+Indoleamine+2%2C3+Dioxygenase+1&doi=10.1021%2Fjacs.8b03691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition Mechanisms of Human Indoleamine 2,3 Dioxygenase 1</span></div><div class="casAuthors">Lewis-Ballester, Ariel; Karkashon, Shay; Batabyal, Dipanwita; Poulos, Thomas L.; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">8518-8525</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan dioxygenase (hTDO) catalyze the same dioxygenation reaction of Trp to generate N-formyl kynurenine (NFK).  They share high structural similarity, esp. in the active site.  However, hIDO1 possesses a unique inhibitory substrate binding site (Si) that is absent in hTDO.  In addn., in hIDO1, the indoleamine group of the substrate Trp is H-bonded to S167 through a bridging water, while that in hTDO is directly H-bonded to H76.  Here we show that Trp binding to the Si site or the mutation of S167 to histidine in hIDO1 retards its turnover activity, and that the inhibited activity can be rescued by an effector, 3-indole ethanol (IDE).  Kinetic studies reveal that the inhibited activity introduced by Trp binding to the Si site is a result of retarded recombination of the ferryl moiety with Trp epoxide to form NFK, and that IDE reverses the effect by preventing Trp from binding to the Si site.  In contrast, the abolished activity induced by the S167H mutation is primarily a result of ∼5000-fold redn. in the O2 binding rate const., possibly due to the blockage of a ligand delivery tunnel, and that IDE binding to the Si site reverses the effect by reopening the tunnel.  The data offer new insights into structure-based design of hIDO1-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwWFk_K5ySNrVg90H21EOLACvtfcHk0ljTMK41eX1jfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFamtbbO&md5=7bc0b5d948e2109f9c3905f35454f647</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b03691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b03691%26sid%3Dliteratum%253Aachs%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DKarkashon%26aufirst%3DS.%26aulast%3DBatabyal%26aufirst%3DD.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DInhibition%2520Mechanisms%2520of%2520Human%2520Indoleamine%25202%252C3%2520Dioxygenase%25201%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D8518%26epage%3D8525%26doi%3D10.1021%2Fjacs.8b03691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondanelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panfili, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Filippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iamandii, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proietti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annunziato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppelenbosch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santambrogio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span> <span> </span><span class="NLM_article-title">Positive Allosteric Modulation of Indoleamine 2,3-Dioxygenase 1 Restrains Neuroinflammation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3848</span>– <span class="NLM_lpage">3857</span>, <span class="refDoi"> DOI: 10.1073/pnas.1918215117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.1918215117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32024760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFyhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=3848-3857&author=G.+Mondanelliauthor=A.+Colettiauthor=F.+A.+Grecoauthor=M.+T.+Pallottaauthor=C.+Orabonaauthor=A.+Iaconoauthor=M.+L.+Belladonnaauthor=E.+Albiniauthor=E.+Panfiliauthor=F.+Fallarinoauthor=M.+Gargaroauthor=G.+Manniauthor=D.+Matinoauthor=A.+Carvalhoauthor=C.+Cunhaauthor=P.+Macielauthor=M.+Di+Filippoauthor=L.+Gaetaniauthor=R.+Bianchiauthor=C.+Vaccaauthor=I.+M.+Iamandiiauthor=E.+Proiettiauthor=F.+Bosciaauthor=L.+Annunziatoauthor=M.+Peppelenboschauthor=P.+Puccettiauthor=P.+Calabresiauthor=A.+Macchiaruloauthor=L.+Santambrogioauthor=C.+Volpiauthor=U.+Grohmann&title=Positive+Allosteric+Modulation+of+Indoleamine+2%2C3-Dioxygenase+1+Restrains+Neuroinflammation&doi=10.1073%2Fpnas.1918215117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation</span></div><div class="casAuthors">Mondanelli, Giada; Coletti, Alice; Greco, Francesco Antonio; Pallotta, Maria Teresa; Orabona, Ciriana; Iacono, Alberta; Belladonna, Maria Laura; Albini, Elisa; Panfili, Eleonora; Fallarino, Francesca; Gargaro, Marco; Manni, Giorgia; Matino, Davide; Carvalho, Agostinho; Cunha, Cristina; Maciel, Patricia; Di Filippo, Massimiliano; Gaetani, Lorenzo; Bianchi, Roberta; Vacca, Carmine; Iamandii, Ioana Maria; Proietti, Elisa; Boscia, Francesca; Annunziato, Lucio; Peppelenbosch, Maikel; Puccetti, Paolo; Calabresi, Paolo; Macchiarulo, Antonio; Santambrogio, Laura; Volpi, Claudia; Grohmann, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3848-3857</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">L-tryptophan (Trp), an essential amino acid for mammals, is the precursor of a wide array of immunomodulatory metabolites produced by the kynurenine and serotonin pathways.  The kynurenine pathway is a paramount source of several immunoregulatory metabolites, including L-kynurenine (Kyn), the main product of indoleamine 2,3-dioxygenase 1 (IDO1) that catalyzes the rate-limiting step of the pathway.  In the serotonin pathway, the metabolite N-acetylserotonin (NAS) has been shown to possess antioxidant, antiinflammatory, and neuroprotective properties in exptl. autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).  However, little is known about the exact mode of action of the serotonin metabolite and the possible interplay between the 2 Trp metabolic pathways.  Prompted by the discovery that NAS neuroprotective effects in EAE are abrogated in mice lacking IDO1 expression, we investigated the NAS mode of action in neuroinflammation.  We found that NAS directly binds IDO1 and acts as a pos. allosteric modulator (PAM) of the IDO1 enzyme in vitro and in vivo.  As a result, increased Kyn will activate the ligand-activated transcription factor aryl hydrocarbon receptor and, consequently, antiinflammatory and immunoregulatory effects.  Because NAS also increased IDO1 activity in peripheral blood mononuclear cells of a significant proportion of MS patients, our data may set the basis for the development of IDO1 PAMs as first-in-class drugs in autoimmune/neuroinflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS-Hm1fDHd0rVg90H21EOLACvtfcHk0ljTMK41eX1jfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFyhu78%253D&md5=13c9788f554d27f9a372cf6551e3f3eb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1918215117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1918215117%26sid%3Dliteratum%253Aachs%26aulast%3DMondanelli%26aufirst%3DG.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DGreco%26aufirst%3DF.%2BA.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DIacono%26aufirst%3DA.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DAlbini%26aufirst%3DE.%26aulast%3DPanfili%26aufirst%3DE.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DGargaro%26aufirst%3DM.%26aulast%3DManni%26aufirst%3DG.%26aulast%3DMatino%26aufirst%3DD.%26aulast%3DCarvalho%26aufirst%3DA.%26aulast%3DCunha%26aufirst%3DC.%26aulast%3DMaciel%26aufirst%3DP.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DGaetani%26aufirst%3DL.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DIamandii%26aufirst%3DI.%2BM.%26aulast%3DProietti%26aufirst%3DE.%26aulast%3DBoscia%26aufirst%3DF.%26aulast%3DAnnunziato%26aufirst%3DL.%26aulast%3DPeppelenbosch%26aufirst%3DM.%26aulast%3DPuccetti%26aufirst%3DP.%26aulast%3DCalabresi%26aufirst%3DP.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DSantambrogio%26aufirst%3DL.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DGrohmann%26aufirst%3DU.%26atitle%3DPositive%2520Allosteric%2520Modulation%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Restrains%2520Neuroinflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26spage%3D3848%26epage%3D3857%26doi%3D10.1073%2Fpnas.1918215117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meininger, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wienkers, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, D. A.</span></span> <span> </span><span class="NLM_article-title">In Vitro Modulation of Cytochrome P450 Reductase Supported Indoleamine 2,3-Dioxygenase Activity by Allosteric Effectors Cytochrome B(5) and Methylene Blue</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2647</span>– <span class="NLM_lpage">2656</span>, <span class="refDoi"> DOI: 10.1021/bi100022c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100022c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVGrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=2647-2656&author=J.+T.+Pearsonauthor=S.+Siuauthor=D.+P.+Meiningerauthor=L.+C.+Wienkersauthor=D.+A.+Rock&title=In+Vitro+Modulation+of+Cytochrome+P450+Reductase+Supported+Indoleamine+2%2C3-Dioxygenase+Activity+by+Allosteric+Effectors+Cytochrome+B%285%29+and+Methylene+Blue&doi=10.1021%2Fbi100022c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro modulation of cytochrome P 450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b5 and methylene blue</span></div><div class="casAuthors">Pearson, Josh T.; Siu, Sophia; Meininger, David P.; Wienkers, Larry C.; Rock, Dan A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2647-2656</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is a heme-contg. dioxygenase involved in the degrdn. of several indoleamine derivs. and has been indicated as an immunosuppressive.  IDO is an attractive target for therapeutic intervention in diseases which are known to capitalize on immune suppression, including cancer, HIV, and inflammatory diseases.  Conventionally, IDO activity is measured through chem. redn. by the addn. of ascorbate and methylene blue.  The identification of potential coenzymes involved in the redn. of IDO in vivo should improve in vitro reconstitution systems used to identify potential IDO inhibitors.  Here, the authors show that NADPH-cytochrome P 450 reductase (CPR) is capable of supporting IDO activity in vitro and that oxidn. of L-tryptophan (L-Trp) follows substrate inhibition kinetics (kcat = 0.89 s-1, Km = 0.72 μM, and Ki = 9.4 μM).  The addn. of cytochrome b5 to CPR-supported L-Trp incubations resulted in modulation from substrate inhibition to sigmoidal kinetics (kcat = 1.7 s-1, Km = 1.5 μM, and Ki = 1.9 μM).  CPR-supported D-Trp oxidns. (±cytochrome b5) exhibited Michaelis-Menten kinetics.  The addn. of methylene blue (minus ascorbate) to CPR-supported reactions resulted in the inhibition of D-Trp turnover and modulation of L-Trp kinetics from allosteric to Michaelis-Menten with a concurrent decrease in substrate affinity for IDO.  Thus, these data indicate that CPR is capable of supporting IDO activity in vitro and the oxidn. of Trp by IDO displays substrate stereochem.-dependent atypical kinetics which can be modulated by the addn. of cytochrome b5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMqKrIR9We6LVg90H21EOLACvtfcHk0lgnkRW3TGF3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVGrurk%253D&md5=487e05df4db931852d0eded173719e25</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fbi100022c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100022c%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DJ.%2BT.%26aulast%3DSiu%26aufirst%3DS.%26aulast%3DMeininger%26aufirst%3DD.%2BP.%26aulast%3DWienkers%26aufirst%3DL.%2BC.%26aulast%3DRock%26aufirst%3DD.%2BA.%26atitle%3DIn%2520Vitro%2520Modulation%2520of%2520Cytochrome%2520P450%2520Reductase%2520Supported%2520Indoleamine%25202%252C3-Dioxygenase%2520Activity%2520by%2520Allosteric%2520Effectors%2520Cytochrome%2520B%25285%2529%2520and%2520Methylene%2520Blue%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D2647%26epage%3D2656%26doi%3D10.1021%2Fbi100022c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uyttenhove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theate, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Evidence for a Tumoral Immune Resistance Mechanism Based on Tryptophan Degradation by Indoleamine 2,3-Dioxygenase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1274</span>, <span class="refDoi"> DOI: 10.1038/nm934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fnm934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=14502282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1Clu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=1269-1274&author=C.+Uyttenhoveauthor=L.+Pilotteauthor=I.+Theateauthor=V.+Stroobantauthor=D.+Colauauthor=N.+Parmentierauthor=T.+Boonauthor=B.+J.+Van+den%0AEynde&title=Evidence+for+a+Tumoral+Immune+Resistance+Mechanism+Based+on+Tryptophan+Degradation+by+Indoleamine+2%2C3-Dioxygenase&doi=10.1038%2Fnm934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</span></div><div class="casAuthors">Uyttenhove, Catherine; Pilotte, Luc; Theate, Ivan; Stroobant, Vincent; Colau, Didier; Parmentier, Nicolas; Boon, Thierry; Van den Eynde, Benoit J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1269-1274</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">T lymphocytes undergo proliferation arrest when exposed to tryptophan shortage, which can be provoked by indoleamine 2,3-dioxygenase (IDO), an enzyme that is expressed in placenta and catalyzes tryptophan degrdn.  Here we show that most human tumors constitutively express IDO.  We also obsd. that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice.  This effect is accompanied by a lack of accumulation of specific T cells at the tumor site and can be partly reverted by systemic treatment of mice with an inhibitor of IDO, in the absence of noticeable toxicity.  These results suggest that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2g0Nw1Orz7rVg90H21EOLACvtfcHk0lgnkRW3TGF3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1Clu7c%253D&md5=c2be3620862064fb40da547f976ccf95</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnm934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm934%26sid%3Dliteratum%253Aachs%26aulast%3DUyttenhove%26aufirst%3DC.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DTheate%26aufirst%3DI.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DParmentier%26aufirst%3DN.%26aulast%3DBoon%26aufirst%3DT.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DEvidence%2520for%2520a%2520Tumoral%2520Immune%2520Resistance%2520Mechanism%2520Based%2520on%2520Tryptophan%2520Degradation%2520by%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D1269%26epage%3D1274%26doi%3D10.1038%2Fnm934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dancsok, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. O.</span></span> <span> </span><span class="NLM_article-title">Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development</span>. <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi"> DOI: 10.1007/s11912-019-0750-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1007%2Fs11912-019-0750-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30659394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BB3cjjtVeisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=2&author=M.+M.+T.+Zhuauthor=A.+R.+Dancsokauthor=T.+O.+Nielsen&title=Indoleamine+Dioxygenase+Inhibitors%3A+Clinical+Rationale+and+Current+Development&doi=10.1007%2Fs11912-019-0750-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development</span></div><div class="casAuthors">Zhu Mayanne M T; Dancsok Amanda R; Nielsen Torsten O</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  This review focuses on the recent clinical development of indolamine-2,3-dioxygenase-1 (IDO-1) inhibitors.  RECENT FINDINGS:  IDO-1 alters tryptophan metabolism in a manner enhancing T-regulatory cell activity, but pre-clinical data show that its role in tumorigenesis is context-dependent on host and tumor interaction, highlighting some challenges in understanding the molecular oncology of this enzymatic drug target.  Because results from phase I/II trials of IDO-1 inhibitor monotherapy have been disappointing, current clinical trials employ IDO-1 inhibitors in combination strategies with other immunotherapy agents or with chemotherapy ± radiation.  Combinations with anti-PD-1/PD-L1 antibodies are already showing promise, and related strategies are under active evaluation.  While further research is needed to elucidate the precise role of IDO-1 in tumor development, its mechanisms of action appear sufficiently distinct from other immunotherapy targets to warrant inclusion in combination immunotherapy regimens, an approach where multiple clinical trials are currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzTQoELJ1EfO3MPKNEWB5RfW6udTcc2ea4IhQk0QGfx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjjtVeisQ%253D%253D&md5=81e82735e4d32baea00039d21ea7ac83</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs11912-019-0750-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-019-0750-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DM.%2BM.%2BT.%26aulast%3DDancsok%26aufirst%3DA.%2BR.%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26atitle%3DIndoleamine%2520Dioxygenase%2520Inhibitors%253A%2520Clinical%2520Rationale%2520and%2520Current%2520Development%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2019%26volume%3D21%26spage%3D2%26doi%3D10.1007%2Fs11912-019-0750-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span> <span> </span><span class="NLM_article-title">Immune Control by Amino Acid Catabolism During Tumorigenesis and Therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1038/s41568-019-0106-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41568-019-0106-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30696923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVymtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=162-175&author=H.+Lemosauthor=L.+Huangauthor=G.+C.+Prendergastauthor=A.+L.+Mellor&title=Immune+Control+by+Amino+Acid+Catabolism+During+Tumorigenesis+and+Therapy&doi=10.1038%2Fs41568-019-0106-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Immune control by amino acid catabolism during tumorigenesis and therapy</span></div><div class="casAuthors">Lemos, Henrique; Huang, Lei; Prendergast, George C.; Mellor, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">162-175</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Immune checkpoints arise from physiol. changes during tumorigenesis that reprogramme inflammatory, immunol. and metabolic processes in malignant lesions and local lymphoid tissues, which constitute the immunol. tumor microenvironment (TME).  Improving clin. responses to immune checkpoint blockade will require deeper understanding of factors that impact local immune balance in the TME.  Elevated catabolism of the amino acids tryptophan (Trp) and arginine (Arg) is a common TME hallmark at clin. presentation of cancer.  Cells catabolizing Trp and Arg suppress effector T cells and stabilize regulatory T cells to suppress immunity in chronic inflammatory diseases of clin. importance, including cancers.  Processes that induce Trp and Arg catabolism in the TME remain incompletely defined.  Indoleamine 2,3 dioxygenase (IDO) and arginase 1 (ARG1), which catabolize Trp and Arg, resp., respond to inflammatory cues including interferons and transforming growth factor-β (TGFβ) cytokines.  Dying cells generate inflammatory signals including DNA, which is sensed to stimulate the prodn. of type I interferons via the stimulator of interferon genes (STING) adaptor.  Thus, dying cells help establish local conditions that suppress antitumor immunity to promote tumorigenesis.  Here, we review evidence that Trp and Arg catabolism contributes to inflammatory processes that promote tumorigenesis, impede immune responses to therapy and might promote neurol. comorbidities assocd. with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYjtO-kD36rbVg90H21EOLACvtfcHk0ljEDCBdJ7VcLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVymtr0%253D&md5=ace250be08c88ffa307620152a19523b</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fs41568-019-0106-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-019-0106-z%26sid%3Dliteratum%253Aachs%26aulast%3DLemos%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26atitle%3DImmune%2520Control%2520by%2520Amino%2520Acid%2520Catabolism%2520During%2520Tumorigenesis%2520and%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2019%26volume%3D19%26spage%3D162%26epage%3D175%26doi%3D10.1038%2Fs41568-019-0106-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaipuri, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potturi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brincks, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahanian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, C. J.</span></span> <span> </span><span class="NLM_article-title">Abstract 4076: A Novel Prodrug of Indoximod with Enhanced Pharmacokinetic Properties</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4076</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-4076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F1538-7445.AM2017-4076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4076&author=M.+R.+Mautinoauthor=S.+Kumarauthor=H.+Zhuangauthor=J.+P.+Waldoauthor=F.+A.+Jaipuriauthor=H.+Potturiauthor=E.+L.+Brincksauthor=J.+Adamsauthor=A.+Marcinowiczauthor=C.+Allenauthor=N.+Vahanianauthor=C.+J.+Link&title=Abstract+4076%3A+A+Novel+Prodrug+of+Indoximod+with+Enhanced+Pharmacokinetic+Properties&doi=10.1158%2F1538-7445.AM2017-4076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-4076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-4076%26sid%3Dliteratum%253Aachs%26aulast%3DMautino%26aufirst%3DM.%2BR.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DH.%26aulast%3DWaldo%26aufirst%3DJ.%2BP.%26aulast%3DJaipuri%26aufirst%3DF.%2BA.%26aulast%3DPotturi%26aufirst%3DH.%26aulast%3DBrincks%26aufirst%3DE.%2BL.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DMarcinowicz%26aufirst%3DA.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DVahanian%26aufirst%3DN.%26aulast%3DLink%26aufirst%3DC.%2BJ.%26atitle%3DAbstract%25204076%253A%2520A%2520Novel%2520Prodrug%2520of%2520Indoximod%2520with%2520Enhanced%2520Pharmacokinetic%2520Properties%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4076%26doi%3D10.1158%2F1538-7445.AM2017-4076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaipuri, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potturi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahanian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brincks, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Indoximod Prodrugs and Characterization of Clinical Candidate Nlg802</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">112373</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2020.112373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32422549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsl2hsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2020&pages=112373&author=S.+Kumarauthor=F.+A.+Jaipuriauthor=J.+P.+Waldoauthor=H.+Potturiauthor=A.+Marcinowiczauthor=J.+Adamsauthor=C.+Van+Allenauthor=H.+Zhuangauthor=N.+Vahanianauthor=C.+Linkauthor=E.+L.+Brincksauthor=M.+R.+Mautino&title=Discovery+of+Indoximod+Prodrugs+and+Characterization+of+Clinical+Candidate+Nlg802&doi=10.1016%2Fj.ejmech.2020.112373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of indoximod prodrugs and characterization of clinical candidate NLG802</span></div><div class="casAuthors">Kumar, Sanjeev; Jaipuri, Firoz A.; Waldo, Jesse P.; Potturi, Hima; Marcinowicz, Agnieszka; Adams, James; Van Allen, Clarissa; Zhuang, Hong; Vahanian, Nicholas; Link, Charles Jr.; Brincks, Erik L.; Mautino, Mario R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112373</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of different prodrugs of indoximod, including esters and peptide amides were synthesized with the aim of improving its oral bioavailability in humans.  The pharmacokinetics of prodrugs that were stable in buffers, plasma and simulated gastric and intestinal fluids was first assessed in rats after oral dosing in soln. or in capsule formulation.  Two prodrugs that produced the highest exposure to indoximod in rats were further tested in Cynomolgus monkeys, a species in which indoximod has oral bioavailability of 6-10% and an equiv. dose-dependent exposure profile as humans.  NLG802 was selected as the clin. development candidate after increasing oral bioavailability (>5-fold), Cmax (6.1-3.6 fold) and AUC (2.9-5.2 fold) in monkeys, compared to equiv. molar oral doses of indoximod.  NLG802 is extensively absorbed and rapidly metabolized to indoximod in all species tested and shows a safe toxicol. profile at the anticipated therapeutic doses.  NLG802 markedly enhanced the anti-tumor responses of tumor-specific pmel-1 T cells in a melanoma tumor model.  In conclusion, NLG802 is a prodrug of indoximod expected to increase clin. drug exposure to indoximod above the current achievable levels, thus increasing the possibility of therapeutic effects in a larger fraction of the target patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIUrIcvEBaBbVg90H21EOLACvtfcHk0lgSlGnDuv8ZmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsl2hsLc%253D&md5=9bd32935ecc631a92b4d68807b161fce</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112373%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DJaipuri%26aufirst%3DF.%2BA.%26aulast%3DWaldo%26aufirst%3DJ.%2BP.%26aulast%3DPotturi%26aufirst%3DH.%26aulast%3DMarcinowicz%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DVan%2BAllen%26aufirst%3DC.%26aulast%3DZhuang%26aufirst%3DH.%26aulast%3DVahanian%26aufirst%3DN.%26aulast%3DLink%26aufirst%3DC.%26aulast%3DBrincks%26aufirst%3DE.%2BL.%26aulast%3DMautino%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520Indoximod%2520Prodrugs%2520and%2520Characterization%2520of%2520Clinical%2520Candidate%2520Nlg802%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D198%26spage%3D112373%26doi%3D10.1016%2Fj.ejmech.2020.112373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F0008-5472.CAN-06-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=17234791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=792-801&author=D.+Y.+Houauthor=A.+J.+Mullerauthor=M.+D.+Sharmaauthor=J.+DuHadawayauthor=T.+Banerjeeauthor=M.+Johnsonauthor=A.+L.+Mellorauthor=G.+C.+Prendergastauthor=D.+H.+Munn&title=Inhibition+of+Indoleamine+2%2C3-Dioxygenase+in+Dendritic+Cells+by+Stereoisomers+of+1-Methyl-Tryptophan+Correlates+with+Antitumor+Responses&doi=10.1158%2F0008-5472.CAN-06-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses</span></div><div class="casAuthors">Hou, De-Yan; Muller, Alexander J.; Sharma, Madhav D.; DuHadaway, James; Banerjee, Tinku; Johnson, Maribeth; Mellor, Andrew L.; Prendergast, George C.; Munn, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">792-801</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that contributes to tolerance in a no. of biol. settings.  In cancer, IDO activity may help promote acquired tolerance to tumor antigens.  The IDO inhibitor 1-methyl-tryptophan is being developed for clin. trials.  However, 1-methyl-tryptophan exists in two stereoisomers with potentially different biol. properties, and it has been unclear which isomer might be preferable for initial development.  In this study, we provide evidence that the D and L stereoisomers exhibit important cell type-specific variations in activity.  The L isomer was the more potent inhibitor of IDO activity using the purified enzyme and in HeLa cell-based assays.  However, the D isomer was significantly more effective in reversing the suppression of T cells created by IDO-expressing dendritic cells, using both human monocyte-derived dendritic cells and murine dendritic cells isolated directly from tumor-draining lymph nodes.  In vivo, the D isomer was more efficacious as an anticancer agent in chemo-immunotherapy regimens using cyclophosphamide, paclitaxel, or gemcitabine, when tested in mouse models of transplantable melanoma and transplantable and autochthonous breast cancer.  The D isomer of 1-methyl-tryptophan specifically targeted the IDO gene because the antitumor effect of D-1-methyl-tryptophan was completely lost in mice with a disruption of the IDO gene (IDO-knockout mice).  Taken together, our findings support the suitability of D-1-methyl-tryptophan for human trials aiming to assess the utility of IDO inhibition to block host-mediated immunosuppression and enhance antitumor immunity in the setting of combined chemo-immunotherapy regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Qarb_QtEIrVg90H21EOLACvtfcHk0lgSlGnDuv8ZmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVKqtQ%253D%253D&md5=9e514bc8feb7f8251b73d19ad421f922</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-2925%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DD.%2BY.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DSharma%26aufirst%3DM.%2BD.%26aulast%3DDuHadaway%26aufirst%3DJ.%26aulast%3DBanerjee%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26atitle%3DInhibition%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520in%2520Dendritic%2520Cells%2520by%2520Stereoisomers%2520of%25201-Methyl-Tryptophan%2520Correlates%2520with%2520Antitumor%2520Responses%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D792%26epage%3D801%26doi%3D10.1158%2F0008-5472.CAN-06-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rust, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duhadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahanian, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Ido Inhibits a Tryptophan Sufficiency Signal That Stimulates Mtor: A Novel Ido Effector Pathway Targeted by D-1-Methyl-Tryptophan</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">1460</span>– <span class="NLM_lpage">1468</span>, <span class="refDoi"> DOI: 10.4161/onci.21716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.4161%2Fonci.21716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=23264892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC2sris1egsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=1460-1468&author=R.+Metzauthor=S.+Rustauthor=J.+B.+Duhadawayauthor=M.+R.+Mautinoauthor=D.+H.+Munnauthor=N.+N.+Vahanianauthor=C.+J.+Linkauthor=G.+C.+Prendergast&title=Ido+Inhibits+a+Tryptophan+Sufficiency+Signal+That+Stimulates+Mtor%3A+A+Novel+Ido+Effector+Pathway+Targeted+by+D-1-Methyl-Tryptophan&doi=10.4161%2Fonci.21716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">IDO inhibits a tryptophan sufficiency signal that stimulates mTOR:  A novel IDO effector pathway targeted by D-1-methyl-tryptophan</span></div><div class="casAuthors">Metz Richard; Rust Sonja; Duhadaway James B; Mautino Mario R; Munn David H; Vahanian Nicholas N; Link Charles J; Prendergast George C</div><div class="citationInfo"><span class="NLM_cas:title">Oncoimmunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1460-1468</span>
        ISSN:<span class="NLM_cas:issn">2162-4011</span>.
    </div><div class="casAbstract">Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO) alters inflammation and favors T-cell tolerance in cancer, but the underlying molecular mechanisms remain poorly understood.  The integrated stress response kinase GCN2, a sensor of uncharged tRNA that is activated by amino acid deprivation, is recognized as an important effector of the IDO pathway.  However, in a mouse model of inflammatory carcinogenesis, ablation of Gcn2 did not promote resistance against tumor development like the absence of IDO does, implying the existence of additional cancer-relevant pathways that operate downstream of IDO.  Addressing this gap in knowledge, we report that the IDO-mediated catabolism of tryptophan also inhibits the immunoregulatory kinases mTOR and PKC-Θ, along with the induction of autophagy.  These effects were relieved specifically by tryptophan but also by the experimental agent 1-methyl-D-tryptophan (D-1MT, also known as NLG8189), the latter of which reversed the inhibitory signals generated by IDO with higher potency.  Taken together, our results implicate mTOR and PKC-Θ in IDO-mediated immunosuppressive signaling, and they provide timely insights into the unique mechanism of action of D-1MT as compared with traditional biochemical inhibitors of IDO.  These findings are important translationally, because they suggest broader clinical uses for D-1MT against cancers that overexpress any tryptophan catabolic enzyme (IDO, IDO2 or TDO).  Moreover, they define mTOR and PKC-Θ as candidate pharmacodynamic markers for D-1MT responses in patients recruited to ongoing phase IB/II cancer trials, addressing a current clinical need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYpqhzQ3xPO691pGlMMoT5fW6udTcc2earcR94cbGKx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sris1egsQ%253D%253D&md5=a8ff204c01c08b7cce3fade1796623fe</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.4161%2Fonci.21716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fonci.21716%26sid%3Dliteratum%253Aachs%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DRust%26aufirst%3DS.%26aulast%3DDuhadaway%26aufirst%3DJ.%2BB.%26aulast%3DMautino%26aufirst%3DM.%2BR.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DVahanian%26aufirst%3DN.%2BN.%26aulast%3DLink%26aufirst%3DC.%2BJ.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DIdo%2520Inhibits%2520a%2520Tryptophan%2520Sufficiency%2520Signal%2520That%2520Stimulates%2520Mtor%253A%2520A%2520Novel%2520Ido%2520Effector%2520Pathway%2520Targeted%2520by%2520D-1-Methyl-Tryptophan%26jtitle%3DOncoimmunology%26date%3D2012%26volume%3D1%26spage%3D1460%26epage%3D1468%26doi%3D10.4161%2Fonci.21716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takvorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Incb24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitor for Immuno-Oncology</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=486-491&author=E.+W.+Yueauthor=R.+Sparksauthor=P.+Polamauthor=D.+Modiauthor=B.+Doutyauthor=B.+Waylandauthor=B.+Glassauthor=A.+Takvorianauthor=J.+Glennauthor=W.+Zhuauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=T.+Emmauthor=P.+A.+Scherleauthor=B.+Metcalfauthor=A.+P.+Combs&title=Incb24360+%28Epacadostat%29%2C+a+Highly+Potent+and+Selective+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitor+for+Immuno-Oncology&doi=10.1021%2Facsmedchemlett.6b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology</span></div><div class="casAuthors">Yue, Eddy W.; Sparks, Richard; Polam, Padmaja; Modi, Dilip; Douty, Brent; Wayland, Brian; Glass, Brian; Takvorian, Amy; Glenn, Joseph; Zhu, Wenyu; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Emm, Tom; Scherle, Peggy A.; Metcalf, Brian; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A data-centric medicinal chem. approach led to the invention of a potent and selective IDO1 inhibitor 4f, INCB24360 (epacadostat).  The mol. structure of INCB24360 contains several previously unknown or underutilized functional groups in drug substances, including a hydroxyamidine, furazan, bromide and sulfamide.  These moieties taken together in a single structure afford a compd. which falls outside of "drug-like" space.  Nevertheless, the in vitro ADME data is consistent with the good cell permeability and oral bioavailability obsd. in all species (rat, dog, monkey) tested.  The extensive intramol. hydrogen bonding obsd. in the small mol. crystal structure of 4f is believed to significantly contribute to the obsd. permeability and PK.  Epacadostat in combination with anti-PD1 mAb pembrolizumab is currently being studied in a phase 3 clin. trial in patients with unresectable or metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpm79ArpY1yLVg90H21EOLACvtfcHk0ljPkbrijLYPzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D&md5=92bebde519334e9e2a776250bb0258ac</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00391%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DSparks%26aufirst%3DR.%26aulast%3DPolam%26aufirst%3DP.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DGlass%26aufirst%3DB.%26aulast%3DTakvorian%26aufirst%3DA.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DIncb24360%2520%2528Epacadostat%2529%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitor%2520for%2520Immuno-Oncology%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D486%26epage%3D491%26doi%3D10.1021%2Facsmedchemlett.6b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caglevic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diede, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span> <span> </span><span class="NLM_article-title">Epacadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma (Echo-301/Keynote-252): A Phase 3, Randomised, Double-Blind Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30274-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2FS1470-2045%2819%2930274-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31221619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1083-1097&author=G.+V.+Longauthor=R.+Dummerauthor=O.+Hamidauthor=T.+F.+Gajewskiauthor=C.+Caglevicauthor=S.+Dalleauthor=A.+Aranceauthor=M.+S.+Carlinoauthor=J.+J.+Grobauthor=T.+M.+Kimauthor=L.+Demidovauthor=C.+Robertauthor=J.+Larkinauthor=J.+R.+Andersonauthor=J.+Maleskiauthor=M.+Jonesauthor=S.+J.+Diedeauthor=T.+C.+Mitchell&title=Epacadostat+Plus+Pembrolizumab+Versus+Placebo+Plus+Pembrolizumab+in+Patients+with+Unresectable+or+Metastatic+Melanoma+%28Echo-301%2FKeynote-252%29%3A+A+Phase+3%2C+Randomised%2C+Double-Blind+Study&doi=10.1016%2FS1470-2045%2819%2930274-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study</span></div><div class="casAuthors">Long, Georgina V.; Dummer, Reinhard; Hamid, Omid; Gajewski, Thomas F.; Caglevic, Christian; Dalle, Stephane; Arance, Ana; Carlino, Matteo S.; Grob, Jean-Jacques; Kim, Tae Min; Demidov, Lev; Robert, Caroline; Larkin, James; Anderson, James R.; Maleski, Janet; Jones, Mark; Diede, Scott J.; Mitchell, Tara C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1083-1097</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immunotherapy combination treatments can improve patient outcomes.  Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumor activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma.  In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab vs. placebo plus pembrolizumab.  In this international, randomised, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAFV600 mutant status or consented to BRAFV600 mutation testing during screening.  Patients were stratified by PD-L1 expression and BRAFV600 mutation status and randomly assigned (1:1) through a central interactive voice and integrated web response system to receive epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg i.v. every 3 wk or placebo plus pembrolizumab for up to 2 years.  We used block randomisation with a block size of four in each stratum.  Primary endpoints were progression-free survival and overall survival in the intention-to-treat population.  The safety anal. population included randomly assigned patients who received at least one dose of study treatment.  The study was stopped after the second interim anal.; follow-up for safety is ongoing.  This study is registered with ClinicalTrials.gov, no. NCT02752074.  Between June 21, 2016, and Aug 7, 2017, 928 patients were screened and 706 patients were randomly assigned to receive epacadostat plus pembrolizumab (n=354) or placebo plus pembrolizumab (n=352).  Median follow-up was 12·4 mo (IQR 10·3-14·5).  No significant differences were found between the treatment groups for progression-free survival (median 4·7 mo, 95% CI 2·9-6·8, for epacadostat plus pembrolizumab vs 4·9 mo, 2·9-6·8, for placebo plus pembrolizumab; hazard ratio [HR] 1·00, 95% CI 0·83-1·21; one-sided p=0·52) or overall survival (median not reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1·13, 0·86-1·49; one-sided p=0·81).  The most common grade 3 or worse treatment-related adverse event was lipase increase, which occurred in 14 (4%) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving placebo plus pembrolizumab.  Treatment-related serious adverse events were reported in 37 (10%) of 353 patients receiving epacadostat plus pembrolizumab and 32 (9%) of 352 patients receiving placebo plus pembrolizumab.  There were no treatment-related deaths in either treatment group.  Epacadostat 100 mg twice daily plus pembrolizumab did not improve progression-free survival or overall survival compared with placebo plus pembrolizumab in patients with unresectable or metastatic melanoma.  The usefulness of IDO1 inhibition as a strategy to enhance anti-PD-1 therapy activity in cancer remains uncertain.  Incyte Corporation, in collaboration with Merck Sharp & Dohme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8j2WQ35JqjbVg90H21EOLACvtfcHk0lg78h4rHUg6PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM&md5=f1dce1f431d2650fe4f8b8e46677e03d</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930274-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930274-8%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DCaglevic%26aufirst%3DC.%26aulast%3DDalle%26aufirst%3DS.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DDiede%26aufirst%3DS.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26atitle%3DEpacadostat%2520Plus%2520Pembrolizumab%2520Versus%2520Placebo%2520Plus%2520Pembrolizumab%2520in%2520Patients%2520with%2520Unresectable%2520or%2520Metastatic%2520Melanoma%2520%2528Echo-301%252FKeynote-252%2529%253A%2520A%2520Phase%25203%252C%2520Randomised%252C%2520Double-Blind%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D1083%26epage%3D1097%26doi%3D10.1016%2FS1470-2045%2819%2930274-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03661320" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03661320</a> (accessed Aug 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03661320+%28accessed+Aug+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaipuri, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesharwani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Clinical Candidate (1r,4r)-4-((R)-2-((S)-6-Fluoro-5h-Imidazo[5,1-a]Isoindol-5-Yl)-1-Hydroxyethyl)Cyc Lohexan-1-Ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6705</span>– <span class="NLM_lpage">6733</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00662</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00662" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2gsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6705-6733&author=S.+Kumarauthor=J.+P.+Waldoauthor=F.+A.+Jaipuriauthor=A.+Marcinowiczauthor=C.+Van+Allenauthor=J.+Adamsauthor=T.+Kesharwaniauthor=X.+Zhangauthor=R.+Metzauthor=A.+J.+Ohauthor=S.+F.+Harrisauthor=M.+R.+Mautino&title=Discovery+of+Clinical+Candidate+%281r%2C4r%29-4-%28%28R%29-2-%28%28S%29-6-Fluoro-5h-Imidazo%5B5%2C1-a%5DIsoindol-5-Yl%29-1-Hydroxyethyl%29Cyc+Lohexan-1-Ol+%28Navoximod%29%2C+a+Potent+and+Selective+Inhibitor+of+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1021%2Facs.jmedchem.9b00662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1</span></div><div class="casAuthors">Kumar, Sanjeev; Waldo, Jesse P.; Jaipuri, Firoz A.; Marcinowicz, Agnieszka; Van Allen, Clarissa; Adams, James; Kesharwani, Tanay; Zhang, Xiaoxia; Metz, Richard; Oh, Angela J.; Harris, Seth F.; Mautino, Mario R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6705-6733</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of 5-substituted 5H-imidazo[5,1-a]isoindoles are described as potent inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1).  A structure-based drug design approach was used to elaborate the 5H-imidazo[5,1-a]isoindole core and to improve potency and pharmacol. properties.  Suitably placed hydrophobic and polar functional groups in the lead mol. allowed improvement of IDO1 inhibitory activity while minimizing off-target liabilities.  Structure-activity relationship studies focused on optimizing IDO1 inhibition potency and a pharmacokinetic profile amenable to oral dosing while controlling CYP450 and hERG inhibitory properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsaXqUemSD7Vg90H21EOLACvtfcHk0lg78h4rHUg6PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2gsbvE&md5=061789cf93bfde1204516aae79a403d4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00662%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DWaldo%26aufirst%3DJ.%2BP.%26aulast%3DJaipuri%26aufirst%3DF.%2BA.%26aulast%3DMarcinowicz%26aufirst%3DA.%26aulast%3DVan%2BAllen%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DKesharwani%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DA.%2BJ.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DMautino%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520Clinical%2520Candidate%2520%25281r%252C4r%2529-4-%2528%2528R%2529-2-%2528%2528S%2529-6-Fluoro-5h-Imidazo%255B5%252C1-a%255DIsoindol-5-Yl%2529-1-Hydroxyethyl%2529Cyc%2520Lohexan-1-Ol%2520%2528Navoximod%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6705%26epage%3D6733%26doi%3D10.1021%2Facs.jmedchem.9b00662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhadji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolayev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalos, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geeganage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J.</span></span> <span> </span><span class="NLM_article-title">Abstract 5245: Identification and Characterization of the Ido1 Inhibitor Ly3381916</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5245</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-5245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F1538-7445.AM2018-5245" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5245&author=F.+Dorseyauthor=K.+Benhadjiauthor=L.+Samsauthor=D.+Youngauthor=J.+Schindlerauthor=K.+Hussauthor=A.+Nikolayevauthor=C.+Carpenitoauthor=D.+Clawsonauthor=B.+Jonesauthor=A.+Faberauthor=J.+Thomasauthor=S.+Haneyauthor=G.+Zhaoauthor=W.+McMillenauthor=T.+Smealauthor=D.+Sallauthor=M.+D.+Kalosauthor=S.+Geeganageauthor=J.+Henry&title=Abstract+5245%3A+Identification+and+Characterization+of+the+Ido1+Inhibitor+Ly3381916&doi=10.1158%2F1538-7445.AM2018-5245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-5245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-5245%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DF.%26aulast%3DBenhadji%26aufirst%3DK.%26aulast%3DSams%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DD.%26aulast%3DSchindler%26aufirst%3DJ.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DNikolayev%26aufirst%3DA.%26aulast%3DCarpenito%26aufirst%3DC.%26aulast%3DClawson%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DFaber%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DHaney%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DMcMillen%26aufirst%3DW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSall%26aufirst%3DD.%26aulast%3DKalos%26aufirst%3DM.%2BD.%26aulast%3DGeeganage%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DJ.%26atitle%3DAbstract%25205245%253A%2520Identification%2520and%2520Characterization%2520of%2520the%2520Ido1%2520Inhibitor%2520Ly3381916%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5245%26doi%3D10.1158%2F1538-7445.AM2018-5245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03343613" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03343613</a> (accessed Aug 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03343613+%28accessed+Aug+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahebjam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efuni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grebennik, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collaku, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogunmefun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rixe, O.</span></span> <span> </span><span class="NLM_article-title">First-in-Human Study of Khk2455, a Long-Acting, Potent and Selective Indoleamine 2,3-Dioxygenase 1 (Ido-1) Inhibitor, in Combination with Mogamulizumab (Moga), an Anti-Ccr4Monoclonal Antibody, in Patients (Pts) with Advanced Solid Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3040</span>– <span class="NLM_lpage">3040</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.3040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1200%2FJCO.2018.36.15_suppl.3040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29847297" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=3040-3040&author=T.+A.+Yapauthor=S.+Sahebjamauthor=D.+S.+Hongauthor=V.+K.+Chiuauthor=E.+Yilmazauthor=S.+Efuniauthor=D.+O.+Grebennikauthor=A.+Collakuauthor=E.+Ogunmefunauthor=Y.+Liuauthor=T.+Tayamaauthor=R.+R.+Latekauthor=O.+Rixe&title=First-in-Human+Study+of+Khk2455%2C+a+Long-Acting%2C+Potent+and+Selective+Indoleamine+2%2C3-Dioxygenase+1+%28Ido-1%29+Inhibitor%2C+in+Combination+with+Mogamulizumab+%28Moga%29%2C+an+Anti-Ccr4Monoclonal+Antibody%2C+in+Patients+%28Pts%29+with+Advanced+Solid+Tumors&doi=10.1200%2FJCO.2018.36.15_suppl.3040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.3040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.3040%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DSahebjam%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DChiu%26aufirst%3DV.%2BK.%26aulast%3DYilmaz%26aufirst%3DE.%26aulast%3DEfuni%26aufirst%3DS.%26aulast%3DGrebennik%26aufirst%3DD.%2BO.%26aulast%3DCollaku%26aufirst%3DA.%26aulast%3DOgunmefun%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTayama%26aufirst%3DT.%26aulast%3DLatek%26aufirst%3DR.%2BR.%26aulast%3DRixe%26aufirst%3DO.%26atitle%3DFirst-in-Human%2520Study%2520of%2520Khk2455%252C%2520a%2520Long-Acting%252C%2520Potent%2520and%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido-1%2529%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Mogamulizumab%2520%2528Moga%2529%252C%2520an%2520Anti-Ccr4Monoclonal%2520Antibody%252C%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D3040%26epage%3D3040%26doi%3D10.1200%2FJCO.2018.36.15_suppl.3040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03364049" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03364049</a> (accessed May 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03364049+%28accessed+May+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03208959" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03208959</a> (accessed Aug 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03208959+%28accessed+Aug+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Oren-Gedoku-to and Its Constituents with Therapeutic Potential in Alzheimer’s Disease Inhibit Indoleamine 2, 3-Dioxygenase Activity in Vitro</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.3233/JAD-2010-100684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3233%2FJAD-2010-100684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=20847417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=257-266&author=C.+J.+Yuauthor=M.+F.+Zhengauthor=C.+X.+Kuangauthor=W.+D.+Huangauthor=Q.+Yang&title=Oren-Gedoku-to+and+Its+Constituents+with+Therapeutic+Potential+in+Alzheimer%E2%80%99s+Disease+Inhibit+Indoleamine+2%2C+3-Dioxygenase+Activity+in+Vitro&doi=10.3233%2FJAD-2010-100684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Oren-gedoku-to and its Constituents with Therapeutic Potential in Alzheimer's Disease Inhibit Indoleamine 2, 3-Dioxygenase Activity In Vitro</span></div><div class="casAuthors">Yu, Cun-Jing; Zheng, Mao-Fa; Kuang, Chun-Xiang; Huang, Wei-Da; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">257-266</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A well-known traditional Chinese medicinal prescription, Oren-gedoku-to (OGT), has been used in clin. therapies for many types of dementia in China and Japan.  Addnl., it ameliorates the age-related deterioration of learning and memory in an Alzheimer's disease (AD) rat model.  Indoleamine 2, 3-dioxygenase (IDO-1) is the first and rate-limiting enzyme in the kynurenine pathway of tryptophan catabolism, which ultimately leads to the prodn. of the excitotoxin quinolinic acid (QUIN).  IDO-1 has recently been established as one of the key players involved in the pathogenesis of AD.  OGT is indicated to prevent cholinergic dysfunction and reduce oxidative stress; however, the exact mechanism underlying its ability to improve cognitive ability remains elusive.  Here we present a novel mechanism of OGT's therapeutic potential in AD.  We demonstrated that OGT significantly inhibited recombinant human IDO-1 (rhIDO-1) activity in vitro, and its four main constituents (i.e., berberine, palmatine, jatrorrhizine, and baicalein) were potent IDO-1 inhibitors.  IC50 values, obtained from a cell-based assay, of HEK 293 cells and an enzymic assay were much lower than the most commonly used IDO-1 inhibitor, 1-Me tryptophan (1-MT).  Berberine was the best inhibitor and had IC50 values of 7 μM (cell-based assay) and 9.3 μM (enzymic assay).  Jatrorrhizine and palmatine exhibited irreversible inhibition of rhIDO-1, whereas berberine and baicalein behaved as uncompetitive, reversible inhibitors with Ki values of 8 μM and 215 μM, resp.  In conclusion, constituents of OGT show strong IDO-1 inhibitory activity and may have significant therapeutic potential for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSaPOq-g2sBbVg90H21EOLACvtfcHk0lhDUNJ49my7zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtb%252FN&md5=16d4a67c4306a4bff61d6219fc6d04c1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-100684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-100684%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%2BJ.%26aulast%3DZheng%26aufirst%3DM.%2BF.%26aulast%3DKuang%26aufirst%3DC.%2BX.%26aulast%3DHuang%26aufirst%3DW.%2BD.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DOren-Gedoku-to%2520and%2520Its%2520Constituents%2520with%2520Therapeutic%2520Potential%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Inhibit%2520Indoleamine%25202%252C%25203-Dioxygenase%2520Activity%2520in%2520Vitro%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2010%26volume%3D22%26spage%3D257%26epage%3D266%26doi%3D10.3233%2FJAD-2010-100684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passacantilli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famiglini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsilinakos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoccoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisinni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Regina, G.</span></span> <span> </span><span class="NLM_article-title">New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9760</span>– <span class="NLM_lpage">9773</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9760-9773&author=A.+Colucciaauthor=S.+Passacantilliauthor=V.+Famigliniauthor=M.+Sabatinoauthor=A.+Patsilinakosauthor=R.+Ragnoauthor=C.+Mazzoccoliauthor=L.+Sisinniauthor=A.+Okunoauthor=O.+Takikawaauthor=R.+Silvestriauthor=G.+La+Regina&title=New+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+1%3A+Molecular+Modeling+Studies%2C+Synthesis%2C+and+Biological+Evaluation&doi=10.1021%2Facs.jmedchem.6b00718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation</span></div><div class="casAuthors">Coluccia, Antonio; Passacantilli, Sara; Famiglini, Valeria; Sabatino, Manuela; Patsilinakos, Alexandros; Ragno, Rino; Mazzoccoli, Carmela; Sisinni, Lorenza; Okuno, Alato; Takikawa, Osamu; Silvestri, Romano; La Regina, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9760-9773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy.  Herein, we report a virtual screening study which led to the identification of compd. I as a new IDO1 inhibitor.  In order to improve the biol. activity of the identified hit, arylthioindoles were synthesized and tested.  Among these, deriv. II exhibited an IC50 value of 7 μM, being the most active compd. of the series.  Furthermore, compds. I and II induced a dose-dependent growth inhibition in IDO1 expressing cancer cell lines HTC116 and HT29.  3-D QSAR studies were carried out in order to rationalize obtained results and suggest new chem. modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxfHwAbMNZXrVg90H21EOLACvtfcHk0lhDUNJ49my7zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtL7I&md5=9a1267db6fdeadfbbb693464ba4dddd6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00718%26sid%3Dliteratum%253Aachs%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DPassacantilli%26aufirst%3DS.%26aulast%3DFamiglini%26aufirst%3DV.%26aulast%3DSabatino%26aufirst%3DM.%26aulast%3DPatsilinakos%26aufirst%3DA.%26aulast%3DRagno%26aufirst%3DR.%26aulast%3DMazzoccoli%26aufirst%3DC.%26aulast%3DSisinni%26aufirst%3DL.%26aulast%3DOkuno%26aufirst%3DA.%26aulast%3DTakikawa%26aufirst%3DO.%26aulast%3DSilvestri%26aufirst%3DR.%26aulast%3DLa%2BRegina%26aufirst%3DG.%26atitle%3DNew%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%253A%2520Molecular%2520Modeling%2520Studies%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9760%26epage%3D9773%26doi%3D10.1021%2Facs.jmedchem.6b00718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camponeschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Custodi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ianni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Approach to Identify Ido1 Inhibitor Building Blocks</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2017.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29031064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2017&pages=169-177&author=A.+Colettiauthor=F.+Camponeschiauthor=E.+Albiniauthor=F.+A.+Grecoauthor=V.+Maioneauthor=C.+Custodiauthor=F.+Ianniauthor=U.+Grohmannauthor=C.+Orabonaauthor=F.+Cantiniauthor=A.+Macchiarulo&title=Fragment-Based+Approach+to+Identify+Ido1+Inhibitor+Building+Blocks&doi=10.1016%2Fj.ejmech.2017.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based approach to identify IDO1 inhibitor building blocks</span></div><div class="casAuthors">Coletti, Alice; Camponeschi, Francesca; Albini, Elisa; Greco, Francesco Antonio; Maione, Vincenzo; Custodi, Chiara; Ianni, Federica; Grohmann, Ursula; Orabona, Ciriana; Cantini, Francesca; Macchiarulo, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is attracting a great deal of interest as drug target in immune-oncol. being highly expressed in cancer cells and participating to the tumor immune-editing process.  Although several classes of IDO1 inhibitors have been reported in literature and patent applications, only few compds. have proved optimal pharmacol. profile in preclin. studies to be advanced in clin. trials.  Accordingly, the quest for novel structural classes of IDO1 inhibitors is still open.  In this paper, the authors report a fragment-based screening campaign that combines Water-LOGSY NMR expts. and microscale thermophoresis approach to identify fragments that may be helpful for the development of novel IDO1 inhibitors as therapeutic agents in immune-oncol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_0x5BjMTidbVg90H21EOLACvtfcHk0liSIdMJRaQDQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltrjF&md5=50e7de9e473de649fde48b2b0171850c</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DCamponeschi%26aufirst%3DF.%26aulast%3DAlbini%26aufirst%3DE.%26aulast%3DGreco%26aufirst%3DF.%2BA.%26aulast%3DMaione%26aufirst%3DV.%26aulast%3DCustodi%26aufirst%3DC.%26aulast%3DIanni%26aufirst%3DF.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DCantini%26aufirst%3DF.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DFragment-Based%2520Approach%2520to%2520Identify%2520Ido1%2520Inhibitor%2520Building%2520Blocks%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D141%26spage%3D169%26epage%3D177%26doi%3D10.1016%2Fj.ejmech.2017.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauwenberghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denies, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letellier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabolli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (Ido1) Catalytic Inhibitor Eos200271/Pf-06840003 Supports Ido1 as a Critical Resistance Mechanism to Pd-(L)1 Blockade Therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2530</span>– <span class="NLM_lpage">2542</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-1104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F1535-7163.MCT-17-1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30232146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1eltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=2530-2542&author=B.+Gomesauthor=G.+Driessensauthor=D.+Bartlettauthor=D.+Caiauthor=S.+Cauwenberghsauthor=S.+Crosignaniauthor=D.+Dalvieauthor=S.+Deniesauthor=C.+P.+Dillonauthor=V.+R.+Fantinauthor=J.+Guoauthor=M.+C.+Letellierauthor=W.+Liauthor=K.+Maegleyauthor=R.+Marillierauthor=N.+Millerauthor=R.+Pirsonauthor=V.+Rabolliauthor=C.+Rayauthor=N.+Streinerauthor=V.+R.+Tortiauthor=K.+Tsaparikosauthor=B.+J.+Van+den+Eyndeauthor=M.+Wythesauthor=L.+C.+Yaoauthor=X.+Zhengauthor=J.+Tumangauthor=M.+Kraus&title=Characterization+of+the+Selective+Indoleamine+2%2C3-Dioxygenase-1+%28Ido1%29+Catalytic+Inhibitor+Eos200271%2FPf-06840003+Supports+Ido1+as+a+Critical+Resistance+Mechanism+to+Pd-%28L%291+Blockade+Therapy&doi=10.1158%2F1535-7163.MCT-17-1104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy</span></div><div class="casAuthors">Gomes, Bruno; Driessens, Gregory; Bartlett, Derek; Cai, Danying; Cauwenberghs, Sandra; Crosignani, Stefano; Dalvie, Deepak; Denies, Sofie; Dillon, Christopher P.; Fantin, Valeria R.; Guo, Jie; Letellier, Marie-Claire; Li, Wenlin; Maegley, Karen; Marillier, Reece; Miller, Nichol; Pirson, Romain; Rabolli, Virginie; Ray, Chad; Streiner, Nicole; Torti, Vince R.; Tsaparikos, Konstantinos; Van den Eynde, Benoit J.; Wythes, Martin; Yao, Li-Chin; Zheng, Xianxian; Tumang, Joseph; Kraus, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2530-2542</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumors use IDO1 as a major mechanism to induce an immunosuppressive micro-environment.  IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies.  IDO1 is induced in response to inflammatory stimuli such as IFNγ and promotes immune tolerance by depleting tryptophan and producing tryptophan catabolites, including kynurenine, in the tumor microenvironment.  This leads to effector T-cell anergy and enhanced Treg function through upregulation of FoxP3.  As a nexus for the induction of key immunosuppressive mechanisms, IDOl represents an important immunotherapeutic target in oncol.  Mere, we report the identification and characterization of the novel selective, orally bioavaiiable IDO1 inhibitor EOS200271/PF-06840003.  It reversed IDO1-induced T-cell anergy in vitro.  In mice carrying syngeneic tumor graft, PF-06840003 reduced intratumoral kynurenine levels by over 80% and inhibited tumor growth both in monotherapy and, with an increased efficacy, in combination with antibodies blocking the immune checkpoint ligand PD-L1.  We demonstrate that anti-PD-L1 therapy results in increased IDO1 metabolic activity thereby providing addnl. mechanistic rationale for combining PD-(L)1 blockade with IDO1 inhibition in cancer immunotherapies.  Supported by these preclin. data and favorable predicted human pharmacokinetic properties of PF-06840003, a phase I open-label, multicenter clin. study (NCT02764151) has been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsq6oIvKPAfrVg90H21EOLACvtfcHk0liSIdMJRaQDQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1eltLY%253D&md5=a7b306730692fede2e2fa69697a49495</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-1104%26sid%3Dliteratum%253Aachs%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DDriessens%26aufirst%3DG.%26aulast%3DBartlett%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DCauwenberghs%26aufirst%3DS.%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDenies%26aufirst%3DS.%26aulast%3DDillon%26aufirst%3DC.%2BP.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLetellier%26aufirst%3DM.%2BC.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DMarillier%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DPirson%26aufirst%3DR.%26aulast%3DRabolli%26aufirst%3DV.%26aulast%3DRay%26aufirst%3DC.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DTorti%26aufirst%3DV.%2BR.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DL.%2BC.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DTumang%26aufirst%3DJ.%26aulast%3DKraus%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520the%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528Ido1%2529%2520Catalytic%2520Inhibitor%2520Eos200271%252FPf-06840003%2520Supports%2520Ido1%2520as%2520a%2520Critical%2520Resistance%2520Mechanism%2520to%2520Pd-%2528L%25291%2520Blockade%2520Therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D2530%26epage%3D2542%26doi%3D10.1158%2F1535-7163.MCT-17-1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pantouris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loudon-Griffiths, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C. G.</span></span> <span> </span><span class="NLM_article-title">Insights into the Mechanism of Inhibition of Tryptophan 2,3-Dioxygenase by Isatin Derivatives</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.3109/14756366.2016.1170013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3109%2F14756366.2016.1170013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27096472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=70-78&author=G.+Pantourisauthor=J.+Loudon-Griffithsauthor=C.+G.+Mowat&title=Insights+into+the+Mechanism+of+Inhibition+of+Tryptophan+2%2C3-Dioxygenase+by+Isatin+Derivatives&doi=10.3109%2F14756366.2016.1170013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives</span></div><div class="casAuthors">Pantouris, Georgios; Loudon-Griffiths, James; Mowat, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">sup1</span>),
    <span class="NLM_cas:pages">70-78</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Tryptophan 2,3-dioxygenase (TDO) is a cytosolic protein with a proven immunomodulatory function that promotes tumoral immune resistance and proliferation.  Despite the interest in TDO as a therapeutic target in cancer treatment, the no. of biol. useful inhibitors is limited.  Herein, the authors report isatin derivs. as a new class of TDO inhibitors.  Through structure-activity relationships and mol. docking studies, the authors optimized the inhibition potency of isatin derivs. by >130-fold and elucidated the mechanistic details that control their mode of action.  Hydrogen bond interactions between the compd. and key active site residues of TDO, freedom upon rotation of the C3 chem. moiety and the presence of chlorines in the benzene ring of the compd. comprise the properties that an isatin-based inhibitor requires to effectively inhibit the enzymic activity of TDO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI-BFcCqSNNbVg90H21EOLACvtfcHk0liGGedgBBWswg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKqt7k%253D&md5=08aaf32261fbf57b4f83e81079f4b846</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3109%2F14756366.2016.1170013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F14756366.2016.1170013%26sid%3Dliteratum%253Aachs%26aulast%3DPantouris%26aufirst%3DG.%26aulast%3DLoudon-Griffiths%26aufirst%3DJ.%26aulast%3DMowat%26aufirst%3DC.%2BG.%26atitle%3DInsights%2520into%2520the%2520Mechanism%2520of%2520Inhibition%2520of%2520Tryptophan%25202%252C3-Dioxygenase%2520by%2520Isatin%2520Derivatives%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2016%26volume%3D31%26spage%3D70%26epage%3D78%26doi%3D10.3109%2F14756366.2016.1170013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deka, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Oxindoles as Promising Inhibitors of the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase 1</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1640</span>– <span class="NLM_lpage">1654</span>, <span class="refDoi"> DOI: 10.1039/C7MD00226B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1039%2FC7MD00226B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30108875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVanurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1640-1654&author=S.+Paulauthor=A.+Royauthor=S.+J.+Dekaauthor=S.+Pandaauthor=G.+N.+Srivastavaauthor=V.+Trivediauthor=D.+Manna&title=Synthesis+and+Evaluation+of+Oxindoles+as+Promising+Inhibitors+of+the+Immunosuppressive+Enzyme+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1039%2FC7MD00226B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Paul, Saurav; Roy, Ashalata; Deka, Suman Jyoti; Panda, Subhankar; Srivastava, Gopal Narayan; Trivedi, Vishal; Manna, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1640-1654</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as an important therapeutic target for the treatment of cancer, chronic infections and other diseases that are assocd. with immune suppression.  Recent developments in understanding the catalytic mechanism of the IDO1 enzyme revealed that conversion of L-tryptophan (L-Trp) to N-formylkynurenine proceeded through an epoxide intermediate state.  Accordingly, we synthesized a series of 3-substituted oxindoles from L-Trp, tryptamine and isatin.  Compds. with C3-substituted oxindole moieties showed moderate inhibitory activity against the purified human IDO1 enzyme.  Their optimization led to the identification of potent compds., 6, 22, 23 and 25 (IC50 = 0.19 to 0.62 μM), which are competitive inhibitors of IDO1 with respect to L-Trp.  These potent compds. also showed IDO1 inhibition potencies in the low-micromolar range (IC50 = 0.33-0.49 μM) in MDA-MB-231 cells.  The cytotoxicity of these potent compds. was trivial in different model cancer (MDA-MB-231, A549 and HeLa) cells and macrophage (J774A.1) cells.  Stronger selectivity for the IDO1 enzyme (124 to 210-fold) over the tryptophan 2,3-dioxygenase (TDO) enzyme was also obsd. for these compds.  These results suggest that the oxindole moiety of the compds. could mimic the epoxide intermediate state of L-Trp.  Therefore, the structural simplicity and low-micromolar inhibition potencies of these 3-substituted oxindoles make them quite attractive for further investigation of IDO1 function and immunotherapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsRZ2MtEaFZbVg90H21EOLACvtfcHk0liGGedgBBWswg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVanurbK&md5=155d1e021fc98ba06b227a2be6ed2fbb</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1039%2FC7MD00226B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00226B%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DDeka%26aufirst%3DS.%2BJ.%26aulast%3DPanda%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DG.%2BN.%26aulast%3DTrivedi%26aufirst%3DV.%26aulast%3DManna%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Oxindoles%2520as%2520Promising%2520Inhibitors%2520of%2520the%2520Immunosuppressive%2520Enzyme%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1640%26epage%3D1654%26doi%3D10.1039%2FC7MD00226B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Indole-2-Carboxylic Acid Derivatives as Ido1/Tdo Dual Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">111985</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.111985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31881488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyru7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=111985&author=G.+Cuiauthor=F.+Laiauthor=X.+Wangauthor=X.+Chenauthor=B.+Xu&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Indole-2-Carboxylic+Acid+Derivatives+as+Ido1%2FTdo+Dual+Inhibitors&doi=10.1016%2Fj.ejmech.2019.111985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors</span></div><div class="casAuthors">Cui, Guonan; Lai, Fangfang; Wang, Xiaoyu; Chen, Xiaoguang; Xu, Bailing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111985</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are involved in the key steps of tryptophan metab. and are potential new targets for tumor immunotherapy.  In this work, a variety of indole-2-carboxylic acid derivs. I (R1 = H, 7-F, NHAc, etc.; X = NH, NMe, S; Y = NH, S, -NHCH2-, etc.; Ar = 4-F-3-Cl-C6H3, 4-F-3-OMe-C6H3, 3-Cl-3-OMe-C6H3, etc.) were synthesized, and their inhibitory activities against both enzymes along with structure-activity relationships were investigated.  As a result, a no. of 6-acetamido-indole-2-carboxylic acid derivs. were found to be potent dual inhibitors with IC50 values at low micromolar levels.  Among them, compd. I (R1 = 6-NHAc, X = N, Y = NH, Ar = 3,4-di-F-C6H3) was the most potent inhibitor with an IC50 value of 1.17μM for IDO1, and 1.55μM for TDO, resp.  In addn., a para-benzoquinone deriv. II, resulted from the oxidn. of compd. I (R1 = 6-NHEt, X = NH, Y = NH, Ar = 4-F-3-Cl-C6H3), was also identified and it showed strong inhibition against the two enzymes with IC50 values at the double digit nanomolar level.  Using mol. docking and mol. dynamic simulations, authors predicted the binding modes of this class of compds. within IDO1 and TDO binding pocket.  The results provide insights for further structural optimization of this series of IDO1/TDO dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnJVN4vhM1rVg90H21EOLACvtfcHk0liO9WiK80g3aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyru7%252FP&md5=21fe6d9fb1b3c754a33e4ab3325fc520</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111985%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Indole-2-Carboxylic%2520Acid%2520Derivatives%2520as%2520Ido1%252FTdo%2520Dual%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D111985%26doi%3D10.1016%2Fj.ejmech.2019.111985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery and Preliminary Structure-Activity Relationship of 1h-Indazoles with Promising Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibition Properties</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6194</span>– <span class="NLM_lpage">6205</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2016.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27769672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6194-6205&author=S.+Qianauthor=T.+Heauthor=W.+Wangauthor=Y.+Heauthor=M.+Zhangauthor=L.+Yangauthor=G.+Liauthor=Z.+Wang&title=Discovery+and+Preliminary+Structure-Activity+Relationship+of+1h-Indazoles+with+Promising+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibition+Properties&doi=10.1016%2Fj.bmc.2016.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties</span></div><div class="casAuthors">Qian, Shan; He, Tao; Wang, Wei; He, Yanying; Zhang, Man; Yang, Lingling; Li, Guobo; Wang, Zhouyu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6194-6205</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1)-mediated kynurenine pathway of tryptophan degrdn. is identified as an important immune effector pathway in the tumor cells to escape a potentially effective immune response.  IDO1 is an attractive target for anticancer therapy and the discovery of IDO1 inhibitors has been intensely ongoing in both academic research labs. and pharmaceutical organizations.  The study discovered that 1H-indazole was a novel key pharmacophore with potent IDO1 inhibitory activity.  A series of new 1H-indazole derivs. were synthesized and detd. the enzyme inhibitory activities, and the compd. I exhibited the highest activity with an IC50 value of 5.3 μM.  The structure-activity relationships (SARs) anal. of the 1H-indazole derivs. as novel IDO1 inhibitors indicated that the 1H-indazole scaffold is necessary for IDO1 inhibition, and the substituent groups at the both 4-position and 6-position largely affect inhibitory activity.  The docking model exhibited that the effective interactions of 1H-indazoles with ferrous ion of heme and key residues of hydrophobic Pocket A and B ensured the IDO1 inhibitory activities.  The study suggested that the 1H-indazole was a novel interesting scaffold for IDO inhibition for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcwuAQrkBWGLVg90H21EOLACvtfcHk0liO9WiK80g3aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FK&md5=e1848f402c00f5a266a1faa82649ef28</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DDiscovery%2520and%2520Preliminary%2520Structure-Activity%2520Relationship%2520of%25201h-Indazoles%2520with%2520Promising%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibition%2520Properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6194%26epage%3D6205%26doi%3D10.1016%2Fj.bmc.2016.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoya, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, S.</span></span> <span> </span><span class="NLM_article-title">4,6-Substituted-1h-Indazoles as Potent Ido1/Tdo Dual Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1087</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2019.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30773421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFOit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1087-1098&author=L.+Yangauthor=Y.+Chenauthor=J.+Heauthor=E.+M.+Njoyaauthor=J.+Chenauthor=S.+Liuauthor=C.+Xieauthor=W.+Huangauthor=F.+Wangauthor=Z.+Wangauthor=Y.+Liauthor=S.+Qian&title=4%2C6-Substituted-1h-Indazoles+as+Potent+Ido1%2FTdo+Dual+Inhibitors&doi=10.1016%2Fj.bmc.2019.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">4,6-Substituted-1H-indazoles as potent IDO1/TDO dual inhibitors</span></div><div class="casAuthors">Yang, Lingling; Chen, Yang; He, Junlin; Njoya, Emmanuel Mfotie; Chen, Jianjun; Liu, Siyan; Xie, Congqiang; Huang, Wenze; Wang, Fei; Wang, Zhouyu; Li, Yuzhi; Qian, Shan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1087-1098</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are constitutively overexpressed in many types of cancer cells and exert important immunosuppressive functions.  In this article, a series of 4,6-substituted-1H-indazole derivs. were synthesized and evaluated the inhibitory activities against IDO1 and TDO, as well as their structure-activity relationships (SARs).  Among these, compd. 35(I) displayed the most IDO1 inhibitory potency with an IC50 value of 0.74 μM in an enzymic assay and 1.37 μM in HeLa cells.  Quant. anal. of the Western blot results indicated that I significantly decreased the INFγ-induced IDO1 expression in a concn.-dependent manner.  In addn., I showed promising TDO inhibition with an IC50 value of 2.93 μM in the enzymic assay and 7.54 μM in A172 cells.  Moreover, I exhibited in vivo antitumor activity in the CT26 xenograft model.  These findings suggest that I is a potent IDO1/TDO dual inhibitor, and has the potential to be developed for IDO1/TDO-related cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrehU24MhIjGbVg90H21EOLACvtfcHk0liO9WiK80g3aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFOit74%253D&md5=7137c203f76db2924373fe59797d7066</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DNjoya%26aufirst%3DE.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DS.%26atitle%3D4%252C6-Substituted-1h-Indazoles%2520as%2520Potent%2520Ido1%252FTdo%2520Dual%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1087%26epage%3D1098%26doi%3D10.1016%2Fj.bmc.2019.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsujino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meguro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akai, S.</span></span> <span> </span><span class="NLM_article-title">Correlation of Indoleamine-2,3-Dioxigenase 1 Inhibitory Activity of 4,6-Disubstituted Indazole Derivatives and Their Heme Binding Affinity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126607</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2019.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31431359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ais7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126607&author=H.+Tsujinoauthor=T.+Unoauthor=T.+Yamashitaauthor=M.+Katsudaauthor=K.+Takadaauthor=T.+Saikiauthor=S.+Maedaauthor=A.+Takagiauthor=S.+Masudaauthor=Y.+Kawanoauthor=K.+Meguroauthor=S.+Akai&title=Correlation+of+Indoleamine-2%2C3-Dioxigenase+1+Inhibitory+Activity+of+4%2C6-Disubstituted+Indazole+Derivatives+and+Their+Heme+Binding+Affinity&doi=10.1016%2Fj.bmcl.2019.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of indoleamine-2,3-dioxigenase 1 inhibitory activity of 4,6-disubstituted indazole derivatives and their heme binding affinity</span></div><div class="casAuthors">Tsujino, Hirofumi; Uno, Tadayuki; Yamashita, Taku; Katsuda, Masafumi; Takada, Kazuki; Saiki, Takeshi; Maeda, Shotaro; Takagi, Akira; Masuda, Shigeaki; Kawano, Yasuhiko; Meguro, Kanji; Akai, Shuji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">126607</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-contg. enzyme that acts on the first and rate-limiting step of the tryptophan/kynurenine pathway.  Since the pathway is one of the means of cancer immune evasion, IDO1 inhibitors have drawn interest as potential therapeutics for cancers.  We found a 4,6-disubstituted indazole 1 as a hit compd. that showed both IDO1 inhibitory activity and binding affinity for IDO1 heme.  Structural modification of 1 yielded compd. 6, whose relatively large substituent at the 4-position and proper size substituent at the 6-position were found to be important for the enhancement of IDO1 inhibitory activity and heme affinity.  A series of compds. synthesized in this work were evaluated by in silico docking simulations and by in vitro expts. using a C129Y mutant of the pocket-A of IDO1.  Our results revealed that proper substituents at the 6- and 4-positions of the compds. interact with pockets A and B, resp., and that, in particular, a good fit in pocket-A is important for the compds.' biol. activities.  Absorption spectral anal. of these compds. showed that they strongly bound to the ferrous heme rather than its ferric heme.  Furthermore, we obsd. that the heme affinities of these compds. strongly correlate with their IDO1 inhibitory activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy3Z3d-CU0aLVg90H21EOLACvtfcHk0lh0DeUyM7bK0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ais7%252FE&md5=d940a8624c05512861dbba038d458ce9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DTsujino%26aufirst%3DH.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DKatsuda%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DT.%26aulast%3DMaeda%26aufirst%3DS.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DMasuda%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DY.%26aulast%3DMeguro%26aufirst%3DK.%26aulast%3DAkai%26aufirst%3DS.%26atitle%3DCorrelation%2520of%2520Indoleamine-2%252C3-Dioxigenase%25201%2520Inhibitory%2520Activity%2520of%25204%252C6-Disubstituted%2520Indazole%2520Derivatives%2520and%2520Their%2520Heme%2520Binding%2520Affinity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126607%26doi%3D10.1016%2Fj.bmcl.2019.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cady, S. G.</span></span> <span> </span><span class="NLM_article-title">Enzyme Kinetic and Spectroscopic Studies of Inhibitor and Effector Interactions with Indoleamine 2,3-Dioxygenase. 1. Norharman and 4-Phenylimidazole Binding to the Enzyme as Inhibitors and Heme Ligands</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">5392</span>– <span class="NLM_lpage">5399</span>, <span class="refDoi"> DOI: 10.1021/bi00439a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00439a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaL1MXktF2qtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=5392-5399&author=M.+Sonoauthor=S.+G.+Cady&title=Enzyme+Kinetic+and+Spectroscopic+Studies+of+Inhibitor+and+Effector+Interactions+with+Indoleamine+2%2C3-Dioxygenase.+1.+Norharman+and+4-Phenylimidazole+Binding+to+the+Enzyme+as+Inhibitors+and+Heme+Ligands&doi=10.1021%2Fbi00439a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands</span></div><div class="casAuthors">Sono, Masanori; Cady, Susan G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5392-9</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The effects of norharman, one of the few known inhibitors of the heme protein indoleamine 2,3-dioxygenase, and of 4-phenylimidazole (4-PheImid), a heme ligand, on the catalytic (Vmax, Km) and spectroscopic properties (optical absorption, CD, and MCD) of rabbit small intestine dioxygenase were investigated.  Assays were performed with the substrate L- or D-tryptophan (Trp) and an ascorbic acid-methylene blue cofactor system at 25°.  Both norharman and 4-PheImid exhibit noncompetitive inhibition with respect to L-Trp and D-Trp.  The binding of norharman to the enzyme results in the formation of a low-spin complex in both the ferric and ferrous enzyme with comparable dissocn. consts. (Kd = ∼10 μM at pH 7.0) that are ∼10-fold smaller than the obsd. Ki.  L-Trp exerts no effect for the ferric enzyme and slight neg. cooperative effects for the ferrous enzyme on norharman binding.  Close spectral similarities are obsd. between the adducts of the enzyme with norharman and 4-PheImid in the resp. oxidn. states.  This, together with competition expts. using CN-, demonstrates that norharman binds directly to the heme Fe of the enzyme as a N donor ligand.  Thus, norharman competes with O2 for the heme Fe of the ferrous (active) enzyme, resulting in the obsd. inhibition.  L-Trp and 4-PheImid appear to compete for the heme-binding site in the ferric enzyme and display slight neg. cooperativity on binding to the ferrous enzyme.  The obsd. Ki for 4-PheImid is comparable with the Kd (∼10 μM at pH 7.0) of its adduct with the ferric enzyme, but is ∼40-fold smaller than the Kd for the corresponding ferrous complex.  Apparently, the inhibition of the dioxygenase activity by 4-PheImid is due to its binding to the heme Fe of the ferric enzyme, preventing the reductive activation of the dioxygenase by the ascorbic acid-methylene blue cofactor system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgFeeIW5--LVg90H21EOLACvtfcHk0lh0DeUyM7bK0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXktF2qtLg%253D&md5=87f3a4be44f5626760b567185013050a</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fbi00439a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00439a012%26sid%3Dliteratum%253Aachs%26aulast%3DSono%26aufirst%3DM.%26aulast%3DCady%26aufirst%3DS.%2BG.%26atitle%3DEnzyme%2520Kinetic%2520and%2520Spectroscopic%2520Studies%2520of%2520Inhibitor%2520and%2520Effector%2520Interactions%2520with%2520Indoleamine%25202%252C3-Dioxygenase.%25201.%2520Norharman%2520and%25204-Phenylimidazole%2520Binding%2520to%2520the%2520Enzyme%2520as%2520Inhibitors%2520and%2520Heme%2520Ligands%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D5392%26epage%3D5399%26doi%3D10.1021%2Fbi00439a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaLonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4968</span>– <span class="NLM_lpage">4977</span>, <span class="refDoi"> DOI: 10.1021/jm800512z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800512z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVyrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4968-4977&author=S.+Kumarauthor=D.+Jallerauthor=B.+Patelauthor=J.+M.+LaLondeauthor=J.+B.+DuHadawayauthor=W.+P.+Malachowskiauthor=G.+C.+Prendergastauthor=A.+J.+Muller&title=Structure+Based+Development+of+Phenylimidazole-Derived+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase&doi=10.1021%2Fjm800512z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase</span></div><div class="casAuthors">Kumar, Sanjeev; Jaller, Daniel; Patel, Bhumika; LaLonde, Judith M.; DuHadaway, James B.; Malachowski, William P.; Prendergast, George C.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4968-4977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathol. immune suppression.  With the goal of developing more potent IDO inhibitors, a systematic study of 4-phenylimidazole (4-PI) derivs. was undertaken.  Computational docking expts. guided design and synthesis efforts with analogs of 4-PI.  In particular, three interactions of 4-PI analogs with IDO were studied: the active site entrance, the interior of the active site, and the heme iron binding.  The three most potent inhibitors I (R = 4-HOC6H4, 3-HSC6H4, 4-HSC6H4) appear to exploit interactions with C129 and S167 in the interior of the active site.  All three inhibitors are approx. 10-fold more potent than 4-PI.  The study represents the first example of enzyme inhibitor development with the recently reported crystal structure of IDO and offers important lessons in the search for more potent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHTIIEf7DjmLVg90H21EOLACvtfcHk0lhD-89CAdeVtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVyrtrY%253D&md5=6e232cb983d0ba2396bea16060a5b7a1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm800512z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800512z%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DJaller%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DLaLonde%26aufirst%3DJ.%2BM.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DStructure%2520Based%2520Development%2520of%2520Phenylimidazole-Derived%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4968%26epage%3D4977%26doi%3D10.1021%2Fjm800512z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesù, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovarruscio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coda Zabetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannelli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span> <span> </span><span class="NLM_article-title">In Silico-Driven Multicomponent Synthesis of 4,5- and 1,5-Disubstituted Imidazoles as Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1039/C5MD00317B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1039%2FC5MD00317B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1aksb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=409-419&author=S.+Fallariniauthor=A.+Massarottiauthor=A.+Ges%C3%B9author=S.+Giovarruscioauthor=G.+Coda+Zabettaauthor=R.+Bergoauthor=B.+Giannelliauthor=A.+Bruncoauthor=G.+Lombardiauthor=G.+Sorbaauthor=T.+Pirali&title=In+Silico-Driven+Multicomponent+Synthesis+of+4%2C5-+and+1%2C5-Disubstituted+Imidazoles+as+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1039%2FC5MD00317B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">In silico-driven multicomponent synthesis of 4,5- and 1,5-disubstituted imidazoles as indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Fallarini, S.; Massarotti, A.; Gesu, A.; Giovarruscio, S.; Coda Zabetta, G.; Bergo, R.; Giannelli, B.; Brunco, A.; Lombardi, G.; Sorba, G.; Pirali, T.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-419</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase is involved in pathol. immune escape and has recently become an attractive target for anti-cancer therapy. 4-Phenylimidazole (4-PI) provides a promising starting point for the development of IDO1 inhibitors.  With the aim of discovering more potent ligands, a virtual library of imidazoles synthesizable via the van Leusen multicomponent reaction was created and filtered to afford a set of 4,5- and 1,5-disubstituted imidazoles as virtual lead candidates.  The compds. were selected according to their docking score and to their synthetic feasibility, synthesized and biol. evaluated.  This exptl. approach yielded IDO1 inhibitors with an enhanced potency compared to 4-PI; the most active compds. displayed a low micromolar potency, both in enzymic and cellular assays, while showing no detectable cellular toxicity.  A 3D quant. structure-activity relationship based on the electrostatic and steric ligand-protein interactions was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvXxeQxfbo57Vg90H21EOLACvtfcHk0lhD-89CAdeVtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1aksb%252FF&md5=c8b5c8e1a32574f651ffeab686b450a2</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1039%2FC5MD00317B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00317B%26sid%3Dliteratum%253Aachs%26aulast%3DFallarini%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DGes%25C3%25B9%26aufirst%3DA.%26aulast%3DGiovarruscio%26aufirst%3DS.%26aulast%3DCoda%2BZabetta%26aufirst%3DG.%26aulast%3DBergo%26aufirst%3DR.%26aulast%3DGiannelli%26aufirst%3DB.%26aulast%3DBrunco%26aufirst%3DA.%26aulast%3DLombardi%26aufirst%3DG.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DPirali%26aufirst%3DT.%26atitle%3DIn%2520Silico-Driven%2520Multicomponent%2520Synthesis%2520of%25204%252C5-%2520and%25201%252C5-Disubstituted%2520Imidazoles%2520as%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D409%26epage%3D419%26doi%3D10.1039%2FC5MD00317B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brant, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin-Tindall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohnig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. F.</span></span> <span> </span><span class="NLM_article-title">Identification of Potent Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors Based on a Phenylimidazole Scaffold</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00488</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00488" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotV2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=131-136&author=M.+G.+Brantauthor=J.+Goodwin-Tindallauthor=K.+R.+Stoverauthor=P.+M.+Staffordauthor=F.+Wuauthor=A.+R.+Meekauthor=P.+Schiaviniauthor=S.+Wohnigauthor=D.+F.+Weaver&title=Identification+of+Potent+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors+Based+on+a+Phenylimidazole+Scaffold&doi=10.1021%2Facsmedchemlett.7b00488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold</span></div><div class="casAuthors">Brant, Michael G.; Goodwin-Tindall, Jake; Stover, Kurt R.; Stafford, Paul M.; Wu, Fan; Meek, Autumn R.; Schiavini, Paolo; Wohnig, Stephanie; Weaver, Donald F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-136</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of indoleamine 2,3-dioxygenase (IDO1) is an attractive immunotherapeutic approach for the treatment of a variety of cancers.  Dysregulation of this enzyme has also been implicated in other disorders including Alzheimer's disease and arthritis.  Herein, the authors report the structure-based design of two related series of mols.: N1-substituted 5-indoleimidazoles and N1-substituted 5-phenylimidazoles.  The latter (and more potent) series was accessed through an unexpected rearrangement of an imine intermediate during a Van Leusen imidazole synthesis reaction.  Evidence for the binding modes for both inhibitor series is supported by computational and structure-activity relationship studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWjv6cCPCyqrVg90H21EOLACvtfcHk0lhD-89CAdeVtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotV2gsg%253D%253D&md5=f83e9d7dce45932e5f94818cebd2b3c8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00488%26sid%3Dliteratum%253Aachs%26aulast%3DBrant%26aufirst%3DM.%2BG.%26aulast%3DGoodwin-Tindall%26aufirst%3DJ.%26aulast%3DStover%26aufirst%3DK.%2BR.%26aulast%3DStafford%26aufirst%3DP.%2BM.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DMeek%26aufirst%3DA.%2BR.%26aulast%3DSchiavini%26aufirst%3DP.%26aulast%3DWohnig%26aufirst%3DS.%26aulast%3DWeaver%26aufirst%3DD.%2BF.%26atitle%3DIdentification%2520of%2520Potent%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%2520Based%2520on%2520a%2520Phenylimidazole%2520Scaffold%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D131%26epage%3D136%26doi%3D10.1021%2Facsmedchemlett.7b00488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosdidier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5270</span>– <span class="NLM_lpage">5290</span>, <span class="refDoi"> DOI: 10.1021/jm300260v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300260v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1yiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5270-5290&author=U.+F.+Rohrigauthor=S.+R.+Majjigapuauthor=A.+Grosdidierauthor=S.+Bronauthor=V.+Stroobantauthor=L.+Pilotteauthor=D.+Colauauthor=P.+Vogelauthor=B.+J.+Van+den%0AEyndeauthor=V.+Zoeteauthor=O.+Michielin&title=Rational+Design+of+4-Aryl-1%2C2%2C3-Triazoles+for+Indoleamine+2%2C3-Dioxygenase+1+Inhibition&doi=10.1021%2Fjm300260v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Grosdidier, Aurelien; Bron, Sylvian; Stroobant, Vincent; Pilotte, Luc; Colau, Didier; Vogel, Pierre; Van den Eynde, Benoit J.; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5270-5290</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an important therapeutic target for the treatment of diseases such as cancer that involve pathol. immune escape.  Starting from the scaffold of our previously discovered IDO1 inhibitor 4-phenyl-1,2,3-triazole, we used computational structure-based methods to design more potent ligands.  This approach yielded highly efficient low mol. wt. inhibitors, the most active being of nanomolar potency both in an enzymic and in a cellular assay, while showing no cellular toxicity and a high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO).  A quant. structure-activity relationship based on the electrostatic ligand-protein interactions in the docked binding modes and on the quantum chem. derived charges of the triazole ring demonstrated a good explanatory power for the obsd. activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CFYZnWiLSLVg90H21EOLACvtfcHk0liUIyLkUC3IkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1yiu7c%253D&md5=6ba6c0b628165673cd49c7a950ed885e</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm300260v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300260v%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DGrosdidier%26aufirst%3DA.%26aulast%3DBron%26aufirst%3DS.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DRational%2520Design%2520of%25204-Aryl-1%252C2%252C3-Triazoles%2520for%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5270%26epage%3D5290%26doi%3D10.1021%2Fjm300260v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, J. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latchem, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westcott, J.</span></span> <span> </span><span class="NLM_article-title">New 4-Amino-1,2,3-Triazole Inhibitors of Indoleamine 2,3-Dioxygenase Form a Long-Lived Complex with the Enzyme and Display Exquisite Cellular Potency</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1002/cbic.201700560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcbic.201700560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29240291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=552-561&author=J.+A.+C.+Alexandreauthor=M.+K.+Swanauthor=M.+J.+Latchemauthor=D.+Boyallauthor=J.+R.+Pollardauthor=S.+W.+Hughesauthor=J.+Westcott&title=New+4-Amino-1%2C2%2C3-Triazole+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+Form+a+Long-Lived+Complex+with+the+Enzyme+and+Display+Exquisite+Cellular+Potency&doi=10.1002%2Fcbic.201700560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">New 4-Amino-1,2,3-Triazole Inhibitors of Indoleamine 2,3-Dioxygenase Form a Long-Lived Complex with the Enzyme and Display Exquisite Cellular Potency</span></div><div class="casAuthors">Alexandre, Julie Anne Christine; Swan, Michael Kenneth; Latchem, Mike John; Boyall, Dean; Pollard, John Robert; Hughes, Stuart Wynn; Westcott, James</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">552-561</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Indoleamine-2,3 dioxygenase 1 (IDO1) has emerged as a central regulator of immune responses in both normal and disease biol.  Due to its established role in promoting tumor immune escape, IDO1 has become an attractive target for cancer treatment.  A novel series of highly cell potent IDO1 inhibitors based on a 4-amino-1,2,3-triazole core have been identified.  Comprehensive kinetic, biochem. and structural studies demonstrate that compds. from this series have a noncompetitive kinetic mechanism of action with respect to the tryptophan substrate.  In co-complex crystal structures, the compds. bind in the tryptophan pocket and make a direct ligand interaction with the haem iron of the porphyrin cofactor.  It is proposed that these data can be rationalised by an ordered-binding mechanism, in which the inhibitor binds an apo form of the enzyme that is not competent to bind tryptophan.  These inhibitors also form a very tight, long-lived complex with the enzyme, which partially explains their exquisite cellular potency.  This novel series represents an attractive starting point for the future development of potent IDO1-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGors3iiMxl2dLVg90H21EOLACvtfcHk0liUIyLkUC3IkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaitrg%253D&md5=2d27c177ab259dcfec42abe8083d6718</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201700560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201700560%26sid%3Dliteratum%253Aachs%26aulast%3DAlexandre%26aufirst%3DJ.%2BA.%2BC.%26aulast%3DSwan%26aufirst%3DM.%2BK.%26aulast%3DLatchem%26aufirst%3DM.%2BJ.%26aulast%3DBoyall%26aufirst%3DD.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DHughes%26aufirst%3DS.%2BW.%26aulast%3DWestcott%26aufirst%3DJ.%26atitle%3DNew%25204-Amino-1%252C2%252C3-Triazole%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Form%2520a%2520Long-Lived%2520Complex%2520with%2520the%2520Enzyme%2520and%2520Display%2520Exquisite%2520Cellular%2520Potency%26jtitle%3DChemBioChem%26date%3D2018%26volume%3D19%26spage%3D552%26epage%3D561%26doi%3D10.1002%2Fcbic.201700560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharyya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span> <span> </span><span class="NLM_article-title">4,5-Disubstituted 1,2,3-Triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T Cell Activity and Mitigates Tumor Growth</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">18455</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-54963-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41598-019-54963-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31804586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=18455&author=S.+Pandaauthor=N.+Pradhanauthor=S.+Chatterjeeauthor=S.+Morlaauthor=A.+Sahaauthor=A.+Royauthor=S.+Kumarauthor=A.+Bhattacharyyaauthor=D.+Manna&title=4%2C5-Disubstituted+1%2C2%2C3-Triazoles%3A+Effective+Inhibition+of+Indoleamine+2%2C3-Dioxygenase+1+Enzyme+Regulates+T+Cell+Activity+and+Mitigates+Tumor+Growth&doi=10.1038%2Fs41598-019-54963-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth</span></div><div class="casAuthors">Panda, Subhankar; Pradhan, Nirmalya; Chatterjee, Soumya; Morla, Sudhir; Saha, Abhishek; Roy, Ashalata; Kumar, Sachin; Bhattacharyya, Arindam; Manna, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18455</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The improvement of body's own immune system is considered one of the safest approaches to fight against cancer and several other diseases.  Excessive catabolism of the essential amino acid, L-tryptophan (L-Trp) assists the cancer cells to escape normal immune obliteration.  The formation of disproportionate kynurenine and other downstream metabolites suppress the T cell functions.  Blocking of this immunosuppressive mechanism is considered as a promising approach against cancer, neurol. disorders, autoimmunity, and other immune-mediated diseases.  Overexpression of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme is directly related to the induction of immunosuppressive mechanisms and represents an important therapeutic target.  Several classes of small mol.-based IDO1 inhibitors have been already reported, but only few compds. are currently being evaluated in various stages of clin. trials as adjuvants or in combination with chemo- and radiotherapies.  In the quest for novel structural class(s) of IDO1 inhibitors, we developed a series of 4,5-disubstituted 1,2,3-triazole derivs.  The optimization of 4,5-disubstituted 1,2,3-triazole scaffold and comprehensive biochem. and biophys. studies led to the identification of compds., 3i, 4i, and 4k as potent and selective inhibitors of IDO1 enzyme with IC50 values at a low nanomolar level.  These potent compds. also showed strong IDO1 inhibitory activities in MDA-MB-231 cells with no/negligible level of cytotoxicity.  The T cell activity studies revealed that controlled regulation of IDO1 enzyme activity in the presence of these potent compds. could induce immune response against breast cancer cells.  The compds. also showed excellent in vivo antitumor efficacy (of tumor growth inhibition = 79-96%) in the female Swiss albino mice.  As a consequence, this study describes the first example of 4,5-disubstituted 1,2,3-triazole based IDO1 inhibitors with potential applications for immunotherapeutic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFvvHiEQTt2bVg90H21EOLACvtfcHk0liUIyLkUC3IkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhsrvE&md5=1c2281948384ef55d772b681ddeeac91</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-54963-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-54963-9%26sid%3Dliteratum%253Aachs%26aulast%3DPanda%26aufirst%3DS.%26aulast%3DPradhan%26aufirst%3DN.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DMorla%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DA.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DBhattacharyya%26aufirst%3DA.%26aulast%3DManna%26aufirst%3DD.%26atitle%3D4%252C5-Disubstituted%25201%252C2%252C3-Triazoles%253A%2520Effective%2520Inhibition%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Enzyme%2520Regulates%2520T%2520Cell%2520Activity%2520and%2520Mitigates%2520Tumor%2520Growth%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D18455%26doi%3D10.1038%2Fs41598-019-54963-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span>; <span class="NLM_string-name">Kumar, S.</span>; <span class="NLM_string-name">Waldo, J. P.</span>; <span class="NLM_string-name">Jaipuri, F. A.</span>; <span class="NLM_string-name">Kesharwani, T.</span></span> <span> </span><span class="NLM_article-title">Fused Imidazole Derivatives Useful as Ido Inhibitors</span>. Patent <span class="NLM_patent">WO2012/142237</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+R.+Mautino&author=S.+Kumar&author=J.+P.+Waldo&author=F.+A.+Jaipuri&author=T.+Kesharwani&title=Fused+Imidazole+Derivatives+Useful+as+Ido+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMautino%26aufirst%3DM.%2BR.%26atitle%3DFused%2520Imidazole%2520Derivatives%2520Useful%2520as%2520Ido%2520Inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Imidazoleisoindole Derivatives as Potent Ido1 Inhibitors: Design, Synthesis, Biological Evaluation and Computational Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2017.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28963992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOltbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=293-304&author=Y.+Zouauthor=F.+Wangauthor=Y.+Wangauthor=Q.+Sunauthor=Y.+Huauthor=Y.+Liauthor=W.+Liuauthor=W.+Guoauthor=Z.+Huangauthor=Y.+Zhangauthor=Q.+Xuauthor=Y.+Lai&title=Discovery+of+Imidazoleisoindole+Derivatives+as+Potent+Ido1+Inhibitors%3A+Design%2C+Synthesis%2C+Biological+Evaluation+and+Computational+Studies&doi=10.1016%2Fj.ejmech.2017.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of imidazoleisoindole derivatives as potent IDO1 inhibitors: Design, synthesis, biological evaluation and computational studies</span></div><div class="casAuthors">Zou, Yi; Wang, Fang; Wang, Yan; Sun, Qirui; Hu, Yue; Li, Yuezhen; Liu, Wen; Guo, Wenjie; Huang, Zhangjian; Zhang, Yihua; Xu, Qiang; Lai, Yisheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">293-304</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase-1 (IDO1) is an attractive target for cancer immunotherapy.  Herein, a series of novel imidazoleisoindole derivs. were prepd. and evaluated for their ability to inhibit IDO1.  Among these, deriv. 11r was the most active compd. with nanomolar potency in the Hela cell-based assay, while showed negligible cellular toxicity.  UV-visible spectra study demonstrated that compds. 11p and 11r bound to IDO1 and coordinated with the heme iron.  Furthermore, they could significantly promote T cell proliferation, increase IFN-γ prodn., and reduce the nos. of Foxp3+ regulatory T cells.  Finally, induced fit docking (IFD) and quantum mechanics/mol. mechanics (QM/MM) calcn. were performed to understand the interactions of these compds. to IDO1 protein, which provided a comprehensive guide for further structural modification and optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEx1hdvWJE7bVg90H21EOLACvtfcHk0lhU4ECDCcbEfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOltbfL&md5=cb05901e3899f03c54d054f3ecb89682</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLai%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Imidazoleisoindole%2520Derivatives%2520as%2520Potent%2520Ido1%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520Biological%2520Evaluation%2520and%2520Computational%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D140%26spage%3D293%26epage%3D304%26doi%3D10.1016%2Fj.ejmech.2017.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-Dioxygenase Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00114</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00114" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyjsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=949-953&author=W.+Tuauthor=F.+Yangauthor=G.+Xuauthor=J.+Chiauthor=Z.+Liuauthor=W.+Pengauthor=B.+Huauthor=L.+Zhangauthor=H.+Wanauthor=N.+Yuauthor=F.+Jinauthor=Q.+Huauthor=L.+Zhangauthor=F.+Heauthor=W.+Tao&title=Discovery+of+Imidazoisoindole+Derivatives+as+Highly+Potent+and+Orally+Active+Indoleamine-2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors</span></div><div class="casAuthors">Tu, Wangyang; Yang, Fanglong; Xu, Guoji; Chi, Jiangtao; Liu, Zhiwei; Peng, Wei; Hu, Bing; Zhang, Lei; Wan, Hong; Yu, Nan; Jin, Fangfang; Hu, Qiyue; Zhang, Lianshan; He, Feng; Tao, Weikang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-953</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of imidazoisoindoles were identified as potent indoleamine-2,3-dioxygenase (IDO) inhibitors.  Lead optimization toward improving potency and eliminating CYP inhibition resulted in the discovery of lead compd. 25, a highly potent IDO inhibitor with favorable pharmacokinetic properties.  In the MC38 xenograft model in hPD-1 transgenic mice, 25 in combination with the anti-PD-1 monoclonal antibody (SHR-1210) achieved a synergistic antitumor effect superior to each single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2TmMZeIai0rVg90H21EOLACvtfcHk0lhU4ECDCcbEfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyjsL%252FI&md5=fc335004d7e1362c03fc13c1395a3734</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00114%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DChi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DTao%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520Imidazoisoindole%2520Derivatives%2520as%2520Highly%2520Potent%2520and%2520Orally%2520Active%2520Indoleamine-2%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D949%26epage%3D953%26doi%3D10.1021%2Facsmedchemlett.9b00114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tojo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamioka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as Ido1 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1021/ml500247w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500247w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1119-1123&author=S.+Tojoauthor=T.+Kohnoauthor=T.+Tanakaauthor=S.+Kamiokaauthor=Y.+Otaauthor=T.+Ishiiauthor=K.+Kamimotoauthor=S.+Asanoauthor=Y.+Isobe&title=Crystal+Structures+and+Structure-Activity+Relationships+of+Imidazothiazole+Derivatives+as+Ido1+Inhibitors&doi=10.1021%2Fml500247w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors</span></div><div class="casAuthors">Tojo, Shingo; Kohno, Tetsuya; Tanaka, Tomoyuki; Kamioka, Seiji; Ota, Yosuke; Ishii, Takayuki; Kamimoto, Keiko; Asano, Shigehiro; Isobe, Yoshiaki</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as a promising target for the treatment of several diseases, including neurol. disorders and cancer.  We report here the crystal structures of two IDO1/IDO1 inhibitor complexes, one of which shows that Amg-1 is directly bound to the heme iron of IDO1 with a clear induced fit.  We also describe the identification and preliminary optimization of imidazothiazole derivs. as novel IDO1 inhibitors.  Using our crystal structure information and structure-activity relationships (SAR) at the pocket-B of IDO1, we found a series of urea derivs. as potent IDO1 inhibitors and revealed that generation of an induced fit and the resulting interaction with Phe226 and Arg231 are essential for potent IDO1 inhibitory activity.  The results of this study are very valuable for understanding the mechanism of IDO1 activation, which is very important for structure-based drug design (SBDD) to discover potent IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO6dAvsq0nObVg90H21EOLACvtfcHk0lj307ygRBdMTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLnI&md5=7eaf3faae0c29a60de5f23a48a079af7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fml500247w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500247w%26sid%3Dliteratum%253Aachs%26aulast%3DTojo%26aufirst%3DS.%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKamioka%26aufirst%3DS.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DKamimoto%26aufirst%3DK.%26aulast%3DAsano%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DY.%26atitle%3DCrystal%2520Structures%2520and%2520Structure-Activity%2520Relationships%2520of%2520Imidazothiazole%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1119%26epage%3D1123%26doi%3D10.1021%2Fml500247w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aprile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as Ido1 Inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1874</span>, <span class="refDoi"> DOI: 10.3390/molecules24101874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3390%2Fmolecules24101874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31096672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1874&author=M.+Serafiniauthor=E.+Torreauthor=S.+Aprileauthor=A.+Massarottiauthor=S.+Fallariniauthor=T.+Pirali&title=Synthesis%2C+Docking+and+Biological+Evaluation+of+a+Novel+Class+of+Imidazothiazoles+as+Ido1+Inhibitors&doi=10.3390%2Fmolecules24101874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, docking and biological evaluation of a novel class of imidazothiazoles as IDO1 inhibitors</span></div><div class="casAuthors">Serafini, Marta; Torre, Enza; Aprile, Silvio; Massarotti, Alberto; Fallarini, Silvia; Pirali, Tracey</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1874</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">IDO1, a key dioxygenase in tryptophan-kynurenine metab., appeared in the last 10 years at the vanguard of druggable targets in cancer therapy due to its well-established role both in immune escape and inflammatory neovascularization.  Among the pool of IDO1 inhibitors that have entered clin. trials, none have reached approval.  The identification of novel inhibitors endowed with better clin. profile, together with the further comprehension of the interactions with residues in IDO1 active site, are still a need.  In this context, we have synthesized a novel class of imidazothiazole derivs. as IDO1 inhibitors and identified three compds. with inhibitory potency in the low micromolar range.  This report strengthens the role played by pocket C in the active site of IDO1, providing novel directions in the design of IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4xFMXgXVQTLVg90H21EOLACvtfcHk0lj307ygRBdMTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb7O&md5=5ed41662e4f25680805801d10aaf091c</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24101874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24101874%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DTorre%26aufirst%3DE.%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DFallarini%26aufirst%3DS.%26aulast%3DPirali%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520Docking%2520and%2520Biological%2520Evaluation%2520of%2520a%2520Novel%2520Class%2520of%2520Imidazothiazoles%2520as%2520Ido1%2520Inhibitors%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D1874%26doi%3D10.3390%2Fmolecules24101874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1642</span>– <span class="NLM_lpage">1659</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01549</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01549" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1642-1659&author=Y.+H.+Pengauthor=F.+Y.+Liaoauthor=C.+T.+Tsengauthor=R.+Kuppusamyauthor=A.+S.+Liauthor=C.+H.+Chenauthor=Y.+S.+Fanauthor=S.+Y.+Wangauthor=M.+H.+Wuauthor=C.+C.+Hsuehauthor=J.+Y.+Changauthor=L.+C.+Leeauthor=C.+Shihauthor=K.+S.+Shiaauthor=T.+K.+Yehauthor=M.+S.+Hungauthor=C.+C.+Kuoauthor=J.+S.+Songauthor=S.+Y.+Wuauthor=S.+H.+Ueng&title=Unique+Sulfur-Aromatic+Interactions+Contribute+to+the+Binding+of+Potent+Imidazothiazole+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors</span></div><div class="casAuthors">Peng, Yi-Hui; Liao, Fang-Yu; Tseng, Chen-Tso; Kuppusamy, Ramajayam; Li, An-Siou; Chen, Chi-Han; Fan, Yu-Shiou; Wang, Sing-Yi; Wu, Mine-Hsine; Hsueh, Ching-Cheng; Chang, Jia-Yu; Lee, Lung-Chun; Shih, Chuan; Shia, Kak-Shan; Yeh, Teng-Kuang; Hung, Ming-Shiu; Kuo, Ching-Chuan; Song, Jen-Shin; Wu, Su-Ying; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1642-1659</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO1) inhibitors are speculated to be useful in cancer immunotherapy, but a phase III clin. trial of the most advanced IDO1 inhibitor, epacadostat, did not meet its primary endpoint and was abandoned.  In previous work we identified the novel IDO1 inhibitor N-(4-chlorophenyl)-2-((5-phenylthiazolo[2,3-c][1,2,4]triazol-3-yl)thio)acetamide 1 through high-throughput screening (HTS).  Herein, we report a structure-activity relationship (SAR) study of this compd., which resulted in the potent IDO1 inhibitor 1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea 47 (hIDO IC50 = 16.4 nM).  X-ray co-crystal structural anal. revealed that the basis for this high potency is a unique sulfur-arom. interaction network formed by the thiourea moiety of 47 with the F163 and F226.  This finding is expected to inspire new approaches towards the discovery of potent IDO1 inhibitors in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLdRgatLF0JLVg90H21EOLACvtfcHk0lj307ygRBdMTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSmu7s%253D&md5=fa171b57b2e03f46d1658ba29419a150</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01549%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DTseng%26aufirst%3DC.%2BT.%26aulast%3DKuppusamy%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DFan%26aufirst%3DY.%2BS.%26aulast%3DWang%26aufirst%3DS.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsueh%26aufirst%3DC.%2BC.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DShia%26aufirst%3DK.%2BS.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DUnique%2520Sulfur-Aromatic%2520Interactions%2520Contribute%2520to%2520the%2520Binding%2520of%2520Potent%2520Imidazothiazole%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1642%26epage%3D1659%26doi%3D10.1021%2Facs.jmedchem.9b01549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7364</span>– <span class="NLM_lpage">7367</span>, <span class="refDoi"> DOI: 10.1021/jm900518f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900518f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7364-7367&author=E.+W.+Yueauthor=B.+Doutyauthor=B.+Waylandauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=C.+Liuauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=B.+Metcalfauthor=P.+A.+Scherleauthor=A.+P.+Combs&title=Discovery+of+Potent+Competitive+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+with+in+Vivo+Pharmacodynamic+Activity+and+Efficacy+in+a+Mouse+Melanoma+Model&doi=10.1021%2Fjm900518f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span></div><div class="casAuthors">Yue, Eddy W.; Douty, Brent; Wayland, Brian; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Liu, Changnian; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Metcalf, Brian; Scherle, Peggy A.; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7364-7367</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).  Optimization led to the identification of (I), which is a potent (HeLa IC50 = 19 nM) competitive inhibitor of IDO.  Testing of I in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsq88hx0J77Vg90H21EOLACvtfcHk0lhVin3ahQVmUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D&md5=328d92bffb88a86da030c31eff707dc6</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm900518f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900518f%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520Potent%2520Competitive%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520with%2520in%2520Vivo%2520Pharmacodynamic%2520Activity%2520and%2520Efficacy%2520in%2520a%2520Mouse%2520Melanoma%2520Model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7364%26epage%3D7367%26doi%3D10.1021%2Fjm900518f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span> <span> </span><span class="NLM_article-title">High-Resolution Structures of Inhibitor Complexes of Human Indoleamine 2,3-Dioxygenase 1 in a New Crystal Form</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1107/S2053230X18012955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1107%2FS2053230X18012955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30387777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOhsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2018&pages=717-724&author=S.+Luoauthor=K.+Xuauthor=S.+Xiangauthor=J.+Chenauthor=C.+Chenauthor=C.+Guoauthor=Y.+Tongauthor=L.+Tong&title=High-Resolution+Structures+of+Inhibitor+Complexes+of+Human+Indoleamine+2%2C3-Dioxygenase+1+in+a+New+Crystal+Form&doi=10.1107%2FS2053230X18012955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution structures of inhibitor complexes of human indoleamine 2,3-dioxygenase 1 in a new crystal form</span></div><div class="casAuthors">Luo, Shukun; Xu, Ke; Xiang, Shaoyun; Chen, Jie; Chen, Chunyun; Guo, Chuangxin; Tong, Youzhi; Tong, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">717-724</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-dependent enzyme with important roles in many cellular processes and is a potential target for drug discovery against cancer and other diseases.  Crystal structures of IDO1 in complex with various inhibitors have been reported.  Many of these crystals belong to the same crystal form and most of the reported structures have resolns. in the range 3.2-2.3 Å.  Here, three new crystal forms of human IDO1 obtained by introducing a surface mutation, K116A/K117A, distant from the active site are reported.  One of these crystal forms diffracted to 1.5 Å resoln. and can be readily used for soaking expts. to det. high-resoln. structures of IDO1 in complex with the substrate tryptophan or inhibitors that coordinate the heme.  In addn., this mutant was used to produce crystals of a complex with an inhibitor that targets the apo form of the enzyme under the same conditions; the structure of this complex was detd. at 1.7 Å resoln.  Overall, this mutant represents a robust platform for detg. the structures of inhibitor and substrate complexes of IDO1 at high resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNOGWhEFr_j7Vg90H21EOLACvtfcHk0lhVin3ahQVmUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOhsrrJ&md5=067ab7c11763cecf0513d56295c2a9ae</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1107%2FS2053230X18012955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X18012955%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DXiang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DL.%26atitle%3DHigh-Resolution%2520Structures%2520of%2520Inhibitor%2520Complexes%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520in%2520a%2520New%2520Crystal%2520Form%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2018%26volume%3D74%26spage%3D717%26epage%3D724%26doi%3D10.1107%2FS2053230X18012955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardolino, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurukulasuriya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinot, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biju, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Amino-Cyclobutarene-Derived Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitors for Cancer Immunotherapy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1536</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00344</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00344" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1530-1536&author=H.+Zhangauthor=K.+Liuauthor=Q.+Puauthor=A.+Achabauthor=M.+J.+Ardolinoauthor=M.+Chengauthor=Y.+Dengauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=X.+Fraderaauthor=I.+Knemeyerauthor=R.+Kurukulasuriyaauthor=Y.+H.+Lamauthor=C.+A.+Lesburgauthor=T.+A.+Martinotauthor=M.+A.+McGowanauthor=J.+R.+Millerauthor=K.+Otteauthor=P.+J.+Bijuauthor=N.+Sciammettaauthor=N.+Solbanauthor=W.+Yuauthor=H.+Zhouauthor=X.+Wangauthor=D.+J.+Bennettauthor=Y.+Han&title=Discovery+of+Amino-Cyclobutarene-Derived+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors+for+Cancer+Immunotherapy&doi=10.1021%2Facsmedchemlett.9b00344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy</span></div><div class="casAuthors">Zhang, Hongjun; Liu, Kun; Pu, Qinglin; Achab, Abdelghani; Ardolino, Michael J.; Cheng, Mangeng; Deng, Yongqi; Doty, Amy C.; Ferguson, Heidi; Fradera, Xavier; Knemeyer, Ian; Kurukulasuriya, Ravi; Lam, Yu-hong; Lesburg, Charles A.; Martinot, Theodore A.; McGowan, Meredeth A.; Miller, J. Richard; Otte, Karin; Biju, Purakattle J.; Sciammetta, Nunzio; Solban, Nicolas; Yu, Wensheng; Zhou, Hua; Wang, Xiao; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1530-1536</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become std. of care for certain types of cancers.  However, low overall response rates often hamper the broad utility and potential of these breakthrough therapies.  Combination therapy strategies are currently under intensive investigation in the clinic, including the combination of PD-1/PD-L1 agents with IDO1 inhibitors.  Here, we report the discovery of a class of IDO1 heme-binding inhibitors featuring a unique amino-cyclobutarene motif, which was discovered through SBDD from a known and weakly active inhibitor.  Subsequent optimization efforts focused on improving metabolic stability and were greatly accelerated by utilizing a robust SNAr reaction of a facile nitro-furazan intermediate to quickly explore different polar side chains.  As a culmination of these efforts, compd. 16 was identified and demonstrated a favorable overall profile with superior potency and selectivity.  Extensive studies confirmed the chem. stability and drug-like properties of compd. 16, rendering it a potential drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmACl12NSJBrVg90H21EOLACvtfcHk0lhVin3ahQVmUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rE&md5=18def13fafda60ed7547810dd97a3c37</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00344%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DArdolino%26aufirst%3DM.%2BJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DKurukulasuriya%26aufirst%3DR.%26aulast%3DLam%26aufirst%3DY.%2BH.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DMartinot%26aufirst%3DT.%2BA.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DBiju%26aufirst%3DP.%2BJ.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DSolban%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Amino-Cyclobutarene-Derived%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%2520for%2520Cancer%2520Immunotherapy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1530%26epage%3D1536%26doi%3D10.1021%2Facsmedchemlett.9b00344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into the Binding Mechanism of Ido1 with Hydroxylamidine Based Inhibitor Incb14943</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.04.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bbrc.2017.04.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28412361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1arsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2017&pages=339-343&author=Y.+Wuauthor=T.+Xuauthor=J.+Liuauthor=K.+Dingauthor=J.+Xu&title=Structural+Insights+into+the+Binding+Mechanism+of+Ido1+with+Hydroxylamidine+Based+Inhibitor+Incb14943&doi=10.1016%2Fj.bbrc.2017.04.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943</span></div><div class="casAuthors">Wu, You; Xu, Tingting; Liu, Jinsong; Ding, Ke; Xu, Jinxin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-343</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">IDO1 (indoleamine 2, 3-dioxygenase 1), a well characterized immunosuppressive enzyme, has attracted growing attention as a potential target for cancer immunotherapy.  Hydroxylamidine compds. INCB024360 and INCB14943 (INCB024360 analog) are highly effective IDO1 inhibitors.  INCB024360 is undergoing clin. trials for treatment of various types of human cancer.  Here, we detd. the co-crystal structure of IDO1 and INCB14943, and elucidate the detailed binding mode.  INCB14943 binds to heme iron in IDO1 protein through the oxime nitrogen.  Further anal. also reveals that a halogen bonding interaction between the chlorine atom (3-Cl) of INCB14943 and the sulfur atom of C129 significantly improves the inhibition activity against IDO1.  Comparing with the other reported inhibitors, the oxime nitrogen and halogen bond interaction are identified as the unique features of INCB14943 among the IDO1 inhibitors.  Thus, our study provides novel insights into the interaction between a small mol. inhibitor INCB14943 and IDO1 protein.  The structural information will facilitate future IDO1 inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWqCzisTLF1rVg90H21EOLACvtfcHk0ljb6MHVHMnCmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1arsbk%253D&md5=8b50144d16e4ad7b3da724953b3b3d66</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.04.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.04.061%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DStructural%2520Insights%2520into%2520the%2520Binding%2520Mechanism%2520of%2520Ido1%2520with%2520Hydroxylamidine%2520Based%2520Inhibitor%2520Incb14943%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D487%26spage%3D339%26epage%3D343%26doi%3D10.1016%2Fj.bbrc.2017.04.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (Ido1)</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4323</span>– <span class="NLM_lpage">4325</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00586</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00586" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ShtL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=4323-4325&author=U.+F.+Rohrigauthor=V.+Zoeteauthor=O.+Michielin&title=The+Binding+Mode+of+N-Hydroxyamidines+to+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29&doi=10.1021%2Facs.biochem.7b00586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The binding mode of N-hydroxyamidines to indoleamine 2,3-dioxygenase 1 (IDO1)</span></div><div class="casAuthors">Rohrig, Ute F.; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4323-4325</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an important target in cancer immunotherapy.  The most advanced clin. compd., epacadostat (INCB 024360), binds to the heme cofactor of IDO1 through an N-hydroxyamidine function.  Conflicting binding modes have recently been proposed, reporting Fe binding either through the hydroxyamidine O atom or through the hydroxyamidine N atom.  Here, we used quantum chem. calcns., mol. docking, and quantum mechanics/mol. mechanics (QM/MM) calcns. based on available x-ray data to resolve this issue and to propose a phys. meaningful binding mode.  These findings will aid the design of novel IDO1 ligands based on this pharmacophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjL9zUh8wtbVg90H21EOLACvtfcHk0ljb6MHVHMnCmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ShtL%252FO&md5=cc379deb32f2617a7f103a0822aad42c</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00586%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DThe%2520Binding%2520Mode%2520of%2520N-Hydroxyamidines%2520to%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26spage%3D4323%26epage%3D4325%26doi%3D10.1021%2Facs.biochem.7b00586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Phosphonamidate Ido1 Inhibitors for the Treatment of Non-Small Cell Lung Cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">111629</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.111629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31445231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1CisLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2019&pages=111629&author=Q.+Duauthor=X.+Fengauthor=Y.+Wangauthor=X.+Xuauthor=Y.+Zhangauthor=X.+Quauthor=Z.+Liauthor=J.+Bian&title=Discovery+of+Phosphonamidate+Ido1+Inhibitors+for+the+Treatment+of+Non-Small+Cell+Lung+Cancer&doi=10.1016%2Fj.ejmech.2019.111629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer</span></div><div class="casAuthors">Du, Qianming; Feng, Xi; Wang, Yinuo; Xu, Xi; Zhang, Yan; Qu, Xinliang; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111629</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as an attractive approach for the development of cancer immunotherapy.  In this study, a series of phosphonamidate ester contg. compds. were designed, synthesized and evaluated for their inhibitory activities against IDO1.  Among them, compds. 16, 17, and 26 with good IDO1 inhibitory (HeLa IDO1 IC50 = 10-21 nM, hIDO1 IC50 = 78-121 nM) activities were selected for further investigation and showed good physicochem. properties.  Furthermore, based on comparable PK profile and excellent IDO2/TDO inhibitory potency, representative compd. 16 was selected for further bio-evaluation and characterized with good efficacy in suppressing lung metastasis (77% inhibition rate) of Lewis cells in vivo.  Thus, compd. 16 could be a potential and efficacious agent for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqHJhVsDBFarVg90H21EOLACvtfcHk0ljb6MHVHMnCmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1CisLbI&md5=bebc21dbfd0faac9b3f993080fd3dd61</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111629%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Phosphonamidate%2520Ido1%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D182%26spage%3D111629%26doi%3D10.1016%2Fj.ejmech.2019.111629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in Vivo Antitumor Evaluation of an Orally Active Potent Phosphonamidate Derivative Targeting Ido1/Ido2/Tdo</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bcp.2019.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31306643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWlu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=214-223&author=X.+Fengauthor=P.+Shenauthor=Y.+Wangauthor=Z.+Liauthor=J.+Bian&title=Synthesis+and+in+Vivo+Antitumor+Evaluation+of+an+Orally+Active+Potent+Phosphonamidate+Derivative+Targeting+Ido1%2FIdo2%2FTdo&doi=10.1016%2Fj.bcp.2019.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO</span></div><div class="casAuthors">Feng, Xi; Shen, Pei; Wang, Yinuo; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214-223</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting Trp-Kyn pathways has been identified as an attractive approach for the cancer immunotherapies.  In this study, a novel phosphonamidate contg. compd. was designed, synthesized and evaluated for its inhibitory activity against key dioxygenases in Trp-Kyn pathway, including IDO1, IDO2 and TDO.  This compd. showed potent IDO1 inhibitory activity with an IC50 value of 94 nM in an enzymic assay and 12.6 nM in HeLa cells.  In addn., this compd. showed promising IDO2 inhibition and TDO inhibition with IC50 values of 310 nM and 2.6 μM, resp., in enzyme assay.  Based on the promising enzyme inhibitory activity toward IDO/TDO, compd. F04(I) was evaluated of its antitumor effects in two tumor models.  Further evaluation of mechanism demonstrated I with the remarkable capacity of reducing kynurenine level in plasma/TME and restoring anti-tumor immune response.  I could be further developed as a potential immunotherapeutic agent combined with immune checkpoint inhibitors or chemotherapeutic drugs for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUO0oCjsL5bVg90H21EOLACvtfcHk0lgFXEDApowktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWlu7jK&md5=465bc2f6148b05c2b00d1dec45f06234</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520in%2520Vivo%2520Antitumor%2520Evaluation%2520of%2520an%2520Orally%2520Active%2520Potent%2520Phosphonamidate%2520Derivative%2520Targeting%2520Ido1%252FIdo2%252FTdo%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D168%26spage%3D214%26epage%3D223%26doi%3D10.1016%2Fj.bcp.2019.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Antitumor Study of a Series of N-Cyclic Sulfamoylaminoethyl Substituted 1,2,5-Oxadiazol-3-Amines as New Indoleamine 2, 3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.06.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31233921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1KjsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=38-55&author=S.+Chenauthor=W.+Guoauthor=X.+Liuauthor=P.+Sunauthor=Y.+Wangauthor=C.+Dingauthor=L.+Mengauthor=A.+Zhang&title=Design%2C+Synthesis+and+Antitumor+Study+of+a+Series+of+N-Cyclic+Sulfamoylaminoethyl+Substituted+1%2C2%2C5-Oxadiazol-3-Amines+as+New+Indoleamine+2%2C+3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.ejmech.2019.06.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Chen, Shulun; Guo, Wei; Liu, Xiaohua; Sun, Pu; Wang, Yi; Ding, Chunyong; Meng, Linghua; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-55</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism which is an important mechanism in immune tolerance.  The small mol. epacadostat is the most advanced IDO1 inhibitor, but its phase III trials as a single agent or in combinations with PD-1 antibody failed to show appreciable objective responses.  To gain more insight on the antitumor efficacy of IDO1 inhibitors, a series of analogs of epacadostat by incorporating a cyclic aminosulfonamide moiety as the sidechain capping functionality has been designed.  N-(3-bromo-4-fluorophenyl)-4-((2-(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)ethyl)amino)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide was found to display significant potency against recombinant hIDO1 and hIDO1 expressed HEK293 cancer cells and this compd. has improved physico-chem. properties, acceptable PK parameters as well as optimal cardiac safety.  Similar to epacadostat, the above compd. is ineffective as single agent in the CT-26 syngeneic xenograft model, however, the combination of this compd. with PD-1 antibody showed both elevated tumor growth inhibition and prolonged median life span.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_p5ZMG6Q-LVg90H21EOLACvtfcHk0lgFXEDApowktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1KjsrfI&md5=fe9f73ec38ea7400e72354e728254ca3</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.037%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Antitumor%2520Study%2520of%2520a%2520Series%2520of%2520N-Cyclic%2520Sulfamoylaminoethyl%2520Substituted%25201%252C2%252C5-Oxadiazol-3-Amines%2520as%2520New%2520Indoleamine%25202%252C%25203-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D38%26epage%3D55%26doi%3D10.1016%2Fj.ejmech.2019.06.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of 1,2,5-Oxadiazole-3-Carboximidamide Derivatives as Novel Indoleamine-2,3-Dioxygenase 1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112059</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2020.112059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31981851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112059&author=X.+Songauthor=P.+Sunauthor=J.+Wangauthor=W.+Guoauthor=Y.+Wangauthor=L.+H.+Mengauthor=H.+Liu&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+1%2C2%2C5-Oxadiazole-3-Carboximidamide+Derivatives+as+Novel+Indoleamine-2%2C3-Dioxygenase+1+Inhibitors&doi=10.1016%2Fj.ejmech.2020.112059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors</span></div><div class="casAuthors">Song, Xiaohan; Sun, Pu; Wang, Jiang; Guo, Wei; Wang, Yi; Meng, Ling-hua; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112059</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of 1,2,5-oxadiazole-3-carboximidamide derivs. I [R = (1-sulfamoylpyrrolidin-3-yl)methyl, (1-methanesulfonylpyrrolidin-3-yl)methyl, [1-(cyclopropanesulfonyl)piperidin-3-yl]methyl, etc] bearing cycle in the side chain were designed, synthesized, and biol. evaluated for their anti-tumor activity.  Most of them exhibited potent activity against hIDO1 in enzymic assays and in HEK293T cells over-expressing hIDO1.  Among them, compd. I [R = [(3R)-1-sulfamoylpyrrolidin-3-yl]methyl, [(3R)-1-sulfamoylpiperidin-3-yl]methyl, [(3S)-1-sulfamoylpiperidin-3-yl]methyl] showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM resp.) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM resp.).  Moreover, compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] displayed improved PK property with longer half-life (t1/2 = 3.81 h in CD-1 mice) and better oral bioavailability (F = 33.6%) compared with epacadostat.  In addn., compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] showed similar potency to inhibit the growth of CT-26 syngeneic xenograft compared to epacadostat, making it justifiable for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVCKyiy04nLVg90H21EOLACvtfcHk0lgFXEDApowktg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D&md5=eaacdbc7d1498bc8644774d4ae1ff3d0</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112059%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%25201%252C2%252C5-Oxadiazole-3-Carboximidamide%2520Derivatives%2520as%2520Novel%2520Indoleamine-2%252C3-Dioxygenase%25201%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112059%26doi%3D10.1016%2Fj.ejmech.2020.112059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderhub, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhaeuser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Hydroxyamidine Based Inhibitors of Ido1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1GhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=179-187&author=C.+Steeneckauthor=O.+Kinzelauthor=S.+Anderhubauthor=M.+Hornbergerauthor=S.+Pintoauthor=B.+Morschhaeuserauthor=F.+Braunauthor=G.+Kleymannauthor=T.+Hoffmann&title=Discovery+of+Hydroxyamidine+Based+Inhibitors+of+Ido1+for+Cancer+Immunotherapy+with+Reduced+Potential+for+Glucuronidation&doi=10.1021%2Facsmedchemlett.9b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation</span></div><div class="casAuthors">Steeneck, Christoph; Kinzel, Olaf; Anderhub, Simon; Hornberger, Martin; Pinto, Sheena; Morschhaeuser, Barbara; Braun, Floriane; Kleymann, Gerald; Hoffmann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-187</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Following the impressive success of checkpoint inhibitors in the treatment of cancer, combinations of IDO1 inhibitors with PD-1/PD-L1 antibodies are in clin. development aiming to increase response rates.  Using the hydroxyamidine pharmacophore of the IDO1 inhibitor INCB14943 as a starting point for the design of new inhibitors, the potential shortcomings of extensive hydroxyamidine glucuronidation in humans was addressed.  Compds. were optimized using a stability assay with recombinant UGT1A9 enzyme together with the measurement of glucuronide formation in human hepatocytes.  Optimized analog 24 showed cellular and biochem. IDO1 IC50 values in the low nanomolar range, a suitable in vitro ADME/PK profile, and efficacy in an animal model of cancer.  In a humanized liver mouse model the lead compd. exhibited significantly reduced glucuronidation compared to epacadostat (2).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL0q_mXp0hC7Vg90H21EOLACvtfcHk0lh6l8Y18GRZfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1GhsLs%253D&md5=ef40add370d8e26624bda069c834442e</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00572%26sid%3Dliteratum%253Aachs%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DAnderhub%26aufirst%3DS.%26aulast%3DHornberger%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DS.%26aulast%3DMorschhaeuser%26aufirst%3DB.%26aulast%3DBraun%26aufirst%3DF.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520Hydroxyamidine%2520Based%2520Inhibitors%2520of%2520Ido1%2520for%2520Cancer%2520Immunotherapy%2520with%2520Reduced%2520Potential%2520for%2520Glucuronidation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D179%26epage%3D187%26doi%3D10.1021%2Facsmedchemlett.9b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Hydroxyamidine Derivatives as Indoleamine 2,3-Dioxygenase 1 Inhibitors with in Vivo Anti-Tumor Efficacy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127038</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2020.127038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32088128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1Krsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127038&author=C.+Liuauthor=Y.+Nanauthor=Z.+Xiaauthor=K.+Guauthor=C.+Chenauthor=X.+Dongauthor=D.+Juauthor=W.+Zhao&title=Discovery+of+Novel+Hydroxyamidine+Derivatives+as+Indoleamine+2%2C3-Dioxygenase+1+Inhibitors+with+in+Vivo+Anti-Tumor+Efficacy&doi=10.1016%2Fj.bmcl.2020.127038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy</span></div><div class="casAuthors">Liu, Chang; Nan, Yanyang; Xia, Zhifeng; Gu, Kedan; Chen, Cheng; Dong, Xiaochun; Ju, Dianwen; Zhao, Weili</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">127038</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is closely assocd. with immune escape in many tumor tissues, and is considered to be a valuable therapeutic target in cancer immunotherapy.  In this study, the modification of amino sidechain was performed with the hydroxyamidine core kept intact to optimize lead compd. Epacadostat.  Nineteen new compds. with hydrazide, thietane or sulfonamide moiety as polar capping group in sidechain were prepd. and their IDO1 inhibitory activities were evaluated.  Sulfonamide I showed potent IDO1 inhibition in both enzymic and cellular assays with the IC50 value of 71 nM and EC50 value of 11 nM, resp.  Furthermore, in vivo Lewis lung cancer (LLC) allograft studies of I indicated that it handicapped the tumor growth with similar efficacy to Epacadostat.  Mol. docking demonstrated that the change of polar capping group affords influence on the orientation of amino ethylene side chain and forms new hydrogen bonding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK5Cp_GBcPlrVg90H21EOLACvtfcHk0lh6l8Y18GRZfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1Krsrs%253D&md5=61c0724d790cfb68adfac055ef7c51d0</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DNan%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DJu%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520Novel%2520Hydroxyamidine%2520Derivatives%2520as%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitors%2520with%2520in%2520Vivo%2520Anti-Tumor%2520Efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127038%26doi%3D10.1016%2Fj.bmcl.2020.127038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Lw106, a Novel Indoleamine 2,3-Dioxygenase 1 Inhibitor, Suppresses Tumour Progression by Limiting Stroma-Immune Crosstalk and Cancer Stem Cell Enrichment in Tumour Micro-Environment</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">3034</span>– <span class="NLM_lpage">3049</span>, <span class="refDoi"> DOI: 10.1111/bph.14351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1111%2Fbph.14351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29722898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGnt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=3034-3049&author=R.+Fuauthor=Y.+W.+Zhangauthor=H.+M.+Liauthor=W.+C.+Lvauthor=L.+Zhaoauthor=Q.+L.+Guoauthor=T.+Luauthor=S.+J.+Weissauthor=Z.+Y.+Liauthor=Z.+Q.+Wu&title=Lw106%2C+a+Novel+Indoleamine+2%2C3-Dioxygenase+1+Inhibitor%2C+Suppresses+Tumour+Progression+by+Limiting+Stroma-Immune+Crosstalk+and+Cancer+Stem+Cell+Enrichment+in+Tumour+Micro-Environment&doi=10.1111%2Fbph.14351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumor progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumor micro-environment</span></div><div class="casAuthors">Fu, Rong; Zhang, Yi-Wei; Li, Hong-Mei; Lv, Wen-Cong; Zhao, Li; Guo, Qing-Long; Lu, Tao; Weiss, Stephen J.; Li, Zhi-Yu; Wu, Zhao-Qiu</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3034-3049</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Indoleamine 2,3-dioxygenase 1 (IDO1) is emerging as an important new therapeutic target for treatment of malignant tumors characterized by dysregulated tryptophan metab.  However, the antitumor efficacy of existing small-mol. inhibitors of IDO1 is still unsatisfactory and the underlying mechanism remains largely undefined.  Hence, we discovered a novel potent small-mol. inhibitor of IDO1, LW106, and studied its antitumor effects and the underlying mechanisms in two tumor models.  Exptl. Approach : C57BL6 mice, athymic nude mice or Ido1-/- mice were inoculated with IDO1-expressing and -nonexpressing tumor cells and treated with vehicle, epacadostat or increasing doses of LW106.  Xenografted tumors, plasma, spleens and other vital organs were harvested and subjected to kynurenine/tryptophan measurement and flow cytometric, histol. and immunohistochem. analyses.  Key Results : LW106 dose-dependently inhibited the outgrowth of xenografted tumors that were inoculated in C57BL6 mice but not nude mice or Ido1-/- mice, showing a stronger antitumor efficacy than epacadostat, an existing IDO1 inhibitor.  LW106 substantially elevated intratumoral infiltration of proliferative Teff cells, while reducing recruitment of proliferative Treg cells and non-hematopoietic stromal cells such as endothelial cells and cancer-assocd. fibroblasts.  LW106 treatment resulted in a reduced subpopulation of cancer stem cells (CSCs) in xenografted tumors in which fewer proliferative/invasive tumor cells and more apoptotic tumor cells were obsd.  Conclusions and Implications : LW106 inhibits tumor outgrowth by limiting stroma-immune crosstalk and CSC enrichment in the tumor micro-environment.  LW106 has potential as a immunotherapeutic agent for use in combination with immune checkpoint inhibitors and (or) chemotherapeutic drugs for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQxcdqCioFbVg90H21EOLACvtfcHk0lh6l8Y18GRZfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGnt7rJ&md5=d4626804567127df685d1329e6c3ee9b</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1111%2Fbph.14351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14351%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%2BW.%26aulast%3DLi%26aufirst%3DH.%2BM.%26aulast%3DLv%26aufirst%3DW.%2BC.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DQ.%2BL.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%2BY.%26aulast%3DWu%26aufirst%3DZ.%2BQ.%26atitle%3DLw106%252C%2520a%2520Novel%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitor%252C%2520Suppresses%2520Tumour%2520Progression%2520by%2520Limiting%2520Stroma-Immune%2520Crosstalk%2520and%2520Cancer%2520Stem%2520Cell%2520Enrichment%2520in%2520Tumour%2520Micro-Environment%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D3034%26epage%3D3049%26doi%3D10.1111%2Fbph.14351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deka, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span> <span> </span><span class="NLM_article-title">Nitrobenzofurazan Derivatives of N′-Hydroxyamidines as Potent Inhibitors of Indoleamine-2,3-Dioxygenase 1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.05.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2016.05.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27267006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1ymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=364-375&author=S.+Paulauthor=A.+Royauthor=S.+J.+Dekaauthor=S.+Pandaauthor=V.+Trivediauthor=D.+Manna&title=Nitrobenzofurazan+Derivatives+of+N%E2%80%B2-Hydroxyamidines+as+Potent+Inhibitors+of+Indoleamine-2%2C3-Dioxygenase+1&doi=10.1016%2Fj.ejmech.2016.05.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1</span></div><div class="casAuthors">Paul, Saurav; Roy, Ashalata; Deka, Suman Jyoti; Panda, Subhankar; Trivedi, Vishal; Manna, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">364-375</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tryptophan metab. through the kynurenine pathway is considered as a crucial mechanism in immune tolerance.  Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism in the immune system and it is also considered as an important therapeutic target for the treatment of cancer and other diseases that are linked with kynurenine pathway.  Nitrobenzofurazan derivs. of N'-hydroxybenzimidamides and N'-hydroxy-2-phenylacetimidamides were synthesized and their inhibitory activities against human IDO1 enzyme were tested using in-vitro and cellular enzyme activity assay.  The optimization leads to the identification of three potent compds. (IC50 = 39-80 nM), which are either competitive or uncompetitive inhibitors of IDO1 enzyme.  These compds. also showed IDO1 inhibition potencies in the nanomolar range (IC50 = 50-71 nM) in MDA-MB-231 cells with no/negligible amt. of cytotoxicity.  The stronger selectivity of the potent compds. for IDO1 enzyme over tryptophan 2,3-dioxygenase (TDO) enzyme (312-1593-fold) also makes them very attractive for further immunotherapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0u7NQidTrFrVg90H21EOLACvtfcHk0lh6l8Y18GRZfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1ymtbg%253D&md5=abe140439fd68f0fe712f068b48f8428</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.05.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.05.061%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DDeka%26aufirst%3DS.%2BJ.%26aulast%3DPanda%26aufirst%3DS.%26aulast%3DTrivedi%26aufirst%3DV.%26aulast%3DManna%26aufirst%3DD.%26atitle%3DNitrobenzofurazan%2520Derivatives%2520of%2520N%25E2%2580%25B2-Hydroxyamidines%2520as%2520Potent%2520Inhibitors%2520of%2520Indoleamine-2%252C3-Dioxygenase%25201%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D364%26epage%3D375%26doi%3D10.1016%2Fj.ejmech.2016.05.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1936</span>, <span class="refDoi"> DOI: 10.3390/molecules22111936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3390%2Fmolecules22111936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1936&author=D.+H.+Leeauthor=J.+Y.+Leeauthor=J.+Jeongauthor=M.+Kimauthor=K.+W.+Leeauthor=E.+Jangauthor=S.+Ahnauthor=C.+H.+Leeauthor=J.+Y.+Hwang&title=Synthesis+and+Molecular+Modeling+Studies+of+N%E2%80%B2-Hydroxyindazolecarboximidamides+as+Novel+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.3390%2Fmolecules22111936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and molecular modeling studies of N'-hydroxyindazolecarboximidamides as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Lee, Dong-Ho; Lee, Joo-Youn; Jeong, Jieun; Kim, Miok; Lee, Kyung Won; Jang, Eunseo; Ahn, Sunjoo; Lee, Chang Hoon; Hwang, Jong Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1936/1-1936/10</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">To discover novel Indoleamine 2,3-dioxygenase (IDO1) inhibitors, a series of N'-hydroxyindazolecarboximidamides I (R = H, 4-F, 3-Cl, etc.) has been designed and synthesized.  Among the synthesized compds., I (R = 3-Br-4-F) inhibited both tryptophan depletion and kynurenine prodn. through the IDO1 enzyme.  Mol. docking studies revealed that compd. I (R = 3-Br-4-F) binds to IDO1 with the same binding mode as the analog, epacadostat (INCB24360).  Here, the synthesis and biol. evaluation of these hydroxyindazolecarboximidamides is reported and the mol. docking study of compd. I (R = 3-Br-4-F) with IDO1 is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfPJ4LQ-G8LVg90H21EOLACvtfcHk0lhiTAQj59POcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGjtbo%253D&md5=d56e9cfcf40bf05ab90846391e39bd04</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22111936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22111936%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DJeong%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DJang%26aufirst%3DE.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DSynthesis%2520and%2520Molecular%2520Modeling%2520Studies%2520of%2520N%25E2%2580%25B2-Hydroxyindazolecarboximidamides%2520as%2520Novel%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1936%26doi%3D10.3390%2Fmolecules22111936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balog, J. A.</span>; <span class="NLM_string-name">Huang, A.</span>; <span class="NLM_string-name">Chen, B.</span>; <span class="NLM_string-name">Chen, L.</span>; <span class="NLM_string-name">Seitz, S. P.</span>; <span class="NLM_string-name">Hart, A. C.</span>; <span class="NLM_string-name">Markwalder, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Indoleamine 2,3-Dioxygenase (Ido)</span>. Patent <span class="NLM_patent">WO2014/150677</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+A.+Balog&author=A.+Huang&author=B.+Chen&author=L.+Chen&author=S.+P.+Seitz&author=A.+C.+Hart&author=J.+A.+Markwalder&title=Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+%28Ido%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBalog%26aufirst%3DJ.%2BA.%26atitle%3DInhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528Ido%2529%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markwalder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabalan, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covello, K.</span></span> <span> </span><span class="NLM_article-title">Identification and Optimization of a Novel Series of Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2016.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28003141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=582-585&author=J.+A.+Markwalderauthor=S.+P.+Seitzauthor=Y.+Blatauthor=L.+Elkinauthor=J.+T.+Huntauthor=J.+G.+Pabalanauthor=M.+N.+Jure-Kunkelauthor=G.+D.+Viteauthor=K.+Covello&title=Identification+and+Optimization+of+a+Novel+Series+of+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1016%2Fj.bmcl.2016.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Markwalder, Jay A.; Seitz, Steven P.; Blat, Yuval; Elkin, Lisa; Hunt, John T.; Pabalan, Jonathan G.; Jure-Kunkel, Maria N.; Vite, Gregory D.; Covello, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">582-585</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of a series of structurally-novel biaryl urea IDO inhibitors is described.  Optimization of a micromolar hit through iterative cycles of synthesis and screening in an assay measuring IDO-mediated intracellular conversion of tryptophan to kynurenine led to potent inhibitors with favorable selectivity and metabolic stability profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhqc8tJqzMrVg90H21EOLACvtfcHk0lhiTAQj59POcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamtLzP&md5=5dd54d9ea6b7d8e24e6f81af379b7b74</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DMarkwalder%26aufirst%3DJ.%2BA.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DElkin%26aufirst%3DL.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DPabalan%26aufirst%3DJ.%2BG.%26aulast%3DJure-Kunkel%26aufirst%3DM.%2BN.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DCovello%26aufirst%3DK.%26atitle%3DIdentification%2520and%2520Optimization%2520of%2520a%2520Novel%2520Series%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D582%26epage%3D585%26doi%3D10.1016%2Fj.bmcl.2016.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markwalder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nation, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covello, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span> <span> </span><span class="NLM_article-title">Development of a Series of Novel O-Phenylenediamine-Based Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2018.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29398543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFejsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=732-736&author=D.+K.+Williamsauthor=J.+A.+Markwalderauthor=A.+J.+Balogauthor=B.+Chenauthor=L.+Chenauthor=J.+Donnellauthor=L.+Haqueauthor=A.+C.+Hartauthor=S.+K.+Mandalauthor=A.+Nationauthor=W.+Shanauthor=G.+D.+Viteauthor=K.+Covelloauthor=J.+T.+Huntauthor=M.+N.+Jure-Kunkelauthor=S.+P.+Seitz&title=Development+of+a+Series+of+Novel+O-Phenylenediamine-Based+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.bmcl.2018.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Williams, David K.; Markwalder, Jay A.; Balog, Aaron J.; Chen, Bin; Chen, Libing; Donnell, Jennifer; Haque, Lauren; Hart, Amy C.; Mandal, Sunil K.; Nation, Andrew; Shan, Weifang; Vite, Gregory D.; Covello, Kelly; Hunt, John T.; Jure-Kunkel, Maria N.; Seitz, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of o-phenylenediamine-based inhibitors of indoleamine 2,3-dioxygenase (IDO) has been identified.  IDO is a heme-contg. enzyme, overexpressed in the tumor microenvironment of many cancers, which can contribute to the suppression of the host immune system.  Synthetic modifications to a previously described diarylether series resulted in an addnl. degree of mol. diversity which was exploited to afford compds. that demonstrated significant potency in the HeLa human cervical cancer IDO1 assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCWbaEvQCnbVg90H21EOLACvtfcHk0liNtoyWud-jqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFejsr8%253D&md5=9a01c59f05a3896a2ad6396bbdfa67c6</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DMarkwalder%26aufirst%3DJ.%2BA.%26aulast%3DBalog%26aufirst%3DA.%2BJ.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDonnell%26aufirst%3DJ.%26aulast%3DHaque%26aufirst%3DL.%26aulast%3DHart%26aufirst%3DA.%2BC.%26aulast%3DMandal%26aufirst%3DS.%2BK.%26aulast%3DNation%26aufirst%3DA.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DCovello%26aufirst%3DK.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJure-Kunkel%26aufirst%3DM.%2BN.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26atitle%3DDevelopment%2520of%2520a%2520Series%2520of%2520Novel%2520O-Phenylenediamine-Based%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D732%26epage%3D736%26doi%3D10.1016%2Fj.bmcl.2018.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 2,5-Dimethylfuran-3-Carboxylic Acid Derivatives as Potential Ido1 Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1605</span>– <span class="NLM_lpage">1618</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2019.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30858027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks1Snsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1605-1618&author=X.+Yangauthor=S.+Caiauthor=X.+Liuauthor=P.+Chenauthor=J.+Zhouauthor=H.+Zhang&title=Design%2C+Synthesis+and+Biological+Evaluation+of+2%2C5-Dimethylfuran-3-Carboxylic+Acid+Derivatives+as+Potential+Ido1+Inhibitors&doi=10.1016%2Fj.bmc.2019.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors</span></div><div class="casAuthors">Yang, Xiaojun; Cai, Shi; Liu, Xueting; Chen, Pan; Zhou, Jinpei; Zhang, Huibin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1605-1618</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a vital role in tumor immune escape and has emerged as a promising target for cancer immunotherapy.  In this study, a novel series of 2,5-dimethylfuran-3-carboxylic acid derivs. were designed, synthesized and evaluated for inhibitory activities against IDO1, and their structure-activity relationship was investigated.  Among these, compd. 19a(I) exhibited excellent IDO1 inhibitory activity (HeLa cellular IC50 = 4.0 nM, THP-1 cellular IC50 = 4.6 nM).  Further mol. docking studies revealed that I formed a coordinate bond with the heme iron through the carboxylic acid moiety.  These results indicate that I is a potential IDO1 inhibitor for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFv19cBLG-5bVg90H21EOLACvtfcHk0liNtoyWud-jqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks1Snsrg%253D&md5=8a874669af2fc16eab7d6798f6fd0368</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25202%252C5-Dimethylfuran-3-Carboxylic%2520Acid%2520Derivatives%2520as%2520Potential%2520Ido1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1605%26epage%3D1618%26doi%3D10.1016%2Fj.bmc.2019.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Bicyclic Carboxylic Acid Derivatives as Ido1 Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">103356</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bioorg.2019.103356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31785855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Crtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=103356&author=S.+Caiauthor=X.+Yangauthor=P.+Chenauthor=X.+Liuauthor=J.+Zhouauthor=H.+Zhang&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Bicyclic+Carboxylic+Acid+Derivatives+as+Ido1+Inhibitors&doi=10.1016%2Fj.bioorg.2019.103356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors</span></div><div class="casAuthors">Cai, Shi; Yang, Xiaojun; Chen, Pan; Liu, Xueting; Zhou, Jinpei; Zhang, Huibin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103356</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a vital role in tumor immune escape and has emerged as a promising target for cancer immunotherapy.  In this study, a novel series of bicyclic carboxylic acid derivs. were designed, synthesized and evaluated for inhibitory activities against IDO1.  Among these, compd. 9c exhibited strong IDO1 inhibitory activity (HeLa cellular IC50 = 2.6 nM, THP-1 cellular IC50 = 11.2 nM).  Further anti-tumor studies in vivo have shown that compd. 9c has a great inhibitory effect on tumor growth in mice CT26 model as a single agent or in combination with 5-fluorouracil (inhibition rate was 53.9% and 92.7%, resp.).  These results indicate that compd. 9c is a effective IDO1 inhibitor for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwS8sIEyKgiLVg90H21EOLACvtfcHk0liNtoyWud-jqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Crtb3E&md5=e5d89ce66c265f746eea6a673c9587d5</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103356%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Bicyclic%2520Carboxylic%2520Acid%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D94%26spage%3D103356%26doi%3D10.1016%2Fj.bioorg.2019.103356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(Iv) Pro-Drug Preferentially Targets Indoleamine-2,3-Dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.+R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28Iv%29+Pro-Drug+Preferentially+Targets+Indoleamine-2%2C3-Dioxygenase%2C+Providing+Enhanced+Ovarian+Cancer+Immuno-Chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0liNtoyWud-jqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528Iv%2529%2520Pro-Drug%2520Preferentially%2520Targets%2520Indoleamine-2%252C3-Dioxygenase%252C%2520Providing%2520Enhanced%2520Ovarian%2520Cancer%2520Immuno-Chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fertan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, K. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diez-Cecilia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R. E.</span></span> <span> </span><span class="NLM_article-title">Effects of the Novel Ido Inhibitor Dwg-1036 on the Behavior of Male and Female 3xtg-Ad Mice</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1044</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffphar.2019.01044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31607909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFWqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1044&author=E.+Fertanauthor=K.+R.+J.+Stoverauthor=M.+G.+Brantauthor=P.+M.+Staffordauthor=B.+Kellyauthor=E.+Diez-Ceciliaauthor=A.+A.+Wongauthor=D.+F.+Weaverauthor=R.+E.+Brown&title=Effects+of+the+Novel+Ido+Inhibitor+Dwg-1036+on+the+Behavior+of+Male+and+Female+3xtg-Ad+Mice&doi=10.3389%2Ffphar.2019.01044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the novel IDO inhibitor DWG-1036 on the behavior of male and female 3xTg-AD mice</span></div><div class="casAuthors">Fertan, Emre; Stover, Kurt R. J.; Brant, Michael G.; Stafford, Paul M.; Kelly, Brendan; Diez-Cecilia, Elena; Wong, Aimee A.; Weaver, Donald F.; Brown, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1044</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The kynurenine pathway metabolizes tryptophan into NAD, producing a no. of intermediary metabolites, including 3-hydroxy kynurenine and quinolinic acid, which are involved in the neurodegenerative mechanisms that underlie Alzheimer's disease (AD).  Indolamine 2,3-dioxygenase (IDO), the first and rate-limiting enzyme of this pathway, is increased in AD, and it has been hypothesized that blocking this enzyme may slow the progression of AD.  In this study, we treated male and female 3xTg-AD and wild-type mice with the novel IDO inhibitor DWG-1036 (80 mg/kg) or vehicle (distd. water) from 2 to 6 mo of age and then tested them in a battery of behavioral tests that measured spatial learning and memory (Barnes maze), working memory (trace fear conditioning), motor coordination and learning (rotarod), anxiety (elevated plus maze), and depression (tail suspension test).  The 3xTg-AD mice treated with DWG-1036 showed better memory in the trace fear conditioning task and significant improvements in learning but poorer spatial memory in the Barnes maze.  DWG-1036 treatment also ameliorated the behaviors assocd. with increased anxiety in the elevated plus maze and depression-like behaviors in the tail suspension test in 3xTg-AD mice.  However, the effects of DWG-1036 treatment on the behavioral tasks were variable, and sex differences were apparent.  In addn., high doses of DWG-1036 resulted in reduced body wt., particularly in females.  Taken together, our results suggest that the kynurenine pathway is a promising target for treating AD, but more work is needed to det. the effective compds., examine sex differences, and understand the side effects of the compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXe0D9TuZxrVg90H21EOLACvtfcHk0lg4d-z-pGPnrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFWqs7w%253D&md5=2dd2cf54313b5282cd7179f26e69580f</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01044%26sid%3Dliteratum%253Aachs%26aulast%3DFertan%26aufirst%3DE.%26aulast%3DStover%26aufirst%3DK.%2BR.%2BJ.%26aulast%3DBrant%26aufirst%3DM.%2BG.%26aulast%3DStafford%26aufirst%3DP.%2BM.%26aulast%3DKelly%26aufirst%3DB.%26aulast%3DDiez-Cecilia%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DA.%2BA.%26aulast%3DWeaver%26aufirst%3DD.%2BF.%26aulast%3DBrown%26aufirst%3DR.%2BE.%26atitle%3DEffects%2520of%2520the%2520Novel%2520Ido%2520Inhibitor%2520Dwg-1036%2520on%2520the%2520Behavior%2520of%2520Male%2520and%2520Female%25203xtg-Ad%2520Mice%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1044%26doi%3D10.3389%2Ffphar.2019.01044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Platinum(Iv) Complexes as Immunostimulatory Agents to Promote Cancer Immunochemotherapy by Inhibiting Tryptophan-2,3-Dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.02.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.02.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30852385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks12itrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2019&pages=29-41&author=S.+Huaauthor=F.+Chenauthor=G.+Xuauthor=S.+Gou&title=Multifunctional+Platinum%28Iv%29+Complexes+as+Immunostimulatory+Agents+to+Promote+Cancer+Immunochemotherapy+by+Inhibiting+Tryptophan-2%2C3-Dioxygenase&doi=10.1016%2Fj.ejmech.2019.02.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Xu, Gang; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-41</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Increasing evidences suggested that cisplatin can be involved in a tumor-specific immune response as an immunomodulator to improve antitumor immunity, but the designation and development are limited.  Here, we report a series of novel Pt(IV) complexes derived from the conjugation of platinum(II) anticancer agents with an immune checkpoint TDO inhibitor.  These complexes not only showed significant cytotoxic effects on the tested cancer cell lines, but also could enhance antitumor immune response.  Particularly, complex T2, the mono-conjugate of oxoplatin and (E)-4-oxo-4-(3-(2-(pyridin-3-yl)vinyl)-1H-indol-1-yl)butanoic acid, displayed 35-fold more potency than cisplatin against TDO-overexpressed HepG-2 cancer cells.  Further study indicated that T2 could inhibit TDO via releasing a deriv. of a TDO inhibitor and block kynurenine prodn., resulting in T-cell activation and proliferation in vitro.  In vivo tests proved that T2 as a potent immunomodulator could highly promote the antitumor activity of cisplatin and effectively suppress the expression of TDO.  This immunochemotherapeutic strategy can be promisingly applied to treat with TDO-overexpressed cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJ66nUl2NzbVg90H21EOLACvtfcHk0lg4d-z-pGPnrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks12itrc%253D&md5=c2abc299a2d18a2bffed504df3e24a4f</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DMultifunctional%2520Platinum%2528Iv%2529%2520Complexes%2520as%2520Immunostimulatory%2520Agents%2520to%2520Promote%2520Cancer%2520Immunochemotherapy%2520by%2520Inhibiting%2520Tryptophan-2%252C3-Dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D169%26spage%3D29%26epage%3D41%26doi%3D10.1016%2Fj.ejmech.2019.02.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Improving the Potency of Cancer Immunotherapy by Dual Targeting of Ido1 and DNA</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcmdc.201700666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29205945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2jsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=30-36&author=K.+Fangauthor=G.+Dongauthor=H.+Wangauthor=S.+Heauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Improving+the+Potency+of+Cancer+Immunotherapy+by+Dual+Targeting+of+Ido1+and+DNA&doi=10.1002%2Fcmdc.201700666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Wang, Hongyu; He, Shipeng; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-mol. cancer immunotherapy.  New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that resp. target IDO1 and DNA were rationally designed.  As the first-in-class examples of such mols., they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity.  This proof-of-concept study has established a crit. step toward the development of a novel and effective immunotherapy for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUSxFALgkwHbVg90H21EOLACvtfcHk0lg4d-z-pGPnrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2jsb3L&md5=bbef804d59cb318294b791064a5b7909</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700666%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DImproving%2520the%2520Potency%2520of%2520Cancer%2520Immunotherapy%2520by%2520Dual%2520Targeting%2520of%2520Ido1%2520and%2520DNA%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D30%26epage%3D36%26doi%3D10.1002%2Fcmdc.201700666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (Ido1) and Histone Deacetylase (Hdac) Dual Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=312-317&author=K.+Fangauthor=G.+Dongauthor=Y.+Liauthor=S.+Heauthor=Y.+Wuauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Discovery+of+Novel+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+and+Histone+Deacetylase+%28Hdac%29+Dual+Inhibitors&doi=10.1021%2Facsmedchemlett.7b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Li, Yu; He, Shipeng; Wu, Ying; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-317</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to take advantage of both immunotherapeutic and epigenetic antitumor agents, the first generation of dual indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) inhibitors were designed.  The highly active dual inhibitor 10 showed excellent and balanced activity against both IDO1 (IC50 = 69.0 nM) and HDAC1 (IC50 = 66.5 nM), whose dual targeting mechanisms were validated in cancer cells.  Compd. 10 had good pharmacokinetic profiles as an orally active antitumor agent and significantly reduced the L-kynurenine level in plasma.  In particular, it showed excellent in vivo antitumor efficacy in the murine LLC tumor model with low toxicity.  This proof-of-concept study provided a novel strategy for cancer treatment.  Compd. 10 represents a promising lead compd. for the development of novel antitumor agents and can also be used as a valuable probe to clarify the relationships and mechanisms between cancer immunotherapy and epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDqXRR2J0zrVg90H21EOLACvtfcHk0li5fDSCN1rJJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D&md5=c808b75f03d703dc7e66798759457f4a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00487%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Novel%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520and%2520Histone%2520Deacetylase%2520%2528Hdac%2529%2520Dual%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D312%26epage%3D317%26doi%3D10.1021%2Facsmedchemlett.7b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (Tdo) Inhibitors through Structure-Based Virtual Screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7807</span>– <span class="NLM_lpage">7819</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7807-7819&author=J.+S.+Wuauthor=S.+Y.+Linauthor=F.+Y.+Liaoauthor=W.+C.+Hsiaoauthor=L.+C.+Leeauthor=Y.+H.+Pengauthor=C.+L.+Hsiehauthor=M.+H.+Wuauthor=J.+S.+Songauthor=A.+Yuehauthor=C.+H.+Chenauthor=S.+H.+Yehauthor=C.+Y.+Liuauthor=S.+Y.+Linauthor=T.+K.+Yehauthor=J.+T.+Hsuauthor=C.+Shihauthor=S.+H.+Uengauthor=M.+S.+Hungauthor=S.+Y.+Wu&title=Identification+of+Substituted+Naphthotriazolediones+as+Novel+Tryptophan+2%2C3-Dioxygenase+%28Tdo%29+Inhibitors+through+Structure-Based+Virtual+Screening&doi=10.1021%2Facs.jmedchem.5b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening</span></div><div class="casAuthors">Wu, Jian-Sung; Lin, Shu-Yu; Liao, Fang-Yu; Hsiao, Wen-Chi; Lee, Lung-Chun; Peng, Yi-Hui; Hsieh, Chia-Ling; Wu, Mine-Hsine; Song, Jen-Shin; Yueh, Andrew; Chen, Chun-Hwa; Yeh, Shiu-Hwa; Liu, Chia-Yeh; Lin, Shu-Yi; Yeh, Teng-Kuang; Hsu, John T.-A.; Shih, Chuan; Ueng, Shau-Hua; Hung, Ming-Shiu; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7807-7819</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based virtual screening strategy, comprising homol. modeling, ligand-support binding site optimization, virtual screening, and structure clustering anal., was developed and used to identify novel tryptophan 2,3-dioxygenase (TDO) inhibitors.  Compd. 1 (IC50 = 711 nM), selected by virtual screening, showed inhibitory activity toward TDO and was subjected to structural modifications and mol. docking studies.  This resulted in the identification of a potent TDO selective inhibitor (11e, IC50 = 30 nM), making it a potential compd. for further investigation as a cancer therapeutic and other TDO-related targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_08WPyOJIMbVg90H21EOLACvtfcHk0li5fDSCN1rJJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7vI&md5=3aea83affb3164c94f8cbfead21dbcce</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00921%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DHsiao%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DYueh%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DYeh%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26atitle%3DIdentification%2520of%2520Substituted%2520Naphthotriazolediones%2520as%2520Novel%2520Tryptophan%25202%252C3-Dioxygenase%2520%2528Tdo%2529%2520Inhibitors%2520through%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7807%26epage%3D7819%26doi%3D10.1021%2Facs.jmedchem.5b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Dual-Functional Conjugates Improving Cancer Immunochemotherapy by Inhibiting Tubulin Polymerization and Indoleamine-2,3-Dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112041</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2020.112041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31954880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112041&author=S.+Huaauthor=F.+Chenauthor=X.+Wangauthor=S.+Gou&title=Dual-Functional+Conjugates+Improving+Cancer+Immunochemotherapy+by+Inhibiting+Tubulin+Polymerization+and+Indoleamine-2%2C3-Dioxygenase&doi=10.1016%2Fj.ejmech.2020.112041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Wang, Xinyi; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112041</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel conjugates comprising tublin and IDO inhibitors were designed, synthesized and evaluated for their antiproliferative activity.  Among them, HI5, composed of combretastatin A-4 (CA-4) and (D)-1-methyltryptophan (D-MT) by a linker, exhibited the most potent antitumor activity, in particular with higher IC50 value (0.07 μM) than CA-4 (0.21 μM) against HeLa cancer cell line.  Mechanism studies indicated that HI5 can inhibit tubulin polymn. and cell migration, cause G2/M phase arrest, concurrent induce apoptosis via the mitochondrial dependent apoptosis pathway and cause reactive oxidative stress generation in HeLa cells.  Furthermore, HI5 can inhibit IDO expression and decrease kynurenine prodn., leading to stimulating T cells activation and proliferation to enhance antitumor immunity in vitro.  Interestingly, HI5 can effectively limit the tumor growth in the HeLa xenograft mice models without causing significant loss of body wt.  Consequently, such a conjugation can be a potent and safe immunochemotherapeutic method for improving cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK6mjQcEaBRbVg90H21EOLACvtfcHk0li5fDSCN1rJJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGjt7Y%253D&md5=f6e05a7ba52c4112d0d767f0f1f7f1f3</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112041%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DDual-Functional%2520Conjugates%2520Improving%2520Cancer%2520Immunochemotherapy%2520by%2520Inhibiting%2520Tubulin%2520Polymerization%2520and%2520Indoleamine-2%252C3-Dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112041%26doi%3D10.1016%2Fj.ejmech.2020.112041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Microtubule Inhibitors Containing Immunostimulatory Agents Promote Cancer Immunochemotherapy by Inhibiting Tubulin Polymerization and Tryptophan-2,3-Dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111949</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.111949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31830637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111949&author=S.+Huaauthor=F.+Chenauthor=S.+Gou&title=Microtubule+Inhibitors+Containing+Immunostimulatory+Agents+Promote+Cancer+Immunochemotherapy+by+Inhibiting+Tubulin+Polymerization+and+Tryptophan-2%2C3-Dioxygenase&doi=10.1016%2Fj.ejmech.2019.111949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111949</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A combination therapeutic regimen via introducing tryptophan 2,3-dioxygenase inhibitors into microtubule inhibitors was performed and evaluated for their antitumor activity.  Thereinto, HT2, composed of combretastatin A-4 (CA-4) and tryptophan-2,3-dioxygenase (TDO) inhibitor by a linker, displayed the most potent activity with 10-fold higher than its parent CA-4 against HepG2, A549 and HCT-116 cancer cell lines.  Mechanism studies suggested that HT2 inhibited tubulin polymn. and cell migration, caused G2 phase arrest, induced apoptosis by mitochondrial mediated apoptotic pathway, concurrent depolarized the mitochondria membrane potentials and caused reactive oxygen species (ROS) prodn. in HepG2 cells.  Moreover, HT2 could enhance T-cell immune responses in vitro by releasing a TDO inhibitor to suppress TDO expression and blockade kynurenine prodn.  As expected, HT2 could remarkably promote the antitumor activity of CA-4 in either immunocompetent H22 or immunodeficient A549 tumor xenograft models without observable toxic effects.  More importantly, HT2 increased the level of splenic and tumor-infiltrated T cells and in turn effectively boosted the inhibition effect in H22 xenografted tumor growth.  Collectively, this immunochemotherapeutic strategy can be applied to promote chemotherapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaKG5W_QhNz7Vg90H21EOLACvtfcHk0livbyAGI_9OXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7zJ&md5=a8d8e6f33d2ad2f5dd02c4403ba2ed94</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111949%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DMicrotubule%2520Inhibitors%2520Containing%2520Immunostimulatory%2520Agents%2520Promote%2520Cancer%2520Immunochemotherapy%2520by%2520Inhibiting%2520Tubulin%2520Polymerization%2520and%2520Tryptophan-2%252C3-Dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111949%26doi%3D10.1016%2Fj.ejmech.2019.111949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted Protein Degradation: Expanding the Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+Protein+Degradation%3A+Expanding+the+Toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0livbyAGI_9OXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520Protein%2520Degradation%253A%2520Expanding%2520the%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of the First Potent Proteolysis Targeting Chimera (Protac) Degrader of Indoleamine 2,3-Dioxygenase 1</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1943</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2020.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.apsb.2020.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=33163345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BB3s3itFWjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1943&author=M.+Huauthor=W.+Zhouauthor=Y.+Wangauthor=D.+Yaoauthor=T.+Yeauthor=Y.+Yaoauthor=B.+Chenauthor=G.+Liuauthor=X.+Yangauthor=W.+Wangauthor=Y.+Xie&title=Discovery+of+the+First+Potent+Proteolysis+Targeting+Chimera+%28Protac%29+Degrader+of+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1016%2Fj.apsb.2020.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Hu Mingxing; Zhou Weilin; Wang Yijie; Yao Dongping; Ye Tinghong; Yao Yuqin; Chen Bin; Wang Wei; Xie Yongmei; Liu Gongping; Liu Gongping; Yang Xifei</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1943-1953</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Cancer immunotherapy is revolutionizing oncology and has emerged as a promising strategy for the treatment of multiple cancers.  Indoleamine 2,3-dioxygenase 1 (IDO1), an immune checkpoint, plays an important role in tumor immune escape through the regulation of multiple immune cells and has been regarded as an attractive target for cancer immunotherapy.  Proteolysis Targeting Chimeras (PROTAC) technology has emerged as a new model for drug research and development for its advantageous mechanism.  Herein, we reported the application of PROTAC technology in targeted degradation of IDO1, leading to the discovery of the first IDO1 PROTAC degrader 2c, which induced significant and persistent degradation of IDO1 with maximum degradation (dmax) of 93% in HeLa cells.  Western-blot based mechanistic studies indicated that IDO1 was degraded by 2c through the ubiquitin proteasome system (UPS).  Label-free real-time cell analysis (RTCA) indicated that 2c moderately improved tumor-killing activity of chimeric antigen receptor-modified T (CAR-T) cells.  Collectively, these data provide a new insight for the application of PROTAC technology in tumor immune-related proteins and a promising tool to study the function of IDO1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWIZtDY9yqhiEJCPKhJPuqfW6udTcc2eYnfl0EBnEXDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s3itFWjtw%253D%253D&md5=c3e3aaf4cc3f9aac0d047a6d8df8149d</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2020.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2020.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DYe%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520the%2520First%2520Potent%2520Proteolysis%2520Targeting%2520Chimera%2520%2528Protac%2529%2520Degrader%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D1943%26doi%3D10.1016%2Fj.apsb.2020.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondanelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span> <span> </span><span class="NLM_article-title">Identification of a 2-Propanol Analogue Modulating the Non-Enzymatic Function of Indoleamine 2,3-Dioxygenase 1</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.10.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bcp.2018.10.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30391205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOis7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=286-297&author=E.+Albiniauthor=A.+Colettiauthor=F.+Grecoauthor=M.+T.+Pallottaauthor=G.+Mondanelliauthor=M.+Gargaroauthor=M.+L.+Belladonnaauthor=C.+Volpiauthor=R.+Bianchiauthor=U.+Grohmannauthor=A.+Macchiaruloauthor=C.+Orabona&title=Identification+of+a+2-Propanol+Analogue+Modulating+the+Non-Enzymatic+Function+of+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1016%2Fj.bcp.2018.10.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Albini, E.; Coletti, A.; Greco, F.; Pallotta, M. T.; Mondanelli, G.; Gargaro, M.; Belladonna, M. L.; Volpi, C.; Bianchi, R.; Grohmann, U.; Macchiarulo, A.; Orabona, C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">286-297</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3 dioxygenase 1 (IDO1) is a metabolic enzyme that catalyzes the conversion of the essential amino acid tryptophan (Trp) into a series of immunoactive catabolites, collectively known as kynurenines.  Through the depletion of Trp and the generation of kynurenines, IDO1 represents a key regulator of the immune responses involved in physiol. homeostasis as well as in neoplastic and autoimmune pathologies.  The IDO1 enzyme has been described as an important immune checkpoint to be targeted by catalytic inhibitors in the treatment of cancer.  In contrast, a defective expression/activity of the enzyme has been demonstrated in autoimmune diseases.  Beside its catalytic activity, the IDO1 protein is endowed with an addnl. function assocd. with the presence of two immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which, once phosphorylated, bind SHP phosphatases and mediate a long-term immunoregulatory activity of IDO1.  Herein, we report the screening of a focused library of mols. bearing a propanol core by a protocol combining microscale thermophoresis (MST) anal. and a cellular assay.  As a result, the combined screening identified a 2-propanolol analog, VIS351, as the first potent activator of the ITIM-mediated function of the IDO1 enzyme.  VIS351 displayed a good dissocn. const. (Kd = 1.90 μM) for IDO1 and a moderate cellular inhibitor activity (IC50 = 11.463 μM), although it did not show any catalytic inhibition of the recombinant IDO1 enzyme.  Because we previously demonstrated that the enzymic and non-enzymic (i.e., ITIM-mediated) functions of IDO1 reside in different conformations of the protein, we hypothesized that in the cellular system VIS351 may shift the dynamic conformational balance towards the ITIM-favoring folding of IDO1, resulting in the activation of the signaling rather than catalytic activity of IDO1.  We demonstrated that VIS351 activated the ITIM-mediated signaling of IDO1 also in mouse plasmacytoid dendritic cells, conferring those cells an immunosuppressive phenotype detectable in vivo.  Thus the manuscript describes for the first time a small mol. as a pos. modulator of IDO1 signaling function, paving the basis for an innovative approach to develop first-in-class drugs acting on the IDO1 target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLg711zZvTGrVg90H21EOLACvtfcHk0lhF_lW6_AuQQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOis7nF&md5=b3e29db845d43756136f67859af2f162</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.10.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.10.033%26sid%3Dliteratum%253Aachs%26aulast%3DAlbini%26aufirst%3DE.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DGreco%26aufirst%3DF.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DMondanelli%26aufirst%3DG.%26aulast%3DGargaro%26aufirst%3DM.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DOrabona%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520a%25202-Propanol%2520Analogue%2520Modulating%2520the%2520Non-Enzymatic%2520Function%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D158%26spage%3D286%26epage%3D297%26doi%3D10.1016%2Fj.bcp.2018.10.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawanishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase by Beta-Carboline and Indole Derivatives</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1016/0003-9861(84)90579-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2F0003-9861%2884%2990579-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=6431906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVKltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=1984&pages=602-609&author=N.+Eguchiauthor=Y.+Watanabeauthor=K.+Kawanishiauthor=Y.+Hashimotoauthor=O.+Hayaishi&title=Inhibition+of+Indoleamine+2%2C3-Dioxygenase+and+Tryptophan+2%2C3-Dioxygenase+by+Beta-Carboline+and+Indole+Derivatives&doi=10.1016%2F0003-9861%2884%2990579-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by β-carboline and indole derivatives</span></div><div class="casAuthors">Eguchi, Naomi; Watanabe, Yasuyoshi; Kawanishi, Kazuko; Hashimoto, Yohei; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">602-9</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    </div><div class="casAbstract">β-Carboline derivs. inhibited both indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase activities from various sources.  Among them, norharman (I) is most potent for both enzymes from mammalian sources.  Kinetic studies revealed that I is uncompetitive (Ki = 0.12 mM) with L-tryptophan for rabbit intestinal indoleamine 2,3-dioxygenase, and linearly competitive (Ki = 0.29 mM) with L-tryptophan for mouse liver tryptophan 2,3-dioxygenase.  In addn., some β-carbolines selectively inhibited one enzyme or the other.  Pseudomonad tryptophan 2,3-dioxygenase was inhibited by a different spectrum of β-carbolines.  Such a selective inhibition by the structure of substrate analogs is more evident by the use of indole derivs.  Indole-3-acetamide, indole-3-acetonitrile, and indole-3-acrylic acid exhibited a potent inhibition for mammalian tryptophan 2,3-dioxygenase, whereas they moderately inhibited the pseudomonad enzyme.  However, they showed no inhibition for indoleamine 2,3-dioxygenase.  These results suggest the difference of the structures of the active sites among these enzymes from various sources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA-VT_50vfwrVg90H21EOLACvtfcHk0lhF_lW6_AuQQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVKltro%253D&md5=cfbdf0d14acce6d935ffa69b7272f5fc</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2F0003-9861%2884%2990579-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-9861%252884%252990579-4%26sid%3Dliteratum%253Aachs%26aulast%3DEguchi%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DKawanishi%26aufirst%3DK.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DInhibition%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520and%2520Tryptophan%25202%252C3-Dioxygenase%2520by%2520Beta-Carboline%2520and%2520Indole%2520Derivatives%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1984%26volume%3D232%26spage%3D602%26epage%3D609%26doi%3D10.1016%2F0003-9861%2884%2990579-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vottero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauk, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, R. J.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase Inhibitors from the Northeastern Pacific Marine Hydroid Garveia Annulata</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1496</span>– <span class="NLM_lpage">1499</span>, <span class="refDoi"> DOI: 10.1021/np060111x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np060111x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVShs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=1496-1499&author=A.+Pereiraauthor=E.+Votteroauthor=M.+Robergeauthor=A.+G.+Maukauthor=R.+J.+Andersen&title=Indoleamine+2%2C3-Dioxygenase+Inhibitors+from+the+Northeastern+Pacific+Marine+Hydroid+Garveia+Annulata&doi=10.1021%2Fnp060111x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific marine hydroid Garveia annulata</span></div><div class="casAuthors">Pereira, Alban; Vottero, Eduardo; Roberge, Michel; Mauk, A. Grant; Andersen, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1496-1499</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Crude exts. of the marine hydroid Garveia annulata show potent inhibition of indoleamine 2,3-dioxygenase (IDO).  Fractionation of the ext. led to the identification of the new polyketides annulin C (e.g. I), 2-hydroxygarveatin E, garveatin E, and garvin C.  Annulins A, B, and C were found to be submicromolar inhibitors of IDO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVZbImHRhbaLVg90H21EOLACvtfcHk0lhF_lW6_AuQQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVShs7nI&md5=c49325bf3597d02ef29730f7d2f9994e</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fnp060111x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp060111x%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DVottero%26aufirst%3DE.%26aulast%3DRoberge%26aufirst%3DM.%26aulast%3DMauk%26aufirst%3DA.%2BG.%26aulast%3DAndersen%26aufirst%3DR.%2BJ.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520Inhibitors%2520from%2520the%2520Northeastern%2520Pacific%2520Marine%2520Hydroid%2520Garveia%2520Annulata%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2006%26volume%3D69%26spage%3D1496%26epage%3D1499%26doi%3D10.1021%2Fnp060111x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, R. J.</span>; <span class="NLM_string-name">Pereira, A.</span>; <span class="NLM_string-name">Huang, X. H.</span>; <span class="NLM_string-name">Mauk, G.</span>; <span class="NLM_string-name">Vottero, E.</span>; <span class="NLM_string-name">Roberge, M.</span>; <span class="NLM_string-name">Balgi, A.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase (Ido) Inhibitors</span>. Patent <span class="NLM_patent">WO2006/005185</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+J.+Andersen&author=A.+Pereira&author=X.+H.+Huang&author=G.+Mauk&author=E.+Vottero&author=M.+Roberge&author=A.+Balgi&title=Indoleamine+2%2C3-Dioxygenase+%28Ido%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DR.%2BJ.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520%2528Ido%2529%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flick, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">The Tumor-Selective Cytotoxic Agent Beta-Lapachone Is a Potent Inhibitor of Ido1</span>. <i>Int. J. Tryptophan Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.4137/IJTR.S12094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.4137%2FIJTR.S12094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24023520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2gs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=35-45&author=H.+E.+Flickauthor=J.+M.+Lalondeauthor=W.+P.+Malachowskiauthor=A.+J.+Muller&title=The+Tumor-Selective+Cytotoxic+Agent+Beta-Lapachone+Is+a+Potent+Inhibitor+of+Ido1&doi=10.4137%2FIJTR.S12094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">The tumor-selective cytotoxic agent β-lapachone is a potent inhibitor of IDO1</span></div><div class="casAuthors">Flick, Hollie E.; LaLonde, Judith M.; Malachowski, William P.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Tryptophan Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-45</span>CODEN:
                <span class="NLM_cas:coden">IJTRBS</span>;
        ISSN:<span class="NLM_cas:issn">1178-6469</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">β-Lapachone is a naturally occurring 1,2-naphthoquinone-based compd. that has been advanced into clin. trials based on its tumor-selective cytotoxic properties.  Previously, we focused on the related 1,4-naphthoquinone pharmacophore as a basic core structure for developing a series of potent indoleamine 2,3-dioxygenase 1 (IDO1) enzyme inhibitors.  In this study, we identified IDO1 inhibitory activity as a previously unrecognized attribute of the clin. candidate β-lapachone.  Enzyme kinetics-based anal. of β-lapachone indicated an uncompetitive mode of inhibition, while computational modeling predicted binding within the IDO1 active site consistent with other naphthoquinone derivs.  Inhibition of IDO1 has previously been shown to breach the pathogenic tolerization that constrains the immune system from being able to mount an effective anti-tumor response.  Thus, the finding that β-lapachone has IDO1 inhibitory activity adds a new dimension to its potential utility as an anti-cancer agent distinct from its cytotoxic properties, and suggests that a synergistic benefit can be achieved from its combined cytotoxic and immunol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVmjPfcd508LVg90H21EOLACvtfcHk0ljT4H04afDGJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2gs73M&md5=d432e109c20ca5a92c26d6dda24ef4b7</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.4137%2FIJTR.S12094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FIJTR.S12094%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DH.%2BE.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520Tumor-Selective%2520Cytotoxic%2520Agent%2520Beta-Lapachone%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Ido1%26jtitle%3DInt.%2520J.%2520Tryptophan%2520Res.%26date%3D2013%26volume%3D6%26spage%3D35%26epage%3D45%26doi%3D10.4137%2FIJTR.S12094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pantouris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C. G.</span></span> <span> </span><span class="NLM_article-title">Antitumour Agents as Inhibitors of Tryptophan 2,3-Dioxygenase</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>443</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2013.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bbrc.2013.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24269239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOhtb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=443&publication_year=2014&pages=28-31&author=G.+Pantourisauthor=C.+G.+Mowat&title=Antitumour+Agents+as+Inhibitors+of+Tryptophan+2%2C3-Dioxygenase&doi=10.1016%2Fj.bbrc.2013.11.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Pantouris, Georgios; Mowat, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">443</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-31</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The involvement of tryptophan 2,3-dioxygenase (TDO) in cancer biol. has recently been described, with the enzyme playing an immunomodulatory role, suppressing antitumor immune responses and promoting tumor cell survival and proliferation.  This finding reinforces the need for specific inhibitors of TDO that may potentially be developed for therapeutic use.  In this work we have screened ∼2800 compds. from the library of the National Cancer Institute USA and identified seven potent inhibitors of TDO with inhibition consts. in the nanomolar or low micromolar range.  All seven have antitumor properties, killing various cancer cell lines.  For comparison, the inhibition potencies of these compds. were tested against IDO and their inhibition consts. are reported.  Interestingly, this work reveals that NSC 36398 (dihydroquercetin, taxifolin), with an in vitro inhibition const. of ∼16 μM, is the first TDO-selective inhibitor reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5TH-gsVsNO7Vg90H21EOLACvtfcHk0ljT4H04afDGJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOhtb%252FL&md5=db2ebf560e56801f65635dc8c260b39a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DPantouris%26aufirst%3DG.%26aulast%3DMowat%26aufirst%3DC.%2BG.%26atitle%3DAntitumour%2520Agents%2520as%2520Inhibitors%2520of%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D443%26spage%3D28%26epage%3D31%26doi%3D10.1016%2Fj.bbrc.2013.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blunt, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torcuk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-Dioxygenase (Ido) as Potential Target for Anticancer Activity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8740</span>– <span class="NLM_lpage">8745</span>, <span class="refDoi"> DOI: 10.1002/anie.201503323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fanie.201503323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVensLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8740-8745&author=C.+E.+Bluntauthor=C.+Torcukauthor=Y.+Liuauthor=W.+Lewisauthor=D.+Siegelauthor=D.+Rossauthor=C.+J.+Moody&title=Synthesis+and+Intracellular+Redox+Cycling+of+Natural+Quinones+and+Their+Analogues+and+Identification+of+Indoleamine-2%2C3-Dioxygenase+%28Ido%29+as+Potential+Target+for+Anticancer+Activity&doi=10.1002%2Fanie.201503323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity</span></div><div class="casAuthors">Blunt, Christopher E.; Torcuk, Canan; Liu, Yang; Lewis, William; Siegel, David; Ross, David; Moody, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8740-8745</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of isothiazoloquinones, including natural naphthoquinone aulosirazole and structurally related pronqodine A, was synthesized and their biol. activity as inhibitors of the immunoregulatory enzyme indoleamine-2,3-dioxygenase (IDO) was studied.  The synthesis of aulosirazole uses a route centered upon a late-stage regioselective Diels-Alder reaction.  The isothiazoloquinones were also found to be efficient substrates for the human quinone reductase NQO1, and underwent intracellular NQO1-dependent redox cycling resulting in the generation of reactive oxygen species, and at lower doses have the potential to alter the ratio of intracellular oxidized to reduced pyridine nucleotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-HIYOL59p6bVg90H21EOLACvtfcHk0ljT4H04afDGJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVensLjI&md5=32d7f95c3253618c4bb00c6d7ad06824</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1002%2Fanie.201503323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201503323%26sid%3Dliteratum%253Aachs%26aulast%3DBlunt%26aufirst%3DC.%2BE.%26aulast%3DTorcuk%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLewis%26aufirst%3DW.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DRoss%26aufirst%3DD.%26aulast%3DMoody%26aufirst%3DC.%2BJ.%26atitle%3DSynthesis%2520and%2520Intracellular%2520Redox%2520Cycling%2520of%2520Natural%2520Quinones%2520and%2520Their%2520Analogues%2520and%2520Identification%2520of%2520Indoleamine-2%252C3-Dioxygenase%2520%2528Ido%2529%2520as%2520Potential%2520Target%2520for%2520Anticancer%2520Activity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D8740%26epage%3D8745%26doi%3D10.1002%2Fanie.201503323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Palladium(Ii)-Catalyzed Reaction of Lawsones and Propargyl Carbonates: Construction of 2,3-Furanonaphthoquinones and Evaluation as Potential Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">8003</span>– <span class="NLM_lpage">8010</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.8b00872</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.8b00872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2htLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=8003-8010&author=X.+Fengauthor=X.+Qiuauthor=H.+Huangauthor=J.+Wangauthor=X.+Xuauthor=P.+Xuauthor=R.+Geauthor=X.+Liuauthor=Z.+Liauthor=J.+Bian&title=Palladium%28Ii%29-Catalyzed+Reaction+of+Lawsones+and+Propargyl+Carbonates%3A+Construction+of+2%2C3-Furanonaphthoquinones+and+Evaluation+as+Potential+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Facs.joc.8b00872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium(II)-Catalyzed Reaction of Lawsones and Propargyl Carbonates: Construction of 2,3-Furanonaphthoquinones and Evaluation as Potential Indoleamine 2,3-Dioxygenase Inhibitors</span></div><div class="casAuthors">Feng, Xi; Qiu, Xiaqiu; Huang, Huidan; Wang, Jubo; Xu, Xi; Xu, Pengfei; Ge, Ruijia; Liu, Xiaojin; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8003-8010</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient reaction utilizing propargyl carbonates through Claisen rearrangement to synthesize furanonaphthoquinones is described.  The remarkable transformation exhibits excellent functional group tolerance, affording the target furanonaphthoquinones in moderate to good yields (41-85%) under mild reaction conditions.  Scaled-up prepn. of the model product can make this reaction a method of choice for synthesis of furanonaphthoquinone derivs.  The resulting furanonaphthoquinones were evaluated as potential indoleamine 2,3-dioxygenase inhibitors in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFjeaVS8zI-bVg90H21EOLACvtfcHk0ljn_I8cu3Fzyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2htLbM&md5=917981a8d83eca26013e27748377ce92</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.8b00872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.8b00872%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DGe%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DPalladium%2528Ii%2529-Catalyzed%2520Reaction%2520of%2520Lawsones%2520and%2520Propargyl%2520Carbonates%253A%2520Construction%2520of%25202%252C3-Furanonaphthoquinones%2520and%2520Evaluation%2520as%2520Potential%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2018%26volume%3D83%26spage%3D8003%26epage%3D8010%26doi%3D10.1021%2Facs.joc.8b00872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Z.</span></span> <span> </span><span class="NLM_article-title">Ethylnaphthoquinone Derivatives as Inhibitors of Indoleamine-2, 3-Dioxygenase from the Mangrove Endophytic Fungus Neofusicoccum Austral Sysu-Sks024</span>. <i>Fitoterapia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.fitote.2018.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.fitote.2018.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29374570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1OjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=281-285&author=H.+Cuiauthor=H.+Zhangauthor=Y.+Liuauthor=Q.+Guauthor=J.+Xuauthor=X.+Huangauthor=Z.+She&title=Ethylnaphthoquinone+Derivatives+as+Inhibitors+of+Indoleamine-2%2C+3-Dioxygenase+from+the+Mangrove+Endophytic+Fungus+Neofusicoccum+Austral+Sysu-Sks024&doi=10.1016%2Fj.fitote.2018.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Ethylnaphthoquinone derivatives as inhibitors of indoleamine-2, 3-dioxygenase from the mangrove endophytic fungus Neofusicoccum austral SYSU-SKS024</span></div><div class="casAuthors">Cui, Hui; Zhang, Hongao; Liu, Yena; Gu, Qiong; Xu, Jun; Huang, Xishan; She, Zhigang</div><div class="citationInfo"><span class="NLM_cas:title">Fitoterapia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">281-285</span>CODEN:
                <span class="NLM_cas:coden">FTRPAE</span>;
        ISSN:<span class="NLM_cas:issn">0367-326X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bioassay-guided fractionation of the dichloromethane ext. of the fungus Neofusicoccum austral SYSU-SKS024 led to the isolation of three new ethylnaphthoquinone derivs., neofusnaphthoquinone A (1), 6-(1-methoxylethy1)-2,7-dimethoxyjuglone (2), (3R,4R)-3-methoxyl-botryosphaerone D (6), together with six known analogs (3-5 and 7-9).  Their structures were elucidated by spectroscopic anal. and single crystal X-ray diffraction anal.  Neofusnaphthoquinone A (1) is the third example of the unsym. naphthoquinone dimer, which is rarely found in natural source.  All of the isolates were evaluated for their indoleamine 2, 3-dioxygenase (IDO) inhibitory activity, compds. 1-6 showed in vitro inhibitory effects against IDO with IC50 values ranging from 0.11 to 10.92μM.  This is the first time naphthoquinone dimer (1), as a novel carbon skeleton possessing IDO inhibitory activity, was reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi-7OmjasLn7Vg90H21EOLACvtfcHk0ljn_I8cu3Fzyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1OjtLc%253D&md5=eda25bdbd6df09621bc9c308c19ff546</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.fitote.2018.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fitote.2018.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DShe%26aufirst%3DZ.%26atitle%3DEthylnaphthoquinone%2520Derivatives%2520as%2520Inhibitors%2520of%2520Indoleamine-2%252C%25203-Dioxygenase%2520from%2520the%2520Mangrove%2520Endophytic%2520Fungus%2520Neofusicoccum%2520Austral%2520Sysu-Sks024%26jtitle%3DFitoterapia%26date%3D2018%26volume%3D125%26spage%3D281%26epage%3D285%26doi%3D10.1016%2Fj.fitote.2018.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Structure-Activity Relationship Study of Novel Naphthoindolizine and Indolizinoquinoline-5,12-Dione Derivatives as Ido1 Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4886</span>– <span class="NLM_lpage">4897</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30170925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Sms7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4886-4897&author=R.+Yangauthor=Y.+Chenauthor=L.+Panauthor=Y.+Yangauthor=Q.+Zhengauthor=Y.+Huauthor=Y.+Wangauthor=L.+Zhangauthor=Y.+Sunauthor=Z.+Liauthor=X.+Meng&title=Design%2C+Synthesis+and+Structure-Activity+Relationship+Study+of+Novel+Naphthoindolizine+and+Indolizinoquinoline-5%2C12-Dione+Derivatives+as+Ido1+Inhibitors&doi=10.1016%2Fj.bmc.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors</span></div><div class="casAuthors">Yang, Rui; Chen, Yu; Pan, Liangkun; Yang, Yanyan; Zheng, Qiang; Hu, Yue; Wang, Yuxi; Zhang, Liangren; Sun, Yang; Li, Zhongjun; Meng, Xiangbao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4886-4897</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is regarded as a promising target for cancer immunotherapy.  Many naphthoquinone derivs. have been reported as IDO1 inhibitors so far.  Herein, two series of naphthoquinone derivs., naphthoindolizine and indolizinoquinoline-5,12-dione derivs., were synthesized and evaluated for their IDO1 inhibitory activity.  Most of the target compds. showed significant inhibition potency and high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO).  The structure-activity relationship was also summarized.  The most potent compds. 5c (IC50 23 nM, IDO1 enzyme), and 5b' (IC50 372 nM, HeLa cell) were identified as promising lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiy6xMGTYZybVg90H21EOLACvtfcHk0ljn_I8cu3Fzyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Sms7%252FI&md5=73c272593ea85fa0ee85a56a5ba9ad69</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DX.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Structure-Activity%2520Relationship%2520Study%2520of%2520Novel%2520Naphthoindolizine%2520and%2520Indolizinoquinoline-5%252C12-Dione%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4886%26epage%3D4897%26doi%3D10.1016%2Fj.bmc.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Novel Naphthoquinone Derivatives as Ido1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2018.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30103191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=423-436&author=L.+Panauthor=Q.+Zhengauthor=Y.+Chenauthor=R.+Yangauthor=Y.+Yangauthor=Z.+Liauthor=X.+Meng&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Novel+Naphthoquinone+Derivatives+as+Ido1+Inhibitors&doi=10.1016%2Fj.ejmech.2018.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors</span></div><div class="casAuthors">Pan, Liangkun; Zheng, Qiang; Chen, Yu; Yang, Rui; Yang, Yanyan; Li, Zhongjun; Meng, Xiangbao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">423-436</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 mediated kynurenine pathway of tryptophan degrdn. is identified as an appealing and novel target in immunotherapy for the treatment of cancer.  In this study, a novel series of naphthoquinone derivs. were synthesized, characterized and evaluated for their inhibitory activities against IDO1, and their structure-activity relationship was investigated.  Among them, five compds., e.g., I,displayed potent IDO1 inhibitory activities with IC50 values ranging between 18 and 61 nM, which are more potent than INCB024360 undergoing clin. trial III evaluation.  In addn., three compds., e.g. II, decreased the kynurenine levels in rat plasma by 30%-50%.  Compds. exhibiting excellent IDO1 inhibitory activities were also evaluated for their inhibitory activities against tryptophan 2,3-dioxygenase (TDO).  Of which, compd. II (IDO1 IC50 = 120 nM) showed promising TDO inhibition (IC50 72 nM) and was identified as an IDO1/TDO dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqrRqE4fWgpLVg90H21EOLACvtfcHk0lgvusg_6V5sLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb7K&md5=187b1c8a9111efa0d7a25955b2d24bd8</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DX.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Naphthoquinone%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D423%26epage%3D436%26doi%3D10.1016%2Fj.ejmech.2018.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynisson, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (Tdo2) and Indoleamine 2,3-Dioxygenase 1 (Ido1) Using Virtual Screening</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4346</span>, <span class="refDoi"> DOI: 10.3390/molecules24234346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3390%2Fmolecules24234346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=4346&author=S.+Sariauthor=P.+Tomekauthor=E.+Leungauthor=J.+Reynisson&title=Discovery+and+Characterisation+of+Dual+Inhibitors+of+Tryptophan+2%2C3-Dioxygenase+%28Tdo2%29+and+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Using+Virtual+Screening&doi=10.3390%2Fmolecules24234346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterisation of dual inhibitors of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1) using virtual screening</span></div><div class="casAuthors">Sari, Suat; Tomek, Petr; Leung, Euphemia; Reynisson, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4346</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cancers express tryptophan catabolising enzymes indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) to produce immunosuppressive tryptophan metabolites that undermine patients' immune systems, leading to poor disease outcomes.  Both enzymes are validated targets for cancer immunotherapy but there is a paucity of potent TDO2 and dual IDO1/TDO2 inhibitors.  To identify novel dual IDO1/TDO2 scaffolds, 3D shape similarity and pharmacophore in silico screening was conducted using TDO2 as a model for both systems.  The obtained hits were tested in cancer cell lines expressing mainly IDO1 (SKOV3-ovarian), predominantly TDO2 (A172-brain), and both IDO1 and TDO2 (BT549-breast).  Three virtual screening hits were confirmed as inhibitors (TD12, TD18 and TD34).  Dose response expts. showed that TD34 is the most potent inhibitor capable of blocking both IDO1 and TDO2 activity, with the IC50 value for BT549 at 3.42μM.  This work identified new scaffolds able to inhibit both IDO1 and TDO2, thus enriching the collection of dual IDO1/TDO2 inhibitors and providing chem. matter for potential development into future anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXAKV3tf7YWbVg90H21EOLACvtfcHk0lgvusg_6V5sLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisrrP&md5=d9a36856de02bee3acbfb9b8fef465a8</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24234346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24234346%26sid%3Dliteratum%253Aachs%26aulast%3DSari%26aufirst%3DS.%26aulast%3DTomek%26aufirst%3DP.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DReynisson%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520Characterisation%2520of%2520Dual%2520Inhibitors%2520of%2520Tryptophan%25202%252C3-Dioxygenase%2520%2528Tdo2%2529%2520and%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Using%2520Virtual%2520Screening%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D4346%26doi%3D10.3390%2Fmolecules24234346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-Dioxygenase and Signal Transducer and Activator of Transcription 3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1563</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01386</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01386" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1544-1563&author=R.+Huangauthor=X.+Jingauthor=X.+Huangauthor=Y.+Panauthor=Y.+Fangauthor=G.+Liangauthor=Z.+Liaoauthor=H.+Wangauthor=Z.+Chenauthor=Y.+Zhang&title=Bifunctional+Naphthoquinone+Aromatic+Amide-Oxime+Derivatives+Exert+Combined+Immunotherapeutic+and+Antitumor+Effects+through+Simultaneous+Targeting+of+Indoleamine-2%2C3-Dioxygenase+and+Signal+Transducer+and+Activator+of+Transcription+3&doi=10.1021%2Facs.jmedchem.9b01386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3</span></div><div class="casAuthors">Huang, Rizhen; Jing, Xiaoteng; Huang, Xiaochao; Pan, Yingming; Fang, Yilin; Liang, Guibin; Liao, Zhixin; Wang, Hengshan; Chen, Zhenfeng; Zhang, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1544-1563</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase 1 (IDO1) and signal transducer and activator of transcription 3 (STAT3) are important targets in the tumor microenvironment for cancer therapy.  In the present study, a set of naphthoquinone arom. amide-oxime derivs. were designed, which stimulated the immune response via IDO1 inhibition and simultaneously displayed powerful antitumor activity against three selected cancer cell lines through suppressing STAT3 signaling.  The representative compd. 8u bound effectively to IDO1, with greater inhibitory activity relative to the com. IDO1 inhibitor 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L) in addn. to the efficient suppression of nuclear translocation of STAT3.  Consistently, in vivo assays demonstrated a higher antiproliferative activity of compd. 8u in both wild-type B16-F10 isograft tumors and an athymic HepG2 xenograft model relative to 1-methyl-L-tryptophan (1-MT) and doxorubicin (DOX).  This bifunctional compd. with dual immunotherapeutic and anticancer efficacy may represent a new generation of highly efficacious drug candidates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojfGgot8_60bVg90H21EOLACvtfcHk0lgvusg_6V5sLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOhuro%253D&md5=6f9aca12e3810617ebb48416b98d6d27</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01386%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DBifunctional%2520Naphthoquinone%2520Aromatic%2520Amide-Oxime%2520Derivatives%2520Exert%2520Combined%2520Immunotherapeutic%2520and%2520Antitumor%2520Effects%2520through%2520Simultaneous%2520Targeting%2520of%2520Indoleamine-2%252C3-Dioxygenase%2520and%2520Signal%2520Transducer%2520and%2520Activator%2520of%2520Transcription%25203%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1544%26epage%3D1563%26doi%3D10.1021%2Facs.jmedchem.9b01386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Rational Design, Synthesis and Biological Evaluation of Ubiquinone Derivatives as Ido1 Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">102870</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.03.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bioorg.2019.03.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31103493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFOmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2019&pages=102870&author=Y.+Dingauthor=F.+Tangauthor=X.+Xueauthor=J.+Luoauthor=M.+Hussainauthor=Y.+Huangauthor=Z.+Wangauthor=H.+Jiangauthor=Z.+Tuauthor=J.+Zhang&title=Rational+Design%2C+Synthesis+and+Biological+Evaluation+of+Ubiquinone+Derivatives+as+Ido1+Inhibitors&doi=10.1016%2Fj.bioorg.2019.03.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design, synthesis and biological evaluation of ubiquinone derivatives as IDO1 inhibitors</span></div><div class="casAuthors">Ding, Yuyang; Tang, Fei; Xue, Xiaoqian; Luo, Jinfeng; Hussain, Muzammal; Huang, Yanhui; Wang, Zhen; Jiang, Hao; Tu, Zhengchao; Zhang, Jiancun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102870</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive therapeutic target for the treatment of cancer, chronic viral infections and neurol. disorders characterized by pathol. immune stimulation.  Herein, a series of known metal-chelating ubiquinone derivs. were designed, synthesized and evaluated for the IDO1 inhibiting activities.  The docking studies showed that the compds. I (R = Me or H, R1 = Ph, 3-MeC6H5, 3-OMeC6H5, etc.) and coenzyme-Q1 exhibited different binding modes to IDO1 protein.  Among these compds., the most active compd. is I (R = H, R1 = 3-BrC6H5) with an IC50 of 0.13 μM in enzymic assay.  The results reveal that a possible halogen bonding interaction between the bromine atom (3-Br) and Cys129 significantly enhances the inhibition activity against IDO1.  This study provides structural insights of the interactions between ubiquinone analogs and IDO1 protein for the further modification and optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorY1xHNqYrVrVg90H21EOLACvtfcHk0lj8DFHrbz6nlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFOmsr4%253D&md5=4d75242a48cb7e1e2a673f08e3584cb3</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.03.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.03.044%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DRational%2520Design%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Ubiquinone%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D89%26spage%3D102870%26doi%3D10.1016%2Fj.bioorg.2019.03.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(Pyridin-3-Yl)-1h-Indole-4,7-Diones as Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">126901</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2019.126901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31882299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyrurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=126901&author=K.+M.+Kongauthor=J.+W.+Zhangauthor=B.+Z.+Liuauthor=G.+R.+Mengauthor=Q.+Zhang&title=Discovery+of+5-%28Pyridin-3-Yl%29-1h-Indole-4%2C7-Diones+as+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.bmcl.2019.126901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Kong, Kai-min; Zhang, Jia-wei; Liu, Bing-zhi; Meng, Guang-rong; Zhang, Qian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">126901</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Early studies demonstrated that over expression of indoleamine 2,3-dioxygenase (IDO1) in tumor microenvironment results in tumor immune escape.  Herein, to simplify the structure of two kinds of IDO1 inhibitors from marine alkaloid, Exiguamine A and Tsitsikammamines, the authors designed, synthesized a series of 1H-indole-4,7-dione derivs. and evaluated their inhibitory activity in IDO1 enzyme and in IFN-γ stimulated Hela cells in vitro.  The structure-activity relation demonstrated that 5-(pyridin-3-yl)-1H-indole-4,7-dione is a promising scaffold for IDO1 inhibitors and most compds. with this core showed moderate inhibition potency at micromole level.  The authors' further enzyme kinetics expts. reveal that these new developed compds. might act as reversible competitive inhibitors of IDO1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqilX4m8KKO1rVg90H21EOLACvtfcHk0lj8DFHrbz6nlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyrurrF&md5=cf2231f64e236e69a669772bbfaca292</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126901%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DK.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DLiu%26aufirst%3DB.%2BZ.%26aulast%3DMeng%26aufirst%3DG.%2BR.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%25205-%2528Pyridin-3-Yl%2529-1h-Indole-4%252C7-Diones%2520as%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D126901%26doi%3D10.1016%2Fj.bmcl.2019.126901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (Pains) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28Pains%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lj8DFHrbz6nlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528Pains%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (Llc) Tumor-Bearing Mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8321</span>– <span class="NLM_lpage">8331</span>, <span class="refDoi"> DOI: 10.1021/jm401195n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401195n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8321-8331&author=S.+Yangauthor=X.+Liauthor=F.+Huauthor=Y.+Liauthor=Y.+Yangauthor=J.+Yanauthor=C.+Kuangauthor=Q.+Yang&title=Discovery+of+Tryptanthrin+Derivatives+as+Potent+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+with+Therapeutic+Activity+in+Lewis+Lung+Cancer+%28Llc%29+Tumor-Bearing+Mice&doi=10.1021%2Fjm401195n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice</span></div><div class="casAuthors">Yang, Shuangshuang; Li, Xishuai; Hu, Fangfang; Li, Yinlong; Yang, Yunyun; Yan, Junkai; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8321-8331</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO-1) is emerging as an important new therapeutic target for the treatment of cancer, neurol. disorders, and other diseases that are characterized by pathol. tryptophan metab.  However, only a few structural classes are known to be IDO-1 inhibitors.  In this study, a natural compd. tryptanthrin was discovered to be a novel potent IDO-1 inhibitor by screening of indole-based structures.  Three series of 13 tryptanthrin derivs. were synthesized, and the structure-activity anal. was undertaken.  The optimization led to the identification of 5c, which exhibited the inhibitory activity at a nanomolar level.  In vitro 5c dramatically augmented the proliferation of T cells.  When administered to Lewis lung cancer (LLC) tumor-bearing mice, 5c significantly inhibited IDO-1 activity and suppressed tumor growth.  In addn., 5c reduced the nos. of Foxp3+ regulatory T cells (Tregs), which are known to prevent the development of efficient antitumor immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5ioPL3rWy1bVg90H21EOLACvtfcHk0lg52KcC2JgPHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrjL&md5=ac744f81ce97b0435f2bfd240e1393a1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm401195n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401195n%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520Tryptanthrin%2520Derivatives%2520as%2520Potent%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520with%2520Therapeutic%2520Activity%2520in%2520Lewis%2520Lung%2520Cancer%2520%2528Llc%2529%2520Tumor-Bearing%2520Mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8321%26epage%3D8331%26doi%3D10.1021%2Fjm401195n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Tryptophan 2,3-Dioxygenase Inhibitory Activities of Tryptanthrin Derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2018.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30321802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeqtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2018&pages=133-145&author=S.+Zhangauthor=F.+Qiauthor=X.+Fangauthor=D.+Yangauthor=H.+Huauthor=Q.+Huangauthor=C.+Kuangauthor=Q.+Yang&title=Tryptophan+2%2C3-Dioxygenase+Inhibitory+Activities+of+Tryptanthrin+Derivatives&doi=10.1016%2Fj.ejmech.2018.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives</span></div><div class="casAuthors">Zhang, Shengnan; Qi, Fangfei; Fang, Xin; Yang, Dan; Hu, Hairong; Huang, Qiang; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-145</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tryptophan 2,3-dioxygenase (TDO) is becoming a promising therapeutic target due to its involvement in cancer and neurodegenerative diseases.  Development of efficient TDO inhibitors is a prime strategy in disease treatment.  However, the lack of a TDO inhibitor bioassay system slows the progress of TDO inhibitor research.  Herein, an active recombinant human TDO (hTDO) was prepd. under optimal expression conditions, an enzymic assay was optimized, and two cellular assays of TDO activity were developed.  Then, the potential TDO inhibitory activities of nine tryptanthrin derivs. were evaluated, and the inhibitory consts. (Ki), enzymic and cellular half maximal inhibitory concns. (IC50) were measured, and the type of inhibition was detd.  The tryptanthrins had various levels of TDO inhibitory activities; tryptanthrins with a substituent at 8-position had stronger inhibitory activities than the other derivs.  Moreover, most of the compds., except two, exhibited better inhibitory activities than the previously reported TDO inhibitor LM10.  Furthermore, the mol. docking study of compds. 8-fluoro-indolo[2,1-b]quinazoline-6,12-dione (5c) and 8-bromo-indolo[2,1-b]quinazoline-6,12-dione (5d) revealed that the O atom of the tryptanthrin ring is directed toward the heme iron (Fe) of hTDO via strong coordination interactions.  These findings suggest that tryptanthrin and its derivs. have the potential to be developed as promising mols. for TDO-related target therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi_AhFhYrRY7Vg90H21EOLACvtfcHk0lg52KcC2JgPHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeqtrbI&md5=f2e6d9afb4c1c276e22353b1aa487650</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DF.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DTryptophan%25202%252C3-Dioxygenase%2520Inhibitory%2520Activities%2520of%2520Tryptanthrin%2520Derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D160%26spage%3D133%26epage%3D145%26doi%3D10.1016%2Fj.ejmech.2018.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9161</span>– <span class="NLM_lpage">9174</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2hs73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9161-9174&author=D.+Yangauthor=S.+Zhangauthor=X.+Fangauthor=L.+Guoauthor=N.+Huauthor=Z.+Guoauthor=X.+Liauthor=S.+Yangauthor=J.+C.+Heauthor=C.+Kuangauthor=Q.+Yang&title=N-Benzyl%2FAryl+Substituted+Tryptanthrin+as+Dual+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+and+Tryptophan+2%2C3-Dioxygenase&doi=10.1021%2Facs.jmedchem.9b01079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase</span></div><div class="casAuthors">Yang, Dan; Zhang, Shengnan; Fang, Xin; Guo, Leilei; Hu, Nan; Guo, Zhanling; Li, Xishuai; Yang, Shuangshuang; He, Jin Chao; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9161-9174</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), which catalyzes the initial and rate-limiting step of the kynurenine pathway of tryptophan catabolism, has emerged as a key target in cancer immunotherapy because of its role in enabling cancers to evade the immune system.  Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase 2 (IDO2) catalyze the same reaction and play a potential role in cancer immunotherapy.  Starting from our previously discovered tryptanthrin IDO1 inhibitor scaffold, we synthesized novel N-benzyl/aryl substituted tryptanthrin derivs. and evaluated their inhibitory efficacy on IDO1, TDO, and IDO2.  Most compds. showed similar high inhibitory activities on both IDO1 and TDO, which were significantly superior over that of IDO2 with magnitude difference.  We showed that N-benzyl/aryl substituted tryptanthrin directly interacted with IDO1, TDO, and IDO2, significantly augmented the proliferation of T cells in vitro, blocked the kynurenine pathway, and suppressed tumor growth when administered to LLC and H22 tumor-bearing mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwPF5CT--OU7Vg90H21EOLACvtfcHk0lg52KcC2JgPHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2hs73I&md5=7fcad745663f2efbdaf868637f6964ef</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01079%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DJ.%2BC.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DN-Benzyl%252FAryl%2520Substituted%2520Tryptanthrin%2520as%2520Dual%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520and%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9161%26epage%3D9174%26doi%3D10.1021%2Facs.jmedchem.9b01079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Novel Tryptanthrin Derivatives as Dual Inhibitors of Indoleamine 2,3-Dioxygenase 1 and Tryptophan 2,3-Dioxygenase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127159</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2020.127159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32247733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsVSnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127159&author=Y.+Liauthor=S.+Zhangauthor=R.+Wangauthor=M.+Cuiauthor=W.+Liuauthor=Q.+Yangauthor=C.+Kuang&title=Synthesis+of+Novel+Tryptanthrin+Derivatives+as+Dual+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+1+and+Tryptophan+2%2C3-Dioxygenase&doi=10.1016%2Fj.bmcl.2020.127159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Li, Yuanyuan; Zhang, Shengnan; Wang, Rong; Cui, Menghan; Liu, Wei; Yang, Qing; Kuang, Chunxiang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">127159</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are promising drug development targets due to their implications in pathologies such as cancer and neurodegenerative diseases.  The search for IDO1 inhibitor has been intensely pursued but there is a paucity of potent TDO and IDO1/TDO dual inhibitors.  Natural product tryptanthrin (indolo[2,1-b]quinazoline-6,12-dione) has been confirmed to bear IDO1 and/or TDO inhibitory activities.  Herein, twelve novel tryptanthrin derivs. were synthesized and evaluated for the IDO1 and TDO inhibitory potency.  All of the compds. were found to be IDO1/TDO dual inhibitors, in particular, compd. I [R = (E)-CH:CHCO2Et, (E)-CH:CHCO2H] bore IDO1 inhibitory activity similar to that of INCB024360; and compd. I [R = CHO, (E)-CH:CHCO2H] had remarkable TDO inhibitory activity superior to that of the well-known TDO inhibitor LM10.  This work enriches the collection of IDO1/TDO dual inhibitors and provides chem. mols. for potential development into drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr72pRgZNipK7Vg90H21EOLACvtfcHk0lgXNBcjGuFJag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsVSnsLg%253D&md5=932367577fc72cb9c63c9046cf07e162</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127159%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DKuang%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520Novel%2520Tryptanthrin%2520Derivatives%2520as%2520Dual%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520and%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127159%26doi%3D10.1016%2Fj.bmcl.2020.127159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Indoleamine 2,3-Dioxygenase 1 (Ido-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1059</span>, <span class="refDoi"> DOI: 10.3390/molecules24061059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3390%2Fmolecules24061059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt1Ciur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1059&author=H.+Zhaoauthor=P.+Sunauthor=W.+Guoauthor=Y.+Wangauthor=A.+Zhangauthor=L.+Mengauthor=C.+Ding&title=Discovery+of+Indoleamine+2%2C3-Dioxygenase+1+%28Ido-1%29+Inhibitors+Based+on+Ortho-Naphthaquinone-Containing+Natural+Product&doi=10.3390%2Fmolecules24061059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitors based on ortho-naphthaquinone-containing natural product</span></div><div class="casAuthors">Zhao, Hongchuan; Sun, Pu; Guo, Wei; Wang, Yi; Zhang, Ao; Meng, Linghua; Ding, Chunyong</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1059</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">There is great interest in developing small mols. agents capable of reversing tumor immune escape to restore the body's immune system.  As an immunosuppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO-1) is considered a promising target for oncol. immunotherapy.  Currently, none of IDO-1 inhibitors have been launched for clin. practice yet.  Thus, the discovery of new IDO-1 inhibitors is still in great demand.  Herein, a series of diverse ortho-naphthaquinone contg. natural product derivs. were synthesized as novel IDO-1 inhibitors.  Among them, 1-ene-3-ketone-17-hydroxyl deriv. 12 exhibited significantly improved enzymic and cellular inhibitory activity against IDO-1 when compared to initial lead compds.  Besides, the mol. docking study disclosed that the two most potent compds. 11 and 12 have more interactions within the binding pocket of IDO-1 via hydrogen-bonding, which may account for their higher IDO-1 inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmIgRATQv9VbVg90H21EOLACvtfcHk0lgXNBcjGuFJag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt1Ciur0%253D&md5=cc39f2a1a24a175b94777a94eaa7931a</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24061059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24061059%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido-1%2529%2520Inhibitors%2520Based%2520on%2520Ortho-Naphthaquinone-Containing%2520Natural%2520Product%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D1059%26doi%3D10.3390%2Fmolecules24061059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Indoleamine 2,3-Dioxygenase Inhibitors Using Machine Learning Based Virtual Screening</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">945</span>, <span class="refDoi"> DOI: 10.1039/C7MD00642J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1039%2FC7MD00642J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30108982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs1agu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=937-945&author=H.+Zhangauthor=W.+Liuauthor=Z.+Liuauthor=Y.+Juauthor=M.+Xuauthor=Y.+Zhangauthor=X.+Wuauthor=Q.+Guauthor=Z.+Wangauthor=J.+Xu&title=Discovery+of+Indoleamine+2%2C3-Dioxygenase+Inhibitors+Using+Machine+Learning+Based+Virtual+Screening&doi=10.1039%2FC7MD00642J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening</span></div><div class="casAuthors">Zhang, Hongao; Liu, Wei; Liu, Zhihong; Ju, Yingchen; Xu, Mengyang; Zhang, Yue; Wu, Xinyu; Gu, Qiong; Wang, Zhong; Xu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">937-945</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO), an immune checkpoint, is a promising target for cancer immunotherapy.  However, current IDO inhibitors are not approved for clin. use yet; therefore, new IDO inhibitors are still demanded.  To identify new IDO inhibitors, we have built naive Bayesian (NB) and recursive partitioning (RP) models from a library of known IDO inhibitors derived from recent publications.  Thirteen mol. fingerprints were used as descriptors for the models to predict IDO inhibitors.  An inhouse compd. library was virtually screened using the best machine learning model, which resulted in 50 hits for further enzyme-based IDO inhibitory assays.  Consequently, we identified three new IDO inhibitors with IC50 values of 1.30, 4.10, and 4.68μM.  These active compds. also showed IDO inhibitory activities in cell-based assays.  The compds. belong to the tanshinone family, a typical scaffold family derived from Danshen (a Chinese herb), the dried root of Salvia miltiorrhiza, which has been widely used in China, Japan, the United States, and other European countries for the treatment of cardiovascular and cerebrovascular diseases.  Thus, we discovered a new use for Danshen using machine learning methods.  Surface plasmon resonance (SPR) expts. proved that the inhibitors interacted with the IDO target.  Mol. dynamic simulations demonstrated the binding modes of the IDO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_WCHHO2IbKbVg90H21EOLACvtfcHk0lgXNBcjGuFJag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs1agu7c%253D&md5=af135cb041c03568ff0cb2d5f45938ff</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1039%2FC7MD00642J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00642J%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%2520Using%2520Machine%2520Learning%2520Based%2520Virtual%2520Screening%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26spage%3D937%26epage%3D945%26doi%3D10.1039%2FC7MD00642J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibitory Effects of Flavonoids Isolated from Sophora Flavescens on Indoleamine 2,3-Dioxygenase 1 Activity</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1488</span>, <span class="refDoi"> DOI: 10.1080/14756366.2019.1640218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1080%2F14756366.2019.1640218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31423846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2lsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=1481-1488&author=M.+Kwonauthor=S.+K.+Koauthor=M.+Jangauthor=G.+H.+Kimauthor=I.+J.+Ryooauthor=S.+Sonauthor=H.+W.+Ryuauthor=S.+R.+Ohauthor=W.+K.+Leeauthor=B.+Y.+Kimauthor=J.+H.+Jangauthor=J.+S.+Ahn&title=Inhibitory+Effects+of+Flavonoids+Isolated+from+Sophora+Flavescens+on+Indoleamine+2%2C3-Dioxygenase+1+Activity&doi=10.1080%2F14756366.2019.1640218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity</span></div><div class="casAuthors">Kwon, Mincheol; Ko, Sung-Kyun; Jang, Mina; Kim, Gun-Hee; Ryoo, In-Ja; Son, Sangkeun; Ryu, Hyung Won; Oh, Sei-Ryang; Lee, Won-Kyu; Kim, Bo Yeon; Jang, Jae-Hyuk; Ahn, Jong Seog</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1481-1488</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), a tryptophan catabolising enzyme, is known as a tumor cell survival factor that causes immune escape in several types of cancer.  Flavonoids of Sophora flavescens have a variety of biol. benefits for humans; however, cancer immunotherapy effect has not been fully investigated.  The flavonoids (1-6) isolated from S. flavescens showed IDO1 inhibitory activities (IC50 4.331.4 μM).  The representative flavonoids () of S. flavescens were detd. to be non-competitive inhibitors of IDO1 by kinetic analyses.  Their binding affinity to IDO1 was confirmed using thermal stability and surface plasmon resonance (SPR) assays.  The mol. docking anal. and mutagenesis assay revealed the structural details of the interactions between the flavonoids (1-6) and IDO1.  These results suggest that the flavonoids (1-6) of S. flavescens, esp. kushenol E, as IDO1 inhibitors might be useful in the development of immunotherapeutic agents against cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-WokkU-v1NLVg90H21EOLACvtfcHk0lhMUv5wAUgJwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2lsLvP&md5=767bc8d281dce0784953c65501314640</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1080%2F14756366.2019.1640218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2019.1640218%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DS.%2BK.%26aulast%3DJang%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DG.%2BH.%26aulast%3DRyoo%26aufirst%3DI.%2BJ.%26aulast%3DSon%26aufirst%3DS.%26aulast%3DRyu%26aufirst%3DH.%2BW.%26aulast%3DOh%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DB.%2BY.%26aulast%3DJang%26aufirst%3DJ.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26atitle%3DInhibitory%2520Effects%2520of%2520Flavonoids%2520Isolated%2520from%2520Sophora%2520Flavescens%2520on%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Activity%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26spage%3D1481%26epage%3D1488%26doi%3D10.1080%2F14756366.2019.1640218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiokawa, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashiwabara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshidome, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2689</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcmdc.201600446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27863031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyrt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2682-2689&author=Z.+Shiokawaauthor=E.+Kashiwabaraauthor=D.+Yoshidomeauthor=K.+Fukaseauthor=S.+Inukiauthor=Y.+Fujimoto&title=Discovery+of+a+Novel+Scaffold+as+an+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitor+Based+on+the+Pyrrolopiperazinone+Alkaloid%2C+Longamide+B&doi=10.1002%2Fcmdc.201600446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B</span></div><div class="casAuthors">Shiokawa, Zenyu; Kashiwabara, Emi; Yoshidome, Daisuke; Fukase, Koichi; Inuki, Shinsuke; Fujimoto, Yukari</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2682-2689</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) has emerged as a key target for cancer therapy, as IDO1 plays a crit. role in the capacity of tumor cells to evade the immune system.  The pyrrolopiperazinone alkaloid longamide B and its derivs. were identified as novel IDO1 inhibitors based on docking studies and small library synthesis.  The thioamide deriv. showed higher IDO1 inhibitory activity than longamide B, and displayed an activity similar to that of a representative IDO1 inhibitor, 1-methyl-tryptophan.  These results suggest that the pyrrolopiperazinone scaffold of longamide B could be used in the development of IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQaejiaLxbbVg90H21EOLACvtfcHk0lhMUv5wAUgJwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyrt7bN&md5=f54d663976681b300b12efb19ed60296</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600446%26sid%3Dliteratum%253Aachs%26aulast%3DShiokawa%26aufirst%3DZ.%26aulast%3DKashiwabara%26aufirst%3DE.%26aulast%3DYoshidome%26aufirst%3DD.%26aulast%3DFukase%26aufirst%3DK.%26aulast%3DInuki%26aufirst%3DS.%26aulast%3DFujimoto%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Scaffold%2520as%2520an%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitor%2520Based%2520on%2520the%2520Pyrrolopiperazinone%2520Alkaloid%252C%2520Longamide%2520B%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2682%26epage%3D2689%26doi%3D10.1002%2Fcmdc.201600446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 through Structure-Based Virtual Screening</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">277</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffphar.2018.00277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29651242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCgt77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=277&author=G.+Zhangauthor=J.+Xingauthor=Y.+Wangauthor=L.+Wangauthor=Y.+Yeauthor=D.+Luauthor=J.+Zhaoauthor=X.+Luoauthor=M.+Zhengauthor=S.+Yan&title=Discovery+of+Novel+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+1+through+Structure-Based+Virtual+Screening&doi=10.3389%2Ffphar.2018.00277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel inhibitors of indoleamine 2,3-dioxygenase 1 through structure-based virtual screening</span></div><div class="casAuthors">Zhang, Guoqing; Xing, Jing; Wang, Yulan; Wang, Lihao; Ye, Yan; Lu, Dong; Zhao, Jihui; Luo, Xiaomin; Zheng, Mingyue; Yan, Shiying</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277/1-277/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an intracellular monomeric heme-contg. enzyme that catalyzes the first and the rate limiting step in catabolism of tryptophan via the kynurenine (KYN) pathway, which plays a significant role in the proliferation and differentiation of T cells.  IDO1 has been proven to be an attractive target for anticancer therapy and chronic viral infections.  In the present study, a class of IDO1 inhibitors with novel scaffolds were identified by virtual screening and biochem. validation, in which the compd. DC-I028 shows moderate IDO1 inhibitory activity with an IC50 of 21.61 μM on enzymic level and 89.11 μM on HeLa cell.  In the following hit expansion stage, DC-I02806, an analog of DC-I028, showed better inhibitory activity with IC50 about 18 μM on both enzymic level and cellular level.  The structure-activity relationship (SAR) of DC-I028 and its analogs was then discussed based on the mol. docking result.  The novel IDO1 inhibitors of DC-I028 and its analogs may provide useful clues for IDO1 inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj6yRzlve-R7Vg90H21EOLACvtfcHk0lg-QTPU2lTq-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCgt77M&md5=e93407a44446fcbadc489025b32d753d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00277%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Novel%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520through%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D277%26doi%3D10.3389%2Ffphar.2018.00277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">A Highly Potent and Selective Inhibitor Roxyl-Wl Targeting Ido1 Promotes Immune Response against Melanoma</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1089</span>– <span class="NLM_lpage">1094</span>, <span class="refDoi"> DOI: 10.1080/14756366.2018.1471688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1080%2F14756366.2018.1471688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29932010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2gs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=1089-1094&author=G.+Xuauthor=T.+Wangauthor=Y.+Liauthor=Z.+Huangauthor=X.+Wangauthor=J.+Zhengauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=A+Highly+Potent+and+Selective+Inhibitor+Roxyl-Wl+Targeting+Ido1+Promotes+Immune+Response+against+Melanoma&doi=10.1080%2F14756366.2018.1471688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma</span></div><div class="casAuthors">Xu, Guangwei; Wang, Tianqi; Li, Yongtao; Huang, Zhi; Wang, Xin; Zheng, Jianyu; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1089-1094</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) activity links to immune escape of cancers.  Inhibition of IDO1 provides a new approach for cancer treatment.  Most clin. IDO1 drugs show marginal efficacy as single agents.  On basis of mol. docking and pharmacophore modeling, a novel inhibitor Roxyl-WL was discovered with a half maximal inhibitory concn. (IC50) value of 1 nM against IDO1 and 10-100-fold increased potent activity compared with IDO1 drugs in clin. trials.  Roxyl-WL displayed excellent kinase spectrum selectivity with no activity out of the 337 protein kinases.  In vitro, Roxyl-WL effectively augmented the proliferation of T cells and reduced the no. of regulatory T cell (Tregs).  When administered to melanoma (B16F10) tumor-bearing mice orally, Roxyl-WL significantly suppressed tumor growth and induced immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV16IiN4_-kbVg90H21EOLACvtfcHk0ljtDjt-2ArLog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2gs7fF&md5=279906de3dd40d98184828437a441146</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1080%2F14756366.2018.1471688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2018.1471688%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DA%2520Highly%2520Potent%2520and%2520Selective%2520Inhibitor%2520Roxyl-Wl%2520Targeting%2520Ido1%2520Promotes%2520Immune%2520Response%2520against%2520Melanoma%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2018%26volume%3D33%26spage%3D1089%26epage%3D1094%26doi%3D10.1080%2F14756366.2018.1471688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span> <span> </span><span class="NLM_article-title">Effective Virtual Screening Strategy toward Heme-Containing Proteins: Identification of Novel Ido1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">111750</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.111750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31610376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFOktbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2019&pages=111750&author=Y.+Zouauthor=Y.+Huauthor=S.+Geauthor=Y.+Zhengauthor=Y.+Liauthor=W.+Liuauthor=W.+Guoauthor=Y.+Zhangauthor=Q.+Xuauthor=Y.+Lai&title=Effective+Virtual+Screening+Strategy+toward+Heme-Containing+Proteins%3A+Identification+of+Novel+Ido1+Inhibitors&doi=10.1016%2Fj.ejmech.2019.111750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors</span></div><div class="casAuthors">Zou, Yi; Hu, Yue; Ge, Shushan; Zheng, Yingbo; Li, Yuezhen; Liu, Wen; Guo, Wenjie; Zhang, Yihua; Xu, Qiang; Lai, Yisheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111750</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Developing small mols. occupying the heme-binding site using computational approaches remains a challenging task because it is difficult to characterize heme-ligand interaction in heme-contg. protein.  Indoleamine 2,3-dioxygenase 1 (IDO1) is an intracellular heme-contg. dioxygenase which is assocd. with the immunosuppressive effects in cancer.  With IDO1 as an example, herein we report a combined virtual screening (VS) strategy including high-specificity heme-binding group (HmBG)-based pharmacophore screening and cascade mol. docking to identify novel IDO1 inhibitors.  A total of four hit compds. were obtained and showed proper binding with the heme iron coordinating site.  Further structural optimization led to a promising compd. S18-3, which exerted potent anti-tumor efficacy in BALB/c mice bearing established CT26 tumors by activating the host's immune system.  These results suggest that S18-3 merits further study to assess its potential for the intervention of cancer.  Furthermore, our study also unveils a novel in silico-based strategy for identifying potential regulators for hemeproteins within short timeframe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqljI0E5qDfmLVg90H21EOLACvtfcHk0ljtDjt-2ArLog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFOktbjE&md5=0c0a708efdbc56f7372d20224cef126c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111750%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLai%26aufirst%3DY.%26atitle%3DEffective%2520Virtual%2520Screening%2520Strategy%2520toward%2520Heme-Containing%2520Proteins%253A%2520Identification%2520of%2520Novel%2520Ido1%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D184%26spage%3D111750%26doi%3D10.1016%2Fj.ejmech.2019.111750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aprile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griglio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orecchini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (Ido1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3047</span>– <span class="NLM_lpage">3065</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01809</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01809" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFaitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3047-3065&author=M.+Serafiniauthor=E.+Torreauthor=S.+Aprileauthor=E.+D.+Grossoauthor=A.+Gesuauthor=A.+Griglioauthor=G.+Colomboauthor=C.+Travelliauthor=S.+Paiellaauthor=A.+Adamoauthor=E.+Orecchiniauthor=A.+Colettiauthor=M.+T.+Pallottaauthor=S.+Ugelauthor=A.+Massarottiauthor=T.+Piraliauthor=S.+Fallarini&title=Discovery+of+Highly+Potent+Benzimidazole+Derivatives+as+Indoleamine+2%2C3-Dioxygenase-1+%28Ido1%29+Inhibitors%3A+From+Structure-Based+Virtual+Screening+to+in+Vivo+Pharmacodynamic+Activity&doi=10.1021%2Facs.jmedchem.9b01809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity</span></div><div class="casAuthors">Serafini, Marta; Torre, Enza; Aprile, Silvio; Grosso, Erika Del; Gesu, Alessandro; Griglio, Alessia; Colombo, Giorgia; Travelli, Cristina; Paiella, Salvatore; Adamo, Annalisa; Orecchini, Elena; Coletti, Alice; Pallotta, Maria Teresa; Ugel, Stefano; Massarotti, Alberto; Pirali, Tracey; Fallarini, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3047-3065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, a successful medicinal chem. campaign that exploited virtual, biophys., and biol. investigations led to the identification of a novel class of IDO1 inhibitors based on a benzimidazole substructure.  This family of compds. is endowed with an extensive bonding network in the protein active site, including the interaction with pocket C, a region not commonly exploited by previously reported IDO1 inhibitors.  The tight packing of selected compds. within the enzyme contributes to the strong binding interaction with IDO1, to the inhibitory potency at the low nanomolar level in several tumoral settings, and to the selectivity toward IDO1 over TDO and CYPs.  Notably, a significant redn. of L-Kyn levels in plasma, together with a potent effect on abrogating immunosuppressive properties of MDSC-like cells isolated from patients affected by pancreatic ductal adenocarcinoma, was obsd., pointing to this class of mols. as a valuable template for boosting the antitumor immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfZttD9qaarVg90H21EOLACvtfcHk0ljtDjt-2ArLog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFaitbs%253D&md5=118293cb0e185b77b209568fa4c151a2</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01809%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DTorre%26aufirst%3DE.%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DGrosso%26aufirst%3DE.%2BD.%26aulast%3DGesu%26aufirst%3DA.%26aulast%3DGriglio%26aufirst%3DA.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DTravelli%26aufirst%3DC.%26aulast%3DPaiella%26aufirst%3DS.%26aulast%3DAdamo%26aufirst%3DA.%26aulast%3DOrecchini%26aufirst%3DE.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DUgel%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DFallarini%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Highly%2520Potent%2520Benzimidazole%2520Derivatives%2520as%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528Ido1%2529%2520Inhibitors%253A%2520From%2520Structure-Based%2520Virtual%2520Screening%2520to%2520in%2520Vivo%2520Pharmacodynamic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3047%26epage%3D3065%26doi%3D10.1021%2Facs.jmedchem.9b01809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Identification and Preliminary Structure-Activity Relationships of 1-Indanone Derivatives as Novel Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3780</span>– <span class="NLM_lpage">3791</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2017.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28526475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVyrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3780-3791&author=D.+Gaoauthor=Y.+Li&title=Identification+and+Preliminary+Structure-Activity+Relationships+of+1-Indanone+Derivatives+as+Novel+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.bmc.2017.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Gao, Dingding; Li, Yingxia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3780-3791</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a vital role in the catabolism of tryptophan along with the kynurenine pathway which is involved in many human diseases including cancer, Alzheimer's disease, etc.  In this study, compd. 1 bearing a 1-Indanone scaffold was identified as a novel IDO1 inhibitor by structure-based virtual screening, with moderate to good enzymic and cellular inhibitory activities.  Also, surface plasmon resonance anal. validated the direct interaction between compd. 1 and IDO1 protein.  The preliminary SAR was further explored and the binding mode with IDO1 protein was predicted by expt. along with mol. docking.  Subsequent ADME properties of these active compds. were analyzed in silico, and the results showed good pharmacokinetic efficiencies.  The authors believe this study contributes a lot to the structural diversity for the future development of highly potent IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpclm1X2v_C6LVg90H21EOLACvtfcHk0lhjlw_fH-Lpkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVyrs7o%253D&md5=e51fb2df493761d7681b8be5c4d9f219</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DIdentification%2520and%2520Preliminary%2520Structure-Activity%2520Relationships%2520of%25201-Indanone%2520Derivatives%2520as%2520Novel%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3780%26epage%3D3791%26doi%3D10.1016%2Fj.bmc.2017.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structure-Activity Relationships of Phenyl Benzenesulfonylhydrazides as Novel Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3403</span>– <span class="NLM_lpage">3406</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2014.05.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24939758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3403-3406&author=M.+F.+Chengauthor=M.+S.+Hungauthor=J.+S.+Songauthor=S.+Y.+Linauthor=F.+Y.+Liaoauthor=M.+H.+Wuauthor=W.+Hsiaoauthor=C.+L.+Hsiehauthor=J.+S.+Wuauthor=Y.+S.+Chaoauthor=C.+Shihauthor=S.+Y.+Wuauthor=S.+H.+Ueng&title=Discovery+and+Structure-Activity+Relationships+of+Phenyl+Benzenesulfonylhydrazides+as+Novel+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1016%2Fj.bmcl.2014.05.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Cheng, Ming-Fu; Hung, Ming-Shiu; Song, Jen-Shin; Lin, Shu-Yu; Liao, Fang-Yu; Wu, Mine-Hsine; Hsiao, Wenchi; Hsieh, Chia-Ling; Wu, Jian-Sung; Chao, Yu-Sheng; Shih, Chuan; Wu, Su-Ying; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3403-3406</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of Ph benzenesulfonylhydrazides has been identified as potent inhibitors of indoleamine 2,3-dioxygenase (IDO), and their structure-activity relationship was explored.  Coupling reactions between various benzenesulfonyl chlorides and phenylhydrazides were utilized to synthesize the sulfonylhydrazides bearing various substituents.  Compd. 3i exhibited 61 nM of IC50 in enzymic assay and 172 nM of EC50 in the HeLa cell.  The computational study of 3i suggested that the major interactions between 3i and IDO protein are the coordination of sulfone and heme iron, the hydrogen bonding and hydrophobic interactions between 3i and IDO.  This novel class of IDO inhibitor provides a new direction to discover effective anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCMHnPLf2u5LVg90H21EOLACvtfcHk0lhjlw_fH-Lpkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrM&md5=560f7daccbb56934079c186991fd1b52</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.084%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsiao%26aufirst%3DW.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DDiscovery%2520and%2520Structure-Activity%2520Relationships%2520of%2520Phenyl%2520Benzenesulfonylhydrazides%2520as%2520Novel%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3403%26epage%3D3406%26doi%3D10.1016%2Fj.bmcl.2014.05.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ltLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=419-430&author=S.+Y.+Linauthor=T.+K.+Yehauthor=C.+C.+Kuoauthor=J.+S.+Songauthor=M.+F.+Chengauthor=F.+Y.+Liaoauthor=M.+W.+Chaoauthor=H.+L.+Huangauthor=Y.+L.+Chenauthor=C.+Y.+Yangauthor=M.+H.+Wuauthor=C.+L.+Hsiehauthor=W.+Hsiaoauthor=Y.+H.+Pengauthor=J.+S.+Wuauthor=L.+M.+Linauthor=M.+Sunauthor=Y.+S.+Chaoauthor=C.+Shihauthor=S.+Y.+Wuauthor=S.+L.+Panauthor=M.+S.+Hungauthor=S.+H.+Ueng&title=Phenyl+Benzenesulfonylhydrazides+Exhibit+Selective+Indoleamine+2%2C3-Dioxygenase+Inhibition+with+Potent+in+Vivo+Pharmacodynamic+Activity+and+Antitumor+Efficacy&doi=10.1021%2Facs.jmedchem.5b01640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy</span></div><div class="casAuthors">Lin, Shu-Yu; Yeh, Teng-Kuang; Kuo, Ching-Chuan; Song, Jen-Shin; Cheng, Ming-Fu; Liao, Fang-Yu; Chao, Min-Wu; Huang, Han-Li; Chen, Yi-Lin; Yang, Chun-Yu; Wu, Mine-Hsine; Hsieh, Chia-Ling; Hsiao, Wenchi; Peng, Yi-Hui; Wu, Jian-Sung; Lin, Li-Mei; Sun, Manwu; Chao, Yu-Sheng; Shih, Chuan; Wu, Su-Ying; Pan, Shiow-Lin; Hung, Ming-Shiu; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tryptophan metab. has been recognized as an important mechanism in immune tolerance.  Indoleamine 2,3-dioxygenase plays a key role in local tryptophan metab. via the kynurenine pathway and has emerged as a therapeutic target for cancer immunotherapy.  The prior study identified Ph benzenesulfonyl hydrazide as a potent in vitro (though not in vivo) inhibitor of indoleamine 2,3-dioxygenase.  Further lead optimization to improve in vitro potencies and pharmacokinetic profiles resulted in N'-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl hydrazide (I), which demonstrated 59% oral bioavailability and 73% of tumor growth delay without apparent body wt. loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg.  Accordingly, I is proposed as a potential drug lead worthy of advanced preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOxVvjSCi13LVg90H21EOLACvtfcHk0lhjlw_fH-Lpkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ltLjE&md5=63287615c2b038f657cab148d4747e03</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01640%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DHsiao%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DL.%2BM.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DPhenyl%2520Benzenesulfonylhydrazides%2520Exhibit%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibition%2520with%2520Potent%2520in%2520Vivo%2520Pharmacodynamic%2520Activity%2520and%2520Antitumor%2520Efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D419%26epage%3D430%26doi%3D10.1021%2Facs.jmedchem.5b01640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deka, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span> <span> </span><span class="NLM_article-title">Fused Heterocyclic Compounds as Potent Indoleamine-2,3-Dioxygenase 1 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1167</span>– <span class="NLM_lpage">1172</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00359</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00359" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yksr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1167-1172&author=S.+Pandaauthor=A.+Royauthor=S.+J.+Dekaauthor=V.+Trivediauthor=D.+Manna&title=Fused+Heterocyclic+Compounds+as+Potent+Indoleamine-2%2C3-Dioxygenase+1+Inhibitors&doi=10.1021%2Facsmedchemlett.6b00359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors</span></div><div class="casAuthors">Panda, Subhankar; Roy, Ashalata; Deka, Suman Jyoti; Trivedi, Vishal; Manna, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1167-1172</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Uncontrolled metab. of L-tryptophan (L-Trp) in the immune system has been recognized as a crit. cellular process in immune tolerance.  Indoleamine 2,3-dioxygenase 1 (IDO1) enzyme plays an important role in the metab. of a local L-Trp through the kynurenine pathway in the immune systems.  In this regard, IDO1 has emerged as a therapeutic target for the treatment of diseases that are assocd. with immune suppression like chronic infections, cancer, and others.  In this study, we synthesized a series of pyridopyrimidine, pyrazolopyranopyrimidine, and dipyrazolopyran derivs.  Further lead optimizations directed to the identification of potent compds., I and II (IC50 = 260 and 151 nM, resp.).  These compds. also exhibited IDO1 inhibitory activities in the low nanomolar range in MDA-MB-231 cells with very low cytotoxicity.  Stronger selectivity for the IDO1 enzyme (>300-fold) over tryptophan 2,3-dioxygenase (TDO) enzyme was also obsd. for these compds.  Hence, these fused heterocyclic compds. are attractive candidates for the advanced study of IDO1-dependent cellular function and immunotherapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3hka_cRkrHrVg90H21EOLACvtfcHk0ljeijMhWjtE-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yksr%252FO&md5=452d3d1d01e3d701c371862ffa67e84d</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00359%26sid%3Dliteratum%253Aachs%26aulast%3DPanda%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DDeka%26aufirst%3DS.%2BJ.%26aulast%3DTrivedi%26aufirst%3DV.%26aulast%3DManna%26aufirst%3DD.%26atitle%3DFused%2520Heterocyclic%2520Compounds%2520as%2520Potent%2520Indoleamine-2%252C3-Dioxygenase%25201%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D1167%26epage%3D1172%26doi%3D10.1021%2Facsmedchemlett.6b00359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaLonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">O-Alkylhydroxylamines as Rationally-Designed Mechanism-Based Inhibitors of Indoleamine 2,3-Dioxygenase-1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2015.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=26717206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyqtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=564-576&author=W.+P.+Malachowskiauthor=M.+Wintersauthor=J.+B.+DuHadawayauthor=A.+Lewis-Ballesterauthor=S.+Badirauthor=J.+Waiauthor=M.+Rahmanauthor=E.+Sheikhauthor=J.+M.+LaLondeauthor=S.+R.+Yehauthor=G.+C.+Prendergastauthor=A.+J.+Muller&title=O-Alkylhydroxylamines+as+Rationally-Designed+Mechanism-Based+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase-1&doi=10.1016%2Fj.ejmech.2015.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1</span></div><div class="casAuthors">Malachowski, William P.; Winters, Maria; DuHadaway, James B.; Lewis-Ballester, Ariel; Badir, Shorouk; Wai, Jenny; Rahman, Maisha; Sheikh, Eesha; LaLonde, Judith M.; Yeh, Syun-Ru; Prendergast, George C.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">564-576</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathol. immune suppression.  Recently important advances have been made in understanding IDO1's catalytic mechanism.  Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state.  Accordingly, the authors explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state.  The authors discovered that O-benzylhydroxylamine, a com. available compd., is a potent sub-micromolar inhibitor of IDO1.  Structure-activity studies of over forty derivs. of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addn. of halogen atoms to the meta position of the arom. ring.  The most potent derivs. and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development.  Notably, two of the most potent compds. demonstrated nanomolar-level cell-based potency and limited toxicity.  The combination of the simplicity of the structures of these compds. and their excellent cellular activity makes them quite attractive for biol. exploration of IDO1 function and antitumor therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDnCWhaQpRTLVg90H21EOLACvtfcHk0ljeijMhWjtE-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyqtbvL&md5=f8705d78d92a94ce0d644fef10c44fac</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DWinters%26aufirst%3DM.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DBadir%26aufirst%3DS.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DM.%26aulast%3DSheikh%26aufirst%3DE.%26aulast%3DLaLonde%26aufirst%3DJ.%2BM.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DO-Alkylhydroxylamines%2520as%2520Rationally-Designed%2520Mechanism-Based%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase-1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D564%26epage%3D576%26doi%3D10.1016%2Fj.ejmech.2015.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span> <span> </span><span class="NLM_article-title">Diaryl Hydroxylamines as Pan or Dual Inhibitors of Indoleamine 2,3-Dioxygenase-1, Indoleamine 2,3-Dioxygenase-2 and Tryptophan Dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2018.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30469041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12lsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=455-464&author=M.+Wintersauthor=J.+B.+DuHadawayauthor=K.+N.+Phamauthor=A.+Lewis-Ballesterauthor=S.+Badirauthor=J.+Waiauthor=E.+Sheikhauthor=S.+R.+Yehauthor=G.+C.+Prendergastauthor=A.+J.+Mullerauthor=W.+P.+Malachowski&title=Diaryl+Hydroxylamines+as+Pan+or+Dual+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase-1%2C+Indoleamine+2%2C3-Dioxygenase-2+and+Tryptophan+Dioxygenase&doi=10.1016%2Fj.ejmech.2018.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase</span></div><div class="casAuthors">Winters, Maria; DuHadaway, James B.; Pham, Khoa N.; Lewis-Ballester, Ariel; Badir, Shorouk; Wai, Jenny; Sheikh, Eesha; Yeh, Syun-Ru; Prendergast, George C.; Muller, Alexander J.; Malachowski, William P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tryptophan (Trp) catabolizing enzymes play an important and complex role in the development of cancer.  Significant evidence implicates them in a range of inflammatory and immunosuppressive activities.  Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) have been reported and analyzed in the clinic, fewer inhibitors have been described for tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have been implicated more recently in cancer, inflammation and immune control.  Consequently the development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a therapeutically important area of research.  This is the first report to describe the development of dual and pan inhibitors of IDO1, TDO and IDO2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdiTONUXSgbVg90H21EOLACvtfcHk0ljeijMhWjtE-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12lsLfJ&md5=b1e562e2738830b58ac5bb544725adff</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DWinters%26aufirst%3DM.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DBadir%26aufirst%3DS.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DSheikh%26aufirst%3DE.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26atitle%3DDiaryl%2520Hydroxylamines%2520as%2520Pan%2520or%2520Dual%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase-1%252C%2520Indoleamine%25202%252C3-Dioxygenase-2%2520and%2520Tryptophan%2520Dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D162%26spage%3D455%26epage%3D464%26doi%3D10.1016%2Fj.ejmech.2018.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turcatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Detailed Analysis and Follow-up Studies of a High-Throughput Screening for Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.06.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2014.06.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25036789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Grs7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2014&pages=284-301&author=U.+F.+Rohrigauthor=S.+R.+Majjigapuauthor=M.+Chambonauthor=S.+Bronauthor=L.+Pilotteauthor=D.+Colauauthor=B.+J.+Van+den+Eyndeauthor=G.+Turcattiauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=Detailed+Analysis+and+Follow-up+Studies+of+a+High-Throughput+Screening+for+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.ejmech.2014.06.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Chambon, Marc; Bron, Sylvian; Pilotte, Luc; Colau, Didier; Van den Eynde, Benoit J.; Turcatti, Gerardo; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">284-301</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulator of immune responses and therefore an important therapeutic target for the treatment of diseases that involve pathol. immune escape, such as cancer.  Here, the authors describe a robust and sensitive high-throughput screen (HTS) for IDO1 inhibitors using the Prestwick Chem. Library of 1200 FDA-approved drugs and the Maybridge HitFinder Collection of 14,000 small mols.  Of the 60 hits selected for follow-up studies, 14 displayed IC50 values below 20 μM under the secondary assay conditions, and 4 showed an activity in cellular tests.  In view of the high attrition rate the authors used both exptl. and computational techniques to identify and to characterize compds. inhibiting IDO1 through unspecific inhibition mechanisms such as chem. reactivity, redox cycling, or aggregation.  One specific IDO1 inhibitor scaffold, the imidazole antifungal agents, was chosen for rational structure-based lead optimization, which led to more sol. and smaller compds. with micromolar activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwX1aSlfQ6VbVg90H21EOLACvtfcHk0lhHk_5GMl7ncw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Grs7fE&md5=3751d1ba733eebcd5587e33533617e6b</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.06.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.06.078%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DChambon%26aufirst%3DM.%26aulast%3DBron%26aufirst%3DS.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DTurcatti%26aufirst%3DG.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DDetailed%2520Analysis%2520and%2520Follow-up%2520Studies%2520of%2520a%2520High-Throughput%2520Screening%2520for%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D84%26spage%3D284%26epage%3D301%26doi%3D10.1016%2Fj.ejmech.2014.06.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Investigation of Multi-Target-Directed Ligands (Mtdls) with Butyrylcholinesterase (Buche) and Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibition: The Design, Synthesis of Miconazole Analogues Targeting Alzheimer’s Disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1665</span>– <span class="NLM_lpage">1674</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2018.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29475581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFakurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1665-1674&author=X.+Luauthor=S.+Y.+Heauthor=Q.+Liauthor=H.+Yangauthor=X.+Jiangauthor=H.+Linauthor=Y.+Chenauthor=W.+Quauthor=F.+Fengauthor=Y.+Bianauthor=Y.+Zhouauthor=H.+Sun&title=Investigation+of+Multi-Target-Directed+Ligands+%28Mtdls%29+with+Butyrylcholinesterase+%28Buche%29+and+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibition%3A+The+Design%2C+Synthesis+of+Miconazole+Analogues+Targeting+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.bmc.2018.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease</span></div><div class="casAuthors">Lu, Xin; He, Si-yu; Li, Qi; Yang, Hongyu; Jiang, Xueyang; Lin, Hongzhi; Chen, Yao; Qu, Wei; Feng, Feng; Bian, Yaoyao; Zhou, You; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1665-1674</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In our endeavor towards the development of potent multi-target ligands for the treatment of Alzheimer's disease, miconazole was identified to show BuChE-IDO1 dual-target inhibitory effects.  Morris water maze test indicated that miconazole obviously ameliorated the cognitive function impaired by scopolamine.  Furthermore, it showed good safety in primary hepatotoxicity evaluation.  Based on these results, we designed, synthesized, and evaluated a series of miconazole derivs. as BuChE-IDO1 dual-target inhibitors.  Out of the 12 compds., 5i and 5j exhibited the best potency in enzymic evaluation, thus were selected for subsequent behavioral study, in which the two compds. exerted much improved effect than tacrine.  Meanwhile, 5i and 5j displayed no apparent hepatotoxicity.  The results suggest that miconazole analog offers an attractive starting point for further development of new BuChE-IDO1 dual-target inhibitors against Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFWgipL3NC8bVg90H21EOLACvtfcHk0lhHk_5GMl7ncw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFakurw%253D&md5=28600c6f86b9f5a30151ff0f0f9c9f58</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DS.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DBian%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DInvestigation%2520of%2520Multi-Target-Directed%2520Ligands%2520%2528Mtdls%2529%2520with%2520Butyrylcholinesterase%2520%2528Buche%2529%2520and%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibition%253A%2520The%2520Design%252C%2520Synthesis%2520of%2520Miconazole%2520Analogues%2520Targeting%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D1665%26epage%3D1674%26doi%3D10.1016%2Fj.bmc.2018.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogbechi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clanchy, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, T. W.</span></span> <span> </span><span class="NLM_article-title">Ido and Kynurenine Metabolites in Peripheral and Cns Disorders</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">388</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.00388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffimmu.2020.00388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32194572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVaku7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=388&author=Y.+S.+Huangauthor=J.+Ogbechiauthor=F.+I.+Clanchyauthor=R.+O.+Williamsauthor=T.+W.+Stone&title=Ido+and+Kynurenine+Metabolites+in+Peripheral+and+Cns+Disorders&doi=10.3389%2Ffimmu.2020.00388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">IDO and kynurenine metabolites in peripheral and CNS disorders</span></div><div class="casAuthors">Huang, Yi-Shu; Ogbechi, Joy; Clanchy, Felix I.; Williams, Richard O.; Stone, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">388</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The importance of the kynurenine pathway in normal immune system function has led to an appreciation of its possible contribution to autoimmune disorders such as rheumatoid arthritis.  Indoleamine-2,3-dioxygenase (IDO) activity exerts a protective function, limiting the severity of exptl. arthritis, whereas deletion or inhibition exacerbates the symptoms.  Other chronic disorder with an inflammatory component, such as atherosclerosis, are also suppressed by IDO activity.  It is suggested that this overall anti-inflammatory activity is mediated by a change in the relative prodn. or activity of Th17 and regulatory T cell populations.  Kynurenines may play an anti-inflammatory role also in CNS disorders such as Huntington's disease, Alzheimer's disease and multiple sclerosis, in which signs of inflammation and neurodegeneration are involved.  The possibility is discussed that in Huntington's disease kynurenines interact with other anti-inflammatory mols. such as Human Lymphocyte Antigen-G which may be relevant in other disorders.  Kynurenine involvement may account for the protection afforded to animals with cerebral malaria and trypanosomiasis when they are treated with an inhibitor of kynurenine-3-monoxygenase (KMO).  There is some evidence that changes in IL-10 may contribute to this protection and the relationship between kynurenines and IL-10 in arthritis and other inflammatory conditions should be explored.  In addn., metabolites of kynurenine downstream of KMO, such as anthranilic acid and 3-hydroxy-anthranilic acid can influence inflammation, and the ratio of these compds. is a valuable biomarker of inflammatory status although the underlying mol. mechanisms of the changes require clarification.  Hence it is essential that more effort be expended to identify their sites of action as potential targets for drug development.  Finally, we discuss increasing awareness of the epigenetic regulation of IDO, for example by DNA methylation, a phenomenon which may explain differences between individuals in their susceptibility to arthritis and other inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDtbLQFAHjeLVg90H21EOLACvtfcHk0lhHk_5GMl7ncw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVaku7fK&md5=89ab5269e749effbf795c44865d0db7a</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.00388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.00388%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%2BS.%26aulast%3DOgbechi%26aufirst%3DJ.%26aulast%3DClanchy%26aufirst%3DF.%2BI.%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26aulast%3DStone%26aufirst%3DT.%2BW.%26atitle%3DIdo%2520and%2520Kynurenine%2520Metabolites%2520in%2520Peripheral%2520and%2520Cns%2520Disorders%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D388%26doi%3D10.3389%2Ffimmu.2020.00388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Favre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbour, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayawardene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aweeka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douek, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenchley, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCune, J. M.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of Th17 to Regulatory T Cells in Hiv Disease</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">32ra36</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3000632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1126%2Fscitranslmed.3000632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=20484731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=32ra36&author=D.+Favreauthor=J.+Moldauthor=P.+W.+Huntauthor=B.+Kanwarauthor=P.+Lokeauthor=L.+Seuauthor=J.+D.+Barbourauthor=M.+M.+Loweauthor=A.+Jayawardeneauthor=F.+Aweekaauthor=Y.+Huangauthor=D.+C.+Douekauthor=J.+M.+Brenchleyauthor=J.+N.+Martinauthor=F.+M.+Hechtauthor=S.+G.+Deeksauthor=J.+M.+McCune&title=Tryptophan+Catabolism+by+Indoleamine+2%2C3-Dioxygenase+1+Alters+the+Balance+of+Th17+to+Regulatory+T+Cells+in+Hiv+Disease&doi=10.1126%2Fscitranslmed.3000632"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000632%26sid%3Dliteratum%253Aachs%26aulast%3DFavre%26aufirst%3DD.%26aulast%3DMold%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DP.%2BW.%26aulast%3DKanwar%26aufirst%3DB.%26aulast%3DLoke%26aufirst%3DP.%26aulast%3DSeu%26aufirst%3DL.%26aulast%3DBarbour%26aufirst%3DJ.%2BD.%26aulast%3DLowe%26aufirst%3DM.%2BM.%26aulast%3DJayawardene%26aufirst%3DA.%26aulast%3DAweeka%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDouek%26aufirst%3DD.%2BC.%26aulast%3DBrenchley%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%2BN.%26aulast%3DHecht%26aufirst%3DF.%2BM.%26aulast%3DDeeks%26aufirst%3DS.%2BG.%26aulast%3DMcCune%26aufirst%3DJ.%2BM.%26atitle%3DTryptophan%2520Catabolism%2520by%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Alters%2520the%2520Balance%2520of%2520Th17%2520to%2520Regulatory%2520T%2520Cells%2520in%2520Hiv%2520Disease%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D32ra36%26doi%3D10.1126%2Fscitranslmed.3000632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT04069026" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT04069026</a> (accessed Aug 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT04069026+%28accessed+Aug+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazlett, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdew, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, C. R.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors Activate the Aryl Hydrocarbon Receptor</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2017.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.taap.2017.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28336214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVCgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2017&pages=74-80&author=B.+J.+Moyerauthor=I.+Y.+Rojasauthor=I.+A.+Murrayauthor=S.+Leeauthor=H.+F.+Hazlettauthor=G.+H.+Perdewauthor=C.+R.+Tomlinson&title=Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors+Activate+the+Aryl+Hydrocarbon+Receptor&doi=10.1016%2Fj.taap.2017.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor</span></div><div class="casAuthors">Moyer, Benjamin J.; Rojas, Itzel Y.; Murray, Iain A.; Lee, Seokwon; Hazlett, Haley F.; Perdew, Gary H.; Tomlinson, Craig R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-80</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in the immune system by regulating tryptophan levels and T cell differentiation.  Several tumor types overexpress IDO1 to avoid immune surveillance making IDO1 of interest as a target for therapeutic intervention.  As a result, several IDO1 inhibitors are currently being tested in clin. trials for cancer treatment as well as several other diseases.  Many of the IDO1 inhibitors in clin. trials naturally bear structural similarities to the IDO1 substrate tryptophan, as such, they fulfill many of the structural and functional criteria as potential AHR ligands.  Using mouse and human cell-based luciferase gene reporter assays, qPCR confirmation expts., and CYP1A1 enzyme activity assays, we report that some of the promising clin. IDO1 inhibitors also act as agonists for the aryl hydrocarbon receptor (AHR), best known for its roles in xenobiotic metab. and as another key regulator of the immune response.  The dual role as IDO antagonist and AHR agonist for many of these IDO target drugs should be considered for full interrogation of their biol. mechanisms and clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqto3BSdWrihrVg90H21EOLACvtfcHk0lhD284ie_owfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVCgsr8%253D&md5=ed02582ccc2902fbe04af590577f211f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2017.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2017.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DB.%2BJ.%26aulast%3DRojas%26aufirst%3DI.%2BY.%26aulast%3DMurray%26aufirst%3DI.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DHazlett%26aufirst%3DH.%2BF.%26aulast%3DPerdew%26aufirst%3DG.%2BH.%26aulast%3DTomlinson%26aufirst%3DC.%2BR.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%2520Activate%2520the%2520Aryl%2520Hydrocarbon%2520Receptor%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2017%26volume%3D323%26spage%3D74%26epage%3D80%26doi%3D10.1016%2Fj.taap.2017.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirthgen, E.</span></span> <span> </span><span class="NLM_article-title">Limitations and Off-Target Effects of Tryptophan-Related Ido Inhibitors in Cancer Treatment</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1801</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2019.01801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffimmu.2019.01801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31417567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BB3MvosVOisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1801&author=J.+Guntherauthor=J.+Dabritzauthor=E.+Wirthgen&title=Limitations+and+Off-Target+Effects+of+Tryptophan-Related+Ido+Inhibitors+in+Cancer+Treatment&doi=10.3389%2Ffimmu.2019.01801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment</span></div><div class="casAuthors">Gunther Juliane; Dabritz Jan; Wirthgen Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immunooncology is still a growing area in cancer therapy.  Drugs within this therapeutic approach do not directly target/attack the tumor but interfere with immune checkpoints and target or reprogram key metabolic pathways critical for anti-cancer immune defense.  Indolamine 2,3-dioxygenase 1 (IDO1) and the tryptophan (TRP)-kynurenine pathway were identified as critical mechanisms in cancer immune escape and their inhibition as an approach with promising therapeutic potential.  Particularly, a multitude of IDO1 inhibiting tryptophan analogs are widely applied in several clinical trials.  However, this therapy results in a variety of implications for the patient's physiology.  This is not only due to the inhibition of an enzyme important in almost every organ and tissue in the body but also because of the general nature of the inhibitor as an analog of a proteinogenic amino acid as well as the initiation of cellular detoxification known to affect inflammatory pathways.  In this review we provide a deeper insight into the physiological consequences of an IDO1 inhibiting therapy based on TRP related molecules.  We discuss potential side and off-target effects that contribute to the interpretation of unexpected positive as well as negative results of ongoing or discontinued clinical studies while we also highlight the potential of these inhibitors independent of the IDO1 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoiYC38uLQOGmbXvSEQle5fW6udTcc2ebzbiubQYafLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvosVOisQ%253D%253D&md5=4952276d1b65968ba9571733840f4cf2</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2019.01801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2019.01801%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DJ.%26aulast%3DDabritz%26aufirst%3DJ.%26aulast%3DWirthgen%26aufirst%3DE.%26atitle%3DLimitations%2520and%2520Off-Target%2520Effects%2520of%2520Tryptophan-Related%2520Ido%2520Inhibitors%2520in%2520Cancer%2520Treatment%26jtitle%3DFront.%2520Immunol.%26date%3D2019%26volume%3D10%26spage%3D1801%26doi%3D10.3389%2Ffimmu.2019.01801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiang-Li Ning, Yu-Zhi Li, Cui Huo, Ji Deng, Cheng Gao, Kai-Rong Zhu, Miao Wang, Yu-Xiang Wu, Jun-Lin Yu, Ya-Li Ren, Zong-Yuan Luo, Gen Li, Yang Chen, Si-Yao Wang, Cheng Peng, Ling-Ling Yang, Zhou-Yu Wang, Yong Wu, Shan Qian, <span class="NLM_string-name hlFld-ContribAuthor">Guo-Bo Li</span>. </span><span class="cited-content_cbyCitation_article-title">X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8303-8332. <a href="https://doi.org/10.1021/acs.jmedchem.1c00303" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00303</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00303%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DX-ray%252BStructure-Guided%252BDiscovery%252Bof%252Ba%252BPotent%25252C%252BOrally%252BBioavailable%25252C%252BDual%252BHuman%252BIndoleamine%25252FTryptophan%252B2%25252C3-Dioxygenase%252B%252528hIDO%25252FhTDO%252529%252BInhibitor%252BThat%252BShows%252BActivity%252Bin%252Ba%252BMouse%252BModel%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DNing%26aufirst%3DXiang-Li%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D16022021%26date%3D10062021%26volume%3D64%26issue%3D12%26spage%3D8303%26epage%3D8332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Yongqi  Deng</span>, <span class="hlFld-ContribAuthor ">Brett  Hopkins</span>, <span class="hlFld-ContribAuthor ">Xianhai  Huang</span>, <span class="hlFld-ContribAuthor ">David  Sloman</span>, <span class="hlFld-ContribAuthor ">Hongjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Derun  Li</span>, <span class="hlFld-ContribAuthor ">Meredeth A.  McGowan</span>, <span class="hlFld-ContribAuthor ">Catherine  White</span>, <span class="hlFld-ContribAuthor ">Qinglin  Pu</span>, <span class="hlFld-ContribAuthor ">Kun  Liu</span>, <span class="hlFld-ContribAuthor ">Xavier  Fradera</span>, <span class="hlFld-ContribAuthor ">Charles A.  Lesburg</span>, <span class="hlFld-ContribAuthor ">Theo  Martinot</span>, <span class="hlFld-ContribAuthor ">Amy  Doty</span>, <span class="hlFld-ContribAuthor ">Heidi  Ferguson</span>, <span class="hlFld-ContribAuthor ">Elliott B.  Nickbarg</span>, <span class="hlFld-ContribAuthor ">Mangeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Prasanthi  Geda</span>, <span class="hlFld-ContribAuthor ">Xuelei  Song</span>, <span class="hlFld-ContribAuthor ">Nadya  Smotrov</span>, <span class="hlFld-ContribAuthor ">Pravien  Abeywickrema</span>, <span class="hlFld-ContribAuthor ">Christine  Andrews</span>, <span class="hlFld-ContribAuthor ">Chad  Chamberlin</span>, <span class="hlFld-ContribAuthor ">Omar  Mabrouk</span>, <span class="hlFld-ContribAuthor ">Patrick  Curran</span>, <span class="hlFld-ContribAuthor ">Matthew  Richards</span>, <span class="hlFld-ContribAuthor ">Peter  Saradjian</span>, <span class="hlFld-ContribAuthor ">J. Richard  Miller</span>, <span class="hlFld-ContribAuthor ">Ian  Knemeyer</span>, <span class="hlFld-ContribAuthor ">Karin  Otte</span>, <span class="hlFld-ContribAuthor ">Stella  Vincent</span>, <span class="hlFld-ContribAuthor ">Nunzio  Sciammetta</span>, <span class="hlFld-ContribAuthor ">David Jonathan  Bennett</span>, <span class="hlFld-ContribAuthor ">Yongxin  Han</span>. </span><span class="cited-content_cbyCitation_article-title">SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>47 </em>, 128214. <a href="https://doi.org/10.1016/j.bmcl.2021.128214" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128214%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSAR%252Btowards%252Bindoline%252Band%252B3-azaindoline%252Bclasses%252Bof%252BIDO1%252Binhibitors%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2021%26volume%3D47%26spage%3D128214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of hIDO1 and hTDO complexed with ligands. (A) Crystal structure of the hIDO1–Trp-IDE complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WMV">5WMV</a>). IDO1 contains a larger CTD that compromises the S<sub>a</sub> site and the S<sub>i</sub> site and a smaller NTD that contains the ITIM site. Substrate Trp (light salmon) occupies the S<sub>a</sub> site in both pockets A and B, and effector 3-indole ethanol (IDE, lime) binds to pocket D. (B) Crystal structure of the hIDO1–epacadostat (green) complex (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WN8">5WN8</a>). Epacadostat coordinates heme iron with the O atom and occupies both pockets A and B. (C) Superimposed structure of apo-IDO1 complexed with BMS986205 and BMS116 (cyan) and their chemical structures (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MQ6">6MQ6</a>/<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZW">6AZW</a>). These inhibitors extend to pocket D and occupy pocket A. (D) Crystal structure of the hTDO-PF-06840002 (pink) adduct (PDB id: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYY">6PYY</a>). Pocket A in the S<sub>a</sub> site of TDO is completed by a neighboring TDO N-terminal chain (residues in violet), and the S<sub>i</sub> site is blocked by Phe158 and Trp324.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of Trp/indole analogues in recent literature. (A) Inhibitors with indole scaffolds. The PDB code for the hIDO1–<b>11</b> complex is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WHR">5WHR</a>. (B) Inhibitors with indolin-2-one and indole-2-carboxylic acid scaffolds. (C) Inhibitors with indazole scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative structures of imidazole/triazole derivatives in recent literature. (A) Phenyl-imidazole derivatives and tricyclic fused phenyl-imidazole derivatives. PDB codes for hIDO1–4PI and hIDO1–<b>4</b> are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2D0T">2D0T</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O3I">6O3I</a>. (B) Imidazothiazole derivatives. PDB codes for hIDO1–<b>25</b> and hIDO1–<b>28</b> are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5">4PK5</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KOF">6KOF</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representative structures of <i>N</i>-hydroxyamidine derivatives. The PDB code for hIDO1–<b>30</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XE1">5XE1</a>. Colored structures represent different optimization strategies based on the scaffold of <b>30</b>. Blue represents extensions in pocket B, red represents aryl moieties in pocket A, and green represents the central oxadiazole moiety.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of heme-competitive inhibitors. PDB codes for hIDO1–<b>41</b> and hIDO1–<b>44</b> complexes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZV">6AZV</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V52">6V52</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative structures of (A) <i>N</i>-aryl urea derivatives and (B) preliminary SAR conclusions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of multifunctional conjugates targeting IDO. (A) IDO inhibitors in conjunction with the DNA cross-linking agent Pt complex. (B) <i>N</i>-Hydroxyamidine-based dual-target molecules. (C) Click chemistry-based dual inhibitors of IDO1 and tubulin. (D) IDO1–PROTAC molecule. (E) Inhibitor functions by modulating the ITIM site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of IDO1 inhibitors based on natural products in recent studies. (A) Inhibitors with a quinone scaffold. (B) Tryptanthrin derivatives. (C) Other natural product inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/medium/jm0c00925_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Recently disclosed IDO1 inhibitors with other scaffolds. (A) Inhibitors discovered from the VS strategy. Highlighted atoms (blue for the N atom and red for the O atom) are proposed to interact with heme iron. Colored areas represent different pockets of the IDO1 S<sub>a</sub> site (cyan for pocket A, salmon for pocket B, and pale yellow for the distal pocket C). (B) Other IDO1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c00925/20201218/images/large/jm0c00925_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00925&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81131" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81131" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 177 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurjao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalani, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signoretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen Hodi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choueiri, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannakis, M.</span></span> <span> </span><span class="NLM_article-title">Metabolomic Adaptations and Correlates of Survival to Immune Checkpoint Blockade</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4346</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-12361-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41467-019-12361-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31554815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BB3MnitFagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=4346&author=H.+Liauthor=K.+Bullockauthor=C.+Gurjaoauthor=D.+Braunauthor=S.+A.+Shuklaauthor=D.+Bosseauthor=A.+A.+Lalaniauthor=S.+Gopalauthor=C.+Jinauthor=C.+Horakauthor=M.+Wind-Rotoloauthor=S.+Signorettiauthor=D.+F.+McDermottauthor=G.+J.+Freemanauthor=E.+M.+Van+Allenauthor=S.+L.+Schreiberauthor=F.+Stephen+Hodiauthor=W.+R.+Sellersauthor=L.+A.+Garrawayauthor=C.+B.+Clishauthor=T.+K.+Choueiriauthor=M.+Giannakis&title=Metabolomic+Adaptations+and+Correlates+of+Survival+to+Immune+Checkpoint+Blockade&doi=10.1038%2Fs41467-019-12361-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomic adaptations and correlates of survival to immune checkpoint blockade</span></div><div class="casAuthors">Li Haoxin; Gurjao Carino; Braun David; Shukla Sachet A; Bosse Dominick; Lalani Aly-Khan A; Signoretti Sabina; Freeman Gordon J; Van Allen Eliezer M; Stephen Hodi F; Sellers William R; Garraway Levi A; Choueiri Toni K; Giannakis Marios; Li Haoxin; Bullock Kevin; Gurjao Carino; Gopal Shuba; Van Allen Eliezer M; Schreiber Stuart L; Sellers William R; Garraway Levi A; Clish Clary B; Giannakis Marios; Li Haoxin; Schreiber Stuart L; Jin Chelsea; Horak Christine; Wind-Rotolo Megan; McDermott David F; Van Allen Eliezer M; Stephen Hodi F; Garraway Levi A; Choueiri Toni K; Giannakis Marios</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4346</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits.  Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an antibody against programmed cell death protein 1 (PD1).  We identify serum kynurenine/tryptophan ratio increases as an adaptive resistance mechanism associated with worse overall survival.  This advocates for patient stratification and metabolic monitoring in immunotherapy clinical trials including those combining PD1 blockade with indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase   (IDO/TDO) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzEc3gtF2lse-MdeMhXAHkfW6udTcc2eb13uLAE3bjkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnitFagtg%253D%253D&md5=162c0b46ddf93b675b9d501bf4fc694a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-12361-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-12361-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DBullock%26aufirst%3DK.%26aulast%3DGurjao%26aufirst%3DC.%26aulast%3DBraun%26aufirst%3DD.%26aulast%3DShukla%26aufirst%3DS.%2BA.%26aulast%3DBosse%26aufirst%3DD.%26aulast%3DLalani%26aufirst%3DA.%2BA.%26aulast%3DGopal%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DC.%26aulast%3DHorak%26aufirst%3DC.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DSignoretti%26aufirst%3DS.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DVan%2BAllen%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DStephen%2BHodi%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DGiannakis%26aufirst%3DM.%26atitle%3DMetabolomic%2520Adaptations%2520and%2520Correlates%2520of%2520Survival%2520to%2520Immune%2520Checkpoint%2520Blockade%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D4346%26doi%3D10.1038%2Fs41467-019-12361-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalakrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Macedo, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin-Breneman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roszik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenwald, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawbi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glitza, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaria, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Integrated Molecular Analysis of Tumor Biopsies on Sequential Ctla-4 and Pd-1 Blockade Reveals Markers of Response and Resistance</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">eaah3560</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aah3560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1126%2Fscitranslmed.aah3560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28251903" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaah3560&author=W.+Rohauthor=P.+L.+Chenauthor=A.+Reubenauthor=C.+N.+Spencerauthor=P.+A.+Prietoauthor=J.+P.+Millerauthor=V.+Gopalakrishnanauthor=F.+Wangauthor=Z.+A.+Cooperauthor=S.+M.+Reddyauthor=C.+Gumbsauthor=L.+Littleauthor=Q.+Changauthor=W.+S.+Chenauthor=K.+Waniauthor=M.+P.+De+Macedoauthor=E.+Chenauthor=J.+L.+Austin-Brenemanauthor=H.+Jiangauthor=J.+Roszikauthor=M.+T.+Tetzlaffauthor=M.+A.+Daviesauthor=J.+E.+Gershenwaldauthor=H.+Tawbiauthor=A.+J.+Lazarauthor=P.+Hwuauthor=W.+J.+Hwuauthor=A.+Diabauthor=I.+C.+Glitzaauthor=S.+P.+Patelauthor=S.+E.+Woodmanauthor=R.+N.+Amariaauthor=V.+G.+Prietoauthor=J.+Huauthor=P.+Sharmaauthor=J.+P.+Allisonauthor=L.+Chinauthor=J.+Zhangauthor=J.+A.+Wargoauthor=P.+A.+Futreal&title=Integrated+Molecular+Analysis+of+Tumor+Biopsies+on+Sequential+Ctla-4+and+Pd-1+Blockade+Reveals+Markers+of+Response+and+Resistance&doi=10.1126%2Fscitranslmed.aah3560"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aah3560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aah3560%26sid%3Dliteratum%253Aachs%26aulast%3DRoh%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DP.%2BL.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DC.%2BN.%26aulast%3DPrieto%26aufirst%3DP.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BP.%26aulast%3DGopalakrishnan%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DReddy%26aufirst%3DS.%2BM.%26aulast%3DGumbs%26aufirst%3DC.%26aulast%3DLittle%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DW.%2BS.%26aulast%3DWani%26aufirst%3DK.%26aulast%3DDe%2BMacedo%26aufirst%3DM.%2BP.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DAustin-Breneman%26aufirst%3DJ.%2BL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRoszik%26aufirst%3DJ.%26aulast%3DTetzlaff%26aufirst%3DM.%2BT.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DGershenwald%26aufirst%3DJ.%2BE.%26aulast%3DTawbi%26aufirst%3DH.%26aulast%3DLazar%26aufirst%3DA.%2BJ.%26aulast%3DHwu%26aufirst%3DP.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DDiab%26aufirst%3DA.%26aulast%3DGlitza%26aufirst%3DI.%2BC.%26aulast%3DPatel%26aufirst%3DS.%2BP.%26aulast%3DWoodman%26aufirst%3DS.%2BE.%26aulast%3DAmaria%26aufirst%3DR.%2BN.%26aulast%3DPrieto%26aufirst%3DV.%2BG.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DIntegrated%2520Molecular%2520Analysis%2520of%2520Tumor%2520Biopsies%2520on%2520Sequential%2520Ctla-4%2520and%2520Pd-1%2520Blockade%2520Reveals%2520Markers%2520of%2520Response%2520and%2520Resistance%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26spage%3Deaah3560%26doi%3D10.1126%2Fscitranslmed.aah3560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Platten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nollen, E. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C. A.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Metabolism as a Common Therapeutic Target in Cancer, Neurodegeneration and Beyond</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0016-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41573-019-0016-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30760888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1ymurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=379-401&author=M.+Plattenauthor=E.+A.+A.+Nollenauthor=U.+F.+Rohrigauthor=F.+Fallarinoauthor=C.+A.+Opitz&title=Tryptophan+Metabolism+as+a+Common+Therapeutic+Target+in+Cancer%2C+Neurodegeneration+and+Beyond&doi=10.1038%2Fs41573-019-0016-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond</span></div><div class="casAuthors">Platten, Michael; Nollen, Ellen A. A.; Roehrig, Ute F.; Fallarino, Francesca; Opitz, Christiane A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">379-401</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  L-Tryptophan (Trp) metab. through the kynurenine pathway (KP) is involved in the regulation of immunity, neuronal function and intestinal homeostasis.  Imbalances in Trp metab. in disorders ranging from cancer to neurodegenerative disease have stimulated interest in therapeutically targeting the KP, particularly the main rate-limiting enzymes indoleamine-2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan-2,3-dioxygenase (TDO) as well as kynurenine monooxygenase (KMO).  However, although small-mol. IDO1 inhibitors showed promise in early-stage cancer immunotherapy clin. trials, a phase III trial was neg.  This Review summarizes the physiol. and pathophysiol. roles of Trp metab., highlighting the vast opportunities and challenges for drug development in multiple diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro8x_NYzQ8rLVg90H21EOLACvtfcHk0lgONQ4iD8D3Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1ymurw%253D&md5=4d6d9b9c7791e83403cb8fdc34a7a4ae</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0016-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0016-5%26sid%3Dliteratum%253Aachs%26aulast%3DPlatten%26aufirst%3DM.%26aulast%3DNollen%26aufirst%3DE.%2BA.%2BA.%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DOpitz%26aufirst%3DC.%2BA.%26atitle%3DTryptophan%2520Metabolism%2520as%2520a%2520Common%2520Therapeutic%2520Target%2520in%2520Cancer%252C%2520Neurodegeneration%2520and%2520Beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D379%26epage%3D401%26doi%3D10.1038%2Fs41573-019-0016-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskesund, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao-Feng Qin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span> <span> </span><span class="NLM_article-title">Tumor-Repopulating Cells Induce Pd-1 Expression in Cd8(+) T Cells by Transferring Kynurenine and Ahr Activation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ccell.2018.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29533786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVent7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=480-494&author=Y.+Liuauthor=X.+Liangauthor=W.+Dongauthor=Y.+Fangauthor=J.+Lvauthor=T.+Zhangauthor=R.+Fiskesundauthor=J.+Xieauthor=J.+Liuauthor=X.+Yinauthor=X.+Jinauthor=D.+Chenauthor=K.+Tangauthor=J.+Maauthor=H.+Zhangauthor=J.+Yuauthor=J.+Yanauthor=H.+Liangauthor=S.+Moauthor=F.+Chengauthor=Y.+Zhouauthor=H.+Zhangauthor=J.+Wangauthor=J.+Liauthor=Y.+Chenauthor=B.+Cuiauthor=Z.+W.+Huauthor=X.+Caoauthor=F.+Xiao-Feng+Qinauthor=B.+Huang&title=Tumor-Repopulating+Cells+Induce+Pd-1+Expression+in+Cd8%28%2B%29+T+Cells+by+Transferring+Kynurenine+and+Ahr+Activation&doi=10.1016%2Fj.ccell.2018.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation</span></div><div class="casAuthors">Liu, Yuying; Liang, Xiaoyu; Dong, Wenqian; Fang, Yi; Lv, Jiadi; Zhang, Tianzhen; Fiskesund, Roland; Xie, Jing; Liu, Jinyan; Yin, Xiaonan; Jin, Xun; Chen, Degao; Tang, Ke; Ma, Jingwei; Zhang, Huafeng; Yu, Jing; Yan, Jun; Liang, Huaping; Mo, Siqi; Cheng, Feiran; Zhou, Yabo; Zhang, Haizeng; Wang, Jing; Li, Jingnan; Chen, Yang; Cui, Bing; Hu, Zhuo-Wei; Cao, Xuetao; Qin, F. Xiao-Feng; Huang, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">480-494.e7</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite the clin. successes fostered by immune checkpoint inhibitors, mechanisms underlying PD-1 upregulation in tumor-infiltrating T cells remain an enigma.  Here, we show that tumor-repopulating cells (TRCs) drive PD-1 upregulation in CD8+ T cells through a transcellular kynurenine (Kyn)-aryl hydrocarbon receptor (AhR) pathway.  Interferon-γ produced by CD8+ T cells stimulates release of high levels of Kyn produced by TRCs, which is transferred into adjacent CD8+ T cells via the transporters SLC7A8 and PAT4.  Kyn induces and activates AhR and thereby upregulates PD-1 expression.  This Kyn-AhR pathway is confirmed in both tumor-bearing mice and cancer patients and its blockade enhances antitumor adoptive T cell therapy efficacy.  Thus, we uncovered a mechanism of PD-1 upregulation with potential tumor immunotherapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgGqEf4d4Vh7Vg90H21EOLACvtfcHk0lgONQ4iD8D3Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVent7g%253D&md5=8cfdf5a8665f56866af781a515c74d4e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DW.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DLv%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DFiskesund%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DTang%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DMo%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DZ.%2BW.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DXiao-Feng%2BQin%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DB.%26atitle%3DTumor-Repopulating%2520Cells%2520Induce%2520Pd-1%2520Expression%2520in%2520Cd8%2528%252B%2529%2520T%2520Cells%2520by%2520Transferring%2520Kynurenine%2520and%2520Ahr%2520Activation%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26spage%3D480%26epage%3D494%26doi%3D10.1016%2Fj.ccell.2018.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Floc’h, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otten, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlot, E.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Metabolism, from Nutrition to Potential Therapeutic Applications</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1205</span>, <span class="refDoi"> DOI: 10.1007/s00726-010-0752-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1007%2Fs00726-010-0752-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=20872026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC3MbltFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=1195-1205&author=N.+Le%0AFloc%E2%80%99hauthor=W.+Ottenauthor=E.+Merlot&title=Tryptophan+Metabolism%2C+from+Nutrition+to+Potential+Therapeutic+Applications&doi=10.1007%2Fs00726-010-0752-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan metabolism, from nutrition to potential therapeutic applications</span></div><div class="casAuthors">Le Floc'h Nathalie; Otten Winfried; Merlot Elodie</div><div class="citationInfo"><span class="NLM_cas:title">Amino acids</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1195-205</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tryptophan is an indispensable amino acid that should to be supplied by dietary protein.  Apart from its incorporation into body proteins, tryptophan is the precursor for serotonin, an important neuromediator, and for kynurenine, an intermediary metabolite of a complex metabolic pathway ending with niacin, CO(2), and kynurenic and xanthurenic acids.  Tryptophan metabolism within different tissues is associated with numerous physiological functions.  The liver regulates tryptophan homeostasis through degrading tryptophan in excess.  Tryptophan degradation into kynurenine by immune cells plays a crucial role in the regulation of immune response during infections, inflammations and pregnancy.  Serotonin is synthesized from tryptophan in the gut and also in the brain, where tryptophan availability is known to influence the sensitivity to mood disorders.  In the present review, we discuss the major functions of tryptophan and its role in the regulation of growth, mood, behavior and immune responses with regard to the low availability of this amino acid and the competition between tissues and metabolic pathways for tryptophan utilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiNDKY6a1l9hBrI9DTGjC0fW6udTcc2eZhLSrc99QQybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbltFGmsA%253D%253D&md5=9920bbbe24950dcf3e744d15aeff96cc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00726-010-0752-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-010-0752-7%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BFloc%25E2%2580%2599h%26aufirst%3DN.%26aulast%3DOtten%26aufirst%3DW.%26aulast%3DMerlot%26aufirst%3DE.%26atitle%3DTryptophan%2520Metabolism%252C%2520from%2520Nutrition%2520to%2520Potential%2520Therapeutic%2520Applications%26jtitle%3DAmino%2520Acids%26date%3D2011%26volume%3D41%26spage%3D1195%26epage%3D1205%26doi%3D10.1007%2Fs00726-010-0752-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
der Goot, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nollen, E. A.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Metabolism: Entering the Field of Aging and Age-Related Pathologies</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2013.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.molmed.2013.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=23562344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1CnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=336-344&author=A.+T.+van%0Ader+Gootauthor=E.+A.+Nollen&title=Tryptophan+Metabolism%3A+Entering+the+Field+of+Aging+and+Age-Related+Pathologies&doi=10.1016%2Fj.molmed.2013.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan metabolism: entering the field of aging and age-related pathologies</span></div><div class="casAuthors">van der Goot, Annemieke T.; Nollen, Ellen A. A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">336-344</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Aging is an important risk factor for many debilitating diseases, including cancer and neurodegeneration.  In model organisms, interfering with metabolic signaling pathways, including the insulin/insulin-like growth factor (IGF) 1 (IIS) and TOR pathways, can protect against age-related pathologies and increase lifespan.  Recent studies in multiple organisms have implicated tryptophan metab. as a powerful regulator of age-related diseases and lifespan.  Its high conservation throughout evolution has enabled studies that begin to dissect the contribution of individual enzymes and metabolites.  Here, we focus on the emerging view of tryptophan metab. as a pathway that integrates environmental and metabolic signals to regulate animal biol. and health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJwqXRFdIxGrVg90H21EOLACvtfcHk0linyF5HMRu9tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1CnsLw%253D&md5=2da4be2be0a30e22eb6dbbad7a71b2af</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2013.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2013.02.007%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BGoot%26aufirst%3DA.%2BT.%26aulast%3DNollen%26aufirst%3DE.%2BA.%26atitle%3DTryptophan%2520Metabolism%253A%2520Entering%2520the%2520Field%2520of%2520Aging%2520and%2520Age-Related%2520Pathologies%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D336%26epage%3D344%26doi%3D10.1016%2Fj.molmed.2013.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J. D.</span></span> <span> </span><span class="NLM_article-title">Targeting Metabolism to Regulate Immune Responses in Autoimmunity and Cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0032-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41573-019-0032-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31363227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=669-688&author=C.+H.+Patelauthor=R.+D.+Leoneauthor=M.+R.+Hortonauthor=J.+D.+Powell&title=Targeting+Metabolism+to+Regulate+Immune+Responses+in+Autoimmunity+and+Cancer&doi=10.1038%2Fs41573-019-0032-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting metabolism to regulate immune responses in autoimmunity and cancer</span></div><div class="casAuthors">Patel, Chirag H.; Leone, Robert D.; Horton, Maureen R.; Powell, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">669-688</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Metabolic programming is emerging as a crit. mechanism to alter immune cell activation, differentiation and function.  Targeting metab. does not completely suppress or activate the immune system but selectively regulates immune responses.  The different metabolic requirements of the diverse cells that constitute an immune response provide a unique opportunity to sep. effector functions from regulatory functions.  Likewise, cells can be metabolically reprogram to promote either their short-term effector functions or long-term memory capacity.  Studies in the growing field of immunometabolism support a paradigm of 'cellular selectivity based on demand', in which generic inhibitors of ubiquitous metabolic processes selectively affect cells with the greatest metabolic demand and have few effects on other cells of the body.  Targeting metab., rather than particular cell types or cytokines, in metabolically demanding processes such as autoimmunity, graft rejection, cancer and uncontrolled inflammation could lead to successful strategies in controlling the pathogenesis of these complex disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHF7lCdfVkZbVg90H21EOLACvtfcHk0linyF5HMRu9tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgtr3F&md5=cce3d41f0d3f68bf19dfd5f2154e7e32</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0032-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0032-5%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DC.%2BH.%26aulast%3DLeone%26aufirst%3DR.%2BD.%26aulast%3DHorton%26aufirst%3DM.%2BR.%26aulast%3DPowell%26aufirst%3DJ.%2BD.%26atitle%3DTargeting%2520Metabolism%2520to%2520Regulate%2520Immune%2520Responses%2520in%2520Autoimmunity%2520and%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D669%26epage%3D688%26doi%3D10.1038%2Fs41573-019-0032-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer</span>. <i>Int. Rev. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>336</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/bs.ircmb.2017.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fbs.ircmb.2017.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29413890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFequrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2018&pages=175-203&author=G.+C.+Prendergastauthor=W.+J.+Malachowskiauthor=A.+Mondalauthor=P.+Scherleauthor=A.+J.+Muller&title=Indoleamine+2%2C3-Dioxygenase+and+Its+Therapeutic+Inhibition+in+Cancer&doi=10.1016%2Fbs.ircmb.2017.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer</span></div><div class="casAuthors">Prendergast, George C.; Malachowski, William J.; Mondal, Arpita; Scherle, Peggy; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-203</span>CODEN:
                <span class="NLM_cas:coden">IRCMAH</span>;
        ISSN:<span class="NLM_cas:issn">1937-6448</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The tryptophan catabolic enzyme indoleamine 2,3-dioxygenase-1 (IDO1) has attracted enormous attention in driving cancer immunosuppression, neovascularization, and metastasis.  IDO1 suppresses local CD8 + T effector cells and natural killer cells and induces CD4 + T regulatory cells (iTreg) and myeloid-derived suppressor cells (MDSC).  The structurally distinct enzyme tryptophan dioxygenase (TDO) also has been implicated recently in immune escape and metastatic progression.  Lastly, emerging evidence suggests that the IDO1-related enzyme IDO2 may support IDO1-mediated iTreg and contribute to B-cell inflammed states in certain cancers.  IDO1 and TDO are upregulated widely in neoplastic cells but also variably in stromal, endothelial, and innate immune cells of the tumor microenvironment and in tumor-draining lymph nodes.  Pharmacol. and genetic proofs in preclin. models of cancer have validated IDO1 as a cancer therapeutic target.  IDO1 inhibitors have limited activity on their own but greatly enhance "immunogenic" chemotherapy or immune checkpoint drugs.  IDO/TDO function is rooted in inflammatory programming, thereby influencing tumor neovascularization, MDSC generation, and metastasis beyond effects on adaptive immune tolerance.  Discovery and development of two small mol. enzyme inhibitors of IDO1 have advanced furthest to date in Phase II/III human trials (epacadostat and navoximod, resp.).  Indoximod, a tryptophan mimetic compd. with a different mechanism of action in the IDO pathway has also advanced in multiple Phase II trials.  Second generation combined IDO/TDO inhibitors may broaden impact in cancer treatment, for example, in addressing IDO1 bypass (inherent resistance) or acquired resistance to IDO1 inhibitors.  This review surveys knowledge about IDO1 function and how IDO1 inhibitors reprogram inflammation to heighten therapeutic responses in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSKEq3iNdyrVg90H21EOLACvtfcHk0lhyutmlyFzdIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFequrrI&md5=75faf654a3c62b133fca5fb01c9ed6b1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fbs.ircmb.2017.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.ircmb.2017.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMalachowski%26aufirst%3DW.%2BJ.%26aulast%3DMondal%26aufirst%3DA.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520and%2520Its%2520Therapeutic%2520Inhibition%2520in%2520Cancer%26jtitle%3DInt.%2520Rev.%2520Cell%2520Mol.%2520Biol.%26date%3D2018%26volume%3D336%26spage%3D175%26epage%3D203%26doi%3D10.1016%2Fbs.ircmb.2017.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoumian, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenhals, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushman, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caetano, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdecanas, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niknam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, J. W.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase 1 Inhibition Targets Anti-Pd1-Resistant Lung Tumors by Blocking Myeloid-Derived Suppressor Cells</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>431</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.canlet.2018.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29746927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=431&publication_year=2018&pages=54-63&author=A.+Liauthor=H.+B.+Barsoumianauthor=J.+E.+Schoenhalsauthor=T.+R.+Cushmanauthor=M.+S.+Caetanoauthor=X.+Wangauthor=D.+R.+Valdecanasauthor=S.+Niknamauthor=A.+I.+Younesauthor=G.+Liauthor=W.+A.+Woodwardauthor=M.+A.+Cortezauthor=J.+W.+Welsh&title=Indoleamine+2%2C3-Dioxygenase+1+Inhibition+Targets+Anti-Pd1-Resistant+Lung+Tumors+by+Blocking+Myeloid-Derived+Suppressor+Cells&doi=10.1016%2Fj.canlet.2018.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells</span></div><div class="casAuthors">Li, Ailin; Barsoumian, Hampartsoum B.; Schoenhals, Jonathan E.; Cushman, Taylor R.; Caetano, Mauricio S.; Wang, Xiaohong; Valdecanas, David R.; Niknam, Sharareh; Younes, Ahmed I.; Li, Guang; Woodward, Wendy A.; Cortez, Maria Angelica; Welsh, James W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">431</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54-63</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), involved in the catabolism of tryptophan (Trp) to kynurenine (Kyn) is an important regulator of tumor-mediated immunosuppression implicated in resistance to anti-PD1 immunotherapy.  We investigated the role of IDO1 in an anti-PD1-resistant lung cancer model (344SQ_R) compared to the parental 344SQ tumors (344SQ_P).  IDO1 was overexpressed in tumor-infiltrating leukocytes, and plasma Kyn levels were increased, in 344SQ_R vs. 344SQ_P.  The IDO1 inhibitor INCB023843 retarded tumor growth and reduced lung metastases in 344SQ_R.  IDO1 was expressed at higher levels in F4/80+Gr1intCD11b+ myeloid-derived suppressor cells (MDSCs) that were prominent in 344SQ_R.  The INCB023843 reduced IDO1 expression and percentages of these MDSCs while increasing CD8+ T cells infiltration, hence reactivating antitumor T-cell responses in 344SQ_R.  Therefore, IDO1 inhibition holds promise for treating lung cancer that does not respond to anti-PD1 therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouljZFOOi7nbVg90H21EOLACvtfcHk0lhyutmlyFzdIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjur7M&md5=a9fbceec8ccbb0b426433ae785ac96ae</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DBarsoumian%26aufirst%3DH.%2BB.%26aulast%3DSchoenhals%26aufirst%3DJ.%2BE.%26aulast%3DCushman%26aufirst%3DT.%2BR.%26aulast%3DCaetano%26aufirst%3DM.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DValdecanas%26aufirst%3DD.%2BR.%26aulast%3DNiknam%26aufirst%3DS.%26aulast%3DYounes%26aufirst%3DA.%2BI.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWoodward%26aufirst%3DW.%2BA.%26aulast%3DCortez%26aufirst%3DM.%2BA.%26aulast%3DWelsh%26aufirst%3DJ.%2BW.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%25201%2520Inhibition%2520Targets%2520Anti-Pd1-Resistant%2520Lung%2520Tumors%2520by%2520Blocking%2520Myeloid-Derived%2520Suppressor%2520Cells%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D431%26spage%3D54%26epage%3D63%26doi%3D10.1016%2Fj.canlet.2018.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badawy, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namboodiri, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffett, J. R.</span></span> <span> </span><span class="NLM_article-title">The End of the Road for the Tryptophan Depletion Concept in Pregnancy and Infection</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1333</span>, <span class="refDoi"> DOI: 10.1042/CS20160153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1042%2FCS20160153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWhs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2016&pages=1327-1333&author=A.+A.+Badawyauthor=A.+M.+Namboodiriauthor=J.+R.+Moffett&title=The+End+of+the+Road+for+the+Tryptophan+Depletion+Concept+in+Pregnancy+and+Infection&doi=10.1042%2FCS20160153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The end of the road for the tryptophan depletion concept in pregnancy and infection</span></div><div class="casAuthors">Badawy, Abdulla A.-B.; Namboodiri, Aryan M. A.; Moffett, John R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1327-1333</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">We hypothesize that: (1) L-tryptophan (Trp) is greatly utilized and not depleted in pregnancy; (2) fetal tolerance is achieved in part through immunosuppressive kynurenine (Kyn) metabolites produced by the flux of plasma free (non-albumin-bound) Trp down the Kyn pathway; (3) the role of indoleamine 2,3-dioxygenase (IDO) in infection is not related to limitation of an essential amino acid, but is rather assocd. with stress responses and the prodn. of Kyn metabolites that regulate the activities of antigen presenting cells and T-cells, as well as increased NAD+ synthesis in IDO-expressing cells; (4) Trp depletion is not a host defense mechanism, but is a consequence of Trp utilization.  We recommend that future studies in normal and abnormal pregnancies and in patients with infections or cancer should include measurements of plasma free Trp, determinants of Trp binding (albumin and non-esterified fatty acids), total Trp, determinants of activities of the Trp-degrading enzymes Trp 2,3-dioxygenase (TDO) (cortisol) and IDO (cytokines) and levels of Kyn metabolites.  We also hypothesize that abnormal pregnancies and failure to combat infections or cancer may be assocd. with excessive Trp metab. that can lead to pathol. immunosuppression by excessive prodn. of Kyn metabolites.  Mounting evidence from many labs. indicates that Trp metabolites are key regulators of immune cell behavior, whereas Trp depletion is an indicator of extensive utilization of this key amino acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWp0RbJKPR1rVg90H21EOLACvtfcHk0lhyutmlyFzdIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWhs77F&md5=8448bba73349f49c3dfa92df670a3ece</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1042%2FCS20160153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20160153%26sid%3Dliteratum%253Aachs%26aulast%3DBadawy%26aufirst%3DA.%2BA.%26aulast%3DNamboodiri%26aufirst%3DA.%2BM.%26aulast%3DMoffett%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520End%2520of%2520the%2520Road%2520for%2520the%2520Tryptophan%2520Depletion%2520Concept%2520in%2520Pregnancy%2520and%2520Infection%26jtitle%3DClin.%2520Sci.%26date%3D2016%26volume%3D130%26spage%3D1327%26epage%3D1333%26doi%3D10.1042%2FCS20160153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonner, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deumelandt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thome, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauschenbach, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munteanu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohapatra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofer, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuerer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platten, M.</span></span> <span> </span><span class="NLM_article-title">The Stress Kinase Gcn2 Does Not Mediate Suppression of Antitumor T Cell Responses by Tryptophan Catabolism in Experimental Melanomas</span>. <i>Oncoimmunology.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1240858</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2016.1240858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1080%2F2162402X.2016.1240858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28123877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2msbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=e1240858&author=J.+K.+Sonnerauthor=K.+Deumelandtauthor=M.+Ottauthor=C.+M.+Thomeauthor=K.+J.+Rauschenbachauthor=S.+Schulzauthor=B.+Munteanuauthor=S.+Mohapatraauthor=I.+Adamauthor=A.+C.+Hoferauthor=M.+Feuererauthor=C.+A.+Opitzauthor=C.+Hopfauthor=W.+Wickauthor=M.+Platten&title=The+Stress+Kinase+Gcn2+Does+Not+Mediate+Suppression+of+Antitumor+T+Cell+Responses+by+Tryptophan+Catabolism+in+Experimental+Melanomas&doi=10.1080%2F2162402X.2016.1240858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas</span></div><div class="casAuthors">Sonner, Jana K.; Deumelandt, Katrin; Ott, Martina; Thome, Carina M.; Rauschenbach, Katharina J.; Schulz, Sandra; Munteanu, Bogdan; Mohapatra, Soumya; Adam, Isabell; Hofer, Ann-Cathrin; Feuerer, Markus; Opitz, Christiane A.; Hopf, Carsten; Wick, Wolfgang; Platten, Michael</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e1240858/1-e1240858/11</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Tryptophan metab. is a key process that shapes the immunosuppressive tumor microenvironment.  The two rate-limiting enzymes that mediate tryptophan depletion, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO), have moved into the focus of research and inhibitors targeting IDO and TDO have entered clin. trials.  Local tryptophan depletion is generally viewed as the crucial immunosuppressive mechanism.  In T cells, the kinase general control non-derepressible 2 (GCN2) has been identified as a mol. sensor of tryptophan deprivation.  GCN2 activation by tryptophan depletion induces apoptosis and mitigates T cell proliferation.  Here, we investigated whether GCN2 attenuates tumor rejection in exptl. B16 melanoma using T cell-specific Gcn2 knockout mice.  Our data demonstrate that GCN2 in T cells did not affect immunity to B16 tumors even when animals were treated with antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA4).  GCN2-deficient gp100 TCR-transgenic T cells were equally effective as wild-type pmel T cells against gp100-expressing B16 melanomas after adoptive transfer and gp100 peptide vaccination.  Even augmentation of tumoral tryptophan metab. in B16 tumors by lentiviral overexpression of Tdo did not differentially affect GCN2-proficient vs.  GCN2-deficient T cells in vivo.  Importantly, GCN2 target genes were not upregulated in tumor-infiltrating T cells.  MALDI-TOF MS imaging of B16 melanomas demonstrated maintenance of intratumoral tryptophan levels despite high tryptophan turnover, which prohibits a drop in tryptophan sufficient to activate GCN2 in tumor-infiltrating T cells.  In conclusion, our results do not suggest that suppression of antitumor immune responses by tryptophan metab. is driven by local tryptophan depletion and subsequent GCN2-mediated T cell anergy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKukQoYLS6bVg90H21EOLACvtfcHk0lhIJC-chWyXJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2msbvM&md5=b603a916e7314a7a907fe49293493493</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2016.1240858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2016.1240858%26sid%3Dliteratum%253Aachs%26aulast%3DSonner%26aufirst%3DJ.%2BK.%26aulast%3DDeumelandt%26aufirst%3DK.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DThome%26aufirst%3DC.%2BM.%26aulast%3DRauschenbach%26aufirst%3DK.%2BJ.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DMunteanu%26aufirst%3DB.%26aulast%3DMohapatra%26aufirst%3DS.%26aulast%3DAdam%26aufirst%3DI.%26aulast%3DHofer%26aufirst%3DA.%2BC.%26aulast%3DFeuerer%26aufirst%3DM.%26aulast%3DOpitz%26aufirst%3DC.%2BA.%26aulast%3DHopf%26aufirst%3DC.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DPlatten%26aufirst%3DM.%26atitle%3DThe%2520Stress%2520Kinase%2520Gcn2%2520Does%2520Not%2520Mediate%2520Suppression%2520of%2520Antitumor%2520T%2520Cell%2520Responses%2520by%2520Tryptophan%2520Catabolism%2520in%2520Experimental%2520Melanomas%26jtitle%3DOncoimmunology.%26date%3D2016%26volume%3D5%26spage%3De1240858%26doi%3D10.1080%2F2162402X.2016.1240858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzenburger, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tritschler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jestaedt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jugold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemin, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radlwimmer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platten, M.</span></span> <span> </span><span class="NLM_article-title">An Endogenous Tumour-Promoting Ligand of the Human Aryl Hydrocarbon Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>478</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1038/nature10491</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fnature10491" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=21976023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ylt7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=478&publication_year=2011&pages=197-203&author=C.+A.+Opitzauthor=U.+M.+Litzenburgerauthor=F.+Sahmauthor=M.+Ottauthor=I.+Tritschlerauthor=S.+Trumpauthor=T.+Schumacherauthor=L.+Jestaedtauthor=D.+Schrenkauthor=M.+Wellerauthor=M.+Jugoldauthor=G.+J.+Guilleminauthor=C.+L.+Millerauthor=C.+Lutzauthor=B.+Radlwimmerauthor=I.+Lehmannauthor=A.+von+Deimlingauthor=W.+Wickauthor=M.+Platten&title=An+Endogenous+Tumour-Promoting+Ligand+of+the+Human+Aryl+Hydrocarbon+Receptor&doi=10.1038%2Fnature10491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">An endogenous tumor-promoting ligand of the human aryl hydrocarbon receptor</span></div><div class="casAuthors">Opitz, Christiane A.; Litzenburger, Ulrike M.; Sahm, Felix; Ott, Martina; Tritschler, Isabel; Trump, Saskia; Schumacher, Theresa; Jestaedt, Leonie; Schrenk, Dieter; Weller, Michael; Jugold, Manfred; Guillemin, Gilles J.; Miller, Christine L.; Lutz, Christian; Radlwimmer, Bernhard; Lehmann, Irina; von Deimling, Andreas; Wick, Wolfgang; Platten, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">478</span>
        (<span class="NLM_cas:issue">7368</span>),
    <span class="NLM_cas:pages">197-203</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of the aryl hydrocarbon receptor (AHR) by environmental xenobiotic toxic chems., for instance 2,3,7,8-tetrachlorodibenzo-p-dioxin, has been implicated in a variety of cellular processes such as embryogenesis, transformation, tumorigenesis and inflammation.  But the identity of an endogenous ligand activating the AHR under physiol. conditions in the absence of environmental toxic chems. is still unknown.  Here we identify the tryptophan (Trp) catabolite kynurenine (Kyn) as an endogenous ligand of the human AHR that is constitutively generated by human tumor cells via tryptophan-2,3-dioxygenase (TDO), a liver- and neuron-derived Trp-degrading enzyme not yet implicated in cancer biol.  TDO-derived Kyn suppresses antitumor immune responses and promotes tumor-cell survival and motility through the AHR in an autocrine/paracrine fashion.  The TDO-AHR pathway is active in human brain tumors and is assocd. with malignant progression and poor survival.  Because Kyn is produced during cancer progression and inflammation in the local microenvironment in amts. sufficient for activating the human AHR, these results provide evidence for a previously unidentified pathophysiol. function of the AHR with profound implications for cancer and immune biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-ctjy8u-ULLVg90H21EOLACvtfcHk0lhIJC-chWyXJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ylt7nI&md5=5f0e0f411501a26b2f79684e0e59830e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature10491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10491%26sid%3Dliteratum%253Aachs%26aulast%3DOpitz%26aufirst%3DC.%2BA.%26aulast%3DLitzenburger%26aufirst%3DU.%2BM.%26aulast%3DSahm%26aufirst%3DF.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DTritschler%26aufirst%3DI.%26aulast%3DTrump%26aufirst%3DS.%26aulast%3DSchumacher%26aufirst%3DT.%26aulast%3DJestaedt%26aufirst%3DL.%26aulast%3DSchrenk%26aufirst%3DD.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3DJugold%26aufirst%3DM.%26aulast%3DGuillemin%26aufirst%3DG.%2BJ.%26aulast%3DMiller%26aufirst%3DC.%2BL.%26aulast%3DLutz%26aufirst%3DC.%26aulast%3DRadlwimmer%26aufirst%3DB.%26aulast%3DLehmann%26aufirst%3DI.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DPlatten%26aufirst%3DM.%26atitle%3DAn%2520Endogenous%2520Tumour-Promoting%2520Ligand%2520of%2520the%2520Human%2520Aryl%2520Hydrocarbon%2520Receptor%26jtitle%3DNature%26date%3D2011%26volume%3D478%26spage%3D197%26epage%3D203%26doi%3D10.1038%2Fnature10491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seok, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltenberger, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satyshur, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortopassi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefcoate, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradfield, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span> <span> </span><span class="NLM_article-title">Trace Derivatives of Kynurenine Potently Activate the Aryl Hydrocarbon Receptor (Ahr)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">1994</span>– <span class="NLM_lpage">2005</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA117.000631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1074%2Fjbc.RA117.000631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29279331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVymsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=1994-2005&author=S.+H.+Seokauthor=Z.+X.+Maauthor=J.+B.+Feltenbergerauthor=H.+Chenauthor=H.+Chenauthor=C.+Scarlettauthor=Z.+Linauthor=K.+A.+Satyshurauthor=M.+Cortopassiauthor=C.+R.+Jefcoateauthor=Y.+Geauthor=W.+Tangauthor=C.+A.+Bradfieldauthor=Y.+Xing&title=Trace+Derivatives+of+Kynurenine+Potently+Activate+the+Aryl+Hydrocarbon+Receptor+%28Ahr%29&doi=10.1074%2Fjbc.RA117.000631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR)</span></div><div class="casAuthors">Seok, Seung-Hyeon; Ma, Zhi-Xiong; Feltenberger, John B.; Chen, Hongbo; Chen, Hui; Scarlett, Cameron; Lin, Ziqing; Satyshur, Kenneth A.; Cortopassi, Marissa; Jefcoate, Colin R.; Ge, Ying; Tang, Weiping; Bradfield, Christopher A.; Xing, Yongna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1994-2005</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cellular metabolites act as important signaling cues, but are subject to complex unknown chem.  Kynurenine is a tryptophan metabolite that plays a crucial role in cancer and the immune system.  Despite its atypical, non-ligand-like, highly polar structure, kynurenine activates the aryl hydrocarbon receptor (AHR), a PER, ARNT, SIM (PAS) family transcription factor that responds to diverse environmental and cellular ligands.  The activity of kynurenine is increased 100-1000-fold by incubation or long-term storage and relies on the hydrophobic ligand-binding pocket of AHR, with identical structural signatures for AHR induction before and after activation.  We purified trace-active derivs. of kynurenine and identified two novel, closely related condensation products, named trace-extended arom. condensation products (TEACOPs), which are active at low picomolar levels.  The synthesized compd. for one of the predicted structures matched the purified compd. in both chem. structure and AHR pharmacol.  Our study provides evidence that kynurenine acts as an AHR pro-ligand, which requires novel chem. conversions to act as a receptor agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiJoODc3vS_7Vg90H21EOLACvtfcHk0lhIJC-chWyXJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVymsL0%253D&md5=022f04b780654f2ad45c91c98e50c466</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA117.000631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA117.000631%26sid%3Dliteratum%253Aachs%26aulast%3DSeok%26aufirst%3DS.%2BH.%26aulast%3DMa%26aufirst%3DZ.%2BX.%26aulast%3DFeltenberger%26aufirst%3DJ.%2BB.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DScarlett%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DSatyshur%26aufirst%3DK.%2BA.%26aulast%3DCortopassi%26aufirst%3DM.%26aulast%3DJefcoate%26aufirst%3DC.%2BR.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DBradfield%26aufirst%3DC.%2BA.%26aulast%3DXing%26aufirst%3DY.%26atitle%3DTrace%2520Derivatives%2520of%2520Kynurenine%2520Potently%2520Activate%2520the%2520Aryl%2520Hydrocarbon%2520Receptor%2520%2528Ahr%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26spage%3D1994%26epage%3D2005%26doi%3D10.1074%2Fjbc.RA117.000631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiro, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of Human Indoleamine 2,3-Dioxygenase: Catalytic Mechanism of O2 Incorporation by a Heme-Containing Dioxygenase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">2611</span>– <span class="NLM_lpage">2616</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508996103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.0508996103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=16477023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD28XksF2rsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=2611-2616&author=H.+Sugimotoauthor=S.+Odaauthor=T.+Otsukiauthor=T.+Hinoauthor=T.+Yoshidaauthor=Y.+Shiro&title=Crystal+Structure+of+Human+Indoleamine+2%2C3-Dioxygenase%3A+Catalytic+Mechanism+of+O2+Incorporation+by+a+Heme-Containing+Dioxygenase&doi=10.1073%2Fpnas.0508996103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase</span></div><div class="casAuthors">Sugimoto, Hiroshi; Oda, Shun-ichiro; Otsuki, Takashi; Hino, Tomoya; Yoshida, Tadashi; Shiro, Yoshitsugu</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2611-2616</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase (IDO) catalyzes the cleavage of the pyrrole ring of L-tryptophan and incorporates both atoms of an O2 mol.  Here, the authors report on the x-ray crystal structure of human IDO, complexed with the inhibitors, 4-phenylimidazole and cyanide.  The overall structure of IDO showed 2 α-helical domains with the heme between them.  Residue Ala-264 of the flexible loop on the heme distal side was in close proximity to the Fe.  A mutant anal. showed that none of the polar amino acid residues in the distal heme pocket were essential for activity, suggesting that, unlike the heme-contg. monooxygenases (e.g., peroxidase and cytochrome P 450), no protein group of IDO is essential in O2 activation or proton abstraction.  These characteristics of the IDO structure provided support for a reaction mechanism involving the abstraction of a proton from the substrate by Fe-bound O2.  The inactive mutants (F226A, F227A, and R231A) retained substrate-binding affinity, and an electron d. map revealed that 2-(N-cyclohexylamino)ethanesulfonic acid (CHES), a component of the crystn. buffer, was bound to these residues, mimicking the substrate.  These findings suggest that strict shape complementarities between the indole ring of the substrate and the protein side-chains are required, not for binding, but, rather, to permit the interaction between the substrate and Fe-bound O2 in the 1st step of the reaction.  This study provides the structural basis for a heme-contg. dioxygenase mechanism, a missing piece in the understanding of heme chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdrCQcNUKrrVg90H21EOLACvtfcHk0lhc3fJQSDPDaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksF2rsb4%253D&md5=aaf94d532920b2b855bf6fe1a58dfa92</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508996103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508996103%26sid%3Dliteratum%253Aachs%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DOda%26aufirst%3DS.%26aulast%3DOtsuki%26aufirst%3DT.%26aulast%3DHino%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DShiro%26aufirst%3DY.%26atitle%3DCrystal%2520Structure%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%253A%2520Catalytic%2520Mechanism%2520of%2520O2%2520Incorporation%2520by%2520a%2520Heme-Containing%2520Dioxygenase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D2611%26epage%3D2616%26doi%3D10.1073%2Fpnas.0508996103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9421</span>– <span class="NLM_lpage">9437</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9421-9437&author=U.+F.+Rohrigauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=Challenges+in+the+Discovery+of+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1021%2Facs.jmedchem.5b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9421-9437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies.  Many novel IDO1 inhibitor scaffolds have been described, and a few potent compds. have entered clin. trials.  However, a significant no. of the reported compds. contain problematic functional groups, suggesting that enzyme inhibition could be the result of undesirable side reactions instead of selective binding to IDO1.  Here, we describe issues in the employed exptl. protocols, review and classify reported IDO1 inhibitors, and suggest different approaches for confirming viable inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR3nr-l4vgNLVg90H21EOLACvtfcHk0lhc3fJQSDPDaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D&md5=1b44178d33badc00215915c28d027b5d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00326%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DChallenges%2520in%2520the%2520Discovery%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9421%26epage%3D9437%26doi%3D10.1021%2Facs.jmedchem.5b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Recent Discovery of Indoleamine-2,3-Dioxygenase 1 Inhibitors Targeting Cancer Immunotherapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2017.11.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29220788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejt7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=656-669&author=T.+Wengauthor=X.+Qiuauthor=J.+Wangauthor=Z.+Liauthor=J.+Bian&title=Recent+Discovery+of+Indoleamine-2%2C3-Dioxygenase+1+Inhibitors+Targeting+Cancer+Immunotherapy&doi=10.1016%2Fj.ejmech.2017.11.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy</span></div><div class="casAuthors">Weng, Tianwei; Qiu, Xiaqiu; Wang, Jubo; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">656-669</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  There has been great attention on indoleamine-2,3-dioxygenase 1 (IDO1) around cancer immunotherapy because of its role in enabling cancers to evade the immune system.  The most recent spurt of high potent IDO1 inhibitors has been driven by the soln. of the increased crystal structures of inhibitors with IDO1.  Though the structural information of the active site of IDO1 obtained from the crystals are quite similar, the structures of reported potent inhibitors are quite different.  Besides, while thousands of bioactive small mol. inhibitors of IDO1 exist, to date, only five compds. have entered clin. trials.  In an effort to obtain more clin. drugs targeting IDO1, more comprehensive understanding of the active site of IDO1 and the structures of existing potent IDO1 inhibitors are necessary.  Thus, this review mainly focus on the key features reported from specific crystal structures of IDO1 and an overview of the most recently developed IDO1 inhibitors under investigation and their other derived applications which may contribute to a better usage in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYo7DIaMiLULVg90H21EOLACvtfcHk0lhc3fJQSDPDaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejt7jL&md5=c31f1baddbed4d5270d4a76e9f02f321</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.088%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DT.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DRecent%2520Discovery%2520of%2520Indoleamine-2%252C3-Dioxygenase%25201%2520Inhibitors%2520Targeting%2520Cancer%2520Immunotherapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D656%26epage%3D669%26doi%3D10.1016%2Fj.ejmech.2017.11.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Research Progress of Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.4155%2Ffmc.14.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25686005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=185-201&author=T.+Jiangauthor=Y.+Sunauthor=Z.+Yinauthor=S.+Fengauthor=L.+Sunauthor=Z.+Li&title=Research+Progress+of+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.4155%2Ffmc.14.151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Research progress of indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Jiang, Tianze; Sun, Yingying; Yin, Zhichao; Feng, Sen; Sun, Liping; Li, Zhiyu</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">185-201</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase (IDO, subsequently named IDO1) can degrade the level of essential amino acid tryptophan in mammals, and catalyze the initial and rate-limiting step through the kynurenine pathway.  Broad evidence implies that IDO is overexpressed in both tumor cells and antigen-presenting cells, facilitating the escape of malignant tumors from immune surveillance.  In the past decades, the inhibition of IDO has been one of the most promising areas in cancer immunotherapy and many potential inhibitors of IDO have been designed, synthesized and evaluated, among which d-1-methyl-tryptophan and INCB24360 have advanced to clin. trial stage.  This review aims to give an overview of the rationale for IDO as a therapeutic target as well as the research progress of IDO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXd5sCUii9PLVg90H21EOLACvtfcHk0lhI1pSa6z2R7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrk%253D&md5=5006b4f16ba69b770210bf7416b4257b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.151%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DResearch%2520Progress%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D185%26epage%3D201%26doi%3D10.4155%2Ffmc.14.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornyak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koncz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanyi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szekvolgyi, L.</span></span> <span> </span><span class="NLM_article-title">The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">151</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.00151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffimmu.2018.00151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29445380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WrsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=151&author=L.+Hornyakauthor=N.+Dobosauthor=G.+Konczauthor=Z.+Karanyiauthor=D.+Pallauthor=Z.+Szaboauthor=G.+Halmosauthor=L.+Szekvolgyi&title=The+Role+of+Indoleamine-2%2C3-Dioxygenase+in+Cancer+Development%2C+Diagnostics%2C+and+Therapy&doi=10.3389%2Ffimmu.2018.00151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy</span></div><div class="casAuthors">Hornyak, Lilla; Dobos, Nikoletta; Koncz, Gabor; Karanyi, Zsolt; Pall, Denes; Szabo, Zoltan; Halmos, Gabor; Szekvolgyi, Lorant</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151/1-151/8</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Tumors are composed of abnormally transformed cell types and tissues that differ from normal tissues in their genetic and epigenetic makeup, metab., and immunol.  Mol. compds. that modulate the immune response against neoplasms offer promising new strategies to combat cancer.  Inhibitors targeting the indoleamine-2,3- dioxygenase 1 enzyme (IDO1) represent one of the most potent therapeutic opportunities to inhibit tumor growth.  Herein, we assess the biochem. role of IDO1 in tumor metab. and immune surveillance, and review current diagnostic and therapeutic approaches that are intended to increase the effectiveness of immunotherapies against highly aggressive and difficult-to-treat IDO-expressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWxC9Vek4FX7Vg90H21EOLACvtfcHk0lhI1pSa6z2R7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WrsrnN&md5=f4395174d6614557b6e2538a31eaa465</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.00151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.00151%26sid%3Dliteratum%253Aachs%26aulast%3DHornyak%26aufirst%3DL.%26aulast%3DDobos%26aufirst%3DN.%26aulast%3DKoncz%26aufirst%3DG.%26aulast%3DKaranyi%26aufirst%3DZ.%26aulast%3DPall%26aufirst%3DD.%26aulast%3DSzabo%26aufirst%3DZ.%26aulast%3DHalmos%26aufirst%3DG.%26aulast%3DSzekvolgyi%26aufirst%3DL.%26atitle%3DThe%2520Role%2520of%2520Indoleamine-2%252C3-Dioxygenase%2520in%2520Cancer%2520Development%252C%2520Diagnostics%252C%2520and%2520Therapy%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D151%26doi%3D10.3389%2Ffimmu.2018.00151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting the Ido1 Pathway in Cancer: From Bench to Bedside</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">100</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0644-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1186%2Fs13045-018-0644-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30068361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=100&author=M.+Liuauthor=X.+Wangauthor=L.+Wangauthor=X.+Maauthor=Z.+Gongauthor=S.+Zhangauthor=Y.+Li&title=Targeting+the+Ido1+Pathway+in+Cancer%3A+From+Bench+to+Bedside&doi=10.1186%2Fs13045-018-0644-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the IDO1 pathway in cancer: from bench to bedside</span></div><div class="casAuthors">Liu, Ming; Wang, Xu; Wang, Lei; Ma, Xiaodong; Gong, Zhaojian; Zhang, Shanshan; Li, Yong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100/1-100/12</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase (TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into kynurenine.  The depletion of tryptophan and the increase in kynurenine exert important immunosuppressive functions by activating T regulatory cells and myeloid-derived suppressor cells, suppressing the functions of effector T and natural killer cells, and promoting neovascularization of solid tumors.  Targeting IDO1 represents a therapeutic opportunity in cancer immunotherapy beyond checkpoint blockade or adoptive transfer of chimeric antigen receptor T cells.  In this review, we discuss the function of the IDO1 pathway in tumor progression and immune surveillance.  We highlight recent preclin. and clin. progress in targeting the IDO1 pathway in cancer therapeutics, including peptide vaccines, expression inhibitors, enzymic inhibitors, and effector inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR8DO7cQ8EH7Vg90H21EOLACvtfcHk0lhI1pSa6z2R7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqurk%253D&md5=22d837bc560deee6c172e246bca37266</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0644-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0644-y%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DTargeting%2520the%2520Ido1%2520Pathway%2520in%2520Cancer%253A%2520From%2520Bench%2520to%2520Bedside%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D100%26doi%3D10.1186%2Fs13045-018-0644-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toulmonde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevreau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cesne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bompas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piperno-Neumann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grellety, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckewaert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessede, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiringhelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiano, A.</span></span> <span> </span><span class="NLM_article-title">Use of Pd-1 Targeting, Macrophage Infiltration, and Ido Pathway Activation in Sarcomas: A Phase 2 Clinical Trial</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2017.1617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1001%2Fjamaoncol.2017.1617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28662235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC1cjjtVejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=93-97&author=M.+Toulmondeauthor=N.+Penelauthor=J.+Adamauthor=C.+Chevreauauthor=J.+Y.+Blayauthor=A.+Le+Cesneauthor=E.+Bompasauthor=S.+Piperno-Neumannauthor=S.+Cousinauthor=T.+Grelletyauthor=T.+Ryckewaertauthor=A.+Bessedeauthor=F.+Ghiringhelliauthor=M.+Pulidoauthor=A.+Italiano&title=Use+of+Pd-1+Targeting%2C+Macrophage+Infiltration%2C+and+Ido+Pathway+Activation+in+Sarcomas%3A+A+Phase+2+Clinical+Trial&doi=10.1001%2Fjamaoncol.2017.1617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial</span></div><div class="casAuthors">Toulmonde Maud; Cousin Sophie; Grellety Thomas; Italiano Antoine; Penel Nicolas; Adam Julien; Adam Julien; Chevreau Christine; Blay Jean-Yves; Le Cesne Axel; Bompas Emmanuelle; Piperno-Neumann Sophie; Ryckewaert Thomas; Bessede Alban; Ghiringhelli Francois; Pulido Marina; Pulido Marina</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  There is a strong rationale for treating sarcomas with immunotherapy.  Objective:  To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas.  Design, Setting, and Participants:  This was an open-label, multicenter, phase 2 study of 4 cohorts of patients with advanced soft-tissue sarcoma (STS), including leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), other sarcomas (others), and gastrointestinal stromal tumor (GIST).  All patients received 50 mg twice daily cyclophosphamide 1 week on and 1 week off and 200 mg of intravenous pembrolizumab every 3 weeks.  Intervention or Exposure:  Pembrolizumab in combination with metronomic cyclophosphamide.  Main Outcomes and Measures:  There was a dual primary end point, encompassing both the nonprogression and objective responses at 6 months per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 for LMS, UPS, and others and 6-month nonprogression for GIST.  An objective response rate of 20% and/or a 6-month nonprogression rate of 60% were determined as reasonable objectives for treatment with meaningful effect.  Correlative studies of immune biomarkers were planned from patient tumor and plasma samples.  Results:  Between June 2015 and July 2016, 57 patients were included (median [range] age, 59.5 [18.5-84.0] years; 24 women [42%]); 50 patients were assessable for the efficacy end point.  Three patients experienced tumor shrinkage, resulting in a partial response in a single solitary fibrous tumor.  The 6-month nonprogression rates were 0%, 0%, 14.3% (95% CI, 1.8%-42.8%) for LMS, UPS, and others, respectively, and 11.1% (95% CI, 2.8%-48.3%) for GIST.  The most frequent adverse events were grade 1 or 2 fatigue, diarrhea, and anemia.  The only patient who experienced partial response was the only one with strong programmed cell death 1 ligand 1-positive staining in immune cell.  Strong infiltration by macrophage expressing the inhibitory enzyme indoleamine 2,3-dioxygenase 1 (IDO1) was observed in the majority of cases.  Moreover, a significant increase in the kynurenine to tryptophan ratio was observed in patient plasma samples during the study treatment.  Conclusions and Relevance:  We found that PD-1 inhibition has limited activity in selected STS and GIST.  This may be explained by an immunosuppressive tumor microenvironment resulting from macrophage infiltration and IDO1 pathway activation.  Trial Registration:  clinicaltrials.gov Identifier: NCT02406781.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmP7k1aAt8B3T4ugvCDgnZfW6udTcc2eaED35k6_akyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjjtVejsQ%253D%253D&md5=0d4c2df318b06dc4d8bd4017202173eb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2017.1617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2017.1617%26sid%3Dliteratum%253Aachs%26aulast%3DToulmonde%26aufirst%3DM.%26aulast%3DPenel%26aufirst%3DN.%26aulast%3DAdam%26aufirst%3DJ.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DBompas%26aufirst%3DE.%26aulast%3DPiperno-Neumann%26aufirst%3DS.%26aulast%3DCousin%26aufirst%3DS.%26aulast%3DGrellety%26aufirst%3DT.%26aulast%3DRyckewaert%26aufirst%3DT.%26aulast%3DBessede%26aufirst%3DA.%26aulast%3DGhiringhelli%26aufirst%3DF.%26aulast%3DPulido%26aufirst%3DM.%26aulast%3DItaliano%26aufirst%3DA.%26atitle%3DUse%2520of%2520Pd-1%2520Targeting%252C%2520Macrophage%2520Infiltration%252C%2520and%2520Ido%2520Pathway%2520Activation%2520in%2520Sarcomas%253A%2520A%2520Phase%25202%2520Clinical%2520Trial%26jtitle%3DJAMA%2520Oncol.%26date%3D2018%26volume%3D4%26spage%3D93%26epage%3D97%26doi%3D10.1001%2Fjamaoncol.2017.1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holmgaard, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamarin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase Is a Critical Resistance Mechanism in Antitumor T Cell Immunotherapy Targeting Ctla-4</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">1389</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.1084/jem.20130066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1084%2Fjem.20130066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=23752227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVGiurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=1389-1402&author=R.+B.+Holmgaardauthor=D.+Zamarinauthor=D.+H.+Munnauthor=J.+D.+Wolchokauthor=J.+P.+Allison&title=Indoleamine+2%2C3-Dioxygenase+Is+a+Critical+Resistance+Mechanism+in+Antitumor+T+Cell+Immunotherapy+Targeting+Ctla-4&doi=10.1084%2Fjem.20130066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4</span></div><div class="casAuthors">Holmgaard, Rikke B.; Zamarin, Dmitriy; Munn, David H.; Wolchok, Jedd D.; Allison, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1389-1402</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab results in durable responses in metastatic melanoma, though therapeutic benefit has been limited to a fraction of patients.  This calls for identification of resistance mechanisms and development of combinatorial strategies.  Here, we examine the inhibitory role of indoleamine 2,3-dioxygenase (IDO) on the antitumor efficacy of CTLA-4 blockade.  In IDO knockout mice treated with anti-CTLA-4 antibody, we demonstrate a striking delay in B16 melanoma tumor growth and increased overall survival when compared with wild-type mice.  This was also obsd. with antibodies targeting PD-1-PD-L1 and GITR.  To highlight the therapeutic relevance of these findings, we show that CTLA-4 blockade strongly synergizes with IDO inhibitors to mediate rejection of both IDO-expressing and nonexpressing poorly immunogenic tumors, emphasizing the importance of the inhibitory role of both tumor- and host-derived IDO.  This effect was T cell dependent, leading to enhanced infiltration of tumor-specific effector T cells and a marked increase in the effector-to-regulatory T cell ratios in the tumors.  Overall, these data demonstrate the immunosuppressive role of IDO in the context of immunotherapies targeting immune checkpoints and provide a strong incentive to clin. explore combination therapies using IDO inhibitors irresp. of IDO expression by the tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn2vZr-icci7Vg90H21EOLACvtfcHk0ljUfUZ_TDcZ8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVGiurnP&md5=ed5a4e2074d7f0448eb503d7e11c2e91</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1084%2Fjem.20130066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20130066%26sid%3Dliteratum%253Aachs%26aulast%3DHolmgaard%26aufirst%3DR.%2BB.%26aulast%3DZamarin%26aufirst%3DD.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520Is%2520a%2520Critical%2520Resistance%2520Mechanism%2520in%2520Antitumor%2520T%2520Cell%2520Immunotherapy%2520Targeting%2520Ctla-4%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D1389%26epage%3D1402%26doi%3D10.1084%2Fjem.20130066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakharia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Ido Pathways to Treat Cancer: Lessons from the Echo-301 Trial and Beyond</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1007/s00281-018-0702-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1007%2Fs00281-018-0702-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30203227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=41-48&author=A.+J.+Mullerauthor=M.+G.+Manfrediauthor=Y.+Zakhariaauthor=G.+C.+Prendergast&title=Inhibiting+Ido+Pathways+to+Treat+Cancer%3A+Lessons+from+the+Echo-301+Trial+and+Beyond&doi=10.1007%2Fs00281-018-0702-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond</span></div><div class="casAuthors">Muller, Alexander J.; Manfredi, Mark G.; Zakharia, Yousef; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-48</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  With immunotherapy enjoying a rapid resurgence based on the achievement of durable remissions in some patients with agents that derepress immune function, commonly referred to as "checkpoint inhibitors," enormous attention developed around the IDO1 enzyme as a metabolic mediator of immune escape in cancer.  In particular, outcomes of multiple phase 1/2 trials encouraged the idea that small mol. inhibitors of IDO1 may improve patient responses to anti-PD1 immune checkpoint therapy.  However, recent results from ECHO-301, the first large phase 3 trial to evaluate an IDO1-selective enzyme inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in advanced melanoma, showed no indication that epacadostat provided an increased benefit.  Here it discuss several caveats assocd. with this failed trial.  First is the uncertainty as to whether the target was adequately inhibited.  In particular, there remains a lack of direct evidence regarding the degree of IDO1 inhibition within the tumor, and previous trial data suggest that sufficient drug exposure may not have been achieved at the dose tested in ECHO-301.  Second, while there is a mechanistic rationale for the combination tested, the preclin. data were not particularly compelling.  More efficacious combinations have been demonstrated with DNA damaging modalities which may therefore be a more attractive alternative.  Third, as a highly selective IDO1 inhibitor, epacadostat was advanced aggressively despite preclin. genetic evidence of tumors bypassing IDO1 blockade.  Indeed, a well-grounded literature starting in 2011 points to targeting strategies that account for both IDO and tryptophan 2,3-dioxygenase as more appealing directions to pursue, including dual inhibitors and inhibitors of nodal downstream effector pathways such as aryl hydrocarbon receptor blockade.  Overall, the clin. readout from a single trial with significant limitations is by no means a definitive test for the field.  While biomarker information yet to be gleaned from ECHO-301 may yet reveal useful information regarding IDO1 pathway drugs, better rationalized compds. and better rationalized trial designs will be important in the future to accurately gage medical impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR-55ynvYhvLVg90H21EOLACvtfcHk0ljUfUZ_TDcZ8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yltrfI&md5=b672f039dcfd843d6c849167846e13a5</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2Fs00281-018-0702-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-018-0702-0%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DManfredi%26aufirst%3DM.%2BG.%26aulast%3DZakharia%26aufirst%3DY.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibiting%2520Ido%2520Pathways%2520to%2520Treat%2520Cancer%253A%2520Lessons%2520from%2520the%2520Echo-301%2520Trial%2520and%2520Beyond%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2019%26volume%3D41%26spage%3D41%26epage%3D48%26doi%3D10.1007%2Fs00281-018-0702-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baurain, J.-F.</span></span> <span> </span><span class="NLM_article-title">Is There a Clinical Future for Ido1 Inhibitors after the Failure of Epacadostat in Melanoma?</span>. <i>Annu. Rev. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1146/annurev-cancerbio-030419-033635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1146%2Fannurev-cancerbio-030419-033635" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2020&pages=241-256&author=B.+J.+Van%0Aden+Eyndeauthor=N.+van+Barenauthor=J.-F.+Baurain&title=Is+There+a+Clinical+Future+for+Ido1+Inhibitors+after+the+Failure+of+Epacadostat+in+Melanoma%3F&doi=10.1146%2Fannurev-cancerbio-030419-033635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1146%2Fannurev-cancerbio-030419-033635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-cancerbio-030419-033635%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3Dvan%2BBaren%26aufirst%3DN.%26aulast%3DBaurain%26aufirst%3DJ.-F.%26atitle%3DIs%2520There%2520a%2520Clinical%2520Future%2520for%2520Ido1%2520Inhibitors%2520after%2520the%2520Failure%2520of%2520Epacadostat%2520in%2520Melanoma%253F%26jtitle%3DAnnu.%2520Rev.%2520Cancer%2520Biol.%26date%3D2020%26volume%3D4%26spage%3D241%26epage%3D256%26doi%3D10.1146%2Fannurev-cancerbio-030419-033635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jusof, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakmiwewa, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Too, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. J.</span></span> <span> </span><span class="NLM_article-title">Investigation of the Tissue Distribution and Physiological Roles of Indoleamine 2,3-Dioxygenase-2</span>. <i>Int. J. Tryptophan Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">117864691773509</span>, <span class="refDoi"> DOI: 10.1177/1178646917735098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1177%2F1178646917735098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=117864691773509&author=F.+F.+Jusofauthor=S.+M.+Bakmiwewaauthor=S.+Weiserauthor=L.+K.+Tooauthor=R.+Metzauthor=G.+C.+Prendergastauthor=S.+T.+Fraserauthor=N.+H.+Huntauthor=H.+J.+Ball&title=Investigation+of+the+Tissue+Distribution+and+Physiological+Roles+of+Indoleamine+2%2C3-Dioxygenase-2&doi=10.1177%2F1178646917735098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F1178646917735098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1178646917735098%26sid%3Dliteratum%253Aachs%26aulast%3DJusof%26aufirst%3DF.%2BF.%26aulast%3DBakmiwewa%26aufirst%3DS.%2BM.%26aulast%3DWeiser%26aufirst%3DS.%26aulast%3DToo%26aufirst%3DL.%2BK.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DFraser%26aufirst%3DS.%2BT.%26aulast%3DHunt%26aufirst%3DN.%2BH.%26aulast%3DBall%26aufirst%3DH.%2BJ.%26atitle%3DInvestigation%2520of%2520the%2520Tissue%2520Distribution%2520and%2520Physiological%2520Roles%2520of%2520Indoleamine%25202%252C3-Dioxygenase-2%26jtitle%3DInt.%2520J.%2520Tryptophan%2520Res.%26date%3D2017%26volume%3D10%26spage%3D117864691773509%26doi%3D10.1177%2F1178646917735098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baban, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigott, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keough, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rust, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandik-Nayak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Ido2 Is Critical for Ido1-Mediated T-Cell Regulation and Exerts a Non-Redundant Function in Inflammation</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxt073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1093%2Fintimm%2Fdxt073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24402311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyit7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=357-367&author=R.+Metzauthor=C.+Smithauthor=J.+B.+DuHadawayauthor=P.+Chandlerauthor=B.+Babanauthor=L.+M.+Merloauthor=E.+Pigottauthor=M.+P.+Keoughauthor=S.+Rustauthor=A.+L.+Mellorauthor=L.+Mandik-Nayakauthor=A.+J.+Mullerauthor=G.+C.+Prendergast&title=Ido2+Is+Critical+for+Ido1-Mediated+T-Cell+Regulation+and+Exerts+a+Non-Redundant+Function+in+Inflammation&doi=10.1093%2Fintimm%2Fdxt073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation</span></div><div class="casAuthors">Metz, Richard; Smith, Courtney; Du Hadaway, James B.; Chandler, Phillip; Baban, Babak; Merlo, Lauren M. F.; Pigott, Elizabeth; Keough, Martin P.; Rust, Sonja; Mellor, Andrew L.; Mandik-Nayak, Laura; Muller, Alexander J.; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">357-367</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">IDO2 and IDO1 cooperate in some inflammatory responses but IDO2 also has unique roles.  IDO2 is implicated in tryptophan catabolism and immunity but its physiol. functions are not well established.  Here we report the characterization of mice genetically deficient in IDO2, which develop normally but exhibit defects in IDO-mediated T-cell regulation and inflammatory responses.  Construction of this strain was prompted in part by our discovery that IDO2 function is attenuated in macrophages from Ido1 -/- mice due to altered message splicing, generating a functional mosaic with implications for interpreting findings in Ido1 -/- mice.  No apparent defects were obsd. in Ido2 -/- mice in embryonic development or hematopoietic differentiation, with wild-type profiles documented for kynurenine in blood serum and for immune cells in spleen, lymph nodes, peritoneum, thymus and bone marrow of naive mice.  In contrast, upon immune stimulation we detd. that IDO1-dependent T regulatory cell generation was defective in Ido2 -/- mice, supporting Ido1-Ido2 genetic interaction and establishing a functional role for Ido2 in immune modulation.  Pathophysiol., both Ido1 -/- and Ido2 -/- mice displayed reduced skin contact hypersensitivity responses, but mechanistic distinctions were apparent, with only Ido2 deficiency assocd. with a suppression of immune regulatory cytokines that included GM-CSF, G-CSF, IFN-γ, TNF-α, IL-6 and MCP-1/CCL2.  Different contributions to inflammation were likewise indicated by the finding that Ido2 -/- mice did not phenocopy Ido1 -/- mice in the reduced susceptibility of the latter to inflammatory skin cancer.  Taken together, our results offer an initial glimpse into immune modulation by IDO2, revealing its genetic interaction with IDO1 and distinguishing its non-redundant contributions to inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBg-WyevvaRrVg90H21EOLACvtfcHk0ljs2Ovcl8AGmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyit7vK&md5=2f9c4c96ead35f3885de16ea9ccb638c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxt073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxt073%26sid%3Dliteratum%253Aachs%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DChandler%26aufirst%3DP.%26aulast%3DBaban%26aufirst%3DB.%26aulast%3DMerlo%26aufirst%3DL.%2BM.%26aulast%3DPigott%26aufirst%3DE.%26aulast%3DKeough%26aufirst%3DM.%2BP.%26aulast%3DRust%26aufirst%3DS.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26aulast%3DMandik-Nayak%26aufirst%3DL.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DIdo2%2520Is%2520Critical%2520for%2520Ido1-Mediated%2520T-Cell%2520Regulation%2520and%2520Exerts%2520a%2520Non-Redundant%2520Function%2520in%2520Inflammation%26jtitle%3DInt.%2520Immunol.%26date%3D2014%26volume%3D26%26spage%3D357%26epage%3D367%26doi%3D10.1093%2Fintimm%2Fdxt073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolusic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Plaen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uyttenhove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masereel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Reversal of Tumoral Immune Resistance by Inhibition of Tryptophan 2,3-Dioxygenase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2502</span>, <span class="refDoi"> DOI: 10.1073/pnas.1113873109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.1113873109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=22308364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVKnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=2497-2502&author=L.+Pilotteauthor=P.+Larrieuauthor=V.+Stroobantauthor=D.+Colauauthor=E.+Dolusicauthor=R.+Frederickauthor=E.+De+Plaenauthor=C.+Uyttenhoveauthor=J.+Woutersauthor=B.+Masereelauthor=B.+J.+Van+den+Eynde&title=Reversal+of+Tumoral+Immune+Resistance+by+Inhibition+of+Tryptophan+2%2C3-Dioxygenase&doi=10.1073%2Fpnas.1113873109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Pilotte, Luc; Larrieu, Pierre; Stroobant, Vincent; Colau, Didier; Dolusic, Eduard; Frederick, Raphael; De Plaen, Etienne; Uyttenhove, Catherine; Wouters, Johan; Masereel, Bernard; Vand den Eynde, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2497-2502, S2497/1-S2497/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance, and IDO1 inhibition is an active area of drug development.  Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway.  Here, we show that enzymically active TDO is expressed in a significant proportion of human tumors.  In a preclin. model, TDO expression by tumors prevented their rejection by immunized mice.  We developed a TDO inhibitor, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors.  Our results describe a mechanism of tumoral immune resistance based on TDO expression and establish proof-of-concept for the use of TDO inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUOPsopvoi1LVg90H21EOLACvtfcHk0ljs2Ovcl8AGmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVKnt7o%253D&md5=e29b0d7a9180526a2b79173c75765e6c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1113873109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1113873109%26sid%3Dliteratum%253Aachs%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DLarrieu%26aufirst%3DP.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DDolusic%26aufirst%3DE.%26aulast%3DFrederick%26aufirst%3DR.%26aulast%3DDe%2BPlaen%26aufirst%3DE.%26aulast%3DUyttenhove%26aufirst%3DC.%26aulast%3DWouters%26aufirst%3DJ.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DReversal%2520of%2520Tumoral%2520Immune%2520Resistance%2520by%2520Inhibition%2520of%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D2497%26epage%3D2502%26doi%3D10.1073%2Fpnas.1113873109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dvorakova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouzin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daumerie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solvay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaessens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letellier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renauld, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Baren, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelotte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbaix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-19-0040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F2326-6066.CIR-19-0040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31806639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Krur%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=19-31&author=D.+Hoffmannauthor=T.+Dvorakovaauthor=V.+Stroobantauthor=C.+Bouzinauthor=A.+Daumerieauthor=M.+Solvayauthor=S.+Klaessensauthor=M.+C.+Letellierauthor=J.+C.+Renauldauthor=N.+van+Barenauthor=J.+Lelotteauthor=E.+Marbaixauthor=B.+J.+Van+den+Eynde&title=Tryptophan+2%2C3-Dioxygenase+Expression+Identified+in+Human+Hepatocellular+Carcinoma+Cells+and+in+Intratumoral+Pericytes+of+Most+Cancers&doi=10.1158%2F2326-6066.CIR-19-0040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan 2,3-dioxygenase expression identified in human hepatocellular carcinoma cells and in intratumoral pericytes of most cancers</span></div><div class="casAuthors">Hoffmann, Delia; Dvorakova, Tereza; Stroobant, Vincent; Bouzin, Caroline; Daumerie, Aurelie; Solvay, Marie; Klaessens, Simon; Letellier, Marie-Claire; Renauld, Jean Christophe; van Baren, Nicolas; Lelotte, Julie; Marbaix, Etienne; Van den Eynde, Benoit J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-31</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tryptophan catabolism is used by tumors to resist immune attack.  It can be catalyzed by indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO).  IDO1 is frequently expressed in tumors and has been widely studied as a potential therapeutic target to reduce resistance to cancer immunotherapy.  In contrast, TDO expression in tumors is not well characterized.  Several human tumor cell lines constitutively express enzymically active TDO.  In human tumor samples, TDO expression has previously been detected by transcriptomics, but the lack of validated antibodies has precluded detection of the TDO protein and identification of TDO-expressing cells.  Here we developed novel TDO-specific monoclonal antibodies and confirmed by immunohistochem. the expression of TDO in the majority of human cancers.  In all hepatocarcinomas (10/10), TDO was expressed by most tumor cells.  Some glioblastomas (10/39) and kidney carcinomas (1/10) also expressed TDO in tumor cells themselves, but only in focal tumor areas.  In addn., all cancers tested contained foci of non-tumoral TDO-expressing cells, which were identified as pericytes by their expression of PDGFRβ and their location in vascular structures.  These TDO-expressing pericytes belonged to morphol. abnormal tumor vessels and were found in high-grade tumors in the vicinity of necrotic or hemorrhagic areas, which were characterized by neoangiogenesis.  We obsd. similar TDO-expressing pericytes in inflammatory pulmonary lesions contg. granulation tissue, and in chorionic villi, two tissue types that also feature neoangiogenesis.  Our results confirm TDO as a relevant immunotherapeutic target in hepatocellular carcinoma, and suggest a proangiogenic role of TDO in other cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCXx-A0Kw2LVg90H21EOLACvtfcHk0liZX-WMJX9_FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Krur%252FM&md5=047cf84e64d7472efd7c637ddd7ba520</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-19-0040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-19-0040%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DD.%26aulast%3DDvorakova%26aufirst%3DT.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DBouzin%26aufirst%3DC.%26aulast%3DDaumerie%26aufirst%3DA.%26aulast%3DSolvay%26aufirst%3DM.%26aulast%3DKlaessens%26aufirst%3DS.%26aulast%3DLetellier%26aufirst%3DM.%2BC.%26aulast%3DRenauld%26aufirst%3DJ.%2BC.%26aulast%3Dvan%2BBaren%26aufirst%3DN.%26aulast%3DLelotte%26aufirst%3DJ.%26aulast%3DMarbaix%26aufirst%3DE.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DTryptophan%25202%252C3-Dioxygenase%2520Expression%2520Identified%2520in%2520Human%2520Hepatocellular%2520Carcinoma%2520Cells%2520and%2520in%2520Intratumoral%2520Pericytes%2520of%2520Most%2520Cancers%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2020%26volume%3D8%26spage%3D19%26epage%3D31%26doi%3D10.1158%2F2326-6066.CIR-19-0040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03491631" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03491631</a> (accessed May 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03491631+%28accessed+May+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03641794" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03641794</a> (accessed May 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03641794+%28accessed+May+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioretti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span> <span> </span><span class="NLM_article-title">Socs3 Drives Proteasomal Degradation of Indoleamine 2,3-Dioxygenase (Ido) and Antagonizes Ido-Dependent Tolerogenesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">20828</span>– <span class="NLM_lpage">20833</span>, <span class="refDoi"> DOI: 10.1073/pnas.0810278105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.0810278105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=19088199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=20828-20833&author=C.+Orabonaauthor=M.+T.+Pallottaauthor=C.+Volpiauthor=F.+Fallarinoauthor=C.+Vaccaauthor=R.+Bianchiauthor=M.+L.+Belladonnaauthor=M.+C.+Fiorettiauthor=U.+Grohmannauthor=P.+Puccetti&title=Socs3+Drives+Proteasomal+Degradation+of+Indoleamine+2%2C3-Dioxygenase+%28Ido%29+and+Antagonizes+Ido-Dependent+Tolerogenesis&doi=10.1073%2Fpnas.0810278105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis</span></div><div class="casAuthors">Orabona, Ciriana; Pallotta, Maria T.; Volpi, Claudia; Fallarino, Francesca; Vacca, Carmine; Bianchi, Roberta; Belladonna, Maria L.; Fioretti, Maria C.; Grohmann, Ursula; Puccetti, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">20828-20833</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite their common ability to activate intracellular signaling through CD80/CD86 mols., cytotoxic T lymphocyte antigen 4 (CTLA-4)-Ig and CD28-Ig bias the downstream response in opposite directions, the latter promoting immunity, and CTLA-4-Ig tolerance, in dendritic cells (DCs) with opposite but flexible programs of antigen presentation.  Nevertheless, in the absence of suppressor of cytokine signaling 3 (SOCS3), CD28-Ig - and the assocd., dominant IL-6 response-become immunosuppressive and mimic the effect of CTLA-4-Ig, including a high functional expression of the tolerogenic enzyme indoleamine 2,3-dioxygenase (IDO).  Here we show that forced SOCS3 expression antagonized CTLA-4-Ig activity in a proteasome-dependent fashion.  Unrecognized by previous studies, IDO appeared to possess two tyrosine residues within two distinct putative immunoreceptor tyrosine-based inhibitory motifs, VPY115CEL and LLY253EGV.  We found that SOCS3 - known to interact with phosphotyrosine-contg. peptides and be selectively induced by CD28-Ig/IL-6 - would bind IDO and target the IDO/SOCS3 complex for ubiquitination and subsequent proteasomal degrdn.  This event accounted for the ability of CD28-Ig and IL-6 to convert otherwise tolerogenic, IDO-competent DCs into immunogenic cells.  Thus onset of immunity in response to antigen within an early inflammatory context requires that IDO be degraded in tolerogenic DCs.  In addn. to identifying SOCS3 as a candidate signature for mouse DC subsets programmed to direct immunity, this study demonstrates that IDO undergoes regulatory proteolysis in response to immunogenic stimuli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX7Y39qFDWH7Vg90H21EOLACvtfcHk0liZX-WMJX9_FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFSnsw%253D%253D&md5=31aa780e675a4e11490f79a329ca2e01</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0810278105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0810278105%26sid%3Dliteratum%253Aachs%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DFioretti%26aufirst%3DM.%2BC.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DPuccetti%26aufirst%3DP.%26atitle%3DSocs3%2520Drives%2520Proteasomal%2520Degradation%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528Ido%2529%2520and%2520Antagonizes%2520Ido-Dependent%2520Tolerogenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D20828%26epage%3D20833%26doi%3D10.1073%2Fpnas.0810278105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunacci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvitti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicciato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazza, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioretti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase Is a Signaling Protein in Long-Term Tolerance by Dendritic Cells</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">870</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1038/ni.2077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fni.2077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=21804557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFKrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=870-878&author=M.+T.+Pallottaauthor=C.+Orabonaauthor=C.+Volpiauthor=C.+Vaccaauthor=M.+L.+Belladonnaauthor=R.+Bianchiauthor=G.+Servilloauthor=C.+Brunacciauthor=M.+Calvittiauthor=S.+Bicciatoauthor=E.+M.+Mazzaauthor=L.+Boonauthor=F.+Grassiauthor=M.+C.+Fiorettiauthor=F.+Fallarinoauthor=P.+Puccettiauthor=U.+Grohmann&title=Indoleamine+2%2C3-Dioxygenase+Is+a+Signaling+Protein+in+Long-Term+Tolerance+by+Dendritic+Cells&doi=10.1038%2Fni.2077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells</span></div><div class="casAuthors">Pallotta, Maria T.; Orabona, Ciriana; Volpi, Claudia; Vacca, Carmine; Belladonna, Maria L.; Bianchi, Roberta; Servillo, Giuseppe; Brunacci, Cinzia; Calvitti, Mario; Bicciato, Silvio; Mazza, Emilia M. C.; Boon, Louis; Grassi, Fabio; Fioretti, Maria C.; Fallarino, Francesca; Puccetti, Paolo; Grohmann, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">870-878</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Regulation of tryptophan metab. by indoleamine 2,3-dioxygenase (IDO) in dendritic cells (DCs) is a highly versatile modulator of immunity.  In inflammation, interferon-γ is the main inducer of IDO for the prevention of hyperinflammatory responses, yet IDO is also responsible for self-tolerance effects in the longer term.  Here we show that treatment of mouse plasmacytoid DCs (pDCs) with transforming growth factor-β (TGF-β) conferred regulatory effects on IDO that were mechanistically separable from its enzymic activity.  We found that IDO was involved in intracellular signaling events responsible for the self-amplification and maintenance of a stably regulatory phenotype in pDCs.  Thus, IDO has a tonic, nonenzymic function that contributes to TGF-β-driven tolerance in noninflammatory contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOrM5pvb6iRbVg90H21EOLACvtfcHk0liiMEKdzKx7AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFKrurg%253D&md5=a3dc34802dc62b40d2255ce20bff1e54</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fni.2077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2077%26sid%3Dliteratum%253Aachs%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DServillo%26aufirst%3DG.%26aulast%3DBrunacci%26aufirst%3DC.%26aulast%3DCalvitti%26aufirst%3DM.%26aulast%3DBicciato%26aufirst%3DS.%26aulast%3DMazza%26aufirst%3DE.%2BM.%26aulast%3DBoon%26aufirst%3DL.%26aulast%3DGrassi%26aufirst%3DF.%26aulast%3DFioretti%26aufirst%3DM.%2BC.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DPuccetti%26aufirst%3DP.%26aulast%3DGrohmann%26aufirst%3DU.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520Is%2520a%2520Signaling%2520Protein%2520in%2520Long-Term%2520Tolerance%2520by%2520Dendritic%2520Cells%26jtitle%3DNat.%2520Immunol.%26date%3D2011%26volume%3D12%26spage%3D870%26epage%3D878%26doi%3D10.1038%2Fni.2077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span> <span> </span><span class="NLM_article-title">Different Partners, Opposite Outcomes: A New Perspective of the Immunobiology of Indoleamine 2,3-Dioxygenase</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.2119/molmed.2012.00029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.2119%2Fmolmed.2012.00029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=22481272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOgu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=834-842&author=C.+Orabonaauthor=M.+T.+Pallottaauthor=U.+Grohmann&title=Different+Partners%2C+Opposite+Outcomes%3A+A+New+Perspective+of+the+Immunobiology+of+Indoleamine+2%2C3-Dioxygenase&doi=10.2119%2Fmolmed.2012.00029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase</span></div><div class="casAuthors">Orabona, Ciriana; Pallotta, Maria Teresa; Grohmann, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Manhasset, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">834-842</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1076-1551</span>.
    
            (<span class="NLM_cas:orgname">Feinstein Institute for Medical Research</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase (IDO), a metabolic enzyme that catalyzes tryptophan conversion into kynurenines, is a crucial regulator of immunity.  Altered IDO activity is often assocd. with pathol., including neoplasia and autoimmunity.  IDO is highly expressed in dendritic cells (DCs) that exploit the enzyme's activity and the prodn. of tryptophan catabolites to regulate immune responses by acting on several cell types, including T lymphocytes, of which they promote a regulatory phenotype.  IDO also contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that, once bound by distinct mol. partners, will either promote degrdn. or initiate signaling activity and self-maintenance of the enzyme.  We here discuss how ITIM-dependent mol. events can affect the functional plasticity of IDO by modifying the protein half-life and its enzymic and nonenzymic functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVWmgYosVfx7Vg90H21EOLACvtfcHk0liiMEKdzKx7AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOgu7rL&md5=374d70b6c8d944b8d9821367f1e53210</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2119%2Fmolmed.2012.00029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2119%252Fmolmed.2012.00029%26sid%3Dliteratum%253Aachs%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DGrohmann%26aufirst%3DU.%26atitle%3DDifferent%2520Partners%252C%2520Opposite%2520Outcomes%253A%2520A%2520New%2520Perspective%2520of%2520the%2520Immunobiology%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DMol.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D834%26epage%3D842%26doi%3D10.2119%2Fmolmed.2012.00029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondanelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antognelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span> <span> </span><span class="NLM_article-title">Distinct Roles of Immunoreceptor Tyrosine-Based Motifs in Immunosuppressive Indoleamine 2,3-Dioxygenase 1</span>. <i>J. Cell Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1111%2Fjcmm.12954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27696702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis12m" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=165-176&author=E.+Albiniauthor=V.+Rosiniauthor=M.+Gargaroauthor=G.+Mondanelliauthor=M.+L.+Belladonnaauthor=M.+T.+Pallottaauthor=C.+Volpiauthor=F.+Fallarinoauthor=A.+Macchiaruloauthor=C.+Antognelliauthor=R.+Bianchiauthor=C.+Vaccaauthor=P.+Puccettiauthor=U.+Grohmannauthor=C.+Orabona&title=Distinct+Roles+of+Immunoreceptor+Tyrosine-Based+Motifs+in+Immunosuppressive+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1111%2Fjcmm.12954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Albini, Elisa; Rosini, Verdiana; Gargaro, Marco; Mondanelli, Giada; Belladonna, Maria L.; Pallotta, Maria Teresa; Volpi, Claudia; Fallarino, Francesca; Macchiarulo, Antonio; Antognelli, Cinzia; Bianchi, Roberta; Vacca, Carmine; Puccetti, Paolo; Grohmann, Ursula; Orabona, Ciriana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-176</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the initial, rate-limiting step in tryptophan (Trp) degrdn., resulting in tryptophan starvation and the prodn. of immunoregulatory kynurenines.  IDO1's catalytic function has long been considered as the one mechanism responsible for IDO1-dependent immune suppression by dendritic cells (DCs), which are master regulators of the balance between immunity and tolerance.  However, IDO1 also harbors immunoreceptor tyrosine-based inhibitory motifs, (ITIM1 and ITIM2), that, once phosphorylated, bind protein tyrosine phosphatases, (SHP-1 and SHP-2), and thus trigger an immunoregulatory signalling in DCs.  This mechanism leads to sustained IDO1 expression, in a feedforward loop, which is particularly important in restraining autoimmunity and chronic inflammation.  Yet, under specific conditions requiring that early and protective inflammation be unrelieved, tyrosine-phosphorylated ITIMs will instead bind the suppressor of cytokine signalling 3 (SOCS3), which drives IDO1 proteasomal degrdn. and shortens the enzyme half-life.  To dissect any differential roles of the two IDO1's ITIMs, we generated protein mutants by replacing one or both ITIM-assocd. tyrosines with phospho-mimicking glutamic acid residues.  Although all mutants lost their enzymic activity, the ITIM1 - but not ITIM2 mutant - did bind SHPs and conferred immunosuppressive effects on DCs, making cells capable of restraining an antigen-specific response in vivo.  Conversely, the ITIM2 mutant would preferentially bind SOCS3, and IDO1's degrdn. was accelerated.  Thus, it is the selective phosphorylation of either ITIM that controls the duration of IDO1 expression and function, in that it dictates whether enhanced tolerogenic signalling or shutdown of IDO1-dependent events will occur in a local microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolWXs-y6HUa7Vg90H21EOLACvtfcHk0liiMEKdzKx7AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis12m&md5=641c240294f776eb3cfc79f042aab83b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12954%26sid%3Dliteratum%253Aachs%26aulast%3DAlbini%26aufirst%3DE.%26aulast%3DRosini%26aufirst%3DV.%26aulast%3DGargaro%26aufirst%3DM.%26aulast%3DMondanelli%26aufirst%3DG.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DAntognelli%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DPuccetti%26aufirst%3DP.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DOrabona%26aufirst%3DC.%26atitle%3DDistinct%2520Roles%2520of%2520Immunoreceptor%2520Tyrosine-Based%2520Motifs%2520in%2520Immunosuppressive%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2017%26volume%3D21%26spage%3D165%26epage%3D176%26doi%3D10.1111%2Fjcmm.12954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batabyal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkashon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into Substrate and Inhibitor Binding Sites in Human Indoleamine 2,3-Dioxygenase 1</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1700</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-01725-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41467-017-01725-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29167421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ktFOhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1693-1700&author=A.+Lewis-Ballesterauthor=K.+N.+Phamauthor=D.+Batabyalauthor=S.+Karkashonauthor=J.+B.+Bonannoauthor=T.+L.+Poulosauthor=S.+R.+Yeh&title=Structural+Insights+into+Substrate+and+Inhibitor+Binding+Sites+in+Human+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1038%2Fs41467-017-01725-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Lewis-Ballester Ariel; Pham Khoa N; Karkashon Shay; Yeh Syun-Ru; Batabyal Dipanwita; Poulos Thomas L; Batabyal Dipanwita; Poulos Thomas L; Batabyal Dipanwita; Poulos Thomas L; Bonanno Jeffrey B</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1693</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an attractive cancer immunotherapeutic target owing to its role in promoting tumoral immune escape.  However, drug development has been hindered by limited structural information.  Here, we report the crystal structures of hIDO1 in complex with its substrate, Trp, an inhibitor, epacadostat, and/or an effector, indole ethanol (IDE).  The data reveal structural features of the active site (Sa) critical for substrate activation; in addition, they disclose a new inhibitor-binding mode and a distinct small molecule binding site (Si).  Structure-guided mutation of a critical residue, F270, to glycine perturbs the Si site, allowing structural determination of an inhibitory complex, where both the Sa and Si sites are occupied by Trp.  The Si site offers a novel target site for allosteric inhibitors and a molecular explanation for the previously baffling substrate-inhibition behavior of the enzyme.  Taken together, the data open exciting new avenues for structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI81SqDTDg0dbHMBt0mMIXfW6udTcc2eY3yO--6ssDIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ktFOhtQ%253D%253D&md5=36b0221b0726c73a6c4345e4cf2ec8be</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01725-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01725-8%26sid%3Dliteratum%253Aachs%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DBatabyal%26aufirst%3DD.%26aulast%3DKarkashon%26aufirst%3DS.%26aulast%3DBonanno%26aufirst%3DJ.%2BB.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DStructural%2520Insights%2520into%2520Substrate%2520and%2520Inhibitor%2520Binding%2520Sites%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D1693%26epage%3D1700%26doi%3D10.1038%2Fs41467-017-01725-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelp, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kates, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, J. T.</span></span> <span> </span><span class="NLM_article-title">Immune-Modulating Enzyme Indoleamine 2,3-Dioxygenase Is Effectively Inhibited by Targeting Its Apo-Form</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3249</span>– <span class="NLM_lpage">3254</span>, <span class="refDoi"> DOI: 10.1073/pnas.1719190115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.1719190115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29531094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Ckur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=3249-3254&author=M.+T.+Nelpauthor=P.+A.+Katesauthor=J.+T.+Huntauthor=J.+A.+Newittauthor=A.+Balogauthor=D.+Maleyauthor=X.+Zhuauthor=L.+Abellauthor=A.+Allentoffauthor=R.+Borzilleriauthor=H.+A.+Lewisauthor=Z.+Linauthor=S.+P.+Seitzauthor=C.+Yanauthor=J.+T.+Groves&title=Immune-Modulating+Enzyme+Indoleamine+2%2C3-Dioxygenase+Is+Effectively+Inhibited+by+Targeting+Its+Apo-Form&doi=10.1073%2Fpnas.1719190115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form</span></div><div class="casAuthors">Nelp, Micah T.; Kates, Patrick A.; Hunt, John T.; Newitt, John A.; Balog, Aaron; Maley, Derrick; Zhu, Xiao; Abelle, Lynn; Allentoff, Alban; Borzilleri, Robert; Lewis, Hal A.; Lin, Zeyu; Seitz, Steven P.; Yan, Chunhong; Groves, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3249-3254</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">For cancer cells to survive and proliferate, they must escape normal immune destruction.  One mechanism by which this is accomplished is through immune suppression effected by up-regulation of indole- amine 2,3-dioxygenase (IDO1), a heme enzyme that catalyzes the oxidn. of tryptophan to N-formylkynurenine.  On deformylation, kynurenine and downstream metabolites suppress T cell function.  The importance of this immunosuppressive mechanism has spurred intense interest in the development of clin. IDO1 inhibitors.  Herein, we describe the mechanism by which a class of compds. effectively and specifically inhibits IDO1 by targeting its apo- form.  We show that the in vitro kinetics of inhibition coincide with an unusually high rate of intrinsic enzyme-heme dissocn., esp. in the ferric form.  X-ray crystal structures of the inhibitor-enzyme complexes show that heme is displaced from the enzyme and blocked from rebinding by these compds.  The results reveal that apo-IDO1 serves as a unique target for inhibition and that heme lability plays an important role in posttranslational regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoqG51BFbfm7Vg90H21EOLACvtfcHk0lhKwP1FppCJ3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Ckur7I&md5=b44352b022692d150053696bb984665f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1719190115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1719190115%26sid%3Dliteratum%253Aachs%26aulast%3DNelp%26aufirst%3DM.%2BT.%26aulast%3DKates%26aufirst%3DP.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DBalog%26aufirst%3DA.%26aulast%3DMaley%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DAbell%26aufirst%3DL.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DBorzilleri%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DGroves%26aufirst%3DJ.%2BT.%26atitle%3DImmune-Modulating%2520Enzyme%2520Indoleamine%25202%252C3-Dioxygenase%2520Is%2520Effectively%2520Inhibited%2520by%2520Targeting%2520Its%2520Apo-Form%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3D3249%26epage%3D3254%26doi%3D10.1073%2Fpnas.1719190115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">14538</span>– <span class="NLM_lpage">14541</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b07994</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b07994" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFygsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=14538-14541&author=K.+N.+Phamauthor=S.+R.+Yeh&title=Mapping+the+Binding+Trajectory+of+a+Suicide+Inhibitor+in+Human+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1021%2Fjacs.8b07994"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1</span></div><div class="casAuthors">Pham, Khoa N.; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">14538-14541</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) is an important heme-contg. enzyme that is a key drug target for cancer immunotherapy.  Several hIDO1 inhibitors have entered clin. trials, among which BMS-986205 (BMS) stands out as the only suicide inhibitor.  Despite its "best-in-class" activity, the action mechanism of BMS remains elusive.  Here, we report three crystal structures of hIDO1-BMS complexes that define the complete binding trajectory of the inhibitor.  BMS first binds in a solvent exposed surface cleft near the active site in an extended conformation.  The initial binding partially unfolds the active site, which triggers heme release, thereby exposing a new binding pocket.  The inhibitor then undergoes a large scale movement to this new binding pocket, where it binds by adopting a high energy kinked conformation.  Finally, the inhibitor relaxes to a bent conformation, via an addnl. large scale rearrangement, culminating in the energy min. state.  The structural data offer a mol. explanation for the remarkable efficacy and suicide inhibition activity of the inhibitor.  They also suggest a novel strategy that can be applied for drug development targeting hIDO1 and related enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo49tBUq_145rVg90H21EOLACvtfcHk0lhKwP1FppCJ3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFygsbfJ&md5=833164c8276bd3b8d9d93df197cf4780</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b07994&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b07994%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DMapping%2520the%2520Binding%2520Trajectory%2520of%2520a%2520Suicide%2520Inhibitor%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D14538%26epage%3D14541%26doi%3D10.1021%2Fjacs.8b07994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottemanne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannelle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauwenberghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordonnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroose, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrerie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Eynde, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (Ido-1) Inhibitor 3-(5-Fluoro-1h-Indol-3-Yl)Pyrrolidine-2,5-Dione (Eos200271/Pf-06840003) and Its Characterization as a Potential Clinical Candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9617</span>– <span class="NLM_lpage">9629</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00974</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00974" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9617-9629&author=S.+Crosignaniauthor=P.+Binghamauthor=P.+Bottemanneauthor=H.+Cannelleauthor=S.+Cauwenberghsauthor=M.+Cordonnierauthor=D.+Dalvieauthor=F.+Derooseauthor=J.+L.+Fengauthor=B.+Gomesauthor=S.+Greasleyauthor=S.+E.+Kaiserauthor=M.+Krausauthor=M.+Negrerieauthor=K.+Maegleyauthor=N.+Millerauthor=B.+W.+Murrayauthor=M.+Schneiderauthor=J.+Soloweijauthor=A.+E.+Stewartauthor=J.+Tumangauthor=V.+R.+Tortiauthor=B.+Van+Den+Eyndeauthor=M.+Wythes&title=Discovery+of+a+Novel+and+Selective+Indoleamine+2%2C3-Dioxygenase+%28Ido-1%29+Inhibitor+3-%285-Fluoro-1h-Indol-3-Yl%29Pyrrolidine-2%2C5-Dione+%28Eos200271%2FPf-06840003%29+and+Its+Characterization+as+a+Potential+Clinical+Candidate&doi=10.1021%2Facs.jmedchem.7b00974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate</span></div><div class="casAuthors">Crosignani, Stefano; Bingham, Patrick; Bottemanne, Pauline; Cannelle, Helene; Cauwenberghs, Sandra; Cordonnier, Marie; Dalvie, Deepak; Deroose, Frederik; Feng, Jun Li; Gomes, Bruno; Greasley, Samantha; Kaiser, Stephen E.; Kraus, Manfred; Negrerie, Michel; Maegley, Karen; Miller, Nichol; Murray, Brion W.; Schneider, Manfred; Soloweij, James; Stewart, Albert E.; Tumang, Joseph; Torti, Vince R.; Van Den Eynde, Benoit; Wythes, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9617-9629</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment.  IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function.  As such, IDO-1 is a nexus for the induction of a key immunosuppressive mechanism and represents an important immunotherapeutic target in oncol.  Starting from HTS hit I, IDO-1 inhibitor II has been developed.  The structure-activity relationship around II is described and rationalized using the x-ray crystal structure of II bound to human IDO-1, which shows that II, differently from most of the IDO-1 inhibitors described so far, does not bind to the heme iron atom and has a novel binding mode.  Clin. candidate II shows good potency in an IDO-1 human whole blood assay and also shows a very favorable ADME profile leading to favorable predicted human pharmacokinetic properties, including a predicted half-life of 16-19 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogfHmZRAC-dLVg90H21EOLACvtfcHk0lh978Fv9vMQyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK&md5=dc2e45c243aa22c100ccc39db9b5918a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00974%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBottemanne%26aufirst%3DP.%26aulast%3DCannelle%26aufirst%3DH.%26aulast%3DCauwenberghs%26aufirst%3DS.%26aulast%3DCordonnier%26aufirst%3DM.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDeroose%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DGreasley%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DS.%2BE.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DNegrerie%26aufirst%3DM.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSoloweij%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTumang%26aufirst%3DJ.%26aulast%3DTorti%26aufirst%3DV.%2BR.%26aulast%3DVan%2BDen%2BEynde%26aufirst%3DB.%26aulast%3DWythes%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520and%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528Ido-1%2529%2520Inhibitor%25203-%25285-Fluoro-1h-Indol-3-Yl%2529Pyrrolidine-2%252C5-Dione%2520%2528Eos200271%252FPf-06840003%2529%2520and%2520Its%2520Characterization%2520as%2520a%2520Potential%2520Clinical%2520Candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9617%26epage%3D9629%26doi%3D10.1021%2Facs.jmedchem.7b00974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosdidier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerundolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1172</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1021/jm9014718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9014718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1emsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1172-1189&author=U.+F.+Rohrigauthor=L.+Awadauthor=A.+Grosdidierauthor=P.+Larrieuauthor=V.+Stroobantauthor=D.+Colauauthor=V.+Cerundoloauthor=A.+J.+Simpsonauthor=P.+Vogelauthor=B.+J.+Van+den+Eyndeauthor=V.+Zoeteauthor=O.+Michielin&title=Rational+Design+of+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Fjm9014718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Awad, Loay; Grosdidier, Aurelien; Larrieu, Pierre; Stroobant, Vincent; Colau, Didier; Cerundolo, Vincenzo; Simpson, Andrew J. G.; Vogel, Pierre; Van den Eynde, Benoit J.; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1172-1189</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is an important therapeutic target for the treatment of diseases such as cancer that involve pathol. immune escape.  We have used the evolutionary docking algorithm EADock to design new inhibitors of this enzyme.  First, we investigated the modes of binding of all known IDO inhibitors.  On the basis of the obsd. docked conformations, we developed a pharmacophore model, which was then used to devise new compds. to be tested for IDO inhibition.  We also used a fragment-based approach to design and to optimize small org. mol. inhibitors.  Both approaches yielded several new low-mol. wt. inhibitor scaffolds, the most active being of nanomolar potency in an enzymic assay.  Cellular assays confirmed the potential biol. relevance of four different scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9k4hgz-V8J7Vg90H21EOLACvtfcHk0lh978Fv9vMQyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1emsA%253D%253D&md5=be50f3dff0bcee6ae59f19d2fc4e5552</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm9014718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9014718%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DAwad%26aufirst%3DL.%26aulast%3DGrosdidier%26aufirst%3DA.%26aulast%3DLarrieu%26aufirst%3DP.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DCerundolo%26aufirst%3DV.%26aulast%3DSimpson%26aufirst%3DA.%2BJ.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DRational%2520Design%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1172%26epage%3D1189%26doi%3D10.1021%2Fjm9014718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griglio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coda Zabetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span> <span> </span><span class="NLM_article-title">A Multicomponent Approach in the Discovery of Indoleamine 2,3-Dioxygenase 1 Inhibitors: Synthesis, Biological Investigation and Docking Studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2018.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29398544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFejsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=651-657&author=A.+Griglioauthor=E.+Torreauthor=M.+Serafiniauthor=A.+Bianchiauthor=R.+Schmidauthor=G.+Coda+Zabettaauthor=A.+Massarottiauthor=G.+Sorbaauthor=T.+Piraliauthor=S.+Fallarini&title=A+Multicomponent+Approach+in+the+Discovery+of+Indoleamine+2%2C3-Dioxygenase+1+Inhibitors%3A+Synthesis%2C+Biological+Investigation+and+Docking+Studies&doi=10.1016%2Fj.bmcl.2018.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: Synthesis, biological investigation and docking studies</span></div><div class="casAuthors">Griglio, Alessia; Torre, Enza; Serafini, Marta; Bianchi, Alice; Schmid, Roberta; Coda Zabetta, Giulia; Massarotti, Alberto; Sorba, Giovanni; Pirali, Tracey; Fallarini, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">651-657</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase plays a crucial role in immune tolerance and has emerged as an attractive target for cancer immunotherapy.  The Passerini and Ugi multicomponent reactions were employed to assemble a small library of imidazothiazoles that target IDO1.  While the p-bromophenyl and the imidazothiazole moieties were kept fixed, a full SAR study was performed on the side-chain, leading to the discovery of nine compds. with sub-micromolar IC50 values in the enzyme-based assay.  Compd. 2(((3-(4-bromophenyl)imidazo[2,1-b]bromophenyl)thiazol-5-yl)methyl)amino-2-oxoethyl-2-(4-hydroxyphenyl)acetate displaying a α-acyloxyamide substructure, is the most potent compd., with an IC50 value of 0.20 μM, but a low activity in a cell-based assay.  Compd. N-(2-((((4-bromophenyl)imidazo[2,1-b]thiazol-yl)methyl)amino)-2-oxoethyl)-N-methyl-2-(4-nitrophenyl)acetamide, contg. a α-acylaminoamide moiety, shows an IC50 value of 0.81 μM in the IDO1-based assay, a full biocompatibility at 10 μM, together with a modest inhibitory activity in A375 cells.  Mol. docking studies show that both 2(((3-(4-bromophenyl)imidazo[2,1-b]bromophenyl)thiazol-5-yl)methyl)amino-2-oxoethyl-2-(4-hydroxyphenyl)acetate and N-(2-((((4-bromophenyl)imidazolo[2,1-b]thiazol-yl)methyl)amino)-2-oxoethyl)-N-methyl-2-(4-nitrophenyl)acetamide display a unique binding mode in the IDO1 active site, with the side-chain protruding in an addnl. pocket C, where a crucial hydrogen bond is formed with Lys238.  Overall, this work describes an isocyanide based-multicomponent approach as a straightforward and versatile tool to rapidly access IDO1 inhibitors, providing a new direction for their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64_p69vrWELVg90H21EOLACvtfcHk0ljyS-ljqUZ6YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFejsr4%253D&md5=4390159c52c08f3eb23e84f10ecb7138</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DGriglio%26aufirst%3DA.%26aulast%3DTorre%26aufirst%3DE.%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DBianchi%26aufirst%3DA.%26aulast%3DSchmid%26aufirst%3DR.%26aulast%3DCoda%2BZabetta%26aufirst%3DG.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DFallarini%26aufirst%3DS.%26atitle%3DA%2520Multicomponent%2520Approach%2520in%2520the%2520Discovery%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitors%253A%2520Synthesis%252C%2520Biological%2520Investigation%2520and%2520Docking%2520Studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D651%26epage%3D657%26doi%3D10.1016%2Fj.bmcl.2018.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Meoz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matico, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De la Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Midgett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mebrahtu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoritis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campobasso, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mülbaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmierski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">324947</span>, <span class="refDoi"> DOI: 10.1002/cbic.202000298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcbic.202000298" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=324947&author=R.+Ortiz-Meozauthor=L.+Wangauthor=R.+Maticoauthor=A.+Rutkowskaauthor=M.+De+la+Rosaauthor=S.+Bedardauthor=R.+Midgettauthor=K.+Strohmerauthor=D.+Thomsonauthor=C.+Zhangauthor=M.+Mebrahtuauthor=J.+Gussauthor=R.+Totoritisauthor=T.+Conslerauthor=N.+Campobassoauthor=D.+Taylorauthor=T.+Lewisauthor=K.+Weaverauthor=M.+M%C3%BClbaierauthor=J.+Sealauthor=R.+Dunhamauthor=W.+Kazmierskiauthor=D.+Favreauthor=G.+Bergaminiauthor=L.+Shewchukauthor=A.+Rendinaauthor=G.+Zhang&title=Characterization+of+Apo-Form+Selective+Inhibition+of+Indoleamine+2%2C3-Dioxygenase&doi=10.1002%2Fcbic.202000298"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fcbic.202000298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.202000298%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz-Meoz%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMatico%26aufirst%3DR.%26aulast%3DRutkowska%26aufirst%3DA.%26aulast%3DDe%2Bla%2BRosa%26aufirst%3DM.%26aulast%3DBedard%26aufirst%3DS.%26aulast%3DMidgett%26aufirst%3DR.%26aulast%3DStrohmer%26aufirst%3DK.%26aulast%3DThomson%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMebrahtu%26aufirst%3DM.%26aulast%3DGuss%26aufirst%3DJ.%26aulast%3DTotoritis%26aufirst%3DR.%26aulast%3DConsler%26aufirst%3DT.%26aulast%3DCampobasso%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DLewis%26aufirst%3DT.%26aulast%3DWeaver%26aufirst%3DK.%26aulast%3DM%25C3%25BClbaier%26aufirst%3DM.%26aulast%3DSeal%26aufirst%3DJ.%26aulast%3DDunham%26aufirst%3DR.%26aulast%3DKazmierski%26aufirst%3DW.%26aulast%3DFavre%26aufirst%3DD.%26aulast%3DBergamini%26aufirst%3DG.%26aulast%3DShewchuk%26aufirst%3DL.%26aulast%3DRendina%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DG.%26atitle%3DCharacterization%2520of%2520Apo-Form%2520Selective%2520Inhibition%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DChemBioChem%26date%3D2020%26spage%3D324947%26doi%3D10.1002%2Fcbic.202000298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Koenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacciapoli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smotrov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrema, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-Dioxygenase-1 (Ido1)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">550</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=550-557&author=C.+Whiteauthor=M.+A.+McGowanauthor=H.+Zhouauthor=N.+Sciammettaauthor=X.+Fraderaauthor=J.+Limauthor=E.+M.+Joshiauthor=C.+Andrewsauthor=E.+B.+Nickbargauthor=P.+Cowleyauthor=S.+Trewickauthor=M.+Augustinauthor=K.+von+Koenigauthor=C.+A.+Lesburgauthor=K.+Otteauthor=I.+Knemeyerauthor=H.+Wooauthor=W.+Yuauthor=M.+Chengauthor=P.+Spacciapoliauthor=P.+Gedaauthor=X.+Songauthor=N.+Smotrovauthor=P.+Curranauthor=M.+R.+Heoauthor=P.+Abeywickremaauthor=J.+R.+Millerauthor=D.+J.+Bennettauthor=Y.+Han&title=Strategic+Incorporation+of+Polarity+in+Heme-Displacing+Inhibitors+of+Indoleamine-2%2C3-Dioxygenase-1+%28Ido1%29&doi=10.1021%2Facsmedchemlett.0c00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)</span></div><div class="casAuthors">White, Catherine; McGowan, Meredeth A.; Zhou, Hua; Sciammetta, Nunzio; Fradera, Xavier; Lim, Jongwon; Joshi, Elizabeth M.; Andrews, Christine; Nickbarg, Elliott B.; Cowley, Phillip; Trewick, Sarah; Augustin, Martin; von Koenig, Konstanze; Lesburg, Charles A.; Otte, Karin; Knemeyer, Ian; Woo, Hyun; Yu, Wensheng; Cheng, Mangeng; Spacciapoli, Peter; Geda, Prasanthi; Song, Xuelei; Smotrov, Nadya; Curran, Patrick; Heo, Mee Ra; Abeywickrema, Pravien; Miller, J. Richard; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">550-557</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as a target of significant interest to the field of cancer immunotherapy, as the upregulation of IDO1 in certain cancers has been linked to host immune evasion and poor prognosis for patients.  In particular, IDO1 inhibition is of interest as a combination therapy with immune checkpoint inhibition.  Through an Automated Ligand Identification System (ALIS) screen, a diamide class of compds. was identified as a promising lead for the inhibition of IDO1.  While hit 1() possessed attractive cell-based potency, it suffered from a significant right-shift in a whole blood assay, poor soly., and poor pharmacokinetic properties.  Through a physicochem. property-based approach, including a focus on lowering AlogP98 via the strategic introduction of polar substitution, compd. 13 was identified bearing a pyridyl oxetane core.  Compd. 13() demonstrated improved whole blood potency and soly., and an improved pharmacokinetic profile resulting in a low predicted human dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnzfQfxAahcbVg90H21EOLACvtfcHk0ljyS-ljqUZ6YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWksbc%253D&md5=cad9d7aa1db10d920c558cd4ba4af9cd</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00010%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DC.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DJoshi%26aufirst%3DE.%2BM.%26aulast%3DAndrews%26aufirst%3DC.%26aulast%3DNickbarg%26aufirst%3DE.%2BB.%26aulast%3DCowley%26aufirst%3DP.%26aulast%3DTrewick%26aufirst%3DS.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3Dvon%2BKoenig%26aufirst%3DK.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DWoo%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DSpacciapoli%26aufirst%3DP.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSmotrov%26aufirst%3DN.%26aulast%3DCurran%26aufirst%3DP.%26aulast%3DHeo%26aufirst%3DM.%2BR.%26aulast%3DAbeywickrema%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DStrategic%2520Incorporation%2520of%2520Polarity%2520in%2520Heme-Displacing%2520Inhibitors%2520of%2520Indoleamine-2%252C3-Dioxygenase-1%2520%2528Ido1%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D550%26epage%3D557%26doi%3D10.1021%2Facsmedchemlett.0c00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazmierski, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De la Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mebrahtu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evindar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samano, V.</span></span> <span> </span><span class="NLM_article-title">DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (Ido1) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3552</span>– <span class="NLM_lpage">3562</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01799</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01799" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3552-3562&author=W.+M.+Kazmierskiauthor=B.+Xiaauthor=J.+Millerauthor=M.+De+la+Rosaauthor=D.+Favreauthor=R.+M.+Dunhamauthor=Y.+Washioauthor=Z.+Zhuauthor=F.+Wangauthor=M.+Mebrahtuauthor=H.+Dengauthor=J.+Basillaauthor=L.+Wangauthor=G.+Evindarauthor=L.+Fanauthor=A.+Olszewskiauthor=N.+Prabhuauthor=C.+Davieauthor=J.+A.+Messerauthor=V.+Samano&title=DNA-Encoded+Library+Technology-Based+Discovery%2C+Lead+Optimization%2C+and+Prodrug+Strategy+toward+Structurally+Unique+Indoleamine+2%2C3-Dioxygenase-1+%28Ido1%29+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors</span></div><div class="casAuthors">Kazmierski, Wieslaw M.; Xia, Bing; Miller, John; De la Rosa, Martha; Favre, David; Dunham, Richard M.; Washio, Yoshiaki; Zhu, Zhengrong; Wang, Feng; Mebrahtu, Makda; Deng, Hongfeng; Basilla, Jonathan; Wang, Liping; Evindar, Ghotas; Fan, Lijun; Olszewski, Alison; Prabhu, Ninad; Davie, Christopher; Messer, Jeffrey A.; Samano, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3552-3562</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the discovery of a novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor class through the affinity selection of a previously unreported indole-based DNA-encoded library (DEL).  The DEL exemplar, spiro-chromane 1, had moderate IDO1 potency but high in vivo clearance.  Series optimization quickly afforded a potent, low in vivo clearance lead 11.  Although amorphous 11 was highly bio-available, cryst. 11 was poorly sol. and suffered disappointingly low bio-availability because of soly.-limited absorption.  A prodrug approach was deployed and proved effective in discovering the highly bio-available phosphonooxymethyl 31, which rapidly converted to 11 in vivo.  Obtaining cryst. 31 proved problematic, however; thus salt screening was performed in an attempt to circumvent this obstacle and successfully delivered greatly sol. and bio-available cryst. tris-salt 32.  IDO1 inhibitor 32 is characterized by a low calcd. human dose, best-in-class potential, and an unusual inhibition mode by binding the IDO1 heme-free (apo) form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSTj0UyMSxbVg90H21EOLACvtfcHk0lgGv0PsJdrUjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOms7k%253D&md5=8cddeffb12cefd9b3e1c2e0641ad7226</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01799%26sid%3Dliteratum%253Aachs%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26aulast%3DXia%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DJ.%26aulast%3DDe%2Bla%2BRosa%26aufirst%3DM.%26aulast%3DFavre%26aufirst%3DD.%26aulast%3DDunham%26aufirst%3DR.%2BM.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DMebrahtu%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DBasilla%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEvindar%26aufirst%3DG.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DOlszewski%26aufirst%3DA.%26aulast%3DPrabhu%26aufirst%3DN.%26aulast%3DDavie%26aufirst%3DC.%26aulast%3DMesser%26aufirst%3DJ.%2BA.%26aulast%3DSamano%26aufirst%3DV.%26atitle%3DDNA-Encoded%2520Library%2520Technology-Based%2520Discovery%252C%2520Lead%2520Optimization%252C%2520and%2520Prodrug%2520Strategy%2520toward%2520Structurally%2520Unique%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3552%26epage%3D3562%26doi%3D10.1021%2Facs.jmedchem.9b01799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent and Orally Available Bicyclo[1.1.1]Pentane-Derived Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1548</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00195</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1548-1554&author=Q.+Puauthor=H.+Zhangauthor=L.+Guoauthor=M.+Chengauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=X.+Fraderaauthor=C.+A.+Lesburgauthor=M.+A.+McGowanauthor=J.+R.+Millerauthor=P.+Gedaauthor=X.+Songauthor=K.+Otteauthor=N.+Sciammettaauthor=N.+Solbanauthor=W.+Yuauthor=D.+L.+Slomanauthor=H.+Zhouauthor=A.+Lammensauthor=L.+Neumannauthor=D.+J.+Bennettauthor=A.+Pasternakauthor=Y.+Han&title=Discovery+of+Potent+and+Orally+Available+Bicyclo%5B1.1.1%5DPentane-Derived+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1021%2Facsmedchemlett.0c00195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Pu, Qinglin; Zhang, Hongjun; Guo, Liangqin; Cheng, Mangeng; Doty, Amy C.; Ferguson, Heidi; Fradera, Xavier; Lesburg, Charles A.; McGowan, Meredeth A.; Miller, J. Richard; Geda, Prasanthi; Song, Xuelei; Otte, Karin; Sciammetta, Nunzio; Solban, Nicolas; Yu, Wensheng; Sloman, David L.; Zhou, Hua; Lammens, Alfred; Neumann, Lars; Bennett, David Jonathan; Pasternak, Alexander; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1548-1554</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase 1 (IDO1) inhibition and its combination with immune checkpoint inhibitors like pembrolizumab have drawn considerable attention from both academia and the pharmaceutical industry.  Here, we describe the discovery of a novel class of highly potent IDO1 heme-displacing inhibitors featuring a unique bicyclo[1.1.1]pentane motif.  Compd. 1, evolving from an ALIS (automated ligand identification system) hit, exhibited excellent potency but lacked the desired pharmacokinetic profile due to extensive amide hydrolysis of the benzamide moiety.  Replacing the central Ph ring in 1 with a bicyclo[1.1.1]pentane bioisostere effectively circumvented the amide hydrolysis issue, resulting in the discovery of compd. 2(I) with a favorable overall profile such as excellent potency, selectivity, pharmacokinetics, and a low predicted human dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCRMnzRWR18LVg90H21EOLACvtfcHk0lgGv0PsJdrUjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jtLbI&md5=d55b05877e5ee16eeaa7937ef0b83cef</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00195%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DGeda%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DSolban%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DSloman%26aufirst%3DD.%2BL.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLammens%26aufirst%3DA.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DPasternak%26aufirst%3DA.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Potent%2520and%2520Orally%2520Available%2520Bicyclo%255B1.1.1%255DPentane-Derived%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1548%26epage%3D1554%26doi%3D10.1021%2Facsmedchemlett.0c00195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pojer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (Ido1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8784</span>– <span class="NLM_lpage">8795</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00942</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00942" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOqu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8784-8795&author=U.+F.+Rohrigauthor=A.+Reynaudauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=F.+Pojerauthor=V.+Zoete&title=Inhibition+Mechanisms+of+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29&doi=10.1021%2Facs.jmedchem.9b00942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)</span></div><div class="casAuthors">Rohrig, Ute F.; Reynaud, Aline; Majjigapu, Somi Reddy; Vogel, Pierre; Pojer, Florence; Zoete, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8784-8795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in the kynurenine pathway of tryptophan metab., which is involved in immunity, neuronal function, and aging.  Its implication in pathologies such as cancer and neurodegenerative diseases has stimulated the development of IDO1 inhibitors.  However, neg. phase III clin. trial results of the IDO1 inhibitor epacadostat in cancer immunotherapy call for a better understanding of the role and the mechanisms of IDO1 inhibition.  In this work, we investigate the mol. inhibition mechanisms of four known IDO1 inhibitors and of two quinones in detail, using different exptl. and computational approaches.  We also det. for the first time the X-ray structure of the highly efficient 1,2,3-triazole inhibitor MMG-0358.  Based on our results and a comprehensive literature overview, we propose a classification scheme for IDO1 inhibitors according to their inhibition mechanism, which will be useful for further developments in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTZnLePiNWE7Vg90H21EOLACvtfcHk0lgGv0PsJdrUjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOqu7%252FP&md5=01919796d4821743975fe01a5527008c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00942%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DReynaud%26aufirst%3DA.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DPojer%26aufirst%3DF.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DInhibition%2520Mechanisms%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8784%26epage%3D8795%26doi%3D10.1021%2Facs.jmedchem.9b00942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mammoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballarotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camaioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span> <span> </span><span class="NLM_article-title">New Insights from Crystallographic Data: Diversity of Structural Motifs and Molecular Recognition Properties between Groups of Ido1 Structures</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1002/cmdc.202000116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcmdc.202000116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32190988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFymsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=891-899&author=A.+Mammoliauthor=A.+Colettiauthor=M.+Ballarottoauthor=A.+Riccioauthor=A.+Carottiauthor=U.+Grohmannauthor=E.+Camaioniauthor=A.+Macchiarulo&title=New+Insights+from+Crystallographic+Data%3A+Diversity+of+Structural+Motifs+and+Molecular+Recognition+Properties+between+Groups+of+Ido1+Structures&doi=10.1002%2Fcmdc.202000116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New Insights from Crystallographic Data: Diversity of Structural Motifs and Molecular Recognition Properties between Groups of IDO1 Structures</span></div><div class="casAuthors">Mammoli, Andrea; Coletti, Alice; Ballarotto, Marco; Riccio, Alessandra; Carotti, Andrea; Grohmann, Ursula; Camaioni, Emidio; Macchiarulo, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A large no. of crystallog. structures of IDO1 in different ligand-bound and -unbound states have been disclosed over the last decade.  Yet, only a few of them have been exploited for structure-based drug design (SBDD) campaigns.  In this study, we analyzed the structural motifs and mol.-recognition properties of three groups of IDO1 structures: 1) structures contg. the heme group and inhibitors in the catalytic site; 2) heme-free structures of IDO1; 3) substrate-bound structures of IDO1.  The results suggest that unrelated conformations of the enzyme have been solved with different ligand-induced changes of secondary motifs that localize even in regions remote from the catalytic site.  Moreover, the study identified an uncharted region of mol.-recognition space covered by IDO1 binding sites that could guide the selection of diverse structures for addnl. SBDD studies aimed at the identification of novel lead compds. with differentiated chem. scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvEOO4u9CtwrVg90H21EOLACvtfcHk0lipB0aQcRi2mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFymsbo%253D&md5=c73af36eed2b144f3cc1c38f0d0772ac</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.202000116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.202000116%26sid%3Dliteratum%253Aachs%26aulast%3DMammoli%26aufirst%3DA.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DBallarotto%26aufirst%3DM.%26aulast%3DRiccio%26aufirst%3DA.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DNew%2520Insights%2520from%2520Crystallographic%2520Data%253A%2520Diversity%2520of%2520Structural%2520Motifs%2520and%2520Molecular%2520Recognition%2520Properties%2520between%2520Groups%2520of%2520Ido1%2520Structures%26jtitle%3DChemMedChem%26date%3D2020%26volume%3D15%26spage%3D891%26epage%3D899%26doi%3D10.1002%2Fcmdc.202000116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><a href="http://www.rcsb.org/" class="extLink">http://www.rcsb.org/</a> (accessed May
2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.rcsb.org%2F+%28accessed+May%0A2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Cyanopyridine Scaffold as Novel Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitors through Virtual Screening and Preliminary Hit Optimisation</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1080/14756366.2018.1480614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1080%2F14756366.2018.1480614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30734612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsVSqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=250-263&author=X.+Xuauthor=J.+Renauthor=Y.+Maauthor=H.+Liuauthor=Q.+Rongauthor=Y.+Fengauthor=Y.+Wangauthor=Y.+Chengauthor=R.+Geauthor=Z.+Liauthor=J.+Bian&title=Discovery+of+Cyanopyridine+Scaffold+as+Novel+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors+through+Virtual+Screening+and+Preliminary+Hit+Optimisation&doi=10.1080%2F14756366.2018.1480614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation</span></div><div class="casAuthors">Xu, Xi; Ren, Jie; Ma, Yinghe; Liu, Hongting; Rong, Quanjin; Feng, Yifan; Wang, Yameng; Cheng, Yu; Ge, Ruijia; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250-263</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">With the aim of discovering novel IDO1 inhibitors, a combined similarity search and mol. docking approach was employed to the discovery of 32 hit compds.  Testing the screened hit compds. has led to several novel submicromolar inhibitors.  Compds. with cyanopyridine scaffold showed good IDO1 inhibitory activity.  To discover more compds. with similar structures, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivs.  Mol. docking studies suggested a possible binding mode of cyanopyridine compd., which provides a good starting point for the development of cyanopyridine scaffold compds. as potent IDO1 inhibitor.  To improve potency of these hits, the authors further designed and synthesized another 14 derivs. of the cyanopyridine compd.  Among these compds., N-(3-chloro-4-fluorophenyl)-2-((3-cyano-6-(trifluoromethyl)pyridin-2-yl)thio)acetamide [2314464-14-5] (LBJ-10) showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analog.  LBJ-10 can serve as an ideal lead for further modifications as IDO1 inhibitors for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZpDOXHrMlwrVg90H21EOLACvtfcHk0lipB0aQcRi2mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsVSqtA%253D%253D&md5=ed7377b92b76dec05b9527c95ea6fcc0</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1080%2F14756366.2018.1480614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2018.1480614%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DRong%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Cyanopyridine%2520Scaffold%2520as%2520Novel%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%2520through%2520Virtual%2520Screening%2520and%2520Preliminary%2520Hit%2520Optimisation%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26spage%3D250%26epage%3D263%26doi%3D10.1080%2F14756366.2018.1480614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labadie, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span> <span> </span><span class="NLM_article-title">Reimagining Ido Pathway Inhibition in Cancer Immunotherapy Via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1462</span>– <span class="NLM_lpage">1471</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-2882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F1078-0432.CCR-18-2882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30377198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=1462-1471&author=B.+W.+Labadieauthor=R.+Baoauthor=J.+J.+Luke&title=Reimagining+Ido+Pathway+Inhibition+in+Cancer+Immunotherapy+Via+Downstream+Focus+on+the+Tryptophan-Kynurenine-Aryl+Hydrocarbon+Axis&doi=10.1158%2F1078-0432.CCR-18-2882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis</span></div><div class="casAuthors">Labadie, Brian W.; Bao, Riyue; Luke, Jason J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1462-1471</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Significant progress has been made in cancer immunotherapy with checkpoint inhibitors targeting programmed cell death protein 1 (PD-l)-programmed death-ligand 1 signaling pathways.  Tumors from patients showing sustained treatment response predominately demonstrate a T cell-inflamed tumor microenvironment prior to, or early on, treatment.  Not all tumors with this phenotype respond, however, and one mediator of immuno suppression in 'I' cell-inflamed tumors is die tryptophan-kynurenine-aryl hydrocarbon receptor (Trp-Kyn-AhR) pathway.  Multiple mechanisms of immuno suppression may be mediated by this pathway including depletion of tryptophan, direct immuno suppression of Kyn, and activity of Kyn-bound AhR.  Indoleamine 2,3-dioxygenase 1 (IDO 1), a principle enzyme inTrp catabolism, is the target of small-mol. inhibitors in clin. development in combination with PD-I checkpoint inhibitors.  Despite promising results in early-phase clin. trials in a range of tumor types, a phase III study of the IDOl-selective inhibitor epacadostat in combination with pembrolizumab showed no difference between the epacadostat-treated group vs. placebo in patients with metastatic melanoma.  This has led to a diminution ofinterest in IDOl inhibitors; however, other approaches to inhibit this pathway continue to be considered.  Novel TrpKyn-AhR pathway inhibitors,such as Kyn-degrading enzymes, direct AhR antagonists, and tryptophan mimetics are advancing in early-stage or preclin. development.  Despite uncertainty surrounding IDOl inhibition, ample preclin. evidence supports continued development of Trp-Kyn-AhR pathway inhibitorsto augment immune-checkpoint and other cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBgR1gxNYFxrVg90H21EOLACvtfcHk0lipB0aQcRi2mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOmt7rF&md5=29f1f1a3e300aa38c32167ecd03a552e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-2882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-2882%26sid%3Dliteratum%253Aachs%26aulast%3DLabadie%26aufirst%3DB.%2BW.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26atitle%3DReimagining%2520Ido%2520Pathway%2520Inhibition%2520in%2520Cancer%2520Immunotherapy%2520Via%2520Downstream%2520Focus%2520on%2520the%2520Tryptophan-Kynurenine-Aryl%2520Hydrocarbon%2520Axis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D1462%26epage%3D1471%26doi%3D10.1158%2F1078-0432.CCR-18-2882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">18771</span>– <span class="NLM_lpage">18779</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b08871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b08871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitV2hs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=18771-18779&author=K.+N.+Phamauthor=A.+Lewis-Ballesterauthor=S.+R.+Yeh&title=Structural+Basis+of+Inhibitor+Selectivity+in+Human+Indoleamine+2%2C3-Dioxygenase+1+and+Tryptophan+Dioxygenase&doi=10.1021%2Fjacs.9b08871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase</span></div><div class="casAuthors">Pham, Khoa N.; Lewis-Ballester, Ariel; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">18771-18779</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan dioxygenase (hTDO) are two of the only three heme-based dioxygenases in humans.  They have recently been identified as key cancer immunotherapeutic drug targets.  While structures of hIDO1 in complex with inhibitors have been documented, so far there are no structures of hTDO-inhibitor complexes available.  Here we use PF-06840003 (IPD), a hIDO1-selective inhibitor in clin. trials, as a structural probe to elucidate inhibitor-selectivity in hIDO1 vs. hTDO.  Spectroscopic studies show that IPD exhibits 400-fold higher inhibition activity towards hIDO1 with respect to hTDO.  Crystallog. structures reveal that the binding pocket of IPD in the active site in hIDO1 is much more flexible as compared to that in hTDO, which offer a mol. explanation for the superior inhibition activity of IPD in hIDO1 with respect to hTDO.  In addn. to the IPD bound in the active site, a second IPD mol. was identified in an inhibitory site on the proximal side of the heme in hIDO1 and in an exosite that is ∼40 Å away from the active site in hTDO.  Taken together the data provide new insights into structure-based design of mono and dual inhibitors targeting hIDO1 and/or hTDO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6hKwhl2zTBbVg90H21EOLACvtfcHk0ljf1mUEJjypYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitV2hs7fF&md5=1f784cd43f5025672c10cf3c39a3913f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b08871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b08871%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DStructural%2520Basis%2520of%2520Inhibitor%2520Selectivity%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520and%2520Tryptophan%2520Dioxygenase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D18771%26epage%3D18779%26doi%3D10.1021%2Fjacs.9b08871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forouhar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkashon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seetharaman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batabyal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis for Catalysis and Substrate-Mediated Cellular Stabilization of Human Tryptophan 2,3-Dioxygenase</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">35169</span>, <span class="refDoi"> DOI: 10.1038/srep35169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fsrep35169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27762317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWis7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=35169&author=A.+Lewis-Ballesterauthor=F.+Forouharauthor=S.+M.+Kimauthor=S.+Lewauthor=Y.+Wangauthor=S.+Karkashonauthor=J.+Seetharamanauthor=D.+Batabyalauthor=B.+Y.+Chiangauthor=M.+Hussainauthor=M.+A.+Correiaauthor=S.+R.+Yehauthor=L.+Tong&title=Molecular+Basis+for+Catalysis+and+Substrate-Mediated+Cellular+Stabilization+of+Human+Tryptophan+2%2C3-Dioxygenase&doi=10.1038%2Fsrep35169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Lewis-Ballester, Ariel; Forouhar, Farhad; Kim, Sung-Mi; Lew, Scott; Wang, Yong Qiang; Karkashon, Shay; Seetharaman, Jayaraman; Batabyal, Dipanwita; Chiang, Bing-Yu; Hussain, Munif; Correia, Maria Almira; Yeh, Syun-Ru; Tong, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35169</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) play a central role in tryptophan metab. and are involved in many cellular and disease processes.  Here we report the crystal structure of human TDO (hTDO) in a ternary complex with the substrates L-Trp and O2 and in a binary complex with the product N-formylkynurenine (NFK), defining for the first time the binding modes of both substrates and the product of this enzyme.  The structure indicates that the dioxygenation reaction is initiated by a direct attack of O2 on the C2 atom of the L-Trp indole ring.  The structure also reveals an exo binding site for L-Trp, located ∼42 Å from the active site and formed by residues conserved among tryptophan-auxotrophic TDOs.  Biochem. and cellular studies indicate that Trp binding at this exo site does not affect enzyme catalysis but instead it retards the degrdn. of hTDO through the ubiquitin-dependent proteasomal pathway.  This exo site may therefore provide a novel L-Trp-mediated regulation mechanism for cellular degrdn. of hTDO, which may have important implications in human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrusyw4Y4d7-7Vg90H21EOLACvtfcHk0ljf1mUEJjypYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWis7fI&md5=d990ab3173c0c0b232016b92fab79741</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fsrep35169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep35169%26sid%3Dliteratum%253Aachs%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DForouhar%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DS.%2BM.%26aulast%3DLew%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKarkashon%26aufirst%3DS.%26aulast%3DSeetharaman%26aufirst%3DJ.%26aulast%3DBatabyal%26aufirst%3DD.%26aulast%3DChiang%26aufirst%3DB.%2BY.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DCorreia%26aufirst%3DM.%2BA.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26aulast%3DTong%26aufirst%3DL.%26atitle%3DMolecular%2520Basis%2520for%2520Catalysis%2520and%2520Substrate-Mediated%2520Cellular%2520Stabilization%2520of%2520Human%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D35169%26doi%3D10.1038%2Fsrep35169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandik-Nayak, L.</span></span> <span> </span><span class="NLM_article-title">Ido2 in Immunomodulation and Autoimmune Disease</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">585</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2014.00585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffimmu.2014.00585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25477879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC2Mzpt1yqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=585&author=G.+C.+Prendergastauthor=R.+Metzauthor=A.+J.+Mullerauthor=L.+M.+Merloauthor=L.+Mandik-Nayak&title=Ido2+in+Immunomodulation+and+Autoimmune+Disease&doi=10.3389%2Ffimmu.2014.00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">IDO2 in Immunomodulation and Autoimmune Disease</span></div><div class="casAuthors">Prendergast George C; Metz Richard; Muller Alexander J; Mandik-Nayak Laura; Merlo Lauren M F</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">585</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">IDO2 is a relative of IDO1 implicated in tryptophan catabolism and immune modulation but its specific contributions to normal physiology and pathophysiology are not known.  Evolutionary genetic studies suggest that IDO2 has a unique function ancestral to IDO1.  In mice, IDO2 gene deletion does not appreciably affect embryonic development or hematopoiesis, but it leads to defects in allergic or autoimmune responses and in the ability of IDO1 to influence the generation of T regulatory cells.  Gene expression studies indicate that IDO2 is a basally and more narrowly expressed gene than IDO1 and that IDO2 is uniquely regulated by AhR, which serves as a physiological receptor for the tryptophan catabolite kynurenine.  In the established KRN transgenic mouse model of rheumatoid arthritis, where IDO1 gene deletion has no effect, IDO2 deletion selectively blunts responses to autoantigen but has no effect on responses to neoantigen challenge.  In human populations, natural variations in IDO2 gene sequence that attenuate enzymatic activity have been reported to influence brain cancer control and adaptive immune responses to the IDO2 protein itself, consistent with the concept that IDO2 is involved in shaping immune tolerance in human beings.  Biochemical and pharmacological studies provide further evidence of differences in IDO2 enzymology and function relative to IDO1.  We suggest that IDO2 may act in a distinct manner from IDO1 as a set-point for tolerance to "altered-self" antigens along the self-non-self continuum where immune challenges from cancer and autoimmunity may arise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9Jutbth7-rBLDWw4HIq2sfW6udTcc2ebDCEVc1H8Hcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mzpt1yqtw%253D%253D&md5=985ae32af953b4281555f7236f81fe73</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2014.00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2014.00585%26sid%3Dliteratum%253Aachs%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DMerlo%26aufirst%3DL.%2BM.%26aulast%3DMandik-Nayak%26aufirst%3DL.%26atitle%3DIdo2%2520in%2520Immunomodulation%2520and%2520Autoimmune%2520Disease%26jtitle%3DFront.%2520Immunol.%26date%3D2014%26volume%3D5%26spage%3D585%26doi%3D10.3389%2Ffimmu.2014.00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldelari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dilek, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichenbach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascencao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irving, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">1,2,3-Triazoles as Inhibitors of Indoleamine 2,3-Dioxygenase 2 (Ido2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4330</span>– <span class="NLM_lpage">4333</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2016.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27469130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Ghs7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=4330-4333&author=U.+F.+Rohrigauthor=S.+R.+Majjigapuauthor=D.+Caldelariauthor=N.+Dilekauthor=P.+Reichenbachauthor=K.+Ascencaoauthor=M.+Irvingauthor=G.+Coukosauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=1%2C2%2C3-Triazoles+as+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+2+%28Ido2%29&doi=10.1016%2Fj.bmcl.2016.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2)</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Caldelari, Daniela; Dilek, Nahzli; Reichenbach, Patrick; Ascencao, Kelly; Irving, Melita; Coukos, George; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4330-4333</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 2 (IDO2) is a potential therapeutic target for the treatment of diseases that involve immune escape such as cancer.  In contrast to IDO1, only a very limited no. of inhibitors have been described for IDO2 due to inherent difficulties in expressing and purifying a functionally active, sol. form of the enzyme.  Starting from our previously discovered highly efficient 4-aryl-1,2,3-triazole IDO1 inhibitor scaffold, we used computational structure-based methods to design inhibitors of IDO2 which we then tested in cellular assays.  Our approach yielded low mol. wt. inhibitors of IDO2, the most active displaying an IC50 value of 51 μM for mIDO2, and twofold selectivity over hIDO1.  These compds. could be useful as mol. probes to investigate the biol. role of IDO2, and could inspire the design of new IDO2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIu_BQk1XmmrVg90H21EOLACvtfcHk0linQx5ie8CAiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Ghs7zJ&md5=981c536378ef1bf11333c132b3de2c8b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DCaldelari%26aufirst%3DD.%26aulast%3DDilek%26aufirst%3DN.%26aulast%3DReichenbach%26aufirst%3DP.%26aulast%3DAscencao%26aufirst%3DK.%26aulast%3DIrving%26aufirst%3DM.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3D1%252C2%252C3-Triazoles%2520as%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25202%2520%2528Ido2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D4330%26epage%3D4333%26doi%3D10.1016%2Fj.bmcl.2016.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Establishment of a Human Indoleamine 2, 3-Dioxygenase 2 (Hido2) Bioassay System and Discovery of Tryptanthrin Derivatives as Potent Hido2 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2016.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27475108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1OntrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2016&pages=171-179&author=J.+Liauthor=Y.+Liauthor=D.+Yangauthor=N.+Huauthor=Z.+Guoauthor=C.+Kuangauthor=Q.+Yang&title=Establishment+of+a+Human+Indoleamine+2%2C+3-Dioxygenase+2+%28Hido2%29+Bioassay+System+and+Discovery+of+Tryptanthrin+Derivatives+as+Potent+Hido2+Inhibitors&doi=10.1016%2Fj.ejmech.2016.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors</span></div><div class="casAuthors">Li, Juanjuan; Li, Yang; Yang, Dan; Hu, Nan; Guo, Zhanling; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">As an analog of IDO1 (indoleamine 2, 3-dioxygenase 1), the well-known new therapeutic target, IDO2 is receiving increased attention.  Herein, the expression and purifn. of recombinant human IDO2 (hIDO2) and the establishment of a hIDO2 bioassay system on both enzymic and cellular levels are described.  Nine tryptanthrin derivs. were screened for potential hIDO2 inhibitory activities, and their Ki values, enzymic and cellular IC50 values, as well as the types of inhibition were measured.  The tryptanthrin derivs. 5i, 5c and 5d (esp. 5i) were found to be potent hIDO2 inhibitors with superior efficiency far better than that of the most frequently-used inhibitor L-1-MT.  Two ultimate purposes of the present study have been achieved: establishing an IDO2 bioassay system and screening novel IDO2 inhibitors that can be used (directly or with some modifications) for potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJvpfpI4_MpbVg90H21EOLACvtfcHk0linQx5ie8CAiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1OntrvN&md5=1e878364aad6db454a308b68ef472320</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DEstablishment%2520of%2520a%2520Human%2520Indoleamine%25202%252C%25203-Dioxygenase%25202%2520%2528Hido2%2529%2520Bioassay%2520System%2520and%2520Discovery%2520of%2520Tryptanthrin%2520Derivatives%2520as%2520Potent%2520Hido2%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D123%26spage%3D171%26epage%3D179%26doi%3D10.1016%2Fj.ejmech.2016.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakmiwewa, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fatokun, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. J.</span></span> <span> </span><span class="NLM_article-title">Identification of Selective Inhibitors of Indoleamine 2,3-Dioxygenase 2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7641</span>– <span class="NLM_lpage">7646</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2012.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=23122865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1WjsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7641-7646&author=S.+M.+Bakmiwewaauthor=A.+A.+Fatokunauthor=A.+Tranauthor=R.+J.+Payneauthor=N.+H.+Huntauthor=H.+J.+Ball&title=Identification+of+Selective+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+2&doi=10.1016%2Fj.bmcl.2012.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2</span></div><div class="casAuthors">Bakmiwewa, Supun M.; Fatokun, Amos A.; Tran, Anh; Payne, Richard J.; Hunt, Nicholas H.; Ball, Helen J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7641-7646</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The kynurenine pathway is responsible for the breakdown of the majority of the essential amino acid, tryptophan (Trp).  The first and rate-limiting step of the kynurenine pathway can be independently catalyzed by tryptophan 2,3-dioxygenase (Tdo2), indoleamine 2,3-dioxygenase 1 (Ido1) or indoleamine 2,3-dioxygenase 2 (Ido2).  Tdo2 or Ido1 enzymic activity has been implicated in a no. of actions of the kynurenine pathway, including immune evasion by tumors.  IDO2 is expressed in several human pancreatic cancer cell lines, suggesting it also may play a role in tumorigenesis.  Although Ido2 was originally suggested to be a target of the chemotherapeutic agent dextro-1-methyl-tryptophan, subsequent studies suggest this compd. does not inhibit Ido2 activity.  The development of selective Ido2 inhibitors could provide valuable tools for investigating its activity in tumor development and normal physiol.  In this study, a library of Food and Drug Administration-approved drugs was screened for inhibition of mouse Ido2 enzymic activity.  A no. of candidates were identified and IC50 values of each compd. for Ido1 and Ido2 were estd.  The Ido2 inhibitors were also tested for inhibition of Tdo2 activity.  Our results showed that compds. from a class of drugs used to inhibit proton pumps were the most potent and selective Ido2 inhibitors identified in the library screen.  These included tenatoprazole, which exhibited an IC50 value of 1.8 μM for Ido2 with no inhibition of Ido1 or Tdo2 activity detected at a concn. of 100 μM tenatoprazole.  These highly-selective Ido2 inhibitors will be useful for defining the distinct biol. roles of the three Trp-catabolizing enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0JQcC4uWoS7Vg90H21EOLACvtfcHk0linQx5ie8CAiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1WjsrbE&md5=2b3da2f1699f032a0d9ebcf634a49dd7</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DBakmiwewa%26aufirst%3DS.%2BM.%26aulast%3DFatokun%26aufirst%3DA.%2BA.%26aulast%3DTran%26aufirst%3DA.%26aulast%3DPayne%26aufirst%3DR.%2BJ.%26aulast%3DHunt%26aufirst%3DN.%2BH.%26aulast%3DBall%26aufirst%3DH.%2BJ.%26atitle%3DIdentification%2520of%2520Selective%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25202%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7641%26epage%3D7646%26doi%3D10.1016%2Fj.bmcl.2012.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meininger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, C. L.</span></span> <span> </span><span class="NLM_article-title">Purification and Kinetic Characterization of Human Indoleamine 2,3-Dioxygenases 1 and 2 (Ido1 and Ido2) and Discovery of Selective Ido1 Inhibitors</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1814</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1954</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2011.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bbapap.2011.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=21835273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSjtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1814&publication_year=2011&pages=1947-1954&author=D.+Meiningerauthor=L.+Zalamedaauthor=Y.+Liuauthor=L.+P.+Stepanauthor=L.+Borgesauthor=J.+D.+McCarterauthor=C.+L.+Sutherland&title=Purification+and+Kinetic+Characterization+of+Human+Indoleamine+2%2C3-Dioxygenases+1+and+2+%28Ido1+and+Ido2%29+and+Discovery+of+Selective+Ido1+Inhibitors&doi=10.1016%2Fj.bbapap.2011.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors</span></div><div class="casAuthors">Meininger, David; Zalameda, Leeanne; Liu, Yichin; Stepan, Lara P.; Borges, Luis; McCarter, John D.; Sutherland, Claire L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1814</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1947-1954</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO1) catalyzes the 1st step in tryptophan breakdown along the kynurenine pathway.  Therapeutic inhibition of IDO1 is receiving much attention due to its proposed role in the pathogenesis of several diseases including cancer, hypotension, and neurodegenerative disorders.  A related enzyme, IDO2 has recently been described.  Here. the authors report the 1st purifn. and kinetic characterization of human IDO2 using a facile L-tryptophan consumption assay amenable to high throughput screening.  The authors found that the Km of human IDO2 for L-tryptophan was much higher than that of IDO1.  The authors also described the identification and characterization of a new IDO1 inhibitor compd., Amg-1, by high-throughput screening, and compared the inhibition profiles of IDO1 and IDO2 with Amg-1 and previously described compds.  The data indicated that human IDO1 and IDO2 have different kinetic parameters and different inhibition profiles.  Docking of Amg-1 and related analogs to the known structure of IDO1 and to homol.-modeled IDO2 suggested possible rationales for the different inhibition profiles of IDO1 and IDO2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkjKusST0FNrVg90H21EOLACvtfcHk0lhSyd9kT3XKew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSjtbzN&md5=95b88d7de219c1dcc63da1003b73c8f5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2011.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2011.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DMeininger%26aufirst%3DD.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DStepan%26aufirst%3DL.%2BP.%26aulast%3DBorges%26aufirst%3DL.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DSutherland%26aufirst%3DC.%2BL.%26atitle%3DPurification%2520and%2520Kinetic%2520Characterization%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenases%25201%2520and%25202%2520%2528Ido1%2520and%2520Ido2%2529%2520and%2520Discovery%2520of%2520Selective%2520Ido1%2520Inhibitors%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2011%26volume%3D1814%26spage%3D1947%26epage%3D1954%26doi%3D10.1016%2Fj.bbapap.2011.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pantouris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serys, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuasa, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C. G.</span></span> <span> </span><span class="NLM_article-title">Human Indoleamine 2,3-Dioxygenase-2 Has Substrate Specificity and Inhibition Characteristics Distinct from Those of Indoleamine 2,3-Dioxygenase-1</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">2155</span>– <span class="NLM_lpage">2163</span>, <span class="refDoi"> DOI: 10.1007/s00726-014-1766-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1007%2Fs00726-014-1766-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24875753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVKmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2014&pages=2155-2163&author=G.+Pantourisauthor=M.+Serysauthor=H.+J.+Yuasaauthor=H.+J.+Ballauthor=C.+G.+Mowat&title=Human+Indoleamine+2%2C3-Dioxygenase-2+Has+Substrate+Specificity+and+Inhibition+Characteristics+Distinct+from+Those+of+Indoleamine+2%2C3-Dioxygenase-1&doi=10.1007%2Fs00726-014-1766-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1</span></div><div class="casAuthors">Pantouris, Georgios; Serys, Martynas; Yuasa, Hajime J.; Ball, Helen J.; Mowat, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2155-2163</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-2 (IDO2) is one of three enzymes (alongside tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase (IDO1)) that catalyze dioxygenation of L-tryptophan as the first step in the kynurenine pathway.  Despite the reported expression of IDO2 in tumors, some fundamental characteristics of the enzyme, such as substrate specificity and inhibition selectivity, are still to be clearly defined.  In this study, the authors report the kinetic and inhibition characteristics of recombinant human IDO2.  Choosing from a series of likely IDO2 substrates, the authors screened 54 tryptophan derivs. and tryptophan-like mols., and characterized the 8 with which the enzyme was most active.  Specificity of IDO2 for the two isomers of 1-methyltryptophan was also evaluated and the findings compared with those obtained in other studies on IDO2 and IDO1.  Interestingly, IDO2 demonstrates behavior distinct from that of IDO1 in terms of substrate specificity and affinity, such that we have identified tryptophan derivs. that are mutually exclusive as substrates for IDO1 and IDO2.  Our results support the idea that the antitumor activity of 1-Me-D-Trp is unlikely to be related with competitive inhibition of IDO2, and also imply that there are subtle differences in active site structure in the two enzymes that may be exploited in the development of specific inhibitors of these enzymes, a route which may prove important in defining their role(s) in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVPhgndNQ9erVg90H21EOLACvtfcHk0lhSyd9kT3XKew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVKmsr4%253D&md5=c76ded6a96502b50cdb118cbb5ce4de5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs00726-014-1766-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-014-1766-3%26sid%3Dliteratum%253Aachs%26aulast%3DPantouris%26aufirst%3DG.%26aulast%3DSerys%26aufirst%3DM.%26aulast%3DYuasa%26aufirst%3DH.%2BJ.%26aulast%3DBall%26aufirst%3DH.%2BJ.%26aulast%3DMowat%26aufirst%3DC.%2BG.%26atitle%3DHuman%2520Indoleamine%25202%252C3-Dioxygenase-2%2520Has%2520Substrate%2520Specificity%2520and%2520Inhibition%2520Characteristics%2520Distinct%2520from%2520Those%2520of%2520Indoleamine%25202%252C3-Dioxygenase-1%26jtitle%3DAmino%2520Acids%26date%3D2014%26volume%3D46%26spage%3D2155%26epage%3D2163%26doi%3D10.1007%2Fs00726-014-1766-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulter, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J. H.</span></span> <span> </span><span class="NLM_article-title">Heme-Containing Oxygenases</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">2841</span>– <span class="NLM_lpage">2888</span>, <span class="refDoi"> DOI: 10.1021/cr9500500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9500500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaK28Xmt1Gmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1996&pages=2841-2888&author=M.+Sonoauthor=M.+P.+Roachauthor=E.+D.+Coulterauthor=J.+H.+Dawson&title=Heme-Containing+Oxygenases&doi=10.1021%2Fcr9500500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Heme-Containing Oxygenases</span></div><div class="casAuthors">Sono, Masanori; Roach, Mark P.; Coulter, Eric D.; Dawson, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2841-2887</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, with 342 refs.  The authors review here structure and activity of cytochrome P 450, secondary amine monooxygenase, heme oxygenase, prostaglandin H synthase, indoleamine 2,3-dioxygenase, and tryptophan 2,3-dioxygenase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVfrK0pt1dkrVg90H21EOLACvtfcHk0lhSyd9kT3XKew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmt1Gmsr4%253D&md5=a7813ce8b87cd91b99ca9f9172222077</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fcr9500500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9500500%26sid%3Dliteratum%253Aachs%26aulast%3DSono%26aufirst%3DM.%26aulast%3DRoach%26aufirst%3DM.%2BP.%26aulast%3DCoulter%26aufirst%3DE.%2BD.%26aulast%3DDawson%26aufirst%3DJ.%2BH.%26atitle%3DHeme-Containing%2520Oxygenases%26jtitle%3DChem.%2520Rev.%26date%3D1996%26volume%3D96%26spage%3D2841%26epage%3D2888%26doi%3D10.1021%2Fcr9500500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Key Dioxygenases in Tryptophan-Kynurenine Metabolism for Immunomodulation and Cancer Chemotherapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.drudis.2014.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25478733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitV2gu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=609-617&author=C.+J.+Austinauthor=L.+M.+Rendina&title=Targeting+Key+Dioxygenases+in+Tryptophan-Kynurenine+Metabolism+for+Immunomodulation+and+Cancer+Chemotherapy&doi=10.1016%2Fj.drudis.2014.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy</span></div><div class="casAuthors">Austin, Christopher J. D.; Rendina, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">609-617</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Tryptophan to kynurenine metab. is controlled by three distinct dioxygenase enzymes: tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 1 (IDO1), and indoleamine 2,3-dioxygenase 2 (IDO2).  Collectively, the activity of these enzymes contributes to tumor immune tolerance and immune dysregulation in a variety of disease pathologies, including cancer.  Whereas IDO1 inhibitor drug design has been the focus of study for more than two decades (with novel compds. currently in Phase II clin. trials), only recently have the roles of TDO and IDO2 been elucidated in immunosuppression.  Consequently, little comparative work on inhibitor cross-reactivity and selectivity has been performed.  Here, we provide an overview of the current and future drug discovery landscape for targeting TDO, IDO1, and IDO2 (individually and collectively) for pharmacol. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOoUq5iFaItLVg90H21EOLACvtfcHk0ljZTFqvsPd7cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitV2gu7nJ&md5=3e49304fea87a6564ef051ac67332a06</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DC.%2BJ.%26aulast%3DRendina%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520Key%2520Dioxygenases%2520in%2520Tryptophan-Kynurenine%2520Metabolism%2520for%2520Immunomodulation%2520and%2520Cancer%2520Chemotherapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D609%26epage%3D617%26doi%3D10.1016%2Fj.drudis.2014.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolawole, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hixon, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dameron, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrisman, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnov, V. V.</span></span> <span> </span><span class="NLM_article-title">Catalytic Activity of Human Indoleamine 2,3-Dioxygenase (Hido1) at Low Oxygen</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>570</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2015.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.abb.2015.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25712221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1eis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=570&publication_year=2015&pages=47-57&author=A.+O.+Kolawoleauthor=B.+P.+Hixonauthor=L.+S.+Dameronauthor=I.+M.+Chrismanauthor=V.+V.+Smirnov&title=Catalytic+Activity+of+Human+Indoleamine+2%2C3-Dioxygenase+%28Hido1%29+at+Low+Oxygen&doi=10.1016%2Fj.abb.2015.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic activity of human indoleamine 2,3-dioxygenase (hIDO1) at low oxygen</span></div><div class="casAuthors">Kolawole, Ayodele O.; Hixon, Brian P.; Dameron, Laura S.; Chrisman, Ian M.; Smirnov, Valeriy V.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">570</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-57</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A cytokine-inducible extrahepatic human indoleamine 2,3-dioxygenase (hIDO1) catalyzes the 1st step of the kynurenine pathway.  Immunosuppressive activity of hIDO1 in tumor cells weakens host T-cell immunity, contributing to the progression of cancer.  Here, the authors report on the enzyme kinetics and catalytic mechanism of hIDO1, studied at varied levels of O2 and L-tryptophan.  Using a cytochrome b5-based activating system, the authors measured the initial rates of O2 decay with a Clark-type oxygen electrode at physiol.-relevant levels of both substrates.  Enzyme kinetics were also studied in the presence of 2 substrate analogs, 1-methyl-L-tryptophan and norharmane.  Quant. anal. supported a steady-state rather than a rapid equil. kinetic mechanism, where the rates of individual pathways, leading to a ternary complex, were significantly different, and the overall rate of catalysis depended on contributions of both routes.  One path, where O2 binds to ferrous hIDO1 1st, was faster than the 2nd route, which started with the binding of L-tryptophan.  However, L-tryptophan complexation with free ferrous hIDO1 was more rapid than that of O2.  As the level of L-tryptophan increased, the slower route became a significant contributor to the overall rate, resulting in obsd. substrate inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU55j_-1MfGLVg90H21EOLACvtfcHk0ljZTFqvsPd7cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1eis7Y%253D&md5=02a0adb017dc96032a573ff43fab35dc</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2015.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2015.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DKolawole%26aufirst%3DA.%2BO.%26aulast%3DHixon%26aufirst%3DB.%2BP.%26aulast%3DDameron%26aufirst%3DL.%2BS.%26aulast%3DChrisman%26aufirst%3DI.%2BM.%26aulast%3DSmirnov%26aufirst%3DV.%2BV.%26atitle%3DCatalytic%2520Activity%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528Hido1%2529%2520at%2520Low%2520Oxygen%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2015%26volume%3D570%26spage%3D47%26epage%3D57%26doi%3D10.1016%2Fj.abb.2015.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Efimov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raven, E. L.</span></span> <span> </span><span class="NLM_article-title">The Mechanism of Substrate Inhibition in Human Indoleamine 2,3-Dioxygenase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">3034</span>– <span class="NLM_lpage">3041</span>, <span class="refDoi"> DOI: 10.1021/ja208694g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja208694g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ehsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=3034-3041&author=I.+Efimovauthor=J.+Basranauthor=X.+Sunauthor=N.+Chauhanauthor=S.+K.+Chapmanauthor=C.+G.+Mowatauthor=E.+L.+Raven&title=The+Mechanism+of+Substrate+Inhibition+in+Human+Indoleamine+2%2C3-Dioxygenase&doi=10.1021%2Fja208694g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The Mechanism of Substrate Inhibition in Human Indoleamine 2,3-Dioxygenase</span></div><div class="casAuthors">Efimov, Igor; Basran, Jaswir; Sun, Xiao; Chauhan, Nishma; Chapman, Stephen K.; Mowat, Christopher G.; Raven, Emma Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3034-3041</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase catalyzes the O2-dependent oxidn. of L-tryptophan (L-Trp) to N-formylkynurenine (NFK) as part of the kynurenine pathway.  Inhibition of enzyme activity at high L-Trp concns. was first noted more than 30 years ago, but the mechanism of inhibition has not been established.  Using a combination of kinetic and redn. potential measurements, we present evidence showing that inhibition of enzyme activity in human indoleamine 2,3-dioxygenase (hIDO) and a no. of site-directed variants during turnover with L-tryptophan (L-Trp) can be accounted for by the sequential, ordered binding of O2 and L-Trp.  Anal. of the data shows that at low concns. of L-Trp, O2 binds first followed by the binding of L-Trp; at higher concns. of L-Trp, the order of binding is reversed.  In addn., we show that the heme redn. potential (Em0) has a regulatory role in controlling the overall rate of catalysis (and hence the extent of inhibition) because there is a quantifiable correlation between Em0 (that increases in the presence of L-Trp) and the rate const. for O2 binding.  This means that the initial formation of ferric superoxide (Fe3+-O2̇-) from Fe2+-O2 becomes thermodynamically less favorable as substrate binds, and we propose that it is the slowing down of this oxidn. step at higher concns. of substrate that is the origin of the inhibition.  In contrast, we show that regeneration of the ferrous enzyme (and formation of NFK) in the final step of the mechanism, which formally requires redn. of the heme, is facilitated by the higher redn. potential in the substrate-bound enzyme and the two consts. (kcat and Em0) are shown also to be correlated.  Thus, the overall catalytic activity is balanced between the equal and opposite dependencies of the initial and final steps of the mechanism on the heme redn. potential.  This tuning of the redn. potential provides a simple mechanism for regulation of the reactivity, which may be used more widely across this family of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQoUAJsxHgSrVg90H21EOLACvtfcHk0ljZTFqvsPd7cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ehsLk%253D&md5=ab8ebfbe728ed51d5a5ce1713f4db846</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fja208694g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja208694g%26sid%3Dliteratum%253Aachs%26aulast%3DEfimov%26aufirst%3DI.%26aulast%3DBasran%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DChauhan%26aufirst%3DN.%26aulast%3DChapman%26aufirst%3DS.%2BK.%26aulast%3DMowat%26aufirst%3DC.%2BG.%26aulast%3DRaven%26aufirst%3DE.%2BL.%26atitle%3DThe%2520Mechanism%2520of%2520Substrate%2520Inhibition%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D3034%26epage%3D3041%26doi%3D10.1021%2Fja208694g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijeratne, G. B.</span></span> <span> </span><span class="NLM_article-title">Modeling Tryptophan/Indoleamine 2,3-Dioxygenase with Heme Superoxide Mimics: Is Ferryl the Key Intermediate?</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">1846</span>– <span class="NLM_lpage">1856</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b10498</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b10498" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyitLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=1846-1856&author=P.+Mondalauthor=G.+B.+Wijeratne&title=Modeling+Tryptophan%2FIndoleamine+2%2C3-Dioxygenase+with+Heme+Superoxide+Mimics%3A+Is+Ferryl+the+Key+Intermediate%3F&doi=10.1021%2Fjacs.9b10498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling Tryptophan/Indoleamine 2,3-Dioxygenase with Heme Superoxide Mimics: Is Ferryl the Key Intermediate?</span></div><div class="casAuthors">Mondal, Pritam; Wijeratne, Gayan B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1846-1856</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tryptophan oxidn. in biol. has been recently implicated in a vast array of paramount pathogenic conditions in humans, including multiple sclerosis, rheumatoid arthritis, type-I diabetes, and cancer.  This 2,3-dioxygenative cleavage of the indole ring of tryptophan with dioxygen is mediated by two heme enzymes, tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO), during its conversion to N-formylkynurenine in the first and rate-limiting step of kynurenine pathway.  Despite the pivotal significance of this enzymic transformation, a vivid viewpoint of the precise mechanistic events is far from complete.  A heme superoxide adduct is thought to be the active oxidant in both TDO and IDO, which, following O-O bond cleavage, presumably generates a key ferryl (FeIV=O) reaction intermediate.  This study, for the first time in model chem., demonstrates the potential of synthetic heme superoxide adducts to mimic the bioinorg. chem. of indole dioxygenation by TDO and IDO, challenging the widely accepted categorization of these metal adducts as weak oxidants.  Herein, an electronically divergent series of ferric heme superoxo oxidants mediates the facile conversion of an array of indole substrates into their corresponding 2,3-dioxygenated products, while shedding light on an unequivocally occurring, putative ferryl intermediate.  The oxygenated indole products have been isolated in ∼31% yield, and characterized by LC-MS, 1H and 13C NMR, and FT-IR methodologies, as well as by 18O2(g) labeling expts.  Distinctly, the most electron-deficient superoxo adduct is obsd. to react the fastest, specifically with the most electron-rich indole substrate, underscoring the cruciality of electrophilicity of the heme superoxide moiety in facilitating the initial indole activation step.  Comprehensive understanding of such mechanistic subtleties will benefit future attempts in the rational design of salient therapeutic agents, including next generation anticancer drug targets with amplified effectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF8LnnFDaoWbVg90H21EOLACvtfcHk0lh5VA5VPgLT2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyitLrE&md5=e4f32c8c24c0e46b5cd2b74b8da779f4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b10498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b10498%26sid%3Dliteratum%253Aachs%26aulast%3DMondal%26aufirst%3DP.%26aulast%3DWijeratne%26aufirst%3DG.%2BB.%26atitle%3DModeling%2520Tryptophan%252FIndoleamine%25202%252C3-Dioxygenase%2520with%2520Heme%2520Superoxide%2520Mimics%253A%2520Is%2520Ferryl%2520the%2520Key%2520Intermediate%253F%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D1846%26epage%3D1856%26doi%3D10.1021%2Fjacs.9b10498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Pyrrolase of Rabbit Intestine. D- and L-Tryptophan-Cleaving Enzyme or Enzymes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>242</i></span>,  <span class="NLM_fpage">5260</span>– <span class="NLM_lpage">5266</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=6065097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaF1cXkt1A%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=242&publication_year=1967&pages=5260-5266&author=S.+Yamamotoauthor=O.+Hayaishi&title=Tryptophan+Pyrrolase+of+Rabbit+Intestine.+D-+and+L-Tryptophan-Cleaving+Enzyme+or+Enzymes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan pyrrolase of rabbit intestine.  D- and L-Tryptophan-cleaving enzyme or enzymes</span></div><div class="casAuthors">Yamamoto, Shozo; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">242</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5260-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">An enzyme that catalyzes the formation of formyl-D-kynurenine from D-tryptophan was purified ∼100-fold from a homogenate of rabbit small intestine.  Formyl-D-kynurenine thus produced was converted to D-kynurenine by formamidase present in rabbit intestine.  Methylene blue and ascorbic acid were required as cofactors.  Xanthine oxidase with hypoxanthine could replace ascorbic acid, but H2O2, added as such or enzymically generated by glucose oxidase or L-amino acid oxidase, was not effective.  Addn. of catalase failed to inhibit the enzyme.  Several lines of evidence indicated the involvement of heme in the catalysis by the enzyme.  An absorption spectrum characteristic of hemoprotein was observed in the purified active enzyme prepns.  Inhibition by KCN or CO was observed.  The inhibition by CO was reversed by illumination.  The purified enzyme could oxidize L-tryptophan as well as D-tryptophan.  Kynurenine derived from L-tryptophan via formylkynurenine was identified as the L-isomer.  Methylene blue and ascorbic acid were also required.  A marked substrate inhibition was observed with L-tryptophan, but not with D-tryptophan.  23 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5eCISBapnE7Vg90H21EOLACvtfcHk0lh5VA5VPgLT2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXkt1A%253D&md5=736f1863a116d5d17b05aabd6a9e031b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DS.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DTryptophan%2520Pyrrolase%2520of%2520Rabbit%2520Intestine.%2520D-%2520and%2520L-Tryptophan-Cleaving%2520Enzyme%2520or%2520Enzymes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1967%26volume%3D242%26spage%3D5260%26epage%3D5266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase. Equilibrium Studies of the Tryptophan Binding to the Ferric, Ferrous, and Co-Bound Enzymes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>255</i></span>,  <span class="NLM_fpage">1339</span>– <span class="NLM_lpage">1345</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=7354029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaL3cXhsF2lurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1980&pages=1339-1345&author=M.+Sonoauthor=T.+Taniguchiauthor=Y.+Watanabeauthor=O.+Hayaishi&title=Indoleamine+2%2C3-Dioxygenase.+Equilibrium+Studies+of+the+Tryptophan+Binding+to+the+Ferric%2C+Ferrous%2C+and+Co-Bound+Enzymes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase.  Equilibrium studies of the tryptophan binding to the ferric, ferrous, and carbon monoxide-bound enzymes</span></div><div class="casAuthors">Sono, Masanori; Taniguchi, Taketoshi; Watanabe, Yasuyoshi; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1339-45</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The equil. consts. for the tryptophan binding to rabbit intestinal indoleamine 2,3-dioxygenase (I), a protohemoprotein, in its Fe(III), Fe(II), and CO-bound (Fe(II)CO) forms were detd. by the spectrophotometric titrn. method.  All of these I derivs. showed marked spectral changes upon tryptophan binding.  Such a spectral change for Fe(III)-I was, however, specific for the L isomer and accompanied the spin state change of the Fe(III)-heme from high spin to low spin.  The dissocn. consts. (Kd) thus obtained for the complexes of L-tryptophan with Fe(III)-, Fe(III)CO-, and Fe(II)-I in 0.1M K phosphate buffer, pH 7.0 at 24°, were 5.8 mM, 350 μM, and 13 μM, resp., being a ratio of 450:27:1.  The Kd Fe(III)-I enzyme was ∼450-fold greater than the Km and agreed well with the Ki, indicating that L-tryptophan binding to the Fe(III)-I is not catalytically significant, but is directly correlated to the substrate inhibition which is stereospecific to the L isomer.  The Kd for Fe(II)-I showed a good agreement with the Km at various pH values examd.  Assuming that the Fe(II)CO-I has a tryptophan-binding property similar to the oxygenated enzyme (Fe(II)O2 of Fe(III)O2-), it is suggested that the binding of tryptophan to Fe(II)-I (Kd ≈ Km) rather than that of tryptophan to the oxygenated enzyme (Kd ≠ Km) is involved in a steady state of the catalytic reaction.  On the basis of the evidence described above, a reaction mechanism for I is proposed.  In the principal pathway of the sequence, Fe(II)-I binds predominantly with tryptophan, followed by O2.  Fe(III)-I, on the other hand, binds 1st with the superoxide anion and the resulting oxygenated enzyme reacts with tryptophan either directly or via Fe(II)-I to form the ternary complex.  The Fe(III)-I-tryptophan complex appears to be catalytically inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAoucco47SWLVg90H21EOLACvtfcHk0lh5VA5VPgLT2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhsF2lurk%253D&md5=b36c389e1058a9b51dd4c87f97804cac</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSono%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase.%2520Equilibrium%2520Studies%2520of%2520the%2520Tryptophan%2520Binding%2520to%2520the%2520Ferric%252C%2520Ferrous%252C%2520and%2520Co-Bound%2520Enzymes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1980%26volume%3D255%26spage%3D1339%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienhaus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nienhaus, G. U.</span></span> <span> </span><span class="NLM_article-title">Substrate Inhibition in Human Indoleamine 2,3-Dioxygenase</span>. <i>J. Phys. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">761</span>, <span class="refDoi"> DOI: 10.1021/jz500220k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jz500220k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVOqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=756-761&author=B.+Weberauthor=E.+Nickelauthor=M.+Hornauthor=K.+Nienhausauthor=G.+U.+Nienhaus&title=Substrate+Inhibition+in+Human+Indoleamine+2%2C3-Dioxygenase&doi=10.1021%2Fjz500220k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate inhibition in human indoleamine 2,3-dioxygenase</span></div><div class="casAuthors">Weber, Benjamin; Nickel, Elena; Horn, Michael; Nienhaus, Karin; Nienhaus, G. Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">756-761</span>CODEN:
                <span class="NLM_cas:coden">JPCLCD</span>;
        ISSN:<span class="NLM_cas:issn">1948-7185</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase (I) catalyzes the oxidative cleavage of the L-tryptophan (II) pyrrole ring to produce N-formylkynurenine.  Catalysis is inhibited at high substrate concns.; mechanistic details of this observation are, however, still under debate.  Here, using time-resolved optical spectroscopy, the authors analyzed the dynamics of ternary complex formation between I, II, and a diat. ligand.  The physiol. ligand, O2 was replaced by CO to exclude enzymic turnover.  Quant. anal. of the kinetics revealed that the ternary complex forms whenever O2 binds 1st, whereas a II substrate mol. arriving prior to O2 in the active site causes self-inhibition.  Bound II prevents the ligand from approaching the heme Fe and, therefore, impedes the formation of the catalytically active ternary complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWqjrnO8kA4bVg90H21EOLACvtfcHk0lh5VA5VPgLT2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVOqsbo%253D&md5=caa9a38bbe1a4097a34de8bd438ab949</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjz500220k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjz500220k%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DB.%26aulast%3DNickel%26aufirst%3DE.%26aulast%3DHorn%26aufirst%3DM.%26aulast%3DNienhaus%26aufirst%3DK.%26aulast%3DNienhaus%26aufirst%3DG.%2BU.%26atitle%3DSubstrate%2520Inhibition%2520in%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Phys.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D756%26epage%3D761%26doi%3D10.1021%2Fjz500220k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Inhibitory Substrate Binding Site of Human Indoleamine 2,3-Dioxygenase</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">12866</span>– <span class="NLM_lpage">12867</span>, <span class="refDoi"> DOI: 10.1021/ja9029768</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9029768" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWku7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=12866-12867&author=C.+Luauthor=Y.+Linauthor=S.+R.+Yeh&title=Inhibitory+Substrate+Binding+Site+of+Human+Indoleamine+2%2C3-Dioxygenase&doi=10.1021%2Fja9029768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory Substrate Binding Site of Human Indoleamine 2,3-Dioxygenase</span></div><div class="casAuthors">Lu, Changyuan; Lin, Yu; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12866-12867</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase (hIDO) is an intracellular heme-contg. enzyme, which catalyzes the initial and rate-detg. step of L-tryptophan (L-Trp) metab. via the kynurenine pathway.  Due to its immunosuppressive function, hIDO has been recognized as an important drug target for cancer.  Here, evidence supporting the presence of an inhibitory substrate binding site (Si) in hIDO that is capable of binding mols. with a wide variety of structures, including substrates (L-Trp and 1-methyl-L-tryptophan), an effector (3-indole ethanol), and an uncompetitive inhibitor (Mitomycin C) is reported.  The data offer useful guidelines for future development of more potent hIDO inhibitors; they also call for the re-evaluation of the action mechanism of Mitomycin C (MtoC), a widely used antitumor chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiWLyIFomwX7Vg90H21EOLACvtfcHk0ljjbdPVGFhUkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWku7jK&md5=03246bbadb7c52484ad414500c8cf886</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fja9029768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9029768%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DInhibitory%2520Substrate%2520Binding%2520Site%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D12866%26epage%3D12867%26doi%3D10.1021%2Fja9029768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkashon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batabyal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span> <span> </span><span class="NLM_article-title">Inhibition Mechanisms of Human Indoleamine 2,3 Dioxygenase 1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">8518</span>– <span class="NLM_lpage">8525</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b03691</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b03691" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFamtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=8518-8525&author=A.+Lewis-Ballesterauthor=S.+Karkashonauthor=D.+Batabyalauthor=T.+L.+Poulosauthor=S.+R.+Yeh&title=Inhibition+Mechanisms+of+Human+Indoleamine+2%2C3+Dioxygenase+1&doi=10.1021%2Fjacs.8b03691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition Mechanisms of Human Indoleamine 2,3 Dioxygenase 1</span></div><div class="casAuthors">Lewis-Ballester, Ariel; Karkashon, Shay; Batabyal, Dipanwita; Poulos, Thomas L.; Yeh, Syun-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">8518-8525</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan dioxygenase (hTDO) catalyze the same dioxygenation reaction of Trp to generate N-formyl kynurenine (NFK).  They share high structural similarity, esp. in the active site.  However, hIDO1 possesses a unique inhibitory substrate binding site (Si) that is absent in hTDO.  In addn., in hIDO1, the indoleamine group of the substrate Trp is H-bonded to S167 through a bridging water, while that in hTDO is directly H-bonded to H76.  Here we show that Trp binding to the Si site or the mutation of S167 to histidine in hIDO1 retards its turnover activity, and that the inhibited activity can be rescued by an effector, 3-indole ethanol (IDE).  Kinetic studies reveal that the inhibited activity introduced by Trp binding to the Si site is a result of retarded recombination of the ferryl moiety with Trp epoxide to form NFK, and that IDE reverses the effect by preventing Trp from binding to the Si site.  In contrast, the abolished activity induced by the S167H mutation is primarily a result of ∼5000-fold redn. in the O2 binding rate const., possibly due to the blockage of a ligand delivery tunnel, and that IDE binding to the Si site reverses the effect by reopening the tunnel.  The data offer new insights into structure-based design of hIDO1-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwWFk_K5ySNrVg90H21EOLACvtfcHk0ljjbdPVGFhUkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFamtbbO&md5=7bc0b5d948e2109f9c3905f35454f647</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b03691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b03691%26sid%3Dliteratum%253Aachs%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DKarkashon%26aufirst%3DS.%26aulast%3DBatabyal%26aufirst%3DD.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26atitle%3DInhibition%2520Mechanisms%2520of%2520Human%2520Indoleamine%25202%252C3%2520Dioxygenase%25201%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2018%26volume%3D140%26spage%3D8518%26epage%3D8525%26doi%3D10.1021%2Fjacs.8b03691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondanelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacono, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panfili, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Filippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iamandii, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proietti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boscia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annunziato, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppelenbosch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santambrogio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span> <span> </span><span class="NLM_article-title">Positive Allosteric Modulation of Indoleamine 2,3-Dioxygenase 1 Restrains Neuroinflammation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3848</span>– <span class="NLM_lpage">3857</span>, <span class="refDoi"> DOI: 10.1073/pnas.1918215117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1073%2Fpnas.1918215117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32024760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFyhu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=3848-3857&author=G.+Mondanelliauthor=A.+Colettiauthor=F.+A.+Grecoauthor=M.+T.+Pallottaauthor=C.+Orabonaauthor=A.+Iaconoauthor=M.+L.+Belladonnaauthor=E.+Albiniauthor=E.+Panfiliauthor=F.+Fallarinoauthor=M.+Gargaroauthor=G.+Manniauthor=D.+Matinoauthor=A.+Carvalhoauthor=C.+Cunhaauthor=P.+Macielauthor=M.+Di+Filippoauthor=L.+Gaetaniauthor=R.+Bianchiauthor=C.+Vaccaauthor=I.+M.+Iamandiiauthor=E.+Proiettiauthor=F.+Bosciaauthor=L.+Annunziatoauthor=M.+Peppelenboschauthor=P.+Puccettiauthor=P.+Calabresiauthor=A.+Macchiaruloauthor=L.+Santambrogioauthor=C.+Volpiauthor=U.+Grohmann&title=Positive+Allosteric+Modulation+of+Indoleamine+2%2C3-Dioxygenase+1+Restrains+Neuroinflammation&doi=10.1073%2Fpnas.1918215117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation</span></div><div class="casAuthors">Mondanelli, Giada; Coletti, Alice; Greco, Francesco Antonio; Pallotta, Maria Teresa; Orabona, Ciriana; Iacono, Alberta; Belladonna, Maria Laura; Albini, Elisa; Panfili, Eleonora; Fallarino, Francesca; Gargaro, Marco; Manni, Giorgia; Matino, Davide; Carvalho, Agostinho; Cunha, Cristina; Maciel, Patricia; Di Filippo, Massimiliano; Gaetani, Lorenzo; Bianchi, Roberta; Vacca, Carmine; Iamandii, Ioana Maria; Proietti, Elisa; Boscia, Francesca; Annunziato, Lucio; Peppelenbosch, Maikel; Puccetti, Paolo; Calabresi, Paolo; Macchiarulo, Antonio; Santambrogio, Laura; Volpi, Claudia; Grohmann, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3848-3857</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">L-tryptophan (Trp), an essential amino acid for mammals, is the precursor of a wide array of immunomodulatory metabolites produced by the kynurenine and serotonin pathways.  The kynurenine pathway is a paramount source of several immunoregulatory metabolites, including L-kynurenine (Kyn), the main product of indoleamine 2,3-dioxygenase 1 (IDO1) that catalyzes the rate-limiting step of the pathway.  In the serotonin pathway, the metabolite N-acetylserotonin (NAS) has been shown to possess antioxidant, antiinflammatory, and neuroprotective properties in exptl. autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).  However, little is known about the exact mode of action of the serotonin metabolite and the possible interplay between the 2 Trp metabolic pathways.  Prompted by the discovery that NAS neuroprotective effects in EAE are abrogated in mice lacking IDO1 expression, we investigated the NAS mode of action in neuroinflammation.  We found that NAS directly binds IDO1 and acts as a pos. allosteric modulator (PAM) of the IDO1 enzyme in vitro and in vivo.  As a result, increased Kyn will activate the ligand-activated transcription factor aryl hydrocarbon receptor and, consequently, antiinflammatory and immunoregulatory effects.  Because NAS also increased IDO1 activity in peripheral blood mononuclear cells of a significant proportion of MS patients, our data may set the basis for the development of IDO1 PAMs as first-in-class drugs in autoimmune/neuroinflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS-Hm1fDHd0rVg90H21EOLACvtfcHk0ljjbdPVGFhUkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFyhu78%253D&md5=13c9788f554d27f9a372cf6551e3f3eb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1918215117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1918215117%26sid%3Dliteratum%253Aachs%26aulast%3DMondanelli%26aufirst%3DG.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DGreco%26aufirst%3DF.%2BA.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DIacono%26aufirst%3DA.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DAlbini%26aufirst%3DE.%26aulast%3DPanfili%26aufirst%3DE.%26aulast%3DFallarino%26aufirst%3DF.%26aulast%3DGargaro%26aufirst%3DM.%26aulast%3DManni%26aufirst%3DG.%26aulast%3DMatino%26aufirst%3DD.%26aulast%3DCarvalho%26aufirst%3DA.%26aulast%3DCunha%26aufirst%3DC.%26aulast%3DMaciel%26aufirst%3DP.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DGaetani%26aufirst%3DL.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DVacca%26aufirst%3DC.%26aulast%3DIamandii%26aufirst%3DI.%2BM.%26aulast%3DProietti%26aufirst%3DE.%26aulast%3DBoscia%26aufirst%3DF.%26aulast%3DAnnunziato%26aufirst%3DL.%26aulast%3DPeppelenbosch%26aufirst%3DM.%26aulast%3DPuccetti%26aufirst%3DP.%26aulast%3DCalabresi%26aufirst%3DP.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DSantambrogio%26aufirst%3DL.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DGrohmann%26aufirst%3DU.%26atitle%3DPositive%2520Allosteric%2520Modulation%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Restrains%2520Neuroinflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26spage%3D3848%26epage%3D3857%26doi%3D10.1073%2Fpnas.1918215117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meininger, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wienkers, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, D. A.</span></span> <span> </span><span class="NLM_article-title">In Vitro Modulation of Cytochrome P450 Reductase Supported Indoleamine 2,3-Dioxygenase Activity by Allosteric Effectors Cytochrome B(5) and Methylene Blue</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2647</span>– <span class="NLM_lpage">2656</span>, <span class="refDoi"> DOI: 10.1021/bi100022c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100022c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVGrurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=2647-2656&author=J.+T.+Pearsonauthor=S.+Siuauthor=D.+P.+Meiningerauthor=L.+C.+Wienkersauthor=D.+A.+Rock&title=In+Vitro+Modulation+of+Cytochrome+P450+Reductase+Supported+Indoleamine+2%2C3-Dioxygenase+Activity+by+Allosteric+Effectors+Cytochrome+B%285%29+and+Methylene+Blue&doi=10.1021%2Fbi100022c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro modulation of cytochrome P 450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b5 and methylene blue</span></div><div class="casAuthors">Pearson, Josh T.; Siu, Sophia; Meininger, David P.; Wienkers, Larry C.; Rock, Dan A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2647-2656</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is a heme-contg. dioxygenase involved in the degrdn. of several indoleamine derivs. and has been indicated as an immunosuppressive.  IDO is an attractive target for therapeutic intervention in diseases which are known to capitalize on immune suppression, including cancer, HIV, and inflammatory diseases.  Conventionally, IDO activity is measured through chem. redn. by the addn. of ascorbate and methylene blue.  The identification of potential coenzymes involved in the redn. of IDO in vivo should improve in vitro reconstitution systems used to identify potential IDO inhibitors.  Here, the authors show that NADPH-cytochrome P 450 reductase (CPR) is capable of supporting IDO activity in vitro and that oxidn. of L-tryptophan (L-Trp) follows substrate inhibition kinetics (kcat = 0.89 s-1, Km = 0.72 μM, and Ki = 9.4 μM).  The addn. of cytochrome b5 to CPR-supported L-Trp incubations resulted in modulation from substrate inhibition to sigmoidal kinetics (kcat = 1.7 s-1, Km = 1.5 μM, and Ki = 1.9 μM).  CPR-supported D-Trp oxidns. (±cytochrome b5) exhibited Michaelis-Menten kinetics.  The addn. of methylene blue (minus ascorbate) to CPR-supported reactions resulted in the inhibition of D-Trp turnover and modulation of L-Trp kinetics from allosteric to Michaelis-Menten with a concurrent decrease in substrate affinity for IDO.  Thus, these data indicate that CPR is capable of supporting IDO activity in vitro and the oxidn. of Trp by IDO displays substrate stereochem.-dependent atypical kinetics which can be modulated by the addn. of cytochrome b5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMqKrIR9We6LVg90H21EOLACvtfcHk0lg9YRkzZvYoxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVGrurk%253D&md5=487e05df4db931852d0eded173719e25</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fbi100022c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100022c%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DJ.%2BT.%26aulast%3DSiu%26aufirst%3DS.%26aulast%3DMeininger%26aufirst%3DD.%2BP.%26aulast%3DWienkers%26aufirst%3DL.%2BC.%26aulast%3DRock%26aufirst%3DD.%2BA.%26atitle%3DIn%2520Vitro%2520Modulation%2520of%2520Cytochrome%2520P450%2520Reductase%2520Supported%2520Indoleamine%25202%252C3-Dioxygenase%2520Activity%2520by%2520Allosteric%2520Effectors%2520Cytochrome%2520B%25285%2529%2520and%2520Methylene%2520Blue%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D2647%26epage%3D2656%26doi%3D10.1021%2Fbi100022c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uyttenhove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theate, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Evidence for a Tumoral Immune Resistance Mechanism Based on Tryptophan Degradation by Indoleamine 2,3-Dioxygenase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1274</span>, <span class="refDoi"> DOI: 10.1038/nm934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fnm934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=14502282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1Clu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=1269-1274&author=C.+Uyttenhoveauthor=L.+Pilotteauthor=I.+Theateauthor=V.+Stroobantauthor=D.+Colauauthor=N.+Parmentierauthor=T.+Boonauthor=B.+J.+Van+den%0AEynde&title=Evidence+for+a+Tumoral+Immune+Resistance+Mechanism+Based+on+Tryptophan+Degradation+by+Indoleamine+2%2C3-Dioxygenase&doi=10.1038%2Fnm934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</span></div><div class="casAuthors">Uyttenhove, Catherine; Pilotte, Luc; Theate, Ivan; Stroobant, Vincent; Colau, Didier; Parmentier, Nicolas; Boon, Thierry; Van den Eynde, Benoit J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1269-1274</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">T lymphocytes undergo proliferation arrest when exposed to tryptophan shortage, which can be provoked by indoleamine 2,3-dioxygenase (IDO), an enzyme that is expressed in placenta and catalyzes tryptophan degrdn.  Here we show that most human tumors constitutively express IDO.  We also obsd. that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice.  This effect is accompanied by a lack of accumulation of specific T cells at the tumor site and can be partly reverted by systemic treatment of mice with an inhibitor of IDO, in the absence of noticeable toxicity.  These results suggest that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2g0Nw1Orz7rVg90H21EOLACvtfcHk0lg9YRkzZvYoxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1Clu7c%253D&md5=c2be3620862064fb40da547f976ccf95</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnm934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm934%26sid%3Dliteratum%253Aachs%26aulast%3DUyttenhove%26aufirst%3DC.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DTheate%26aufirst%3DI.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DParmentier%26aufirst%3DN.%26aulast%3DBoon%26aufirst%3DT.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DEvidence%2520for%2520a%2520Tumoral%2520Immune%2520Resistance%2520Mechanism%2520Based%2520on%2520Tryptophan%2520Degradation%2520by%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D1269%26epage%3D1274%26doi%3D10.1038%2Fnm934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dancsok, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. O.</span></span> <span> </span><span class="NLM_article-title">Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development</span>. <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi"> DOI: 10.1007/s11912-019-0750-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1007%2Fs11912-019-0750-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30659394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BB3cjjtVeisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=2&author=M.+M.+T.+Zhuauthor=A.+R.+Dancsokauthor=T.+O.+Nielsen&title=Indoleamine+Dioxygenase+Inhibitors%3A+Clinical+Rationale+and+Current+Development&doi=10.1007%2Fs11912-019-0750-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development</span></div><div class="casAuthors">Zhu Mayanne M T; Dancsok Amanda R; Nielsen Torsten O</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  This review focuses on the recent clinical development of indolamine-2,3-dioxygenase-1 (IDO-1) inhibitors.  RECENT FINDINGS:  IDO-1 alters tryptophan metabolism in a manner enhancing T-regulatory cell activity, but pre-clinical data show that its role in tumorigenesis is context-dependent on host and tumor interaction, highlighting some challenges in understanding the molecular oncology of this enzymatic drug target.  Because results from phase I/II trials of IDO-1 inhibitor monotherapy have been disappointing, current clinical trials employ IDO-1 inhibitors in combination strategies with other immunotherapy agents or with chemotherapy ± radiation.  Combinations with anti-PD-1/PD-L1 antibodies are already showing promise, and related strategies are under active evaluation.  While further research is needed to elucidate the precise role of IDO-1 in tumor development, its mechanisms of action appear sufficiently distinct from other immunotherapy targets to warrant inclusion in combination immunotherapy regimens, an approach where multiple clinical trials are currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzTQoELJ1EfO3MPKNEWB5RfW6udTcc2ebGBMSCe7Kdvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjjtVeisQ%253D%253D&md5=81e82735e4d32baea00039d21ea7ac83</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs11912-019-0750-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-019-0750-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DM.%2BM.%2BT.%26aulast%3DDancsok%26aufirst%3DA.%2BR.%26aulast%3DNielsen%26aufirst%3DT.%2BO.%26atitle%3DIndoleamine%2520Dioxygenase%2520Inhibitors%253A%2520Clinical%2520Rationale%2520and%2520Current%2520Development%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2019%26volume%3D21%26spage%3D2%26doi%3D10.1007%2Fs11912-019-0750-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span> <span> </span><span class="NLM_article-title">Immune Control by Amino Acid Catabolism During Tumorigenesis and Therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1038/s41568-019-0106-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41568-019-0106-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30696923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVymtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=162-175&author=H.+Lemosauthor=L.+Huangauthor=G.+C.+Prendergastauthor=A.+L.+Mellor&title=Immune+Control+by+Amino+Acid+Catabolism+During+Tumorigenesis+and+Therapy&doi=10.1038%2Fs41568-019-0106-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Immune control by amino acid catabolism during tumorigenesis and therapy</span></div><div class="casAuthors">Lemos, Henrique; Huang, Lei; Prendergast, George C.; Mellor, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">162-175</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Immune checkpoints arise from physiol. changes during tumorigenesis that reprogramme inflammatory, immunol. and metabolic processes in malignant lesions and local lymphoid tissues, which constitute the immunol. tumor microenvironment (TME).  Improving clin. responses to immune checkpoint blockade will require deeper understanding of factors that impact local immune balance in the TME.  Elevated catabolism of the amino acids tryptophan (Trp) and arginine (Arg) is a common TME hallmark at clin. presentation of cancer.  Cells catabolizing Trp and Arg suppress effector T cells and stabilize regulatory T cells to suppress immunity in chronic inflammatory diseases of clin. importance, including cancers.  Processes that induce Trp and Arg catabolism in the TME remain incompletely defined.  Indoleamine 2,3 dioxygenase (IDO) and arginase 1 (ARG1), which catabolize Trp and Arg, resp., respond to inflammatory cues including interferons and transforming growth factor-β (TGFβ) cytokines.  Dying cells generate inflammatory signals including DNA, which is sensed to stimulate the prodn. of type I interferons via the stimulator of interferon genes (STING) adaptor.  Thus, dying cells help establish local conditions that suppress antitumor immunity to promote tumorigenesis.  Here, we review evidence that Trp and Arg catabolism contributes to inflammatory processes that promote tumorigenesis, impede immune responses to therapy and might promote neurol. comorbidities assocd. with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYjtO-kD36rbVg90H21EOLACvtfcHk0li86g1V9IlWHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVymtr0%253D&md5=ace250be08c88ffa307620152a19523b</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fs41568-019-0106-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-019-0106-z%26sid%3Dliteratum%253Aachs%26aulast%3DLemos%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26atitle%3DImmune%2520Control%2520by%2520Amino%2520Acid%2520Catabolism%2520During%2520Tumorigenesis%2520and%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2019%26volume%3D19%26spage%3D162%26epage%3D175%26doi%3D10.1038%2Fs41568-019-0106-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaipuri, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potturi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brincks, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahanian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, C. J.</span></span> <span> </span><span class="NLM_article-title">Abstract 4076: A Novel Prodrug of Indoximod with Enhanced Pharmacokinetic Properties</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">4076</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2017-4076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F1538-7445.AM2017-4076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=4076&author=M.+R.+Mautinoauthor=S.+Kumarauthor=H.+Zhuangauthor=J.+P.+Waldoauthor=F.+A.+Jaipuriauthor=H.+Potturiauthor=E.+L.+Brincksauthor=J.+Adamsauthor=A.+Marcinowiczauthor=C.+Allenauthor=N.+Vahanianauthor=C.+J.+Link&title=Abstract+4076%3A+A+Novel+Prodrug+of+Indoximod+with+Enhanced+Pharmacokinetic+Properties&doi=10.1158%2F1538-7445.AM2017-4076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2017-4076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2017-4076%26sid%3Dliteratum%253Aachs%26aulast%3DMautino%26aufirst%3DM.%2BR.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DH.%26aulast%3DWaldo%26aufirst%3DJ.%2BP.%26aulast%3DJaipuri%26aufirst%3DF.%2BA.%26aulast%3DPotturi%26aufirst%3DH.%26aulast%3DBrincks%26aufirst%3DE.%2BL.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DMarcinowicz%26aufirst%3DA.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DVahanian%26aufirst%3DN.%26aulast%3DLink%26aufirst%3DC.%2BJ.%26atitle%3DAbstract%25204076%253A%2520A%2520Novel%2520Prodrug%2520of%2520Indoximod%2520with%2520Enhanced%2520Pharmacokinetic%2520Properties%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D4076%26doi%3D10.1158%2F1538-7445.AM2017-4076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaipuri, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potturi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahanian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brincks, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Indoximod Prodrugs and Characterization of Clinical Candidate Nlg802</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">112373</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2020.112373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32422549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsl2hsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2020&pages=112373&author=S.+Kumarauthor=F.+A.+Jaipuriauthor=J.+P.+Waldoauthor=H.+Potturiauthor=A.+Marcinowiczauthor=J.+Adamsauthor=C.+Van+Allenauthor=H.+Zhuangauthor=N.+Vahanianauthor=C.+Linkauthor=E.+L.+Brincksauthor=M.+R.+Mautino&title=Discovery+of+Indoximod+Prodrugs+and+Characterization+of+Clinical+Candidate+Nlg802&doi=10.1016%2Fj.ejmech.2020.112373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of indoximod prodrugs and characterization of clinical candidate NLG802</span></div><div class="casAuthors">Kumar, Sanjeev; Jaipuri, Firoz A.; Waldo, Jesse P.; Potturi, Hima; Marcinowicz, Agnieszka; Adams, James; Van Allen, Clarissa; Zhuang, Hong; Vahanian, Nicholas; Link, Charles Jr.; Brincks, Erik L.; Mautino, Mario R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112373</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of different prodrugs of indoximod, including esters and peptide amides were synthesized with the aim of improving its oral bioavailability in humans.  The pharmacokinetics of prodrugs that were stable in buffers, plasma and simulated gastric and intestinal fluids was first assessed in rats after oral dosing in soln. or in capsule formulation.  Two prodrugs that produced the highest exposure to indoximod in rats were further tested in Cynomolgus monkeys, a species in which indoximod has oral bioavailability of 6-10% and an equiv. dose-dependent exposure profile as humans.  NLG802 was selected as the clin. development candidate after increasing oral bioavailability (>5-fold), Cmax (6.1-3.6 fold) and AUC (2.9-5.2 fold) in monkeys, compared to equiv. molar oral doses of indoximod.  NLG802 is extensively absorbed and rapidly metabolized to indoximod in all species tested and shows a safe toxicol. profile at the anticipated therapeutic doses.  NLG802 markedly enhanced the anti-tumor responses of tumor-specific pmel-1 T cells in a melanoma tumor model.  In conclusion, NLG802 is a prodrug of indoximod expected to increase clin. drug exposure to indoximod above the current achievable levels, thus increasing the possibility of therapeutic effects in a larger fraction of the target patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIUrIcvEBaBbVg90H21EOLACvtfcHk0li86g1V9IlWHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsl2hsLc%253D&md5=9bd32935ecc631a92b4d68807b161fce</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112373%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DJaipuri%26aufirst%3DF.%2BA.%26aulast%3DWaldo%26aufirst%3DJ.%2BP.%26aulast%3DPotturi%26aufirst%3DH.%26aulast%3DMarcinowicz%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DVan%2BAllen%26aufirst%3DC.%26aulast%3DZhuang%26aufirst%3DH.%26aulast%3DVahanian%26aufirst%3DN.%26aulast%3DLink%26aufirst%3DC.%26aulast%3DBrincks%26aufirst%3DE.%2BL.%26aulast%3DMautino%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520Indoximod%2520Prodrugs%2520and%2520Characterization%2520of%2520Clinical%2520Candidate%2520Nlg802%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D198%26spage%3D112373%26doi%3D10.1016%2Fj.ejmech.2020.112373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F0008-5472.CAN-06-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=17234791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=792-801&author=D.+Y.+Houauthor=A.+J.+Mullerauthor=M.+D.+Sharmaauthor=J.+DuHadawayauthor=T.+Banerjeeauthor=M.+Johnsonauthor=A.+L.+Mellorauthor=G.+C.+Prendergastauthor=D.+H.+Munn&title=Inhibition+of+Indoleamine+2%2C3-Dioxygenase+in+Dendritic+Cells+by+Stereoisomers+of+1-Methyl-Tryptophan+Correlates+with+Antitumor+Responses&doi=10.1158%2F0008-5472.CAN-06-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses</span></div><div class="casAuthors">Hou, De-Yan; Muller, Alexander J.; Sharma, Madhav D.; DuHadaway, James; Banerjee, Tinku; Johnson, Maribeth; Mellor, Andrew L.; Prendergast, George C.; Munn, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">792-801</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that contributes to tolerance in a no. of biol. settings.  In cancer, IDO activity may help promote acquired tolerance to tumor antigens.  The IDO inhibitor 1-methyl-tryptophan is being developed for clin. trials.  However, 1-methyl-tryptophan exists in two stereoisomers with potentially different biol. properties, and it has been unclear which isomer might be preferable for initial development.  In this study, we provide evidence that the D and L stereoisomers exhibit important cell type-specific variations in activity.  The L isomer was the more potent inhibitor of IDO activity using the purified enzyme and in HeLa cell-based assays.  However, the D isomer was significantly more effective in reversing the suppression of T cells created by IDO-expressing dendritic cells, using both human monocyte-derived dendritic cells and murine dendritic cells isolated directly from tumor-draining lymph nodes.  In vivo, the D isomer was more efficacious as an anticancer agent in chemo-immunotherapy regimens using cyclophosphamide, paclitaxel, or gemcitabine, when tested in mouse models of transplantable melanoma and transplantable and autochthonous breast cancer.  The D isomer of 1-methyl-tryptophan specifically targeted the IDO gene because the antitumor effect of D-1-methyl-tryptophan was completely lost in mice with a disruption of the IDO gene (IDO-knockout mice).  Taken together, our findings support the suitability of D-1-methyl-tryptophan for human trials aiming to assess the utility of IDO inhibition to block host-mediated immunosuppression and enhance antitumor immunity in the setting of combined chemo-immunotherapy regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Qarb_QtEIrVg90H21EOLACvtfcHk0lhX5BhBsu7NFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVKqtQ%253D%253D&md5=9e514bc8feb7f8251b73d19ad421f922</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-2925%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DD.%2BY.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DSharma%26aufirst%3DM.%2BD.%26aulast%3DDuHadaway%26aufirst%3DJ.%26aulast%3DBanerjee%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26atitle%3DInhibition%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520in%2520Dendritic%2520Cells%2520by%2520Stereoisomers%2520of%25201-Methyl-Tryptophan%2520Correlates%2520with%2520Antitumor%2520Responses%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D792%26epage%3D801%26doi%3D10.1158%2F0008-5472.CAN-06-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rust, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duhadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahanian, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Ido Inhibits a Tryptophan Sufficiency Signal That Stimulates Mtor: A Novel Ido Effector Pathway Targeted by D-1-Methyl-Tryptophan</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">1460</span>– <span class="NLM_lpage">1468</span>, <span class="refDoi"> DOI: 10.4161/onci.21716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.4161%2Fonci.21716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=23264892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BC2sris1egsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=1460-1468&author=R.+Metzauthor=S.+Rustauthor=J.+B.+Duhadawayauthor=M.+R.+Mautinoauthor=D.+H.+Munnauthor=N.+N.+Vahanianauthor=C.+J.+Linkauthor=G.+C.+Prendergast&title=Ido+Inhibits+a+Tryptophan+Sufficiency+Signal+That+Stimulates+Mtor%3A+A+Novel+Ido+Effector+Pathway+Targeted+by+D-1-Methyl-Tryptophan&doi=10.4161%2Fonci.21716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">IDO inhibits a tryptophan sufficiency signal that stimulates mTOR:  A novel IDO effector pathway targeted by D-1-methyl-tryptophan</span></div><div class="casAuthors">Metz Richard; Rust Sonja; Duhadaway James B; Mautino Mario R; Munn David H; Vahanian Nicholas N; Link Charles J; Prendergast George C</div><div class="citationInfo"><span class="NLM_cas:title">Oncoimmunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1460-1468</span>
        ISSN:<span class="NLM_cas:issn">2162-4011</span>.
    </div><div class="casAbstract">Tryptophan catabolism by indoleamine 2,3-dioxygenase (IDO) alters inflammation and favors T-cell tolerance in cancer, but the underlying molecular mechanisms remain poorly understood.  The integrated stress response kinase GCN2, a sensor of uncharged tRNA that is activated by amino acid deprivation, is recognized as an important effector of the IDO pathway.  However, in a mouse model of inflammatory carcinogenesis, ablation of Gcn2 did not promote resistance against tumor development like the absence of IDO does, implying the existence of additional cancer-relevant pathways that operate downstream of IDO.  Addressing this gap in knowledge, we report that the IDO-mediated catabolism of tryptophan also inhibits the immunoregulatory kinases mTOR and PKC-Θ, along with the induction of autophagy.  These effects were relieved specifically by tryptophan but also by the experimental agent 1-methyl-D-tryptophan (D-1MT, also known as NLG8189), the latter of which reversed the inhibitory signals generated by IDO with higher potency.  Taken together, our results implicate mTOR and PKC-Θ in IDO-mediated immunosuppressive signaling, and they provide timely insights into the unique mechanism of action of D-1MT as compared with traditional biochemical inhibitors of IDO.  These findings are important translationally, because they suggest broader clinical uses for D-1MT against cancers that overexpress any tryptophan catabolic enzyme (IDO, IDO2 or TDO).  Moreover, they define mTOR and PKC-Θ as candidate pharmacodynamic markers for D-1MT responses in patients recruited to ongoing phase IB/II cancer trials, addressing a current clinical need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYpqhzQ3xPO691pGlMMoT5fW6udTcc2ebReJulSCtWB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sris1egsQ%253D%253D&md5=a8ff204c01c08b7cce3fade1796623fe</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.4161%2Fonci.21716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fonci.21716%26sid%3Dliteratum%253Aachs%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DRust%26aufirst%3DS.%26aulast%3DDuhadaway%26aufirst%3DJ.%2BB.%26aulast%3DMautino%26aufirst%3DM.%2BR.%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DVahanian%26aufirst%3DN.%2BN.%26aulast%3DLink%26aufirst%3DC.%2BJ.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DIdo%2520Inhibits%2520a%2520Tryptophan%2520Sufficiency%2520Signal%2520That%2520Stimulates%2520Mtor%253A%2520A%2520Novel%2520Ido%2520Effector%2520Pathway%2520Targeted%2520by%2520D-1-Methyl-Tryptophan%26jtitle%3DOncoimmunology%26date%3D2012%26volume%3D1%26spage%3D1460%26epage%3D1468%26doi%3D10.4161%2Fonci.21716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takvorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Incb24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitor for Immuno-Oncology</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=486-491&author=E.+W.+Yueauthor=R.+Sparksauthor=P.+Polamauthor=D.+Modiauthor=B.+Doutyauthor=B.+Waylandauthor=B.+Glassauthor=A.+Takvorianauthor=J.+Glennauthor=W.+Zhuauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=T.+Emmauthor=P.+A.+Scherleauthor=B.+Metcalfauthor=A.+P.+Combs&title=Incb24360+%28Epacadostat%29%2C+a+Highly+Potent+and+Selective+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitor+for+Immuno-Oncology&doi=10.1021%2Facsmedchemlett.6b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology</span></div><div class="casAuthors">Yue, Eddy W.; Sparks, Richard; Polam, Padmaja; Modi, Dilip; Douty, Brent; Wayland, Brian; Glass, Brian; Takvorian, Amy; Glenn, Joseph; Zhu, Wenyu; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Emm, Tom; Scherle, Peggy A.; Metcalf, Brian; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A data-centric medicinal chem. approach led to the invention of a potent and selective IDO1 inhibitor 4f, INCB24360 (epacadostat).  The mol. structure of INCB24360 contains several previously unknown or underutilized functional groups in drug substances, including a hydroxyamidine, furazan, bromide and sulfamide.  These moieties taken together in a single structure afford a compd. which falls outside of "drug-like" space.  Nevertheless, the in vitro ADME data is consistent with the good cell permeability and oral bioavailability obsd. in all species (rat, dog, monkey) tested.  The extensive intramol. hydrogen bonding obsd. in the small mol. crystal structure of 4f is believed to significantly contribute to the obsd. permeability and PK.  Epacadostat in combination with anti-PD1 mAb pembrolizumab is currently being studied in a phase 3 clin. trial in patients with unresectable or metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpm79ArpY1yLVg90H21EOLACvtfcHk0lhX5BhBsu7NFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D&md5=92bebde519334e9e2a776250bb0258ac</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00391%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DSparks%26aufirst%3DR.%26aulast%3DPolam%26aufirst%3DP.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DGlass%26aufirst%3DB.%26aulast%3DTakvorian%26aufirst%3DA.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DIncb24360%2520%2528Epacadostat%2529%252C%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitor%2520for%2520Immuno-Oncology%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D486%26epage%3D491%26doi%3D10.1021%2Facsmedchemlett.6b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajewski, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caglevic, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maleski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diede, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, T. C.</span></span> <span> </span><span class="NLM_article-title">Epacadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma (Echo-301/Keynote-252): A Phase 3, Randomised, Double-Blind Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30274-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2FS1470-2045%2819%2930274-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31221619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1083-1097&author=G.+V.+Longauthor=R.+Dummerauthor=O.+Hamidauthor=T.+F.+Gajewskiauthor=C.+Caglevicauthor=S.+Dalleauthor=A.+Aranceauthor=M.+S.+Carlinoauthor=J.+J.+Grobauthor=T.+M.+Kimauthor=L.+Demidovauthor=C.+Robertauthor=J.+Larkinauthor=J.+R.+Andersonauthor=J.+Maleskiauthor=M.+Jonesauthor=S.+J.+Diedeauthor=T.+C.+Mitchell&title=Epacadostat+Plus+Pembrolizumab+Versus+Placebo+Plus+Pembrolizumab+in+Patients+with+Unresectable+or+Metastatic+Melanoma+%28Echo-301%2FKeynote-252%29%3A+A+Phase+3%2C+Randomised%2C+Double-Blind+Study&doi=10.1016%2FS1470-2045%2819%2930274-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study</span></div><div class="casAuthors">Long, Georgina V.; Dummer, Reinhard; Hamid, Omid; Gajewski, Thomas F.; Caglevic, Christian; Dalle, Stephane; Arance, Ana; Carlino, Matteo S.; Grob, Jean-Jacques; Kim, Tae Min; Demidov, Lev; Robert, Caroline; Larkin, James; Anderson, James R.; Maleski, Janet; Jones, Mark; Diede, Scott J.; Mitchell, Tara C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1083-1097</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immunotherapy combination treatments can improve patient outcomes.  Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumor activity in the phase 1-2 ECHO-202/KEYNOTE-037 study in advanced melanoma.  In this trial, we aimed to compare progression-free survival and overall survival in patients with unresectable stage III or IV melanoma receiving epacadostat plus pembrolizumab vs. placebo plus pembrolizumab.  In this international, randomised, placebo-controlled, double-blind, parallel-group, phase 3 trial, eligible participants were aged 18 years or older, with unresectable stage III or IV melanoma previously untreated with PD-1 or PD-L1 checkpoint inhibitors, an ECOG performance status of 0 or 1, and had a known BRAFV600 mutant status or consented to BRAFV600 mutation testing during screening.  Patients were stratified by PD-L1 expression and BRAFV600 mutation status and randomly assigned (1:1) through a central interactive voice and integrated web response system to receive epacadostat 100 mg orally twice daily plus pembrolizumab 200 mg i.v. every 3 wk or placebo plus pembrolizumab for up to 2 years.  We used block randomisation with a block size of four in each stratum.  Primary endpoints were progression-free survival and overall survival in the intention-to-treat population.  The safety anal. population included randomly assigned patients who received at least one dose of study treatment.  The study was stopped after the second interim anal.; follow-up for safety is ongoing.  This study is registered with ClinicalTrials.gov, no. NCT02752074.  Between June 21, 2016, and Aug 7, 2017, 928 patients were screened and 706 patients were randomly assigned to receive epacadostat plus pembrolizumab (n=354) or placebo plus pembrolizumab (n=352).  Median follow-up was 12·4 mo (IQR 10·3-14·5).  No significant differences were found between the treatment groups for progression-free survival (median 4·7 mo, 95% CI 2·9-6·8, for epacadostat plus pembrolizumab vs 4·9 mo, 2·9-6·8, for placebo plus pembrolizumab; hazard ratio [HR] 1·00, 95% CI 0·83-1·21; one-sided p=0·52) or overall survival (median not reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1·13, 0·86-1·49; one-sided p=0·81).  The most common grade 3 or worse treatment-related adverse event was lipase increase, which occurred in 14 (4%) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving placebo plus pembrolizumab.  Treatment-related serious adverse events were reported in 37 (10%) of 353 patients receiving epacadostat plus pembrolizumab and 32 (9%) of 352 patients receiving placebo plus pembrolizumab.  There were no treatment-related deaths in either treatment group.  Epacadostat 100 mg twice daily plus pembrolizumab did not improve progression-free survival or overall survival compared with placebo plus pembrolizumab in patients with unresectable or metastatic melanoma.  The usefulness of IDO1 inhibition as a strategy to enhance anti-PD-1 therapy activity in cancer remains uncertain.  Incyte Corporation, in collaboration with Merck Sharp & Dohme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8j2WQ35JqjbVg90H21EOLACvtfcHk0ljwzEhh12PU_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2kurbM&md5=f1dce1f431d2650fe4f8b8e46677e03d</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930274-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930274-8%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGajewski%26aufirst%3DT.%2BF.%26aulast%3DCaglevic%26aufirst%3DC.%26aulast%3DDalle%26aufirst%3DS.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DJ.%2BR.%26aulast%3DMaleski%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DM.%26aulast%3DDiede%26aufirst%3DS.%2BJ.%26aulast%3DMitchell%26aufirst%3DT.%2BC.%26atitle%3DEpacadostat%2520Plus%2520Pembrolizumab%2520Versus%2520Placebo%2520Plus%2520Pembrolizumab%2520in%2520Patients%2520with%2520Unresectable%2520or%2520Metastatic%2520Melanoma%2520%2528Echo-301%252FKeynote-252%2529%253A%2520A%2520Phase%25203%252C%2520Randomised%252C%2520Double-Blind%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D1083%26epage%3D1097%26doi%3D10.1016%2FS1470-2045%2819%2930274-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03661320" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03661320</a> (accessed Aug 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03661320+%28accessed+Aug+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldo, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaipuri, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcinowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesharwani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of Clinical Candidate (1r,4r)-4-((R)-2-((S)-6-Fluoro-5h-Imidazo[5,1-a]Isoindol-5-Yl)-1-Hydroxyethyl)Cyc Lohexan-1-Ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6705</span>– <span class="NLM_lpage">6733</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00662</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00662" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2gsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6705-6733&author=S.+Kumarauthor=J.+P.+Waldoauthor=F.+A.+Jaipuriauthor=A.+Marcinowiczauthor=C.+Van+Allenauthor=J.+Adamsauthor=T.+Kesharwaniauthor=X.+Zhangauthor=R.+Metzauthor=A.+J.+Ohauthor=S.+F.+Harrisauthor=M.+R.+Mautino&title=Discovery+of+Clinical+Candidate+%281r%2C4r%29-4-%28%28R%29-2-%28%28S%29-6-Fluoro-5h-Imidazo%5B5%2C1-a%5DIsoindol-5-Yl%29-1-Hydroxyethyl%29Cyc+Lohexan-1-Ol+%28Navoximod%29%2C+a+Potent+and+Selective+Inhibitor+of+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1021%2Facs.jmedchem.9b00662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1</span></div><div class="casAuthors">Kumar, Sanjeev; Waldo, Jesse P.; Jaipuri, Firoz A.; Marcinowicz, Agnieszka; Van Allen, Clarissa; Adams, James; Kesharwani, Tanay; Zhang, Xiaoxia; Metz, Richard; Oh, Angela J.; Harris, Seth F.; Mautino, Mario R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6705-6733</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of 5-substituted 5H-imidazo[5,1-a]isoindoles are described as potent inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1).  A structure-based drug design approach was used to elaborate the 5H-imidazo[5,1-a]isoindole core and to improve potency and pharmacol. properties.  Suitably placed hydrophobic and polar functional groups in the lead mol. allowed improvement of IDO1 inhibitory activity while minimizing off-target liabilities.  Structure-activity relationship studies focused on optimizing IDO1 inhibition potency and a pharmacokinetic profile amenable to oral dosing while controlling CYP450 and hERG inhibitory properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsaXqUemSD7Vg90H21EOLACvtfcHk0ljwzEhh12PU_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2gsbvE&md5=061789cf93bfde1204516aae79a403d4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00662%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DWaldo%26aufirst%3DJ.%2BP.%26aulast%3DJaipuri%26aufirst%3DF.%2BA.%26aulast%3DMarcinowicz%26aufirst%3DA.%26aulast%3DVan%2BAllen%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DKesharwani%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DA.%2BJ.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DMautino%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520Clinical%2520Candidate%2520%25281r%252C4r%2529-4-%2528%2528R%2529-2-%2528%2528S%2529-6-Fluoro-5h-Imidazo%255B5%252C1-a%255DIsoindol-5-Yl%2529-1-Hydroxyethyl%2529Cyc%2520Lohexan-1-Ol%2520%2528Navoximod%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6705%26epage%3D6733%26doi%3D10.1021%2Facs.jmedchem.9b00662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorsey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhadji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sams, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolayev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalos, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geeganage, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J.</span></span> <span> </span><span class="NLM_article-title">Abstract 5245: Identification and Characterization of the Ido1 Inhibitor Ly3381916</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5245</span>, <span class="refDoi"> DOI: 10.1158/1538-7445.AM2018-5245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F1538-7445.AM2018-5245" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5245&author=F.+Dorseyauthor=K.+Benhadjiauthor=L.+Samsauthor=D.+Youngauthor=J.+Schindlerauthor=K.+Hussauthor=A.+Nikolayevauthor=C.+Carpenitoauthor=D.+Clawsonauthor=B.+Jonesauthor=A.+Faberauthor=J.+Thomasauthor=S.+Haneyauthor=G.+Zhaoauthor=W.+McMillenauthor=T.+Smealauthor=D.+Sallauthor=M.+D.+Kalosauthor=S.+Geeganageauthor=J.+Henry&title=Abstract+5245%3A+Identification+and+Characterization+of+the+Ido1+Inhibitor+Ly3381916&doi=10.1158%2F1538-7445.AM2018-5245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2018-5245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2018-5245%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DF.%26aulast%3DBenhadji%26aufirst%3DK.%26aulast%3DSams%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DD.%26aulast%3DSchindler%26aufirst%3DJ.%26aulast%3DHuss%26aufirst%3DK.%26aulast%3DNikolayev%26aufirst%3DA.%26aulast%3DCarpenito%26aufirst%3DC.%26aulast%3DClawson%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DFaber%26aufirst%3DA.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DHaney%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DMcMillen%26aufirst%3DW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSall%26aufirst%3DD.%26aulast%3DKalos%26aufirst%3DM.%2BD.%26aulast%3DGeeganage%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DJ.%26atitle%3DAbstract%25205245%253A%2520Identification%2520and%2520Characterization%2520of%2520the%2520Ido1%2520Inhibitor%2520Ly3381916%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5245%26doi%3D10.1158%2F1538-7445.AM2018-5245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03343613" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03343613</a> (accessed Aug 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03343613+%28accessed+Aug+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahebjam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmaz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efuni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grebennik, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collaku, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogunmefun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latek, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rixe, O.</span></span> <span> </span><span class="NLM_article-title">First-in-Human Study of Khk2455, a Long-Acting, Potent and Selective Indoleamine 2,3-Dioxygenase 1 (Ido-1) Inhibitor, in Combination with Mogamulizumab (Moga), an Anti-Ccr4Monoclonal Antibody, in Patients (Pts) with Advanced Solid Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3040</span>– <span class="NLM_lpage">3040</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.3040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1200%2FJCO.2018.36.15_suppl.3040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29847297" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=3040-3040&author=T.+A.+Yapauthor=S.+Sahebjamauthor=D.+S.+Hongauthor=V.+K.+Chiuauthor=E.+Yilmazauthor=S.+Efuniauthor=D.+O.+Grebennikauthor=A.+Collakuauthor=E.+Ogunmefunauthor=Y.+Liuauthor=T.+Tayamaauthor=R.+R.+Latekauthor=O.+Rixe&title=First-in-Human+Study+of+Khk2455%2C+a+Long-Acting%2C+Potent+and+Selective+Indoleamine+2%2C3-Dioxygenase+1+%28Ido-1%29+Inhibitor%2C+in+Combination+with+Mogamulizumab+%28Moga%29%2C+an+Anti-Ccr4Monoclonal+Antibody%2C+in+Patients+%28Pts%29+with+Advanced+Solid+Tumors&doi=10.1200%2FJCO.2018.36.15_suppl.3040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.3040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.3040%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DSahebjam%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DD.%2BS.%26aulast%3DChiu%26aufirst%3DV.%2BK.%26aulast%3DYilmaz%26aufirst%3DE.%26aulast%3DEfuni%26aufirst%3DS.%26aulast%3DGrebennik%26aufirst%3DD.%2BO.%26aulast%3DCollaku%26aufirst%3DA.%26aulast%3DOgunmefun%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTayama%26aufirst%3DT.%26aulast%3DLatek%26aufirst%3DR.%2BR.%26aulast%3DRixe%26aufirst%3DO.%26atitle%3DFirst-in-Human%2520Study%2520of%2520Khk2455%252C%2520a%2520Long-Acting%252C%2520Potent%2520and%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido-1%2529%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Mogamulizumab%2520%2528Moga%2529%252C%2520an%2520Anti-Ccr4Monoclonal%2520Antibody%252C%2520in%2520Patients%2520%2528Pts%2529%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D3040%26epage%3D3040%26doi%3D10.1200%2FJCO.2018.36.15_suppl.3040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03364049" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03364049</a> (accessed May 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03364049+%28accessed+May+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT03208959" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT03208959</a> (accessed Aug 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03208959+%28accessed+Aug+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Oren-Gedoku-to and Its Constituents with Therapeutic Potential in Alzheimer’s Disease Inhibit Indoleamine 2, 3-Dioxygenase Activity in Vitro</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.3233/JAD-2010-100684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3233%2FJAD-2010-100684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=20847417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=257-266&author=C.+J.+Yuauthor=M.+F.+Zhengauthor=C.+X.+Kuangauthor=W.+D.+Huangauthor=Q.+Yang&title=Oren-Gedoku-to+and+Its+Constituents+with+Therapeutic+Potential+in+Alzheimer%E2%80%99s+Disease+Inhibit+Indoleamine+2%2C+3-Dioxygenase+Activity+in+Vitro&doi=10.3233%2FJAD-2010-100684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Oren-gedoku-to and its Constituents with Therapeutic Potential in Alzheimer's Disease Inhibit Indoleamine 2, 3-Dioxygenase Activity In Vitro</span></div><div class="casAuthors">Yu, Cun-Jing; Zheng, Mao-Fa; Kuang, Chun-Xiang; Huang, Wei-Da; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">257-266</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A well-known traditional Chinese medicinal prescription, Oren-gedoku-to (OGT), has been used in clin. therapies for many types of dementia in China and Japan.  Addnl., it ameliorates the age-related deterioration of learning and memory in an Alzheimer's disease (AD) rat model.  Indoleamine 2, 3-dioxygenase (IDO-1) is the first and rate-limiting enzyme in the kynurenine pathway of tryptophan catabolism, which ultimately leads to the prodn. of the excitotoxin quinolinic acid (QUIN).  IDO-1 has recently been established as one of the key players involved in the pathogenesis of AD.  OGT is indicated to prevent cholinergic dysfunction and reduce oxidative stress; however, the exact mechanism underlying its ability to improve cognitive ability remains elusive.  Here we present a novel mechanism of OGT's therapeutic potential in AD.  We demonstrated that OGT significantly inhibited recombinant human IDO-1 (rhIDO-1) activity in vitro, and its four main constituents (i.e., berberine, palmatine, jatrorrhizine, and baicalein) were potent IDO-1 inhibitors.  IC50 values, obtained from a cell-based assay, of HEK 293 cells and an enzymic assay were much lower than the most commonly used IDO-1 inhibitor, 1-Me tryptophan (1-MT).  Berberine was the best inhibitor and had IC50 values of 7 μM (cell-based assay) and 9.3 μM (enzymic assay).  Jatrorrhizine and palmatine exhibited irreversible inhibition of rhIDO-1, whereas berberine and baicalein behaved as uncompetitive, reversible inhibitors with Ki values of 8 μM and 215 μM, resp.  In conclusion, constituents of OGT show strong IDO-1 inhibitory activity and may have significant therapeutic potential for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSaPOq-g2sBbVg90H21EOLACvtfcHk0lgNVQYZGoRlaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtb%252FN&md5=16d4a67c4306a4bff61d6219fc6d04c1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.3233%2FJAD-2010-100684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2010-100684%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%2BJ.%26aulast%3DZheng%26aufirst%3DM.%2BF.%26aulast%3DKuang%26aufirst%3DC.%2BX.%26aulast%3DHuang%26aufirst%3DW.%2BD.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DOren-Gedoku-to%2520and%2520Its%2520Constituents%2520with%2520Therapeutic%2520Potential%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Inhibit%2520Indoleamine%25202%252C%25203-Dioxygenase%2520Activity%2520in%2520Vitro%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2010%26volume%3D22%26spage%3D257%26epage%3D266%26doi%3D10.3233%2FJAD-2010-100684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passacantilli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famiglini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsilinakos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoccoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisinni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Regina, G.</span></span> <span> </span><span class="NLM_article-title">New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9760</span>– <span class="NLM_lpage">9773</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9760-9773&author=A.+Colucciaauthor=S.+Passacantilliauthor=V.+Famigliniauthor=M.+Sabatinoauthor=A.+Patsilinakosauthor=R.+Ragnoauthor=C.+Mazzoccoliauthor=L.+Sisinniauthor=A.+Okunoauthor=O.+Takikawaauthor=R.+Silvestriauthor=G.+La+Regina&title=New+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+1%3A+Molecular+Modeling+Studies%2C+Synthesis%2C+and+Biological+Evaluation&doi=10.1021%2Facs.jmedchem.6b00718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation</span></div><div class="casAuthors">Coluccia, Antonio; Passacantilli, Sara; Famiglini, Valeria; Sabatino, Manuela; Patsilinakos, Alexandros; Ragno, Rino; Mazzoccoli, Carmela; Sisinni, Lorenza; Okuno, Alato; Takikawa, Osamu; Silvestri, Romano; La Regina, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9760-9773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy.  Herein, we report a virtual screening study which led to the identification of compd. I as a new IDO1 inhibitor.  In order to improve the biol. activity of the identified hit, arylthioindoles were synthesized and tested.  Among these, deriv. II exhibited an IC50 value of 7 μM, being the most active compd. of the series.  Furthermore, compds. I and II induced a dose-dependent growth inhibition in IDO1 expressing cancer cell lines HTC116 and HT29.  3-D QSAR studies were carried out in order to rationalize obtained results and suggest new chem. modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxfHwAbMNZXrVg90H21EOLACvtfcHk0lgw-8OE0AVMCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtL7I&md5=9a1267db6fdeadfbbb693464ba4dddd6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00718%26sid%3Dliteratum%253Aachs%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DPassacantilli%26aufirst%3DS.%26aulast%3DFamiglini%26aufirst%3DV.%26aulast%3DSabatino%26aufirst%3DM.%26aulast%3DPatsilinakos%26aufirst%3DA.%26aulast%3DRagno%26aufirst%3DR.%26aulast%3DMazzoccoli%26aufirst%3DC.%26aulast%3DSisinni%26aufirst%3DL.%26aulast%3DOkuno%26aufirst%3DA.%26aulast%3DTakikawa%26aufirst%3DO.%26aulast%3DSilvestri%26aufirst%3DR.%26aulast%3DLa%2BRegina%26aufirst%3DG.%26atitle%3DNew%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%253A%2520Molecular%2520Modeling%2520Studies%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9760%26epage%3D9773%26doi%3D10.1021%2Facs.jmedchem.6b00718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camponeschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Custodi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ianni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Approach to Identify Ido1 Inhibitor Building Blocks</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2017.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29031064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GltrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2017&pages=169-177&author=A.+Colettiauthor=F.+Camponeschiauthor=E.+Albiniauthor=F.+A.+Grecoauthor=V.+Maioneauthor=C.+Custodiauthor=F.+Ianniauthor=U.+Grohmannauthor=C.+Orabonaauthor=F.+Cantiniauthor=A.+Macchiarulo&title=Fragment-Based+Approach+to+Identify+Ido1+Inhibitor+Building+Blocks&doi=10.1016%2Fj.ejmech.2017.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based approach to identify IDO1 inhibitor building blocks</span></div><div class="casAuthors">Coletti, Alice; Camponeschi, Francesca; Albini, Elisa; Greco, Francesco Antonio; Maione, Vincenzo; Custodi, Chiara; Ianni, Federica; Grohmann, Ursula; Orabona, Ciriana; Cantini, Francesca; Macchiarulo, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is attracting a great deal of interest as drug target in immune-oncol. being highly expressed in cancer cells and participating to the tumor immune-editing process.  Although several classes of IDO1 inhibitors have been reported in literature and patent applications, only few compds. have proved optimal pharmacol. profile in preclin. studies to be advanced in clin. trials.  Accordingly, the quest for novel structural classes of IDO1 inhibitors is still open.  In this paper, the authors report a fragment-based screening campaign that combines Water-LOGSY NMR expts. and microscale thermophoresis approach to identify fragments that may be helpful for the development of novel IDO1 inhibitors as therapeutic agents in immune-oncol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_0x5BjMTidbVg90H21EOLACvtfcHk0lgw-8OE0AVMCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GltrjF&md5=50e7de9e473de649fde48b2b0171850c</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DCamponeschi%26aufirst%3DF.%26aulast%3DAlbini%26aufirst%3DE.%26aulast%3DGreco%26aufirst%3DF.%2BA.%26aulast%3DMaione%26aufirst%3DV.%26aulast%3DCustodi%26aufirst%3DC.%26aulast%3DIanni%26aufirst%3DF.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DOrabona%26aufirst%3DC.%26aulast%3DCantini%26aufirst%3DF.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DFragment-Based%2520Approach%2520to%2520Identify%2520Ido1%2520Inhibitor%2520Building%2520Blocks%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D141%26spage%3D169%26epage%3D177%26doi%3D10.1016%2Fj.ejmech.2017.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauwenberghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denies, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letellier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marillier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabolli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsaparikos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (Ido1) Catalytic Inhibitor Eos200271/Pf-06840003 Supports Ido1 as a Critical Resistance Mechanism to Pd-(L)1 Blockade Therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2530</span>– <span class="NLM_lpage">2542</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-1104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1158%2F1535-7163.MCT-17-1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30232146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1eltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=2530-2542&author=B.+Gomesauthor=G.+Driessensauthor=D.+Bartlettauthor=D.+Caiauthor=S.+Cauwenberghsauthor=S.+Crosignaniauthor=D.+Dalvieauthor=S.+Deniesauthor=C.+P.+Dillonauthor=V.+R.+Fantinauthor=J.+Guoauthor=M.+C.+Letellierauthor=W.+Liauthor=K.+Maegleyauthor=R.+Marillierauthor=N.+Millerauthor=R.+Pirsonauthor=V.+Rabolliauthor=C.+Rayauthor=N.+Streinerauthor=V.+R.+Tortiauthor=K.+Tsaparikosauthor=B.+J.+Van+den+Eyndeauthor=M.+Wythesauthor=L.+C.+Yaoauthor=X.+Zhengauthor=J.+Tumangauthor=M.+Kraus&title=Characterization+of+the+Selective+Indoleamine+2%2C3-Dioxygenase-1+%28Ido1%29+Catalytic+Inhibitor+Eos200271%2FPf-06840003+Supports+Ido1+as+a+Critical+Resistance+Mechanism+to+Pd-%28L%291+Blockade+Therapy&doi=10.1158%2F1535-7163.MCT-17-1104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy</span></div><div class="casAuthors">Gomes, Bruno; Driessens, Gregory; Bartlett, Derek; Cai, Danying; Cauwenberghs, Sandra; Crosignani, Stefano; Dalvie, Deepak; Denies, Sofie; Dillon, Christopher P.; Fantin, Valeria R.; Guo, Jie; Letellier, Marie-Claire; Li, Wenlin; Maegley, Karen; Marillier, Reece; Miller, Nichol; Pirson, Romain; Rabolli, Virginie; Ray, Chad; Streiner, Nicole; Torti, Vince R.; Tsaparikos, Konstantinos; Van den Eynde, Benoit J.; Wythes, Martin; Yao, Li-Chin; Zheng, Xianxian; Tumang, Joseph; Kraus, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2530-2542</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumors use IDO1 as a major mechanism to induce an immunosuppressive micro-environment.  IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies.  IDO1 is induced in response to inflammatory stimuli such as IFNγ and promotes immune tolerance by depleting tryptophan and producing tryptophan catabolites, including kynurenine, in the tumor microenvironment.  This leads to effector T-cell anergy and enhanced Treg function through upregulation of FoxP3.  As a nexus for the induction of key immunosuppressive mechanisms, IDOl represents an important immunotherapeutic target in oncol.  Mere, we report the identification and characterization of the novel selective, orally bioavaiiable IDO1 inhibitor EOS200271/PF-06840003.  It reversed IDO1-induced T-cell anergy in vitro.  In mice carrying syngeneic tumor graft, PF-06840003 reduced intratumoral kynurenine levels by over 80% and inhibited tumor growth both in monotherapy and, with an increased efficacy, in combination with antibodies blocking the immune checkpoint ligand PD-L1.  We demonstrate that anti-PD-L1 therapy results in increased IDO1 metabolic activity thereby providing addnl. mechanistic rationale for combining PD-(L)1 blockade with IDO1 inhibition in cancer immunotherapies.  Supported by these preclin. data and favorable predicted human pharmacokinetic properties of PF-06840003, a phase I open-label, multicenter clin. study (NCT02764151) has been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsq6oIvKPAfrVg90H21EOLACvtfcHk0lgw-8OE0AVMCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1eltLY%253D&md5=a7b306730692fede2e2fa69697a49495</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-1104%26sid%3Dliteratum%253Aachs%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DDriessens%26aufirst%3DG.%26aulast%3DBartlett%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DCauwenberghs%26aufirst%3DS.%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDenies%26aufirst%3DS.%26aulast%3DDillon%26aufirst%3DC.%2BP.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLetellier%26aufirst%3DM.%2BC.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DMarillier%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DPirson%26aufirst%3DR.%26aulast%3DRabolli%26aufirst%3DV.%26aulast%3DRay%26aufirst%3DC.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DTorti%26aufirst%3DV.%2BR.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DL.%2BC.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DTumang%26aufirst%3DJ.%26aulast%3DKraus%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520the%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528Ido1%2529%2520Catalytic%2520Inhibitor%2520Eos200271%252FPf-06840003%2520Supports%2520Ido1%2520as%2520a%2520Critical%2520Resistance%2520Mechanism%2520to%2520Pd-%2528L%25291%2520Blockade%2520Therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D2530%26epage%3D2542%26doi%3D10.1158%2F1535-7163.MCT-17-1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pantouris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loudon-Griffiths, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C. G.</span></span> <span> </span><span class="NLM_article-title">Insights into the Mechanism of Inhibition of Tryptophan 2,3-Dioxygenase by Isatin Derivatives</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.3109/14756366.2016.1170013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3109%2F14756366.2016.1170013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27096472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2016&pages=70-78&author=G.+Pantourisauthor=J.+Loudon-Griffithsauthor=C.+G.+Mowat&title=Insights+into+the+Mechanism+of+Inhibition+of+Tryptophan+2%2C3-Dioxygenase+by+Isatin+Derivatives&doi=10.3109%2F14756366.2016.1170013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives</span></div><div class="casAuthors">Pantouris, Georgios; Loudon-Griffiths, James; Mowat, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">sup1</span>),
    <span class="NLM_cas:pages">70-78</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Tryptophan 2,3-dioxygenase (TDO) is a cytosolic protein with a proven immunomodulatory function that promotes tumoral immune resistance and proliferation.  Despite the interest in TDO as a therapeutic target in cancer treatment, the no. of biol. useful inhibitors is limited.  Herein, the authors report isatin derivs. as a new class of TDO inhibitors.  Through structure-activity relationships and mol. docking studies, the authors optimized the inhibition potency of isatin derivs. by >130-fold and elucidated the mechanistic details that control their mode of action.  Hydrogen bond interactions between the compd. and key active site residues of TDO, freedom upon rotation of the C3 chem. moiety and the presence of chlorines in the benzene ring of the compd. comprise the properties that an isatin-based inhibitor requires to effectively inhibit the enzymic activity of TDO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI-BFcCqSNNbVg90H21EOLACvtfcHk0lhzOnP3gZ9Yrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKqt7k%253D&md5=08aaf32261fbf57b4f83e81079f4b846</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3109%2F14756366.2016.1170013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F14756366.2016.1170013%26sid%3Dliteratum%253Aachs%26aulast%3DPantouris%26aufirst%3DG.%26aulast%3DLoudon-Griffiths%26aufirst%3DJ.%26aulast%3DMowat%26aufirst%3DC.%2BG.%26atitle%3DInsights%2520into%2520the%2520Mechanism%2520of%2520Inhibition%2520of%2520Tryptophan%25202%252C3-Dioxygenase%2520by%2520Isatin%2520Derivatives%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2016%26volume%3D31%26spage%3D70%26epage%3D78%26doi%3D10.3109%2F14756366.2016.1170013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deka, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Oxindoles as Promising Inhibitors of the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase 1</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1640</span>– <span class="NLM_lpage">1654</span>, <span class="refDoi"> DOI: 10.1039/C7MD00226B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1039%2FC7MD00226B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30108875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVanurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1640-1654&author=S.+Paulauthor=A.+Royauthor=S.+J.+Dekaauthor=S.+Pandaauthor=G.+N.+Srivastavaauthor=V.+Trivediauthor=D.+Manna&title=Synthesis+and+Evaluation+of+Oxindoles+as+Promising+Inhibitors+of+the+Immunosuppressive+Enzyme+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1039%2FC7MD00226B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Paul, Saurav; Roy, Ashalata; Deka, Suman Jyoti; Panda, Subhankar; Srivastava, Gopal Narayan; Trivedi, Vishal; Manna, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1640-1654</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as an important therapeutic target for the treatment of cancer, chronic infections and other diseases that are assocd. with immune suppression.  Recent developments in understanding the catalytic mechanism of the IDO1 enzyme revealed that conversion of L-tryptophan (L-Trp) to N-formylkynurenine proceeded through an epoxide intermediate state.  Accordingly, we synthesized a series of 3-substituted oxindoles from L-Trp, tryptamine and isatin.  Compds. with C3-substituted oxindole moieties showed moderate inhibitory activity against the purified human IDO1 enzyme.  Their optimization led to the identification of potent compds., 6, 22, 23 and 25 (IC50 = 0.19 to 0.62 μM), which are competitive inhibitors of IDO1 with respect to L-Trp.  These potent compds. also showed IDO1 inhibition potencies in the low-micromolar range (IC50 = 0.33-0.49 μM) in MDA-MB-231 cells.  The cytotoxicity of these potent compds. was trivial in different model cancer (MDA-MB-231, A549 and HeLa) cells and macrophage (J774A.1) cells.  Stronger selectivity for the IDO1 enzyme (124 to 210-fold) over the tryptophan 2,3-dioxygenase (TDO) enzyme was also obsd. for these compds.  These results suggest that the oxindole moiety of the compds. could mimic the epoxide intermediate state of L-Trp.  Therefore, the structural simplicity and low-micromolar inhibition potencies of these 3-substituted oxindoles make them quite attractive for further investigation of IDO1 function and immunotherapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsRZ2MtEaFZbVg90H21EOLACvtfcHk0lhzOnP3gZ9Yrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVanurbK&md5=155d1e021fc98ba06b227a2be6ed2fbb</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1039%2FC7MD00226B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00226B%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DDeka%26aufirst%3DS.%2BJ.%26aulast%3DPanda%26aufirst%3DS.%26aulast%3DSrivastava%26aufirst%3DG.%2BN.%26aulast%3DTrivedi%26aufirst%3DV.%26aulast%3DManna%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Oxindoles%2520as%2520Promising%2520Inhibitors%2520of%2520the%2520Immunosuppressive%2520Enzyme%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1640%26epage%3D1654%26doi%3D10.1039%2FC7MD00226B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Indole-2-Carboxylic Acid Derivatives as Ido1/Tdo Dual Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">111985</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.111985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31881488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyru7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=111985&author=G.+Cuiauthor=F.+Laiauthor=X.+Wangauthor=X.+Chenauthor=B.+Xu&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Indole-2-Carboxylic+Acid+Derivatives+as+Ido1%2FTdo+Dual+Inhibitors&doi=10.1016%2Fj.ejmech.2019.111985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors</span></div><div class="casAuthors">Cui, Guonan; Lai, Fangfang; Wang, Xiaoyu; Chen, Xiaoguang; Xu, Bailing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111985</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are involved in the key steps of tryptophan metab. and are potential new targets for tumor immunotherapy.  In this work, a variety of indole-2-carboxylic acid derivs. I (R1 = H, 7-F, NHAc, etc.; X = NH, NMe, S; Y = NH, S, -NHCH2-, etc.; Ar = 4-F-3-Cl-C6H3, 4-F-3-OMe-C6H3, 3-Cl-3-OMe-C6H3, etc.) were synthesized, and their inhibitory activities against both enzymes along with structure-activity relationships were investigated.  As a result, a no. of 6-acetamido-indole-2-carboxylic acid derivs. were found to be potent dual inhibitors with IC50 values at low micromolar levels.  Among them, compd. I (R1 = 6-NHAc, X = N, Y = NH, Ar = 3,4-di-F-C6H3) was the most potent inhibitor with an IC50 value of 1.17μM for IDO1, and 1.55μM for TDO, resp.  In addn., a para-benzoquinone deriv. II, resulted from the oxidn. of compd. I (R1 = 6-NHEt, X = NH, Y = NH, Ar = 4-F-3-Cl-C6H3), was also identified and it showed strong inhibition against the two enzymes with IC50 values at the double digit nanomolar level.  Using mol. docking and mol. dynamic simulations, authors predicted the binding modes of this class of compds. within IDO1 and TDO binding pocket.  The results provide insights for further structural optimization of this series of IDO1/TDO dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnJVN4vhM1rVg90H21EOLACvtfcHk0lhzOnP3gZ9Yrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyru7%252FP&md5=21fe6d9fb1b3c754a33e4ab3325fc520</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111985%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Indole-2-Carboxylic%2520Acid%2520Derivatives%2520as%2520Ido1%252FTdo%2520Dual%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D111985%26doi%3D10.1016%2Fj.ejmech.2019.111985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery and Preliminary Structure-Activity Relationship of 1h-Indazoles with Promising Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibition Properties</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6194</span>– <span class="NLM_lpage">6205</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2016.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27769672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6194-6205&author=S.+Qianauthor=T.+Heauthor=W.+Wangauthor=Y.+Heauthor=M.+Zhangauthor=L.+Yangauthor=G.+Liauthor=Z.+Wang&title=Discovery+and+Preliminary+Structure-Activity+Relationship+of+1h-Indazoles+with+Promising+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibition+Properties&doi=10.1016%2Fj.bmc.2016.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties</span></div><div class="casAuthors">Qian, Shan; He, Tao; Wang, Wei; He, Yanying; Zhang, Man; Yang, Lingling; Li, Guobo; Wang, Zhouyu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6194-6205</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1)-mediated kynurenine pathway of tryptophan degrdn. is identified as an important immune effector pathway in the tumor cells to escape a potentially effective immune response.  IDO1 is an attractive target for anticancer therapy and the discovery of IDO1 inhibitors has been intensely ongoing in both academic research labs. and pharmaceutical organizations.  The study discovered that 1H-indazole was a novel key pharmacophore with potent IDO1 inhibitory activity.  A series of new 1H-indazole derivs. were synthesized and detd. the enzyme inhibitory activities, and the compd. I exhibited the highest activity with an IC50 value of 5.3 μM.  The structure-activity relationships (SARs) anal. of the 1H-indazole derivs. as novel IDO1 inhibitors indicated that the 1H-indazole scaffold is necessary for IDO1 inhibition, and the substituent groups at the both 4-position and 6-position largely affect inhibitory activity.  The docking model exhibited that the effective interactions of 1H-indazoles with ferrous ion of heme and key residues of hydrophobic Pocket A and B ensured the IDO1 inhibitory activities.  The study suggested that the 1H-indazole was a novel interesting scaffold for IDO inhibition for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcwuAQrkBWGLVg90H21EOLACvtfcHk0lj-Kk4HBM7E8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslShu7%252FK&md5=e1848f402c00f5a266a1faa82649ef28</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DDiscovery%2520and%2520Preliminary%2520Structure-Activity%2520Relationship%2520of%25201h-Indazoles%2520with%2520Promising%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibition%2520Properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6194%26epage%3D6205%26doi%3D10.1016%2Fj.bmc.2016.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoya, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, S.</span></span> <span> </span><span class="NLM_article-title">4,6-Substituted-1h-Indazoles as Potent Ido1/Tdo Dual Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1087</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2019.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30773421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFOit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1087-1098&author=L.+Yangauthor=Y.+Chenauthor=J.+Heauthor=E.+M.+Njoyaauthor=J.+Chenauthor=S.+Liuauthor=C.+Xieauthor=W.+Huangauthor=F.+Wangauthor=Z.+Wangauthor=Y.+Liauthor=S.+Qian&title=4%2C6-Substituted-1h-Indazoles+as+Potent+Ido1%2FTdo+Dual+Inhibitors&doi=10.1016%2Fj.bmc.2019.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">4,6-Substituted-1H-indazoles as potent IDO1/TDO dual inhibitors</span></div><div class="casAuthors">Yang, Lingling; Chen, Yang; He, Junlin; Njoya, Emmanuel Mfotie; Chen, Jianjun; Liu, Siyan; Xie, Congqiang; Huang, Wenze; Wang, Fei; Wang, Zhouyu; Li, Yuzhi; Qian, Shan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1087-1098</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are constitutively overexpressed in many types of cancer cells and exert important immunosuppressive functions.  In this article, a series of 4,6-substituted-1H-indazole derivs. were synthesized and evaluated the inhibitory activities against IDO1 and TDO, as well as their structure-activity relationships (SARs).  Among these, compd. 35(I) displayed the most IDO1 inhibitory potency with an IC50 value of 0.74 μM in an enzymic assay and 1.37 μM in HeLa cells.  Quant. anal. of the Western blot results indicated that I significantly decreased the INFγ-induced IDO1 expression in a concn.-dependent manner.  In addn., I showed promising TDO inhibition with an IC50 value of 2.93 μM in the enzymic assay and 7.54 μM in A172 cells.  Moreover, I exhibited in vivo antitumor activity in the CT26 xenograft model.  These findings suggest that I is a potent IDO1/TDO dual inhibitor, and has the potential to be developed for IDO1/TDO-related cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrehU24MhIjGbVg90H21EOLACvtfcHk0lj-Kk4HBM7E8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFOit74%253D&md5=7137c203f76db2924373fe59797d7066</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DNjoya%26aufirst%3DE.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DS.%26atitle%3D4%252C6-Substituted-1h-Indazoles%2520as%2520Potent%2520Ido1%252FTdo%2520Dual%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1087%26epage%3D1098%26doi%3D10.1016%2Fj.bmc.2019.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsujino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meguro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akai, S.</span></span> <span> </span><span class="NLM_article-title">Correlation of Indoleamine-2,3-Dioxigenase 1 Inhibitory Activity of 4,6-Disubstituted Indazole Derivatives and Their Heme Binding Affinity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126607</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2019.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31431359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ais7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126607&author=H.+Tsujinoauthor=T.+Unoauthor=T.+Yamashitaauthor=M.+Katsudaauthor=K.+Takadaauthor=T.+Saikiauthor=S.+Maedaauthor=A.+Takagiauthor=S.+Masudaauthor=Y.+Kawanoauthor=K.+Meguroauthor=S.+Akai&title=Correlation+of+Indoleamine-2%2C3-Dioxigenase+1+Inhibitory+Activity+of+4%2C6-Disubstituted+Indazole+Derivatives+and+Their+Heme+Binding+Affinity&doi=10.1016%2Fj.bmcl.2019.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of indoleamine-2,3-dioxigenase 1 inhibitory activity of 4,6-disubstituted indazole derivatives and their heme binding affinity</span></div><div class="casAuthors">Tsujino, Hirofumi; Uno, Tadayuki; Yamashita, Taku; Katsuda, Masafumi; Takada, Kazuki; Saiki, Takeshi; Maeda, Shotaro; Takagi, Akira; Masuda, Shigeaki; Kawano, Yasuhiko; Meguro, Kanji; Akai, Shuji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">126607</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-contg. enzyme that acts on the first and rate-limiting step of the tryptophan/kynurenine pathway.  Since the pathway is one of the means of cancer immune evasion, IDO1 inhibitors have drawn interest as potential therapeutics for cancers.  We found a 4,6-disubstituted indazole 1 as a hit compd. that showed both IDO1 inhibitory activity and binding affinity for IDO1 heme.  Structural modification of 1 yielded compd. 6, whose relatively large substituent at the 4-position and proper size substituent at the 6-position were found to be important for the enhancement of IDO1 inhibitory activity and heme affinity.  A series of compds. synthesized in this work were evaluated by in silico docking simulations and by in vitro expts. using a C129Y mutant of the pocket-A of IDO1.  Our results revealed that proper substituents at the 6- and 4-positions of the compds. interact with pockets A and B, resp., and that, in particular, a good fit in pocket-A is important for the compds.' biol. activities.  Absorption spectral anal. of these compds. showed that they strongly bound to the ferrous heme rather than its ferric heme.  Furthermore, we obsd. that the heme affinities of these compds. strongly correlate with their IDO1 inhibitory activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy3Z3d-CU0aLVg90H21EOLACvtfcHk0lj-Kk4HBM7E8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ais7%252FE&md5=d940a8624c05512861dbba038d458ce9</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DTsujino%26aufirst%3DH.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DKatsuda%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DK.%26aulast%3DSaiki%26aufirst%3DT.%26aulast%3DMaeda%26aufirst%3DS.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DMasuda%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DY.%26aulast%3DMeguro%26aufirst%3DK.%26aulast%3DAkai%26aufirst%3DS.%26atitle%3DCorrelation%2520of%2520Indoleamine-2%252C3-Dioxigenase%25201%2520Inhibitory%2520Activity%2520of%25204%252C6-Disubstituted%2520Indazole%2520Derivatives%2520and%2520Their%2520Heme%2520Binding%2520Affinity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126607%26doi%3D10.1016%2Fj.bmcl.2019.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cady, S. G.</span></span> <span> </span><span class="NLM_article-title">Enzyme Kinetic and Spectroscopic Studies of Inhibitor and Effector Interactions with Indoleamine 2,3-Dioxygenase. 1. Norharman and 4-Phenylimidazole Binding to the Enzyme as Inhibitors and Heme Ligands</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">5392</span>– <span class="NLM_lpage">5399</span>, <span class="refDoi"> DOI: 10.1021/bi00439a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00439a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaL1MXktF2qtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1989&pages=5392-5399&author=M.+Sonoauthor=S.+G.+Cady&title=Enzyme+Kinetic+and+Spectroscopic+Studies+of+Inhibitor+and+Effector+Interactions+with+Indoleamine+2%2C3-Dioxygenase.+1.+Norharman+and+4-Phenylimidazole+Binding+to+the+Enzyme+as+Inhibitors+and+Heme+Ligands&doi=10.1021%2Fbi00439a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands</span></div><div class="casAuthors">Sono, Masanori; Cady, Susan G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5392-9</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The effects of norharman, one of the few known inhibitors of the heme protein indoleamine 2,3-dioxygenase, and of 4-phenylimidazole (4-PheImid), a heme ligand, on the catalytic (Vmax, Km) and spectroscopic properties (optical absorption, CD, and MCD) of rabbit small intestine dioxygenase were investigated.  Assays were performed with the substrate L- or D-tryptophan (Trp) and an ascorbic acid-methylene blue cofactor system at 25°.  Both norharman and 4-PheImid exhibit noncompetitive inhibition with respect to L-Trp and D-Trp.  The binding of norharman to the enzyme results in the formation of a low-spin complex in both the ferric and ferrous enzyme with comparable dissocn. consts. (Kd = ∼10 μM at pH 7.0) that are ∼10-fold smaller than the obsd. Ki.  L-Trp exerts no effect for the ferric enzyme and slight neg. cooperative effects for the ferrous enzyme on norharman binding.  Close spectral similarities are obsd. between the adducts of the enzyme with norharman and 4-PheImid in the resp. oxidn. states.  This, together with competition expts. using CN-, demonstrates that norharman binds directly to the heme Fe of the enzyme as a N donor ligand.  Thus, norharman competes with O2 for the heme Fe of the ferrous (active) enzyme, resulting in the obsd. inhibition.  L-Trp and 4-PheImid appear to compete for the heme-binding site in the ferric enzyme and display slight neg. cooperativity on binding to the ferrous enzyme.  The obsd. Ki for 4-PheImid is comparable with the Kd (∼10 μM at pH 7.0) of its adduct with the ferric enzyme, but is ∼40-fold smaller than the Kd for the corresponding ferrous complex.  Apparently, the inhibition of the dioxygenase activity by 4-PheImid is due to its binding to the heme Fe of the ferric enzyme, preventing the reductive activation of the dioxygenase by the ascorbic acid-methylene blue cofactor system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgFeeIW5--LVg90H21EOLACvtfcHk0lgpdwDMqTDzGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXktF2qtLg%253D&md5=87f3a4be44f5626760b567185013050a</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fbi00439a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00439a012%26sid%3Dliteratum%253Aachs%26aulast%3DSono%26aufirst%3DM.%26aulast%3DCady%26aufirst%3DS.%2BG.%26atitle%3DEnzyme%2520Kinetic%2520and%2520Spectroscopic%2520Studies%2520of%2520Inhibitor%2520and%2520Effector%2520Interactions%2520with%2520Indoleamine%25202%252C3-Dioxygenase.%25201.%2520Norharman%2520and%25204-Phenylimidazole%2520Binding%2520to%2520the%2520Enzyme%2520as%2520Inhibitors%2520and%2520Heme%2520Ligands%26jtitle%3DBiochemistry%26date%3D1989%26volume%3D28%26spage%3D5392%26epage%3D5399%26doi%3D10.1021%2Fbi00439a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaLonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4968</span>– <span class="NLM_lpage">4977</span>, <span class="refDoi"> DOI: 10.1021/jm800512z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800512z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVyrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4968-4977&author=S.+Kumarauthor=D.+Jallerauthor=B.+Patelauthor=J.+M.+LaLondeauthor=J.+B.+DuHadawayauthor=W.+P.+Malachowskiauthor=G.+C.+Prendergastauthor=A.+J.+Muller&title=Structure+Based+Development+of+Phenylimidazole-Derived+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase&doi=10.1021%2Fjm800512z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase</span></div><div class="casAuthors">Kumar, Sanjeev; Jaller, Daniel; Patel, Bhumika; LaLonde, Judith M.; DuHadaway, James B.; Malachowski, William P.; Prendergast, George C.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4968-4977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathol. immune suppression.  With the goal of developing more potent IDO inhibitors, a systematic study of 4-phenylimidazole (4-PI) derivs. was undertaken.  Computational docking expts. guided design and synthesis efforts with analogs of 4-PI.  In particular, three interactions of 4-PI analogs with IDO were studied: the active site entrance, the interior of the active site, and the heme iron binding.  The three most potent inhibitors I (R = 4-HOC6H4, 3-HSC6H4, 4-HSC6H4) appear to exploit interactions with C129 and S167 in the interior of the active site.  All three inhibitors are approx. 10-fold more potent than 4-PI.  The study represents the first example of enzyme inhibitor development with the recently reported crystal structure of IDO and offers important lessons in the search for more potent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHTIIEf7DjmLVg90H21EOLACvtfcHk0lgpdwDMqTDzGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVyrtrY%253D&md5=6e232cb983d0ba2396bea16060a5b7a1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm800512z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800512z%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DJaller%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DLaLonde%26aufirst%3DJ.%2BM.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DStructure%2520Based%2520Development%2520of%2520Phenylimidazole-Derived%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4968%26epage%3D4977%26doi%3D10.1021%2Fjm800512z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesù, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovarruscio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coda Zabetta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannelli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span> <span> </span><span class="NLM_article-title">In Silico-Driven Multicomponent Synthesis of 4,5- and 1,5-Disubstituted Imidazoles as Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1039/C5MD00317B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1039%2FC5MD00317B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1aksb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=409-419&author=S.+Fallariniauthor=A.+Massarottiauthor=A.+Ges%C3%B9author=S.+Giovarruscioauthor=G.+Coda+Zabettaauthor=R.+Bergoauthor=B.+Giannelliauthor=A.+Bruncoauthor=G.+Lombardiauthor=G.+Sorbaauthor=T.+Pirali&title=In+Silico-Driven+Multicomponent+Synthesis+of+4%2C5-+and+1%2C5-Disubstituted+Imidazoles+as+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1039%2FC5MD00317B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">In silico-driven multicomponent synthesis of 4,5- and 1,5-disubstituted imidazoles as indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Fallarini, S.; Massarotti, A.; Gesu, A.; Giovarruscio, S.; Coda Zabetta, G.; Bergo, R.; Giannelli, B.; Brunco, A.; Lombardi, G.; Sorba, G.; Pirali, T.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-419</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase is involved in pathol. immune escape and has recently become an attractive target for anti-cancer therapy. 4-Phenylimidazole (4-PI) provides a promising starting point for the development of IDO1 inhibitors.  With the aim of discovering more potent ligands, a virtual library of imidazoles synthesizable via the van Leusen multicomponent reaction was created and filtered to afford a set of 4,5- and 1,5-disubstituted imidazoles as virtual lead candidates.  The compds. were selected according to their docking score and to their synthetic feasibility, synthesized and biol. evaluated.  This exptl. approach yielded IDO1 inhibitors with an enhanced potency compared to 4-PI; the most active compds. displayed a low micromolar potency, both in enzymic and cellular assays, while showing no detectable cellular toxicity.  A 3D quant. structure-activity relationship based on the electrostatic and steric ligand-protein interactions was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvXxeQxfbo57Vg90H21EOLACvtfcHk0lgpdwDMqTDzGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1aksb%252FF&md5=c8b5c8e1a32574f651ffeab686b450a2</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1039%2FC5MD00317B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00317B%26sid%3Dliteratum%253Aachs%26aulast%3DFallarini%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DGes%25C3%25B9%26aufirst%3DA.%26aulast%3DGiovarruscio%26aufirst%3DS.%26aulast%3DCoda%2BZabetta%26aufirst%3DG.%26aulast%3DBergo%26aufirst%3DR.%26aulast%3DGiannelli%26aufirst%3DB.%26aulast%3DBrunco%26aufirst%3DA.%26aulast%3DLombardi%26aufirst%3DG.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DPirali%26aufirst%3DT.%26atitle%3DIn%2520Silico-Driven%2520Multicomponent%2520Synthesis%2520of%25204%252C5-%2520and%25201%252C5-Disubstituted%2520Imidazoles%2520as%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D409%26epage%3D419%26doi%3D10.1039%2FC5MD00317B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brant, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin-Tindall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohnig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. F.</span></span> <span> </span><span class="NLM_article-title">Identification of Potent Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors Based on a Phenylimidazole Scaffold</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00488</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00488" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotV2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=131-136&author=M.+G.+Brantauthor=J.+Goodwin-Tindallauthor=K.+R.+Stoverauthor=P.+M.+Staffordauthor=F.+Wuauthor=A.+R.+Meekauthor=P.+Schiaviniauthor=S.+Wohnigauthor=D.+F.+Weaver&title=Identification+of+Potent+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors+Based+on+a+Phenylimidazole+Scaffold&doi=10.1021%2Facsmedchemlett.7b00488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold</span></div><div class="casAuthors">Brant, Michael G.; Goodwin-Tindall, Jake; Stover, Kurt R.; Stafford, Paul M.; Wu, Fan; Meek, Autumn R.; Schiavini, Paolo; Wohnig, Stephanie; Weaver, Donald F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-136</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of indoleamine 2,3-dioxygenase (IDO1) is an attractive immunotherapeutic approach for the treatment of a variety of cancers.  Dysregulation of this enzyme has also been implicated in other disorders including Alzheimer's disease and arthritis.  Herein, the authors report the structure-based design of two related series of mols.: N1-substituted 5-indoleimidazoles and N1-substituted 5-phenylimidazoles.  The latter (and more potent) series was accessed through an unexpected rearrangement of an imine intermediate during a Van Leusen imidazole synthesis reaction.  Evidence for the binding modes for both inhibitor series is supported by computational and structure-activity relationship studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWjv6cCPCyqrVg90H21EOLACvtfcHk0lgKG-DMrs9SJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotV2gsg%253D%253D&md5=f83e9d7dce45932e5f94818cebd2b3c8</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00488%26sid%3Dliteratum%253Aachs%26aulast%3DBrant%26aufirst%3DM.%2BG.%26aulast%3DGoodwin-Tindall%26aufirst%3DJ.%26aulast%3DStover%26aufirst%3DK.%2BR.%26aulast%3DStafford%26aufirst%3DP.%2BM.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DMeek%26aufirst%3DA.%2BR.%26aulast%3DSchiavini%26aufirst%3DP.%26aulast%3DWohnig%26aufirst%3DS.%26aulast%3DWeaver%26aufirst%3DD.%2BF.%26atitle%3DIdentification%2520of%2520Potent%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%2520Based%2520on%2520a%2520Phenylimidazole%2520Scaffold%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D131%26epage%3D136%26doi%3D10.1021%2Facsmedchemlett.7b00488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosdidier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5270</span>– <span class="NLM_lpage">5290</span>, <span class="refDoi"> DOI: 10.1021/jm300260v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300260v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1yiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5270-5290&author=U.+F.+Rohrigauthor=S.+R.+Majjigapuauthor=A.+Grosdidierauthor=S.+Bronauthor=V.+Stroobantauthor=L.+Pilotteauthor=D.+Colauauthor=P.+Vogelauthor=B.+J.+Van+den%0AEyndeauthor=V.+Zoeteauthor=O.+Michielin&title=Rational+Design+of+4-Aryl-1%2C2%2C3-Triazoles+for+Indoleamine+2%2C3-Dioxygenase+1+Inhibition&doi=10.1021%2Fjm300260v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Grosdidier, Aurelien; Bron, Sylvian; Stroobant, Vincent; Pilotte, Luc; Colau, Didier; Vogel, Pierre; Van den Eynde, Benoit J.; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5270-5290</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an important therapeutic target for the treatment of diseases such as cancer that involve pathol. immune escape.  Starting from the scaffold of our previously discovered IDO1 inhibitor 4-phenyl-1,2,3-triazole, we used computational structure-based methods to design more potent ligands.  This approach yielded highly efficient low mol. wt. inhibitors, the most active being of nanomolar potency both in an enzymic and in a cellular assay, while showing no cellular toxicity and a high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO).  A quant. structure-activity relationship based on the electrostatic ligand-protein interactions in the docked binding modes and on the quantum chem. derived charges of the triazole ring demonstrated a good explanatory power for the obsd. activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CFYZnWiLSLVg90H21EOLACvtfcHk0lgKG-DMrs9SJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1yiu7c%253D&md5=6ba6c0b628165673cd49c7a950ed885e</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm300260v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300260v%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DGrosdidier%26aufirst%3DA.%26aulast%3DBron%26aufirst%3DS.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DRational%2520Design%2520of%25204-Aryl-1%252C2%252C3-Triazoles%2520for%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5270%26epage%3D5290%26doi%3D10.1021%2Fjm300260v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexandre, J. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latchem, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westcott, J.</span></span> <span> </span><span class="NLM_article-title">New 4-Amino-1,2,3-Triazole Inhibitors of Indoleamine 2,3-Dioxygenase Form a Long-Lived Complex with the Enzyme and Display Exquisite Cellular Potency</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1002/cbic.201700560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcbic.201700560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29240291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFaitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=552-561&author=J.+A.+C.+Alexandreauthor=M.+K.+Swanauthor=M.+J.+Latchemauthor=D.+Boyallauthor=J.+R.+Pollardauthor=S.+W.+Hughesauthor=J.+Westcott&title=New+4-Amino-1%2C2%2C3-Triazole+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+Form+a+Long-Lived+Complex+with+the+Enzyme+and+Display+Exquisite+Cellular+Potency&doi=10.1002%2Fcbic.201700560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">New 4-Amino-1,2,3-Triazole Inhibitors of Indoleamine 2,3-Dioxygenase Form a Long-Lived Complex with the Enzyme and Display Exquisite Cellular Potency</span></div><div class="casAuthors">Alexandre, Julie Anne Christine; Swan, Michael Kenneth; Latchem, Mike John; Boyall, Dean; Pollard, John Robert; Hughes, Stuart Wynn; Westcott, James</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">552-561</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Indoleamine-2,3 dioxygenase 1 (IDO1) has emerged as a central regulator of immune responses in both normal and disease biol.  Due to its established role in promoting tumor immune escape, IDO1 has become an attractive target for cancer treatment.  A novel series of highly cell potent IDO1 inhibitors based on a 4-amino-1,2,3-triazole core have been identified.  Comprehensive kinetic, biochem. and structural studies demonstrate that compds. from this series have a noncompetitive kinetic mechanism of action with respect to the tryptophan substrate.  In co-complex crystal structures, the compds. bind in the tryptophan pocket and make a direct ligand interaction with the haem iron of the porphyrin cofactor.  It is proposed that these data can be rationalised by an ordered-binding mechanism, in which the inhibitor binds an apo form of the enzyme that is not competent to bind tryptophan.  These inhibitors also form a very tight, long-lived complex with the enzyme, which partially explains their exquisite cellular potency.  This novel series represents an attractive starting point for the future development of potent IDO1-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGors3iiMxl2dLVg90H21EOLACvtfcHk0lgZ-0WHzBwKfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFaitrg%253D&md5=2d27c177ab259dcfec42abe8083d6718</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201700560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201700560%26sid%3Dliteratum%253Aachs%26aulast%3DAlexandre%26aufirst%3DJ.%2BA.%2BC.%26aulast%3DSwan%26aufirst%3DM.%2BK.%26aulast%3DLatchem%26aufirst%3DM.%2BJ.%26aulast%3DBoyall%26aufirst%3DD.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DHughes%26aufirst%3DS.%2BW.%26aulast%3DWestcott%26aufirst%3DJ.%26atitle%3DNew%25204-Amino-1%252C2%252C3-Triazole%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Form%2520a%2520Long-Lived%2520Complex%2520with%2520the%2520Enzyme%2520and%2520Display%2520Exquisite%2520Cellular%2520Potency%26jtitle%3DChemBioChem%26date%3D2018%26volume%3D19%26spage%3D552%26epage%3D561%26doi%3D10.1002%2Fcbic.201700560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharyya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span> <span> </span><span class="NLM_article-title">4,5-Disubstituted 1,2,3-Triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T Cell Activity and Mitigates Tumor Growth</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">18455</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-54963-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41598-019-54963-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31804586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=18455&author=S.+Pandaauthor=N.+Pradhanauthor=S.+Chatterjeeauthor=S.+Morlaauthor=A.+Sahaauthor=A.+Royauthor=S.+Kumarauthor=A.+Bhattacharyyaauthor=D.+Manna&title=4%2C5-Disubstituted+1%2C2%2C3-Triazoles%3A+Effective+Inhibition+of+Indoleamine+2%2C3-Dioxygenase+1+Enzyme+Regulates+T+Cell+Activity+and+Mitigates+Tumor+Growth&doi=10.1038%2Fs41598-019-54963-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth</span></div><div class="casAuthors">Panda, Subhankar; Pradhan, Nirmalya; Chatterjee, Soumya; Morla, Sudhir; Saha, Abhishek; Roy, Ashalata; Kumar, Sachin; Bhattacharyya, Arindam; Manna, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18455</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The improvement of body's own immune system is considered one of the safest approaches to fight against cancer and several other diseases.  Excessive catabolism of the essential amino acid, L-tryptophan (L-Trp) assists the cancer cells to escape normal immune obliteration.  The formation of disproportionate kynurenine and other downstream metabolites suppress the T cell functions.  Blocking of this immunosuppressive mechanism is considered as a promising approach against cancer, neurol. disorders, autoimmunity, and other immune-mediated diseases.  Overexpression of indoleamine 2,3-dioxygenase 1 (IDO1) enzyme is directly related to the induction of immunosuppressive mechanisms and represents an important therapeutic target.  Several classes of small mol.-based IDO1 inhibitors have been already reported, but only few compds. are currently being evaluated in various stages of clin. trials as adjuvants or in combination with chemo- and radiotherapies.  In the quest for novel structural class(s) of IDO1 inhibitors, we developed a series of 4,5-disubstituted 1,2,3-triazole derivs.  The optimization of 4,5-disubstituted 1,2,3-triazole scaffold and comprehensive biochem. and biophys. studies led to the identification of compds., 3i, 4i, and 4k as potent and selective inhibitors of IDO1 enzyme with IC50 values at a low nanomolar level.  These potent compds. also showed strong IDO1 inhibitory activities in MDA-MB-231 cells with no/negligible level of cytotoxicity.  The T cell activity studies revealed that controlled regulation of IDO1 enzyme activity in the presence of these potent compds. could induce immune response against breast cancer cells.  The compds. also showed excellent in vivo antitumor efficacy (of tumor growth inhibition = 79-96%) in the female Swiss albino mice.  As a consequence, this study describes the first example of 4,5-disubstituted 1,2,3-triazole based IDO1 inhibitors with potential applications for immunotherapeutic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFvvHiEQTt2bVg90H21EOLACvtfcHk0lgZ-0WHzBwKfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhsrvE&md5=1c2281948384ef55d772b681ddeeac91</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-54963-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-54963-9%26sid%3Dliteratum%253Aachs%26aulast%3DPanda%26aufirst%3DS.%26aulast%3DPradhan%26aufirst%3DN.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DMorla%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DA.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DBhattacharyya%26aufirst%3DA.%26aulast%3DManna%26aufirst%3DD.%26atitle%3D4%252C5-Disubstituted%25201%252C2%252C3-Triazoles%253A%2520Effective%2520Inhibition%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Enzyme%2520Regulates%2520T%2520Cell%2520Activity%2520and%2520Mitigates%2520Tumor%2520Growth%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D18455%26doi%3D10.1038%2Fs41598-019-54963-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mautino, M. R.</span>; <span class="NLM_string-name">Kumar, S.</span>; <span class="NLM_string-name">Waldo, J. P.</span>; <span class="NLM_string-name">Jaipuri, F. A.</span>; <span class="NLM_string-name">Kesharwani, T.</span></span> <span> </span><span class="NLM_article-title">Fused Imidazole Derivatives Useful as Ido Inhibitors</span>. Patent <span class="NLM_patent">WO2012/142237</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+R.+Mautino&author=S.+Kumar&author=J.+P.+Waldo&author=F.+A.+Jaipuri&author=T.+Kesharwani&title=Fused+Imidazole+Derivatives+Useful+as+Ido+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMautino%26aufirst%3DM.%2BR.%26atitle%3DFused%2520Imidazole%2520Derivatives%2520Useful%2520as%2520Ido%2520Inhibitors%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Imidazoleisoindole Derivatives as Potent Ido1 Inhibitors: Design, Synthesis, Biological Evaluation and Computational Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.09.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2017.09.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28963992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOltbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=293-304&author=Y.+Zouauthor=F.+Wangauthor=Y.+Wangauthor=Q.+Sunauthor=Y.+Huauthor=Y.+Liauthor=W.+Liuauthor=W.+Guoauthor=Z.+Huangauthor=Y.+Zhangauthor=Q.+Xuauthor=Y.+Lai&title=Discovery+of+Imidazoleisoindole+Derivatives+as+Potent+Ido1+Inhibitors%3A+Design%2C+Synthesis%2C+Biological+Evaluation+and+Computational+Studies&doi=10.1016%2Fj.ejmech.2017.09.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of imidazoleisoindole derivatives as potent IDO1 inhibitors: Design, synthesis, biological evaluation and computational studies</span></div><div class="casAuthors">Zou, Yi; Wang, Fang; Wang, Yan; Sun, Qirui; Hu, Yue; Li, Yuezhen; Liu, Wen; Guo, Wenjie; Huang, Zhangjian; Zhang, Yihua; Xu, Qiang; Lai, Yisheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">293-304</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase-1 (IDO1) is an attractive target for cancer immunotherapy.  Herein, a series of novel imidazoleisoindole derivs. were prepd. and evaluated for their ability to inhibit IDO1.  Among these, deriv. 11r was the most active compd. with nanomolar potency in the Hela cell-based assay, while showed negligible cellular toxicity.  UV-visible spectra study demonstrated that compds. 11p and 11r bound to IDO1 and coordinated with the heme iron.  Furthermore, they could significantly promote T cell proliferation, increase IFN-γ prodn., and reduce the nos. of Foxp3+ regulatory T cells.  Finally, induced fit docking (IFD) and quantum mechanics/mol. mechanics (QM/MM) calcn. were performed to understand the interactions of these compds. to IDO1 protein, which provided a comprehensive guide for further structural modification and optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEx1hdvWJE7bVg90H21EOLACvtfcHk0lgZ-0WHzBwKfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOltbfL&md5=cb05901e3899f03c54d054f3ecb89682</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.09.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.09.025%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLai%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Imidazoleisoindole%2520Derivatives%2520as%2520Potent%2520Ido1%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520Biological%2520Evaluation%2520and%2520Computational%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D140%26spage%3D293%26epage%3D304%26doi%3D10.1016%2Fj.ejmech.2017.09.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-Dioxygenase Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00114</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00114" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyjsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=949-953&author=W.+Tuauthor=F.+Yangauthor=G.+Xuauthor=J.+Chiauthor=Z.+Liuauthor=W.+Pengauthor=B.+Huauthor=L.+Zhangauthor=H.+Wanauthor=N.+Yuauthor=F.+Jinauthor=Q.+Huauthor=L.+Zhangauthor=F.+Heauthor=W.+Tao&title=Discovery+of+Imidazoisoindole+Derivatives+as+Highly+Potent+and+Orally+Active+Indoleamine-2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors</span></div><div class="casAuthors">Tu, Wangyang; Yang, Fanglong; Xu, Guoji; Chi, Jiangtao; Liu, Zhiwei; Peng, Wei; Hu, Bing; Zhang, Lei; Wan, Hong; Yu, Nan; Jin, Fangfang; Hu, Qiyue; Zhang, Lianshan; He, Feng; Tao, Weikang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-953</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of imidazoisoindoles were identified as potent indoleamine-2,3-dioxygenase (IDO) inhibitors.  Lead optimization toward improving potency and eliminating CYP inhibition resulted in the discovery of lead compd. 25, a highly potent IDO inhibitor with favorable pharmacokinetic properties.  In the MC38 xenograft model in hPD-1 transgenic mice, 25 in combination with the anti-PD-1 monoclonal antibody (SHR-1210) achieved a synergistic antitumor effect superior to each single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2TmMZeIai0rVg90H21EOLACvtfcHk0lgQfgdgmil4pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyjsL%252FI&md5=fc335004d7e1362c03fc13c1395a3734</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00114%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DChi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DTao%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520Imidazoisoindole%2520Derivatives%2520as%2520Highly%2520Potent%2520and%2520Orally%2520Active%2520Indoleamine-2%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D949%26epage%3D953%26doi%3D10.1021%2Facsmedchemlett.9b00114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tojo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamioka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as Ido1 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1021/ml500247w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500247w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1119-1123&author=S.+Tojoauthor=T.+Kohnoauthor=T.+Tanakaauthor=S.+Kamiokaauthor=Y.+Otaauthor=T.+Ishiiauthor=K.+Kamimotoauthor=S.+Asanoauthor=Y.+Isobe&title=Crystal+Structures+and+Structure-Activity+Relationships+of+Imidazothiazole+Derivatives+as+Ido1+Inhibitors&doi=10.1021%2Fml500247w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors</span></div><div class="casAuthors">Tojo, Shingo; Kohno, Tetsuya; Tanaka, Tomoyuki; Kamioka, Seiji; Ota, Yosuke; Ishii, Takayuki; Kamimoto, Keiko; Asano, Shigehiro; Isobe, Yoshiaki</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as a promising target for the treatment of several diseases, including neurol. disorders and cancer.  We report here the crystal structures of two IDO1/IDO1 inhibitor complexes, one of which shows that Amg-1 is directly bound to the heme iron of IDO1 with a clear induced fit.  We also describe the identification and preliminary optimization of imidazothiazole derivs. as novel IDO1 inhibitors.  Using our crystal structure information and structure-activity relationships (SAR) at the pocket-B of IDO1, we found a series of urea derivs. as potent IDO1 inhibitors and revealed that generation of an induced fit and the resulting interaction with Phe226 and Arg231 are essential for potent IDO1 inhibitory activity.  The results of this study are very valuable for understanding the mechanism of IDO1 activation, which is very important for structure-based drug design (SBDD) to discover potent IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO6dAvsq0nObVg90H21EOLACvtfcHk0lgQfgdgmil4pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLnI&md5=7eaf3faae0c29a60de5f23a48a079af7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fml500247w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500247w%26sid%3Dliteratum%253Aachs%26aulast%3DTojo%26aufirst%3DS.%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKamioka%26aufirst%3DS.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DKamimoto%26aufirst%3DK.%26aulast%3DAsano%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DY.%26atitle%3DCrystal%2520Structures%2520and%2520Structure-Activity%2520Relationships%2520of%2520Imidazothiazole%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1119%26epage%3D1123%26doi%3D10.1021%2Fml500247w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aprile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as Ido1 Inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1874</span>, <span class="refDoi"> DOI: 10.3390/molecules24101874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3390%2Fmolecules24101874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31096672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1874&author=M.+Serafiniauthor=E.+Torreauthor=S.+Aprileauthor=A.+Massarottiauthor=S.+Fallariniauthor=T.+Pirali&title=Synthesis%2C+Docking+and+Biological+Evaluation+of+a+Novel+Class+of+Imidazothiazoles+as+Ido1+Inhibitors&doi=10.3390%2Fmolecules24101874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, docking and biological evaluation of a novel class of imidazothiazoles as IDO1 inhibitors</span></div><div class="casAuthors">Serafini, Marta; Torre, Enza; Aprile, Silvio; Massarotti, Alberto; Fallarini, Silvia; Pirali, Tracey</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1874</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">IDO1, a key dioxygenase in tryptophan-kynurenine metab., appeared in the last 10 years at the vanguard of druggable targets in cancer therapy due to its well-established role both in immune escape and inflammatory neovascularization.  Among the pool of IDO1 inhibitors that have entered clin. trials, none have reached approval.  The identification of novel inhibitors endowed with better clin. profile, together with the further comprehension of the interactions with residues in IDO1 active site, are still a need.  In this context, we have synthesized a novel class of imidazothiazole derivs. as IDO1 inhibitors and identified three compds. with inhibitory potency in the low micromolar range.  This report strengthens the role played by pocket C in the active site of IDO1, providing novel directions in the design of IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4xFMXgXVQTLVg90H21EOLACvtfcHk0lgQfgdgmil4pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb7O&md5=5ed41662e4f25680805801d10aaf091c</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24101874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24101874%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DTorre%26aufirst%3DE.%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DFallarini%26aufirst%3DS.%26aulast%3DPirali%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520Docking%2520and%2520Biological%2520Evaluation%2520of%2520a%2520Novel%2520Class%2520of%2520Imidazothiazoles%2520as%2520Ido1%2520Inhibitors%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D1874%26doi%3D10.3390%2Fmolecules24101874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppusamy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1642</span>– <span class="NLM_lpage">1659</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01549</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01549" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1642-1659&author=Y.+H.+Pengauthor=F.+Y.+Liaoauthor=C.+T.+Tsengauthor=R.+Kuppusamyauthor=A.+S.+Liauthor=C.+H.+Chenauthor=Y.+S.+Fanauthor=S.+Y.+Wangauthor=M.+H.+Wuauthor=C.+C.+Hsuehauthor=J.+Y.+Changauthor=L.+C.+Leeauthor=C.+Shihauthor=K.+S.+Shiaauthor=T.+K.+Yehauthor=M.+S.+Hungauthor=C.+C.+Kuoauthor=J.+S.+Songauthor=S.+Y.+Wuauthor=S.+H.+Ueng&title=Unique+Sulfur-Aromatic+Interactions+Contribute+to+the+Binding+of+Potent+Imidazothiazole+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors</span></div><div class="casAuthors">Peng, Yi-Hui; Liao, Fang-Yu; Tseng, Chen-Tso; Kuppusamy, Ramajayam; Li, An-Siou; Chen, Chi-Han; Fan, Yu-Shiou; Wang, Sing-Yi; Wu, Mine-Hsine; Hsueh, Ching-Cheng; Chang, Jia-Yu; Lee, Lung-Chun; Shih, Chuan; Shia, Kak-Shan; Yeh, Teng-Kuang; Hung, Ming-Shiu; Kuo, Ching-Chuan; Song, Jen-Shin; Wu, Su-Ying; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1642-1659</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO1) inhibitors are speculated to be useful in cancer immunotherapy, but a phase III clin. trial of the most advanced IDO1 inhibitor, epacadostat, did not meet its primary endpoint and was abandoned.  In previous work we identified the novel IDO1 inhibitor N-(4-chlorophenyl)-2-((5-phenylthiazolo[2,3-c][1,2,4]triazol-3-yl)thio)acetamide 1 through high-throughput screening (HTS).  Herein, we report a structure-activity relationship (SAR) study of this compd., which resulted in the potent IDO1 inhibitor 1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea 47 (hIDO IC50 = 16.4 nM).  X-ray co-crystal structural anal. revealed that the basis for this high potency is a unique sulfur-arom. interaction network formed by the thiourea moiety of 47 with the F163 and F226.  This finding is expected to inspire new approaches towards the discovery of potent IDO1 inhibitors in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLdRgatLF0JLVg90H21EOLACvtfcHk0lgLbgTxseqIWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSmu7s%253D&md5=fa171b57b2e03f46d1658ba29419a150</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01549%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DTseng%26aufirst%3DC.%2BT.%26aulast%3DKuppusamy%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DA.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DFan%26aufirst%3DY.%2BS.%26aulast%3DWang%26aufirst%3DS.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsueh%26aufirst%3DC.%2BC.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DShia%26aufirst%3DK.%2BS.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DUnique%2520Sulfur-Aromatic%2520Interactions%2520Contribute%2520to%2520the%2520Binding%2520of%2520Potent%2520Imidazothiazole%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1642%26epage%3D1659%26doi%3D10.1021%2Facs.jmedchem.9b01549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7364</span>– <span class="NLM_lpage">7367</span>, <span class="refDoi"> DOI: 10.1021/jm900518f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900518f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7364-7367&author=E.+W.+Yueauthor=B.+Doutyauthor=B.+Waylandauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=C.+Liuauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=B.+Metcalfauthor=P.+A.+Scherleauthor=A.+P.+Combs&title=Discovery+of+Potent+Competitive+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+with+in+Vivo+Pharmacodynamic+Activity+and+Efficacy+in+a+Mouse+Melanoma+Model&doi=10.1021%2Fjm900518f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span></div><div class="casAuthors">Yue, Eddy W.; Douty, Brent; Wayland, Brian; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Liu, Changnian; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Metcalf, Brian; Scherle, Peggy A.; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7364-7367</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).  Optimization led to the identification of (I), which is a potent (HeLa IC50 = 19 nM) competitive inhibitor of IDO.  Testing of I in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsq88hx0J77Vg90H21EOLACvtfcHk0lgLbgTxseqIWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D&md5=328d92bffb88a86da030c31eff707dc6</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm900518f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900518f%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520Potent%2520Competitive%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520with%2520in%2520Vivo%2520Pharmacodynamic%2520Activity%2520and%2520Efficacy%2520in%2520a%2520Mouse%2520Melanoma%2520Model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7364%26epage%3D7367%26doi%3D10.1021%2Fjm900518f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span> <span> </span><span class="NLM_article-title">High-Resolution Structures of Inhibitor Complexes of Human Indoleamine 2,3-Dioxygenase 1 in a New Crystal Form</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1107/S2053230X18012955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1107%2FS2053230X18012955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30387777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOhsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2018&pages=717-724&author=S.+Luoauthor=K.+Xuauthor=S.+Xiangauthor=J.+Chenauthor=C.+Chenauthor=C.+Guoauthor=Y.+Tongauthor=L.+Tong&title=High-Resolution+Structures+of+Inhibitor+Complexes+of+Human+Indoleamine+2%2C3-Dioxygenase+1+in+a+New+Crystal+Form&doi=10.1107%2FS2053230X18012955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution structures of inhibitor complexes of human indoleamine 2,3-dioxygenase 1 in a new crystal form</span></div><div class="casAuthors">Luo, Shukun; Xu, Ke; Xiang, Shaoyun; Chen, Jie; Chen, Chunyun; Guo, Chuangxin; Tong, Youzhi; Tong, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">717-724</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Human indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-dependent enzyme with important roles in many cellular processes and is a potential target for drug discovery against cancer and other diseases.  Crystal structures of IDO1 in complex with various inhibitors have been reported.  Many of these crystals belong to the same crystal form and most of the reported structures have resolns. in the range 3.2-2.3 Å.  Here, three new crystal forms of human IDO1 obtained by introducing a surface mutation, K116A/K117A, distant from the active site are reported.  One of these crystal forms diffracted to 1.5 Å resoln. and can be readily used for soaking expts. to det. high-resoln. structures of IDO1 in complex with the substrate tryptophan or inhibitors that coordinate the heme.  In addn., this mutant was used to produce crystals of a complex with an inhibitor that targets the apo form of the enzyme under the same conditions; the structure of this complex was detd. at 1.7 Å resoln.  Overall, this mutant represents a robust platform for detg. the structures of inhibitor and substrate complexes of IDO1 at high resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNOGWhEFr_j7Vg90H21EOLACvtfcHk0lgLbgTxseqIWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOhsrrJ&md5=067ab7c11763cecf0513d56295c2a9ae</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1107%2FS2053230X18012955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X18012955%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DXiang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DL.%26atitle%3DHigh-Resolution%2520Structures%2520of%2520Inhibitor%2520Complexes%2520of%2520Human%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520in%2520a%2520New%2520Crystal%2520Form%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2018%26volume%3D74%26spage%3D717%26epage%3D724%26doi%3D10.1107%2FS2053230X18012955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardolino, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knemeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurukulasuriya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesburg, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinot, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biju, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciammetta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solban, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Amino-Cyclobutarene-Derived Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitors for Cancer Immunotherapy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1530</span>– <span class="NLM_lpage">1536</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00344</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00344" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1530-1536&author=H.+Zhangauthor=K.+Liuauthor=Q.+Puauthor=A.+Achabauthor=M.+J.+Ardolinoauthor=M.+Chengauthor=Y.+Dengauthor=A.+C.+Dotyauthor=H.+Fergusonauthor=X.+Fraderaauthor=I.+Knemeyerauthor=R.+Kurukulasuriyaauthor=Y.+H.+Lamauthor=C.+A.+Lesburgauthor=T.+A.+Martinotauthor=M.+A.+McGowanauthor=J.+R.+Millerauthor=K.+Otteauthor=P.+J.+Bijuauthor=N.+Sciammettaauthor=N.+Solbanauthor=W.+Yuauthor=H.+Zhouauthor=X.+Wangauthor=D.+J.+Bennettauthor=Y.+Han&title=Discovery+of+Amino-Cyclobutarene-Derived+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors+for+Cancer+Immunotherapy&doi=10.1021%2Facsmedchemlett.9b00344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy</span></div><div class="casAuthors">Zhang, Hongjun; Liu, Kun; Pu, Qinglin; Achab, Abdelghani; Ardolino, Michael J.; Cheng, Mangeng; Deng, Yongqi; Doty, Amy C.; Ferguson, Heidi; Fradera, Xavier; Knemeyer, Ian; Kurukulasuriya, Ravi; Lam, Yu-hong; Lesburg, Charles A.; Martinot, Theodore A.; McGowan, Meredeth A.; Miller, J. Richard; Otte, Karin; Biju, Purakattle J.; Sciammetta, Nunzio; Solban, Nicolas; Yu, Wensheng; Zhou, Hua; Wang, Xiao; Bennett, David Jonathan; Han, Yongxin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1530-1536</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become std. of care for certain types of cancers.  However, low overall response rates often hamper the broad utility and potential of these breakthrough therapies.  Combination therapy strategies are currently under intensive investigation in the clinic, including the combination of PD-1/PD-L1 agents with IDO1 inhibitors.  Here, we report the discovery of a class of IDO1 heme-binding inhibitors featuring a unique amino-cyclobutarene motif, which was discovered through SBDD from a known and weakly active inhibitor.  Subsequent optimization efforts focused on improving metabolic stability and were greatly accelerated by utilizing a robust SNAr reaction of a facile nitro-furazan intermediate to quickly explore different polar side chains.  As a culmination of these efforts, compd. 16 was identified and demonstrated a favorable overall profile with superior potency and selectivity.  Extensive studies confirmed the chem. stability and drug-like properties of compd. 16, rendering it a potential drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmACl12NSJBrVg90H21EOLACvtfcHk0ljvO0XEtSSfTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7rE&md5=18def13fafda60ed7547810dd97a3c37</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00344%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DArdolino%26aufirst%3DM.%2BJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DDoty%26aufirst%3DA.%2BC.%26aulast%3DFerguson%26aufirst%3DH.%26aulast%3DFradera%26aufirst%3DX.%26aulast%3DKnemeyer%26aufirst%3DI.%26aulast%3DKurukulasuriya%26aufirst%3DR.%26aulast%3DLam%26aufirst%3DY.%2BH.%26aulast%3DLesburg%26aufirst%3DC.%2BA.%26aulast%3DMartinot%26aufirst%3DT.%2BA.%26aulast%3DMcGowan%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DJ.%2BR.%26aulast%3DOtte%26aufirst%3DK.%26aulast%3DBiju%26aufirst%3DP.%2BJ.%26aulast%3DSciammetta%26aufirst%3DN.%26aulast%3DSolban%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBennett%26aufirst%3DD.%2BJ.%26aulast%3DHan%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Amino-Cyclobutarene-Derived%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%2520for%2520Cancer%2520Immunotherapy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1530%26epage%3D1536%26doi%3D10.1021%2Facsmedchemlett.9b00344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into the Binding Mechanism of Ido1 with Hydroxylamidine Based Inhibitor Incb14943</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.04.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bbrc.2017.04.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28412361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1arsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2017&pages=339-343&author=Y.+Wuauthor=T.+Xuauthor=J.+Liuauthor=K.+Dingauthor=J.+Xu&title=Structural+Insights+into+the+Binding+Mechanism+of+Ido1+with+Hydroxylamidine+Based+Inhibitor+Incb14943&doi=10.1016%2Fj.bbrc.2017.04.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943</span></div><div class="casAuthors">Wu, You; Xu, Tingting; Liu, Jinsong; Ding, Ke; Xu, Jinxin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">339-343</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">IDO1 (indoleamine 2, 3-dioxygenase 1), a well characterized immunosuppressive enzyme, has attracted growing attention as a potential target for cancer immunotherapy.  Hydroxylamidine compds. INCB024360 and INCB14943 (INCB024360 analog) are highly effective IDO1 inhibitors.  INCB024360 is undergoing clin. trials for treatment of various types of human cancer.  Here, we detd. the co-crystal structure of IDO1 and INCB14943, and elucidate the detailed binding mode.  INCB14943 binds to heme iron in IDO1 protein through the oxime nitrogen.  Further anal. also reveals that a halogen bonding interaction between the chlorine atom (3-Cl) of INCB14943 and the sulfur atom of C129 significantly improves the inhibition activity against IDO1.  Comparing with the other reported inhibitors, the oxime nitrogen and halogen bond interaction are identified as the unique features of INCB14943 among the IDO1 inhibitors.  Thus, our study provides novel insights into the interaction between a small mol. inhibitor INCB14943 and IDO1 protein.  The structural information will facilitate future IDO1 inhibitor design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWqCzisTLF1rVg90H21EOLACvtfcHk0ljvO0XEtSSfTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1arsbk%253D&md5=8b50144d16e4ad7b3da724953b3b3d66</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.04.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.04.061%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DStructural%2520Insights%2520into%2520the%2520Binding%2520Mechanism%2520of%2520Ido1%2520with%2520Hydroxylamidine%2520Based%2520Inhibitor%2520Incb14943%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D487%26spage%3D339%26epage%3D343%26doi%3D10.1016%2Fj.bbrc.2017.04.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (Ido1)</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4323</span>– <span class="NLM_lpage">4325</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00586</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00586" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ShtL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=4323-4325&author=U.+F.+Rohrigauthor=V.+Zoeteauthor=O.+Michielin&title=The+Binding+Mode+of+N-Hydroxyamidines+to+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29&doi=10.1021%2Facs.biochem.7b00586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The binding mode of N-hydroxyamidines to indoleamine 2,3-dioxygenase 1 (IDO1)</span></div><div class="casAuthors">Rohrig, Ute F.; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4323-4325</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an important target in cancer immunotherapy.  The most advanced clin. compd., epacadostat (INCB 024360), binds to the heme cofactor of IDO1 through an N-hydroxyamidine function.  Conflicting binding modes have recently been proposed, reporting Fe binding either through the hydroxyamidine O atom or through the hydroxyamidine N atom.  Here, we used quantum chem. calcns., mol. docking, and quantum mechanics/mol. mechanics (QM/MM) calcns. based on available x-ray data to resolve this issue and to propose a phys. meaningful binding mode.  These findings will aid the design of novel IDO1 ligands based on this pharmacophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFjL9zUh8wtbVg90H21EOLACvtfcHk0ljvO0XEtSSfTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ShtL%252FO&md5=cc379deb32f2617a7f103a0822aad42c</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00586%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DThe%2520Binding%2520Mode%2520of%2520N-Hydroxyamidines%2520to%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26spage%3D4323%26epage%3D4325%26doi%3D10.1021%2Facs.biochem.7b00586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Phosphonamidate Ido1 Inhibitors for the Treatment of Non-Small Cell Lung Cancer</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">111629</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.111629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31445231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1CisLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2019&pages=111629&author=Q.+Duauthor=X.+Fengauthor=Y.+Wangauthor=X.+Xuauthor=Y.+Zhangauthor=X.+Quauthor=Z.+Liauthor=J.+Bian&title=Discovery+of+Phosphonamidate+Ido1+Inhibitors+for+the+Treatment+of+Non-Small+Cell+Lung+Cancer&doi=10.1016%2Fj.ejmech.2019.111629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer</span></div><div class="casAuthors">Du, Qianming; Feng, Xi; Wang, Yinuo; Xu, Xi; Zhang, Yan; Qu, Xinliang; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111629</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as an attractive approach for the development of cancer immunotherapy.  In this study, a series of phosphonamidate ester contg. compds. were designed, synthesized and evaluated for their inhibitory activities against IDO1.  Among them, compds. 16, 17, and 26 with good IDO1 inhibitory (HeLa IDO1 IC50 = 10-21 nM, hIDO1 IC50 = 78-121 nM) activities were selected for further investigation and showed good physicochem. properties.  Furthermore, based on comparable PK profile and excellent IDO2/TDO inhibitory potency, representative compd. 16 was selected for further bio-evaluation and characterized with good efficacy in suppressing lung metastasis (77% inhibition rate) of Lewis cells in vivo.  Thus, compd. 16 could be a potential and efficacious agent for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqHJhVsDBFarVg90H21EOLACvtfcHk0limTyvI61V2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1CisLbI&md5=bebc21dbfd0faac9b3f993080fd3dd61</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111629%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Phosphonamidate%2520Ido1%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D182%26spage%3D111629%26doi%3D10.1016%2Fj.ejmech.2019.111629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in Vivo Antitumor Evaluation of an Orally Active Potent Phosphonamidate Derivative Targeting Ido1/Ido2/Tdo</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bcp.2019.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31306643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWlu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=214-223&author=X.+Fengauthor=P.+Shenauthor=Y.+Wangauthor=Z.+Liauthor=J.+Bian&title=Synthesis+and+in+Vivo+Antitumor+Evaluation+of+an+Orally+Active+Potent+Phosphonamidate+Derivative+Targeting+Ido1%2FIdo2%2FTdo&doi=10.1016%2Fj.bcp.2019.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO</span></div><div class="casAuthors">Feng, Xi; Shen, Pei; Wang, Yinuo; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214-223</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting Trp-Kyn pathways has been identified as an attractive approach for the cancer immunotherapies.  In this study, a novel phosphonamidate contg. compd. was designed, synthesized and evaluated for its inhibitory activity against key dioxygenases in Trp-Kyn pathway, including IDO1, IDO2 and TDO.  This compd. showed potent IDO1 inhibitory activity with an IC50 value of 94 nM in an enzymic assay and 12.6 nM in HeLa cells.  In addn., this compd. showed promising IDO2 inhibition and TDO inhibition with IC50 values of 310 nM and 2.6 μM, resp., in enzyme assay.  Based on the promising enzyme inhibitory activity toward IDO/TDO, compd. F04(I) was evaluated of its antitumor effects in two tumor models.  Further evaluation of mechanism demonstrated I with the remarkable capacity of reducing kynurenine level in plasma/TME and restoring anti-tumor immune response.  I could be further developed as a potential immunotherapeutic agent combined with immune checkpoint inhibitors or chemotherapeutic drugs for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruUO0oCjsL5bVg90H21EOLACvtfcHk0limTyvI61V2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWlu7jK&md5=465bc2f6148b05c2b00d1dec45f06234</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520in%2520Vivo%2520Antitumor%2520Evaluation%2520of%2520an%2520Orally%2520Active%2520Potent%2520Phosphonamidate%2520Derivative%2520Targeting%2520Ido1%252FIdo2%252FTdo%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D168%26spage%3D214%26epage%3D223%26doi%3D10.1016%2Fj.bcp.2019.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Antitumor Study of a Series of N-Cyclic Sulfamoylaminoethyl Substituted 1,2,5-Oxadiazol-3-Amines as New Indoleamine 2, 3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.06.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.06.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31233921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1KjsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2019&pages=38-55&author=S.+Chenauthor=W.+Guoauthor=X.+Liuauthor=P.+Sunauthor=Y.+Wangauthor=C.+Dingauthor=L.+Mengauthor=A.+Zhang&title=Design%2C+Synthesis+and+Antitumor+Study+of+a+Series+of+N-Cyclic+Sulfamoylaminoethyl+Substituted+1%2C2%2C5-Oxadiazol-3-Amines+as+New+Indoleamine+2%2C+3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.ejmech.2019.06.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Chen, Shulun; Guo, Wei; Liu, Xiaohua; Sun, Pu; Wang, Yi; Ding, Chunyong; Meng, Linghua; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-55</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism which is an important mechanism in immune tolerance.  The small mol. epacadostat is the most advanced IDO1 inhibitor, but its phase III trials as a single agent or in combinations with PD-1 antibody failed to show appreciable objective responses.  To gain more insight on the antitumor efficacy of IDO1 inhibitors, a series of analogs of epacadostat by incorporating a cyclic aminosulfonamide moiety as the sidechain capping functionality has been designed.  N-(3-bromo-4-fluorophenyl)-4-((2-(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)ethyl)amino)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide was found to display significant potency against recombinant hIDO1 and hIDO1 expressed HEK293 cancer cells and this compd. has improved physico-chem. properties, acceptable PK parameters as well as optimal cardiac safety.  Similar to epacadostat, the above compd. is ineffective as single agent in the CT-26 syngeneic xenograft model, however, the combination of this compd. with PD-1 antibody showed both elevated tumor growth inhibition and prolonged median life span.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg_p5ZMG6Q-LVg90H21EOLACvtfcHk0limTyvI61V2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1KjsrfI&md5=fe9f73ec38ea7400e72354e728254ca3</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.06.037%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Antitumor%2520Study%2520of%2520a%2520Series%2520of%2520N-Cyclic%2520Sulfamoylaminoethyl%2520Substituted%25201%252C2%252C5-Oxadiazol-3-Amines%2520as%2520New%2520Indoleamine%25202%252C%25203-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D179%26spage%3D38%26epage%3D55%26doi%3D10.1016%2Fj.ejmech.2019.06.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of 1,2,5-Oxadiazole-3-Carboximidamide Derivatives as Novel Indoleamine-2,3-Dioxygenase 1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112059</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2020.112059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31981851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112059&author=X.+Songauthor=P.+Sunauthor=J.+Wangauthor=W.+Guoauthor=Y.+Wangauthor=L.+H.+Mengauthor=H.+Liu&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+1%2C2%2C5-Oxadiazole-3-Carboximidamide+Derivatives+as+Novel+Indoleamine-2%2C3-Dioxygenase+1+Inhibitors&doi=10.1016%2Fj.ejmech.2020.112059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors</span></div><div class="casAuthors">Song, Xiaohan; Sun, Pu; Wang, Jiang; Guo, Wei; Wang, Yi; Meng, Ling-hua; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112059</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of 1,2,5-oxadiazole-3-carboximidamide derivs. I [R = (1-sulfamoylpyrrolidin-3-yl)methyl, (1-methanesulfonylpyrrolidin-3-yl)methyl, [1-(cyclopropanesulfonyl)piperidin-3-yl]methyl, etc] bearing cycle in the side chain were designed, synthesized, and biol. evaluated for their anti-tumor activity.  Most of them exhibited potent activity against hIDO1 in enzymic assays and in HEK293T cells over-expressing hIDO1.  Among them, compd. I [R = [(3R)-1-sulfamoylpyrrolidin-3-yl]methyl, [(3R)-1-sulfamoylpiperidin-3-yl]methyl, [(3S)-1-sulfamoylpiperidin-3-yl]methyl] showed significant inhibitory activity against hIDO1 (IC50 = 108.7, 178.1 and 139.1 nM resp.) and in HEK293T cells expressing hIDO1 (cellular IC50 = 19.88, 68.59 and 57.76 nM resp.).  Moreover, compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] displayed improved PK property with longer half-life (t1/2 = 3.81 h in CD-1 mice) and better oral bioavailability (F = 33.6%) compared with epacadostat.  In addn., compd. I [R = [(3R)-1-sulfamoylpiperidin-3-yl]methyl] showed similar potency to inhibit the growth of CT-26 syngeneic xenograft compared to epacadostat, making it justifiable for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVCKyiy04nLVg90H21EOLACvtfcHk0lgo72Xoh17j0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSgtrc%253D&md5=eaacdbc7d1498bc8644774d4ae1ff3d0</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112059%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DL.%2BH.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%25201%252C2%252C5-Oxadiazole-3-Carboximidamide%2520Derivatives%2520as%2520Novel%2520Indoleamine-2%252C3-Dioxygenase%25201%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112059%26doi%3D10.1016%2Fj.ejmech.2020.112059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steeneck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderhub, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhaeuser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleymann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Hydroxyamidine Based Inhibitors of Ido1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1GhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=179-187&author=C.+Steeneckauthor=O.+Kinzelauthor=S.+Anderhubauthor=M.+Hornbergerauthor=S.+Pintoauthor=B.+Morschhaeuserauthor=F.+Braunauthor=G.+Kleymannauthor=T.+Hoffmann&title=Discovery+of+Hydroxyamidine+Based+Inhibitors+of+Ido1+for+Cancer+Immunotherapy+with+Reduced+Potential+for+Glucuronidation&doi=10.1021%2Facsmedchemlett.9b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation</span></div><div class="casAuthors">Steeneck, Christoph; Kinzel, Olaf; Anderhub, Simon; Hornberger, Martin; Pinto, Sheena; Morschhaeuser, Barbara; Braun, Floriane; Kleymann, Gerald; Hoffmann, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-187</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Following the impressive success of checkpoint inhibitors in the treatment of cancer, combinations of IDO1 inhibitors with PD-1/PD-L1 antibodies are in clin. development aiming to increase response rates.  Using the hydroxyamidine pharmacophore of the IDO1 inhibitor INCB14943 as a starting point for the design of new inhibitors, the potential shortcomings of extensive hydroxyamidine glucuronidation in humans was addressed.  Compds. were optimized using a stability assay with recombinant UGT1A9 enzyme together with the measurement of glucuronide formation in human hepatocytes.  Optimized analog 24 showed cellular and biochem. IDO1 IC50 values in the low nanomolar range, a suitable in vitro ADME/PK profile, and efficacy in an animal model of cancer.  In a humanized liver mouse model the lead compd. exhibited significantly reduced glucuronidation compared to epacadostat (2).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL0q_mXp0hC7Vg90H21EOLACvtfcHk0lgo72Xoh17j0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1GhsLs%253D&md5=ef40add370d8e26624bda069c834442e</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00572%26sid%3Dliteratum%253Aachs%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DAnderhub%26aufirst%3DS.%26aulast%3DHornberger%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DS.%26aulast%3DMorschhaeuser%26aufirst%3DB.%26aulast%3DBraun%26aufirst%3DF.%26aulast%3DKleymann%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520Hydroxyamidine%2520Based%2520Inhibitors%2520of%2520Ido1%2520for%2520Cancer%2520Immunotherapy%2520with%2520Reduced%2520Potential%2520for%2520Glucuronidation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D179%26epage%3D187%26doi%3D10.1021%2Facsmedchemlett.9b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Hydroxyamidine Derivatives as Indoleamine 2,3-Dioxygenase 1 Inhibitors with in Vivo Anti-Tumor Efficacy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127038</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2020.127038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32088128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1Krsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127038&author=C.+Liuauthor=Y.+Nanauthor=Z.+Xiaauthor=K.+Guauthor=C.+Chenauthor=X.+Dongauthor=D.+Juauthor=W.+Zhao&title=Discovery+of+Novel+Hydroxyamidine+Derivatives+as+Indoleamine+2%2C3-Dioxygenase+1+Inhibitors+with+in+Vivo+Anti-Tumor+Efficacy&doi=10.1016%2Fj.bmcl.2020.127038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy</span></div><div class="casAuthors">Liu, Chang; Nan, Yanyang; Xia, Zhifeng; Gu, Kedan; Chen, Cheng; Dong, Xiaochun; Ju, Dianwen; Zhao, Weili</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">127038</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is closely assocd. with immune escape in many tumor tissues, and is considered to be a valuable therapeutic target in cancer immunotherapy.  In this study, the modification of amino sidechain was performed with the hydroxyamidine core kept intact to optimize lead compd. Epacadostat.  Nineteen new compds. with hydrazide, thietane or sulfonamide moiety as polar capping group in sidechain were prepd. and their IDO1 inhibitory activities were evaluated.  Sulfonamide I showed potent IDO1 inhibition in both enzymic and cellular assays with the IC50 value of 71 nM and EC50 value of 11 nM, resp.  Furthermore, in vivo Lewis lung cancer (LLC) allograft studies of I indicated that it handicapped the tumor growth with similar efficacy to Epacadostat.  Mol. docking demonstrated that the change of polar capping group affords influence on the orientation of amino ethylene side chain and forms new hydrogen bonding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK5Cp_GBcPlrVg90H21EOLACvtfcHk0lgo72Xoh17j0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1Krsrs%253D&md5=61c0724d790cfb68adfac055ef7c51d0</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DNan%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DJu%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520Novel%2520Hydroxyamidine%2520Derivatives%2520as%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitors%2520with%2520in%2520Vivo%2520Anti-Tumor%2520Efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127038%26doi%3D10.1016%2Fj.bmcl.2020.127038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. Q.</span></span> <span> </span><span class="NLM_article-title">Lw106, a Novel Indoleamine 2,3-Dioxygenase 1 Inhibitor, Suppresses Tumour Progression by Limiting Stroma-Immune Crosstalk and Cancer Stem Cell Enrichment in Tumour Micro-Environment</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">3034</span>– <span class="NLM_lpage">3049</span>, <span class="refDoi"> DOI: 10.1111/bph.14351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1111%2Fbph.14351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29722898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGnt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=3034-3049&author=R.+Fuauthor=Y.+W.+Zhangauthor=H.+M.+Liauthor=W.+C.+Lvauthor=L.+Zhaoauthor=Q.+L.+Guoauthor=T.+Luauthor=S.+J.+Weissauthor=Z.+Y.+Liauthor=Z.+Q.+Wu&title=Lw106%2C+a+Novel+Indoleamine+2%2C3-Dioxygenase+1+Inhibitor%2C+Suppresses+Tumour+Progression+by+Limiting+Stroma-Immune+Crosstalk+and+Cancer+Stem+Cell+Enrichment+in+Tumour+Micro-Environment&doi=10.1111%2Fbph.14351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumor progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumor micro-environment</span></div><div class="casAuthors">Fu, Rong; Zhang, Yi-Wei; Li, Hong-Mei; Lv, Wen-Cong; Zhao, Li; Guo, Qing-Long; Lu, Tao; Weiss, Stephen J.; Li, Zhi-Yu; Wu, Zhao-Qiu</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3034-3049</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Indoleamine 2,3-dioxygenase 1 (IDO1) is emerging as an important new therapeutic target for treatment of malignant tumors characterized by dysregulated tryptophan metab.  However, the antitumor efficacy of existing small-mol. inhibitors of IDO1 is still unsatisfactory and the underlying mechanism remains largely undefined.  Hence, we discovered a novel potent small-mol. inhibitor of IDO1, LW106, and studied its antitumor effects and the underlying mechanisms in two tumor models.  Exptl. Approach : C57BL6 mice, athymic nude mice or Ido1-/- mice were inoculated with IDO1-expressing and -nonexpressing tumor cells and treated with vehicle, epacadostat or increasing doses of LW106.  Xenografted tumors, plasma, spleens and other vital organs were harvested and subjected to kynurenine/tryptophan measurement and flow cytometric, histol. and immunohistochem. analyses.  Key Results : LW106 dose-dependently inhibited the outgrowth of xenografted tumors that were inoculated in C57BL6 mice but not nude mice or Ido1-/- mice, showing a stronger antitumor efficacy than epacadostat, an existing IDO1 inhibitor.  LW106 substantially elevated intratumoral infiltration of proliferative Teff cells, while reducing recruitment of proliferative Treg cells and non-hematopoietic stromal cells such as endothelial cells and cancer-assocd. fibroblasts.  LW106 treatment resulted in a reduced subpopulation of cancer stem cells (CSCs) in xenografted tumors in which fewer proliferative/invasive tumor cells and more apoptotic tumor cells were obsd.  Conclusions and Implications : LW106 inhibits tumor outgrowth by limiting stroma-immune crosstalk and CSC enrichment in the tumor micro-environment.  LW106 has potential as a immunotherapeutic agent for use in combination with immune checkpoint inhibitors and (or) chemotherapeutic drugs for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofQxcdqCioFbVg90H21EOLACvtfcHk0ljdzSDiZkQkeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGnt7rJ&md5=d4626804567127df685d1329e6c3ee9b</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1111%2Fbph.14351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14351%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%2BW.%26aulast%3DLi%26aufirst%3DH.%2BM.%26aulast%3DLv%26aufirst%3DW.%2BC.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DQ.%2BL.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DS.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%2BY.%26aulast%3DWu%26aufirst%3DZ.%2BQ.%26atitle%3DLw106%252C%2520a%2520Novel%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Inhibitor%252C%2520Suppresses%2520Tumour%2520Progression%2520by%2520Limiting%2520Stroma-Immune%2520Crosstalk%2520and%2520Cancer%2520Stem%2520Cell%2520Enrichment%2520in%2520Tumour%2520Micro-Environment%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D3034%26epage%3D3049%26doi%3D10.1111%2Fbph.14351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deka, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span> <span> </span><span class="NLM_article-title">Nitrobenzofurazan Derivatives of N′-Hydroxyamidines as Potent Inhibitors of Indoleamine-2,3-Dioxygenase 1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.05.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2016.05.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27267006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1ymtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=364-375&author=S.+Paulauthor=A.+Royauthor=S.+J.+Dekaauthor=S.+Pandaauthor=V.+Trivediauthor=D.+Manna&title=Nitrobenzofurazan+Derivatives+of+N%E2%80%B2-Hydroxyamidines+as+Potent+Inhibitors+of+Indoleamine-2%2C3-Dioxygenase+1&doi=10.1016%2Fj.ejmech.2016.05.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1</span></div><div class="casAuthors">Paul, Saurav; Roy, Ashalata; Deka, Suman Jyoti; Panda, Subhankar; Trivedi, Vishal; Manna, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">364-375</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tryptophan metab. through the kynurenine pathway is considered as a crucial mechanism in immune tolerance.  Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism in the immune system and it is also considered as an important therapeutic target for the treatment of cancer and other diseases that are linked with kynurenine pathway.  Nitrobenzofurazan derivs. of N'-hydroxybenzimidamides and N'-hydroxy-2-phenylacetimidamides were synthesized and their inhibitory activities against human IDO1 enzyme were tested using in-vitro and cellular enzyme activity assay.  The optimization leads to the identification of three potent compds. (IC50 = 39-80 nM), which are either competitive or uncompetitive inhibitors of IDO1 enzyme.  These compds. also showed IDO1 inhibition potencies in the nanomolar range (IC50 = 50-71 nM) in MDA-MB-231 cells with no/negligible amt. of cytotoxicity.  The stronger selectivity of the potent compds. for IDO1 enzyme over tryptophan 2,3-dioxygenase (TDO) enzyme (312-1593-fold) also makes them very attractive for further immunotherapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0u7NQidTrFrVg90H21EOLACvtfcHk0ljdzSDiZkQkeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1ymtbg%253D&md5=abe140439fd68f0fe712f068b48f8428</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.05.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.05.061%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DDeka%26aufirst%3DS.%2BJ.%26aulast%3DPanda%26aufirst%3DS.%26aulast%3DTrivedi%26aufirst%3DV.%26aulast%3DManna%26aufirst%3DD.%26atitle%3DNitrobenzofurazan%2520Derivatives%2520of%2520N%25E2%2580%25B2-Hydroxyamidines%2520as%2520Potent%2520Inhibitors%2520of%2520Indoleamine-2%252C3-Dioxygenase%25201%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D364%26epage%3D375%26doi%3D10.1016%2Fj.ejmech.2016.05.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1936</span>, <span class="refDoi"> DOI: 10.3390/molecules22111936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3390%2Fmolecules22111936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1936&author=D.+H.+Leeauthor=J.+Y.+Leeauthor=J.+Jeongauthor=M.+Kimauthor=K.+W.+Leeauthor=E.+Jangauthor=S.+Ahnauthor=C.+H.+Leeauthor=J.+Y.+Hwang&title=Synthesis+and+Molecular+Modeling+Studies+of+N%E2%80%B2-Hydroxyindazolecarboximidamides+as+Novel+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.3390%2Fmolecules22111936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and molecular modeling studies of N'-hydroxyindazolecarboximidamides as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Lee, Dong-Ho; Lee, Joo-Youn; Jeong, Jieun; Kim, Miok; Lee, Kyung Won; Jang, Eunseo; Ahn, Sunjoo; Lee, Chang Hoon; Hwang, Jong Yeon</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1936/1-1936/10</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">To discover novel Indoleamine 2,3-dioxygenase (IDO1) inhibitors, a series of N'-hydroxyindazolecarboximidamides I (R = H, 4-F, 3-Cl, etc.) has been designed and synthesized.  Among the synthesized compds., I (R = 3-Br-4-F) inhibited both tryptophan depletion and kynurenine prodn. through the IDO1 enzyme.  Mol. docking studies revealed that compd. I (R = 3-Br-4-F) binds to IDO1 with the same binding mode as the analog, epacadostat (INCB24360).  Here, the synthesis and biol. evaluation of these hydroxyindazolecarboximidamides is reported and the mol. docking study of compd. I (R = 3-Br-4-F) with IDO1 is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfPJ4LQ-G8LVg90H21EOLACvtfcHk0ljdzSDiZkQkeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGjtbo%253D&md5=d56e9cfcf40bf05ab90846391e39bd04</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22111936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22111936%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DJeong%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DJang%26aufirst%3DE.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DHwang%26aufirst%3DJ.%2BY.%26atitle%3DSynthesis%2520and%2520Molecular%2520Modeling%2520Studies%2520of%2520N%25E2%2580%25B2-Hydroxyindazolecarboximidamides%2520as%2520Novel%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1936%26doi%3D10.3390%2Fmolecules22111936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balog, J. A.</span>; <span class="NLM_string-name">Huang, A.</span>; <span class="NLM_string-name">Chen, B.</span>; <span class="NLM_string-name">Chen, L.</span>; <span class="NLM_string-name">Seitz, S. P.</span>; <span class="NLM_string-name">Hart, A. C.</span>; <span class="NLM_string-name">Markwalder, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Indoleamine 2,3-Dioxygenase (Ido)</span>. Patent <span class="NLM_patent">WO2014/150677</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+A.+Balog&author=A.+Huang&author=B.+Chen&author=L.+Chen&author=S.+P.+Seitz&author=A.+C.+Hart&author=J.+A.+Markwalder&title=Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+%28Ido%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBalog%26aufirst%3DJ.%2BA.%26atitle%3DInhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520%2528Ido%2529%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markwalder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabalan, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covello, K.</span></span> <span> </span><span class="NLM_article-title">Identification and Optimization of a Novel Series of Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2016.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28003141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFamtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=582-585&author=J.+A.+Markwalderauthor=S.+P.+Seitzauthor=Y.+Blatauthor=L.+Elkinauthor=J.+T.+Huntauthor=J.+G.+Pabalanauthor=M.+N.+Jure-Kunkelauthor=G.+D.+Viteauthor=K.+Covello&title=Identification+and+Optimization+of+a+Novel+Series+of+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1016%2Fj.bmcl.2016.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Markwalder, Jay A.; Seitz, Steven P.; Blat, Yuval; Elkin, Lisa; Hunt, John T.; Pabalan, Jonathan G.; Jure-Kunkel, Maria N.; Vite, Gregory D.; Covello, Kelly</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">582-585</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of a series of structurally-novel biaryl urea IDO inhibitors is described.  Optimization of a micromolar hit through iterative cycles of synthesis and screening in an assay measuring IDO-mediated intracellular conversion of tryptophan to kynurenine led to potent inhibitors with favorable selectivity and metabolic stability profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhqc8tJqzMrVg90H21EOLACvtfcHk0lj8wzO9IapRzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFamtLzP&md5=5dd54d9ea6b7d8e24e6f81af379b7b74</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DMarkwalder%26aufirst%3DJ.%2BA.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DElkin%26aufirst%3DL.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DPabalan%26aufirst%3DJ.%2BG.%26aulast%3DJure-Kunkel%26aufirst%3DM.%2BN.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DCovello%26aufirst%3DK.%26atitle%3DIdentification%2520and%2520Optimization%2520of%2520a%2520Novel%2520Series%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D582%26epage%3D585%26doi%3D10.1016%2Fj.bmcl.2016.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markwalder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balog, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nation, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covello, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span> <span> </span><span class="NLM_article-title">Development of a Series of Novel O-Phenylenediamine-Based Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">732</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2018.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29398543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFejsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=732-736&author=D.+K.+Williamsauthor=J.+A.+Markwalderauthor=A.+J.+Balogauthor=B.+Chenauthor=L.+Chenauthor=J.+Donnellauthor=L.+Haqueauthor=A.+C.+Hartauthor=S.+K.+Mandalauthor=A.+Nationauthor=W.+Shanauthor=G.+D.+Viteauthor=K.+Covelloauthor=J.+T.+Huntauthor=M.+N.+Jure-Kunkelauthor=S.+P.+Seitz&title=Development+of+a+Series+of+Novel+O-Phenylenediamine-Based+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.bmcl.2018.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Williams, David K.; Markwalder, Jay A.; Balog, Aaron J.; Chen, Bin; Chen, Libing; Donnell, Jennifer; Haque, Lauren; Hart, Amy C.; Mandal, Sunil K.; Nation, Andrew; Shan, Weifang; Vite, Gregory D.; Covello, Kelly; Hunt, John T.; Jure-Kunkel, Maria N.; Seitz, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">732-736</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of o-phenylenediamine-based inhibitors of indoleamine 2,3-dioxygenase (IDO) has been identified.  IDO is a heme-contg. enzyme, overexpressed in the tumor microenvironment of many cancers, which can contribute to the suppression of the host immune system.  Synthetic modifications to a previously described diarylether series resulted in an addnl. degree of mol. diversity which was exploited to afford compds. that demonstrated significant potency in the HeLa human cervical cancer IDO1 assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCWbaEvQCnbVg90H21EOLACvtfcHk0lj8wzO9IapRzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFejsr8%253D&md5=9a01c59f05a3896a2ad6396bbdfa67c6</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DMarkwalder%26aufirst%3DJ.%2BA.%26aulast%3DBalog%26aufirst%3DA.%2BJ.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDonnell%26aufirst%3DJ.%26aulast%3DHaque%26aufirst%3DL.%26aulast%3DHart%26aufirst%3DA.%2BC.%26aulast%3DMandal%26aufirst%3DS.%2BK.%26aulast%3DNation%26aufirst%3DA.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DCovello%26aufirst%3DK.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJure-Kunkel%26aufirst%3DM.%2BN.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26atitle%3DDevelopment%2520of%2520a%2520Series%2520of%2520Novel%2520O-Phenylenediamine-Based%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D732%26epage%3D736%26doi%3D10.1016%2Fj.bmcl.2018.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of 2,5-Dimethylfuran-3-Carboxylic Acid Derivatives as Potential Ido1 Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1605</span>– <span class="NLM_lpage">1618</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2019.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30858027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks1Snsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=1605-1618&author=X.+Yangauthor=S.+Caiauthor=X.+Liuauthor=P.+Chenauthor=J.+Zhouauthor=H.+Zhang&title=Design%2C+Synthesis+and+Biological+Evaluation+of+2%2C5-Dimethylfuran-3-Carboxylic+Acid+Derivatives+as+Potential+Ido1+Inhibitors&doi=10.1016%2Fj.bmc.2019.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors</span></div><div class="casAuthors">Yang, Xiaojun; Cai, Shi; Liu, Xueting; Chen, Pan; Zhou, Jinpei; Zhang, Huibin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1605-1618</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a vital role in tumor immune escape and has emerged as a promising target for cancer immunotherapy.  In this study, a novel series of 2,5-dimethylfuran-3-carboxylic acid derivs. were designed, synthesized and evaluated for inhibitory activities against IDO1, and their structure-activity relationship was investigated.  Among these, compd. 19a(I) exhibited excellent IDO1 inhibitory activity (HeLa cellular IC50 = 4.0 nM, THP-1 cellular IC50 = 4.6 nM).  Further mol. docking studies revealed that I formed a coordinate bond with the heme iron through the carboxylic acid moiety.  These results indicate that I is a potential IDO1 inhibitor for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFv19cBLG-5bVg90H21EOLACvtfcHk0lhPGHpMMm4D0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks1Snsrg%253D&md5=8a874669af2fc16eab7d6798f6fd0368</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%25202%252C5-Dimethylfuran-3-Carboxylic%2520Acid%2520Derivatives%2520as%2520Potential%2520Ido1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D1605%26epage%3D1618%26doi%3D10.1016%2Fj.bmc.2019.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Bicyclic Carboxylic Acid Derivatives as Ido1 Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">103356</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bioorg.2019.103356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31785855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Crtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=103356&author=S.+Caiauthor=X.+Yangauthor=P.+Chenauthor=X.+Liuauthor=J.+Zhouauthor=H.+Zhang&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Bicyclic+Carboxylic+Acid+Derivatives+as+Ido1+Inhibitors&doi=10.1016%2Fj.bioorg.2019.103356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors</span></div><div class="casAuthors">Cai, Shi; Yang, Xiaojun; Chen, Pan; Liu, Xueting; Zhou, Jinpei; Zhang, Huibin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103356</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a vital role in tumor immune escape and has emerged as a promising target for cancer immunotherapy.  In this study, a novel series of bicyclic carboxylic acid derivs. were designed, synthesized and evaluated for inhibitory activities against IDO1.  Among these, compd. 9c exhibited strong IDO1 inhibitory activity (HeLa cellular IC50 = 2.6 nM, THP-1 cellular IC50 = 11.2 nM).  Further anti-tumor studies in vivo have shown that compd. 9c has a great inhibitory effect on tumor growth in mice CT26 model as a single agent or in combination with 5-fluorouracil (inhibition rate was 53.9% and 92.7%, resp.).  These results indicate that compd. 9c is a effective IDO1 inhibitor for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwS8sIEyKgiLVg90H21EOLACvtfcHk0lhPGHpMMm4D0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Crtb3E&md5=e5d89ce66c265f746eea6a673c9587d5</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103356%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Bicyclic%2520Carboxylic%2520Acid%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D94%26spage%3D103356%26doi%3D10.1016%2Fj.bioorg.2019.103356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(Iv) Pro-Drug Preferentially Targets Indoleamine-2,3-Dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.+R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28Iv%29+Pro-Drug+Preferentially+Targets+Indoleamine-2%2C3-Dioxygenase%2C+Providing+Enhanced+Ovarian+Cancer+Immuno-Chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0li9xDxUJg_ZLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528Iv%2529%2520Pro-Drug%2520Preferentially%2520Targets%2520Indoleamine-2%252C3-Dioxygenase%252C%2520Providing%2520Enhanced%2520Ovarian%2520Cancer%2520Immuno-Chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fertan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, K. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brant, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diez-Cecilia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R. E.</span></span> <span> </span><span class="NLM_article-title">Effects of the Novel Ido Inhibitor Dwg-1036 on the Behavior of Male and Female 3xtg-Ad Mice</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1044</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffphar.2019.01044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31607909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsFWqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1044&author=E.+Fertanauthor=K.+R.+J.+Stoverauthor=M.+G.+Brantauthor=P.+M.+Staffordauthor=B.+Kellyauthor=E.+Diez-Ceciliaauthor=A.+A.+Wongauthor=D.+F.+Weaverauthor=R.+E.+Brown&title=Effects+of+the+Novel+Ido+Inhibitor+Dwg-1036+on+the+Behavior+of+Male+and+Female+3xtg-Ad+Mice&doi=10.3389%2Ffphar.2019.01044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the novel IDO inhibitor DWG-1036 on the behavior of male and female 3xTg-AD mice</span></div><div class="casAuthors">Fertan, Emre; Stover, Kurt R. J.; Brant, Michael G.; Stafford, Paul M.; Kelly, Brendan; Diez-Cecilia, Elena; Wong, Aimee A.; Weaver, Donald F.; Brown, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1044</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The kynurenine pathway metabolizes tryptophan into NAD, producing a no. of intermediary metabolites, including 3-hydroxy kynurenine and quinolinic acid, which are involved in the neurodegenerative mechanisms that underlie Alzheimer's disease (AD).  Indolamine 2,3-dioxygenase (IDO), the first and rate-limiting enzyme of this pathway, is increased in AD, and it has been hypothesized that blocking this enzyme may slow the progression of AD.  In this study, we treated male and female 3xTg-AD and wild-type mice with the novel IDO inhibitor DWG-1036 (80 mg/kg) or vehicle (distd. water) from 2 to 6 mo of age and then tested them in a battery of behavioral tests that measured spatial learning and memory (Barnes maze), working memory (trace fear conditioning), motor coordination and learning (rotarod), anxiety (elevated plus maze), and depression (tail suspension test).  The 3xTg-AD mice treated with DWG-1036 showed better memory in the trace fear conditioning task and significant improvements in learning but poorer spatial memory in the Barnes maze.  DWG-1036 treatment also ameliorated the behaviors assocd. with increased anxiety in the elevated plus maze and depression-like behaviors in the tail suspension test in 3xTg-AD mice.  However, the effects of DWG-1036 treatment on the behavioral tasks were variable, and sex differences were apparent.  In addn., high doses of DWG-1036 resulted in reduced body wt., particularly in females.  Taken together, our results suggest that the kynurenine pathway is a promising target for treating AD, but more work is needed to det. the effective compds., examine sex differences, and understand the side effects of the compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOXe0D9TuZxrVg90H21EOLACvtfcHk0li9xDxUJg_ZLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsFWqs7w%253D&md5=2dd2cf54313b5282cd7179f26e69580f</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01044%26sid%3Dliteratum%253Aachs%26aulast%3DFertan%26aufirst%3DE.%26aulast%3DStover%26aufirst%3DK.%2BR.%2BJ.%26aulast%3DBrant%26aufirst%3DM.%2BG.%26aulast%3DStafford%26aufirst%3DP.%2BM.%26aulast%3DKelly%26aufirst%3DB.%26aulast%3DDiez-Cecilia%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DA.%2BA.%26aulast%3DWeaver%26aufirst%3DD.%2BF.%26aulast%3DBrown%26aufirst%3DR.%2BE.%26atitle%3DEffects%2520of%2520the%2520Novel%2520Ido%2520Inhibitor%2520Dwg-1036%2520on%2520the%2520Behavior%2520of%2520Male%2520and%2520Female%25203xtg-Ad%2520Mice%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1044%26doi%3D10.3389%2Ffphar.2019.01044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Platinum(Iv) Complexes as Immunostimulatory Agents to Promote Cancer Immunochemotherapy by Inhibiting Tryptophan-2,3-Dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.02.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.02.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30852385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks12itrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2019&pages=29-41&author=S.+Huaauthor=F.+Chenauthor=G.+Xuauthor=S.+Gou&title=Multifunctional+Platinum%28Iv%29+Complexes+as+Immunostimulatory+Agents+to+Promote+Cancer+Immunochemotherapy+by+Inhibiting+Tryptophan-2%2C3-Dioxygenase&doi=10.1016%2Fj.ejmech.2019.02.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Xu, Gang; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-41</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Increasing evidences suggested that cisplatin can be involved in a tumor-specific immune response as an immunomodulator to improve antitumor immunity, but the designation and development are limited.  Here, we report a series of novel Pt(IV) complexes derived from the conjugation of platinum(II) anticancer agents with an immune checkpoint TDO inhibitor.  These complexes not only showed significant cytotoxic effects on the tested cancer cell lines, but also could enhance antitumor immune response.  Particularly, complex T2, the mono-conjugate of oxoplatin and (E)-4-oxo-4-(3-(2-(pyridin-3-yl)vinyl)-1H-indol-1-yl)butanoic acid, displayed 35-fold more potency than cisplatin against TDO-overexpressed HepG-2 cancer cells.  Further study indicated that T2 could inhibit TDO via releasing a deriv. of a TDO inhibitor and block kynurenine prodn., resulting in T-cell activation and proliferation in vitro.  In vivo tests proved that T2 as a potent immunomodulator could highly promote the antitumor activity of cisplatin and effectively suppress the expression of TDO.  This immunochemotherapeutic strategy can be promisingly applied to treat with TDO-overexpressed cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJ66nUl2NzbVg90H21EOLACvtfcHk0li9xDxUJg_ZLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks12itrc%253D&md5=c2abc299a2d18a2bffed504df3e24a4f</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DMultifunctional%2520Platinum%2528Iv%2529%2520Complexes%2520as%2520Immunostimulatory%2520Agents%2520to%2520Promote%2520Cancer%2520Immunochemotherapy%2520by%2520Inhibiting%2520Tryptophan-2%252C3-Dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D169%26spage%3D29%26epage%3D41%26doi%3D10.1016%2Fj.ejmech.2019.02.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Improving the Potency of Cancer Immunotherapy by Dual Targeting of Ido1 and DNA</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcmdc.201700666" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29205945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2jsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=30-36&author=K.+Fangauthor=G.+Dongauthor=H.+Wangauthor=S.+Heauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Improving+the+Potency+of+Cancer+Immunotherapy+by+Dual+Targeting+of+Ido1+and+DNA&doi=10.1002%2Fcmdc.201700666"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Wang, Hongyu; He, Shipeng; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-36</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-mol. cancer immunotherapy.  New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that resp. target IDO1 and DNA were rationally designed.  As the first-in-class examples of such mols., they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity.  This proof-of-concept study has established a crit. step toward the development of a novel and effective immunotherapy for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUSxFALgkwHbVg90H21EOLACvtfcHk0li9xDxUJg_ZLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2jsb3L&md5=bbef804d59cb318294b791064a5b7909</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700666%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DImproving%2520the%2520Potency%2520of%2520Cancer%2520Immunotherapy%2520by%2520Dual%2520Targeting%2520of%2520Ido1%2520and%2520DNA%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D30%26epage%3D36%26doi%3D10.1002%2Fcmdc.201700666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (Ido1) and Histone Deacetylase (Hdac) Dual Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=312-317&author=K.+Fangauthor=G.+Dongauthor=Y.+Liauthor=S.+Heauthor=Y.+Wuauthor=S.+Wuauthor=W.+Wangauthor=C.+Sheng&title=Discovery+of+Novel+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+and+Histone+Deacetylase+%28Hdac%29+Dual+Inhibitors&doi=10.1021%2Facsmedchemlett.7b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors</span></div><div class="casAuthors">Fang, Kun; Dong, Guoqiang; Li, Yu; He, Shipeng; Wu, Ying; Wu, Shanchao; Wang, Wei; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">312-317</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In order to take advantage of both immunotherapeutic and epigenetic antitumor agents, the first generation of dual indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase (HDAC) inhibitors were designed.  The highly active dual inhibitor 10 showed excellent and balanced activity against both IDO1 (IC50 = 69.0 nM) and HDAC1 (IC50 = 66.5 nM), whose dual targeting mechanisms were validated in cancer cells.  Compd. 10 had good pharmacokinetic profiles as an orally active antitumor agent and significantly reduced the L-kynurenine level in plasma.  In particular, it showed excellent in vivo antitumor efficacy in the murine LLC tumor model with low toxicity.  This proof-of-concept study provided a novel strategy for cancer treatment.  Compd. 10 represents a promising lead compd. for the development of novel antitumor agents and can also be used as a valuable probe to clarify the relationships and mechanisms between cancer immunotherapy and epigenetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDqXRR2J0zrVg90H21EOLACvtfcHk0lhTXInIDQmidg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVWrurc%253D&md5=c808b75f03d703dc7e66798759457f4a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00487%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Novel%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520and%2520Histone%2520Deacetylase%2520%2528Hdac%2529%2520Dual%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D312%26epage%3D317%26doi%3D10.1021%2Facsmedchemlett.7b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (Tdo) Inhibitors through Structure-Based Virtual Screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7807</span>– <span class="NLM_lpage">7819</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7807-7819&author=J.+S.+Wuauthor=S.+Y.+Linauthor=F.+Y.+Liaoauthor=W.+C.+Hsiaoauthor=L.+C.+Leeauthor=Y.+H.+Pengauthor=C.+L.+Hsiehauthor=M.+H.+Wuauthor=J.+S.+Songauthor=A.+Yuehauthor=C.+H.+Chenauthor=S.+H.+Yehauthor=C.+Y.+Liuauthor=S.+Y.+Linauthor=T.+K.+Yehauthor=J.+T.+Hsuauthor=C.+Shihauthor=S.+H.+Uengauthor=M.+S.+Hungauthor=S.+Y.+Wu&title=Identification+of+Substituted+Naphthotriazolediones+as+Novel+Tryptophan+2%2C3-Dioxygenase+%28Tdo%29+Inhibitors+through+Structure-Based+Virtual+Screening&doi=10.1021%2Facs.jmedchem.5b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening</span></div><div class="casAuthors">Wu, Jian-Sung; Lin, Shu-Yu; Liao, Fang-Yu; Hsiao, Wen-Chi; Lee, Lung-Chun; Peng, Yi-Hui; Hsieh, Chia-Ling; Wu, Mine-Hsine; Song, Jen-Shin; Yueh, Andrew; Chen, Chun-Hwa; Yeh, Shiu-Hwa; Liu, Chia-Yeh; Lin, Shu-Yi; Yeh, Teng-Kuang; Hsu, John T.-A.; Shih, Chuan; Ueng, Shau-Hua; Hung, Ming-Shiu; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7807-7819</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based virtual screening strategy, comprising homol. modeling, ligand-support binding site optimization, virtual screening, and structure clustering anal., was developed and used to identify novel tryptophan 2,3-dioxygenase (TDO) inhibitors.  Compd. 1 (IC50 = 711 nM), selected by virtual screening, showed inhibitory activity toward TDO and was subjected to structural modifications and mol. docking studies.  This resulted in the identification of a potent TDO selective inhibitor (11e, IC50 = 30 nM), making it a potential compd. for further investigation as a cancer therapeutic and other TDO-related targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_08WPyOJIMbVg90H21EOLACvtfcHk0lhTXInIDQmidg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7vI&md5=3aea83affb3164c94f8cbfead21dbcce</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00921%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DHsiao%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DYueh%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DYeh%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26atitle%3DIdentification%2520of%2520Substituted%2520Naphthotriazolediones%2520as%2520Novel%2520Tryptophan%25202%252C3-Dioxygenase%2520%2528Tdo%2529%2520Inhibitors%2520through%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7807%26epage%3D7819%26doi%3D10.1021%2Facs.jmedchem.5b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Dual-Functional Conjugates Improving Cancer Immunochemotherapy by Inhibiting Tubulin Polymerization and Indoleamine-2,3-Dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112041</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2020.112041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31954880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112041&author=S.+Huaauthor=F.+Chenauthor=X.+Wangauthor=S.+Gou&title=Dual-Functional+Conjugates+Improving+Cancer+Immunochemotherapy+by+Inhibiting+Tubulin+Polymerization+and+Indoleamine-2%2C3-Dioxygenase&doi=10.1016%2Fj.ejmech.2020.112041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Wang, Xinyi; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112041</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel conjugates comprising tublin and IDO inhibitors were designed, synthesized and evaluated for their antiproliferative activity.  Among them, HI5, composed of combretastatin A-4 (CA-4) and (D)-1-methyltryptophan (D-MT) by a linker, exhibited the most potent antitumor activity, in particular with higher IC50 value (0.07 μM) than CA-4 (0.21 μM) against HeLa cancer cell line.  Mechanism studies indicated that HI5 can inhibit tubulin polymn. and cell migration, cause G2/M phase arrest, concurrent induce apoptosis via the mitochondrial dependent apoptosis pathway and cause reactive oxidative stress generation in HeLa cells.  Furthermore, HI5 can inhibit IDO expression and decrease kynurenine prodn., leading to stimulating T cells activation and proliferation to enhance antitumor immunity in vitro.  Interestingly, HI5 can effectively limit the tumor growth in the HeLa xenograft mice models without causing significant loss of body wt.  Consequently, such a conjugation can be a potent and safe immunochemotherapeutic method for improving cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK6mjQcEaBRbVg90H21EOLACvtfcHk0lhrKxP_gitbSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGjt7Y%253D&md5=f6e05a7ba52c4112d0d767f0f1f7f1f3</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112041%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DDual-Functional%2520Conjugates%2520Improving%2520Cancer%2520Immunochemotherapy%2520by%2520Inhibiting%2520Tubulin%2520Polymerization%2520and%2520Indoleamine-2%252C3-Dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112041%26doi%3D10.1016%2Fj.ejmech.2020.112041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Microtubule Inhibitors Containing Immunostimulatory Agents Promote Cancer Immunochemotherapy by Inhibiting Tubulin Polymerization and Tryptophan-2,3-Dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111949</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.111949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31830637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111949&author=S.+Huaauthor=F.+Chenauthor=S.+Gou&title=Microtubule+Inhibitors+Containing+Immunostimulatory+Agents+Promote+Cancer+Immunochemotherapy+by+Inhibiting+Tubulin+Polymerization+and+Tryptophan-2%2C3-Dioxygenase&doi=10.1016%2Fj.ejmech.2019.111949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111949</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A combination therapeutic regimen via introducing tryptophan 2,3-dioxygenase inhibitors into microtubule inhibitors was performed and evaluated for their antitumor activity.  Thereinto, HT2, composed of combretastatin A-4 (CA-4) and tryptophan-2,3-dioxygenase (TDO) inhibitor by a linker, displayed the most potent activity with 10-fold higher than its parent CA-4 against HepG2, A549 and HCT-116 cancer cell lines.  Mechanism studies suggested that HT2 inhibited tubulin polymn. and cell migration, caused G2 phase arrest, induced apoptosis by mitochondrial mediated apoptotic pathway, concurrent depolarized the mitochondria membrane potentials and caused reactive oxygen species (ROS) prodn. in HepG2 cells.  Moreover, HT2 could enhance T-cell immune responses in vitro by releasing a TDO inhibitor to suppress TDO expression and blockade kynurenine prodn.  As expected, HT2 could remarkably promote the antitumor activity of CA-4 in either immunocompetent H22 or immunodeficient A549 tumor xenograft models without observable toxic effects.  More importantly, HT2 increased the level of splenic and tumor-infiltrated T cells and in turn effectively boosted the inhibition effect in H22 xenografted tumor growth.  Collectively, this immunochemotherapeutic strategy can be applied to promote chemotherapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaKG5W_QhNz7Vg90H21EOLACvtfcHk0lhrKxP_gitbSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7zJ&md5=a8d8e6f33d2ad2f5dd02c4403ba2ed94</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111949%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DMicrotubule%2520Inhibitors%2520Containing%2520Immunostimulatory%2520Agents%2520Promote%2520Cancer%2520Immunochemotherapy%2520by%2520Inhibiting%2520Tubulin%2520Polymerization%2520and%2520Tryptophan-2%252C3-Dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111949%26doi%3D10.1016%2Fj.ejmech.2019.111949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabrese, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted Protein Degradation: Expanding the Toolbox</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0047-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1038%2Fs41573-019-0047-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31666732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=949-963&author=M.+Schapiraauthor=M.+F.+Calabreseauthor=A.+N.+Bullockauthor=C.+M.+Crews&title=Targeted+Protein+Degradation%3A+Expanding+the+Toolbox&doi=10.1038%2Fs41573-019-0047-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation: expanding the toolbox</span></div><div class="casAuthors">Schapira, Matthieu; Calabrese, Matthew F.; Bullock, Alex N.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">949-963</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review. Proteolysis-targeting chimeras (PROTACs) and related mols. that induce targeted protein degrdn. by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets.  However, the technol. is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated.  Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degrdn., and expansion of knowledge in this area is a key opportunity.  Here, we briefly discuss lessons learned about targeted protein degrdn. in chem. biol. and drug discovery and systematically review the expression profile, domain architecture and chem. tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUvM27MU3WrVg90H21EOLACvtfcHk0lhrKxP_gitbSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtLrM&md5=9bfd48c6c47fc1cce15129495fea7079</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0047-y%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DCalabrese%26aufirst%3DM.%2BF.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520Protein%2520Degradation%253A%2520Expanding%2520the%2520Toolbox%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D949%26epage%3D963%26doi%3D10.1038%2Fs41573-019-0047-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of the First Potent Proteolysis Targeting Chimera (Protac) Degrader of Indoleamine 2,3-Dioxygenase 1</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1943</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2020.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.apsb.2020.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=33163345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BB3s3itFWjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=1943&author=M.+Huauthor=W.+Zhouauthor=Y.+Wangauthor=D.+Yaoauthor=T.+Yeauthor=Y.+Yaoauthor=B.+Chenauthor=G.+Liuauthor=X.+Yangauthor=W.+Wangauthor=Y.+Xie&title=Discovery+of+the+First+Potent+Proteolysis+Targeting+Chimera+%28Protac%29+Degrader+of+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1016%2Fj.apsb.2020.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Hu Mingxing; Zhou Weilin; Wang Yijie; Yao Dongping; Ye Tinghong; Yao Yuqin; Chen Bin; Wang Wei; Xie Yongmei; Liu Gongping; Liu Gongping; Yang Xifei</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1943-1953</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Cancer immunotherapy is revolutionizing oncology and has emerged as a promising strategy for the treatment of multiple cancers.  Indoleamine 2,3-dioxygenase 1 (IDO1), an immune checkpoint, plays an important role in tumor immune escape through the regulation of multiple immune cells and has been regarded as an attractive target for cancer immunotherapy.  Proteolysis Targeting Chimeras (PROTAC) technology has emerged as a new model for drug research and development for its advantageous mechanism.  Herein, we reported the application of PROTAC technology in targeted degradation of IDO1, leading to the discovery of the first IDO1 PROTAC degrader 2c, which induced significant and persistent degradation of IDO1 with maximum degradation (dmax) of 93% in HeLa cells.  Western-blot based mechanistic studies indicated that IDO1 was degraded by 2c through the ubiquitin proteasome system (UPS).  Label-free real-time cell analysis (RTCA) indicated that 2c moderately improved tumor-killing activity of chimeric antigen receptor-modified T (CAR-T) cells.  Collectively, these data provide a new insight for the application of PROTAC technology in tumor immune-related proteins and a promising tool to study the function of IDO1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWIZtDY9yqhiEJCPKhJPuqfW6udTcc2eYdM_VsaOxpiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s3itFWjtw%253D%253D&md5=c3e3aaf4cc3f9aac0d047a6d8df8149d</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2020.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2020.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DYe%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520the%2520First%2520Potent%2520Proteolysis%2520Targeting%2520Chimera%2520%2528Protac%2529%2520Degrader%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D1943%26doi%3D10.1016%2Fj.apsb.2020.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondanelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belladonna, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchiarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orabona, C.</span></span> <span> </span><span class="NLM_article-title">Identification of a 2-Propanol Analogue Modulating the Non-Enzymatic Function of Indoleamine 2,3-Dioxygenase 1</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.10.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bcp.2018.10.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30391205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOis7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=286-297&author=E.+Albiniauthor=A.+Colettiauthor=F.+Grecoauthor=M.+T.+Pallottaauthor=G.+Mondanelliauthor=M.+Gargaroauthor=M.+L.+Belladonnaauthor=C.+Volpiauthor=R.+Bianchiauthor=U.+Grohmannauthor=A.+Macchiaruloauthor=C.+Orabona&title=Identification+of+a+2-Propanol+Analogue+Modulating+the+Non-Enzymatic+Function+of+Indoleamine+2%2C3-Dioxygenase+1&doi=10.1016%2Fj.bcp.2018.10.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1</span></div><div class="casAuthors">Albini, E.; Coletti, A.; Greco, F.; Pallotta, M. T.; Mondanelli, G.; Gargaro, M.; Belladonna, M. L.; Volpi, C.; Bianchi, R.; Grohmann, U.; Macchiarulo, A.; Orabona, C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">286-297</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3 dioxygenase 1 (IDO1) is a metabolic enzyme that catalyzes the conversion of the essential amino acid tryptophan (Trp) into a series of immunoactive catabolites, collectively known as kynurenines.  Through the depletion of Trp and the generation of kynurenines, IDO1 represents a key regulator of the immune responses involved in physiol. homeostasis as well as in neoplastic and autoimmune pathologies.  The IDO1 enzyme has been described as an important immune checkpoint to be targeted by catalytic inhibitors in the treatment of cancer.  In contrast, a defective expression/activity of the enzyme has been demonstrated in autoimmune diseases.  Beside its catalytic activity, the IDO1 protein is endowed with an addnl. function assocd. with the presence of two immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which, once phosphorylated, bind SHP phosphatases and mediate a long-term immunoregulatory activity of IDO1.  Herein, we report the screening of a focused library of mols. bearing a propanol core by a protocol combining microscale thermophoresis (MST) anal. and a cellular assay.  As a result, the combined screening identified a 2-propanolol analog, VIS351, as the first potent activator of the ITIM-mediated function of the IDO1 enzyme.  VIS351 displayed a good dissocn. const. (Kd = 1.90 μM) for IDO1 and a moderate cellular inhibitor activity (IC50 = 11.463 μM), although it did not show any catalytic inhibition of the recombinant IDO1 enzyme.  Because we previously demonstrated that the enzymic and non-enzymic (i.e., ITIM-mediated) functions of IDO1 reside in different conformations of the protein, we hypothesized that in the cellular system VIS351 may shift the dynamic conformational balance towards the ITIM-favoring folding of IDO1, resulting in the activation of the signaling rather than catalytic activity of IDO1.  We demonstrated that VIS351 activated the ITIM-mediated signaling of IDO1 also in mouse plasmacytoid dendritic cells, conferring those cells an immunosuppressive phenotype detectable in vivo.  Thus the manuscript describes for the first time a small mol. as a pos. modulator of IDO1 signaling function, paving the basis for an innovative approach to develop first-in-class drugs acting on the IDO1 target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLg711zZvTGrVg90H21EOLACvtfcHk0lhrjV8RlcleuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOis7nF&md5=b3e29db845d43756136f67859af2f162</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.10.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.10.033%26sid%3Dliteratum%253Aachs%26aulast%3DAlbini%26aufirst%3DE.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DGreco%26aufirst%3DF.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DMondanelli%26aufirst%3DG.%26aulast%3DGargaro%26aufirst%3DM.%26aulast%3DBelladonna%26aufirst%3DM.%2BL.%26aulast%3DVolpi%26aufirst%3DC.%26aulast%3DBianchi%26aufirst%3DR.%26aulast%3DGrohmann%26aufirst%3DU.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DOrabona%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520a%25202-Propanol%2520Analogue%2520Modulating%2520the%2520Non-Enzymatic%2520Function%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D158%26spage%3D286%26epage%3D297%26doi%3D10.1016%2Fj.bcp.2018.10.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawanishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayaishi, O.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase by Beta-Carboline and Indole Derivatives</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1016/0003-9861(84)90579-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2F0003-9861%2884%2990579-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=6431906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVKltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=1984&pages=602-609&author=N.+Eguchiauthor=Y.+Watanabeauthor=K.+Kawanishiauthor=Y.+Hashimotoauthor=O.+Hayaishi&title=Inhibition+of+Indoleamine+2%2C3-Dioxygenase+and+Tryptophan+2%2C3-Dioxygenase+by+Beta-Carboline+and+Indole+Derivatives&doi=10.1016%2F0003-9861%2884%2990579-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by β-carboline and indole derivatives</span></div><div class="casAuthors">Eguchi, Naomi; Watanabe, Yasuyoshi; Kawanishi, Kazuko; Hashimoto, Yohei; Hayaishi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">602-9</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    </div><div class="casAbstract">β-Carboline derivs. inhibited both indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase activities from various sources.  Among them, norharman (I) is most potent for both enzymes from mammalian sources.  Kinetic studies revealed that I is uncompetitive (Ki = 0.12 mM) with L-tryptophan for rabbit intestinal indoleamine 2,3-dioxygenase, and linearly competitive (Ki = 0.29 mM) with L-tryptophan for mouse liver tryptophan 2,3-dioxygenase.  In addn., some β-carbolines selectively inhibited one enzyme or the other.  Pseudomonad tryptophan 2,3-dioxygenase was inhibited by a different spectrum of β-carbolines.  Such a selective inhibition by the structure of substrate analogs is more evident by the use of indole derivs.  Indole-3-acetamide, indole-3-acetonitrile, and indole-3-acrylic acid exhibited a potent inhibition for mammalian tryptophan 2,3-dioxygenase, whereas they moderately inhibited the pseudomonad enzyme.  However, they showed no inhibition for indoleamine 2,3-dioxygenase.  These results suggest the difference of the structures of the active sites among these enzymes from various sources.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA-VT_50vfwrVg90H21EOLACvtfcHk0lhrjV8RlcleuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVKltro%253D&md5=cfbdf0d14acce6d935ffa69b7272f5fc</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2F0003-9861%2884%2990579-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0003-9861%252884%252990579-4%26sid%3Dliteratum%253Aachs%26aulast%3DEguchi%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DKawanishi%26aufirst%3DK.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DHayaishi%26aufirst%3DO.%26atitle%3DInhibition%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520and%2520Tryptophan%25202%252C3-Dioxygenase%2520by%2520Beta-Carboline%2520and%2520Indole%2520Derivatives%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1984%26volume%3D232%26spage%3D602%26epage%3D609%26doi%3D10.1016%2F0003-9861%2884%2990579-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vottero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauk, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, R. J.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase Inhibitors from the Northeastern Pacific Marine Hydroid Garveia Annulata</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1496</span>– <span class="NLM_lpage">1499</span>, <span class="refDoi"> DOI: 10.1021/np060111x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np060111x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVShs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=1496-1499&author=A.+Pereiraauthor=E.+Votteroauthor=M.+Robergeauthor=A.+G.+Maukauthor=R.+J.+Andersen&title=Indoleamine+2%2C3-Dioxygenase+Inhibitors+from+the+Northeastern+Pacific+Marine+Hydroid+Garveia+Annulata&doi=10.1021%2Fnp060111x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific marine hydroid Garveia annulata</span></div><div class="casAuthors">Pereira, Alban; Vottero, Eduardo; Roberge, Michel; Mauk, A. Grant; Andersen, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1496-1499</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Crude exts. of the marine hydroid Garveia annulata show potent inhibition of indoleamine 2,3-dioxygenase (IDO).  Fractionation of the ext. led to the identification of the new polyketides annulin C (e.g. I), 2-hydroxygarveatin E, garveatin E, and garvin C.  Annulins A, B, and C were found to be submicromolar inhibitors of IDO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVZbImHRhbaLVg90H21EOLACvtfcHk0lhrjV8RlcleuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVShs7nI&md5=c49325bf3597d02ef29730f7d2f9994e</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fnp060111x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp060111x%26sid%3Dliteratum%253Aachs%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DVottero%26aufirst%3DE.%26aulast%3DRoberge%26aufirst%3DM.%26aulast%3DMauk%26aufirst%3DA.%2BG.%26aulast%3DAndersen%26aufirst%3DR.%2BJ.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520Inhibitors%2520from%2520the%2520Northeastern%2520Pacific%2520Marine%2520Hydroid%2520Garveia%2520Annulata%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2006%26volume%3D69%26spage%3D1496%26epage%3D1499%26doi%3D10.1021%2Fnp060111x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, R. J.</span>; <span class="NLM_string-name">Pereira, A.</span>; <span class="NLM_string-name">Huang, X. H.</span>; <span class="NLM_string-name">Mauk, G.</span>; <span class="NLM_string-name">Vottero, E.</span>; <span class="NLM_string-name">Roberge, M.</span>; <span class="NLM_string-name">Balgi, A.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase (Ido) Inhibitors</span>. Patent <span class="NLM_patent">WO2006/005185</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+J.+Andersen&author=A.+Pereira&author=X.+H.+Huang&author=G.+Mauk&author=E.+Vottero&author=M.+Roberge&author=A.+Balgi&title=Indoleamine+2%2C3-Dioxygenase+%28Ido%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DR.%2BJ.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%2520%2528Ido%2529%2520Inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flick, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">The Tumor-Selective Cytotoxic Agent Beta-Lapachone Is a Potent Inhibitor of Ido1</span>. <i>Int. J. Tryptophan Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.4137/IJTR.S12094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.4137%2FIJTR.S12094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24023520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2gs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=35-45&author=H.+E.+Flickauthor=J.+M.+Lalondeauthor=W.+P.+Malachowskiauthor=A.+J.+Muller&title=The+Tumor-Selective+Cytotoxic+Agent+Beta-Lapachone+Is+a+Potent+Inhibitor+of+Ido1&doi=10.4137%2FIJTR.S12094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">The tumor-selective cytotoxic agent β-lapachone is a potent inhibitor of IDO1</span></div><div class="casAuthors">Flick, Hollie E.; LaLonde, Judith M.; Malachowski, William P.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Tryptophan Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-45</span>CODEN:
                <span class="NLM_cas:coden">IJTRBS</span>;
        ISSN:<span class="NLM_cas:issn">1178-6469</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">β-Lapachone is a naturally occurring 1,2-naphthoquinone-based compd. that has been advanced into clin. trials based on its tumor-selective cytotoxic properties.  Previously, we focused on the related 1,4-naphthoquinone pharmacophore as a basic core structure for developing a series of potent indoleamine 2,3-dioxygenase 1 (IDO1) enzyme inhibitors.  In this study, we identified IDO1 inhibitory activity as a previously unrecognized attribute of the clin. candidate β-lapachone.  Enzyme kinetics-based anal. of β-lapachone indicated an uncompetitive mode of inhibition, while computational modeling predicted binding within the IDO1 active site consistent with other naphthoquinone derivs.  Inhibition of IDO1 has previously been shown to breach the pathogenic tolerization that constrains the immune system from being able to mount an effective anti-tumor response.  Thus, the finding that β-lapachone has IDO1 inhibitory activity adds a new dimension to its potential utility as an anti-cancer agent distinct from its cytotoxic properties, and suggests that a synergistic benefit can be achieved from its combined cytotoxic and immunol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVmjPfcd508LVg90H21EOLACvtfcHk0ljtcePbxuK2bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2gs73M&md5=d432e109c20ca5a92c26d6dda24ef4b7</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.4137%2FIJTR.S12094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FIJTR.S12094%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DH.%2BE.%26aulast%3DLalonde%26aufirst%3DJ.%2BM.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520Tumor-Selective%2520Cytotoxic%2520Agent%2520Beta-Lapachone%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Ido1%26jtitle%3DInt.%2520J.%2520Tryptophan%2520Res.%26date%3D2013%26volume%3D6%26spage%3D35%26epage%3D45%26doi%3D10.4137%2FIJTR.S12094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pantouris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowat, C. G.</span></span> <span> </span><span class="NLM_article-title">Antitumour Agents as Inhibitors of Tryptophan 2,3-Dioxygenase</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>443</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2013.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bbrc.2013.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24269239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOhtb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=443&publication_year=2014&pages=28-31&author=G.+Pantourisauthor=C.+G.+Mowat&title=Antitumour+Agents+as+Inhibitors+of+Tryptophan+2%2C3-Dioxygenase&doi=10.1016%2Fj.bbrc.2013.11.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Pantouris, Georgios; Mowat, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">443</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-31</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The involvement of tryptophan 2,3-dioxygenase (TDO) in cancer biol. has recently been described, with the enzyme playing an immunomodulatory role, suppressing antitumor immune responses and promoting tumor cell survival and proliferation.  This finding reinforces the need for specific inhibitors of TDO that may potentially be developed for therapeutic use.  In this work we have screened ∼2800 compds. from the library of the National Cancer Institute USA and identified seven potent inhibitors of TDO with inhibition consts. in the nanomolar or low micromolar range.  All seven have antitumor properties, killing various cancer cell lines.  For comparison, the inhibition potencies of these compds. were tested against IDO and their inhibition consts. are reported.  Interestingly, this work reveals that NSC 36398 (dihydroquercetin, taxifolin), with an in vitro inhibition const. of ∼16 μM, is the first TDO-selective inhibitor reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5TH-gsVsNO7Vg90H21EOLACvtfcHk0ljtcePbxuK2bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOhtb%252FL&md5=db2ebf560e56801f65635dc8c260b39a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DPantouris%26aufirst%3DG.%26aulast%3DMowat%26aufirst%3DC.%2BG.%26atitle%3DAntitumour%2520Agents%2520as%2520Inhibitors%2520of%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D443%26spage%3D28%26epage%3D31%26doi%3D10.1016%2Fj.bbrc.2013.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blunt, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torcuk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-Dioxygenase (Ido) as Potential Target for Anticancer Activity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8740</span>– <span class="NLM_lpage">8745</span>, <span class="refDoi"> DOI: 10.1002/anie.201503323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fanie.201503323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVensLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8740-8745&author=C.+E.+Bluntauthor=C.+Torcukauthor=Y.+Liuauthor=W.+Lewisauthor=D.+Siegelauthor=D.+Rossauthor=C.+J.+Moody&title=Synthesis+and+Intracellular+Redox+Cycling+of+Natural+Quinones+and+Their+Analogues+and+Identification+of+Indoleamine-2%2C3-Dioxygenase+%28Ido%29+as+Potential+Target+for+Anticancer+Activity&doi=10.1002%2Fanie.201503323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity</span></div><div class="casAuthors">Blunt, Christopher E.; Torcuk, Canan; Liu, Yang; Lewis, William; Siegel, David; Ross, David; Moody, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8740-8745</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of isothiazoloquinones, including natural naphthoquinone aulosirazole and structurally related pronqodine A, was synthesized and their biol. activity as inhibitors of the immunoregulatory enzyme indoleamine-2,3-dioxygenase (IDO) was studied.  The synthesis of aulosirazole uses a route centered upon a late-stage regioselective Diels-Alder reaction.  The isothiazoloquinones were also found to be efficient substrates for the human quinone reductase NQO1, and underwent intracellular NQO1-dependent redox cycling resulting in the generation of reactive oxygen species, and at lower doses have the potential to alter the ratio of intracellular oxidized to reduced pyridine nucleotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-HIYOL59p6bVg90H21EOLACvtfcHk0ljtcePbxuK2bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVensLjI&md5=32d7f95c3253618c4bb00c6d7ad06824</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1002%2Fanie.201503323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201503323%26sid%3Dliteratum%253Aachs%26aulast%3DBlunt%26aufirst%3DC.%2BE.%26aulast%3DTorcuk%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLewis%26aufirst%3DW.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DRoss%26aufirst%3DD.%26aulast%3DMoody%26aufirst%3DC.%2BJ.%26atitle%3DSynthesis%2520and%2520Intracellular%2520Redox%2520Cycling%2520of%2520Natural%2520Quinones%2520and%2520Their%2520Analogues%2520and%2520Identification%2520of%2520Indoleamine-2%252C3-Dioxygenase%2520%2528Ido%2529%2520as%2520Potential%2520Target%2520for%2520Anticancer%2520Activity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D8740%26epage%3D8745%26doi%3D10.1002%2Fanie.201503323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span> <span> </span><span class="NLM_article-title">Palladium(Ii)-Catalyzed Reaction of Lawsones and Propargyl Carbonates: Construction of 2,3-Furanonaphthoquinones and Evaluation as Potential Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">8003</span>– <span class="NLM_lpage">8010</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.8b00872</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.8b00872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2htLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=8003-8010&author=X.+Fengauthor=X.+Qiuauthor=H.+Huangauthor=J.+Wangauthor=X.+Xuauthor=P.+Xuauthor=R.+Geauthor=X.+Liuauthor=Z.+Liauthor=J.+Bian&title=Palladium%28Ii%29-Catalyzed+Reaction+of+Lawsones+and+Propargyl+Carbonates%3A+Construction+of+2%2C3-Furanonaphthoquinones+and+Evaluation+as+Potential+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1021%2Facs.joc.8b00872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium(II)-Catalyzed Reaction of Lawsones and Propargyl Carbonates: Construction of 2,3-Furanonaphthoquinones and Evaluation as Potential Indoleamine 2,3-Dioxygenase Inhibitors</span></div><div class="casAuthors">Feng, Xi; Qiu, Xiaqiu; Huang, Huidan; Wang, Jubo; Xu, Xi; Xu, Pengfei; Ge, Ruijia; Liu, Xiaojin; Li, Zhiyu; Bian, Jinlei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8003-8010</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient reaction utilizing propargyl carbonates through Claisen rearrangement to synthesize furanonaphthoquinones is described.  The remarkable transformation exhibits excellent functional group tolerance, affording the target furanonaphthoquinones in moderate to good yields (41-85%) under mild reaction conditions.  Scaled-up prepn. of the model product can make this reaction a method of choice for synthesis of furanonaphthoquinone derivs.  The resulting furanonaphthoquinones were evaluated as potential indoleamine 2,3-dioxygenase inhibitors in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFjeaVS8zI-bVg90H21EOLACvtfcHk0lip2iRc_E86rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2htLbM&md5=917981a8d83eca26013e27748377ce92</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.8b00872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.8b00872%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DGe%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DJ.%26atitle%3DPalladium%2528Ii%2529-Catalyzed%2520Reaction%2520of%2520Lawsones%2520and%2520Propargyl%2520Carbonates%253A%2520Construction%2520of%25202%252C3-Furanonaphthoquinones%2520and%2520Evaluation%2520as%2520Potential%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2018%26volume%3D83%26spage%3D8003%26epage%3D8010%26doi%3D10.1021%2Facs.joc.8b00872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Z.</span></span> <span> </span><span class="NLM_article-title">Ethylnaphthoquinone Derivatives as Inhibitors of Indoleamine-2, 3-Dioxygenase from the Mangrove Endophytic Fungus Neofusicoccum Austral Sysu-Sks024</span>. <i>Fitoterapia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1016/j.fitote.2018.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.fitote.2018.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29374570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1OjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=281-285&author=H.+Cuiauthor=H.+Zhangauthor=Y.+Liuauthor=Q.+Guauthor=J.+Xuauthor=X.+Huangauthor=Z.+She&title=Ethylnaphthoquinone+Derivatives+as+Inhibitors+of+Indoleamine-2%2C+3-Dioxygenase+from+the+Mangrove+Endophytic+Fungus+Neofusicoccum+Austral+Sysu-Sks024&doi=10.1016%2Fj.fitote.2018.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Ethylnaphthoquinone derivatives as inhibitors of indoleamine-2, 3-dioxygenase from the mangrove endophytic fungus Neofusicoccum austral SYSU-SKS024</span></div><div class="casAuthors">Cui, Hui; Zhang, Hongao; Liu, Yena; Gu, Qiong; Xu, Jun; Huang, Xishan; She, Zhigang</div><div class="citationInfo"><span class="NLM_cas:title">Fitoterapia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">281-285</span>CODEN:
                <span class="NLM_cas:coden">FTRPAE</span>;
        ISSN:<span class="NLM_cas:issn">0367-326X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bioassay-guided fractionation of the dichloromethane ext. of the fungus Neofusicoccum austral SYSU-SKS024 led to the isolation of three new ethylnaphthoquinone derivs., neofusnaphthoquinone A (1), 6-(1-methoxylethy1)-2,7-dimethoxyjuglone (2), (3R,4R)-3-methoxyl-botryosphaerone D (6), together with six known analogs (3-5 and 7-9).  Their structures were elucidated by spectroscopic anal. and single crystal X-ray diffraction anal.  Neofusnaphthoquinone A (1) is the third example of the unsym. naphthoquinone dimer, which is rarely found in natural source.  All of the isolates were evaluated for their indoleamine 2, 3-dioxygenase (IDO) inhibitory activity, compds. 1-6 showed in vitro inhibitory effects against IDO with IC50 values ranging from 0.11 to 10.92μM.  This is the first time naphthoquinone dimer (1), as a novel carbon skeleton possessing IDO inhibitory activity, was reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi-7OmjasLn7Vg90H21EOLACvtfcHk0lip2iRc_E86rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1OjtLc%253D&md5=eda25bdbd6df09621bc9c308c19ff546</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.fitote.2018.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fitote.2018.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DShe%26aufirst%3DZ.%26atitle%3DEthylnaphthoquinone%2520Derivatives%2520as%2520Inhibitors%2520of%2520Indoleamine-2%252C%25203-Dioxygenase%2520from%2520the%2520Mangrove%2520Endophytic%2520Fungus%2520Neofusicoccum%2520Austral%2520Sysu-Sks024%26jtitle%3DFitoterapia%26date%3D2018%26volume%3D125%26spage%3D281%26epage%3D285%26doi%3D10.1016%2Fj.fitote.2018.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Structure-Activity Relationship Study of Novel Naphthoindolizine and Indolizinoquinoline-5,12-Dione Derivatives as Ido1 Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4886</span>– <span class="NLM_lpage">4897</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30170925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Sms7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4886-4897&author=R.+Yangauthor=Y.+Chenauthor=L.+Panauthor=Y.+Yangauthor=Q.+Zhengauthor=Y.+Huauthor=Y.+Wangauthor=L.+Zhangauthor=Y.+Sunauthor=Z.+Liauthor=X.+Meng&title=Design%2C+Synthesis+and+Structure-Activity+Relationship+Study+of+Novel+Naphthoindolizine+and+Indolizinoquinoline-5%2C12-Dione+Derivatives+as+Ido1+Inhibitors&doi=10.1016%2Fj.bmc.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors</span></div><div class="casAuthors">Yang, Rui; Chen, Yu; Pan, Liangkun; Yang, Yanyan; Zheng, Qiang; Hu, Yue; Wang, Yuxi; Zhang, Liangren; Sun, Yang; Li, Zhongjun; Meng, Xiangbao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4886-4897</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is regarded as a promising target for cancer immunotherapy.  Many naphthoquinone derivs. have been reported as IDO1 inhibitors so far.  Herein, two series of naphthoquinone derivs., naphthoindolizine and indolizinoquinoline-5,12-dione derivs., were synthesized and evaluated for their IDO1 inhibitory activity.  Most of the target compds. showed significant inhibition potency and high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO).  The structure-activity relationship was also summarized.  The most potent compds. 5c (IC50 23 nM, IDO1 enzyme), and 5b' (IC50 372 nM, HeLa cell) were identified as promising lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiy6xMGTYZybVg90H21EOLACvtfcHk0lip2iRc_E86rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Sms7%252FI&md5=73c272593ea85fa0ee85a56a5ba9ad69</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DX.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Structure-Activity%2520Relationship%2520Study%2520of%2520Novel%2520Naphthoindolizine%2520and%2520Indolizinoquinoline-5%252C12-Dione%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4886%26epage%3D4897%26doi%3D10.1016%2Fj.bmc.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Biological Evaluation of Novel Naphthoquinone Derivatives as Ido1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2018.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30103191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=423-436&author=L.+Panauthor=Q.+Zhengauthor=Y.+Chenauthor=R.+Yangauthor=Y.+Yangauthor=Z.+Liauthor=X.+Meng&title=Design%2C+Synthesis+and+Biological+Evaluation+of+Novel+Naphthoquinone+Derivatives+as+Ido1+Inhibitors&doi=10.1016%2Fj.ejmech.2018.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors</span></div><div class="casAuthors">Pan, Liangkun; Zheng, Qiang; Chen, Yu; Yang, Rui; Yang, Yanyan; Li, Zhongjun; Meng, Xiangbao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">423-436</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 mediated kynurenine pathway of tryptophan degrdn. is identified as an appealing and novel target in immunotherapy for the treatment of cancer.  In this study, a novel series of naphthoquinone derivs. were synthesized, characterized and evaluated for their inhibitory activities against IDO1, and their structure-activity relationship was investigated.  Among them, five compds., e.g., I,displayed potent IDO1 inhibitory activities with IC50 values ranging between 18 and 61 nM, which are more potent than INCB024360 undergoing clin. trial III evaluation.  In addn., three compds., e.g. II, decreased the kynurenine levels in rat plasma by 30%-50%.  Compds. exhibiting excellent IDO1 inhibitory activities were also evaluated for their inhibitory activities against tryptophan 2,3-dioxygenase (TDO).  Of which, compd. II (IDO1 IC50 = 120 nM) showed promising TDO inhibition (IC50 72 nM) and was identified as an IDO1/TDO dual inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqrRqE4fWgpLVg90H21EOLACvtfcHk0lgAA-icdA6XYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb7K&md5=187b1c8a9111efa0d7a25955b2d24bd8</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DX.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Naphthoquinone%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D423%26epage%3D436%26doi%3D10.1016%2Fj.ejmech.2018.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynisson, J.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (Tdo2) and Indoleamine 2,3-Dioxygenase 1 (Ido1) Using Virtual Screening</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4346</span>, <span class="refDoi"> DOI: 10.3390/molecules24234346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3390%2Fmolecules24234346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=4346&author=S.+Sariauthor=P.+Tomekauthor=E.+Leungauthor=J.+Reynisson&title=Discovery+and+Characterisation+of+Dual+Inhibitors+of+Tryptophan+2%2C3-Dioxygenase+%28Tdo2%29+and+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Using+Virtual+Screening&doi=10.3390%2Fmolecules24234346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterisation of dual inhibitors of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1) using virtual screening</span></div><div class="casAuthors">Sari, Suat; Tomek, Petr; Leung, Euphemia; Reynisson, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4346</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cancers express tryptophan catabolising enzymes indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) to produce immunosuppressive tryptophan metabolites that undermine patients' immune systems, leading to poor disease outcomes.  Both enzymes are validated targets for cancer immunotherapy but there is a paucity of potent TDO2 and dual IDO1/TDO2 inhibitors.  To identify novel dual IDO1/TDO2 scaffolds, 3D shape similarity and pharmacophore in silico screening was conducted using TDO2 as a model for both systems.  The obtained hits were tested in cancer cell lines expressing mainly IDO1 (SKOV3-ovarian), predominantly TDO2 (A172-brain), and both IDO1 and TDO2 (BT549-breast).  Three virtual screening hits were confirmed as inhibitors (TD12, TD18 and TD34).  Dose response expts. showed that TD34 is the most potent inhibitor capable of blocking both IDO1 and TDO2 activity, with the IC50 value for BT549 at 3.42μM.  This work identified new scaffolds able to inhibit both IDO1 and TDO2, thus enriching the collection of dual IDO1/TDO2 inhibitors and providing chem. matter for potential development into future anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXAKV3tf7YWbVg90H21EOLACvtfcHk0lgAA-icdA6XYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisrrP&md5=d9a36856de02bee3acbfb9b8fef465a8</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24234346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24234346%26sid%3Dliteratum%253Aachs%26aulast%3DSari%26aufirst%3DS.%26aulast%3DTomek%26aufirst%3DP.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DReynisson%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520Characterisation%2520of%2520Dual%2520Inhibitors%2520of%2520Tryptophan%25202%252C3-Dioxygenase%2520%2528Tdo2%2529%2520and%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Using%2520Virtual%2520Screening%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D4346%26doi%3D10.3390%2Fmolecules24234346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-Dioxygenase and Signal Transducer and Activator of Transcription 3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1563</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01386</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01386" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1544-1563&author=R.+Huangauthor=X.+Jingauthor=X.+Huangauthor=Y.+Panauthor=Y.+Fangauthor=G.+Liangauthor=Z.+Liaoauthor=H.+Wangauthor=Z.+Chenauthor=Y.+Zhang&title=Bifunctional+Naphthoquinone+Aromatic+Amide-Oxime+Derivatives+Exert+Combined+Immunotherapeutic+and+Antitumor+Effects+through+Simultaneous+Targeting+of+Indoleamine-2%2C3-Dioxygenase+and+Signal+Transducer+and+Activator+of+Transcription+3&doi=10.1021%2Facs.jmedchem.9b01386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3</span></div><div class="casAuthors">Huang, Rizhen; Jing, Xiaoteng; Huang, Xiaochao; Pan, Yingming; Fang, Yilin; Liang, Guibin; Liao, Zhixin; Wang, Hengshan; Chen, Zhenfeng; Zhang, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1544-1563</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine-2,3-dioxygenase 1 (IDO1) and signal transducer and activator of transcription 3 (STAT3) are important targets in the tumor microenvironment for cancer therapy.  In the present study, a set of naphthoquinone arom. amide-oxime derivs. were designed, which stimulated the immune response via IDO1 inhibition and simultaneously displayed powerful antitumor activity against three selected cancer cell lines through suppressing STAT3 signaling.  The representative compd. 8u bound effectively to IDO1, with greater inhibitory activity relative to the com. IDO1 inhibitor 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L) in addn. to the efficient suppression of nuclear translocation of STAT3.  Consistently, in vivo assays demonstrated a higher antiproliferative activity of compd. 8u in both wild-type B16-F10 isograft tumors and an athymic HepG2 xenograft model relative to 1-methyl-L-tryptophan (1-MT) and doxorubicin (DOX).  This bifunctional compd. with dual immunotherapeutic and anticancer efficacy may represent a new generation of highly efficacious drug candidates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojfGgot8_60bVg90H21EOLACvtfcHk0lgAA-icdA6XYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOhuro%253D&md5=6f9aca12e3810617ebb48416b98d6d27</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01386%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DJing%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DBifunctional%2520Naphthoquinone%2520Aromatic%2520Amide-Oxime%2520Derivatives%2520Exert%2520Combined%2520Immunotherapeutic%2520and%2520Antitumor%2520Effects%2520through%2520Simultaneous%2520Targeting%2520of%2520Indoleamine-2%252C3-Dioxygenase%2520and%2520Signal%2520Transducer%2520and%2520Activator%2520of%2520Transcription%25203%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1544%26epage%3D1563%26doi%3D10.1021%2Facs.jmedchem.9b01386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Rational Design, Synthesis and Biological Evaluation of Ubiquinone Derivatives as Ido1 Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">102870</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.03.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bioorg.2019.03.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31103493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFOmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2019&pages=102870&author=Y.+Dingauthor=F.+Tangauthor=X.+Xueauthor=J.+Luoauthor=M.+Hussainauthor=Y.+Huangauthor=Z.+Wangauthor=H.+Jiangauthor=Z.+Tuauthor=J.+Zhang&title=Rational+Design%2C+Synthesis+and+Biological+Evaluation+of+Ubiquinone+Derivatives+as+Ido1+Inhibitors&doi=10.1016%2Fj.bioorg.2019.03.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design, synthesis and biological evaluation of ubiquinone derivatives as IDO1 inhibitors</span></div><div class="casAuthors">Ding, Yuyang; Tang, Fei; Xue, Xiaoqian; Luo, Jinfeng; Hussain, Muzammal; Huang, Yanhui; Wang, Zhen; Jiang, Hao; Tu, Zhengchao; Zhang, Jiancun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102870</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive therapeutic target for the treatment of cancer, chronic viral infections and neurol. disorders characterized by pathol. immune stimulation.  Herein, a series of known metal-chelating ubiquinone derivs. were designed, synthesized and evaluated for the IDO1 inhibiting activities.  The docking studies showed that the compds. I (R = Me or H, R1 = Ph, 3-MeC6H5, 3-OMeC6H5, etc.) and coenzyme-Q1 exhibited different binding modes to IDO1 protein.  Among these compds., the most active compd. is I (R = H, R1 = 3-BrC6H5) with an IC50 of 0.13 μM in enzymic assay.  The results reveal that a possible halogen bonding interaction between the bromine atom (3-Br) and Cys129 significantly enhances the inhibition activity against IDO1.  This study provides structural insights of the interactions between ubiquinone analogs and IDO1 protein for the further modification and optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorY1xHNqYrVrVg90H21EOLACvtfcHk0lg3_owbIinaXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFOmsr4%253D&md5=4d75242a48cb7e1e2a673f08e3584cb3</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.03.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.03.044%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DHussain%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DRational%2520Design%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Ubiquinone%2520Derivatives%2520as%2520Ido1%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D89%26spage%3D102870%26doi%3D10.1016%2Fj.bioorg.2019.03.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(Pyridin-3-Yl)-1h-Indole-4,7-Diones as Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">126901</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2019.126901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31882299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVyrurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=126901&author=K.+M.+Kongauthor=J.+W.+Zhangauthor=B.+Z.+Liuauthor=G.+R.+Mengauthor=Q.+Zhang&title=Discovery+of+5-%28Pyridin-3-Yl%29-1h-Indole-4%2C7-Diones+as+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.bmcl.2019.126901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Kong, Kai-min; Zhang, Jia-wei; Liu, Bing-zhi; Meng, Guang-rong; Zhang, Qian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">126901</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Early studies demonstrated that over expression of indoleamine 2,3-dioxygenase (IDO1) in tumor microenvironment results in tumor immune escape.  Herein, to simplify the structure of two kinds of IDO1 inhibitors from marine alkaloid, Exiguamine A and Tsitsikammamines, the authors designed, synthesized a series of 1H-indole-4,7-dione derivs. and evaluated their inhibitory activity in IDO1 enzyme and in IFN-γ stimulated Hela cells in vitro.  The structure-activity relation demonstrated that 5-(pyridin-3-yl)-1H-indole-4,7-dione is a promising scaffold for IDO1 inhibitors and most compds. with this core showed moderate inhibition potency at micromole level.  The authors' further enzyme kinetics expts. reveal that these new developed compds. might act as reversible competitive inhibitors of IDO1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqilX4m8KKO1rVg90H21EOLACvtfcHk0lg3_owbIinaXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVyrurrF&md5=cf2231f64e236e69a669772bbfaca292</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126901%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DK.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26aulast%3DLiu%26aufirst%3DB.%2BZ.%26aulast%3DMeng%26aufirst%3DG.%2BR.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%25205-%2528Pyridin-3-Yl%2529-1h-Indole-4%252C7-Diones%2520as%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D126901%26doi%3D10.1016%2Fj.bmcl.2019.126901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (Pains) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28Pains%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lg3_owbIinaXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528Pains%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (Llc) Tumor-Bearing Mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8321</span>– <span class="NLM_lpage">8331</span>, <span class="refDoi"> DOI: 10.1021/jm401195n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401195n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8321-8331&author=S.+Yangauthor=X.+Liauthor=F.+Huauthor=Y.+Liauthor=Y.+Yangauthor=J.+Yanauthor=C.+Kuangauthor=Q.+Yang&title=Discovery+of+Tryptanthrin+Derivatives+as+Potent+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+with+Therapeutic+Activity+in+Lewis+Lung+Cancer+%28Llc%29+Tumor-Bearing+Mice&doi=10.1021%2Fjm401195n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice</span></div><div class="casAuthors">Yang, Shuangshuang; Li, Xishuai; Hu, Fangfang; Li, Yinlong; Yang, Yunyun; Yan, Junkai; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8321-8331</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO-1) is emerging as an important new therapeutic target for the treatment of cancer, neurol. disorders, and other diseases that are characterized by pathol. tryptophan metab.  However, only a few structural classes are known to be IDO-1 inhibitors.  In this study, a natural compd. tryptanthrin was discovered to be a novel potent IDO-1 inhibitor by screening of indole-based structures.  Three series of 13 tryptanthrin derivs. were synthesized, and the structure-activity anal. was undertaken.  The optimization led to the identification of 5c, which exhibited the inhibitory activity at a nanomolar level.  In vitro 5c dramatically augmented the proliferation of T cells.  When administered to Lewis lung cancer (LLC) tumor-bearing mice, 5c significantly inhibited IDO-1 activity and suppressed tumor growth.  In addn., 5c reduced the nos. of Foxp3+ regulatory T cells (Tregs), which are known to prevent the development of efficient antitumor immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5ioPL3rWy1bVg90H21EOLACvtfcHk0ljsbt5EkyzPRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrjL&md5=ac744f81ce97b0435f2bfd240e1393a1</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm401195n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401195n%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520Tryptanthrin%2520Derivatives%2520as%2520Potent%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520with%2520Therapeutic%2520Activity%2520in%2520Lewis%2520Lung%2520Cancer%2520%2528Llc%2529%2520Tumor-Bearing%2520Mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8321%26epage%3D8331%26doi%3D10.1021%2Fjm401195n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Tryptophan 2,3-Dioxygenase Inhibitory Activities of Tryptanthrin Derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2018.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30321802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeqtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2018&pages=133-145&author=S.+Zhangauthor=F.+Qiauthor=X.+Fangauthor=D.+Yangauthor=H.+Huauthor=Q.+Huangauthor=C.+Kuangauthor=Q.+Yang&title=Tryptophan+2%2C3-Dioxygenase+Inhibitory+Activities+of+Tryptanthrin+Derivatives&doi=10.1016%2Fj.ejmech.2018.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives</span></div><div class="casAuthors">Zhang, Shengnan; Qi, Fangfei; Fang, Xin; Yang, Dan; Hu, Hairong; Huang, Qiang; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-145</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tryptophan 2,3-dioxygenase (TDO) is becoming a promising therapeutic target due to its involvement in cancer and neurodegenerative diseases.  Development of efficient TDO inhibitors is a prime strategy in disease treatment.  However, the lack of a TDO inhibitor bioassay system slows the progress of TDO inhibitor research.  Herein, an active recombinant human TDO (hTDO) was prepd. under optimal expression conditions, an enzymic assay was optimized, and two cellular assays of TDO activity were developed.  Then, the potential TDO inhibitory activities of nine tryptanthrin derivs. were evaluated, and the inhibitory consts. (Ki), enzymic and cellular half maximal inhibitory concns. (IC50) were measured, and the type of inhibition was detd.  The tryptanthrins had various levels of TDO inhibitory activities; tryptanthrins with a substituent at 8-position had stronger inhibitory activities than the other derivs.  Moreover, most of the compds., except two, exhibited better inhibitory activities than the previously reported TDO inhibitor LM10.  Furthermore, the mol. docking study of compds. 8-fluoro-indolo[2,1-b]quinazoline-6,12-dione (5c) and 8-bromo-indolo[2,1-b]quinazoline-6,12-dione (5d) revealed that the O atom of the tryptanthrin ring is directed toward the heme iron (Fe) of hTDO via strong coordination interactions.  These findings suggest that tryptanthrin and its derivs. have the potential to be developed as promising mols. for TDO-related target therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi_AhFhYrRY7Vg90H21EOLACvtfcHk0ljsbt5EkyzPRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeqtrbI&md5=f2e6d9afb4c1c276e22353b1aa487650</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DF.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DTryptophan%25202%252C3-Dioxygenase%2520Inhibitory%2520Activities%2520of%2520Tryptanthrin%2520Derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D160%26spage%3D133%26epage%3D145%26doi%3D10.1016%2Fj.ejmech.2018.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9161</span>– <span class="NLM_lpage">9174</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2hs73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9161-9174&author=D.+Yangauthor=S.+Zhangauthor=X.+Fangauthor=L.+Guoauthor=N.+Huauthor=Z.+Guoauthor=X.+Liauthor=S.+Yangauthor=J.+C.+Heauthor=C.+Kuangauthor=Q.+Yang&title=N-Benzyl%2FAryl+Substituted+Tryptanthrin+as+Dual+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+and+Tryptophan+2%2C3-Dioxygenase&doi=10.1021%2Facs.jmedchem.9b01079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">N-Benzyl/Aryl Substituted Tryptanthrin as Dual Inhibitors of Indoleamine 2,3-Dioxygenase and Tryptophan 2,3-Dioxygenase</span></div><div class="casAuthors">Yang, Dan; Zhang, Shengnan; Fang, Xin; Guo, Leilei; Hu, Nan; Guo, Zhanling; Li, Xishuai; Yang, Shuangshuang; He, Jin Chao; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9161-9174</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), which catalyzes the initial and rate-limiting step of the kynurenine pathway of tryptophan catabolism, has emerged as a key target in cancer immunotherapy because of its role in enabling cancers to evade the immune system.  Tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase 2 (IDO2) catalyze the same reaction and play a potential role in cancer immunotherapy.  Starting from our previously discovered tryptanthrin IDO1 inhibitor scaffold, we synthesized novel N-benzyl/aryl substituted tryptanthrin derivs. and evaluated their inhibitory efficacy on IDO1, TDO, and IDO2.  Most compds. showed similar high inhibitory activities on both IDO1 and TDO, which were significantly superior over that of IDO2 with magnitude difference.  We showed that N-benzyl/aryl substituted tryptanthrin directly interacted with IDO1, TDO, and IDO2, significantly augmented the proliferation of T cells in vitro, blocked the kynurenine pathway, and suppressed tumor growth when administered to LLC and H22 tumor-bearing mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwPF5CT--OU7Vg90H21EOLACvtfcHk0ljsbt5EkyzPRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2hs73I&md5=7fcad745663f2efbdaf868637f6964ef</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01079%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DJ.%2BC.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DN-Benzyl%252FAryl%2520Substituted%2520Tryptanthrin%2520as%2520Dual%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520and%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9161%26epage%3D9174%26doi%3D10.1021%2Facs.jmedchem.9b01079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Novel Tryptanthrin Derivatives as Dual Inhibitors of Indoleamine 2,3-Dioxygenase 1 and Tryptophan 2,3-Dioxygenase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127159</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2020.127159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32247733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsVSnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127159&author=Y.+Liauthor=S.+Zhangauthor=R.+Wangauthor=M.+Cuiauthor=W.+Liuauthor=Q.+Yangauthor=C.+Kuang&title=Synthesis+of+Novel+Tryptanthrin+Derivatives+as+Dual+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+1+and+Tryptophan+2%2C3-Dioxygenase&doi=10.1016%2Fj.bmcl.2020.127159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Li, Yuanyuan; Zhang, Shengnan; Wang, Rong; Cui, Menghan; Liu, Wei; Yang, Qing; Kuang, Chunxiang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">127159</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are promising drug development targets due to their implications in pathologies such as cancer and neurodegenerative diseases.  The search for IDO1 inhibitor has been intensely pursued but there is a paucity of potent TDO and IDO1/TDO dual inhibitors.  Natural product tryptanthrin (indolo[2,1-b]quinazoline-6,12-dione) has been confirmed to bear IDO1 and/or TDO inhibitory activities.  Herein, twelve novel tryptanthrin derivs. were synthesized and evaluated for the IDO1 and TDO inhibitory potency.  All of the compds. were found to be IDO1/TDO dual inhibitors, in particular, compd. I [R = (E)-CH:CHCO2Et, (E)-CH:CHCO2H] bore IDO1 inhibitory activity similar to that of INCB024360; and compd. I [R = CHO, (E)-CH:CHCO2H] had remarkable TDO inhibitory activity superior to that of the well-known TDO inhibitor LM10.  This work enriches the collection of IDO1/TDO dual inhibitors and provides chem. mols. for potential development into drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr72pRgZNipK7Vg90H21EOLACvtfcHk0lgV582rhiEFAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsVSnsLg%253D&md5=932367577fc72cb9c63c9046cf07e162</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127159%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DCui%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DKuang%26aufirst%3DC.%26atitle%3DSynthesis%2520of%2520Novel%2520Tryptanthrin%2520Derivatives%2520as%2520Dual%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520and%2520Tryptophan%25202%252C3-Dioxygenase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127159%26doi%3D10.1016%2Fj.bmcl.2020.127159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Indoleamine 2,3-Dioxygenase 1 (Ido-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1059</span>, <span class="refDoi"> DOI: 10.3390/molecules24061059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3390%2Fmolecules24061059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt1Ciur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1059&author=H.+Zhaoauthor=P.+Sunauthor=W.+Guoauthor=Y.+Wangauthor=A.+Zhangauthor=L.+Mengauthor=C.+Ding&title=Discovery+of+Indoleamine+2%2C3-Dioxygenase+1+%28Ido-1%29+Inhibitors+Based+on+Ortho-Naphthaquinone-Containing+Natural+Product&doi=10.3390%2Fmolecules24061059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitors based on ortho-naphthaquinone-containing natural product</span></div><div class="casAuthors">Zhao, Hongchuan; Sun, Pu; Guo, Wei; Wang, Yi; Zhang, Ao; Meng, Linghua; Ding, Chunyong</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1059</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">There is great interest in developing small mols. agents capable of reversing tumor immune escape to restore the body's immune system.  As an immunosuppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO-1) is considered a promising target for oncol. immunotherapy.  Currently, none of IDO-1 inhibitors have been launched for clin. practice yet.  Thus, the discovery of new IDO-1 inhibitors is still in great demand.  Herein, a series of diverse ortho-naphthaquinone contg. natural product derivs. were synthesized as novel IDO-1 inhibitors.  Among them, 1-ene-3-ketone-17-hydroxyl deriv. 12 exhibited significantly improved enzymic and cellular inhibitory activity against IDO-1 when compared to initial lead compds.  Besides, the mol. docking study disclosed that the two most potent compds. 11 and 12 have more interactions within the binding pocket of IDO-1 via hydrogen-bonding, which may account for their higher IDO-1 inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmIgRATQv9VbVg90H21EOLACvtfcHk0lgV582rhiEFAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt1Ciur0%253D&md5=cc39f2a1a24a175b94777a94eaa7931a</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24061059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24061059%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido-1%2529%2520Inhibitors%2520Based%2520on%2520Ortho-Naphthaquinone-Containing%2520Natural%2520Product%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D1059%26doi%3D10.3390%2Fmolecules24061059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Indoleamine 2,3-Dioxygenase Inhibitors Using Machine Learning Based Virtual Screening</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">945</span>, <span class="refDoi"> DOI: 10.1039/C7MD00642J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1039%2FC7MD00642J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30108982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs1agu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=937-945&author=H.+Zhangauthor=W.+Liuauthor=Z.+Liuauthor=Y.+Juauthor=M.+Xuauthor=Y.+Zhangauthor=X.+Wuauthor=Q.+Guauthor=Z.+Wangauthor=J.+Xu&title=Discovery+of+Indoleamine+2%2C3-Dioxygenase+Inhibitors+Using+Machine+Learning+Based+Virtual+Screening&doi=10.1039%2FC7MD00642J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening</span></div><div class="casAuthors">Zhang, Hongao; Liu, Wei; Liu, Zhihong; Ju, Yingchen; Xu, Mengyang; Zhang, Yue; Wu, Xinyu; Gu, Qiong; Wang, Zhong; Xu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">937-945</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO), an immune checkpoint, is a promising target for cancer immunotherapy.  However, current IDO inhibitors are not approved for clin. use yet; therefore, new IDO inhibitors are still demanded.  To identify new IDO inhibitors, we have built naive Bayesian (NB) and recursive partitioning (RP) models from a library of known IDO inhibitors derived from recent publications.  Thirteen mol. fingerprints were used as descriptors for the models to predict IDO inhibitors.  An inhouse compd. library was virtually screened using the best machine learning model, which resulted in 50 hits for further enzyme-based IDO inhibitory assays.  Consequently, we identified three new IDO inhibitors with IC50 values of 1.30, 4.10, and 4.68μM.  These active compds. also showed IDO inhibitory activities in cell-based assays.  The compds. belong to the tanshinone family, a typical scaffold family derived from Danshen (a Chinese herb), the dried root of Salvia miltiorrhiza, which has been widely used in China, Japan, the United States, and other European countries for the treatment of cardiovascular and cerebrovascular diseases.  Thus, we discovered a new use for Danshen using machine learning methods.  Surface plasmon resonance (SPR) expts. proved that the inhibitors interacted with the IDO target.  Mol. dynamic simulations demonstrated the binding modes of the IDO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_WCHHO2IbKbVg90H21EOLACvtfcHk0lgV582rhiEFAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs1agu7c%253D&md5=af135cb041c03568ff0cb2d5f45938ff</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1039%2FC7MD00642J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00642J%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%2520Using%2520Machine%2520Learning%2520Based%2520Virtual%2520Screening%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26spage%3D937%26epage%3D945%26doi%3D10.1039%2FC7MD00642J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibitory Effects of Flavonoids Isolated from Sophora Flavescens on Indoleamine 2,3-Dioxygenase 1 Activity</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1488</span>, <span class="refDoi"> DOI: 10.1080/14756366.2019.1640218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1080%2F14756366.2019.1640218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31423846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2lsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=1481-1488&author=M.+Kwonauthor=S.+K.+Koauthor=M.+Jangauthor=G.+H.+Kimauthor=I.+J.+Ryooauthor=S.+Sonauthor=H.+W.+Ryuauthor=S.+R.+Ohauthor=W.+K.+Leeauthor=B.+Y.+Kimauthor=J.+H.+Jangauthor=J.+S.+Ahn&title=Inhibitory+Effects+of+Flavonoids+Isolated+from+Sophora+Flavescens+on+Indoleamine+2%2C3-Dioxygenase+1+Activity&doi=10.1080%2F14756366.2019.1640218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity</span></div><div class="casAuthors">Kwon, Mincheol; Ko, Sung-Kyun; Jang, Mina; Kim, Gun-Hee; Ryoo, In-Ja; Son, Sangkeun; Ryu, Hyung Won; Oh, Sei-Ryang; Lee, Won-Kyu; Kim, Bo Yeon; Jang, Jae-Hyuk; Ahn, Jong Seog</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1481-1488</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), a tryptophan catabolising enzyme, is known as a tumor cell survival factor that causes immune escape in several types of cancer.  Flavonoids of Sophora flavescens have a variety of biol. benefits for humans; however, cancer immunotherapy effect has not been fully investigated.  The flavonoids (1-6) isolated from S. flavescens showed IDO1 inhibitory activities (IC50 4.331.4 μM).  The representative flavonoids () of S. flavescens were detd. to be non-competitive inhibitors of IDO1 by kinetic analyses.  Their binding affinity to IDO1 was confirmed using thermal stability and surface plasmon resonance (SPR) assays.  The mol. docking anal. and mutagenesis assay revealed the structural details of the interactions between the flavonoids (1-6) and IDO1.  These results suggest that the flavonoids (1-6) of S. flavescens, esp. kushenol E, as IDO1 inhibitors might be useful in the development of immunotherapeutic agents against cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-WokkU-v1NLVg90H21EOLACvtfcHk0ljlt-I0X4liMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2lsLvP&md5=767bc8d281dce0784953c65501314640</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1080%2F14756366.2019.1640218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2019.1640218%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DS.%2BK.%26aulast%3DJang%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DG.%2BH.%26aulast%3DRyoo%26aufirst%3DI.%2BJ.%26aulast%3DSon%26aufirst%3DS.%26aulast%3DRyu%26aufirst%3DH.%2BW.%26aulast%3DOh%26aufirst%3DS.%2BR.%26aulast%3DLee%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DB.%2BY.%26aulast%3DJang%26aufirst%3DJ.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26atitle%3DInhibitory%2520Effects%2520of%2520Flavonoids%2520Isolated%2520from%2520Sophora%2520Flavescens%2520on%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Activity%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26spage%3D1481%26epage%3D1488%26doi%3D10.1080%2F14756366.2019.1640218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiokawa, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashiwabara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshidome, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2689</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1002%2Fcmdc.201600446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=27863031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyrt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2682-2689&author=Z.+Shiokawaauthor=E.+Kashiwabaraauthor=D.+Yoshidomeauthor=K.+Fukaseauthor=S.+Inukiauthor=Y.+Fujimoto&title=Discovery+of+a+Novel+Scaffold+as+an+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitor+Based+on+the+Pyrrolopiperazinone+Alkaloid%2C+Longamide+B&doi=10.1002%2Fcmdc.201600446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B</span></div><div class="casAuthors">Shiokawa, Zenyu; Kashiwabara, Emi; Yoshidome, Daisuke; Fukase, Koichi; Inuki, Shinsuke; Fujimoto, Yukari</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2682-2689</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) has emerged as a key target for cancer therapy, as IDO1 plays a crit. role in the capacity of tumor cells to evade the immune system.  The pyrrolopiperazinone alkaloid longamide B and its derivs. were identified as novel IDO1 inhibitors based on docking studies and small library synthesis.  The thioamide deriv. showed higher IDO1 inhibitory activity than longamide B, and displayed an activity similar to that of a representative IDO1 inhibitor, 1-methyl-tryptophan.  These results suggest that the pyrrolopiperazinone scaffold of longamide B could be used in the development of IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQaejiaLxbbVg90H21EOLACvtfcHk0ljlt-I0X4liMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyrt7bN&md5=f54d663976681b300b12efb19ed60296</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600446%26sid%3Dliteratum%253Aachs%26aulast%3DShiokawa%26aufirst%3DZ.%26aulast%3DKashiwabara%26aufirst%3DE.%26aulast%3DYoshidome%26aufirst%3DD.%26aulast%3DFukase%26aufirst%3DK.%26aulast%3DInuki%26aufirst%3DS.%26aulast%3DFujimoto%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Scaffold%2520as%2520an%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitor%2520Based%2520on%2520the%2520Pyrrolopiperazinone%2520Alkaloid%252C%2520Longamide%2520B%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2682%26epage%3D2689%26doi%3D10.1002%2Fcmdc.201600446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 through Structure-Based Virtual Screening</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">277</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffphar.2018.00277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29651242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCgt77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=277&author=G.+Zhangauthor=J.+Xingauthor=Y.+Wangauthor=L.+Wangauthor=Y.+Yeauthor=D.+Luauthor=J.+Zhaoauthor=X.+Luoauthor=M.+Zhengauthor=S.+Yan&title=Discovery+of+Novel+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase+1+through+Structure-Based+Virtual+Screening&doi=10.3389%2Ffphar.2018.00277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel inhibitors of indoleamine 2,3-dioxygenase 1 through structure-based virtual screening</span></div><div class="casAuthors">Zhang, Guoqing; Xing, Jing; Wang, Yulan; Wang, Lihao; Ye, Yan; Lu, Dong; Zhao, Jihui; Luo, Xiaomin; Zheng, Mingyue; Yan, Shiying</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">277/1-277/10</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an intracellular monomeric heme-contg. enzyme that catalyzes the first and the rate limiting step in catabolism of tryptophan via the kynurenine (KYN) pathway, which plays a significant role in the proliferation and differentiation of T cells.  IDO1 has been proven to be an attractive target for anticancer therapy and chronic viral infections.  In the present study, a class of IDO1 inhibitors with novel scaffolds were identified by virtual screening and biochem. validation, in which the compd. DC-I028 shows moderate IDO1 inhibitory activity with an IC50 of 21.61 μM on enzymic level and 89.11 μM on HeLa cell.  In the following hit expansion stage, DC-I02806, an analog of DC-I028, showed better inhibitory activity with IC50 about 18 μM on both enzymic level and cellular level.  The structure-activity relationship (SAR) of DC-I028 and its analogs was then discussed based on the mol. docking result.  The novel IDO1 inhibitors of DC-I028 and its analogs may provide useful clues for IDO1 inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj6yRzlve-R7Vg90H21EOLACvtfcHk0ljlt-I0X4liMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCgt77M&md5=e93407a44446fcbadc489025b32d753d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00277%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Novel%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520through%2520Structure-Based%2520Virtual%2520Screening%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D277%26doi%3D10.3389%2Ffphar.2018.00277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, R.</span></span> <span> </span><span class="NLM_article-title">A Highly Potent and Selective Inhibitor Roxyl-Wl Targeting Ido1 Promotes Immune Response against Melanoma</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1089</span>– <span class="NLM_lpage">1094</span>, <span class="refDoi"> DOI: 10.1080/14756366.2018.1471688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1080%2F14756366.2018.1471688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29932010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2gs7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=1089-1094&author=G.+Xuauthor=T.+Wangauthor=Y.+Liauthor=Z.+Huangauthor=X.+Wangauthor=J.+Zhengauthor=S.+Yangauthor=Y.+Fanauthor=R.+Xiang&title=A+Highly+Potent+and+Selective+Inhibitor+Roxyl-Wl+Targeting+Ido1+Promotes+Immune+Response+against+Melanoma&doi=10.1080%2F14756366.2018.1471688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma</span></div><div class="casAuthors">Xu, Guangwei; Wang, Tianqi; Li, Yongtao; Huang, Zhi; Wang, Xin; Zheng, Jianyu; Yang, Shengyong; Fan, Yan; Xiang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1089-1094</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) activity links to immune escape of cancers.  Inhibition of IDO1 provides a new approach for cancer treatment.  Most clin. IDO1 drugs show marginal efficacy as single agents.  On basis of mol. docking and pharmacophore modeling, a novel inhibitor Roxyl-WL was discovered with a half maximal inhibitory concn. (IC50) value of 1 nM against IDO1 and 10-100-fold increased potent activity compared with IDO1 drugs in clin. trials.  Roxyl-WL displayed excellent kinase spectrum selectivity with no activity out of the 337 protein kinases.  In vitro, Roxyl-WL effectively augmented the proliferation of T cells and reduced the no. of regulatory T cell (Tregs).  When administered to melanoma (B16F10) tumor-bearing mice orally, Roxyl-WL significantly suppressed tumor growth and induced immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV16IiN4_-kbVg90H21EOLACvtfcHk0ljlt-I0X4liMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2gs7fF&md5=279906de3dd40d98184828437a441146</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1080%2F14756366.2018.1471688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2018.1471688%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DA%2520Highly%2520Potent%2520and%2520Selective%2520Inhibitor%2520Roxyl-Wl%2520Targeting%2520Ido1%2520Promotes%2520Immune%2520Response%2520against%2520Melanoma%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2018%26volume%3D33%26spage%3D1089%26epage%3D1094%26doi%3D10.1080%2F14756366.2018.1471688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span> <span> </span><span class="NLM_article-title">Effective Virtual Screening Strategy toward Heme-Containing Proteins: Identification of Novel Ido1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">111750</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2019.111750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31610376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFOktbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2019&pages=111750&author=Y.+Zouauthor=Y.+Huauthor=S.+Geauthor=Y.+Zhengauthor=Y.+Liauthor=W.+Liuauthor=W.+Guoauthor=Y.+Zhangauthor=Q.+Xuauthor=Y.+Lai&title=Effective+Virtual+Screening+Strategy+toward+Heme-Containing+Proteins%3A+Identification+of+Novel+Ido1+Inhibitors&doi=10.1016%2Fj.ejmech.2019.111750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors</span></div><div class="casAuthors">Zou, Yi; Hu, Yue; Ge, Shushan; Zheng, Yingbo; Li, Yuezhen; Liu, Wen; Guo, Wenjie; Zhang, Yihua; Xu, Qiang; Lai, Yisheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111750</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Developing small mols. occupying the heme-binding site using computational approaches remains a challenging task because it is difficult to characterize heme-ligand interaction in heme-contg. protein.  Indoleamine 2,3-dioxygenase 1 (IDO1) is an intracellular heme-contg. dioxygenase which is assocd. with the immunosuppressive effects in cancer.  With IDO1 as an example, herein we report a combined virtual screening (VS) strategy including high-specificity heme-binding group (HmBG)-based pharmacophore screening and cascade mol. docking to identify novel IDO1 inhibitors.  A total of four hit compds. were obtained and showed proper binding with the heme iron coordinating site.  Further structural optimization led to a promising compd. S18-3, which exerted potent anti-tumor efficacy in BALB/c mice bearing established CT26 tumors by activating the host's immune system.  These results suggest that S18-3 merits further study to assess its potential for the intervention of cancer.  Furthermore, our study also unveils a novel in silico-based strategy for identifying potential regulators for hemeproteins within short timeframe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqljI0E5qDfmLVg90H21EOLACvtfcHk0lh-zLOl9OpD4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFOktbjE&md5=0c0a708efdbc56f7372d20224cef126c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111750%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DGe%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DLai%26aufirst%3DY.%26atitle%3DEffective%2520Virtual%2520Screening%2520Strategy%2520toward%2520Heme-Containing%2520Proteins%253A%2520Identification%2520of%2520Novel%2520Ido1%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D184%26spage%3D111750%26doi%3D10.1016%2Fj.ejmech.2019.111750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aprile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griglio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orecchini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallotta, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massarotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallarini, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (Ido1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3047</span>– <span class="NLM_lpage">3065</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01809</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01809" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFaitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3047-3065&author=M.+Serafiniauthor=E.+Torreauthor=S.+Aprileauthor=E.+D.+Grossoauthor=A.+Gesuauthor=A.+Griglioauthor=G.+Colomboauthor=C.+Travelliauthor=S.+Paiellaauthor=A.+Adamoauthor=E.+Orecchiniauthor=A.+Colettiauthor=M.+T.+Pallottaauthor=S.+Ugelauthor=A.+Massarottiauthor=T.+Piraliauthor=S.+Fallarini&title=Discovery+of+Highly+Potent+Benzimidazole+Derivatives+as+Indoleamine+2%2C3-Dioxygenase-1+%28Ido1%29+Inhibitors%3A+From+Structure-Based+Virtual+Screening+to+in+Vivo+Pharmacodynamic+Activity&doi=10.1021%2Facs.jmedchem.9b01809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity</span></div><div class="casAuthors">Serafini, Marta; Torre, Enza; Aprile, Silvio; Grosso, Erika Del; Gesu, Alessandro; Griglio, Alessia; Colombo, Giorgia; Travelli, Cristina; Paiella, Salvatore; Adamo, Annalisa; Orecchini, Elena; Coletti, Alice; Pallotta, Maria Teresa; Ugel, Stefano; Massarotti, Alberto; Pirali, Tracey; Fallarini, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3047-3065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, a successful medicinal chem. campaign that exploited virtual, biophys., and biol. investigations led to the identification of a novel class of IDO1 inhibitors based on a benzimidazole substructure.  This family of compds. is endowed with an extensive bonding network in the protein active site, including the interaction with pocket C, a region not commonly exploited by previously reported IDO1 inhibitors.  The tight packing of selected compds. within the enzyme contributes to the strong binding interaction with IDO1, to the inhibitory potency at the low nanomolar level in several tumoral settings, and to the selectivity toward IDO1 over TDO and CYPs.  Notably, a significant redn. of L-Kyn levels in plasma, together with a potent effect on abrogating immunosuppressive properties of MDSC-like cells isolated from patients affected by pancreatic ductal adenocarcinoma, was obsd., pointing to this class of mols. as a valuable template for boosting the antitumor immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfZttD9qaarVg90H21EOLACvtfcHk0lh-zLOl9OpD4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFaitbs%253D&md5=118293cb0e185b77b209568fa4c151a2</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01809%26sid%3Dliteratum%253Aachs%26aulast%3DSerafini%26aufirst%3DM.%26aulast%3DTorre%26aufirst%3DE.%26aulast%3DAprile%26aufirst%3DS.%26aulast%3DGrosso%26aufirst%3DE.%2BD.%26aulast%3DGesu%26aufirst%3DA.%26aulast%3DGriglio%26aufirst%3DA.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DTravelli%26aufirst%3DC.%26aulast%3DPaiella%26aufirst%3DS.%26aulast%3DAdamo%26aufirst%3DA.%26aulast%3DOrecchini%26aufirst%3DE.%26aulast%3DColetti%26aufirst%3DA.%26aulast%3DPallotta%26aufirst%3DM.%2BT.%26aulast%3DUgel%26aufirst%3DS.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DFallarini%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Highly%2520Potent%2520Benzimidazole%2520Derivatives%2520as%2520Indoleamine%25202%252C3-Dioxygenase-1%2520%2528Ido1%2529%2520Inhibitors%253A%2520From%2520Structure-Based%2520Virtual%2520Screening%2520to%2520in%2520Vivo%2520Pharmacodynamic%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3047%26epage%3D3065%26doi%3D10.1021%2Facs.jmedchem.9b01809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Identification and Preliminary Structure-Activity Relationships of 1-Indanone Derivatives as Novel Indoleamine-2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3780</span>– <span class="NLM_lpage">3791</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2017.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28526475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVyrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=3780-3791&author=D.+Gaoauthor=Y.+Li&title=Identification+and+Preliminary+Structure-Activity+Relationships+of+1-Indanone+Derivatives+as+Novel+Indoleamine-2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.bmc.2017.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Gao, Dingding; Li, Yingxia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3780-3791</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a vital role in the catabolism of tryptophan along with the kynurenine pathway which is involved in many human diseases including cancer, Alzheimer's disease, etc.  In this study, compd. 1 bearing a 1-Indanone scaffold was identified as a novel IDO1 inhibitor by structure-based virtual screening, with moderate to good enzymic and cellular inhibitory activities.  Also, surface plasmon resonance anal. validated the direct interaction between compd. 1 and IDO1 protein.  The preliminary SAR was further explored and the binding mode with IDO1 protein was predicted by expt. along with mol. docking.  Subsequent ADME properties of these active compds. were analyzed in silico, and the results showed good pharmacokinetic efficiencies.  The authors believe this study contributes a lot to the structural diversity for the future development of highly potent IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpclm1X2v_C6LVg90H21EOLACvtfcHk0ljE8EiEBsVHGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVyrs7o%253D&md5=e51fb2df493761d7681b8be5c4d9f219</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DIdentification%2520and%2520Preliminary%2520Structure-Activity%2520Relationships%2520of%25201-Indanone%2520Derivatives%2520as%2520Novel%2520Indoleamine-2%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D3780%26epage%3D3791%26doi%3D10.1016%2Fj.bmc.2017.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structure-Activity Relationships of Phenyl Benzenesulfonylhydrazides as Novel Indoleamine 2,3-Dioxygenase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3403</span>– <span class="NLM_lpage">3406</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmcl.2014.05.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=24939758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3403-3406&author=M.+F.+Chengauthor=M.+S.+Hungauthor=J.+S.+Songauthor=S.+Y.+Linauthor=F.+Y.+Liaoauthor=M.+H.+Wuauthor=W.+Hsiaoauthor=C.+L.+Hsiehauthor=J.+S.+Wuauthor=Y.+S.+Chaoauthor=C.+Shihauthor=S.+Y.+Wuauthor=S.+H.+Ueng&title=Discovery+and+Structure-Activity+Relationships+of+Phenyl+Benzenesulfonylhydrazides+as+Novel+Indoleamine+2%2C3-Dioxygenase+Inhibitors&doi=10.1016%2Fj.bmcl.2014.05.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Cheng, Ming-Fu; Hung, Ming-Shiu; Song, Jen-Shin; Lin, Shu-Yu; Liao, Fang-Yu; Wu, Mine-Hsine; Hsiao, Wenchi; Hsieh, Chia-Ling; Wu, Jian-Sung; Chao, Yu-Sheng; Shih, Chuan; Wu, Su-Ying; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3403-3406</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of Ph benzenesulfonylhydrazides has been identified as potent inhibitors of indoleamine 2,3-dioxygenase (IDO), and their structure-activity relationship was explored.  Coupling reactions between various benzenesulfonyl chlorides and phenylhydrazides were utilized to synthesize the sulfonylhydrazides bearing various substituents.  Compd. 3i exhibited 61 nM of IC50 in enzymic assay and 172 nM of EC50 in the HeLa cell.  The computational study of 3i suggested that the major interactions between 3i and IDO protein are the coordination of sulfone and heme iron, the hydrogen bonding and hydrophobic interactions between 3i and IDO.  This novel class of IDO inhibitor provides a new direction to discover effective anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCMHnPLf2u5LVg90H21EOLACvtfcHk0ljE8EiEBsVHGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrM&md5=560f7daccbb56934079c186991fd1b52</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.084%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsiao%26aufirst%3DW.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DDiscovery%2520and%2520Structure-Activity%2520Relationships%2520of%2520Phenyl%2520Benzenesulfonylhydrazides%2520as%2520Novel%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3403%26epage%3D3406%26doi%3D10.1016%2Fj.bmcl.2014.05.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ltLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=419-430&author=S.+Y.+Linauthor=T.+K.+Yehauthor=C.+C.+Kuoauthor=J.+S.+Songauthor=M.+F.+Chengauthor=F.+Y.+Liaoauthor=M.+W.+Chaoauthor=H.+L.+Huangauthor=Y.+L.+Chenauthor=C.+Y.+Yangauthor=M.+H.+Wuauthor=C.+L.+Hsiehauthor=W.+Hsiaoauthor=Y.+H.+Pengauthor=J.+S.+Wuauthor=L.+M.+Linauthor=M.+Sunauthor=Y.+S.+Chaoauthor=C.+Shihauthor=S.+Y.+Wuauthor=S.+L.+Panauthor=M.+S.+Hungauthor=S.+H.+Ueng&title=Phenyl+Benzenesulfonylhydrazides+Exhibit+Selective+Indoleamine+2%2C3-Dioxygenase+Inhibition+with+Potent+in+Vivo+Pharmacodynamic+Activity+and+Antitumor+Efficacy&doi=10.1021%2Facs.jmedchem.5b01640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy</span></div><div class="casAuthors">Lin, Shu-Yu; Yeh, Teng-Kuang; Kuo, Ching-Chuan; Song, Jen-Shin; Cheng, Ming-Fu; Liao, Fang-Yu; Chao, Min-Wu; Huang, Han-Li; Chen, Yi-Lin; Yang, Chun-Yu; Wu, Mine-Hsine; Hsieh, Chia-Ling; Hsiao, Wenchi; Peng, Yi-Hui; Wu, Jian-Sung; Lin, Li-Mei; Sun, Manwu; Chao, Yu-Sheng; Shih, Chuan; Wu, Su-Ying; Pan, Shiow-Lin; Hung, Ming-Shiu; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tryptophan metab. has been recognized as an important mechanism in immune tolerance.  Indoleamine 2,3-dioxygenase plays a key role in local tryptophan metab. via the kynurenine pathway and has emerged as a therapeutic target for cancer immunotherapy.  The prior study identified Ph benzenesulfonyl hydrazide as a potent in vitro (though not in vivo) inhibitor of indoleamine 2,3-dioxygenase.  Further lead optimization to improve in vitro potencies and pharmacokinetic profiles resulted in N'-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl hydrazide (I), which demonstrated 59% oral bioavailability and 73% of tumor growth delay without apparent body wt. loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg.  Accordingly, I is proposed as a potential drug lead worthy of advanced preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOxVvjSCi13LVg90H21EOLACvtfcHk0ljE8EiEBsVHGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ltLjE&md5=63287615c2b038f657cab148d4747e03</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01640%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DHsiao%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DL.%2BM.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DPhenyl%2520Benzenesulfonylhydrazides%2520Exhibit%2520Selective%2520Indoleamine%25202%252C3-Dioxygenase%2520Inhibition%2520with%2520Potent%2520in%2520Vivo%2520Pharmacodynamic%2520Activity%2520and%2520Antitumor%2520Efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D419%26epage%3D430%26doi%3D10.1021%2Facs.jmedchem.5b01640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deka, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span> <span> </span><span class="NLM_article-title">Fused Heterocyclic Compounds as Potent Indoleamine-2,3-Dioxygenase 1 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1167</span>– <span class="NLM_lpage">1172</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00359</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00359" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yksr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1167-1172&author=S.+Pandaauthor=A.+Royauthor=S.+J.+Dekaauthor=V.+Trivediauthor=D.+Manna&title=Fused+Heterocyclic+Compounds+as+Potent+Indoleamine-2%2C3-Dioxygenase+1+Inhibitors&doi=10.1021%2Facsmedchemlett.6b00359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors</span></div><div class="casAuthors">Panda, Subhankar; Roy, Ashalata; Deka, Suman Jyoti; Trivedi, Vishal; Manna, Debasis</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1167-1172</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Uncontrolled metab. of L-tryptophan (L-Trp) in the immune system has been recognized as a crit. cellular process in immune tolerance.  Indoleamine 2,3-dioxygenase 1 (IDO1) enzyme plays an important role in the metab. of a local L-Trp through the kynurenine pathway in the immune systems.  In this regard, IDO1 has emerged as a therapeutic target for the treatment of diseases that are assocd. with immune suppression like chronic infections, cancer, and others.  In this study, we synthesized a series of pyridopyrimidine, pyrazolopyranopyrimidine, and dipyrazolopyran derivs.  Further lead optimizations directed to the identification of potent compds., I and II (IC50 = 260 and 151 nM, resp.).  These compds. also exhibited IDO1 inhibitory activities in the low nanomolar range in MDA-MB-231 cells with very low cytotoxicity.  Stronger selectivity for the IDO1 enzyme (>300-fold) over tryptophan 2,3-dioxygenase (TDO) enzyme was also obsd. for these compds.  Hence, these fused heterocyclic compds. are attractive candidates for the advanced study of IDO1-dependent cellular function and immunotherapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3hka_cRkrHrVg90H21EOLACvtfcHk0lgJibSw_xybjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yksr%252FO&md5=452d3d1d01e3d701c371862ffa67e84d</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00359%26sid%3Dliteratum%253Aachs%26aulast%3DPanda%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DDeka%26aufirst%3DS.%2BJ.%26aulast%3DTrivedi%26aufirst%3DV.%26aulast%3DManna%26aufirst%3DD.%26atitle%3DFused%2520Heterocyclic%2520Compounds%2520as%2520Potent%2520Indoleamine-2%252C3-Dioxygenase%25201%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D1167%26epage%3D1172%26doi%3D10.1021%2Facsmedchemlett.6b00359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaLonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">O-Alkylhydroxylamines as Rationally-Designed Mechanism-Based Inhibitors of Indoleamine 2,3-Dioxygenase-1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2015.12.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=26717206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVyqtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=564-576&author=W.+P.+Malachowskiauthor=M.+Wintersauthor=J.+B.+DuHadawayauthor=A.+Lewis-Ballesterauthor=S.+Badirauthor=J.+Waiauthor=M.+Rahmanauthor=E.+Sheikhauthor=J.+M.+LaLondeauthor=S.+R.+Yehauthor=G.+C.+Prendergastauthor=A.+J.+Muller&title=O-Alkylhydroxylamines+as+Rationally-Designed+Mechanism-Based+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase-1&doi=10.1016%2Fj.ejmech.2015.12.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1</span></div><div class="casAuthors">Malachowski, William P.; Winters, Maria; DuHadaway, James B.; Lewis-Ballester, Ariel; Badir, Shorouk; Wai, Jenny; Rahman, Maisha; Sheikh, Eesha; LaLonde, Judith M.; Yeh, Syun-Ru; Prendergast, George C.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">564-576</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathol. immune suppression.  Recently important advances have been made in understanding IDO1's catalytic mechanism.  Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state.  Accordingly, the authors explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state.  The authors discovered that O-benzylhydroxylamine, a com. available compd., is a potent sub-micromolar inhibitor of IDO1.  Structure-activity studies of over forty derivs. of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addn. of halogen atoms to the meta position of the arom. ring.  The most potent derivs. and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development.  Notably, two of the most potent compds. demonstrated nanomolar-level cell-based potency and limited toxicity.  The combination of the simplicity of the structures of these compds. and their excellent cellular activity makes them quite attractive for biol. exploration of IDO1 function and antitumor therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDnCWhaQpRTLVg90H21EOLACvtfcHk0lgJibSw_xybjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVyqtbvL&md5=f8705d78d92a94ce0d644fef10c44fac</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.028%26sid%3Dliteratum%253Aachs%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DWinters%26aufirst%3DM.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DBadir%26aufirst%3DS.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DRahman%26aufirst%3DM.%26aulast%3DSheikh%26aufirst%3DE.%26aulast%3DLaLonde%26aufirst%3DJ.%2BM.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DO-Alkylhydroxylamines%2520as%2520Rationally-Designed%2520Mechanism-Based%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase-1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D564%26epage%3D576%26doi%3D10.1016%2Fj.ejmech.2015.12.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis-Ballester, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span> <span> </span><span class="NLM_article-title">Diaryl Hydroxylamines as Pan or Dual Inhibitors of Indoleamine 2,3-Dioxygenase-1, Indoleamine 2,3-Dioxygenase-2 and Tryptophan Dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2018.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=30469041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12lsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=455-464&author=M.+Wintersauthor=J.+B.+DuHadawayauthor=K.+N.+Phamauthor=A.+Lewis-Ballesterauthor=S.+Badirauthor=J.+Waiauthor=E.+Sheikhauthor=S.+R.+Yehauthor=G.+C.+Prendergastauthor=A.+J.+Mullerauthor=W.+P.+Malachowski&title=Diaryl+Hydroxylamines+as+Pan+or+Dual+Inhibitors+of+Indoleamine+2%2C3-Dioxygenase-1%2C+Indoleamine+2%2C3-Dioxygenase-2+and+Tryptophan+Dioxygenase&doi=10.1016%2Fj.ejmech.2018.11.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase</span></div><div class="casAuthors">Winters, Maria; DuHadaway, James B.; Pham, Khoa N.; Lewis-Ballester, Ariel; Badir, Shorouk; Wai, Jenny; Sheikh, Eesha; Yeh, Syun-Ru; Prendergast, George C.; Muller, Alexander J.; Malachowski, William P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">455-464</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Tryptophan (Trp) catabolizing enzymes play an important and complex role in the development of cancer.  Significant evidence implicates them in a range of inflammatory and immunosuppressive activities.  Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) have been reported and analyzed in the clinic, fewer inhibitors have been described for tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have been implicated more recently in cancer, inflammation and immune control.  Consequently the development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a therapeutically important area of research.  This is the first report to describe the development of dual and pan inhibitors of IDO1, TDO and IDO2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdiTONUXSgbVg90H21EOLACvtfcHk0lir8tlFF_bUCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12lsLfJ&md5=b1e562e2738830b58ac5bb544725adff</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DWinters%26aufirst%3DM.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DPham%26aufirst%3DK.%2BN.%26aulast%3DLewis-Ballester%26aufirst%3DA.%26aulast%3DBadir%26aufirst%3DS.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DSheikh%26aufirst%3DE.%26aulast%3DYeh%26aufirst%3DS.%2BR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26atitle%3DDiaryl%2520Hydroxylamines%2520as%2520Pan%2520or%2520Dual%2520Inhibitors%2520of%2520Indoleamine%25202%252C3-Dioxygenase-1%252C%2520Indoleamine%25202%252C3-Dioxygenase-2%2520and%2520Tryptophan%2520Dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D162%26spage%3D455%26epage%3D464%26doi%3D10.1016%2Fj.ejmech.2018.11.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rohrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turcatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Detailed Analysis and Follow-up Studies of a High-Throughput Screening for Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.06.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.ejmech.2014.06.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=25036789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Grs7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2014&pages=284-301&author=U.+F.+Rohrigauthor=S.+R.+Majjigapuauthor=M.+Chambonauthor=S.+Bronauthor=L.+Pilotteauthor=D.+Colauauthor=B.+J.+Van+den+Eyndeauthor=G.+Turcattiauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=Detailed+Analysis+and+Follow-up+Studies+of+a+High-Throughput+Screening+for+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors&doi=10.1016%2Fj.ejmech.2014.06.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Chambon, Marc; Bron, Sylvian; Pilotte, Luc; Colau, Didier; Van den Eynde, Benoit J.; Turcatti, Gerardo; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">284-301</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulator of immune responses and therefore an important therapeutic target for the treatment of diseases that involve pathol. immune escape, such as cancer.  Here, the authors describe a robust and sensitive high-throughput screen (HTS) for IDO1 inhibitors using the Prestwick Chem. Library of 1200 FDA-approved drugs and the Maybridge HitFinder Collection of 14,000 small mols.  Of the 60 hits selected for follow-up studies, 14 displayed IC50 values below 20 μM under the secondary assay conditions, and 4 showed an activity in cellular tests.  In view of the high attrition rate the authors used both exptl. and computational techniques to identify and to characterize compds. inhibiting IDO1 through unspecific inhibition mechanisms such as chem. reactivity, redox cycling, or aggregation.  One specific IDO1 inhibitor scaffold, the imidazole antifungal agents, was chosen for rational structure-based lead optimization, which led to more sol. and smaller compds. with micromolar activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwX1aSlfQ6VbVg90H21EOLACvtfcHk0lir8tlFF_bUCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Grs7fE&md5=3751d1ba733eebcd5587e33533617e6b</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.06.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.06.078%26sid%3Dliteratum%253Aachs%26aulast%3DRohrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DChambon%26aufirst%3DM.%26aulast%3DBron%26aufirst%3DS.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DTurcatti%26aufirst%3DG.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DDetailed%2520Analysis%2520and%2520Follow-up%2520Studies%2520of%2520a%2520High-Throughput%2520Screening%2520for%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D84%26spage%3D284%26epage%3D301%26doi%3D10.1016%2Fj.ejmech.2014.06.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Investigation of Multi-Target-Directed Ligands (Mtdls) with Butyrylcholinesterase (Buche) and Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibition: The Design, Synthesis of Miconazole Analogues Targeting Alzheimer’s Disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1665</span>– <span class="NLM_lpage">1674</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.bmc.2018.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=29475581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFakurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1665-1674&author=X.+Luauthor=S.+Y.+Heauthor=Q.+Liauthor=H.+Yangauthor=X.+Jiangauthor=H.+Linauthor=Y.+Chenauthor=W.+Quauthor=F.+Fengauthor=Y.+Bianauthor=Y.+Zhouauthor=H.+Sun&title=Investigation+of+Multi-Target-Directed+Ligands+%28Mtdls%29+with+Butyrylcholinesterase+%28Buche%29+and+Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibition%3A+The+Design%2C+Synthesis+of+Miconazole+Analogues+Targeting+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.bmc.2018.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease</span></div><div class="casAuthors">Lu, Xin; He, Si-yu; Li, Qi; Yang, Hongyu; Jiang, Xueyang; Lin, Hongzhi; Chen, Yao; Qu, Wei; Feng, Feng; Bian, Yaoyao; Zhou, You; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1665-1674</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In our endeavor towards the development of potent multi-target ligands for the treatment of Alzheimer's disease, miconazole was identified to show BuChE-IDO1 dual-target inhibitory effects.  Morris water maze test indicated that miconazole obviously ameliorated the cognitive function impaired by scopolamine.  Furthermore, it showed good safety in primary hepatotoxicity evaluation.  Based on these results, we designed, synthesized, and evaluated a series of miconazole derivs. as BuChE-IDO1 dual-target inhibitors.  Out of the 12 compds., 5i and 5j exhibited the best potency in enzymic evaluation, thus were selected for subsequent behavioral study, in which the two compds. exerted much improved effect than tacrine.  Meanwhile, 5i and 5j displayed no apparent hepatotoxicity.  The results suggest that miconazole analog offers an attractive starting point for further development of new BuChE-IDO1 dual-target inhibitors against Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFWgipL3NC8bVg90H21EOLACvtfcHk0livkvWEEm6fZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFakurw%253D&md5=28600c6f86b9f5a30151ff0f0f9c9f58</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DS.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DBian%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DInvestigation%2520of%2520Multi-Target-Directed%2520Ligands%2520%2528Mtdls%2529%2520with%2520Butyrylcholinesterase%2520%2528Buche%2529%2520and%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibition%253A%2520The%2520Design%252C%2520Synthesis%2520of%2520Miconazole%2520Analogues%2520Targeting%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D1665%26epage%3D1674%26doi%3D10.1016%2Fj.bmc.2018.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogbechi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clanchy, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, T. W.</span></span> <span> </span><span class="NLM_article-title">Ido and Kynurenine Metabolites in Peripheral and Cns Disorders</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">388</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.00388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffimmu.2020.00388" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=32194572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVaku7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=388&author=Y.+S.+Huangauthor=J.+Ogbechiauthor=F.+I.+Clanchyauthor=R.+O.+Williamsauthor=T.+W.+Stone&title=Ido+and+Kynurenine+Metabolites+in+Peripheral+and+Cns+Disorders&doi=10.3389%2Ffimmu.2020.00388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">IDO and kynurenine metabolites in peripheral and CNS disorders</span></div><div class="casAuthors">Huang, Yi-Shu; Ogbechi, Joy; Clanchy, Felix I.; Williams, Richard O.; Stone, Trevor W.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">388</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The importance of the kynurenine pathway in normal immune system function has led to an appreciation of its possible contribution to autoimmune disorders such as rheumatoid arthritis.  Indoleamine-2,3-dioxygenase (IDO) activity exerts a protective function, limiting the severity of exptl. arthritis, whereas deletion or inhibition exacerbates the symptoms.  Other chronic disorder with an inflammatory component, such as atherosclerosis, are also suppressed by IDO activity.  It is suggested that this overall anti-inflammatory activity is mediated by a change in the relative prodn. or activity of Th17 and regulatory T cell populations.  Kynurenines may play an anti-inflammatory role also in CNS disorders such as Huntington's disease, Alzheimer's disease and multiple sclerosis, in which signs of inflammation and neurodegeneration are involved.  The possibility is discussed that in Huntington's disease kynurenines interact with other anti-inflammatory mols. such as Human Lymphocyte Antigen-G which may be relevant in other disorders.  Kynurenine involvement may account for the protection afforded to animals with cerebral malaria and trypanosomiasis when they are treated with an inhibitor of kynurenine-3-monoxygenase (KMO).  There is some evidence that changes in IL-10 may contribute to this protection and the relationship between kynurenines and IL-10 in arthritis and other inflammatory conditions should be explored.  In addn., metabolites of kynurenine downstream of KMO, such as anthranilic acid and 3-hydroxy-anthranilic acid can influence inflammation, and the ratio of these compds. is a valuable biomarker of inflammatory status although the underlying mol. mechanisms of the changes require clarification.  Hence it is essential that more effort be expended to identify their sites of action as potential targets for drug development.  Finally, we discuss increasing awareness of the epigenetic regulation of IDO, for example by DNA methylation, a phenomenon which may explain differences between individuals in their susceptibility to arthritis and other inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDtbLQFAHjeLVg90H21EOLACvtfcHk0livkvWEEm6fZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVaku7fK&md5=89ab5269e749effbf795c44865d0db7a</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.00388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.00388%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%2BS.%26aulast%3DOgbechi%26aufirst%3DJ.%26aulast%3DClanchy%26aufirst%3DF.%2BI.%26aulast%3DWilliams%26aufirst%3DR.%2BO.%26aulast%3DStone%26aufirst%3DT.%2BW.%26atitle%3DIdo%2520and%2520Kynurenine%2520Metabolites%2520in%2520Peripheral%2520and%2520Cns%2520Disorders%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D388%26doi%3D10.3389%2Ffimmu.2020.00388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Favre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbour, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayawardene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aweeka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douek, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenchley, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCune, J. M.</span></span> <span> </span><span class="NLM_article-title">Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of Th17 to Regulatory T Cells in Hiv Disease</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">32ra36</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3000632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1126%2Fscitranslmed.3000632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=20484731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=32ra36&author=D.+Favreauthor=J.+Moldauthor=P.+W.+Huntauthor=B.+Kanwarauthor=P.+Lokeauthor=L.+Seuauthor=J.+D.+Barbourauthor=M.+M.+Loweauthor=A.+Jayawardeneauthor=F.+Aweekaauthor=Y.+Huangauthor=D.+C.+Douekauthor=J.+M.+Brenchleyauthor=J.+N.+Martinauthor=F.+M.+Hechtauthor=S.+G.+Deeksauthor=J.+M.+McCune&title=Tryptophan+Catabolism+by+Indoleamine+2%2C3-Dioxygenase+1+Alters+the+Balance+of+Th17+to+Regulatory+T+Cells+in+Hiv+Disease&doi=10.1126%2Fscitranslmed.3000632"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000632%26sid%3Dliteratum%253Aachs%26aulast%3DFavre%26aufirst%3DD.%26aulast%3DMold%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DP.%2BW.%26aulast%3DKanwar%26aufirst%3DB.%26aulast%3DLoke%26aufirst%3DP.%26aulast%3DSeu%26aufirst%3DL.%26aulast%3DBarbour%26aufirst%3DJ.%2BD.%26aulast%3DLowe%26aufirst%3DM.%2BM.%26aulast%3DJayawardene%26aufirst%3DA.%26aulast%3DAweeka%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDouek%26aufirst%3DD.%2BC.%26aulast%3DBrenchley%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%2BN.%26aulast%3DHecht%26aufirst%3DF.%2BM.%26aulast%3DDeeks%26aufirst%3DS.%2BG.%26aulast%3DMcCune%26aufirst%3DJ.%2BM.%26atitle%3DTryptophan%2520Catabolism%2520by%2520Indoleamine%25202%252C3-Dioxygenase%25201%2520Alters%2520the%2520Balance%2520of%2520Th17%2520to%2520Regulatory%2520T%2520Cells%2520in%2520Hiv%2520Disease%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D32ra36%26doi%3D10.1126%2Fscitranslmed.3000632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><a href="https://www.clinicaltrials.gov/ct2/show/NCT04069026" class="extLink">https://www.clinicaltrials.gov/ct2/show/NCT04069026</a> (accessed Aug 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT04069026+%28accessed+Aug+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojas, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazlett, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdew, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, C. R.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-Dioxygenase 1 (Ido1) Inhibitors Activate the Aryl Hydrocarbon Receptor</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2017.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.1016%2Fj.taap.2017.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=28336214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVCgsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2017&pages=74-80&author=B.+J.+Moyerauthor=I.+Y.+Rojasauthor=I.+A.+Murrayauthor=S.+Leeauthor=H.+F.+Hazlettauthor=G.+H.+Perdewauthor=C.+R.+Tomlinson&title=Indoleamine+2%2C3-Dioxygenase+1+%28Ido1%29+Inhibitors+Activate+the+Aryl+Hydrocarbon+Receptor&doi=10.1016%2Fj.taap.2017.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor</span></div><div class="casAuthors">Moyer, Benjamin J.; Rojas, Itzel Y.; Murray, Iain A.; Lee, Seokwon; Hazlett, Haley F.; Perdew, Gary H.; Tomlinson, Craig R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-80</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in the immune system by regulating tryptophan levels and T cell differentiation.  Several tumor types overexpress IDO1 to avoid immune surveillance making IDO1 of interest as a target for therapeutic intervention.  As a result, several IDO1 inhibitors are currently being tested in clin. trials for cancer treatment as well as several other diseases.  Many of the IDO1 inhibitors in clin. trials naturally bear structural similarities to the IDO1 substrate tryptophan, as such, they fulfill many of the structural and functional criteria as potential AHR ligands.  Using mouse and human cell-based luciferase gene reporter assays, qPCR confirmation expts., and CYP1A1 enzyme activity assays, we report that some of the promising clin. IDO1 inhibitors also act as agonists for the aryl hydrocarbon receptor (AHR), best known for its roles in xenobiotic metab. and as another key regulator of the immune response.  The dual role as IDO antagonist and AHR agonist for many of these IDO target drugs should be considered for full interrogation of their biol. mechanisms and clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqto3BSdWrihrVg90H21EOLACvtfcHk0lh_k8TMKJ4gsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVCgsr8%253D&md5=ed02582ccc2902fbe04af590577f211f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2017.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2017.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DB.%2BJ.%26aulast%3DRojas%26aufirst%3DI.%2BY.%26aulast%3DMurray%26aufirst%3DI.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DHazlett%26aufirst%3DH.%2BF.%26aulast%3DPerdew%26aufirst%3DG.%2BH.%26aulast%3DTomlinson%26aufirst%3DC.%2BR.%26atitle%3DIndoleamine%25202%252C3-Dioxygenase%25201%2520%2528Ido1%2529%2520Inhibitors%2520Activate%2520the%2520Aryl%2520Hydrocarbon%2520Receptor%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2017%26volume%3D323%26spage%3D74%26epage%3D80%26doi%3D10.1016%2Fj.taap.2017.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirthgen, E.</span></span> <span> </span><span class="NLM_article-title">Limitations and Off-Target Effects of Tryptophan-Related Ido Inhibitors in Cancer Treatment</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1801</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2019.01801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=10.3389%2Ffimmu.2019.01801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=31417567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;key=1%3ACAS%3A280%3ADC%252BB3MvosVOisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1801&author=J.+Guntherauthor=J.+Dabritzauthor=E.+Wirthgen&title=Limitations+and+Off-Target+Effects+of+Tryptophan-Related+Ido+Inhibitors+in+Cancer+Treatment&doi=10.3389%2Ffimmu.2019.01801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment</span></div><div class="casAuthors">Gunther Juliane; Dabritz Jan; Wirthgen Elisa</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1801</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immunooncology is still a growing area in cancer therapy.  Drugs within this therapeutic approach do not directly target/attack the tumor but interfere with immune checkpoints and target or reprogram key metabolic pathways critical for anti-cancer immune defense.  Indolamine 2,3-dioxygenase 1 (IDO1) and the tryptophan (TRP)-kynurenine pathway were identified as critical mechanisms in cancer immune escape and their inhibition as an approach with promising therapeutic potential.  Particularly, a multitude of IDO1 inhibiting tryptophan analogs are widely applied in several clinical trials.  However, this therapy results in a variety of implications for the patient's physiology.  This is not only due to the inhibition of an enzyme important in almost every organ and tissue in the body but also because of the general nature of the inhibitor as an analog of a proteinogenic amino acid as well as the initiation of cellular detoxification known to affect inflammatory pathways.  In this review we provide a deeper insight into the physiological consequences of an IDO1 inhibiting therapy based on TRP related molecules.  We discuss potential side and off-target effects that contribute to the interpretation of unexpected positive as well as negative results of ongoing or discontinued clinical studies while we also highlight the potential of these inhibitors independent of the IDO1 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRoiYC38uLQOGmbXvSEQle5fW6udTcc2eZKHwEDw50vM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvosVOisQ%253D%253D&md5=4952276d1b65968ba9571733840f4cf2</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2019.01801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2019.01801%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DJ.%26aulast%3DDabritz%26aufirst%3DJ.%26aulast%3DWirthgen%26aufirst%3DE.%26atitle%3DLimitations%2520and%2520Off-Target%2520Effects%2520of%2520Tryptophan-Related%2520Ido%2520Inhibitors%2520in%2520Cancer%2520Treatment%26jtitle%3DFront.%2520Immunol.%26date%3D2019%26volume%3D10%26spage%3D1801%26doi%3D10.3389%2Ffimmu.2019.01801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WMV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WMV','PDB','5WMV'); return false;">PDB: 5WMV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WN8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WN8','PDB','5WN8'); return false;">PDB: 5WN8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MQ6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MQ6','PDB','6MQ6'); return false;">PDB: 6MQ6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZW','PDB','6AZW'); return false;">PDB: 6AZW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYY','PDB','6PYY'); return false;">PDB: 6PYY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WHR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WHR','PDB','5WHR'); return false;">PDB: 5WHR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2D0T" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2D0T','PDB','2D0T'); return false;">PDB: 2D0T</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O3I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O3I','PDB','6O3I'); return false;">PDB: 6O3I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5','PDB','4PK5'); return false;">PDB: 4PK5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KOF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KOF','PDB','6KOF'); return false;">PDB: 6KOF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F0A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6F0A','PDB','6F0A'); return false;">PDB: 6F0A</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XE1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XE1','PDB','5XE1'); return false;">PDB: 5XE1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6AZV','PDB','6AZV'); return false;">PDB: 6AZV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V52" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V52','PDB','6V52'); return false;">PDB: 6V52</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i24"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00925">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_12324"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00925?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00925</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Reported IDO1 structures in the past 5 years; compound <b>78</b> showing high structural similarity with reported heme-competitive inhibitors <b>3</b> and <b>7</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00925/suppl_file/jm0c00925_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00925/suppl_file/jm0c00925_si_001.pdf">jm0c00925_si_001.pdf (264.37 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00925&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00925%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00925" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e1029de92bd956","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
